<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />
<meta name="author" content="Tim Woelfle" />

<meta name="date" content="2023-08-11" />


<title>PRISMA &amp; AMSTAR Scores in Cullis 2017: Human Consensus vs LLM (Claude 2) - 2nd run</title>

<meta property="og:title" content="PRISMA &amp; AMSTAR Scores in Cullis 2017: Human Consensus vs LLM (Claude 2) - 2nd run" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script id="flexdashboard-navbar" type="application/json">
[{"title":"Source Code","icon":"fa-code","href":"","align":"right"}]
</script>
<script src="lib/header-attrs-2.21/header-attrs.js"></script>
<script src="lib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="lib/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="lib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="lib/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<link href="lib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="lib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<link href="lib/value-box-accent-static-0.6.1/theme-cosmo-value-box.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/flexdashboard.min.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/theme-cosmo.css" rel="stylesheet" />
<script src="lib/htmlwidgets-1.6.2/htmlwidgets.js"></script>
<link href="lib/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="lib/datatables-binding-0.28/datatables.js"></script>
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="lib/dt-core-1.13.4/js/jquery.dataTables.min.js"></script>
<link href="lib/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
<script src="lib/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<style type="text/css">
/*
  CSS for flexdashboard.js' use of Sly(). The sizing/position of this CSS needs to be
  applied _before_ flexdashboard.js initializes, which is why this CSS has been pulled
  out from flexdashboard.scss and inlined in the document's head.
*/

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  text-align: left;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.sbframe-commentary {
  width: 300px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}
@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  PRISMA &amp; AMSTAR Scores in Cullis 2017: Human Consensus vs LLM (Claude 2) - 2nd run
  <span class="navbar-author">
    Tim Woelfle &mdash; 2023-08-11
    </span>
</span>

<button id="navbar-button" type="button" class="navbar-toggle collapsed pull-right" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false,
      resize_reload: true
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.append(h1.contents());
        h3.insertBefore(h1);
        h1.detach();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if resize_reload is set to true and it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    if (_options.resize_reload) {
      $(window).on('resize', function() {
        if (_options.isMobile !== isMobilePhone() ||
            _options.isPortrait !== isPortrait()) {
          window.location.reload();
        }
      });
    } else {
      // if in desktop mode and resizing to mobile, make sure the heights are 100%
      // This enforces what `fillpage.css` does for "wider" pages.
      // Since we are not reloading once the page becomes small, we need to force the height to 100%
      // This is a new situation introduced when `_options.resize_reload` is `false`
      if (! _options.isMobile) {
        // only add if `fillpage.css` was added in the first place
        if (_options.fillPage) {
          // fillpage.css
          $("html,body,#dashboard").css("height", "100%");
        }
      }
    }
    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          var a = navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target);
          a.removeClass("nav-link").addClass("dropdown-item");
          li.append(a);
          menu.append(li);
        }
      } else {
        var li = $('<li class="nav-item"></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li class="nav-item"></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('data-bs-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover its inner contens, then detach it
    var h1 = wrapper.find('h1').first();
    var title = h1.contents();
    h1.detach();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      li.find("> a").removeClass("nav-link").addClass("dropdown-item");
      menu.append(li);
    } else {
      li.addClass("nav-item")
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a class="nav-link"></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = null;
      var iconSplit = icon.split(" ");
      if (iconSplit.length > 1) {
        iconSet = iconSplit[0];
        icon = iconSplit.slice(1).join(" ");
      } else {
        iconSet = icon.substring(0, dashPos);
      }
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.append(h2.contents());
      h3.insertBefore(h2);
      h2.detach();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.append(h3.contents());
      h3.detach();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.append(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingDom = heading.contents();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab" class="nav-link"></a>');
      a.append(headingDom);
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation" class="nav-item"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children()[activeTab]).tab("show");
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.contents();
    h3.detach();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.empty().append(blockquote.children('p:first-child').contents());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.empty().append(caption.contents());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.decodeURIComponent(window.location.hash);
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.decodeURIComponent(window.location.hash);
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from currently active tabs
    $('.navbar ul.nav .active').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").tab("show");
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.append(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var iconSplit = chartIcon.split(" ");
      if (iconSplit.length > 1) {
        iconLib = iconSplit[0];
        chartIcon = iconSplit.slice(1).join(" ");
      } else {
        var components = chartIcon.split("-");
        if (components.length > 1)
          iconLib = components[0];
      }
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // If valueBox(color=) was an accent color, this attr should
      // be populated with the accent color and the relevant CSS comes
      // in through HTML dependencies
      var dataColorAccent = valueOutput.attr('data-color-accent');
      var valueBoxClasses = "value-box-" + (["primary", "info", "danger", "warning", "success"].join(" value-box-"));
      if (dataColorAccent) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.addClass('value-box-' + dataColorAccent);
      }

      // If valueBox(color=) was a CSS color, these other data-color-*
      // attrs will be populated
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.css('background-color', dataColor);
      }
      var dataColorText = valueOutput.attr('data-color-text');
      if (dataColorText) {
        valueBox.find(".inner").css('color', dataColorText);
      }
      var dataColorIcon = valueOutput.attr('data-color-icon');
      if (dataColorIcon) {
        valueBox.find(".icon").css('color', dataColorIcon);
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});
</script>

<div id="dashboard-container">

<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<style type="text/css">
table {
  margin: auto;
  border-top: 1px solid #666;
  border-bottom: 1px solid #666;
}
table thead th { border-bottom: 1px solid #ddd; }
th, td { padding: 5px; }

pre {
  white-space: pre-wrap;
  word-break: keep-all;
}

/* Hack to make prompt-tab scrollable again */
div.level3.tab-pane .chart-stage {
  overflow: scroll;
}
</style>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="column" class="section level2" data-width="55">
<h2>Column</h2>
<div id="score-comparisons-of-111-publications" class="section level3">
<h3>Score comparisons of 111 publications</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-e435ce5766af2e57e3b6" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-e435ce5766af2e57e3b6">{"x":{"filter":"none","vertical":false,"fillContainer":true,"data":[["61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","171","172"],["<a href='#61' title='Jump to individual results on the right'>Aikenhead 2011<\/a>","<a href='#62' title='Jump to individual results on the right'>Al-Hozaim 2010<\/a>","<a href='#63' title='Jump to individual results on the right'>Allen 2015<\/a>","<a href='#64' title='Jump to individual results on the right'>Allin 2015<\/a>","<a href='#65' title='Jump to individual results on the right'>Alzahem 2011<\/a>","<a href='#66' title='Jump to individual results on the right'>Apelt 2013<\/a>","<a href='#67' title='Jump to individual results on the right'>Aworanti 2014<\/a>","<a href='#68' title='Jump to individual results on the right'>Baker 2015<\/a>","<a href='#69' title='Jump to individual results on the right'>Berger 2012<\/a>","<a href='#70' title='Jump to individual results on the right'>Billingham 2010<\/a>","<a href='#71' title='Jump to individual results on the right'>Black 2013<\/a>","<a href='#72' title='Jump to individual results on the right'>Borruto 2010<\/a>","<a href='#73' title='Jump to individual results on the right'>Castagnetti 2010<\/a>","<a href='#74' title='Jump to individual results on the right'>Castagnetti 2016<\/a>","<a href='#75' title='Jump to individual results on the right'>Chan 2014 (Pediatr Surg Int)<\/a>","<a href='#76' title='Jump to individual results on the right'>Chan 2014 (J Pediatr Surg)<\/a>","<a href='#77' title='Jump to individual results on the right'>Chang 2015<\/a>","<a href='#78' title='Jump to individual results on the right'>Chen 2013<\/a>","<a href='#79' title='Jump to individual results on the right'>Corbett 2015<\/a>","<a href='#80' title='Jump to individual results on the right'>Cullis 2016<\/a>","<a href='#81' title='Jump to individual results on the right'>Cundy 2014 (BJU Int)<\/a>","<a href='#82' title='Jump to individual results on the right'>Cundy 2014 (J Pediatr Surg)<\/a>","<a href='#83' title='Jump to individual results on the right'>Cundy 2014 (Eur J Pediatr Surg)<\/a>","<a href='#84' title='Jump to individual results on the right'>Ding 2013<\/a>","<a href='#85' title='Jump to individual results on the right'>Dingemann 2014<\/a>","<a href='#86' title='Jump to individual results on the right'>Dingemann 2013<\/a>","<a href='#87' title='Jump to individual results on the right'>Ells 2015<\/a>","<a href='#88' title='Jump to individual results on the right'>Elyas 2010<\/a>","<a href='#89' title='Jump to individual results on the right'>Esposito 2014<\/a>","<a href='#90' title='Jump to individual results on the right'>Feng 2016<\/a>","<a href='#91' title='Jump to individual results on the right'>Feng 2015<\/a>","<a href='#92' title='Jump to individual results on the right'>Friedmacher 2011<\/a>","<a href='#93' title='Jump to individual results on the right'>Friedmacher 2012<\/a>","<a href='#94' title='Jump to individual results on the right'>Frongia 2013<\/a>","<a href='#95' title='Jump to individual results on the right'>Gallo 2012<\/a>","<a href='#96' title='Jump to individual results on the right'>Gosemann 2013<\/a>","<a href='#97' title='Jump to individual results on the right'>Graziano 2015<\/a>","<a href='#98' title='Jump to individual results on the right'>Guo 2011<\/a>","<a href='#99' title='Jump to individual results on the right'>Hall 2011<\/a>","<a href='#100' title='Jump to individual results on the right'>Healy 2015<\/a>","<a href='#101' title='Jump to individual results on the right'>Healy 2016<\/a>","<a href='#102' title='Jump to individual results on the right'>Heloury 2012<\/a>","<a href='#103' title='Jump to individual results on the right'>Huang 2015<\/a>","<a href='#104' title='Jump to individual results on the right'>Ishii 2014<\/a>","<a href='#105' title='Jump to individual results on the right'>Ishii 2015<\/a>","<a href='#106' title='Jump to individual results on the right'>Ito 2014<\/a>","<a href='#107' title='Jump to individual results on the right'>Jia 2011<\/a>","<a href='#108' title='Jump to individual results on the right'>Kapralik 2016<\/a>","<a href='#109' title='Jump to individual results on the right'>Kunz 2013<\/a>","<a href='#110' title='Jump to individual results on the right'>Landisch 2015<\/a>","<a href='#111' title='Jump to individual results on the right'>Lane 2010<\/a>","<a href='#112' title='Jump to individual results on the right'>Lansdale 2010<\/a>","<a href='#113' title='Jump to individual results on the right'>Lee 2010<\/a>","<a href='#114' title='Jump to individual results on the right'>LeeVan 2016<\/a>","<a href='#115' title='Jump to individual results on the right'>Liang 2011<\/a>","<a href='#116' title='Jump to individual results on the right'>Lishuang 2015<\/a>","<a href='#117' title='Jump to individual results on the right'>Livingston 2015<\/a>","<a href='#118' title='Jump to individual results on the right'>Mauritz 2013<\/a>","<a href='#119' title='Jump to individual results on the right'>Mauritz 2011<\/a>","<a href='#120' title='Jump to individual results on the right'>Mei 2011<\/a>","<a href='#121' title='Jump to individual results on the right'>Mullassery 2014<\/a>","<a href='#122' title='Jump to individual results on the right'>Nagler 2011<\/a>","<a href='#123' title='Jump to individual results on the right'>Narayanan 2013<\/a>","<a href='#124' title='Jump to individual results on the right'>Nasr 2010<\/a>","<a href='#125' title='Jump to individual results on the right'>Nasr 2013<\/a>","<a href='#126' title='Jump to individual results on the right'>Nataraja 2013<\/a>","<a href='#127' title='Jump to individual results on the right'>Nicolau 2011<\/a>","<a href='#128' title='Jump to individual results on the right'>Oliveira 2016<\/a>","<a href='#129' title='Jump to individual results on the right'>Oomen 2012<\/a>","<a href='#130' title='Jump to individual results on the right'>Parolini 2016<\/a>","<a href='#131' title='Jump to individual results on the right'>Parolini 2014<\/a>","<a href='#132' title='Jump to individual results on the right'>Peters 2013<\/a>","<a href='#133' title='Jump to individual results on the right'>Peycelon 2014<\/a>","<a href='#134' title='Jump to individual results on the right'>Pfistermuller 2015<\/a>","<a href='#135' title='Jump to individual results on the right'>Puligandla 2015<\/a>","<a href='#136' title='Jump to individual results on the right'>Reddy 2010<\/a>","<a href='#137' title='Jump to individual results on the right'>Romao 2012<\/a>","<a href='#138' title='Jump to individual results on the right'>Ross 2015<\/a>","<a href='#139' title='Jump to individual results on the right'>Ruttenstock 2010<\/a>","<a href='#140' title='Jump to individual results on the right'>Rynja 2011<\/a>","<a href='#141' title='Jump to individual results on the right'>Saldaña 2013<\/a>","<a href='#142' title='Jump to individual results on the right'>Sauerland 2010<\/a>","<a href='#143' title='Jump to individual results on the right'>Scholfield 2016<\/a>","<a href='#144' title='Jump to individual results on the right'>Sharp 2015<\/a>","<a href='#145' title='Jump to individual results on the right'>Shawyer 2014<\/a>","<a href='#146' title='Jump to individual results on the right'>Shawyer 2015<\/a>","<a href='#147' title='Jump to individual results on the right'>Shen 2015<\/a>","<a href='#148' title='Jump to individual results on the right'>Siddiqui 2011<\/a>","<a href='#149' title='Jump to individual results on the right'>Siminas 2015<\/a>","<a href='#150' title='Jump to individual results on the right'>Sklar 2014<\/a>","<a href='#151' title='Jump to individual results on the right'>Sola 2010<\/a>","<a href='#152' title='Jump to individual results on the right'>Symeonidis 2016<\/a>","<a href='#153' title='Jump to individual results on the right'>Tan 2016<\/a>","<a href='#154' title='Jump to individual results on the right'>Terui 2015<\/a>","<a href='#155' title='Jump to individual results on the right'>Thomson 2015<\/a>","<a href='#156' title='Jump to individual results on the right'>Thyoka 2013<\/a>","<a href='#157' title='Jump to individual results on the right'>van Dalen 2015<\/a>","<a href='#158' title='Jump to individual results on the right'>Vanden Berg 2016<\/a>","<a href='#159' title='Jump to individual results on the right'>van den Hondel 2014<\/a>","<a href='#160' title='Jump to individual results on the right'>Vernon-Roberts 2013<\/a>","<a href='#161' title='Jump to individual results on the right'>Wang 2013<\/a>","<a href='#162' title='Jump to individual results on the right'>Wayne 2015<\/a>","<a href='#163' title='Jump to individual results on the right'>Weih 2012<\/a>","<a href='#164' title='Jump to individual results on the right'>Wenk 2015<\/a>","<a href='#165' title='Jump to individual results on the right'>Wilkinson 2012<\/a>","<a href='#166' title='Jump to individual results on the right'>Wright 2013<\/a>","<a href='#167' title='Jump to individual results on the right'>Yang 2011<\/a>","<a href='#168' title='Jump to individual results on the right'>Yang 2013<\/a>","<a href='#169' title='Jump to individual results on the right'>Youssef 2016<\/a>","<a href='#171' title='Jump to individual results on the right'>Zhao 2015<\/a>","<a href='#172' title='Jump to individual results on the right'>Zhu 2016<\/a>"],[0.701986754966887,0.557377049180328,0.832989690721649,0.82,0.289473684210526,0.549060542797495,0.829831932773109,0.475728155339806,0.331428571428571,0.517857142857143,0.604105571847507,0.201970443349754,0.558282208588957,0.4,0.364705882352941,0.452173913043478,0.295180722891566,0.658227848101266,0.708423326133909,0.669117647058823,0.0470588235294117,0.114754098360656,0.0240963855421685,0.352739726027397,0.709677419354839,0.560975609756098,0.428571428571429,0.188376753507014,0.60625,0.210855949895616,0.316455696202532,0.382857142857143,0.36768149882904,0.605427974947808,0.48936170212766,0.486257928118393,0.617408906882591,0.357142857142857,0.625,0.480769230769231,0.719334719334719,0.62929061784897,0.184563758389262,0.658947368421053,0.64,0.362204724409449,0.118367346938775,0.537671232876712,0.422018348623853,0.766233766233766,0.488151658767773,0.427272727272727,0.719334719334719,0.464285714285714,0.311224489795918,0.0939597315436241,0.232227488151659,0.468503937007874,0.599576271186441,0.557377049180328,0.558823529411765,0.224137931034483,0.5,0.405867970660147,0.181818181818182,0.62707182320442,0.55,0.562753036437247,0.318181818181818,0.454545454545454,0.826552462526767,0.716386554621849,0.609638554216867,0.298701298701299,0.658227848101266,0.562753036437247,0.25635593220339,0.493297587131367,0.172413793103448,0.559183673469388,0.704595185995624,0.136986301369863,0.386363636363636,0.746478873239437,0.753424657534247,0.479338842975207,0.390977443609023,0.209205020920502,0.599576271186441,0.355748373101952,0.188841201716738,0.635135135135135,0.792838874680307,0.571428571428571,0.292134831460674,0.659663865546218,0.584615384615385,0.643956043956044,0.64,0.489189189189189,0.10989010989011,0.803874092009685,0.691075514874142,0.466666666666667,0.478540772532189,0.359050445103858,0.262295081967213,0.51497005988024,0.47741935483871,0.346774193548387,0.52],[0.814814814814815,0.703703703703704,0.888888888888889,0.925925925925926,0.555555555555556,0.703703703703704,0.888888888888889,0.777777777777778,0.518518518518518,0.703703703703704,0.814814814814815,0.555555555555556,0.703703703703704,0.666666666666667,0.555555555555556,0.740740740740741,0.518518518518518,0.814814814814815,0.814814814814815,0.814814814814815,0.666666666666667,0.481481481481481,0.444444444444444,0.740740740740741,0.814814814814815,0.703703703703704,0.703703703703704,0.444444444444444,0.740740740740741,0.481481481481481,0.555555555555556,0.555555555555556,0.62962962962963,0.740740740740741,0.703703703703704,0.666666666666667,0.740740740740741,0.703703703703704,0.740740740740741,0.777777777777778,0.814814814814815,0.777777777777778,0.666666666666667,0.777777777777778,0.777777777777778,0.666666666666667,0.407407407407407,0.814814814814815,0.740740740740741,0.851851851851852,0.703703703703704,0.740740740740741,0.814814814814815,0.62962962962963,0.62962962962963,0.444444444444444,0.555555555555556,0.814814814814815,0.740740740740741,0.777777777777778,0.814814814814815,0.814814814814815,0.703703703703704,0.666666666666667,0.481481481481481,0.814814814814815,0.703703703703704,0.703703703703704,0.62962962962963,0.62962962962963,0.888888888888889,0.814814814814815,0.777777777777778,0.555555555555556,0.777777777777778,0.703703703703704,0.518518518518518,0.740740740740741,0.407407407407407,0.703703703703704,0.814814814814815,0.740740740740741,0.62962962962963,0.851851851851852,0.851851851851852,0.740740740740741,0.666666666666667,0.481481481481481,0.740740740740741,0.592592592592593,0.481481481481481,0.777777777777778,0.888888888888889,0.814814814814815,0.740740740740741,0.777777777777778,0.777777777777778,0.777777777777778,0.777777777777778,0.740740740740741,0.555555555555556,0.888888888888889,0.814814814814815,0.703703703703704,0.666666666666667,0.703703703703704,0.62962962962963,0.666666666666667,0.777777777777778,0.666666666666667,0.703703703703704],[0.521739130434783,0.702702702702703,0.246575342465753,0.476190476190476,0.428571428571428,0.440677966101695,0.840579710144927,0.440677966101695,0.266666666666667,0.440677966101695,0.476190476190476,0,-0.03125,-0.166666666666667,-0.0206185567010309,0.421052631578947,0.405405405405405,0.405405405405405,0.405405405405405,0.828125,0.333333333333333,0.382022471910112,-0.166666666666667,0.0983606557377047,0.467741935483871,0.16304347826087,0.12,-0.0694444444444446,0.541666666666667,0.0833333333333333,0.645161290322581,0.371428571428571,0.440677966101695,0.431034482758621,0.803571428571429,0.17910447761194,0.30379746835443,0.166666666666667,0.661538461538462,0.607142857142857,0.443037974683544,0.371428571428571,0.0704225352112676,0.541666666666667,0.541666666666667,0.459016393442623,0.380281690140845,0.241379310344828,0.0149253731343283,0.30379746835443,0.214285714285714,0.153846153846154,0.0434782608695653,0.290322580645161,-0.0153846153846153,0.126984126984127,0.185185185185185,0.241379310344828,0.421052631578947,0.0149253731343283,0.816666666666667,0,0.256756756756757,0.126984126984127,0.266666666666666,0.333333333333333,0.0434782608695653,0.440677966101695,0.421052631578947,0.661538461538462,0.12,0.443037974683544,0.371428571428571,0.102040816326531,0.142857142857143,0.443037974683544,0.333333333333333,0.5,0.0149253731343283,0.371428571428571,0.514705882352941,-0.137931034482758,0.214285714285714,0.541666666666667,0.857142857142857,0.521739130434783,0.645161290322581,0.266666666666667,0.702702702702703,0.290322580645161,0.166666666666667,0.56,0.813559322033898,0.352941176470588,0.12,0.333333333333333,0.571428571428571,0.582278481012658,0.337349397590361,0.554054054054054,0.266666666666667,0.676470588235294,0.440677966101695,0,0.236111111111111,0.377358490566038,0.5,0.3125,0.410714285714286,0.639344262295082,0.476190476190476],[0.727272727272727,0.818181818181818,0.545454545454545,0.727272727272727,0.636363636363636,0.727272727272727,0.909090909090909,0.727272727272727,0.454545454545455,0.727272727272727,0.727272727272727,0.636363636363636,0.454545454545455,0.363636363636364,0.181818181818182,0.727272727272727,0.636363636363636,0.636363636363636,0.636363636363636,0.909090909090909,0.636363636363636,0.545454545454545,0.363636363636364,0.545454545454545,0.727272727272727,0.363636363636364,0.454545454545455,0.363636363636364,0.727272727272727,0.454545454545455,0.818181818181818,0.636363636363636,0.727272727272727,0.727272727272727,0.909090909090909,0.545454545454545,0.545454545454545,0.545454545454545,0.818181818181818,0.818181818181818,0.636363636363636,0.636363636363636,0.454545454545455,0.727272727272727,0.727272727272727,0.727272727272727,0.636363636363636,0.636363636363636,0.454545454545455,0.545454545454545,0.636363636363636,0.545454545454545,0.454545454545455,0.454545454545455,0.454545454545455,0.545454545454545,0.636363636363636,0.636363636363636,0.636363636363636,0.454545454545455,0.909090909090909,0.909090909090909,0.545454545454545,0.545454545454545,0.545454545454545,0.636363636363636,0.454545454545455,0.727272727272727,0.727272727272727,0.818181818181818,0.454545454545455,0.636363636363636,0.636363636363636,0.636363636363636,0.454545454545455,0.636363636363636,0.636363636363636,0.727272727272727,0.454545454545455,0.636363636363636,0.727272727272727,0.727272727272727,0.636363636363636,0.727272727272727,0.909090909090909,0.727272727272727,0.818181818181818,0.636363636363636,0.818181818181818,0.636363636363636,0.545454545454545,0.727272727272727,0.909090909090909,0.636363636363636,0.636363636363636,0.636363636363636,0.727272727272727,0.727272727272727,0.545454545454545,0.727272727272727,0.636363636363636,0.818181818181818,0.727272727272727,0.454545454545455,0.545454545454545,0.727272727272727,0.727272727272727,0.636363636363636,0.727272727272727,0.818181818181818,0.727272727272727]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th>Ref.<\/th>\n      <th>Author & Year<\/th>\n      <th>PRISMA κ<\/th>\n      <th>PRISMA agreement<\/th>\n      <th>AMSTAR κ<\/th>\n      <th>AMSTAR agreement<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"t","order":[[0,"asc"]],"columnDefs":[{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":4,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":5,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[2,3,4,5]}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render","options.columnDefs.2.render","options.columnDefs.3.render"],"jsHooks":[]}</script>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
<div id="score-heatmaps-prisma-amstar" class="section level3"
data-height="720">
<h3>Score heatmaps
(<a onclick="data = 'data:image/png;base64,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'; $('#score-heatmaps-prisma-amstar p.image-container')[0].style = 'background: url(&quot;' + data + '&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = data;" style="cursor: pointer">PRISMA</a>
/
<a onclick="data = 'data:image/png;base64,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'; $('#score-heatmaps-prisma-amstar p.image-container')[0].style = 'background: url(&quot;' + data + '&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = data;" style="cursor: pointer">AMSTAR</a>)</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><img data-figure-id="fig1" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAB4AAAAQ4CAIAAABnsVYUAAAACXBIWXMAABMRAAATEQE5YH/wAAAgAElEQVR4nOzdd2ATZR8H8Oe5y05XuksnLS177z0UlD1URECWiigqKspwIL4qQxFBUHGDoOJgI6gICDIFZMumzKaTjqRt1t29fxRqW9L2kibNpf1+/iPkLs/d8+1zT55cfqGCIBAAAAAAAAAAAAAAAFdjPN0AAAAAAAAAAAAAAKiZsAANAAAAAAAAAAAAAG6BBWgAAAAAAAAAAAAAcAssQAMAAAAAAAAAAACAW2ABGgAAAAAAAAAAAADcAgvQAAAAAAAAAAAAAOAWWIAGAAAAAAAAAAAAALfAAjQAAAAAAAAAAAAAuAUWoAEAAAAAAAAAAADALbAADQAAAAAAAAAAAABugQVoAAAAAAAAAAAAAHALLEADAAAAAAAAAAAAgFtgARoAAAAAAAAAAAAA3AIL0AAAAAAAAAAAAADgFliABgAAAAAAAAAAAAC3wAI0AAAAAAAAAAAAALgFFqABAAAAAAAAAAAAwC2wAA0AAAAAAAAAAAAAblGrF6D5iws6KShVD//ZbPf/uX/faaOgjP+jG+3/v/eypR1cMfvxge3rRwX7qJTagIik9v0ff2v10Sze0y2rUYTUNaNjo0b+nCEQQvjLH3RRUmXXRVcqPsnc+fntFVTZ+f1Lru8M06FXmwd3e/+0xeV7Fsf2z2uN5ZSNenpHhS0Q8zTz5nGBDKWUUXZacJEr50ncufntFZRSygSO2+zZP2Lzxkf9GTb6mZ1WjzajIqXi6halT4Kn0wjgTSy/TwxnaRkMq/QNiW/d94l5my8UlLelkLF/1dJv9qQ6ckVx/2gA7lNOj7tjyHU+ls5ALGsgl8cSmazxvG72WLVM8qm7v/pg0U/HjCJfDZmsgTBOgkfZGYWqmEmhFuMuvNdRTojqoZ9Mdv/fdvrt1nJC/UZvsP//3slyZc3klv4MJYRQVhUQVidcp2YpIYRQeZ373z+c5+kG1hR8xrpHI7Vd3j9vEwRBELhLCzsriKLLB8lchZvZzs1rJyeKTgsuVvw859qUtWZUuF/3Redsrt+3CNYjrzaSESbyqe3mqj7NtGmsrii1io4LLtg/Vbbz73ZQFD1JN3ZTxX/E5uvbFz87pH29iAC1Uu1fp1H3Ua9/fzyHF3FQ4pg2jPajTNTkHRaX7dK1ysTVLcqcBA+nEcCbmH97IowhVBFQJ+4/USFaGSWEEMIEdHxzv92rN3flw+4qWeLLB6yiX8vNo0H+hfVvj+nRINxPrQmMbTVwyrJ96eJeqJINTRsfDaAVTHflbeb869HBxskD53NP//S/sfc0idJpVNrguFYDJn+4M6WC3iy3x90w5Docyypcar00lkXM13csnjywbXyIr0qh9q/TsNuIGcsPZbphluc4Jw9c7BFV2uOujqWjmaxK10g1k+7m5qEs/8LmeU/c1zxGp1EofcOSOj308pcHSr2At80enb58C4Jgu/x5/2CGKHouvS4qlFLNpIgNLX8+G8NK8totOHng4o+o2jPvWCar1jVSzaRgSv51waT7W8QG+WiD6rboOfL1n88Y7ey+kq7xmGqaUgrljUJVyiQWoGvXAjSf9dvk+gpK2eAOTy3bcTG3KDPW3Eu7v3q+W5iMUjZm/MYM1y271WKm/dMaKsLHbLgzz5bEArQgWI7OaqYIffiHdE90sssXoCnLslTRyf4KNHdxQScFZVmWVrYAXXB0Qa9glhLKaCMatGyeFK6VUUKopsET6266qBekvgBdNq7ueZGyJ8GjaQTwJkXvFmTN3jhWap7Im/R/fzmhiYYSqmj55vG75pD8re3PNZRT1pEFaHeOBnzO3jc6BjCEMtrwBs2axOkUlFB5/Mjvr1QygxWxoWnTuCC5zC6WoYQquyy85LEVP2cPnLux9olGWkooVQTENG5WP1zLUkJlEQOWnbF/Tauwx10+5DoWyypdar01loIgWM4uGxAuu3PcrZrEBaooJVSZMOanG55dg3b2wMUekbged20sHcpk1bpGkpl0NzcPZfytP2e29WMIoQr/qAZNG8eHaFhKqDzmga/Ol5g/e9fs0cnLtyAIlrOLewUwhIhegJZkJsVtyGd+1U9FKWXuuoCr288948nYO3vgIo/II5l3KJNV6xpJZlLgb+16rYOOoZTxiWjQrHFcoJISwui6zj2SX/JJorrGA6ptSilUNApVIZNYgK5NC9B89uYJUSxhgnt/cKLgrv8t+Oet9hpK5S3/d1L8nVJgH5+6amigrN6Le4qjI5EFaIFL/rCHWtn67VMe6GSXL0Ar2nbvpClnBZq79EEXJdV07N5WUfECdOHBmU0UlCqTRn15PKdoP/nn107tFMgQJnjoyhSXXDGlvQB9d1zd4u6T4Mk0AniTct4tCIIgCJZjb7SQEyJrPvv47aknl31x36+rP37zyXvjNZQQ4sACtFtHg/w9LzWUUya45zt7M22CIAgF578dk6igTPDgFRWu9zi9oSAIfNbWJxNkykYv/JnrscUKJ9vPJX/Sx59SeeygBX+lFvVtwcV1UzsFMVTdfs7JEpcTkT3u6iHXkVhW6VLrxbHkbnzR149SRf0x35zOKzpI883tb/QIYghTZ8JmT37r0NlYijwi0T3u0lg6kMmqdY00M+lubh7KTHterCejTFCPWduuFRZteevYl6PqySn17/dFiRfwqtmjY5fv/5iOz+3kU3RHqrgFaGlmUuSG1kMzG8ioetDKbDc0viqcPnBxR+SZzDuUyap0jTQzyaf+MCKcoYp6j3xx++JUmLzu6WZqStUd3i1eUhfdNdXO7VPK/1Q4CjmfSSxAu3kB2lqYb3Lrx3ZWs8kq8j2V7fzCLmpKfXotvWS3SXz68oE+lMiazrIzHLmhPa5QzS8nFnd5UVeVrP70g//9MUtlAVrgbizrrWbjn99d/R+ruHwBWtX/3QX3a6m9s8UlL+qmpNr7F8zvr6pwAdr0+8QIhrD1puzKL7X9tWV9fChV9lhy1V5HOBo8xxegbXm5Rqej7Vjz7MTVxe0pYuckeDCNAN6koncLguWv5+PYkpMVw3dDVSW/Jil+AVrUaOAk/tbqBwMo1XRfXPJO5LytT0SzRN7ifyfLnSs5vaEgCHzGpglxMlXL1w7mV/As93K2/dZDMxvKCBs76fdSS2F8yorBgQwTNm6TofgxsT3u4iHXgVg6d6m98yzvjSWv/6yPijKhYzaU6kTrkdcai5gOuZOzBy72iBzocVfGUnwmq9Y1ksyku7l7KLP+PaOBjLCJL+0veVb59C/7qinVDFmV89+D3jR7dOzyfUf+wddbqdmQ+8cMqMOKW4CWZCZFb2j44UEtZeuV7nvPq8Ifo6gj8lDmHcpkFbpGkpkULH/PaCijsvov/lWy5EbhjsmxLJG3ePPE7XV38V1TvaphSnlHZaOQ05ms1T9C6CDboZkN5VQ95FtDqYctv08MZ9ngCVtvV+Hmb3zUS8loH/7xyva3BtcP9vVRK5T+kc36Tf3uTAERjP+unjG0TVygVqXWxbQe8srai6ZSezNf37F0yrDODeroNEqlJiCyYdeHXv7iYEaJ35K5vf8RP+dc/PnFe+oGatQKmdI3omGvCe/vTLFV0H7u0rofDhZSXf9JI+vareRDg4ct2LRh/Zo5A0KK6ygKead/fHPMPU2jArUqjS6yUfcRM1ccziz5o2/i2yMY/v35f2PvaRqt0yiU2qC4Vv0mLdpxs/SPstnSD3zx8kOd60f4a7RBMY06PzTjq316qxteTmRvimz2Xaf659UHrVF9B7SU3/2ffO6x5VMHtY4L0qp9guu2HvjsR7v15e9NfDvFnD1CCGEi7h/Qlr368+q95f4sX8FvEyNZKm/86pEygSrcNimq6D+sxKkz42pMaP8Humqsh9duSC79e0v8jc3r/7aouwzrF1bxIMdfP34yk2dC7xnQQVNqz3W692woE2wXz17minYo/u+u4MLGOeN6NY4M0Kj9Ixr2GDt3yxVTZT+8wF9d3E3J+I3eYLZcWvPSfQ2CfOKe22lxdNhxfFgg5cS1vPYQkTETeRJEpBEAKmOz2gghAn9nGFR3f3Xd5s2bN2/evPGzCQ1k4ndkbzQQsr7up6LyBjP+Lh5KuJSNkxprGNa//YydWaJ/Vabgzw1/5BJll5HD65YYln17jRxUh7We3vxLub8n6/SGRLi1ZcYzK/SNX/zklXaa8p5UnsrnYyI52X4h4/Dfl21MQI8BXX1LPk4jBj3QRSFk/Lppf/EMQGyPV+uQWzKWYi+1dnlzLG2Xzly0CrL6rZppS27MRsdFs0TIy81z9FeZPB1LsUfkSI9XXyxLZrJKXSPNTJbD05kRP5TxPE8IlSvkJcv5U4VKxRDC27gSLa45s8eyl+8iht2zJrx7PGDooo/Hxtl9z343aWZS7IbctQvJFkGWUD/egRlL+TydeSL6iKSY+dKZrELXSDOT1sM//HzeJms94cmOJcd+Vff5hy5fubhxcr3bf3Hiu0YUT2fSkSllkcpHIacziQVoN7GeeHfI0Nm/ZoW1vbd3x1hZ+qmtC8fcN/b1qfd3GfXhflNM245NQ203/9kw75FBs/YVL0GbT344sE2f5z5cfyhVVqdh8ybxAYWX9/68YGLPe17Zk196/3z6luf6jly01xDW+p4+3Rv5553b+fXL/e57tezz/iNk7919wkblLXt0Ke93eqhvUo+BgwcNaFunKGZ86uZnurQfMXvlzgumwKSmDcO4K3t+nDe+c/vRqy6VWdOqvD2Gva/37DD8jZV/XraEJDVvEqvKOvHrpy/e33XSxuIfRTWdXvZA664TF6w5eFMIS6wXaLp6cM38x7u3G/bhUaMbXk4UZ/bDp/y+9ajNr3P3u9efhby9r9/bdcIHv5w1BcWGKwxXj25e+uy97Yd/eb7K67aizx4T2aVrItX/tuWf8l5T0/3hwZGs7fyG9SdK9XPBrh836gVFy9GPtpC77AxXDRPW/4GuauvhNaVXoPmbm9cdMItYfyZE1Wjws8+/MHVYkzLXVS5dn8ET6ufvW+LPpfLgCbl7Z/duP/TVFTvPpPOBsRHsjT0rXx3U8aEvL1ayDHz7BVLXT+o9culRpmGP+1pFiJx0OtA8exuVH1c77REVMwdOQuVpBICK5R/YuC2VI2xcvTsfLrN1Wt/fv0jPhrqKfpmvtApHg+In6Tc/d98jn51VtJ22YcvcnkFid2+7ePy0UWDrtm4VXGoTefO2zeXUdu7Ev+VMYJ3eUMjd/vrzK24mPPXhK+3VIlt5hwPzsco4237BbLIIhFCWKXuKFSolS/hbZ/5NuXPdE93j1TfklomlQ5fa0rw6lvIO807mGbO3TY4rNRnJO3zgtI3KGzZz5PMhScRS9BE50uPVFMvSmaxK10gzk3ZJIDOihzJZ88GDE+XcuRVzvjpluP1WwpLy+1sLfyuggX0evMe/xKY1ZPZ49+WbECLc+m3aYx+eDRmxZMkjUWJXaqSZSdEb2pIvJNvY0HqhKevfe3HC8H697xs86tm3V+y96cRiqwQyL/qIJJj5spl0vmukmUn+xoGD1zg2pnOXMvdjMtqQmNiY6KDb00VHuqZSEsikI1NKInYUcjqTDt4xXaPcLsHB+EQk1LMrJkhJ//sKQtGt+KrBq0qXBTP/9kQYwwSN33L7u1rc9aU9FYRQNnLQ4sPZvCAIgk2/dmwsSwih8oSRy/8tut+/8OzS+3QMYeu+sOf2rf3GdaMCKVXUf/yny3cqNJtTtr3cWk2ZwLGbCoVS+ydU2eCxHy7efmLB+c+HhjOECRq7+c7zyrIef6OZjDDhE38X+X0/Xv/9Q6EMYcL6vLNLX9RELuvQkqExMkr9ei25U/NAXHu4q0t6qigT2GvugayirwZwOQff6upH/yufYDo0q4WKMkGdX1pz/vb39QqSN03rqGOoPOn5P42ufTlxvSmi2XYY1ozwp4qOpZ9QVIKDEMKE9n7nzxSzIAgCn3958/TOgQyhvj0WXyh6gTIlOESmTuTZu824ZoQfVXR6v/wqH6adz8ayRNb09aMlvptj/GVCOEPVPZZc4Zw7M64vwTHwm2wu5bP7NFTZ+f0SX0Thbnxyr5qqey+7wWV/M7DiEhz22a5/MzSUIWzC87tvR0rc351h+zMJMkpV9R/98ugtmyAIgjXj7yVDY2SUEFJRCQ7uyqKuCioPjYhuOXl98n9/xY4NOw4PC0I5cS2nPeJi5thJKE5j+U0EqPXsfl/Slp9+6eDPb/SNllNCVW3n2CnDVjTPEVuCw+5owGd+1VdJZPWnH7QKAqf/5ZmmGsr4t5+5M9OxojzmX8YHMUR5z8c3y2xn3jYpgiGKrovKKVDl7IamQ681V7ARI3924gdSxM3HxHH6wAu2Ph7OEFn9aftLX79yNk+IZAmRNX71iBM9XvkEQDxnY/nfc8teau2pMbHkc5L/OfDXtnVfvT2uTRBDtS2mbs9yqLWSiGVJjh9ReT3uslg6l0lHD0SambRHEplxYCgznf9+UisdQ+VBSR179+/bo0WUllJ1/OAF++7qEFcOZW7lYCb5tHVjYlg2bvzGDF4QLDufiRZVgkOamRS7IZe8qKuCUKVWIyu1OkZ9mz3x42XHCoNKIvMOHJEnMu9AJqvQNRLN5B+T6jBE0eujy1d+f2/CPY3r+KtVPiH1Ojw47evDmaU3caBrKiaJTDoypRQ/CjmXSdwBTQhv1F+6aNe1LLOz93JSn/vf+vTZ1kX3GrPhA8YPimQJE/TAvKVjGhbd76+qP3bCvRrKZ6VnFn3ewGfbQrv1H/z0W7OG1b1zr44iosfoAYksn5+ekV+6KWzdiZ98ODzh9hPViWOnjoxjeWOq3lBOk4Wc7FyBUK2vVtxnS9zFVR9uzCAhDy5eObNbeNFHV0xgm8lfLxsXxeTt/vjLf0rdzFhJe7hLZy9YBVnzBx5tG1j0eRPj33by/PdnvTp9cBIVCCG5WxZ9fMISOHjRz+8OS7z9fT113IC537/TS2u7uPLL7fkufTlxnNoPl3zqbAFRx9eLtPPnxYQ8sHjVzO4RCkIIoZq6/ef8sHBAIDXs+fTrY6JukbXPsbOnrJsYw1rPnjhb7sdVyk7Dh8WytjMb1p8ubpVxx4+b0wWfe8Y+FMO47AxXHRPef1gXteXw2g1X7nxwJ6T+sm6fSdVpaP8IZ0Y4IffYFxPuf2p9BhM78t3pXUoX1qwweELm+iXfXObkLaZ///mEFjqWEEJkwW2fWf75YzFi7mYWrLd8hy99f3CcqvLn2uXwsFBxXMu2R1TMHD0JxWl08pgBag/biTdbyGkxmTY0of2Db269blPEDFr49QuNq/jV1QovXoQQLm3r8/cN/+i0vP2MDVve6SH6RpXbjTcaCuxOQqhWq6VEyDcW2B+nnNuQT/5yxuKTbPsXZw0JcayhxNH5WCWcPnB19/GjE2Xc+aVPvrDmUsHtnaXv+2DMU9+kcIQIJpMzc9TKJwCOcjKWFV1qS6o5sbTseKVbx669h054bfmRgqRxX62d2yvQkdZKI5YlOXZEFfW4i2PpaCYd7BqJZtIOaWTGgaFMHhBVLz5UTaxZ5/dv+2Xrn8du5BOZLrZBfIim7Fl0/VDmViIzyd9c/czT36bUfWLZ+wOCHQiORDMpdkNb8vnLNiJYZQ0e/2r/lWyTpSD97B8fTWjpl3/ii3EPzztmsbdz+6SReQeOyHOZF5VJ57tGopkU8nJzBSJkrHu8U99pX/91g4lIiPEtvHLw53cndGk/9odrJQpYONA1FZJGJsWPw46MQs5lEgvQlf4IoXPY2FYtS3QZowvSUSJr3Km9/38PKoKCfCkpDgkT9eDCdZvWffBQdHGv2HIvbv/hj2Q7tVyY0N6DOpUsq8b4B/gxhBBSXoipr58vJUK+UVzMhZx9u45ZqK7v6IGhpWrf+N8zalAd1nZpz54bJQsTVdIeNr5BopJa/5oz7tWVf13MthJCCNV1fHz2W/+bNjCeJcRyeNvOW4Kmx8ODwkslnYm+v19zOZ97cO/pEuuzVX45kZzaD3fz6g2OCYkItfP/TGC/MYNKnVAm8sHH+usY28W9+1IcrwN0m2Nnj7BhEaGMkH/jWvmVlhTthz8Qz9rObNhw5nb88v748ZdMEthv7OBQ6roz7AI0YsADXdSWw2vurEALaVvW7SlUdhw2oI6jAxyXefir57o3aj/xm3+FpJGfbf10WJkTWnHwLId27jEK8g7jxjdXltzMr+fYh+wXXi+DCe3Vt42y8ueVu7mjw0LFcS3THnExc/QkFKdR1CEC1GZUEVAnroS6des1bN3rkVdWHTq57qnGzn5wVazC0YBL+23q/Q8tPZFPtG3HTuxaYnXGdnBakoxWQNFu3lmOEOH2OFTObJbnyivY58yGhu3vvvtnfvjDM59IcuKCJG4+5vYDV3eatWJ2l0DTyU8eqh8altiiZaOooKguU3foenWJZAlVqZUOL62LmgA4yPFYVnapLf3kGhNLeetJn3795aeL3p7yQHPtxeUj2/Z4/c9bDvSCRGLpzBFV2uMujqWjmXSwa6SaybtJJDMihzLh1rYXevZ5eW1a/cc++vXYlVvGPP25Pd/N7EH3vPtQ14c+v1D6Ph3XD2VuJSqTXPJXTz63JjNx8mfz+jhQPYtIN5MiN6R1+s5cuPiTtXt2fTyuQ2yAUq4OqX/P01/8+tUjkUzBkcXvbzHY394OiWRe5BF5NPOiMul810g0k1aTiROI9eT2gyGPrzyZfuv6mZPnUrJv7J5/f7j10reTnlp+/fZqgkNdUyGJZFLkOOzYKORcJl1S6R3sYO8usUKoonQh87vxOac2f/vTtoPHz1y4nJx85Xq60SoIhJC7lqSY4LAQxxbX2PDIMJaezr50OUsgEfabIWTs/3b131lMwv0T+3I3UmwCG1e/XtnXliU0SGBJSsr1FI4UF06rrD1M7GNLPjw4/MXvts8b88d8VhveoHWHTl3v6f/Q8P7NQ2SECIZrV7N4wbxmhD8dYWd7mpGWwf2X16q+nFhO7YfPNxYINEKttnOS2boN7jqhqgaNE1jyT1pKGk9inPpIyMGzR4hao6aENxqMPCHlvDeXt3nogcQP5p1ev+HMq02bsCT3jx+33iLh48f21VHiujPsCjS8/9BOqm1/rd1wZcoL8YyQvnX9X4XKjkMHlPORq31cxoHPZj43a8XhTE6bOOC1ue9NH1bfp2wXVhw8IS8lxcAzgQ0blb3zWt6oWSM5uVxpI9jwyPAqrN47PixUHNfS7REXM8dPwp00OthwgNqHbTBly5HZzd01xFY0GnCXVrzxMfWLqxt8NXnHm9N+HLJ6xJ0VJCas4yNPTkov/xNUNraljhLWx0dFSEFBfoFA/Eq+glCQny8QqvUp5/tZTmzIX1v17sprtOErz9zn79Cb+JL7qHQ+5u4DJ4T4tn/1t79bLZn7waqtf184c04d0XjAy1NmvxT1RZvtfzF+Af7OTBlETAAc41AsRV1qS6k5sWRiuo0c240QQqZMn/LF0HZPbp735PwBp+a3d+BeF0nE0qEjEtnjro2lo0Olg10j0UyWQxKZETOUWY+8//zH/5rDR3yz9bMHb9+rk9T5kXc2JMk6d35ry4xXfh7244gSt0m6fChzKxGZtJ3/+PGXtxoav7T+7Z6OXrkkmkmxG8rrD5hc/66taejApx+OW73wyt5dx61DuogfKCWQeXFH5NnMixonne8aiWZSplSylFBF+9dXLx11p9S/LKzLy8vn7q0/fuMfX/6YPH5qAuNo11RGApkUNQ47PAo5lUksQLuCaz56FXL3zxkyZPauDME3tk2XTp2G3vdoQmLjFoG7nx48/8xdz2YY6ti1iYZ06lKf3X7yyB+7sieOsP/VMsPOD56e8lNB3RfbTuxbVFvd3oswDEMI4Ur/YG+l7VE3fmzl8aGv7Niw/tcdf+3df/Dg+i92r/ti7qvNJ63YvGRwHY7jCGH8Wg1/vJe9UudU2TK2ZKqr+HIVrUyW7k0n9kPlCjkhVqvo7yIwLEMIkckdu92+ZDsdPHvEarURQhUKRQUnUdZy+IMNFrx9av2GczObNDT8/uOv2TT22TG97vxirPNn2OWYiIEPdH5x+19rN16d8nxc1q9rdxUo2w8dKPqXO4hwa++8Rx5+Y1uKENLu8aXvvvFEt0hFOS9VYfCK/jTsUWrUd38iZYcDKbA37Dg8LFQW11LtERczh0/CnTQ62HAAcLGKRgNBoLouszatf+zyE63GrVsz/ZVfen85oGjuzcQNffOjoZXu3RYZE8WSM/obKRwJLzn5LNSnZAtUGRkdan/sYB3e0Hbiy092FSg6PDahop++qYC4+Zi7D7yIOr7vtM/7TivZulsrktN5qklIdOpKK2YC4B7iL7UleXcseZvFxhFGrpCV2o2s7qgn+8/YsuLK34fT+PYiZyvSiKUjR+RAj1d/LKvQNRLNpL3WSCIzRSobyvhru3ZetNGg+0cPKPVNUaJuMerh5nOPHv5rxxHriD7/JchzQ5mbGPb/vjeHKPy3vdR7953HhLwraTyx/fP+4M6rFLIGk1Z+OTbO0fee0h8nyyWLqxcnI5ezb2WL/pKwlDJvR6kj8ubMV941Us2kLkhHiTmpz/31Si2D0pDuvZrJN+49f/qcjSTIHO2aikgpk5WNw7mOjkJOZRIL0FVmvnUrXyBV/uor4f5d+uz/dmWFDv7o1xWTmhZ/pMGd+sdFg4ys0ZChjeacPLll6dfnH5xa/+6uF3L+2PBnvsAEde7WVM6YIyNk9NjV85ctpGGpn4/nki9c5ggb4cStmrLAhn3GN+wzfiYhQkHKkc0fvvTMe7uWTX576H2fdK0T4cMIlsQH33rvAU3le6rqy91bTvLt9mZF+7HT8UxwWDDD59zKsTMic8lnL5pJg1JHaDn37yWOyqPjIsWf0NLtpP6OnT0+51YOT2XBoYEVDVGyZsMfajz/jRPrN5yfHn78h99ymAZPj+lU6v5tBxvmJQYAACAASURBVM+M2zARA4Z1enH7nrUbrj4zes+6XfmKdsMGRoudExQcmTOg3+sHzHGDF6z6bEqnEKc/U6a+UVE6hr919kwqf2+pm9n5G8nXbK78jqCrhp2K41qayJg5ehKK0+hU8wHAZSoaDZg6o7/eMKtzIO2w4H+rdk7etvLF2aO7LenlJ37vsoRmjbT0VPLREzlCyR/vtp46esoqyBo3a6x20YaWg998+69N2e3hB+y+Ua+ca+djTh844QqyswxWVqsL8im5kF54cPchC1F26tjKmc/txE0A3MDZS61Xx9J25LVmneYnt13w756pCaXXObU+akryCgsKxc4NpBFLB47IkR6v/lhWpWskmsm7SSMzIocyged5gRClRl02KVSpVlFC+NJ3PnlsKHMv3nD16IGrZR/NTf7nQDKR2waVF0qJZlLchkLOqd+3nc7zbXTvfU1Lf+efz83O4QkTIv77ndLIvMgjkn7mq9I1Us1k/cb15TTVdvfCeNHZViiVxPGuqYg0MunIlNKBUci5TNaoMbtaCEaDscRpF3J2bNkrevZYkcKT//xrJX69H5/QtOQN9YXXr6aJL/ZVIVnzp6YPDKIF+996bM7BvLvabNw//39rM3k2+oEx9/oSquvYrZlcyNr67S+ZpZ5q+PPb9dc5WVzXrg68s+NOvd8nsW69e+Yfv1Mxh2rqtBn+v9cfCGf4zOQrBkHRpkcnLcnfve7X0i/H3/xmRGKdyOYv/WkWf6SVv9zthyvpTdH7KUUWnxQvE7KvX7/7HBP+1taVm9JLPi7o13y5MUtQtLq3W/lf5KgsdQ6ePe7G1RscG51Ur+LFarbRgw81k1uPr1t/cPOPf+TKW44efed7Os6dGfdh6gwY1lFp+XvthmNb1+00KtoNHSi2mgl3dukz7xwwBg/4ePtPL1Zh9ZkQQuStenT2o9b9y5efLPWjDJaT331/pCq/GOG2YafiuJYhLmaOnoTiNFbxQACgiioaDRjfiAg/Sghh4x/74NWOGu7iZ8/PPVBAiPi6dT49+nX3IYV//bwptcT+zX+v3XSVkyXe37fcYs0ObmjZ/8PaK7yi/dBB4r8GU5rI+ZjbD7xg69NJEeHRgz+/XuKNjqD/+dP1GYJP94cHOfwzB4SIngC4mvOXWq+OJVuveWMNtZ7c/mdq6dbbzu3Zl8YxAQ0a1hF7LqQRS9FH5FiPV38sq9I1Us3kXaSRGZFDGRvVtEkQw6fu/O1o6Xd8QuqO349bqbxxi0Yl7x7y0FDmRrqxm+76USrLzmeiWaLoufQ6JwiWQzMblnOOpZpJURtS2YWVk0Y+POTxT8+WLqxrO7dh4ykbE9K1ZzOx32aSRuZFHpH0M1+VrpFoJmn4ff3bKLiLm9cfK3XS+Wu//nLMStWt2jd1omsqIo1MihyHHR2FnMsk7oAWjwkJD2HIub2ffrB7+LzugQwhJP/M8kkvfJ/Gl1cH3BGK0PBAKqQd2PrXrX73FlXIKLy85f1nn1qh54nCZnHBD57SsBFLPtly+JHv9r55X9eLr8+dMb53o0A5IULBtT3fzX9p+rITJho+7O1XemkJIWzi6Gf6vzd2/Y/PjW0VufyFjiEsIXzO0c8mTvzyKu/b/Zkn2jgQHjYmPjT72rbkj95ZMfCrCY18KCGEzz258vOtabwsoXnTAErlw54dNXvLp99PGp7gu+KV3tFKQog5Zfu80VN/upSbNHVYewd+mq3ylxPXmyL2Y+80B7dum8DuOHPijI10LTsq8xlrnh/7XtSKFzuHyggxXfv1rdHPb8gi4Y88PzrB3ltJcamjoY6cPT7t338zBJ9u7SobOtn6Dz7U8n//HF3+zHs381Sdxz5SPKY5d2bciIkcOKzT1J17vnqu8IpB0XbooFiRb8xtx7/95nAh2/il/42pW+XhkAYNmvxo/IalR+eNnBT3w6LRTfwYIhjPrn5h9PyjVrv1bCrl5mGnkriWeaqomDl4Ev5LoyuOBgCcJ3I0kDd69sOXv+/85tHFzy0csee15jJxdesIDR42ZczsXz76dfbzq7qtfDRBQYiQ9dfsFz69yPv1mTKxRfEIbL2ya83eG7wstutDXaIZBzYkhBBiO7Vt+01O1qx3r/IKVBTtn2OjOz/YLc7euC9yPiayYJ/zB+5z78gh4T+u+POtp5d0WPlsqwCG2NJ2zR01dVO2vNHLsx51an1d9ATAtapwqfXqWFJdv3HDItav+P31JxY2Xj6lQ4iMECLkX1r/6vj3jtlkiaMfK65r5iWxFHtEjvW4B2LpQNfcva2kMin5zIgdytQ9n3ysyco5JxePeSLphw/HNQ9gCCGmq7++M3ba1lwaOuLp4SW/2uihoUyqpJVJRy/fPvdOGBn/w0eH3h71QtKP84bV0xJC+Lx/V0975O2/LZr2z7/QW1Nq/9LPvMgjkn7mxXfNXaSaSabu2BkjPxiyfMHIMeErP366fRBDSMGFNa+MfnVnARP35HPDQilxpGu8JZOSmlKWXeOuTbgL73WUE6J66Ke7lvoFQRAE2+m3W8sJ9Ru9oej/uesrh4UxhFB5cINu/Qb0bpsQqKBMQJNmsTImaPwW8+29Xl/aU0FkzWcft5XY1fHZzWVE2XuZnv/vQfMfkyIY6jtqfdHuzcfmdfKjhMqCGnTtN3hArzb1gpWMf8sxj7RTU6qI6TbmrV9ucuXsXxBsJ//XQk6U932exgsVyj/91aj6GkoIIZRV6yKiI4O1ckoJIVQeed/8/Tn/bc/dXD+xkYYSyqjDG7Vr3zwuQEEJocr4ESsvWoufJK495hMLuusYQijrE9m4XeeOrRuEaxlKqLrR07/cfgqf89cbnXQMIVSuq9uyQ4eW9YJVlBAmqOs7B/Jc/nLielNEs+0w7Zgczco7vHu+RBu5Sws7K6hPYpN4NSVU5hvZqGliiJqhhFBts2e3pN7Zme3cvHZyoui04CIniG+nyLNXJG/NIwGMtt9XlUVFEATuwoJOCkoIob4Dl6eWfL4zZ8Z65NVGMkJl/pH17Gk44uvrnMinmTaN1VGiGvhNdnFTry7pqaKEEKro9P7tkycIQvY3A1WE2vs8r+i06Zf1VhJCZSofuwI6zjllK+oHcX93fPbu19r7M4QQKg+IbdI0IUhJKRPSe+rEdgomavIOS3ln+sqirgoibzfvnK3Mfzg/7IgcFuzFtbz2iIuZIyfBgTQC1F7m354IY4is2RvHrJU/uYSieQ6b+PIBUdvZGw34zK/6Koms/vSDJXZh/OulRnJKfbotPOtIg/hbO6Y211LKaOM69BsysHuDQBmlsqhhX18quZfclYNUhFDNwz+bHNtQEATBdv7dDnLCxjz7Z3mj7e39E9XgVXnlPEPkfMz9B87d+OnReDklVOYX1bh1qwZhakqoPHLgx6cKy3mlynrcpUOu6FiKvtTa5d2x5NM2P9VQQwmlquB6Ldp3aNs4yldGCWXD7nn3kKHs/r0hlmKOyMEed10sHRkqxXaNHVLKpDdkRuxQVnjy40HRCkooo9TFNG7ZLCFUw1JCmIB20//ILB0O75k9Onv5FgShzL2HFZJSJp0YJ3MPvNM9iKGEyv2iGrZq17pBuIahhKqTHv225PO8J/Nij8gjmXdonBR5IHZIN5NZ26e20FJCqVIX16R5/XAtSwllQ3rM2Z/338kV2TXek0knppSCIFQ4CjmZSSxAO7AALQiC8d8fZg5rG6dTsZQSQpUx97+949jSXgpXLEALAn/r0GfP9mse5a9UqPwjm/V54r2tlwu47J2zesb4KJTBfZZcsFV9AVoQBKEgedvSqSN6No0J9lPJFVpdRFKHgRPf+fFY1l3zfz77xPezRvVoVCdArVD5hdfvMnz68kMZpRaqxLaHN/z70+xHezWN1mnkMrkmKLZF73Fv/nAip1R7Cy5tee/Jvi1jg7QKhTowtmW/SQt/v1Kye1z5ciJ6U2Sz7zrBfzwVzap7L7tZYjX/0sLOCibyqW1px799dUSX+mF+KqVPaGLnh1/97kRuiZ2VXYAW205RZ6/oWb8/Gcn69P0iRcxYwV1e1E1JCRM04qfsMs93/MwUrSyXS9Hlg2RO5NPuXoAWuKtLeqgooYqOCy78N0BWsgBtPfxKhZ/ZFSfNkb8747m1b43p0SjCX6XUBid0HDF7/UVj8qKuzi1AC84PO2KHBTtxrag94mIm8iQ4lEaAWquaFqDtjQZ23y0IfM7vT8XLKKO7/9Nkx+bNuce+mfZA+/hgrVIdENm0z8QPdtws0zY77xbEbSgIAp+yrLeKUs3AFVnlDiqVv1sQOR9ziLMHbtXv+vCpAe0b1PHT+IbVaz9s6uf70yt47Up63LVDruhYir7U2uftseRzT6yePe7eZrGhfiqF2j+iYdfhL326J6X0fMCrYlnpETnW4y6MpYNDpaiusUdCmfSSzIgdymwZh1a8MrJH48gAtULpE5LQbtDkRb8n37U84kWzx2pagJZSJp27fFtu7vr4xQc7148IUCvUuqim94x984eTZd5VelfmxRyR4InMO5pJkQdyFylnMu/U6tce6ZIU5qdSaoPi2gx8dsmOa3e9mRXTNd6VSQenlIIgVDQKOZvJWr0AXRU2Y9rlSykGR9MCkuT63rQcmF5fpum97IZDo2hlXNLO/N+fjJIFPfxj+W/OQarcNey4J65iII0A0uK50aB6Gb8fFvjQj/mebkZ189YhF7Gs0bwyllLJJDIDd0glk+6GzHsPZLJGczqT+BFCJ7Ha0LrxET5V+sUykArX96a87VNTejC7l3930UW/IEkIcUk7heytX69Jq/fYC4MCq7tMM1SZu4Yd98S1ckgjgNR4ajSoZlzK9bTIenUVlT+zJvHeIRexrMG8NJYSySQy4+m2SIhEMuluyLyn2+IAZLIGq0ImsQAN4A5M7NjZk+KPLluyO9/TTSmJu7R80UZmyKwX2jnwm45Q43kmrkgjgPRI9OLlSuYjy8aOXhE85bGWtevHq7x5yEUsayyvjaUEMonMeFlm3E0CmXQ3ZN7LMo9M1lhVySQVBMENTQIA4davT7V75Pzzh7c9kyCNW+WF7M2PtRivf+Xg5ifjpdEikIxqjyvSCCBR0rt4uZbtxj/782I6NgquVW8WvH7IRSxrIu+Opaczicx4X2bczdOZdDdk3vt6FZmsiaqWSXb27NmubxMAEKpO6NajIWtRxjeMUEvi+zLWG8m5DR59cWxzf0k0B6Sk2uOKNAJIlPQuXq7F+EXEhmhq2zcAvX7IRSxrIu+OpaczicxAWZ7OpLsh894HmayJqpZJ3AENAAAAAAAAAAAAAG5R25brAQAAAAAAAAAAAKCaYAEaAAAAAAAAAAAAANwCC9AAAAAAAAAAAAAA4BZYgAYAAAAAAAAAAAAAt8ACNAAAAAAAAAAAAAC4BRagAQAAAAAAAAAAAMAtsAANAAAAAAAAAAAAAG6BBWgAAAAAAAAAAAAAcAuZpxvgMW+//bbRaPR0K+A2QRA4jqOUsizr6bYA2GGz2QghMlntHTNByjiOEwSBZVlKqafbArcFBgZOmzat6vvZsmXL7t27q74fMbw0SN47hai2K4sgCBaLRaVSzZ07t+p72759+7Zt26q+HzGQyWpWdMKrZ7ZjNpsppQsXLqz6rvbu3btp06aq70cMnud5nkcmq011ZtJisdhstoULF1b95Q4dOrRmzRqXtKpSRZlkGIZhvOzmQpvN5r2ZrJ5BoCiTc+bM8fHxqeKuTp48+e2337qkVZXy6kwSL3zLX/2ZfO2110JDQ53Y3MvOrAvt3r170aJF3jV1qMFsNpvRaFQoFBqNxtNtAbAjNzeXUurn5+fphgDYUVBQYLFYfH19vW4SX1OZTKbZs2e7ZFcXL16Mj4/v2rWrS/ZWMS8NkvdOIfLy8nieDwgIcOurFBQUZGZmMgwzf/58l+zw8uXLderU6d27t0v2VrHCwkKz2ezj4+Nd7wY5jjMYDN6YSYPBwHGcv7+/W98iFWdyzpw5Ltnh1atXdTrdoEGDXLK3iplMJpPJpNVq5XJ5Nbycq/A8n5eXJ5fLtVqtp9viGKPRaLPZ/Pz83LqSVVhYmJmZKQjCggULBEGo+g5TUlLUavXw4cOrvqtKmc3mwsJCjUajUCiq4eVcRRCE3NxcmUxW9aXVapafn2+1Wqstk0uWLOE4ruo7TEtLEwRh3LhxVd9VpSwWS0FBgddlkhCSk5PDsqyvr6+nG+KY6pnAm83mzMxMm832+eefF63UO8GbJnMu17BhQyxAS4TVas3NzVWpVF53BYJaIisri1IaGBjo6YYA2GEwGMxmc0BAgHet0dRgBQUFLtxbREREw4YNXbjD8hiNRpPJ5HVB8t4pRHZ2NsdxwcHBbtq/2WzW6/WU0rp16wYGBr777ruu2nNYWFj1ZDI/P7+wsNDf39+7FvtsNltOTo5SqfS6N7E5OTk2my0oKMhNb5EsFoteryeEtGnTxrWZDAkJqZ5MFhQUFBQU+Pn5edfCCsdx2dnZCoXC6+6lyM3NtVqtgYGBblrss1qtaWlphJDWrVsHBgYuXrzYVXsOCgqqnkwWFhbm5+f7+voqlcpqeDlXEQQhKytLLpf7+/t7ui2OycvLs1gsOp3OTYt9RZkUBKFFixYhISGff/65q/YcGBhYPZk0mUxGo9HHx0elUlXDy7lQZmamTCZz950BLufud4I2my09PT0nJ6dZs2YhISHff/+907vypjcYAAAAAABQMY7j0tPTs7OzdTpdTEyM130HFmoenuczMzMzMzN1Ol1UVJR3fc0CaqTiTPr5+SUmJnrXJ69QIwmCcOvWrbS0ND8/v6SkJGQSPK44k1qtNjExsep3AyDTAAAAAF6Fd8GXMe/mo1H7aNTu2z9h3LLkJJfL3XcTsVvpdDp37DYnJyc1NVWlUiUkJHjXDXF302q17q0Y4J6oyxgaHKhz3/7d9KdECHHTbV9FmVQqlfHx8V53Q1wZGo3G6yqrEEJYlvXScdJNt8caDIaUlBSFQlEDMqlWq9Vqtadb4TBKqZdm0k1fIzAYDHq9nmXZuLg4bxxkSlKpVO79s+J5N+04uOjrzm7bP3HPDQG+vr7u+MaV0Wgs+iJdbGysqyZjWIAGAAAAAPB6+fn5er2e5/nIyEivK/4ANVJhYaFer7dareHh4V73pWaokUwmk16vt1gsYWFhyCRIQVG9LJPJFBoainqPIAUWiyUtLc1oNBZl0oVVubAADQAAAADgxYpKRubl5QUHB4eEhOA3TsDjiktGIpMgESVrE8XGxqI2EXgcx3GZmZlZWVmolwUSUVybKCAgICkpyeX1srAADQAAAADglXiez8rKysjIQMlIkAiXl4wEqCJBELKzs9PS0jQaTb169bzrByShpqpJ9bKgZsjNzU1NTXVrbSJMUgEAAAAAvE9NKhkJNYM7SkYCVEVRbSJBEKKjo318fDzdHABSWFiYkpLCcRzqZYFEFNfLcndtIixAAwAAAAB4E5SMBKmxWCx6vb6goMDlJSMBnFNUm8hgMAQHBwcHByOT4HE2my01NRX1skA6imsTFY2T7q4DgwVoAAAAAADvgJKRIDXuLhkJ4KjiTPr5+SUmJqI2EXhccW0iX19f1CYCKSjKZHp6enXWJsJYDAAAAADgBVAyEqSmGkpGAjikuDZR3bp11Wq1p5sDgHpZIDlF9bIIIdVcmwgL0AC1V4M3b3i6Cd5k37OYLgAAgGegZCRITbWVjAQQyWQy6fV6s9kcHh6OTIIUmM3m1NRU1CYC6bBYLGlpaUaj0SOZxAI0AAAAAIBEoWQkSE3JkpHIJEhBcSZ1Ol1sbCxqE4HHlayXFRUVhdpE4HFSqE2EBWgAAAAAAMkpLhnp5+eXlJSEMqbgcR4pGQlQsaLaRGq1GpkEiUC9LJAaidTLwkQWAAAAAAghpn3zx3yofmXVcy0wQfQ4lIz0ZjXzT6moZCSlNCYmRqvVero5ACQ/P1+v1wuCgNpEIBFFtYlsNltERIS/v7+nmwMOMe2b/+iH6ldWPdeyJl27JVUvqyadWAAAAABwkpDxy9IPN+4ePIn3dEtquZIlI4OCgjzdHHBYzftT8mzJSIC7Wa3WtLQ0g8EQHBwcHByMTILH2Wy29PT0nJwc1CbyUneu3U/VmGt3cW2ioKCgkJAQKdQmwgI0AAAAQG3GFWZeOX14x6q5s35I5cM83ZraDCUjvVwN/FOSQslIgJJ4ns/KysrIyEAmQSKKaxP5+PgkJibK5XJPtwgcUnztfr3GXLslWy8L4zUAAABA7SWkLx8a9+Rv5qJ/ef7miFoLJSO9Xc37U5JIyUiAYqhNBFJTVJuIYZjY2Fhk0hsJ6cuHxk2sSdfu4tpE0dHRPj4+nm5OKViABgAAAKi9aOCgxbua5vBEyFr33LD3b3i6PbUQSkbWDDXpT0lSJSMBCCFms1mv15tMpvDwcGQSpMBisej1+qJ6WahN5L1o4KDFu5rUjGt3cW0iyWYSC9AAAAAA0iUIgiAIJR9x8XRSFlK/bQghRNAf9asJd354E5vNlpqampeX546SkWVi48Ld2smk9N7keECN+FNya8lIZBKcUJxJnU4XExPjLZm8e+fIZI1RXJvIHfWy3JRJuztHJgkpee0+5r3XbrfWy3JhJqW0AC2kbpr1dsaIxRMaF/0BC9lbZz3+yXFr8RPYyAfmLx2bxBL+1vE1y1f/eeyqwSe2Ra8R4x9orqOEkHIfBwAAAPBCVqs1Pz8/Kyur5IPBgTpPtQdcpRpKRpaJjaveP9hstoKCgrKZDA52yc7Bg6qhZGSZ2PC8a37qyWazFRYWIpM1krtrEyGT4KiiTCqVSjfVJioTG47jXHL5tlqtJpMJmayRDAZDSkqK++pllYmNzWbjOM65XUlmAVow3dy5cv2pgnb/jfl8emo6TRr44rDGt6c/VB1ZhyGEu7p2zjs/c93HPzciKGP3qq/fmce+P2doNFve4x46IgAAAICqoZSyLIsftKlhqqdkpJtiQyllGAaZrGGqp2Rkmdi46uY7hmGQyZqnOJORkZG+vr5uehWMkyBecW0it9aBwTgJ4plMJr1eb7FY3Fov6+5MOh1LKSxACxk7Fr7x9f6beRaBlPwExpqelu2X2KFrp6al1pAtJzZvTo56YNGk+6NZQpoE51x8adMvp/tPanDa/uPNpPKDjwAAAAAOkclkarW6bF1g3sn7DsDjzGZzampq9ZSMLBMbV72W/UyC17JYLGlpaUaj0XszybKsSqVCJmuMojKmbqpNVEaZ2LiqvodMJlMqlchkjWGz2dLT03NycjySSZe8HMuyCoUCmawxStbLio2NdW1tojLKxIZlWadfTgoL0DSg1cNTYwYLefuWvfPnfw/zGWnpQmijUL4wOytfpgvylVNCCOGunz5jDO/Quk7RqjQb07pl6Jqj/+qtWvuP881ivbaQCwAAAADUBG4tGQngBLeWjARwAs/zWVlZGRkZfn5+SUlJyCR4XFFtorS0NK1W66Z6WQAOEQQhOzs7LS3NffWy3EcSY7o8ICohgAjZF9QlP9rhM/QZtowdcyd8nZzLEZlvXOeRzz7Vr548Mz1TCAoJvLOqzASGBAqZ6Rm2ch7nye0F6Fu3bhUWFpZ8XY7jUHZdIorqbQmC4HQ1GYBqgHyCNBXVhuN5HhGVCHQElFFcxtRN5fkAHOXukpEAjjIYDHq9nmXZuLg499UmAhCvqF4WpTQ2Nlar1Xq6OQDVVC/LfSSxAG2XYMjMtqp9EgZOebNrJEk7vnnZki/mfBHy4RMWs42q1cVr1VStVlGL2WIr5/Higu2LFy/+5Zdfivfv5+eXnZ2NBWhJMZvNZrPZ060AsI/n+ezsbE+3AqBceXl5nm4C3FZYWOiqHzICb1dUMtJms0VEROCrryAFJpMpJSXFarW6tWQkgHhms1mv15tMpqI6MJ5uDgCxWCx6vb566mUBiFFUm8hgMAQHBwcHB3tpJqW7AE11fWat7nPnX9HtHnlm2LHJP+w6Pq6bkhVyC00CUVFCCBEKC02C3FfBKuw/XrzDxo0bl1zcPHz4sFKp9NJuq3l4nrdarSzL4ptW1cvk6QZ4E0qpd33DBWoPq9XK87xCocBFTSKw+gykektGAohRsmRkSEiIW0tGAohRnEmdThcTE4NMgscV1yYKCAhISkpCvSzwuJpUL8t7ms4ER9ZRWrMNlsCQYJqclc2TAJYQQvicrBwa1DhIFmT/8eKL2PDhw4cPH168vz59+vj6+uLNgERYrdbc3Fy5XO6N3yPwZrmeboA3oZS67ze4AarCYDCYzWaNRuPVM5KapCq/zgE1AEpGgtR4dclIqKmKaxMlJCQolUpPNwfgdiaVSiVqE4FEFNXLkslkdevWVavVnm5OVUn3nWrB/qVTV9pGzZ3Sxb/oxwdvXrpq0TWODogNbajdcOx4xiN1wykhfOrxE6m+jRpHKmIa230cn1gBAAAAVIpGPPlHwZOeboXXKy4ZiTKmtZbU/pS8vWQk1DyFhYUpKSkcx0VGRuL2DpCConpZVqs1PDwctYlqJ6ldu00mk16vN5vNNSmT0l2AVjft0MQ69/P3Am3DO0SyWad/+3Z9RuOx/RvKFHy/fjEzflryXZ0J3QLTd3659nrCsGebKAjbzP7jAAAAAABuhpKRIDXFJSORSZAIm82Wmpqal5eH2kQgEcV1YJBJkIiStYliY2Nr0rcqpbsATX3aTHxrWsCKH1fN3ZjHBkYltXnirdH31GEIYeIfnDnN+umKpTPWmjSRLQZMf3JoLEsIkZXzOACACwRuWOrpJniV8bM83QIAgGqCkpEgNTWpZCTUDMW1ifz8/JKSkpBJ8LiiTKanp2s0GtTLAokoqgOjVqtrZL0sCY37VNf3rZ/7lnxEHt5+1PT2o+5+KhvSZvRrbUaLfhwAAAAAwA1QMhKkpoaVjIQawGAw6PV6lmVRmwgkorheVkxMjFar9XRzAP6rtDMm+wAAIABJREFUl1WDaxNJaAEaAAAAAMBboGQkSE1RyUiLxRIWFoZMghSYzebU1NTCwsKiOjCebg4AsVgsaWlpRqMRtYlAIorrZQUHBwcHB9fgTGIBGgAAAADAATabLT09PScnByUjQSJqcMlI8FIcx2VmZmZlZel0uujoaGQSPA71skBqeJ7PysrKyMioJfWyavjhAQAAAAC4SnEZU61Wi5KRIAWCIGRnZ6elpWk0mhpZMhK8UVFtIpVKlZCQoFQqPd0cAJKbm5uamqpQKFAvCySiFtYmwgI0AAAAAEDliktGxsbGomQkSEFxycioqKiaWjISvEtRbSKbzRYREeHv7+/p5gD8Vy8LtYlAIsxms16vN5lMta2GGxagAQAAAAAqgpKRIDW1p2QkeAubzZaampqXl4faRCARxbWJgoKCQkJCUAcGPK5kvayYmJjalkksQAMAAAAA2IeSkSA1ta1kJEhfcW0iX19f1CYCKSjKZHp6OmoTgXSgNhHmKwAAAAAAdqBkJEiNwWjUp6bVqpKRIHG1sIwpSJzRaExNTRUEITo62sfHx9PNASD5+fn6tDRBECIjI2tzvSwsQAMAAAB4FcMtT7fAKQGhnm6BAwobNtTPnGmtUyesdetaVZ7PSVMGeboFTpn9uadb4ACzjdPnGE1WW3idOshk5Tirp1vgFJk33adpjo1NnT69oGnT0IYNUZuocoVGT7fAKSvmeroFDrCofNLiWhgDwkKvnQoc+CgyWTMZsz3dAgdYbVxariGvwBTs5xMSFVPLM4kFaAAAAACA27iAgPRJk7KHDg1esSL4yy8Zk8nTLYLajuOFdEN+dr5Jp1XFBPkxWH0GT+M1msxx4zLHjdOtXRs1bRprMHi6RVDb8QybGdUoM6qhX+a1xCObZVYzqd0rfeBxPC9kGfMzco1+GlVSnVAZyyCTWIAGAAAAACCCTHZrxIj0yZM1R47UGzpUkZLi6RYBkJwCU2pevlouqxeqU8hQghw8jdKcgQNTX3xRdfFiwsiRyosXPd0gAGIIjExJaK0w5ccf/12Vn+Pp5gAQQ6FZn53HMjQuNFCj9KavtrgVFqABAAAAoLYztm+vnzGDMEz01Kk++/Z5ujkAJN9s1ecaBYFEBvj6qvD2FTyvsEkT/YwZtsDAiDlz/H//3dPNASAmn8CU+FZWlU/YleMB6VcIETzdIqjtzFabPjvPZLWG+vsG+qAsfilYgAYAAACA2ssSHZ32/PPG9u1Dly0L/O47yvOebhHUdlaOS8sryCs0B/tqQnw0tf47u+B5tpCQ9KefzunXL3jFipAvv6Rms6dbBLUdJ1OkxzTNDosP0l8IOf0nw9k83SKo7TieT881ZucX6LSamBAdg4v3XbAADQAAAAC1Ea9SZU6YkDl+vN+2bYkDB8qyvelnbaBG4gUhy1iYYSjwUyuTwgNlDOPpFkFtV1ybyGffvsQhQ+R6vadbBLWdQGl2WHxabHONIbPeP1sU5nxPtwiA5OQXpubkqeTyhLBgpRwLrfbhvAAAAABALUNpbu/eqS+9pLh5M37UKNX5855uEAAxmCz6XCNLaVywv0Yh93RzAIixQwf9zJmM2Rw7ebLmn3883RwAkh8Qpo9vLVAafX6/TzY+DgHPK7RYU27lcjwfGRjgq1Z6ujmShgVoAAAAAKhFChs21M+YYY2KClu8OGDTJiKgZCR4mNnG6XOMJqst1E8TqFV7ujkAxBIbq582raB5c9QmAomwKjVpsc0MgZGh104F6s9TXLvB06w2Li3XkFdgCvbzCfHzQcmNSmEBGgAAAABqBS4gIH3SpOyhQ4NWrw556immoMDTLYLajuOFdEN+dr5Jp1XFBPmhZCR4HK9WZ44fnzluXMAvvyQNGMDm5Hi6RVDb8QybGdUoM6qhX+a1xCObZVaUIAcPEwThlrEgLcfgp1El1QmVsaiXJQoWoAEAAACghhNYNnvo0LQpUzTHj9cbNkxx86anWwRAcgpMqXn5KpksIVSnlLGebg7UepTmDByY+sILykuX4keOVF286OkGARBDYGRKfGuZ1VT35Ha1IcvTzQEghkKzPjuXZZi40ECNUuHp5ngTLEADAAAAQE2W3769fsYMgWWjZ8zw2bvX080BIPlmqz7XyAtCZICvrwpvX8HzChs31s+YYQ0PD//gg4CNGz3dHABi8tHp41tbVD5hV44HpF8hBDU3wMPMVltqjqHQYgn19w300Xi6Od4HC9AAAAAAtZlgPLtx7rtfbT589nKOKrp+83tHPT9rTKtgyXybcB8hHxKy6q5pq0DI14SsJOQIIeGEPEHI84SU+eE2a3h42nNP77624+d3Pv/h6G9yjqu+doMIXPbFjt+eOWSvuiwbkLB3dKP2DCGEv3Ht8uuHr/+WXpDFs+G6wEFNE2c31gVJrliFkPfvurnzP/thzzm9RRPdtMe4F2ZO7R1V5geJrByXlleQV2gO9tWE+GhQcsNbFFzYuOCtxd/vPHHllkVbp0n3h55785XhTXyk0n9Oj5N5hLyjlK1maNrllMhpb03IvPKS1VKtTQfnFGx8pO7o1YbSa7LK+76+/NM4nVRiSQghlnOPTF+z2lT6QVm9r+cNH6e9/S+j/szcLUc2J2dcLpBFh4ff26nzq93j+Nim2eEJutRLsad3MZy12tsNtYdgPLth7vwvNx8+dzlHGV2/+b2jX5g1pnWZaTDH85l5+VmGfJ2PJjo4FPWynIMFaAAAAIDay3Jm2cC+b+62xfcZ+kj/wIKzOzd88sKQPy/9sOetjn6ebhshRCBkKSG7Cbl7ifJtQmYT0o6QZwk5SMgMQpIJ+YiQovcEvEqVOWFC5vjxvus/2PTZnwd43DolRVTh0ycpMqFM7wqmvy/fSvNRh1BCCMm6eqrnpqvX1LoHGtVLZM1HLt/8eEfmXkPHPR11krr7yHj4/T4PLjxE6vUdMv5hbfq+zZteG3Xg1GebVw2JKHobKwjkVn5hWl6+n1qZFB4oYyTzIQ9Uxnru0wd6TPktL6LTgxMejLFe2rl2zXtjd+y9/ufvLzVXVr65uzk9ThpYphcjHJVH92ieMOLY3gP6868TcpqQVYQgnRLHpSRfMTFhre7vmVDiZ0vlzevKpbUuxuVkX7HSsNjEniEllp7Y8Lp3/mVJOTjw/R27+cA+rZv111rPnjnzyXff/cYuXVtfm/jPFoXJ6JFmQ+1h+feTgX1n77bF9xk2on9g4dkdGz55fvCfl34qOQ3OyS9MzclTyeUJ4cFKORZRnYdzBwAAAFBrGbcsWrzbmPjSlt/mt9MQQshrEz8Y3Hvq5wu+feqnp+p4cgmi8M46yA+EhN31v1cJeZeQ7oT8SoiCEJ6QRwn5gpDHCGlNiKFHj5SZ0/nzJ3OGDvjsRtqP9vYAUsBow9/uE176MeHKqb/bXNW91j02nhIi5C//+/plVcTyh1s/WnS3abuol3/Y//7xS+tbthmp8kSj7eLOL5n+4SG228Jfvp7SQE0I4aeOnDb0kUVvLJ7QZ969GmIwWfS5RpahccH+GoW80v2BhAg5G/43+/fs2PE/7/58QBhDCOFf+ePFe/p9NO+11aM3jg334IJfVcZJY/vmb2b9ezS10bwY+vLePwghPCHTCFlEyARC7q3+gwFHcFcvX+G190z/+tuB6sqf7TlcVvYVQXFP3yHfNre79GTZ8tv+3abgl6aOmx8vzw8I08eENHjmsXmr39/dYFhjSd3KDTVT0TQ46aWtv9+ZBj/5weB7pn7+3rdP/fxUHabQYtVn59k4LkLn56+R9N+aV8BHmwAAAAC1FZd27qKBBHfs0+LOvaTyuvffmyizJp9J9mS1CoGQoYS0JWSxvXv6CCEbCCkgZCohRdVzGUJeIkQg5Nu4BskrVqS8/nrowhkvPDut84208vYA0sQbbzy/Pyu+ddMXgxhCCLHm/JXB+0ZHPVBc60AeMCRWxdiMp/MkdFM7d/m3dae4qAefm9Tg9htUJrDjq1N6+6T8snK38Upm7s1sQ7CPOiFEh9Vn72M7sXt/Dtts/NS+YbffPDPBvaZO7CQ3/LXjsNlz7XJ6nPwuLPrq0qVXnuu447ItKv/Ec/8eI3ee8CohPoR8V23HAE4Ssq9ezaYxiXFSH0+ys3KyiX9iUDnrTrzxXLqJ+Eb3qud/I6nDtQZd/G9ZR8cGyGz6M5kSGuGhxuLSzl3MIyF3TYMtl09ftN7IyklOy/JRKRMjQrH67BJYgAYAAACordiQxHgfcuvYvot3in7yaQf/vsrJY5NiWA+2ixKymJADhOwnpK29J/xNiIKQDiUeqa9V6Ci77+GFijNnEgcO1P12vOI9gCRZNuw7+6s6bnFLv9s/zEf9JvZsvqxZQIl7nQWDhROoPEQ6tz8TwqXcuMkxsXHRJVaDqCYhMYJmH9x7UiZnk8IDA7V4++qdrPlEl9i0e+uEEoMiVWvUlNjMFg9+vuXEONlAKdNRZu/YZWxGRsKkr9N4IVYQSi5h+hISTcg/hKBevrRxVy5f5eSxCbqru9at+ujjz77e9PfVfAmu2PJXMnI5NiBBm7PrnxMf7Tzy9fGbV0t+aMNo64UqSX7OL0H3EUISj2wOuX7478s5HKtLkl6Zf6iB2JDEeF+SdXTfhf+mwQcOXuPkUQHKLEEgiXVCQv19UPDZVVCCAwAAAECiBEHgOM5qLfXzOy6938lv0Ovzxxyb8vbQIRdH9WuhKzy3ffXKfaq+b709IdrDtynUJ4QQIvyfvfsOjJr8/wD+JLm9ete9d8veGxEQ2QJalgiIbBAVUFDLdIEKftkoPwQUEBGVKciWjWzZG9oCpdde73p7Z/z+KKMtbbmWa5NrP6//mt7lPrm88yR5LnmC0LNDUdMIZSAUgJA8/zUEoU9JyXrdP2zoSu337wRbcvHnzaE6KBIbb6FpuuIyacu6PeU206dLYssn5yh8efdaj9azw+XOs9sv30ubfNMVnlC3v5xDZ4S4ws8Pp7MeZpMoKr/r3GBzZNxIz6VppLcG+8ngqh9UYZksvp304jcu6bb4XLfCk+jMrVtOuAUNWzRk93cQz9tJhGHGTp0evhkZOnq1dsXYEP0DDCE/hLIQIh9fIo0QciGkQYhGiEKIzR8hK0uR2DCMd/pwGYahaboi993OjLQsijamtmqm1rkZhBDCBKFtU3/6+fP2QRxqGRGZkWumGGfq1z+qLXT+lyvwi00d9vrnNaQYQmb/+NrTp6W8P2v5iH7GVvENJe6b1y79cofXrXen4f5cWo5KVKmZ5HP9CvqKp+g1c86QC+Nnpbyefxh8Zd9vv53gt/s0dWLDwECh4PkzqAaezWS5Ywkd0AAAAAAAHEWSpN1uNxqNBScGevV8gRfZdvTA5ju/Orx2/tm1CCGEyZu8+36PJE493q0IBiErQjKEcISszZurU1MZPj/6y4n+FK2x5HLwGjBWFImNt05iKYpyOBxFM+mVWTPWVSfv3wtM2pwgKKbjgbEu2Hx4qoZGCFOF19jZITycS70TvNrtOoR9v+yPH9aPWfFmKMrSmynrtW1r9+fRjMThhEzmKxIbmvbO1cMkSTqdzqKZVPl5ZebFcWZsn9b/k73W2BHTh8Zx9qeFgu2kvXZt9ZQp7rCw0DkfBlB0rv4BgxAfoQ4ILUNoPUJDH79rMUK5CElQdXlqawW1k8VnUuq9XyuozLv33Iybihu6dt/EV2OR+tz2BeNT184aPC7mxO+s/378FG26q6MYio5r3Xtfp/hYZD538cT4TRdnrfg74qsRnZs2cUj8wjL+ndQ47Oi29LW7M9YihBCSx7Z4v2EAlw9CKtSz7aRXYkmSpMvlKprJQO/svX0aL7Lt6EEtdn55aO38M/mHwbKGIz9+qxn0Pj9RJDYURZV79w0d0AAAAAAAHIXjOJ/PF4kKn7VSdq99AGM+Nqtf10WZ9Ucv3TauU12l/fbhdamfLuz1mm7D7kW9QzlzEvsMBiEk9c+cNtnerl3gqlWBv/zCuN0IhnsuoGhsvATHcR6PVxEztz5MW5CF9+ocXavYnmVM1LtN41iT425O9sprN3tsRzt7JTXnzsVbwlapM3tse/evUa92/71Li5oS/eX9u86g4BDCauPBCdcjRWKDeemu5orL5LNcmQcWffrRrD+vu+L7/t/m/3Xl9kPSGIQwkVw98T1zSkrgmjWBq1YhpxMVaCdTEdqG0CiEdiGUhNBJhM4gFIKQjcWiK1fFZZIgiArMJB78xuzfGolrtmsRI0EIofiXhy7ajtR139u/eO21d6bV5crV65j0jd79GvED2sUrJQghpHr5pW5bCWv9tWnzbyd0r2NOvn7g3y0/d91rqt++57ZXE+tKyNs3zqf++W+v+bYNk3v09uP09lVBfDWTPooxH/uqb9dFD2u9M2/hgJbNwjHj+c1TUxe+/pp5w57FXD4MrkzPZhLHy/nNwPEQAAAAAABHEQQhFAplMlmhqUavdUDT6s1fLrsq6LJkyzf9QjCEkKpRz082ynLr9f11xoqRvWYU/9B61jFCntBN5bz2NUJ5ST178vLyEEI0QhaEZAhVxxPW4hSJjbdOYovPpBc4t1x8+EAasSK+uMufEUKIVyMyrAZCqHbswICTDQ7fnnEzalddEUfODhkGF3f57qfF0ctWbTuyafVhcXjj1z4/MMoyvtNX9+RSyGS+isukQCAomknK28N9MPozyz8aOe23y87IVz9cs2Dam3UV3F6xBC5imJwe37oimcSUFEFWFkKIKtxORiJ0FKHpCO1GaDtCjRE6gNB4hO5Vm4a0UjNpt3hl5gghhKlqt+9Su9AkPKJHr1Yf7j104YoF1a246//LBhPXrpHwtE4MMwTF2YYMaLR+1qmTG+X1E5H+wpcHNIJ6Pbf0qxuCIYRQo0ZtN4ps9ZZemHGoWa/XQ7l5EFKhisQGx3GvxJIgCD6fXwH7bt9GqzfNXHaVaDd72ZSe9fwVQj4PRaduVGjr9Vk348dRvWZy9DC4khWJDUEQ5c4kR47ZAAAAAABAZSNvXbni5NVt26rgmJHyli83F1B3r1w3cfIebHP79ml/Tg0RIsPu2fKpU/N7nxFCFEIPEYquHuOWVj20OWvVPTI2KbJt4bM9l1G77vrDo+aCWcRiooPrYvQNnZUjz0kzO1y3NXkGO/VS70827zutzXpgu3vq2OK36xnu3SeJuPhoOIP1edSDjaPbtvtgo6HllK0XLu2bM4Djvc+WFi3Sfv04SIgM+75Tvv9+fu8zKq6djEVoHUJahGwIHUOoHkL3EYqD69R8ECZXKnmIISmKk/tuq1/wnYZdc6PqRGapw3CGcdsoBpE5mituvG5yVKGDkISY5jz6bqaGmwchoMqwu9y3T5274iTqtG/fOMRfyH/U7D0+DL4GCfQ66IAGAAAAAKimMKlMhtH6PH3BkSsYo15PI4FUJuRYB4ujZs301asfzpgRvOJERzvjMj04WuC/txHSItQUjm59EpNxN+sEJemZ4Fd0UA3Dw4/2X5h2114ooi63GSExj2A9oU6SvKczZupNAWLD/f071h9MLzB2gfvy4X+z8bi2rcIhkz6OvL5oyPA1WXUmbT2z/bNeiZwenNYVHf1g3rwH8+f7b7/V0c64jBmltJOHEFpZeMCNywhlI9QWGlJuIy8s6tm2w5C19wo2jFT67TsuPCwxjjvPZyXvn+o5Z83g0877yS3v12rrl5uR+N9OyZ07d0gsLFglxxAmFMgwRm91FGrh7XY9jQQiAdcOQkCVQVJ0Vp4xPUcnUyqUGGO2OHziMLgKgD0LAAAAAEA1xa/3audw5vqv32/MfHy7Oq0/tPino26/Dp1bcKiXRSDNTk1NW7dOdONGcq9eyu37eiEkRugHhPLrZhBahhBC6E02qwTl5vonw+gWB3QOLnpuwg8JbCdgTl29d/rJgAqMc9elhzcYYfsoOYsXaVI0nWOy3tUYBDwiOcQ/QCa8/vuMMWM/W3vv0WXZ7vQ/Pl97V9j87aH14FpSH+c4vHjxSWeTT9bOevWZhHIJIcgdN+7Opk2Y05nUo0fAr1tef147eQ2hMQitffynG6HPERIWeCYh4CZefKLq3rn1c+bufPLYXdf9P+f+dJ6J79e3CXfGxsdDA8T6rA377h4wMEnndgRlXsfc+j93nT/P+PdrEs5HiB+Z0FnJXD9xcmPe4w5Axn5o339HKVGHulEcOggBVQXDMDqz9bY6l6KZpPCgiJbdOocz139dUuAwOO/RYXCXlpBAr6vWx0PeesoteHFP1gWsFACqBtiWKx/DMPC1c4QvrQhR62nfvrln+G+DX765IeWV+kr7raN/bzmbq+r87Zw+QZy48gPHSITIbrNckfzEN94QZGbmT45FaDJCXyHUA6HXEDqH0DqERiHUhNViQTm58v7JoUXhAc2fGT8FE4V91uzevuN3u/1uHhCvDEPOy/fVWzXuyOSG06JYG23FYHNkG60iAS8hWCXk5ZcRMfjjoT/0XT6xe+8TfVqFGK/t3XXgCmq7cN47STAojI+j7pw4mUMLFMe/HTOycP8zpnh54ryhddg/o8YwEkNkt6+sTYPiBw0S3bqVPzn2ee3kYIR+QGgiQicQCkFoL0JXEFqIUBJLywE8pegy/fNO+8b/0rfV7X59X44jci/t37rjiqvexD+mNheyXdwjZv8IdcJro9+9f2TutrEjzv3TNDoOs126fmPHQ6pex35T4wiEEOJHT+tff8/Ki4O/zt3QJL6+hLx188aWDKuqTpc5TWH0fOBlFodTrTfhGBYTpJIIBQghJG497dsBe4avH9zm5oaUDvWV9ltHd2w5m6vqPIcrh8FVC/u7S7YwDGM0Gr31nAHwgvLP1Z1OJ0mSbNcCAPACo9HIdgnVCEVRCCGLxQI7NY6w2+00TT//dZyAh7027/hfjWYv+GXr5hU77YKguIZvf7F4xtj2MRy4hsrarFnWmEaud1cQp1ZFb7siKPzfmQgFIbQEoU8QikBoFkKTq82Ds6oYZ472mAslBisUxfwTr9u4+THZ7S8vqjdfyjXQRKhKNbpd4vR6AWFsrGy7m1QbLCRNhyllfuJCHT2Kl2Yc2BY745vVO39ZbuCHNXpl0tap43rECEqaFfAV5P2M+yRjubZ77bUi/8GDef2+G1qHlaqesNeqlfVuC9ekNfiVbbF/nxAU/gW09HZSgdABhGYgtBMhA0KNENqKUI/KXwZQZrzkYetORC6fvfi3XWuW/OESRdRpO3nFp6lv1VNyYC/oFCvU8Y0dUmXw/cvJse1OjpPM/ufKruOn/iD5ERExk99pk9o8+HGdWFiD7sc/DJu9+8LWs2d3uoigoLC3U3rOeCUuBn66A97jIim13mhzuoP9ZP4ySYEzJjysx/zj2xvNnr926+Yfd9oFQfGN3v5iyYx3X+HCYXDVU307oDEMUyqVcK7OEW6322g0VsxD1UEpvPcsZgAKUyqVbJdQjZjNZqfTKZfLebzqu1vnFIFAgONcvk+7CCK4xTuLNryziO06CnKHhORMmGBu3z5w5crjiIdlX3n2NThC7yH03vNmhSG0vyJKBN4jjKqX+UG9kv/Pq5tc64/kWpVXUHFImtaYbAabI1AuCZJLijuFIIKbD12+ZWhlVwYqmLD7Sp17JdtVFINSKjVjx+pTUgI2bDjGF+MZ/z77mue2k8EILa+4EkEFEsV2mrCi0wS2yyiE4gk00fX0oQmq7LvRN4/jpBshIrZOyxV1Wpb8Jiw4vvGicY05dRACqgyaYbQmq9ZkUUrFyeFKopjjcyK4xdBFvw+FBFYCOFMFAAAAAABcQQuFukGDckePVhw4kNSzJ0+nY7siUN0xDJNndWjMNpmQnxTizyd86OclUDUxBJH31lua996TnDuXmJIiyMpiuyJQ7WGYISg2O66RyGpIuLBbaDOxXRAAyGC1ZxtMQh4vPiRAJIBLmtkHHdAAAAAAAIATzO3bq6dMIfLyYkePlly6xHY5ACCL06U2WHAciwlQSOD0FXCAtUULdWoqQxBRkyfLjh9nuxwAkNUvWB3fmMZ5EbdPyvPg5xDAPrvLrdab3CQVqlQopWK2ywGPQAc0AAAAAABgmTMuTv3pp46kpNBFi5TbtyMfepAjqKJcJKU2Wmwud7Bc6i8VwcB9gHXu0NCc8ePN7doFL1vm/9tvGEWxXRGo7twCcU5sA1NAVODDG0GZ1zAaMglYRlK0xmg2WO2BClmQQga7bk6BDmgAAAAAAMAaSqHQjBun79tXtXFj9OTJuAWeTwBYRjOM1mLXmm0qqShSJS9uyEgAKhUtEmmHD9cOG6bYty+pRw+eXs92RaC6o3FCF56cG1lHkZeZfG4Hz2VnuyJQ3TEMk2ex5RjMUpEgKTyIT8CDLDkHOqABAAAAAAAbcNzQo0f25MmimzcT+vcXpqWxXRAAyGBzZButQj4RH6QU8eFcCbDP3L591pQpgqys+MGDRTdvsl0OAMjsH6FOaEK4nbFXD0nMWrbLAQBZHE613oQhFBPkLxUJ2C4HFA8OqgAAAAAAQGWzNm2qTk1lRKKIadPkR4+yXQ4AyO4i1UaLm6JC/aRKiYjtcgBAjlq11KmprsjIEBibCHCDUyxXxzd2SFXB9y/756RBJgHrXCSl1httTnewn8xfJoHxsrgMOqABAAAAAEDlcQcH50ycaHr11cA1a4JWrsRcLrYrAtUdSdMak81gcwTKJUFyCZy8AtZRfn6ad9/Vp6QEbNgQ8+67uM3GdkWguqN4fG1kHV14kio7LfrmvzjpZrsiUN3RDKM1WbUmi1IqTg5XwnhZ3Acd0AAAAAAAoDLQQqFu0KDcUaMUBw8md+/O0+nYrghUdwzD5FkdOSarVMhPCvHnE3D6CljGEIQ+JSVn/HjJpUuJvXsLHj5kuyJQ7WGYISg2O66RyGpIuLBXaDOyXRAAyGizZ+vNAh4RHxIgEvDZLgd4BDqgAQAAAABAhTO3b69OTSUMhtixYyXsLuShAAAgAElEQVQXL7JdDgDI4nSpDRYMw2ICFFIhDBkJ2Gdt3lydmsrw+VFTp8qOHWO7HACQXR6QFd+Y4gkjbp+S58HPIYB9dpdbrTe5SSpEKVdKxWyXA8oAOqABAAAAAEAFcrpJtcHsmDkz+Icf/DdvRjTNdkWgunP5BapbdrflmYLlUn+pCIaMBKxzu8mc3FzzggWBq1YF/vIL5obxDQDLSIrK1ulNdTsEPrwRlHkNoym2KwLVHUVRGo1Gn5cXqJAFyqU4DvtuHwMd0AAAAAAAPsUviO0KPPXoVEGvV6lU0S+3wdu1ZbsiUDGGfMB2BZ6iEablybSEVEnbk5OSCIJguyJQMQifuSObpmmtVqvVahUKRVLz5rzWrdGqVWwXBSoA4zM/vjIMk2ey5OQZ5FJxUvYVPnKhyFi2iwIVoFNNtivwFEMQeS911XR7U3L3emLXngI+9GT6JFhtAAAAAADA+wwGQ3Z2tkgkSkhIEAqFCC6eAmwzEOJsQiFk3PEurYghEfQ+A7aZzeasrCwejxcXFycWw73kgH1mm12t0xM4HhsWLBEJ0TV4UDBgmSWpnjplOEaT0Su+laZdQz1T2K4IlBN0QAMAAAAAAG+y2+1ZWVkURUVERMjlcrbLAQDZMb6ap3BjRChlUlJ2tssBADkcDrVa7XQ6Q0NDlUol2+UAgJwud3aeweZwBqv8Avxg3w3Y5woMzekxyJJUL3jPn/5Hd2G+cxsBKBZ0QAMAAAAAAO8gSTI7O9tkMgUGBgYFBcHQuoB1FIZrCJmekARS1iDSgjEM2xWB6q7g2EQxMTE4jrNdEajuKJrWGkw6k1kll0UGBxCQScA2WiDUdnhd2+ENxcUTSV+P51lNbFcEvAA6oAEAAAAAwItiGCYvLy8nJ0ehUCQnJ/N4cJAJWMYglEdINTy5hHYmuXL5DAwCA1jGMIxer8/JyZFIJImJiQKBgO2KAEAGizVbZxAJ+AkRoUK+zwyeDqosDDPWb5n9+jsCXU78wimirHtsFwS8Bs4NAAAAAADACzGbzWq1miCI2NhYiUTCdjkAIAsmUPMUGELRrjwpA2OYAvZZrVa1Ws0wTGRkJIxNBLjA7nSpdXqSosICVH4y2HcD9tkj49S9R7hVQSE7f1OePYzgpqWqBTqgAQAAAABAOTmdzuzsbJvNFhwcHBAQwHY5ACAXxsvhyS2YIJiy+FNWGAUGsM7tdufk5JjN5sDAwMDAQBibCLCOpKhsncFkswX6KYKUCsgkYB0llWs699O36BBwfHfQ8lm408F2RcD7oAMaAAAAAACUGUVRWq1Wp9OpVKqoqCgYxhSwjkaYlifTElIlbU925xLwtCLANpqmdTpdbm6uQqFISkqCsYkA6xiGyTNZNHqjTCJKigzn8wi2KwLVHYPjeW26abq9Kbl7PXHOhwJ9LtsVgYoCu0AAAAAAAFA2BoMhOztbJBIlJCQIhUK2ywEAGXFRNk8hYKh4l1bEkGyXAwCMTQQ4x2J3qLV6HMdiQoMkIth3A/ZZk+qpew9ncDxqzXzZjQtslwMqFnRAAwAAAAAAT9ntdrVaTZJkWFiYn58f2+UAgOwYX81TuDEihDIrKTvb5QCAnE6nWq12OByhoaFKpZLtcgBATpc7O89gcziDVX7+ChmMuQFY51YG5rz2lrlO0+Ddf/gf24XRcNNS1Qcd0AAAAAAA4PlIkszOzjaZTIGBgUFBQXD6ClhHYbiGkOkJSQBlC3Ln4QieVgRYRlGURqPR6/UqlSo6OhrGJgKso2lGazRpjSaVXBYZHEBAJgHbaL5A++ob2g5vKC6eSJr9Ac9qYrsiUEmgAxoAAAAAAJSGYZi8vLycnBy5XJ6UlMTn89muqCDHv3OGLBZPXTe+IRzX+ijb/X//t2LTb2fSMkykNDC2XafeX4xoX1eCIYSojA2tBvx0prgRNYjogb/+ldoScyY6cwWIquyiSwOZrKbyxyYSi8WJiYkCgYDtckBVR+vP/DL3y+Xbjt0xicLrdBj08ewPOsaKCr3EYLFm6wxCPi8+PETEeiYZ05al8ybca7p1Ts/GBYaetmWd/9/6vb9dfJBhpqT+Ee1e7vTFgOZ1xfAjtw8wWUzfpOl/17vUNBYllw6NDZwUyC80tgtDnVHrvnxgPmajRUJhh7CAqd3a8fqNEOhz4xdOFWVlsFR4YR5sSsAr4KAIAAAAAACUiOPDmDK5fy9d/NeR18fCrZs+yn1ve5+RS/dYA1p37NY3lLx79timtd8euJh76If+DQQIk8Z07tw+oXAHNEnrTx25rA2JqkPqY5CTpcJLBJmshqxWq1qtZhgmIiJCLpezXQ6oBhjt7kmvpay8H9qyy8BRUY6Lf234ov+Rq6tO/ZQSjiOEkN3pUuv0JEWFBaj8ZFzYdzOZh9aN25OZG1bXXWCqO/Ngn09+3WNTtm7Ttm8wdffiuU2bVhy4nndodrcGnPqxGzzDYtR1Pq89gwTdQpRvEuS/GvP0i/YrdaPXhfAeX2ZP7b55P+UhGeonHRjJt7odf6RlHbiRdHDX73HnDiOGGzctPW9TAl4EHdAAAAAAAKAYTqczOzvbZrMFBwf7+/tzbMwNyq7NuHr2wLpvZv6eTYewXQ0oJ8aybfmavabQYd8tXNFWhSOE6EH7503u/sf66Xs6/tXTHw9qNevLVk9e7sKIHJ7s5uZJB07UmTGpXV1u9T5DJqsjt9udk5MDYxOBysUY9385ZlVGzQlbD33Vyg9DiBnfc3S7vn98veSDnl81xDR6o8FiDfRTBCkVHMkklX10zI//5SCsUJ8eY9v269a9lsBh06auaKHAEUJMz/3L53Tf8ff0w63/6ujHidJBsRjXkpu6M5h0ftPwCVIcIUTH+X3yX+bC27rhgSEdCYQQMupyxzx014yO+qdBkLNLf33zhu3H9R/5zzdrTDHfKDiybkvblL5pAv2lXgZfKAAAAAAAKISmaa1Wq9VqVSpVZGQkQRDPf0/lYjSrU2LH7HnU/QjXqPgsKu3IJQuR3GdSG9WjtYj7dRjyWuvNy46euens2erJLbA0wrQ8mZaQyrI2LVl0NuGdhZMSuXUiA5msbmia1ul0ubm5CoUiOTmZx+NWIEFVxuRtW7Ep0++1eR+3fNRHiwX1nLZ0aaPbEjLv1n2nVCxKigzn8ziz7ybVSxf9eSS01YCAU38U/N2QenDkuo2I6zypmeJRo4nJOvRp33rXb0cvpDs7NoRREDiLslm2mJnISP+x0sd7b75kWqxs5RXLen1Qx0AcIWpbpjmTJ/+if8+c3gMl924nfjerhkDuTBYG4wxC3OiALmFT+r7RnWCxG/pLvQ6+UAAAAAAA8FT+MKYikSghIUEoFD7/DWzA/HstOlzPQCNGt2V873mZbNcDyol0IEVkvcbJCQU6bDGhSIwh0kU+GcLCjIuyeAoBQ8U77+5a9P0e/54HB8azPZppUZDJaoXjYxOBKs519uAJm6DZq68UuIzUHtL61Z61MIwKDwyWiDi17yYvbv55xt3Iz+d2oxYX6YB2InlIvXqxhXcBAjGGSDcJoxhxGeV0P0RYgrjQU0HkEkEUsvxnclOBQoJ27DMz/EYj6nTpGrV+iez6eYQQEkvHRElZKrk4xW1KRGyHMeM6sFhUFQYd0AAAAAAAHEXTtNvtdjgcBSeKRBV1SZDdbler1SRJhoWF+fn5VdCneAcvqEazIIQQoz6vgItNi1MkNoyXBlssPpPlnp2o+eL1zQtPYjIPHj1B8hrWSxAh5MD5WYTCjfNCSJOSstsurJuyj+4zu39LDl4XB5l8norLJEmSldZOOp1OtVrtcDjyxyaqoE8BlaNSM+mVWefPPyc9zYIFxynv/vLp4KVbj6fZZFE16r/cd9qnA9uEyzky5sYTtls7hm9Qtxg+fUI0WlDkf8L6i5fULzyJyfz33AmSaFgzmoPNfCV4NpNeiSVN0xRFeTGTOI/wQ0yWgyQR/8nvwS4nqUEM7SAdyghdy3o3jm4OIu7REwf2yzAet9N+YmGrAOWMeEU9zlyaX3RTSrf5xdZr1WXojNR+9WTc2o5YVCQ2NE2XO5PQAQ0AAAAAwFEURTmdTovFUnBiRXSskCSp0WgMBgMMY1plFImNt1AU5XK5imbSa7N3ZxxZ1X/hWWtY96m9InJ4cj0hCaBsQc48HDGIzlq1bOe9pLc2t4eBQX1Skdh4q7Ov+ExWQDtJUZRGo9Hr9SqVKjo6GsfhdwafV3GZdLvdRTMp8dptG4zFZGYY447JnX9yx3bo3LclMl4+uPOnKaduOg9tm9CAUx239lszF+6+X3/gxu4hPJTzvFeTGac29l91xRrSdnqnoOq5gRWJDU1750Lw4jP5AjPkySQdhLpl2Xnro8OHijCEEKKci++ZcxkkDm51e2qqaudMkqLN5//q4mISA+VjAjC10bLpnnqfiTzUyL8BN9ZuwU0psWuPMZ0F6tN/b1o4Zt8ZNec2JfY8m8lyxxI6oAEAAAAAOIogCIFAIJVW4O2KDMPk5eVpNBqZTJaUlMTnw1Pnq4gKig2O4xWUSZfm/KKFP8zaf98V0Xbego/iAgJdjCvRlStgqPwXWM9tXnCB3+ur7rW4ceIKyqpIbLz1QxdBEHw+v0LbSeQjYxOBsqrUTDJur8wcIcSQJMnQphxx/8UbZnUMjQxUiXiWPR927LHqu+kbB/w1OIQrP9Extj0//7zEWG/lFy/H4QiV2mfl0l5ftGr9rKNqV1iz/5sxoGt1vf60SGy89UMXQRA8Hs+b7SQuSU2Ub7tqHnX6/q4QaRJGnsw1nxZIA3CLQ5UY+/3nsisnKQaZnPjoBlHfB/IIhBAT8PbN+z0yddOzFX+F87iwgh9vStLRG/7+vmsIgRCiU9/m4KbEqmczWe5YQgc0AAAAAABH5Xf2icXiCpq/xWJRq9U4jsfExMAwplVMkdh4t2PFy5lkLGc2/TBy6T+XXcHtB0+fPDYlSYaFkQYZXWCsUMaw5fcDD4JeWdFOASeEPqqCMonjuPczWYDdbs/KyqIoKiIiQi6XV9CnAFZUXCZ5PF7RTNq81gHtIAQ4wvhNBn72RmKiIr9vyL/TRyNbrZ16ZP8p2+Be3BhklzGc+3PMHlfK5MGDgkr9YhnbmZ3rR645ednt/2rKqAVvNa8rqb7N/LOZ9Eosi8/ki4kMDTvKE07PMO5+mLedL67dduTPA3lzRy57eOdXCSHGCFyMkEClmhHw+GmYGNEpRtkqS3NEZ7eFy7mQUkwsEWOYoPXYGZ1DHhWJc3BTYlmR2OA4Xu5McqkDmsnePnNW7oBFw+s8HhKGzru4afWGQxfumWUxDTsMGNangQorz3QAAAAAAFCAy+VSq9U2my1/GFMYcwOwhtZsnDVlyPbswFaDV00Z1TLWL5i0+LusRRJJZx9edcIe2//VtnDtKagsbrc7JyfHZDLB2ESAI0iK0uiNBloazsPuJ9SJVzztH8NDoyL46LTBYGOQlBNRZTQZD7JIw+/ffvT7twWn727ZazcR3vX4//VrQSBE521cMn/Ivtygxj22ju3eK5xrz5cFpcBiAwPWRMdouvTXt+qoOrFf9eN3E2kUJ+bxEMIFvHAM3RbyAgukERfyIzB0mqRtCHGhb5cICQ/nYbcjIwMLXNHLvU2p6uBMBzTjeHjwl61XbM2f3pdB3dv89eyNVLth4wcE5B5Z9/Psb4l5X6dEEWWdzuJSAQAAAABwC03TWq1Wq9Uqlcrk5GSCgEMlwCLq+vpvh+/Q1Rgyb8lH7WMZR6gzl1fMfdpMxsHDJ9wh49onwxgxoBLkj02Uk5OjUCiSk5N5PM6cNYPqimGYPJMlJ88gFYuSktu+VJP4587tB3S3xMcdZ9SDtAwX5hcRwZmbRDD/Wi9PHVCHejKBsZ7Yf/igK+6d7rWi/JIicIQQfX3rj8P36ev0nvD3sNrBXKkceIAhD+bYLtVt33bC+/73bifO+VCgyz6XbcpG/CFKHo4QIoRNpdhOm+sBgxIfr1nK4cqgkZ+Ip2Cz9AKk9ZrWIHbeufWA7srhTanq4MKulMk9MP+zn088NLkYFPh0suvSjh3pkX0Wju0aRSBUN9BwZ/L2v6++Nrbm1bJNrw+/oQEAAAAAIPR4GFOhUBgfH18RD+kCoGxcF+f9ds1R+705E15qQuWJaVfxL2P0//x72618pXMtLpy8gCrObDar1WqCIGJjY2FsIsAFFrtDrdVjGIoJDZKKRQj59+nXcNbMHz/blLK6XxQfIURmbZu76gwdOrRXc87cJYIF1mn3eZ0CE+ic7y4cOWROGjMopUX+b9+uG4u33XUmpax9B3qffYw1MemI7sCXO27PEy6e+PACQshtN33+0CVUBg+VYwghhAn7hIpm3TF8ppGvDuHzEUIMuS3dcAbxhgaJuZJSItkXNqWqgwvHcJiy8ZuTol9nTP/+3+xDT6ZSD65et4S2bBKe3zQR0U0aBW86f03tlpZtOl0/Bp5TAgAAAIBqzm63q9Vqt9sdGhqqVCrZLgcA5MD5meqMf3WMQHrm189u/lbon5iiUZ95vWIfnavYrv5z1SVqVK85XP8MKpLT6czOzrbb7fljE7FdDgDI5SZz9AaLzRGs8vNXyB6PA0PUHDnrwz/e+HZE+xtbUzonEumHtmw+p48esPKLTr40TDmVdeekgRFIbn27OLtwpw2mqNt5XqcILnRXgSLcyoCc1waa6zR9m9b9eelM6oar50MlIaRzb671CpIurKlMevxbQs3IoA+zM7+9cu9GjryzBEvPM282UdFhYV8EcKeLropsSr6CE1s0XxmZoESM/ra4wK9etFajZQKC/B9HE/cP8me0mlyyjNNpBB3QAAAAAKi+SJLUaDQGgwGGMQUcQWG4hpDpCak060EOxVjTTq5NK/ISLJho912v2Pw/nFcvHLPiiTUT4H5YUEEoitJqtTqdTqVSRUVF4TicQQKW0TSjNZq0RpNSJk2ODieKZFLW8qu/tkV89fWy7b8t2MWo4psNm/Px52PahPlUcslc7X2Ksdy/vPZ+kf9gwUSz7zpFsFIVKAnNF+he7p7bqY/iyumkb8bzzKYDTUJm3DXsfKg34LxG/gFbE/x7FOzUI8RfNYqMSNMu05gWaJFKLBqWHPB5lCSMU7vyKrEp+QpOdEAXi3I5SUwsfhJfTCwWYS6niyzjdObxDL/55pt9+/Y9mT+O4zqdDs7BOMXhcDidzue/DgDAeTqdju0SqhGGYRBCRqOR7ULAI3a7naafHcSWBU+GMZVKpUlJSXx+Fbx8FAsbs982hu0qgKcYhPS4JIcnlzCuRJdG0GqC7syE575L2PyDzNMfVEJ5XgGZ9Dn5YxOJRKKEhAShEO66BuwzWmzZeXoBjxcfHioSFL/vJgJbvLdo23uLKrm0F4CHfDz/x48LTBA2G67bMZy1ekBZmOs0VfcZQZiNsf/3peTe7fyJwX7K5Y1Lu6mOEIjfqxn1Xs1KKbG8fG9T8lnc7YAmBEKCMdodDBJhCCHE2O0Ohi8XlHX6kxmKxWK5/OlV9FarFcdx6IDmCIZhGIbBMAwuNwCgaoBtuTLRNJ3fhMJOjSM4kn+LxaJWqzEMi4mJkUq58LBxUN1ZcaGap2AQiiQNchquOQDss9vtWVlZFEWFhYX5+fmxXQ4AyO50qXV6N0mG+CuVMth3A/Y5gyPUvYc7QqNC/16vPHsYMczz3wNAcbjbAY0HBAVi6To9jZQEQgjRBp0BC6gTwCvj9CengBMnTpw4ceKT+Xfu3FmlUsG5Oke43W6j0SgUCmUyGdu1VCtWtgsAVZZKpWK7hGrEbDY7nU6FQsHjcXe3Xq0IhUJ2+6BdLpdarbbZbPnDmMLRDmCdGyNyCLmZEAaSlkDKhiE4fQUsI0kyOzvbZDLB2ESAIyia1uiNerMl0E8R6CfnyI/ZoDqjxFJN1zf1rTqqTuyPXv0/3GFnuyLg27jbqBHRdWpJ1Rcu5uYfn9LZFy9ly2vXiRCUcTrB2hIAAAAAAFQqmqY1Gs2dO3f4fH5ycnJAQAD0qgB20QjT8OS3BUEIoSRnbhBlhd5nwC6GYXQ63a1btxiGSUpKCg4OhnYSsIthGJ3RfOt+lstNJkaEBav8oPcZsAzDDc3a3562xBUQkjj3o7AtP0HvM3hxHL5USlC/e/fo1D+XrA8f3tZfc3DV5gcJvT+oK0BEGacDAAAAAFQDRqMxOztbIBDEx8eLRCK2ywEAmXGRmq8gaDrOnSemXWyXAwAym81qtZogiNjYWIlEwnY5ACCL3aHW6hFCUSGBMjHsuwH7rAm11b1HMHxBxK9L5df/Y7scUHVwuAMa8eL7TvnEvXzN0tTNDklEwx6fjkmJIcoxHQAAAACgKrPb7Wq12u12h4SEKJWlPQ0GgMrhxHhqnsKB8UJJs5KCy6YA+5xOZ3Z2NoxNBLjD5SZz9AaLzRGs8vNXyCCTgHVuP/+cHoNM9VoEHvoraP8WjHSzXRGoUjjUAY2pun21sVuhSURQ08HTmw5+5qVlnQ4AAAAAUBVRFKXRaPR6fWBgYGBgINy0C1hHIVzDk+kJqYqyRpMGnKHZrghUdxRFabVanU6nUqkiIyMJAq5RAiyjaUZrNGmNJoVEkhQVxoNMArbRfIHu5e65nXorrpxJnv0ez2xkuyJQBXGoAxoAAAAAAHiIYZi8vDyNRiORSBITEwUCGHYMsA4zEKJsnkJMuxJdGgFDsV0PAMhgMGRnZ4tEooSEBKFQyHY5ACCjxZadpxfw+fHhoSIBn+1yAEDmOk3VvYcTVnPs8lmSjFtslwOqLOiABgAAAADwMRaLRa1WYxgWHR0tlUrZLgcAZMUFap4fg7AIt0FOO9kuB4BHYxORJBkWFubn58d2OQAgu9Ol1undJBXir1TKYN8N2OcMjlCnDHOExwTv/t3/5AEENy2BigQd0AAAAAAAPsPlcuXk5FgsFhjGFHCE2+3O4SnNhCiQNAdSNgwxbFcEqjuSJDUajcFgCAwMDAoKgnYSsI6iKI1OrzdbAhTyIKUfjkMmAcsoitKkDNe36qg6sT96zXzcYWO7IlD1QQc0AAAAAIAPoGlaq9VqtVqFQpGUlMTjefkozmKxOBwOpVLp9Tk/glfIGJdut9toNIpEIplMVhHzrzh6vZ6iqMDAQLYLKT+apnU6XW5uriIgLCk01OvJsVqtdrvdz8+Pz/elu9RJkjQYDEKhUC6Xs11L2RgMBpIkAwICfLfH9snYRDKZLCkpyevJsdlsNptNoVD41qhHFEXp9XqBQKBQKNiupWyMRqPb7fb39/fdJxwwDKPX63NyciQSSWJikteTY7fbrVarXC6vqBFmug+viLkyDKPT6fh8vs/dnWAymVwul0ql8unR5B+NTdS9f0JYmLBRYzTuEy/O3OFwWCwWmUwmEom8ONtKoNVqeTyezz3N22w2O53OCjyA9x6u1wcAAAAAAIxGY3Z2tkAgiI+P97kDelAlmc1mtVpNEERsbKxEImG7HAAejU2E43hMTAxkEnCB1WpVq9UMw0RFRfncr6SgSrLb7VlZWRRFRURE+NyvpMDXQQc0AAAAAAB3uVyutLQ0t9sdEhLicxdlgCqJJMmMjAyHw5E/Dgzb5QCAKIq6d++ezWaDsYkAR9A0nZmZaTabIZOAI/IzaTKZYGwiwBZvdEDT94/9cfSeJ4+5JqJe6ts2Fjq9AQAAAAA84HA4vv/+e4lEUgl3etI0zTAMjuO+dU7CMAxN0xiG+dwN2vlfuM/dw+twONavX//bb79VQuX5KxcyWWkqOZN2u90r83E4HOvWrdu2bRtkshQURUEmn0un03llPk6nc+PGjXv37oVMlgIy6YmcnByvzMfpdO7cufPYsWMEQVR0VCCTlaySD+Bzc3PL/V6MYV74OSHOjf2V/f50PP+FvJqp/17+phk3OqA7d+68Z88en9skqirfHcDRp9X8IpPtEnzJjeif2C7BpwybyXYF1YgPjfxVTdhstrfeemvbtm0vPiu73e50OivnUDj/mNAXD418tPJKLhvDMK/cbOt0Ou12O2SydD5aOWTyuXx0zSKfrbzyy/bKMNmQSU/4aOWVX7ZcLn/xj3O5XDabrTIziWDlVpbKL1smk5UvS944UxX2Xvvf9+a24w/LOoz6YGjXJrFyMjfj0qFfl/54mJcyf9nEZn6PvgjcL7YenBoDAAAAAHhGLBaLxWK2qwDgKaFQWFGPugKgXCCTgGsgk4BrBAKBbz06FVRJXukPtu6f+9U/0sF/nvzp9ZBHveBtXn194KAOo1r2nbtlxJUlr1TbZ0DAFaZlcnYSPFUJAAAAAAAAAAAAAICqwxtX4LvO7tqni+47pntIobnhwd3G9I97uG3zabcXPgQAAAAAAAAAAAAAAACAb/FGBzRjtVgZhqaf/QdN07TJaHr2PwAAAAAAAAAAAAAAAACqOm90QPNrNaiN39u8clduoecZMtq9KzemYYk1EmHcZwAAAAAAAAAAAAAAAKh+vNE3jMcP+WTgor5rBr5s/OiT4Z0aJQQiXdrF/T/Pnbf5nvK16W/XJLzwIQAAAAAAAAAAAAAAAAB8i1cuTsYCX/9+1yre2x+unjViy1dPpopiu8/+ZfWwaG9cZQ0AAAAAAAAAAAAAAADAx3hrdAxJ7SErzvaZfnLfP6dvPDSSwoDY+m06dWgQIvDS/AEAAAAAAAAAAAAAAAD4GG8Oz4xJY1q9MbyVF+cIAAAAAAAAAAAAAAAAwGd5rwOasdzYsWrtrv/SNFSrT39+T3Vin7VWxwZBfK99AAAAAAAAAAAAAAAAAABf4qUOaDL916GdR62/Y2cQwlSiobQrbXHvt3bHvr18+4pBiTAOBwAAAAAAAAAAAAAAAFQ/XnlAIJ32fyPGbtA3+uj382k/9xYhhJC4y4wV42qr140ZuuQm5Y3PAAAAAAAAAAAAAAAAAOBbvNEBTV1dt+oY0+6LX+f2bxguIxBCCGHKBoMXb5rbCRjd27cAACAASURBVD+99rcrpBc+BAAAAAAAAAAAAAAAAIBv8UYHNHn35l2U1L5dVJGZ4eGtX0pEGXcy4BJoAAAAAAAAAAAAAAAAqH680QGN+SkVKE+jfaaf2Z2jzmVkchnmhQ8BAAAAAAAAAAAAAAAA4Fu80QEtaNzpFeXD9XNW3nYWnGy/suzbDWpFmw6N+V74EAAAAAAAAAAAAAAAAAC+heeNmfj1mPFlpz3vjW/V8sCbcTdJp3zn0ll7Dv26ductXrt5M99QwRXQAAAAAAAAAAAAAAAAUP14pQMa8ZLHbjwonz5hxor/22qlGbRs8klCHt9h/M/zvny7Dlz/DAAAAAAAAAAAAAAAANWRNzqgKZvB6CASBy7YP/Cb3Ls30jR2QhGWUCNWBV3PAAAAAAAAAAAAAAAAUH15owPavmN0zNs5s28dHB8jCkpsGJTohXkCAAAAAAAAAAAAAAAA8HHe6ICWtHi1tXj6iTPGD2JguGfwImR/zme7BJ8ybCbbFQAAAAAAAAAAAAAAUBrcG/OIGfnTL4PSv3xn7t67JsoLMwQAAAAAAAAAAAAAAADg+7xxBbT78Kzh8y/ijgtTuyZNE/kFqmT8Av3aoh7/d2XZa0IvfA4AAAAAAAAAAAAAAAAAH+KNDmjEE8lkMkGNNt1rFPNPQazSG5dZex3DMHq9HsNg0BDgq/R6PdslAFAiyGdlomk6cPsPbFfhS/RvfFCh87fb7TRNe212rr2jo7utyCk8QwwXSP0jkpu+2u+9T8b3SJJ47dOY7E1vt5hAzzv/a98gOEjyRXT2kdW//Sd/ZWS/hrJHkxxnprXodnTI4f2T6gi89TEQy3IpZu34OA+WiMk98evvt2P7Dm4TWvCs0OuxhEwWVvXCVuEgk4BVlbH7Ln8mS2jJvaFKRLcCvx+fVEJ0vfHd8F/6dNP2Em369CW+Fz7E6zAMU1Y8tpcSVGWQT8BlL55P4DmBwGt9StVERa8RPz8/HPf24ScmUIbHPhURwHfo0v/bvXLK6807fnnSXPjFzow9897t1ig2UC4LjG/UYdDMTTesHn0Ko932yYSt0R99kVIh5wC2O9tmv/NKrTA/iTQgtkmvictP5Ho0eJsr88Di8Sktk8JVEpFEGVGn/eCZGy4ZmSf/d24fosKxkgmafXOd1VHiyrvgtjt/zxndtWGMv1QoUoTWeKn/Jz+dKv2dVPpPI/uM+ujTZccNT88vRU0nfdb19pfvLbvl7W/Bk1i++NrhaCzL/sZi1w57yr3gT3myRPT9DVNGfTjrr3tFXlFBsSxDU1n27esJrmbyqdJWzQsseAUr84J72Lx4+DLWM8mYrm38amjHelH+UrEsKK5Jz/eXHFKTnn0KNzPpyjy4+P1ezROCFWKhRBlRu91bU9ac1RWIJOy+n6jM3XeZDinzldSSP1b+VouL0XUfHh/DK1Mgn/f9VL6Kak4R8uj7KSG65T87GhKkrJt6wv10AuW02ewuznzfHijly/UWthcRVGWQT8BlL55P4Dm217bv8cmVQtScsPN2+hMPNGZL1ulVw+tKGMPJ2eMWXHpyisroj8xo37j7x8v33nEFxcfKjdcPrf+qf+tu3/5ne+6HOE99N/V3qs/HIxIJry8AY/z3847Nek//5cgDFJ4UrzBd2bHo3XYth2y495wzAfuFed0adZ64ZNsZNQqtWTNKbLx15NevBrZqOWZr1uPjTowgeMUjcAxhuEgkZG1DKe+CM/rDU9s36ZW6Yu91ozS6RmIQnXlq43cjX2765s+33SW8x33z+5Ef79I+cziO+fecPDr2xNczN+Uyxb2v3DyK5YuuHU7GshxvLGntsKLcC16QJ0vE6A/NX/avs7jcVUwsPWwqy7N9PcXJTBZU8qp5sQWvSOVbcA+bF09fxmYm6YdbxrRq3n/m2gO3LPK45Ehe7sW/v5/QqUnK8hvO538IFzPpvrm8T7POE7/fcS6HF1GrboLKkX7092+HtWkxbOPDJ9mE3Xe+yt19e3xI+XSRSmzJ0Qu2WlyMLmNKu6uhMQwvJpbFHuKX/v1UvgptTj38foqPbvk7oB0Wi81ZoHznlrcDFHU+/ZfdHRcAAAAAQHWACUObDf+/dR834DOuy5u3XMs/KGNy/hz35tenrPEDVpzPzLx+8Ur6wxubx9UXGo59+d73N55zwJ2zce7K29EDR3fx8/7pnu3fWSO/Pmnyf2XW0XuZ1y9eTn94Zd2QRCx9wwcTfn1YSgeW4/RXb089qOMlDVp5/mHm9f8u3FRrrm2a1FrluLFq1Pvr1QxCCAl7/Kx1uZ/lytk+Mo4Q1ho3a0QcW3dElnfBnf/OGvndWYuq/cy9d7IfXL905W525rmVgxLQg80fTlxb7Dudl+YNn3aw+CtR+fWHjWxt3jr3x2seXk1XTsXE8gXXDidjWY43lrZ2Kl+5F7yAUpeINtw9sef3ZV+O7dy055Lr7hLOyisllsU2leXYvp7iZiYLKGXVvNCCV6jyLbiHzYvnrRBrmaQzfhw+bOV1V3Sv747c1967cvGGOvfm5kmt/HL+/nDo/CvP6WPhYibph2s//OTvHDx5yJrL6ofX/zt3OV19d//M9v7uu+smzNz16Cpb2H3nv4Xt3Xfxh5QetuQv0mpxMboIUem300gk6rkmt2gwbSdTaz7tKPfs+6l8FdqcIo+/n+KiC8OTAAAAAAD4KH7tju0jCESl38kgEULIfXbh5xtz8OT3f14xor4fjhBCotg35i0cHo3bz63/41ppPdB0xoblu0wJfd5s7v1nRzP67QtX3iDFL89Ymdo6gEAIIXHSwKWL34nEtDsX/FRyXc6jq1Zfc+EJY1f8OPzRAiFJUsrcDV93lDG6nas2PSj5FILR/v3xu6se1vv451ntFCxdQVXuBScv7diZQeIJw76Z3jFKhBBCCFc1GLZgSkcRMh3acejZO2Rtp2cP+/KUuMuQHuHFXUWER/ce0Aa/8NPKEx5cS/eCisayOJ6uHU7GsuxvfM7aqWTlXvACnrNEtl0fd+g6YNxny/en2Uo5J6+0WBbJZNm3rwI4mckCSls1L7TgFckbC15gbp41L8W+jKVMkv/9uPiAEY8esWLdpDYh+StOnPDGdxvn91Q5zyyat8dS2ry4mElGs/OPg2YsaMDcpW/Xlud/vYLwDtPnvVuLR2fv+fuMq7QPhd13AWy1k8izlvyFNl4uRhch5Ei7/YDCI5ITpaV/hId7ukpW8c2pp99PMdGFDmgAAAAAAJ9FukmEEJP/0EP32d833iJ5TYaPaVXwoFDUbs6ZtIw7f71X2v2N1N2NG065I7v1aPT04R2M7ufuIoxfM/X0k35EKuuvsXUkOOHXIvWgzuPDbduhbfuNSNhmYP+ClzLJOwzsFU64r+74+04Jh8P0g4uXtTQe/GqPloUeioOHt3ulFo8h79xIK/HkN29n6vtr1HU+Wja1eZkf8uR8cGDphN4v1QxXSYRCiTKi1sv9Pl55KrfsVweWd8ERomkaIYwv4Bc898YEIhGOEE1SRUsxH5k5fO5FZcrCH96JLX4t42FdezQj7m3ccLzie6ALx7IYHq8dTsayzG98/trxCAdi+dhzl0jcbtqWHTt27Nix468fh9cs+bH3lRfLwpks4/ZVEDcz+cRzVs0LLHhxOJTJpzxsXkp6GSuZZHLPnk4jcWX7Hi/LC74EC+vVp42Ayd29/UQp/bWczCR59/odN8Or0bh+oT4qIio2ikCMyWgquQLYfRfBVjvpWUv+IhsvJ6OLEHX/drqL4SXUiC9554UQ8nxP5xEORPdZxW6MHn8/xUQXOqABAAAAAHyU9eRf+7IpRMQmxhEI0ZknT92niOiX2sQVPonBpUHRMdFRAeKS50Rn7d11nlS81K5RKQ+PptU7xnd568cbgmafbNv5zSsBnl6XRN65eNXCEHFNGgcWegu/QbMGfIy8eelaSSdVotqvfzDxw0m96xY5yKU06lwaYQo/efE1MMZ/Zkxc8zDh3cVTW5Sy1MVyXl7cs2nn8Yu3nsnmhddqUDdeaU87vvF/o195deoxz57l+ET5F5zX4PXXk/jUzTVf/3TF/Oh0y5W196v5e2yYf+e+r/oVfDGTt+eTEYtvBA1YsuStyBIP7vGINi8nYeo9O/+r6AHzCsfyWZ6vHW7Gsmxv9GztPBcnYpnPkyUiwpt0fS3fK7VUpaySSoplkUyWafsqjJuZfOS5q+YFFvxZHMpkAR42L6W8jI1MMk6Hi0EII/CiWRGIhASi865fyyqxH4qbmeS3/PayyaLf915soSSazp68SmL8WvVL7K2D3fez2GknkUct+YtsvNyMLkJk+u10kghODM7a+t1Hw/t379Tl9UEfzFpz/GHRd3i8p3suTkT3GSVsjB5/P8VEFzqgAQAAAAB8DWXLTTu96fN+g5beJjFRo7f61+EhRKbdSiMREZMQlrXvfyM61o1QSsTy4KRW/T5dfU73nGsobGeO/efi1WxUr8TzPTp754Quby67xm/+6dadX7f3+BwAIUQ/vP+QRkR4VJG7SzFpRKQKY+wP7muKLw+P7P7pvAX/m9Q5tNAhK5X5+8IN9ykipnPXOsWewzrP/W/yyvSg/l9Pffk59wc+y7przhf7c4nkkX/cVN+/eu70uSsZ2Rl7P24iclxdsfKgo0zzKveCIyRq/dW2tWMa2LaObRxXs3XnHt1faZSQ3HX+tdBec7f/PCSiwPfBaLZ9OHpFesSQHxb2Di1trfBqNK4noR+cOHG/ogZ6LTaWzyjD2uFmLMvyRo/XznNwJJbIe0v0WAXHsoRMer59FcXNTCKEPFs15V/wZ3AnkwV52LyU+jIWMomH1Kzhj9OG44fOF+7CMR7c/a+DQXRebl6JxXA0k4RAIpFKhDyEEGPMOH/q2P6tP88e1vHtnzJFDT74ZlSNEu4Ggd13cdhpJz3yIhsvR6NLq++kWRhas/qtZn0+WfDzn7v27/1r/dIZQ1+u1Xz0n+kVMhI3R6JbRAkbY5m+n6LRfcHLxAEAAAAAQMUjL33RkP/Fs9MxYXSv+T9/WIeHEGJMRiODmNwtI1sfPKgmFBHxCdHGjLRTG+ee2rHpn9UHVr8ZXdL9/1T6lRs2JI5PLKEDgsrZ9VGX/t9f5bdI3fb3rHb+Zet3Ii1mG4MwqVxa5H2YVCrFkNZq8XzwPMZ4YdX4wRO35uIxg+d+2kZUzEvo9FWpiy4TLebMfCOozB1ktJ4Mbvva67FDZvaOe3xKJAhrP7hH0oJzNzW5VgaJPJ/nCy04XxmZGB8sPq/X3Tqx71b+2/jhMTXjgyQF5kY/3PD+uF+z4kbtmNcj8DmVCeOSogn3jUs33CjBO8MtehLLIsqydjgaS8/fWJa1UyrOxNJrS/SUl2PpaSY9276ewdFMIs9XTTkX/NnP40omCxXlWfPyvJexkElxu2GDk1bPu7V0zIfNN/+vT4IEIURq/l0y6t21WRRChMPhLOkb4G4mn3AdmNq2z28WBiGEiWsOXb35mw4llAG77xKw1E56Mqvyf1FcjS6ZfiuNRAzi1Rz90/epbzQKF5rS/v1z7sdTV59fOfTN6KRj0xsKylTKc3EnugWLKmljLNv3UyS6L3IFNGM8t2HBvMcWbr9FFZ6Sb9GOW2Ub5RoAAAAAABSGCZThsQXExSXWatLhranrzlze8m6d/G5Yt8NBMch9+Z9TQSN/uazJe3D98s0sfeaROV1D3Xd/Hfvu6pKf2Ec9vJdJ4UFhwcX1UFM5eyZ17bf0khVJm70z+uUC5wDkqU+SeVgpBM2/vUEhxDw62C3hAJqmPDpYpLRnfxrfrnaL0WuvMckDf9y1vPgrhsz/zJ17yBr65pRRyeUYbxeP7Dt/y/YtC/pFPTlKJo13/vl9f3rBGit8wZm8fR++0vnjzTk1Rny/+0JGnsWkvnls/ZT22LG5/V7ut+L2o0tMqPSfxozfpE1678dvOz//7k8iJCwYZ6yZ9z0fQ/E5PIllYWVaO1yNpYdvLNvaKRVHYunFJXrKy7H0KJMebl/F4GomPVw15V/wZ3Akk4V42Lw892VsZFLceuaaz9v4Oy4v61cjOCSpYaPakQGRbSYdUHVoE0EgTCQWlrRauZrJAvhNxi7/edXyhbMm9GkgvbN6YLP2Mw7lFffdwu67JGxk0kPlTwhXo4uFd5syf9GyzccO/zC0ZYxSyBcH1Xh13MrdP70VgdvOLZq30+tPa+VIdAspeWMs2/dTJLovcgU0nXf0+0+PFp727BRRv5ixPcrTgAAAAAAAgHxEzQk7z33eoNQjN55QSGAIE7SYsWHpoMfjK/JC2ny8+pvjNYb9tX/VH+nDJiUUe/UBbbXYGCxMLC7meJW6u+azHzBFbFzgvfQDX3zyxxsbBjzu+MVDWr01ZmwpN/MRMY1UGCJkMhFCNpvVxqBCD7RnbFYrgzCprOh1Gs/UkHvyxynjZ645q6WkST2mf/Pdp71ryIp9D31/3dxf7mO1pr7fxa+8PWS04cqOX//cd+ri9dtp6ekZDzQWN8MghJ5edlTRC+4+N2/iD9ecoQPW7vqxb3D+a5Jfemv2tmTeSy99tTN16sbefwwIoG79MPLjXeY6k7fOesWjhRVLxBiiLWYLjZBXDs49iWVBZVw7HI2lZ28ky7p2nof1WHp9iR7xbiw9yaRn21fxDQwnM+npqnmBBS8W65ksXI1nzYsnL6v8TCKE5C2m7TndeMk3C9btOn37+k1xWJ0eH0/4fHLkyqb/HMUVSr+SrhzkZiYLwaPbDnynLUIITfh0wsqU5mN2fDtmTo8rc1oUHvkXdt+lYCWTHs2q/AnhanT5NXq8V+OZqVhwz3Fvxm6Yn3H88EX3G21KGbW6fNiPbqFqStkYy/j9FI5u+TOXumXHO550nRNhTby+cgAAAAAAQBGEKkCFIWdy566JhY7wsKB2Herz/zp+6+pNEiUUe+MgxhfwEXK7i3u+DcNgqjYzt28dkTaq8dAtmz6d+nenVT3y+yjw2JQvvk95bmFkRHQkga6rM7MoFFqwNLs6S89gwoio4FJuymPyjn/71puf7ctigpqPXDr3s1FtI0q++ZG8tGrZYZug5YjhpT3TphSM8cTXb7zx+eFcRh7TtE3r1ild3k5IqtPQ/8i41+dcf/KqCl5w+v7hg3dILKDr4B7BhY78xQ0Hvdngm/Nnjx445x7Q2Xpi73EDEvjtm9zpyJP6TRk5NCL/m/f6S+sEvJpjf1n1ztNHQLndJEKYQCDwYu9hWZR17XA0loRHbzSWde2UhhOxNHtziQqo9Fh6uH35UFPp4aqJfoEFf3ZpuZDJQvPwrHnx6GVsNZXi+G6frOj2SYEpTN6adA2NSRKSShygm5uZRDTpIimE8wW8Qv/nxQ0a81rqzjUZp8/m0C0KPXYPdt9c3n2XyLMdYrE4Gt0S8WITY3koTZ+n9/ZI3JyIbqF5lGdjLOH7KRzd8ndAN+76WrnfCwAAAAAAvIxXo04NPpZNPnswT9M0QkggLHHkQDwwJBCnDXmGYo6q8fDBP2+b+ZI/1vJ/X647+N6+Xz76fHDbJR0UZSgsoX5tKXYl/fwlA1PwqdzuK+evuBlenfp1Sn7Uve3c1z26zzjpjH39f+t+nNA6qPQrf1yn1v56jRS2fbNPmXvB8lHXln7w5WFd8Ovf714ztt6Ta0eoK/+V56SvvAvO0DTNICSUiIsuLiYUi7DHKxQhhBBtvnf+5L2iczCm/3cyHfHJXvYCt+vShjwDjfECg/3ZeQx5mdcOR2NZhjeWYe2UhhuxRAh5bYkKzrHSY1mW7asojmYSIU9WzYsseFEcymQ+D5sXj17GRlNJ2fQ6s5uQqgJkBTt87KeOnHEhYetWjUv8XYCbmSTPTa/fek56s/9dO1bkxiueVCbGkMluK9JawO77EU7uvkv2AhsvN6PLGK7s3XfVJK/dsUu9wmOj0Ea9gUZ4UEiQl1cCN6JbQGkbY1m/nyLR5Vp+AQAAAABAuWChXV5rKqDu7Nh6wVlwOn1/998X3Ji48f+zd9/xTdRvHMC/l500SZs26aB7gmzZiMiSslGmiAxBBbei4AJUFBV/LkBwoiKigAIylC17o7Jkr7Ka0aRJmjT77n5/lFFKgRaa3iX9vF/8Q3q9PGk+ucs9uTzXssGNzmQQZeRkiFjr+fNF1/ePBKqEBDVFCBFmPPbZ+NYK+uQ3L36w00VIxQfSKdt3b6ck7i0LlxtKrd+7e/Hys7Qou2u3Gw5ro4/OePa9nU5tzy/++u2lW3WfCfHtWLA4j5G07NM76Tbf47oP/nvYT9SdHx/ZoPQ3F93nzxpvZxLfbT5wYVKD+jECxrBh9d5rnknCGtav2e+nxPUa1xURohm+3MOW4dvwbLKQSDrMOE+zrG/P63eVugf6wtkLtDA5J0txe3+cO1T5Z4evsazQL1b22bkZfsSyKh9RKdUfywq+vsrFz0xW8Km5kwdeFj8yeVUFNy8VW4yLTaVr5dM5CfHJD3xb+loNrH7h10sKWGW7h3rXumG9/MykMKtRPQXlP/jXRsO1ZQWObd1upAVRde6qdc1vYvfN5933zdz+i5ef0aVEJ356cvBDDz7+9dFrh+IHji1d9l9AoGvboWEVj3jgR3SvuumLsbJ/nzLRrYqxLwAAAADAPUH68NcGf/bg7I8HD4v/6YunW8YICHGdWPTGkPEbXIK00c/3jb3RyRSUtmnzTOH6IweOBEjbG7+zFtd9bvq4eW0m7Z32/KeDtk5oJKrYQDpCafu+MOztP2euevvFuff9NDRTQghr2fL2mK9PMurcF0Y1vvKG1J+3adG2C4wote2Ae5MFJLD/5zl/u4X1xr4zLL0Cb1oD/6396yItati5442+rFyyflqY3Kb/fWnlrVESGx9NscadK7cUdr+/5KI37tMrPnnuqR/1DJEEfJdOLq/gJL7bfuDyDqMfq//T+wenDXsiZ8H0RxtFCQghnrOr3hv+yko7FTvo6YHJlT9EZ4yHDxewyvtaVLjHVKVu/exch6exrPgvVlCoxDIouIjlHby++JrJqn7goZbJCm5eKrYYJ5tK5f2DH4z/9ceN7z79eaufnmsSJSAB46YPHnl5uVVcd9ybQ2/SlOVnJilN90f7Jiz5cc3EJz6tN/uFVjoRIYQtPrVk/IiP9gVE2UMe6xhR+t6w+74pjnffN3X7O0R+Rpco7x85OGPBzD2THxmT8+uUvlkRhBCm6PD8Vx6evNunaPnimM6V/BQgVKJ72S1ejJX7+5SNLv8CDAAAAAC3hYru8fHsF/f2/vTX51svfTM1O0VqPnnSWMwIdO3e/eV/nW/y3UVR/fs7JHz4za6deXTb7JucHCFtMnbas792/OTvD5+fOeCvMbUrNJCOEKLs8O53L27t9elvjzba/UW7xrrio9u2HbOSxD7ffjEy5eo7XPfWT0cMXeZVPPTbg/cmS1nznl0nA4Q+8lFbzWflFd3gja1bXq93uVz6zF9/nQgIE9rce8PTO0rW75E9MLfHfWmqchaQ3DvquVZzX9/+Rbecv1q3rB3puXj0wMHT/rpD+jf/bf6eTe8/9GjBqx+80b1WxSbx3e4DJ0TafMLPUw92f3H5T483+XVsUlZalOfiybwCF01FtRj384z+N/wo4SaK92zfF1Dc0/neiFsvW/Uq8Oxcj5exrMQvVlDIxDIYOInlHby+eJvJqn3gIZbJCm5eKrgYJ5mkInu8N/2RLYPn/jGmZerHtbNj6QtHjhk9osSe0xZMuuemX5nnaSYje374zehdA79aMe6elCmZdTK1YueFo8cuOmhBXMcPfn6n7TVNPOy+b47b3fet3PYOkafRVXV4b+6kgz0mbp7Rv+6cxKysWgrXuSPHjS5WljNk1s8v169sDzVkolvili/GSv19ykYXIzgAAAAAwgYV3fGjzbvmTRjUJlVSePLoBb/u7p7PTV/7z6rXW6luetAjbdWnZy1m/9r1xlsMcY1oM2Hq4+nC4q3vvvh9XsUvxEJpOny0eduP4/rUF5zctHLdfkdixyc+XbNrwaMZN34rT188d5EmhA14nOVz+Up9O5E1rV+7L0BJGzVrcAdnWEgavfLHX18/162eXL973eotx3wZfSb/uXfbD198OK59ssSwa8WW065Kjbm9nQdOCCGy+k8t/nfb7Dcevi9LUXT60DEjm9C01zNTV+3dNKVTzO2MBXTvXLPZobivb1cdF9cwus1nh4+xvLNfvD28iWWV4yqWt//64m0mK6bKNix8ymQFNy8VXIyrTAoS+3+/bd20p3o0rcWcP3LCqmrY5+VvNu/9/al6slv8Jk8zScX2mLlz57y3h3fKiSg6vf/f/y7QSa0HjP1q096V45opr1kUu++b43b3fWu3/eLla3TVLd9Ye2DDzJf6tUig9Uf2HTaKMjsMmzR/9+4fBwdlH8mb6JIKvRgr8fe5LroUy1b+UhFhITc3d/Xq1RQV3NdwnUkXgrr+MHM05XuuSwgpI968wxUgn5WCfFbOHecTKs7hcKgWlnd6KNxIkPPpcrkefvjhpUuXBvVeqp5/12sN7v08ZcbxVaMrPCMhFBXP75eyeND5Xwfwb5RiMLnWPlm7+8I2vxyfNyCan4ew5UMsw1pIxhKZDGvIJI8hk6GTyQpCdMPa9dEN5ycZAAAAACpK3PypF9oLNs/+5SR964VDF51/3piYlS7huo7qxVpX/rDImPXYmN6hdviKWIaxEI0lMhnGkEk+Qya5rqXqIbphrLzoogENAAAAAIQQQerwt5/M2PvV55uLuS4lWLz/fDV8yI/aFx67u2ZdB4U+NXvqMsGDb45pEaRBvkGEWIatkI0lMhm2kEn+QiZDLJMVhOiGrXKjiwY0AAAAABBCCFHc8/qnj1Jz3/3hVJieiiKMazH6h40LH8us+HXwwgBrXfn+1KNt35kyMD4kz59CLMNSSMcSmQxLyCSfIZNc1xIsiG5YukF0a1YPHgAAAABujIruWDLTPAAAIABJREFU8r/Fs387YS9iiSYMj3ZESU3acl1D9fObxW3f/73LwxmhevCDWIaj0I4lMhmOkEk+QybDFqIbjm4QXVyEEBch5BFc5K1ycBHC6oV8Vg4uQliNcBHCSsNFCAEAAAAAAKoLRnAAAAAAAAAAAAAAQFCgAQ0AAAAAAAAAAAAAQYEGNAAAAAAAAAAAAAAEBRrQAAAAAAAAAAAAABAUaEADAAAAAAAAAAAAQFCgAQ0AAAAAAAAAAAAAQYEGNAAAAAAAAAAAAAAEBRrQAAAAAAAAAAAAABAUIq4LAAAAAIDyff311wsWLKie+2JZlhBCUVT13F0VCtHKq7NshmFUKtXy5cvvfFVz5syZPXv2na+nIkL0mSUhW3k1Z1IkEq1bt+7OV7Vo0aKZM2fe+XoqIkSfWRKylVdzJlmWXbt2rUQiucNVrVix4uOPP66Sqm4pRJ9ZErKVV38mly5dGhUVdYer2rRp06RJk6qkqlsq+RMRPLnVpfozOXfu3OTk5Nv4dTSgAQAAAHjK6/WOGTOmV69e1XBfTqfT4/FERUWJRKH0/tDv99vtdplMplQqua6lcqxWK03TWq02eHdB07TZbLZYLBqNZtiwYVWyTq/XO3r06IceeqhK1nZzxcXFbrc7MjJSLBZXw91VlUAgYLPZpFKpSqXiupbKsdlsgUAgJiYmeMexDMOYzWaz2axWq0eMGFEl6/R6vUOGDBk5cmSVrO3mXC6Xy+VSq9V33qOsTjRNW61WiUSiVqu5rqVy7Ha73++Pjo4WCIL11W2GYSwWS0FBgVqtHjVqVJWE3+/39+3b99lnn73zVd2S2+0uLi5WqVRSqbQa7q6qsCxrsVjEYnFkZCTXtVROUVGRz+fTaDRCoTBId8GybGFhoclkUiqVL774YlVlskuXLq+++uqdr+qWPB6P0+lUKpUymawa7q4Kmc1mkUh05+3+auZwOLxeb1DfwLMsa7VajUajQqGYOHHibYefzwcYrHXlm49/ud9/5QZhYr8PZwzPERKmcP+i2fM37jvrUKY27jhoRL9GGooQcsPbAQAAAABqEpvNZjAYZDJZZmZmaDUmIFzZ7XaDwSCRSDIyMkKuMQFhyeFw6PV6oVCYlpamUCi4LgeAOJ1OvV4vEAhSU1MVCkXInY0L4ae4uFiv17Msm5ycrFQq7ySTfG5AMyaDicrp9VLfepc+X6bkibUEhNBnF7//3kK63YjnB8UUbJ77w3tThJ+83ydZeKPbuX0UAAAAAADVx+126/X6QCCQkJAQcieXQVgqyaTf74+Liwu5k8sgLHm9Xr1e7/F4YmNjo6OjuS4HgPh8Pr1e73K5SjKJ1jNwzu/3G41Gh8NRVZnkcwPabzJa1dmt2t7T4Joesu/AH3+cSeo39cmuyUJC6mttJ8cu//NQjyfrHCr/9oah9PUoAAAAAE4olcqQm2JBCBGLxUGdYhE8Go2mytcZCARMJpPNZtNqtTqdLtQPXyMiIiIiIoJ4BwwTjLWKBAJtST8rOOsnQZtFEIzWME3TJpPJarXGxMTodLrgDVKoHgqFIrjnyQYnM0KKCtFMBuMjtCuZ1Gg0KSkpoZ5JuVwul8uDeAfByQxFSHAzSYIVy2DMsbkymygqKionJyd4wz3Kov23XqbyZGKhTBMZvPUTKlh/nxDNpEqlqvKRX6XnZWVnZ1fVcA8eN6CZAqOJja0by7itlmKRJkYlpgghhD5/6IgzvlXTWiWhE6Y0vTt20d7Den9E+bczDVNDe5cCAAAAAHBTpUdGZmdnh9bQZAhLpUdGZmVlhdbQZAhXmE0EfFOSSalUitlEwBMOhyM/P18kEqWnp1ft51u8bkDrCwIF6z8Y+cMZO01EqrQ2g597qnuW2GwyszG66MtdZUG0Lpo1mwoCN7idIZca0HPmzNm5c+fV1TOM3W4P9RNDoCaz2+1clwBwQ8hndaJpmusSQkyw8+l2u5ngnT0BcJ0yIyO5Lgeg7MhIrssBuJRJhmESExND7gKhEJauzCaKj4/HbCLgA4/Ho9frfT5fkOZl8bcBzTrMVr9cmdnrhUltE4lx/x9ffT7r/Vm66U/4vAFKLpdfbhxTcrmM8nl9gRvczl5e4alTp3bv3n1l/Wq12u/3owENocvvD85XWgCqwp3n896ZniqppIY4msJ1BSEl2NtPbJ+h2mBkJPBNlY+MBLhDJZksKioKj9lEEAbCbF4WhIHSs4lSU1ODNJuIvw1oSpP75vzcy/9LbvHws333PbNg0/5H75MKWbvbwxIZRQghrNvtYcUqiVBS/u1XVvjCCy+MGjXqyn9HjBih0WiC/1LXB3n9UHNVxexI5BOCBfkEPgvG7N3SpFJpqM+UBP67Mp5Po9EkJSVV38hIgBsI0shIgNtWMpvIaDSq1eqcnBxkEjh3JZMRERGYlwV8UJ3zskJnEyzQJtaS+q0OX7ROS52xWBkSJSSEEMZmsVEx9WJEMeXffuX47/qL2wqFQnzWBKELh5rAZ8gn8Fmw84n8Q7BhZCTwTcnISIlEgkwCTzgcDr1eLxQK09LSMJsI+KBkXhZFUampqcG9xC5AxVyZl5WUlFQNs4n424B27Zjx8k+BRz544d7IkosPXjx11qeplxyVGntXxNJ9+wseTo+nCGEM+w8YVHXrJUpS6pV7Ow4BAQAAACA8YGQk8E2wR0YCVJbX69Xr9R6Pp2QODNflAGBeFvDOlXlZWq1Wq9VWTyb524CWN2hV3//Btx9FBwa2ShRaDq3+eUlBveE97hJJmO7dU1777fNfao28L9q04bvF5zP7PldfQoQNy78dAAAAACDEYWQk8E31jIwEqDiaps1ms8Vi0Wg0KSkpyCRw7spsoqioqJycHHxJDjjH4bws/jagKWWzUe++EvXjr3M/WFYkjE7KafbEu0M61RIQIsjo//or/q9/nPHaYo8isXHPV0f3SRUSQkQ3uB0AAAAAIFRhZCTwTXWOjASooJLZRDKZLDMzUyqVcl0OALHb7QaDAbOJgD+uzCZKT0+Xy+XVfO/8bUATQsTxLR95teUj1/9AqGs2ZEKzIRW+HQAAAAAgBGFkJPDNlZGRycnJSqWS63IAiNvtzs/Pp2k6MTGxGsaYAtzSlXlZmE0EPHFlNhGHM9x43YAGAAAAAKiZMDIS+IaTkZEANxEIBAwGQ1FREWYTAU9cmU1Usp3EHBjgXOl5WdzOJsKLAQAAAACARxiGMZlMJ0+eFIvFOTk5MTEx6KqEFM/2DwcMmr43wHUdVagkkydOnCCEZGdno9MXasIwkyzLWiyW48ePsyybnZ0dGxuLTIaUcM6kz+fLysqKjY2tad1n14ll7wzrdFeyTh4Rqc1u0++NBf85Wa6LqrgwzCQhxGaznThxoiSTCQkJ3GYSZ0ADAAAAAPBFyRhTqVSKkZEhii34c8b0ZZsfeIrhupKqwu3ISLhzYZzJtLQ0hULBdTlQaeGXyZJ5WYSQGjubyH/s637tX1hdlHBP/5H9U/ynNixe9NHw9dvOb1wztlEojGQPv0xemZfFn9lEaEADAAAAAHDvyshIDsfzwR2g3ea8Q3+vn/vBxAUGJo7raqqEx+PR6/VerxeZDE1hmEmv12swGEpmE8XExHBdDlRWGGbS5/MZjUan01mj52WxtqXvvL3Gmjpi4eZve8YJCCHMG+te6tR95pQJ84csGx7P4z9KGGaSt/Oy0IAGAAAAAOBS6ZGRGG4QoljT7D5po1Z7S/4X8l+7Lj0yMjU1taZ9kTw8hF8mzWazxWLRaDRJSUlCoZDriqDSwiyTDMOYzWaz2axWq7Ozs0WiGtxeCxzYvMMmbPjCy93iLj2vAm3Hl0fd881LW9b/7R3ek7ff5wq/TFosloKCAn5mkl/VAAAAAADUHCzLFhYWmkwmhUKRnZ0tFou5rghuExXde9qm+jaGsJbfn+/7yQWu67kTJXNg5HJ5VlaWRCLhuhy4TeGXSZlMlpmZKZWGwvf5oTzhlEm73W4wGCQSCeZlEUKIv5hoshu0a5pZ6oMhSq6QUyTg9fF5qEU4ZZL/s4nQgAYAAADgKYZhAoGA1+stfSOOvcNGychIiqJSUlIiIiKqduVlYlNVkMkbEulqN9cRQlj9PnXInkQV1JGRyGR1C4tMlswmCgQCCQkJkZGRVbvyMrFh2aq5YBrDMDRNI5PlCKNM+v3+uLi4Kp9NFKRMsixbTiZFVfccKLpN/6fbtTcxF5b8vsMvadyyMa/b82GRSa/Xq9frPR5PyRyYKl956f+yLHvbsUQDGgAAAICnaJr2eDwOh6P0jTiIDQPVMDKyTGyq6iC25AgWmQw/1TAyskxsGKZqzoqjadrn8yGT4ScQCBgMhqKiouDNJgredhKZDEtXZhPFxMTodLpgzCa6fjtZJbEMBAJ+v79sJjVV/IlOKd685eMHvrKmOO2xCY+mh2xfNwSUnpeVkpJSDZmkafq2d99oQAMAAADwlEAgEIvFcrmc60KgypQeGZmTkxO8MaZBig0yGX6qbWRkmdhUVT9RIBCIRCJkMpxcmU2kVCqDOpsoSJkUCoXIZJgpPS8rqLOJgredFAqF1ZNJ34X10159afJvR3wZ/b9a/HFXDS5rESzVM5uoTGwEAsFtt7nRgAYAAADgKaFQKJVKq3w4A3ClOkdGlolNFTZWJBIJMhk2qnNkJDIJFVEym0ggEKSmpoZoJks+qEMmw8aV2UTJyclKpTKo91UmNgKBoEpiKRQKy8kk7b/zNV+Dte75+qXHx8876E3qNObHz8Y/VF+N7nNQlGSSYZhgzMsqowoziQY0AAAAAEBwBXVkJMBtuDIyMj4+HpkEPvB6vQaDweVyBW82EUClXJlNhEzeGn1+4ZPdh83O0+W+vmTauN5ZfLwIXhgoyWRQZxMFDxrQAAAAAADBUg0jIwEqpRpGRgJUypXZRBqNJikpKXiziQAqqPS8rKDOJgoXgSPTho38Mb/ey0v+fL9TLPYqQVB6XlZOTk4oZjL0KgYAAAAA4L9qGxkJUHHVMzISoOJKMimVSqthNhFARTgcjvz8/OqZlxUmPJumT9/pbfr2nMnoPgdFdc7LCh40oAEAAAAAqlh1jowEqIgrmayGkZEAFVEymygQCCQkJERGRnJdDgDxeDx6vd7n82FeVqXQJ3fsNDIS9bYpox+/tv9Mqdu++Mmj9dB5vG1X5mWVzIHhupw7ghgAAAAAAFQZn89nNBqdTidGRgJPhPTISAhLgUDAZDLZbDZkEnii9Lys1NRUzCaqlMC5vHMB1nl41ZzDZX4iiBUN+OjRepxUFepomjabzRaLJWzmZaEBDQAAAABQBTAyEgghVMLoda7RXFdxSRiMjIQ7x6tMlswmMhqNERER2dnZYrGY64qAA3zLpNVqNRqNmJd126TdZ1n8s7iu4o7wKpMkTOdl4S0IAAAAAMCdwshI4JvwGBkJ4cTpdOr1eoqikEngCczLAr5xu935+fk0TYffvCw0oAEAAAAAbp/H48nPz/f7/RgZCTwRTiMjITz4fD69Xu9yuTCbCHiiZDaRw+HQarVarRaZBM4FAgGDwRDG87LQgAYAAAAAuB2lR0bqdLowGM8Hoe5KJsNmZCSEuiuziaKionJycoRCIdcVQU2HeVnAN1dmE6lUqjCeTYRXGgAAAABA5WBkJPBQWI6MhJBWkkmpVIrZRMATJfOyRCJRenq6XC7nuhyAGjQvCw1oAAAAAIBKwMhI4JswHhkJIcrtduv1er/fHx8fj9lEwAcej0ev13u9XmQSeMLr9RoMhpLZRDExMVyXE3RoQAMAAAAAVMiVkZEYYwo8EfYjIyHkXJkDg0wCT5SeTZSamorZRMA5mqbNZrPFYtFoNElJSTVkNhEa0AAAAAAAt4CRkcA3V0ZGqtXqnJwcZBI4V5JJk8mkUCjCeIwphBDMywIeqrHzsvA2BQAAAADgZjAyEvim5oyMhFDhdDr1ej1FUSkpKREREVyXA3B1XlZSUhJmEwEflMwmCgQCCQkJkZGRXJdT3dCABgAAAAAoX8nISJ/PFxcXh5GRwAc1bWQk8J/P5zMajU6nE7OJgCf8fr+xoMDhcGi1Wq1Wi0wC5wKBgMFkquHzstCABgAAAAAoCyMjgW9omjZbLJbCwho1MhL4jGEYs8VitliioqJycnKQSeAcwzCWwsICzMsC3mBZttBqNRUUKJXKGj6bCK9GAAAAgJBiPMt1BbdlzMNcV1BRrEBgbdjG2P5BRf6ZrO79MTLy1qa9xHUFt+Xue7muoOIom1RlUOhkAW9m3UY1amRkzXLuCNcVVII9wBq8RCIgGRlZMpmM63J4j/ZzXcFtGdmJ6woqwZHVUN9poNDlSFv3q2LKj1yXw3teN9cV3JbVP3FdQSU4FRq9LkvAMqkFJxVdh3BdDsfQgAYAAAAAuKQ4tba+80OsSJy0/AfVqf/Ig4O5rghqOrdIplfEBihBQrEx0uck0hZcVwQ1nZtm9T7iZ0iclIoSEYLuM3DNGx2n7zjAo6sVv3lZ1OFdhGW5rghqOq9YbtBluWSq2MJz0bYLNXHixnXQgAYAAAAAIH6Vxti+jyO7oXb7Su2evyg6wHVFUNMFBCKDXFskUWo9Vp2nkEJLBbhGs8TkY61+EiOhdHKCyUTAOVqmMLXpYW14r+bA1pRlswQ+D9cVQU3HCIRmTbJZk6SxG5IMh4UMzXVFfIEGNAAAAADUaIxIbG7d1dyqi/rov9lfTRS5HFxXBDUdS6hCWZRRHq3yu7PteWIGH4cAx1hCCv3E5GMVApKlIBL0noFzlMBWt4WhQ195/pmsHyZLbAVcFwRAbOo4gzZD6i3OOPevzOfiuhx+qbkNaJZlHQ5Hzbz0JIQHhwOHx8BfyCfwWbDz6Xa7GYYJ6l1AFXJkN9LnDhIWO9J/+VR+8TTX5QAQh0Spl+uEhElz5CsCoTmjE8KLM8DqfYQQkiyjlLjQIPBAcXK2vuMAVixJXPGj6vQhrssBIG6ZSq/LCgjFCaaTkU58HFKOmtuApihKJpMFvwFtD/L6oeaqimt9IJ8QLMgn8Fmwr5XEMAw+4Q4JXm2C/v6HPLpa8Rt/j/pvJ0ZGAue8ArEhItYllMV6CqM9VmxHgHM+hhh9xEmTWAkVLSLYuQHn/Moo430PFGU31v69TrdzNeZlAecCIokpJs2mjNXaLuis5yichnIDNbcBTQgRi8U4PoTQJRaLuS4B4IaQT+CzYOcTbzD4j5YpTG17W+9uq9m7JWXxVxgZCZxjKIFZpjHLNBpvUZJTL2Rx+AocY1hi9hOzn1ULSbaCEmG3BlxjRGJLkw4FrbqoTx7ImfWmqBhfuASOsRRVGJlojEmNcNuzz/0t9uP95M3U6AY0AAAAANQslMBWv6Wh0wB5/umsb9+WWPEdSeCeTao2yHUyxptZdF5Ke7kuB4DYA6zBSyQCkiGnZBj3DDzgyGqo7zhA6HamLZyhyD/DdTkAxKnQ6HWZFMOk5f+ncOPLu7eGBjQAAAAA1AjFKTn63EGsSJy4/HvVqf+4LgeAuEUyvSI2QAkTXMZIn5PrcgCIhyH5HtZPSJyUikK3AHjAGx2n7zjAo0uM3fZn9MHtBF8QAa75JAq9NsMlU8cWnou2XcD3QyoIuxQAAAAACHN+VZSxfV9HTiPtthXaPX9hZCRwLiAQmeQxNolK67HqPFYKLRXgGs0Sk4+1+kmMhNJJCM57Bs7RMoWpTQ9rw3s1B7amLP9O4MVFWYFjDCU0RyebNUlRDlPO2T1C2s91RaEEDWgAAACAGsi7/fMXp8uenftEvWvfDgYubJo1cfrC1QfOW/yy+OymvYc+//aQxjE8aEU47ZYP/jP8YXGd9gmSIyPuT096M1OppW6xQLRYbGnWsaBNd/Xx/dlfTRQVF3H3COAGWM+eXbve2Xpiq8kri9J2bN7yvfZpaaVGtbsKTn286p95J8x5LjoiUtuucZNJubXrS7kr+BL6wt/LJ87dsPq40RKQxqfU7t17wNs9s6++WDw7H+7z8XzXtRe3FDf9fvEbvWM1JnmM0u/Ktp8VMzh8hSrn3f7la9Nlo+aOuOvaLTzrPLHmg+nz/th38rRdkpxV7/4BT7z5UMMYilgDrNFHFAKSpaAkPNjgwy25Tiz7+N1p8zYcyCv0RdSq327A85PeGFhfybtzMZ32gg/26/8wu077qORI1f2ZyW9mq0rvuwkb2HPq3DtHzVuLAjJFRMfMlPfqatJEAlvdFob2fWQFFzN/miI16zl7AFBxjHXPT/975+ulW08WyWrV6/jIuPeeuz8tuFf+vjOs4/evPn/h/N1L3u3WRFj6dteev1a+s3LfVr1bFlOrY/uu7/WumyYmNnWcISZD6nNlnNsr8xVzVnbIQgMaAAAAoMZhLX/N+Hbt5m5DmDI3r3+zw/B556Ib93t4dLbE/M+qpV+8+vA2/bytrzZWcFRqCZ9d32td3mZWnpsS20NCHzVYvtxzaKPjrq13q9U3XmC9qNecj16MLHamzZuKkZE8xbpXLfqtz7ai+PT0wfeqPBdOzl+xZLO++66hObUoQgjxm/b3m75htSfinsb1+2uYUydOLFq/cv0Zx8anmzXi8lCGteya1eGNtecis/t1fzBbbP9n65YvPn1rW8GkrY9ll7xYaLMxz0fF1W7eIUly5dcC4hxJTJpNyqY6Lyr8OJsPgoIt3DTjh/Wbcx8qc1697/icXgM/2RxIye35YI8o99Gtq78cP2L96a/njmkWQUiyjFIKy18h8I3/2Nf92r+wuijhnv4j+6f4T21YvOij4eu3nd+4Zmwj7j+cu8pnu9hr1enNrDw3Na6HlD6qN3+588BGR/2tTSPVlxbxr9p9oM9xb7wuenBtqafQPH/voU2etr9NHRsjVySu/El1GvOyQgRrXvVyjz6zzsW36jL4iWTP/mXzJw3cfOi7Xd/3qcXTz7TYC1sWPL0uvyC+7jWfA7POVd9O7bO6ML5O/cFdNZ7T++f/8tWm80/+9tEj0RJpvOV0VJGRq4pDHRrQAAAAADUH7S68cGjftrnTPl5gYuLK/vDs7M8Wno7qMnvVzKEJQkIIeanfuK4PfTLrqyWjvxwcxeF5VfSKwxc2+xVj72/woVZACCFMwmcbDr584sLPtes+pShnAa+m4eRNW97798L6FSvG5mFkJH/Zj24bvd1ep2PfjT0TIylC2Ga9fvml/z87Pm+f9UGKgLDepau2r3GpRzw26Nt6CgEhhG257vffum/ZNeHfu5a1iOAslIxx9pwNp1UtZ3/98lCdgBBChrcfN3riJ4uWLBkwdrCaIoTQBkMeI+s0dMzPbSWEEJ9QolfoXCJZrLsw2m7l3WmKEA4Yt/Xiof07586cvqCALbuFJ8Urvpy12Zkx9td5HzaRE0L8/qGTBw9896cv1w379uUkAYVQhgrWtvSdt9dYU0cs3PxtzzgBIYR5Y91LnbrPnDJh/pBlw+N580zSK/47v9mvGNu18Yc6ISGEMImfrd378tFzP9/V4CkFIYTYL+aNPu6pU7fBxqbqSEL8yrr3/Pf36G3n5m88ONWwFvOyQgdrX/fO6O/y6rywZOO7rSMpQtjne41q1//X9z9/rtcHTfnYeKSN20d/v99IqGvb46x93/LRayx1Hnx245DMSIoEhN3bfDVl1JqV8/d1mRp3kWLwfvL28fSTCAAAAACocqz5tz6N2zUf/Ma0XYXlvIMu3rfloF/Vtm+/hMtnwSkaPdihlsB96tA5uloLLYP1H3PQRKbKjb783lUg65ogFzGeI062zAK0TKHvPOjUEx90rhMr8h06t2sLus/8xbqXbjt2QZ45/v7EyJKWCaXo1bXzzAcbtRAzhBDCFGw+4xUm1n/5LsWl556Sd+zY8B6Bb8txg5ezuglxH99yIqBq2q6f7nImZVkPttAKPBcO6Uvyxlr1Riuly04QMpTAJI85qU4RM4Ece16MB91nCArW8nufVt2aj5g07W9rOVs9uuDYGQfRNs1tIGdYYvKRE77kDm3TRYFz5/IZdJ9DSeDA5h02YcMRL3eLu7QBEmg7vjzqHrFjy/q/udwwlsH6jhUFiDwyN+bymwqBrGstuYhxH3GUzCbyLz1ecEESM76BWi0UWZp2ODFy8v39h3/eOqL9oT/RfQ4lbOHSbxddiOwxflyry3tzXa/xM2Z+8EQLOS/HTNHGGTOXbI5tMSi1TP+5eOmqfy5ENBzfN0MtoCxRScfTOrZ/4pXpj7Vu7z6F7vMd4uMHEQAAAAAQDFRU7rRldWwMYQtXPT/imwtlfiyqN+rDDwdlNi41ry/gcLpZKk4XxelZC5Q4Wykk1uLtRWynkhOxWf8us4cWKHJKToG9vMD6uBaJjzwkM13I/G7i7p35VxcAfqING874JampHUplThiTOvq+1MsL+IlC0yAzLrNUACmxSE6RQIDTA0FhxqgxTw9KyS5VOO1weVlBtE5dUiuTd7GAFiUlaF0/7847YyyOj47t0iRdKEMgIVioqI7Tfsu2MYQtXPf86Nllt/BCbXaakhz+b8MJf1KqSCKgMqTm3Qcu0uLsnCSclxZS/MVEk92gXdPMUiNTKLlCTpGA18ejDhklzlaJSKFju53tpCnZd/t2FXhpgSKnZFY17dhgoiVaTfO7Gp7o1F/ocaUtmqm4ePqpjGhuC4dK8/29YYdL0rxTB/XVfZwwrePopztyWNSNBfYvmTvxdOLb791Pf/n3r6U/tAnkbTjqlWTf1UIbfVKXSRE29eJ/EUT+dNd7OCs2jKABDQAAAFBjiKJrN44mhLDGQ+rr+2CK7O4PZRNCCGE8DluhRX9ww/djF1tr9XxrIMftCWHvRhnDrCcnbzh0MiO6sZQ+pi/4ySTodnfayIhLC3Tqes+DK3Z9NHftmX92NnddvG4B4COmyHbaQ2JjZKd2bxyy8fg2SyAyRtu6bsOJuXUalIwxlaRPH5d+7S+xFw6c2EELG6fpuLyykSype7ekkno8xY4s86G+AAAgAElEQVRCu+Xgrj/GrnPUuu+xgXElLy3/cX0hzbrfHP54gS3AEkIIJYmp/9qEMW83iUQTGoJCqKndUEMIYU1H1eVss5W5L03oe2DC/4Y/eqp/pxbRnmOblv60W9Jt/GsjE9GADimKbtP/6XbtTcyFJb/v8Esat2zMp0u+iXrfnTnMcnzyugMns2IaS+hj+aafjFS3Zpklu2bG4zkZoKIb997lO/vNgF67CzyRyojWifETG8Y2EN9q3cAnjPHMaScVmx516qdXh8xYsu2MKzKtQesuj058bUAD/l0Y03Vi9ciFxpbDxr2QTD679keMzXzKTcVk1N65649v5qzafdETGZfYummbif2bNZDz7oGEHDSgAQAAAHiKYRifz+d2X3OlMnk13DF9+rP+Xd/YHyBEoGk5ZsVHPTi/gIxIETkqXbXigH3OYcccQgghqphazyYpFIT4VVHG9n2LstMfMzy5ddnhedvIvGsXqJnKxIZl2SpZLU3Tfr+/qjLJen0OQuwH1+duZ7LqZY2uK9CfObVo/aq1ec6NTzZrVE4Dgs77b+vApWeLoxtMaMHtafmXMRc/G/PSG8doQihNg0ErxrauJSABgcgkZf8xBdgAnd1j7IaHGqWRwn+2LHn+i3WT3/oiddZrI+Nq4nFskDLJMEw5mZRXx5YyhNAsMflYq6bF8D53b566Y/5X++cTQgilajT82dwMbCdLVGEmA4FA2UxKgtd78eYtHz/wlTXFaY9NeDSdFxvGy0QRUaOyIlfstc45WHRp361NejZZoSCElsqNWdmWpWecO2aNWunKSooZXVutL7AsOnRsrdm38f6kRjXykpjXZ7JKYll+Ju98vZexziIHy9r/GJv7vT+ra8/RuRL97j8XTR29do9+49IXGvHpUxHiPvnmjHXn6g1Y2EUnIgWlf8JQQqNUZiakaPO0UUu8WU0bjW4k1B87sGjJnLXH7Bvfur+8tyXhr0xsGIa57UyiAQ0AAADAUzRN+3y+4uLi0jdWR1tFkNB34oy0C8ZT+9bMmje151DhirlPt+DyVGJ664HDXY94G2ZnLa2jqS9hThiMr/17sfdf9LdjH2/e8wH1sZ0FT/QduN913QL++fdn9a2RnagysakqJR+KVFUmWYYJsGyRQzzqsQEz60YICSFs66EL5/XcvmvC3rLXGPTZzk1btnHyXosvpvZXj7frypOeGRXT98mX0ozWU0d2zVq5oOfrgnlTH0uMjI7wm0aOfqOLOKFdvVgFIYTEt+05ejllqf/R3ukrzw1/NLUGtlbKxKZqPxQpm0k0oC9jWWINsEYvUQicxi9HD/pG33DY+0sfa1c/0nNi28LXJn3Te5B1/m/v9o3lVd+ymlRrJiWRVbLyMnwX1k979aXJvx3xZfT/avHHXTW8+nCL3rrvv67/eRvWqb30ruj6EvqEwfDa7vO91/i/e2Fo8159xbs+FTKMw+Yd1f7umUkSISGETRm6a3/P4+cm5MUuy5Tw6sFUjzKxYapo1hRN04FAoGwmFZIqWTkhhA0EAixTZIwYNf/PmV3jhIQQ5rWhY+7v+d1HExYOWjaENx+6sq7VP/38uaPurImt0wWElPrr2pU6gy5TeGiXkGWcFuGo116f2VQtJISw3Yd+83HPNasmbGmxrGM53x4Me9dn8rZjiQY0AAAAAE8JhUKpVKpUKq+51R6UxuI1qIja93atTQgZNGRw7WGNxs+YuLjvyqHxXPUnGJf5nWPFksSs35vq4gghhNydnDw7Td3sl2OTj+n+cU5Tntgx8mBRmQUWiv0NNpomnkjo3TCiBr7lLRubKiIUCiUSSVWtvGSasyTj7ol3RVxqyFKyzp0atd65afPRfFeL7EuferCePds3Pr786EFa1alDt89y69Tnz+lUlLx2k1a1CSHdujyY9V7Lzxa/s+6RFd3yVQE3adyo4bWLJrZp1fqzvRuPn3WS1KD0ovitTGyoKrrsXdVmMswU08TiZVlCkmQkwrzyidnHJB3f+/3NXnEUISTy7q7PLFRaGjy6aOKcR3qPrYvtZBVmUiwWBz2TrHXP1y89Pn7eQW9SpzE/fjb+ofo8a44xLtM7R5ySpNq/N4+NI4QQ0d0pqT/FyposPPXO2ayd6xZE7flHQYgkNnFiouTyLkDcuX5C65OnN18scmVqa+AMrTKxEQiq5p1X+ZlkfFWycnJpBDkluefJiblxl55KQXTnlx5vPeeNzet2uYb05sdTydr2Lh291tfnxYGPaEu9WCjxxaTGUTJZnOWMympVEEpSt93EJurLmYzo3Oe+1n8t3rzvtKtjY348kGp1fSZvO5Y1cC8DAAAAEBoEAoFYLJbJrm222YN1d768bb/uNqe26dX26jxQYWr7dvWFO48ePUsTzhrQgaLi/xiqfqxaRwghxBsdp+/8kCfyZPMFE1dtmhlopy2zQAmVLrKFwLjM6ioiETXwekZlYlNVjZXyM3m7hGpVLQF1QqMqfSQoUKsThWS32+tiSQRFCONYuGDxsN12XZ0WS/q16K3lxfGLL//grwdtqY3vbRtHEUJ8QoleoSMdOtSdduDc4b9lneuV+1tURESUkLA0TbOE8KtTVB2Cl0mRSFRVmQwbLCE0Tc572AQx0UooihDfqaP/eYX1WzfVlfrDq5q2bCH5bdmR40Vs3WhkMqiZpP1VsvLLazu/8Mnuw2bn6XJfXzJtXO8snnwl5BoBe/F/NFU/PrJk1xxQRhnue6Ao2dx0yeurN06jKK1QJqlFkRMR0mt2AXJZooDs9gdchNTAZt/1maySWAoEAqFQWDaTriprQAvjatUSUSeSkrSl3ikK4pMTxWS3zXZpb8491nT2Qj5tX/DJ+AWflL59Zb/WK4W1Om+b9kBLTVQtITmhjb4mk5roRBHZXezmzQOpVmViIxAIbjuTvHgDBwAAAADcO7P8pRcX1ZnUdOMTV685yDodDpaSy2UcvuWmREIlIVZfwC+NsrXpbmnaXrNvW/K8ucU0kYgoaakFGCK9WrkvYGWJRCSQclc53IJE1yyOWmGynmdJ1uWE0VZbHk1FRqrUFCGEObJp5cjdznodHvyzV0osfw78Lmx9acrGOs/UXj8gvlCmMcs0UT5HtvGim6XkMglFSOD40j6f7tQ8MGZ2t6ujDej8/JMBKiEpXsWfBwJhh2FJgZ+4CCGEZCkoxeWwUYoIJcVYrXaGXJ3qzzrsVppIFBFSZDKUBI5MGzbyx/x6Ly/58/1OvJ2ecmnX7PXTwghr47bGNj1VeUeyZv3iolmJkEgJIWJls0hqRZHrPBt9dRdQ7M5jSKRCquaydqikiAbNagtXnDx+numadTmQ9PnTeT4qMjGRN6fmU9G1W78x4C6aEEKIW6oulpODSxbu8KQPz81OjsxMFBAiS2qWJFiRbzzP1r+aSXNBnp9ExkTx5oGEKr5uqwAAAACgeokbt2mnonf98vNu1+WbaPPK75ceZXXt2+ZweNqCWBOVqyBHzvtm9nnbHZ+S+cMHCWvmbt53fgsr6pioVlxZ4HT+QtflCZ5sYOMRw5UFgKcE0f2axAnO7Xtrb9GlkwMZ59K1B/awEb0aJkgJIf4L0zfle5Obz+nJp+4zIeI6DdpF0LtWbFwsSSsWyTOKztVyHFuzaNNRNqp90xQRIaLEBI3hxC9zFq6wXs6kv+C3n9bsZeMHdMyqkdcxgurgoMlJN3EEWDkhQiERlXrViO9qmxvPHln4w8L8wKWbGNvGb+ZtCag6dmyC7WQo8WyaPn2nt+krcybzt/tMCBFHa3IV5MhZ54yeb9jqtUpb9EXy0i+37Tq1hRF1TFIrCCGUvF+6UmDOf+us99IugPUtPajfw0p6pajx4XEoEeb0G9BY8Pc3by06f+mpDOQv/d93e5j4Xr1b8OappLR173374Z6vjhwy7NW3R495+aM+LR/QUJQyffSgnpN63pVEESKI63dviuDEpre2FV56ILRt6cIte9jIXq3SefNAQhXOgAYAAAAAQgihNF3eeqHZ2slfd+t6fFDXRglswcHNK5YcsCc9+Nn4tlxe0cud3OiRl2v98cFfrwzqszlR2lDCHDcV/m72a2qlf5gipgghwsjxTXSrt5mGrHTPT4ksZwHgKapOm/vG/Ltoytxfju7PydUJzhw/vvi8J6VZt0l3SQghtDl/p4OVyC5Omb+mTJtFndn0k5YxXB3MeDT3Pfb4xtXTfhv18NmH26QlsLaDf+9YctyZ1PH58U2khBAS0XTC403WfrK+/+P5AzrWSxfaD+zZ8cepQINBr79RF/1nqHpehui9rIch8VIqUk6V05aUNRv/5gOrn1sypMep+T3aNIz0HN+x7vd9Zk2HCR/2isF2MoTQJ3fsNDIS9bYpox+/9omm1G1f/OTRejzp8ni12cOf1y7/ZOO4oUM2JUsaSujjBvPvBX5NUuaHaSUXGKTq5GSMOXNwypa9R8/qctXkjN682OxPyagzqVYNvFBrSBPWeXzymF8fnPJY+6NL+uRmCc9s/H3xP9aUQbMmdVZxXdtVPrHcqE13KjSxlrPRtgsUU3TdIoI6XfqM2TJjytT/Hd3RJLeW4MyBfxefLE6579FJd2PQ053iyaYJAAAAADgnqf/UD1sTZrzz3crFP2y1+WXx2U1GvffUhGEtEjg6xyqgijK071tU++7MXat2dcp7/6B+yTnrigClUymHNs6cWDsq9XJhCUkZ2zop3ztsXHLOUO4CwFPSWu8+2S9x5Y4vDx757BCr0SaMeLDl222TEihCCAlYi84xxGnIm2Mo82tUrKD2Ry1jqr9eWiA0yWKsUnWTQe9vVX07edH2xb//YwtI41NyRj3fZ8IDdS+/WIQ5PcftiF3x3oJNK1cs+9UvScyoP/aNAa91TotCqw+qFM0Sk4+1BohGRFLklIAQtvwFBQm5k7b90uC9LxYu+ePnFW6xLq3+0NcmTxxxTyq6AiElcC7vXIB1Hl4153CZnwhiRQM+erT8GfTViZbKza26WO5un3Rwy84uhil7zy85U7CCpnQq1dCmSRPv0lzdNYvV797fIHHf2S/PGz+7QDQq1YjmKW/XiUzAdjLkKFu9u2xp4rvvf7l83mcrWU1G8xEfjnt79L1cvYEsg6EE5ugUsyZZ7SjIztstuslMdnnGu289mzjvzy937f7sb1YTnzZiRNe3u2Ujk3cOuxoAAACAGoeKe2TduUfK+0FE/T6v/trn1WqvqCxWKCps0s54X2/VmcPZ37wlLiokGt20+3TTbvgbVKw2btp9cTdeAHhKqKz1zIB+zwwo50fSurmWz3KrvaLysYQqlEWZ5DGKgDvLnidhArGdHvm1U3mvo0vEaS0e+LbFA9VXItQ8tgAxeFm5gGTJKcnlRg8VO3DdsYHlLS6IbTpw2ncDsZ0MadLusyz+WVxXcQMUZavb0tDuQZlFnzn3f1JzPtFop3XU3iRyQpn6mVYNnmlVfTVCkAi1LZ+ZtvQZ/m1f7EqdQZshCXgzzv8r8xZf/YFAN27KtHHXLS9UZzwz+rlnRldjiTUDGtAAAAAAwC+O7Eb6zg8JPcVpC6YrLpziuhwA4hQp9BE6Qqhkp17pL771LwAEWTFN9F6WJVSilKhEODcPuOeOT9XfPzAgVyb89WvksX+5LgeAuKVKvS7LL5bHWU5HFRm5LqemQwMaAAAAAPjCGx1n6PyQq1Za7NY/o/9eT7E3+Co5QHXxCSVGudYpVsS6LdEeK/p8wDk/S4xe1kETrZhoJYQiSCVwLKCMNLXpYavTXPv3Ot2uNVTgxvMNAKoFLRSbolOt6vgYe74u/6CAobmuCNCABgAAAAAeoKVyc5vulqbtNfu2JS35Vuh1c10R1HQMoczyaLM8Wu11ZNvOiFgcvgLHGJZY/GyBj6hFJFtB4bxn4BwrEBbefZ/p3l7KM4ezf3hXXFTIdUVQ07GEsqrjjdp0haco6+zfkoCH64rgEjSgAQAAAIBTFGWr38rQsZ+sID9z9gfSgnyuCwIgdonSoNBJaH+G/ZyM9nJdDgBx0ETvZYWEpMmJQojeM3DPmVpH32mgIOBPXfSF4sJJrssBIMUKjV6XxRKSbDyqLMbHIfyCBjQAAAAAcMadkKbv8nBAHpGwel7k0X+4LgeAuIVSfUSsXyCOc5ujvEVclwNAvAzRe1kPQ2IlJFqM1jNwz6eJ1Xfs70pIj92xIvrfjZiXBZzzi6TGmHSHMibWcjbadpEiyCTvoAENAAAAABwIqKIM7fsW1blbu3ONbscqjIwEztECoUkWY5WqY7x2nfuigGW4rghqOpolJh9rDRCNiKTIKQHX9QAwYom5RWdz886ag9uSln8v9GG+AXCMoQTm6BSzJlntKMjO2y2i8X6Sp9CABgAAAIBqxQqEhU3bm+7rrTxzOPubt8R2fEcSOMYSUijTmOQxioA7y54nYQJcVwRAbAFi8LIyAZUpJ1L0noFzFGWr29LQ7kGpWZ8x90OZWc91QQDEERGTr8uSBLwZ5/fKvE6uy4GbQQMaAAAAAKqPM+0ufe4gQcCf+usMxfkTXJcDQIrFCr0iliUk2alX+ou5LgeAFNNE72UZliRKKRUO2YEH3PGp+k4D/aqo+E1Log7t5LocAOKRqfS6TJ9IHmc5HVVk5LocuDXszQAAAACgOnij4wz3D3Qlpsdu/TP67/UYGQmc8wtERrnWIVHGui3RHitm6wLn/Awx+tiiANFKKJ2EIJPAuYAy0tSmh61Oc+3f63S71mBeFnCOFopN0anWyASNXZ9qOShgaK4rggpBAxoAAAAAgothWXPbXuZWuZp925KWzhJ63VxXBDUdIxCZ5TFmebTa68i2nRGxOHwFjjEMY/GxBT6iFpGcCEqE3jNwjWXZwqYdjG16Rlw4mT17sthu4boiqOlYlrWqE4zadIWnKOvsHokfI8hDCRrQAAAAACFFHcN1BZVjczgNhVZp7oAMbbSsTm0yaCTXFUFVG/YK1xVUjsPjy7c5JVJpRqxOJpVyXQ4EwXtPcF1B5TjiM/QN2gkVEWmUV8HQBB/ShR93iE2ndbq9+kIb1XlgqkIckdCcNG/OdUVQ1Xat5LqCyimWROiVCWxCTrKEKNXRJLYF1xVB5aABDQAAAABB4fZ69ebCAE0naKMjlRFclwNAPH5ab3f6AnScOiIqNp7rcgCIV6nR17/PE6mLPbozugn6KcA9XyCgt9hdXl9slCqa9VAUzsYHjvkFYmNErEOq0habtepYJDJEhVcDmincv2j2/I37zjqUqY07DhrRr5EGyQQAAACobgGaNhXabE6nNipSFxWJw1fgHM2wJofLWuyJUcpTY9QCZBK4Roul5pzmlvSGmrOHUv5ZJfB7CRrQwCmGZc12p9nuiFIqcnRxQoGAFHm5LgpqNIaizAqdWa5Ve+3ZhSdFTICQWK6LgtsUTg1o+uzi999bSLcb8fygmILNc394b4rwk/f7JAu5rgsAAACgxmBZtrDIYSy0Rshk2cmJYlE4vduEkMSyrNXlNRYVKyTirNgoiQiHB8A1irIl1THUaysrMmduWiB1YLQucM9e7DZY7RKRKCNBJ5OIuS4HgDikKr0yQUgH0u15cr+L63LgToXRIYHvwB9/nEnqN/XJrslCQuprbSfHLv/zUI8nG0q4rgwAAACgRnC63HpLIUWotIR4hQyjdYF7xV6/3l7MsmxytFopRUsFuOfWxOfXb0dLZIn71qoMZ7guB4C4vT59od1P03FR6iilgutyAIhHJNMrE7wCcXyxKcpj47ocqBrh04Cmzx864oxv1bRWySkNwpSmd8cu2ntYzzRMFXBcGgAAAECY8/kDerPF5fHGRkdFq1WYuQGc89OMsajY4fFplXKtUoFIAucCcqXhrnuKErK0p/7VHd9DMTTXFUFNRzOMyeawOoq1kSpdpArbSeAcTQlNETqrPFrjLkwtPitgGa4rgioTPg1oxmwyszG66MvdZkG0Lpo1mwoYcqkBvXbt2qNHj15dnmGKi4txdAShq7i4mOsSAG4I+QQ+C3Y+3W43y7JBvQteYRjWbLebbfYopTInVScU4KN/4BjDsman2+xwq+WS7FiNSIhMAsdYgbAwvYGxdiu14XTOXz+KPHibBBxjWbbQUWyyORRSSVZirATzsoBzFGWTRhqU8XK/K6vwpIT2cV0QVLHw2crQPm+AksvllxvKlFwuo3xe35Xjv61bt/75559Xller1W63O9gN6K3PyIK6/jBjJk9zXUJIcbvvcAXIZ6Ugn5WDfFYv5LNy7jift1p9DWpA2xxOg8UqlYgzEhNkEsw9A+45PL58m1MkEKTrIuXi8DnYgdDliM/QN7hP6POm7VyqKNRzXQ4Acbo9+kI7RVEpsdERmJcFPFAsjtAr41lKkFh0QeVzcl0OBEX4vCcTSqRC1u72sERGEUII63Z7WLHq6oHQwIED27Zte+W/U6ZMUanw/VC+oGna5XKJxWKZDC0n4COn00kIUSqVXBcCUA632x0IBBQKhVCIK2vxglAorAlvMNxer95c6A/Q8TGaKBU2j8A9j5/W251ePx0fGRGlQEsFuOeNiDI0bO+Kio09vjvm9H5SYz6bBN7yBQJGa5HT7Y2NUkWrImrC2xXgOb9AbIyIdUjV2uICrcdCYTsZvsKnAS2I0WmpMxYrQ6KEhBDC2Cw2KqZezJVv3NWrV69evXpXlv/f//4nlUqxweUJv99PCBEKhVIpjhaAj5xOJ0VRyCfwk8/nCwQCEolEhK9P8gNN0+H9BoNmGFOhzepwaKMidVGR4f1gISTQDGtyuKzFHk2ELDVGLUAmgWu0WGrOaW5Jb6g5eyhpzwphAN8lB44xLGu2O81FDrVCnp0YK8JZC8A1hlAWeUxBhE7tLcouPCFiAlxXBMEVPkeqwpR6d0Us3be/4OH0eIoQxrD/gEFVt14iNqsAAAAAVYJl2cIih6nQppBJs5MTxfjMA7jGsqzV5TUWFSsk4qzYKIkI7/2BaxRlS6pjqHevzGHJ3LxAWmThuiAAYi92G6x2iUiUEa+TScRclwNAHFKVXpkgpANptjxFILjD8YAnwuiKHJKG3bun5P32+S+7T50/uWPujMXnM3t2r49ZhAAAAAA35lr2cJyaUqiu+afpP9ta9iuQTpf75Pl8a5EzJT42NSGO4+5zhcuG0OHdPvXxQV/9d/0ZUKztwPcTR3Vo01idXD+nxwsfbTL4CSGEFHv9pwrsFqc7SaNKjVFz3X32X1j3yYjcxrW0UdLIhNQWfZ77do+F4bQiuG2sd88/O3vNnKd558eEqcsf2XQh79pcOk2nxy/4o9EnP6kmz6v79drn95jMLCGEuDVxp9sONNVukXBgY9q2xdXffXad3fzOq0/f1T5XfncHbZfH+3269j/XDbaKbOHvbw1NeeSHf+nqLRHuGH18aovoaEpVzj9R47d2XZtVt9d3Wl9gsNrjotTp8Vruus/e7TOeHTTrcNktvHvNw7VzqMTsa/6lPzHbhr05/9EX/lk24qWXa/UcKu32WOroD59bftJy+Xmjzy1tkTuI6ljOP9Gw+UuUqRcjErTFBZn2M9x1n73bv3pp0A9Hr3vXwRYdW/H604MzmrSQ12+XM/D19zfme7moL/yE03krooz+r7/i//rHGa8t9igSG/d8dXSfVJwDAQAAAHBjdP6ZPI8grknXDpnyq7eKG6WLrw4x8PkDxkKr0+WOjY6KVvPiEhoVKRtCC2teO+Or1Zt7DC/bs/Xsn9y//9sHFC369Hmus2PX0sWvDfr71I/LxjeXOD0+rVKuVSp4EEnWsmpMh37fndM27/foS9lS0z/LFnzxbJdtF1dvfbu5guvioHJYz6o//uiz2xmfkjK4ZYQnP2/+utWbjR12DcioRRFCiM94sNes3ZsZdW79nB6KwNGTp79cdnGDvc9vrwxgErK0p/7VHd9DMRy0df1nFvcb9ulqp/aeLr36JwRO7d646PtJ6/caN343pFHZ87KYC39+/PTiUwXJrfzVXyjcGUpVO7df38wybTPasHvFTmOtRN3lkwxphjHZHFZHcYxaqYtScTubiLVsmPHdus1dBpfZwtOGc3keQVyjDh3SSl0LSlwXe3PeYy27f+gw4a9zkVn9uvXKlhT9s23bF1Pf3VYwcevILAUhVERSbod7Mq/dELKMbef2o6aEOvGMN8d2QcDFdvJqMYWbZ/ywYXPuQ2Uy6dz7Ve6jX+8h6d16DHpIYd6+eu2EJ/79b+qcuT3iwugEXm6EUwOaEKGu2ZAJzYZwXQYAAABAiKDPns5jIjq9+sPPveTX/5RhWLPdbrbZo5TKnNQkoYAv771vXjaEFNptOX9o79a5n05ZYGLiyv6UOfvL+//bR7V7d9Gqp7IkhASeajeow9PfTZj+wJ9jO8dpRDzJJH169gc/nY5+YPb2n4eWjAB8Y8i4ezp/MuOTJc/PGxyNTkoosZ/8e/QeR517u23MjY+kCGEb9lq8pP/+fz9vk/ZBooAQ/4ot+zd7o8Y+/sCHKSJCCNu5wXvzlr654+xiq3DckZ/Ebgc3dbPOpV98u8YeP2L6N9+2jxYQQpgR66Y80/2XHyes6LbswZjSKaQv/DF6ymYjS/Hj9QOVI0joNvnbbtfexuTNHtRsbbMJHz2aISAsyxY6ik02h0IqyUqMlXD5jSXaXXjx0L7tcz//bIGJvW4LT+jzZ/NYRafnP/u5q6yc3wbeYoyzf9p0WtV89hcvDi350GPofeOemvTJ4mVLBowZrKIEMU0nv9706vIUZZOq/1n93po99d54umkrl4Grwglh3NaLh/bvmvvF5wsKrsskferzt7/bI2z16YKpL2TLCCHMM31eGfr01Cnfjuww4X58nnxnsMcBAAAAqLFY69mzViolO62c7+TancUnzl8sdnsyEhNq6WL4032+edkQWtiC+X3qt24+cNy0neXNq2AuLl280xXT4+VhWRJCHB7faXLP8D7p5MzaDWdlfGik/4MAACAASURBVOk+E0Kcu7fs86k6DO535QI0EU0fzE0SuI4dysOAg5DCepbu+j979xnftNEGAPwk75HYzt4JmZAQ9t5QRpkFXvaGltFCKXu1FDoo0AFllELLXmUVwiiUXSCUvSkrgQCB7MSO95L0fggjw0lsx4pl8vx/fMGxz3fWI+n03On0+AU/7PPWfpKClC0m6N6u1S+dYxuxSYQQIrUPc4xI5NcxkI0QUnsHJ7f/uFGrMLbpYcapv5yWfUYIEUlnb6hY1btPbenxasfApe1G9WzG1p67eK/I/ePmZyvnrjwb+P6AaLhf+B1Bvtw5af6/4VN+nBLH1egNj9Oz81SaYG+PUF9Pp2afEZXzZ6/67zUcOnfZ5TxLKxJR8ucv5FhgVAiczV2NLvlcstmtXsv/vZlyz4/o2dATN6T9l158U2s4wmRpeKbq8tKfr0b2HzIj1KkTn3MTejXt2nDU18uuykvGJPH0n333zUE9PhwX9WpEBJc1+HxsK3HGye2X9ZVc1XfPuzUDGgAAAAAA2IB4+uQZwYmJkD07s+/C3XStMLhOu3YNfdjG9Jw8k5nw9ZBK3cTOrmRJlqsdKoJ5pq4Hk72/7HANBYmo3MMTh/76otifjf9dvmviNm5Sj0s8zVHrTYSfxC20fWPPNbuu3colG/gxJQPNrjNmxeoB0Y0KTeEzq1RaCvf39mBKHYFViOzTz83coMC2vLevsWSBY5sGvvoPLojy5KD07LMat8iO7bQyX5+HxxLPPCNYsmiZUw9BZj2ShMQ3qBFRKKuM8fgCDJmN5kJ5FtOtDQvm3o+cv3kwMe/YLsiovAOo3P3zv/3b+8Nj46pnZuepdQYfqZuHm4gJ62Vh0vbL9sUoKETlHZ04al3xIzwinz57SbAjIqSpZ/66djdDJwyMa9eqTqjQ+TUH5WCFjflszICQqEJnPUKlM1KYh7fb27OeCWdninyVPHcv7ZPEH5edkHY43TfUuQ9qw6Rtl+2KUpCIkp+YOHZTsZgkMtNfkqyIkMBCQyKYW3h4MDp9/XYq0SYKRu0qAhLQAAAAAABVluHpkzSCzJ/VtGF6rolCCCGM49P0o0WLvuwY5iOV4jgzLwItVJvr12rW+g3z23gzs8agVGzPmLqeCCEq8657iVQtmfk8RY9J/TyzshU+In6IpzuOYURgSDCLfP70BYEYk4AW1egyrAZCCCFSr5Tn5aTeObpi2o7cgF4/9QthSh2BNUi18okB+XjwHl+/MOTflPN5ZomHR9Po6nPbRMa/Sklzu73fql/2mYXrT95/kt5Y+zjp4YMtT1mdOzcdJXXq4YffdPmfTYu+RL44+c8FM7tO7eg3SSLtnY2jVj9rPG3tZxFoaWVXEdBCe3Hp7L1E1xWjPOVZmFAQFejDZjEmS8b2iKnjgRCisu6VPMIjZHj6LIMglbM6dU7PM786m/s0mbVy6fzmnnA2ZzR+UJf3gxBCCFF6rTpPkXvn8uFpJ1QBrYb388MQQiTCcgWe2UIvd6MqOi/JeGvDnNPk/77o0YRXdrn0Y8liaskQQlTW/ZIxibu5SzAiLT3LjALeJMqNWRlZFEm+zCIQJKArBBLQAAAAAAAMRRCEwWBQq9WFXxQ7sPNLvHj8zESZiGojNh/7rJ1ElfzPnqULf9y7ZtqCBhd2jWLswrWFqn180nthKP3awaUTZ23+dsgnoRd2jgqGfB9CCBULG4qiSnunTSzHpEOKtkSeq8gjMaFQEOkjFbFfhT4mEosx6oVG65gmORbxaGmnhnOumRDCZc3nHl71vwCIx9foi0mj0eiomKQMRhVC+ff/7XiFjIwJHRvNSk999mfimeOp2n9G1KrNxhTB1TNq9O2Tl3Ny7Y3de27vRggh5BYUP6GGlGGrg5qenl7V74dLmoAeX/R6HYaam19+se15oyl7+gWzUapz68cELhGT5SBTVn216WnMmOWtRRHeEj7XpdayINIfp5ooM1Ft4PLj41qGocxrf/8+8evd346dHXp09ajAqnj0LBY2JEk6JCwJgjCZTLTEJJm2dOqMOQ8JhDBZfN/DU5oEYEjFc0sX+7NIc5jymdCkQ1TmrxtOPovotbeFG1N7lq+wo5u081v/676N20f8NKJgTS3tg+W/ncwmKaFex8ReB/2KhQ1BEHbHZJVOQK9cudLZVQCvkCRpMBhYLBaX69wbMgCwTKfTYRjG58PDMQATGY1GgiB4PB7OnOVQqzaTyeSookiSNJlMen2Re6TFIscdi3Cfngv+qCuoXj/eJz8nT8f27Dl+ZRtvVc3xJ5dvvjf885oMnejxutqtG4cKEUIovOWIZQdRes3xJxhd7cpVLGwchSRJs9lcPCZp+MU1BlN6vsasNnIQhgQiHrv4d5AkI68E8cDe320Je57++OqBtZu+7daLdThhRiMGLmPjDMXCxlHJPssxaW9pFEmaKUqpZo8Z1O2XGAELIUTVG3rwQLcrN2YnN10xpivBoZ59NXL4kdxaTVofaBZSU2BOevJg1qFbPdbpd4xu1ZsZ2RVj5tVlPy799u+nxqD3Vq/87H13DCGEKNXRJd+tkDddu6ZbNRZCsDg5nTFJEETxmOQ7/kCpN5qS/1qy7CKnyy+jOgR6MSL4bIJ79fzi17r8yNb1g4QIIRTactDXB7HMmtPPLt/5aPiU6lXwbF6pMemQojGP3mM+C8uUP35wZe3fe7p+wVm/YnyMmO+jyfYwKBBFIYQ0N/9aeofTY067Gsy/UuE1mDWj4/4pR0f3Gnqka5ModvbF48evIC9flkbLqqLp05IxSZKWVnS3QhX9BRFCkyZNoqlfDuyQm5t7+/btkJCQ+Ph4Z9cFAAuOHj3KYrHat2/v7IoAYMGNGzfS0tJatGghkUicXRfwSs2aNR1SDpvNFgqFUqm0yKsmx3VgMFlk8/fc8uS5mdk+HlIPdzcMw0TdejSdfOyfm3fVqCZDQwqTxbbpFFvkJTyQ+dWuXMXCxlGLgbLZbIFAUDwmVTkOKbyAiSCzlBqlzujlJvAM9nbHqedFJztTGrWawsQiRq4SirnFtO0ZgxAaPmZQbLfakxfP3THkyEcwDRqhEjHpqEFTNpvN5/OLx6S9MA5bgCFuaNzcaMHrKfe8tu1r179+7lx2ECvredjVzROOpXNjWu/rEumLIYR4dWPr7+Hq4zc/nHsxrkcHLydfYFOqKzuXfvTzsTtGn/eGz1s6rkNNccGOQikSfxm7R99r8bTBjFm6xunoi0kej1c8JvWOfEAlQZJZCpVcmXpm28EM/z7jewcy8XhYLkwS27xN8bN5x45N55z5585DNapeBc/mJWPSIadvNpvN5XIddZwsAhPE1G0UgxDRuVPHmO/b/rR36eFeJzpRbPL1GBel3LfvfKpns9+bMWOArhx4UPcF59wiv/hl/987Nx3k+9brOO3UMM3EXkufiRnZ66BfsbBhsVgsexf5qboJ6C5duji7CuCta9eurVmzJjo6unfv3s6uCwAWLF++XCgUQnwCZrp58+atW7emTZtWo0YNZ9cFOBiGYTiOs4s9wt5BE6xJkszJV+YolO4iYVRI4JslIzE3qZSNKDNBUAi5Tl/bRatNn+Jh4yCWY9JBKIRIkyE5U+4p4Eb7ydg4jtghITzy2rNUJYXeLAhKpL98SeAxYYHMmRxnfHJ617+Zoa37tXy7AgwrtGPHmqyzD/57TCBIQCPkIjHJEosCcCxJIi6YTUpheF54rcxqMT5Lzt18dkx0P5TIzL5rxmqG+xVeb94tNKAR6/6BjDwl5eXMtYuIzD3zJw3bl+bdfHjC50N7hBS+XYbKepScZs7ZObX7zqmFP7OtSa1trNDB5w+Ob8ycPaqyuERMFkNRlFytzZQrhTxuOHV+/Flt2Jj+rQR0fJVzYG6Sqnw2LxY2jho8dnhMGtPu7rqbH1qnWUsfDGGYgifJEPl6tmhec+nNlAe3qQ5vhxXIrAvrrujDPmjZyumrP1uLE9ZmzNY2Y97833hhwXOCVS0ssGrmTx0Yk1XzBwQAAAAAqNLy1ZqMXDnr0cbpX5/0HL1x4zCvN38iUpKSjbh/ZDXGzlQx31zWa+J+2UcbNg4LfZPXY361QdlUerOOQhRhDvVyl75ZxpQX3ySes/Pq2XPa/j1FBS8RSVdv5GBBg+t6Myirm7xrykfbqv/Q9J9P38YkpVSqKEwg5ENIuhKuZwNv7HBufiqF/HyC0+NbYwQRfHRhtglJxCx3DGFcjhhDcq2BROK321qvl1OIy+XwnLmxiftb5o9KyI4b+eNfkxv6FN89MI863eaMa/R24Q1KeSEh4bQ+dnj/BsGy2q45gbbK0egN6Xn5FEUFe3uIBZwnv+y/YAz+pFttl1r4+S3znbW9Zh2VDVu6sX/Q27P5syfJRtw/PATO5oz28t8pi89W/yT6yICQDJEfgbMCVWmCjJcaChPwuYU2HfU08cIFk9cnLcJdI0rJjH/2JSbL6g5qF/F6WX/znfNXM7CQYY3g5pGKgh8QAAAAAKAK0RuNT16mZ+TKfT2kkY3rej6/vn3x94ezX69wYHy++/v1N6jwvn3qM/ZSgR0eKXt2zeWqDUpjMBNPc/Jf5hs4CLH4ImHhh2jhAT16NhIoTq7640nB1H9K9e+vf9xDUT36MynlwqnftrXEfGnD2sua1y8RWUd+3fGA8m3TNg6m/LgSXPq/eC/8xf1puiYpDbp4PLsbcXrd8YRLVyhh91hfHkIcv+CO7tT967f3KF4vgkkZ/jl3/xzBaxfj58znEBquL998xxA3bPOkktlnhBDmVb/n/E/HfPPm3/j+nXxxTFp77IQxXw1rHASJAWYzmYkXOfLnWXkysTAywEcs4CEq5+TxmybP5h3ruOpTlNhhYbIXt7cvW3U45/XZ3PRy9/IdN1BI3x61GHSIByVwYmq2EhMXj146wA1zM2mi5I/d9C+OJCQ+oCRt6gW/PetR+ScvPTFJYjtGu8qZkLq3d/HYKT9sTn11hDc9PzB/Rwqvfp8RNareTSKO5ipBAAAAAAAAKoQgyaw8hVyl8pS4e0ulOI4h1OmL+R2OT9zSp2lS3z4tq7Gyb59IOHTXGD9p15xGDL5V0t01qw1KIEgqS6WVa/QyET/YR8ixMN8NDxs0Z9offb6ZO6jbo4FdI0zXdq7bmho6etsYRg01YJ4fzJvZ7Picnzo3+29Ajwb+VOadk3sTriuC+q37vJ0zc5LAViSL6zFk1NBnP69dNOX5wbBOHkTK4yd7XxpCarf9KoqDEEIcv8+7Rh3d+WjIL/Id8UG1BOZHT57ue6GTRTdbHC9w5vIbz+5czKW44luLvlxQLJns3mDgT73C4crfRZEklaNU5yhV7kJBVKDPm/WykPriyatGfrNmLnzec2v7xYxWx2fv6dMppW+PRtVYebfPHDl03xQ/bs2ceq6aVa8KKAzL831/6Ojzx37e/kn/+wOaRfhTijvXLyY80gS1Hf95vUIRqXt48oGJH1+jEZNO2WXB/YdM7L9qxJZJ/Ude6N7AV/no2PHEu6jJz9/0jYL8c4XBaQgwQs2aNffv3y8SiZxdEQAs2759u6MeSwKAw02aNGns2LHe3t7OrghgLoqi5Cp1Zq5cyOdFBgVyOW96gOzokVsvBK1ZsPyPI5tW7DLyA+NaTft95qyB8VJG3/rqotUGRSi0hgylhs9mR/hIeWwWpS9l4wnrfrl7p/fXi1bsXz5DxQ2Mb/ftH19Ma+fMhXYt4dWcnJAYuPjrX/bu/fWUwiTwi2k8Zum0L8a08Ifug8vAFMHVM2Kb81R5S4e9qJ1w+td795feRzIPn5Fd6sxv7O//KuYw/xotz4/yXnDmYcKd/w6bcG8P76EdW89tFhjq1PSEOT39OUGpH1/Y/LjYX3AfdvsfeoU7pVagglQ6fVqugo3j1fy8BdwiOTzDtbOJKjyyTrw7w46GtmBFD155IWDLgt8SjuxYv8vIC6zeZNrPE2b9rzqczRlLxXNLF/mxKLJDz5n/Crd9vffS3oTbCoLrFxI95tMeX3Sv4V9o2xke3E3U4JHRYS4Upe6Np5zaFjx3yc7DO7co2D51W36cMGV4t2AYEXEAjKKo8t8FAAAAAAAq3fLly6tVq9a9e/cir+rUNhWi0enTc/IoRPl7eYgF79CDiiqHQOzsGjhGhw4djh8/XvFyfv/9d3d39/79+xd5VZ5hUyE6kzlNriYoyl8icuM776JOLHPaV1cEx3WnOxbhqJjcvn27Xq8fNWpUkVcXjLapEJ3UJz2+jUkg9r1/QZp6v+K1slOvUeW/h4Fimzq7Bo7RpUuX/fv3czgVnau5f//+1NTUCRMmFHlVLbepEL3RlJ6XbzSbfaXuUrHzbqRQ5jrtqysoINLZNXCAPn36rFu3TiKRVLCcEydOXLt2bebMmUVePb3TpkIMLG6G2F/LFvhosz31echZucSw2PLfw0zV4p1dAwcYPnz4woULAwIC7PgszIAGAAAAAHg3mczmzDyFSqP18ZB6uLs56lnqANjNRJCZSo1SZ/RyE3iLhRCSwOnMfFFW9SaKwBivx9e9k65ihNnZNQJVHUGSWQqVXK2RiUWhvp44HCiBsxEYniPyzuV7yPTyIGUqiyLL/wwAJUACGgAAAADgXUOSZE6+MkehdBcJo0IC3y4ZCYCTUBTK0+gylVp3ATfaT8aGha2As1EYnhdeKzOmiSg3Ler0Vo5W6ewagaqOoii5WpspVwp53MgAHy4b0jXA2TBMwZNkiHz5hCFCkcIz651dIeDC4IgGGIDMu/Xnxh3/3HymEofWaTdg5P9qy2CYFzAMlXHwy2+zBywbFQdJHOAkRPLmidP/1DSf8fPU5m8XxiMebvjk8wddVi76wO/Na9p/fxy9+Kw2ZMBPPw8Kh4itilRaXVp2LpfDDg/043Nh0TrgfCq9MT1fw8KxMC93IddVHkUE3mVq7+D0mq0xigy9eECUl+bs6gCANHpDel4+RVFBXjI3Id/Z1QEA6TiCdLG/GWP5q9MlBhiiAxUFCWjgdMSzvd8t2EO0HjlxgGf22a0bFixi/fRdr2DImQDmoPQvT29JuKttBDcbAWej8hLXbWwV/1mj0h/lQamunr2mFQi5LxITn/QPhyc2Vy16ozE9J89oMvt6SKVu78jixcClGcxERr5GZzT7uAs9RJBSAc5nFEkzY5upvYJ9Hl3yeHwLQ/BIJOBkJjORqVCqtHovidjLXQzrZQGnM7M4GUIfJc/dS5frrc3G4NFxwBEgAQ2czXj70KGUoP/9PO79YBZCNb0UydMO/vVf13G1YMYWYAIq+9SSeRsuvFQaKeTl7MoAgPvFVyfP/b6lZewn9cWWr04o5ZWzN0yxfUd5H/j9fGLS4KjqkIGuGgiSzMpTyFVqmZs41M8Xx+HyFTgZQVI5al2uWicT8YM93GAZU+B0JIuTE1U/J7Ke9MXD6FObWQads2sEqjqSpHJV6myFyl0kiAr0gfWygNNRCMsTeGSJfMRGdZQ8mUOYnF0j8O6AxdeAkxGp/91X+9WrH1BwsmWF1K/ro7x/Lx1mmgJmwKT1+k+dt+ineX2iYcAOOB8mrjV4TBvq1G/bbmstz0Sg5BfP3iZqtGjTplk9cda/5x5Ar/HdR1FUnlL16NkLo8kUGRTg7+UB2WfgdAqtISlLrjOaI3yk/hIRZJ+Bs2H5AVFJ7w3VeAaEn90ZcPMkZJ+B06l0+uS0LKVWF+bnFeQlg+wzcDoVzy3JI1LBl4bmPwtWpkL2GTgWJFSAk5E5WTmUp7fH67EQ3MPbg8rJyiZRKAyPACbgSIMipIiSJwng2hkwAeZWf9hHLSb/sOaPFks+jCtxNzuVc+HsXSr2o0aeQmHTuqIzF87eGx5XG+4oeYdpdPr0nDwKUUG+Xm5CobOrAwDSmcxpcjVBUf4SkUTAc3Z1AEA6iXd6rTYmgbvv/X+lqfedXR0AkMFkTs9T6I0mP5lEKoZzN3A+A4ubIfbXsgU+2mwPXS5c+AI6QIoPOBlhNJgxgeBNbg8TCPiY0WCERYYAAMAiTNJ4xMgmmiOrdz4wFP8blXn+7AM8rmVjDwwJ4pvWFeZdPHe3xLvAu8FkNr/IynmekSURiyKDAiD7DJzOTJIv5KqU7Hw3ATfKRwbZZ+B0BFeQHt86pUVfcXZq1ImNkH0GTkeQZHpe/uP0LB6HEx3kB9ln4HQkhmeJfB7LIriEITrvkSdknwFtIAENnIzF5bEovU7/OuFM6XR6isOB6XoAAFAaTNZi5Ij6ikOr9yQbi/yBfJl4LgmFRfspU58/f54jqxbOVVw6e0vvpHoCupAkmSVXJKWmIYSiQgK9ZRJ4YBFwLopCuWrdoww5RaEoX5mPmxBCEjgXheG5EXUedRhhFEoiT23xeXARJwlnVwpUdQq1NullltFkjgzw8feQwNpEwOkUfOkjjygtRxguf+KvzmBRsBIqoBEswQGcDPf09sJScuUkkrIQQohU5CowzzhPGBsBAIBSYV5tPhx6bvLaX/c1GvH2VTI1MfGJ2UTs+PzTHW/feuXcDW2jpjDB5p2hUqnS09JYOF4twE/Ag/Fa4HwqlSo9S87CsTAviZALFxfA+dRqdXqbQQjDgq8cFmc9c3Z1AEAajSY9LYuiqEBPqZuwxApqAFQ6nU6XLg034yx/dbrEoHR2dUCVAH1E4GSskLgaov03b2UPrOaHIURm3Lqd4RYbFwiPYAAAgDJgPu3HDE6cvHH1gVjzq5eIJ2fPPePUm7BuXkePV1NqtJeWjl145ew1dZOWYphl4/IMBkN6erper/fz85NKpQ4vX61W6/V6qVTKZrtS/9BkMuXn5/P5fLFY7Oy62EYulxME4eXl5eyK2M9gMGRkZGi1Wh8fHw8PD4fPxNdoNDqdTiKRcDgcx5ZMK7PZrFAoeDyem5ubs+tiG4VCYTabPT09XfemCqPRmJmZqVarfWJqenh4YE1bObZ8rVar1Wrd3d25XFca/yMIQi6Xc7lcd3d3Z9fFNvn5+SaTycPDA8dddXqSyWTKzMxUKpVeXl7e3t4O37l0Op1Go3Fzc+Px6Fn1SCyjo1SKonJzczkcjkQioaN8+iiVSqPRKJPJWC770Eiz2ZyVlaVQKLwCQ+mISb1er1arxWIxn+9iYy05OTlsNpuOPjatVCqVwWBwiQ68qx7HwbuDW6tLl5Cnu1dsv/w4NfnC1pV7UyO6danpSl06AABwBtyv05iBkS8uX88uuFmOSE48nyZs0L6p7G03Uli3XTMP7Y1zV1WwsL5LIwgiPT398ePHPB4vOjra5XrG4N1DEERmZubjx4+5XG50dLRLpyzBu4EkyaysrOTkZAzDoqKiICaB05EkmZ2dnZSUhBCKjo728fGBmATOVZD3T0pKIggiKioKYhJUMqYnyEEVwA7vM3uGac2mlbP26oWBdbrNHNsr1FVHEwEAoBKxgrqO7Zc4fXMyQgiZHpxNzJQ0HdPArXBHkhvXrpX/scNnL+e3bi+FHqZrksvlN2/e5PP5vr6+XC5XrVbT9EUajUav1+M4zvwJFIWZTCaVSmUymUjSxRYuVKlUBEG41jzKAgqF4ubNmzwez9fXl8fjaTQamr5Iq9XqdDoMw1xuBrRKpTIajRTlYmN/KpXKbDZzOJzKSUk48PdRKpU3b97kcDh+fn48Hk+r1Tqq5GJ0Ol1B4a615xIEoVKpXKvOBQoO72w2u3JmQDvwPKJWq2/duoXjuJ+fn0AgoC8m9Xq9RqOhKIquGdD0oChKpVJV2tHGgQoO7ywWq3JmQDswJjUazc2bNzEM8/f3FwgEOp1Op9M5qvDCDAaDWq2mKMpoNJb/biZRqVSVdrRxILVabTAYKq0DTxD2P1ABc7mOEQAAAABAFbFu3bqjR49yOJxK6A2TJElRFI7jrnU1SFEUSZIYhrncBUNBD77S7uF1c3NbtWpVxcvZvn17QkICm82uhJpDTFaySo5JDoezfv36ipeTkJCwfft2iMmyEQThijFZ8INX5loHGzZsqHgS5+jRo+vWrYOYLJtLx2Rl/uC//vprxRcZO3fu3IoVKyonJgtOgi4ak6gST4KOUvkxuWTJEm9vbzs+CAloAAAAAAAAAAAAAAAAALRwseEmAAAAAAAAAAAAAAAAAK4CEtAAAAAAAAAAAAAAAAAAaAEJaAAAAAAAAAAAAAAAAAC0gAQ0AAAAAAAAAAAAAAAAAFpAAhoAAAAAAAAAAAAAAAAALSABDQAAAAAAAAAAAAAAAIAWkIAGAAAAAAAAAAAAAAAAQAtIQAMAAAAAAAAAAAAAAACgBSSgAQAAAAAAAAAAAAAAANACEtAAAAAAAAAAAAAAAAAAaAEJaAAAAAAAAAAAAAAAAAC0gAQ0AAAAAAAAAAAAAAAAAFpAAhoAAAAAAAAAAAAAAAAALSABDQAAAAAAAAAAAAAAAIAWkIAGAAAAAAAAAAAAAAAAQAtIQAMAAAAAAAAAAAAAAACgBSSgAQAAAAAAAAAAAAAAANACEtAAAAAAAAAAAAAAAAAAaAEJaAAAAAAAAAAAAAAAAAC0gAQ0AAAAAAAAAAAAAAAAAFpAAhoAAAAAAAAAAAAAAAAALSABXS7i0eLGXIzX/KfHpIX/Ws9wYKgEZwVPOG2io5b2Im5/VYeD8TuuyaAq6yupjD+HhAYN2pNdad8I7Ke/8nltr1Y//Wd0dkUAAAAAAAAAAAAAgCuCBDSoXFTO/hmfJYRM+aqXN0ZD8drk/QuGt63hLxGKPMPq95i05kI2Ue6HTGcmhrIxC7gNF94v8nHji1PLJ/ZqEhUgE/KF0sC4NkO+3HE7nwmZdJsbbjg4TIZbanTRtvMbTJ33ftLX4399VP7vCAAAgBbGY2P8WMUP0ziL5+YdXr/z6EWHkrSlfZLKvrB15ebEjHLGzK18W9HPwHByFUd7WNoDwrJKg5gETFMpMUlmnF2/9OfdN9VWVuqdiUlbGw4QguMkfWj8fVxSaRMZKVAO88NFo5aUfAAAIABJREFUjTiI2+zHZMLCf62n3z/EHcODxp8y0lFLe5F51/etX7vhyANt5Xyf/sKMGly/YfsVpOPLJhXn5zWV4gjDRX7Va9UMk3ExhHHCB/3x1Fz253LWd+FjGIazixM0Xnj/7We1N35s58XCEIaL/KvXrR3tJ2JjCGHC6qP3vbQxGBzLrobrD47w5JRoMZvNZrNZOIYwXosljwtaZbzxZS2uT/+dWTRsMwAAAOUzHB3tiyOMKw0IeyvIW8QuGMnFpU2/uqC09EHi6fLWfHbU9IumMsu38m2Fkdn7hgaKWvz0qOwzrL00SQnfDmtT3c9dIPQIrdf9s9X/Zln1RYbUk8s+7dk40l8q4AkkAbGtB8/941axLofxn09DWJa6ypwG392jpznWs7fhFKVP+fvHce/XCfUUizyr1Wk7aO6e+2oLxR9aNLpT7RCZkMtz841u1nf6uovWfkEJdIWlNRuxFC4clta/zQnsarjVOxqZ/9/ur4e/VzNIJuSLvMLqdRu//HSa9ceiwmiKSUPqqWXjuzcM93bjcwWSgBqtBszaeCXHur4/Q2PSGUcMh7K34da1qCJbvHhRNJ++KYoyP/m9qxeOuG1XplpVRWbGpB2/ua0NpxmdO2NZh9MsWxtPS0xWrGfFzJi09aRsR1+aZvSeu8vfZ8ncPwf7ubf++WGRb4UEdLne7QR05SIztvbyYEdOSdTTULgmcVoNDoZ7tV1wPsdMURSlfbRtWBQXw70+2PSirI1lujK7OhsT9NgiL6t43aXZNbkYxosevO6WoqA4zaO9U5t54Aj36rUlzXkXCHY33CIy98jYCDYvdvI/+a+bRKQsbyPg1f/2LmOOpgAAUKUUXC2wa827WeQ4TOrTL68bVVOIIYxb96tbJY7RZN7JiTU4GKuc3rCVbyuCicPJVo4TWzvqXPnsbjhF5p35ookMxzBc7F+9VlyYBw9DCJe1XHhNU/hN/8xu6I4jhHElQdXj48K9hSwMYZyQ/61/ZFfXlJawrNBgvwuH5Ts2y4GyekcjXuwdHSvCEIZxpSFxtWL8RCwMYWz/bqvv23GxQEdMGh+s7ubHfr1l6tUM8+BjGMJ4EcN2W9HLZmRMOumI4TB2x6R1LarYFi+O3tM3RVHGB8vaSXGErM7DMjEm7fnNbW44nejeGcs6nGbbl4B2bExWrGfFxJi0+aRsT1+aTjSfu63cZy1NZIQEdLmYlIA26TT6yrw2Mhn0JgceCIgnP7fks2NmXqKh20Lm7egjxTBh62WPC20Y5ZHRwSzEqfP1nTJ+NtXOPiKMFTntQlnV0h8b448jVuRnZzSFXyaer+4oxjBemxXPnHTmq0DDLZWWfXBUGJtf94tLhZtJvFjdQcAKn3SWjoEDAAAA5SjlaoGiKIoy3pxXh4MQu/b8W68O+IQ8+d+/d6z6amz7cCGGECqlN2zl2yxh5HCytePE1o06O4Hdw8lkxs4BfjjGjRy49lXLdSn7PqklwDBBk+/fXC3oE6dEsjHcs82Xx5/rKIqiKCLv5rrBkRwMk3RZa0dehY6wrNBgvyuH5Ts4y8GqHY1I+bWjBMM4oT1+PJdRECna5H1Tm3nimKDxd3dsbrbjY5J4sbazO4ZxY4Zt/k9ZUB/Dy5Pz2njiCA8YdcjiNMG3GBmTTjtiOIq9DbeuReVscZuvw2k5fRdq1K2FzcQFE1ety8MyMSbt2ctsbjitaN4ZHdxvoSMmK1JDJsak9SflCvSlaUXzudvqfdbCRMYqn4DWPz+5YmKvZjH+UgGXK5AEVG/RZ9rvFwvfymBXAlrzaP+C4W1jAyQCvrtf9dbDvvsrRZFQMgFN5t/dOX9ou5qBMiFPIA2o0ar/rI1Xsguf2ojUlW25mLDfzpQTX/eIlrAxDOe6B8R3nrLtnoYiVf/9MbNn/VCZkMeXBtf7YPafSTpbW/fft/U5iNdhdTpZ6Ov675Yn7Z7cLsyNhWE4V+xXve3IH0+9LDpIpvxv91fD2tUMkgo4XKFHaN3OY5eefFFmZtn86PsmXFbYpHOFf4Gc9Z15iB0z89Kb0s0v94+NFWC4e6OZp3Ks7nqq9w6UYhi/45r0Ih8xnB4fzEKcRoselNphePUTdPo9s4wvI5J+aMpBuP/Y44Zin76/sCEHsYLGn7Ytq17+prGS/Q0vicw99GEoi1d7zsViK7IQT5e14rKCPjkJGWgAAKh8ZV0tUMZzk8JYCHMfsv/VIVq1vRe/8E1zpfSGrXybBYwcTrZ6nNiqUefKZ/9wsvHyrBpsjB0z5Vzhe3Z1p8aHshCnzle3Cz5pujyrOhuxooq2m8xa11mAYcKeWxW2V9nxYVmhwX5XDst3cZaDNTua6crsGmzECh13rEiKiUzb9IEHjvuOUDpoZl8Be2KSTP+tIx/DfYbtL1JD07Uv4tgID/z4ZLHLgqIYGZPOO2I4ht0Nt65F5W3xfFtHRWg5fb+muTS3noDl/f6wbgEs6/KwTIxJO/Yy2xtOJ7p3Rkf3W+iIyQrUkIkxacNJ2f6+NJ1oPnfbss+WnMhYtR9CaLizvHuDjhOXJ1zJYAfUqF0zXKp7cn7Pj2PavjcnUWN3qVT++fkdGvf6fNPp+1mkR6g/60Xils97NO27Ltlc5H1kxqEJLRoPmL/ldJLeIzq+hi/xNHHXopHNGw/Z+rjoO5Hp9vc9e83/O9e3YfsOTUPZWXePLBnWafjcqe+3GLz8gj6kYdN4H/PL6/sXDezx5b/6ireOzDo8sfOgn8+rfOu/17F1rET58PSG6V06ff72Y6rzc9s26Tdvyz9PjN7RtWuG8nNv/71myvstxx0ofeV4Mu3YkRtm9+at63LK+Or0QxM7DfztAbfhjP2HF7b1tPZBhebkW/+pKVa1+vW8inyEU7thbQ5mfnj7nqHUj6YkpZhZPpE+aQk/TBnVr0uHTh8M/vTbTedfFvkEP/aDTydNntq7Jrvop4ms9GwSYe4SNxueqejAwKtAw4uj8k/OnbTpZcTHy+c0FhT9Ex7YomUUln708HWTbdUDAABAN7PJjBCiyNdPPRG0/nzfoUOHDh06dOC3UdXZpX3MyreVRDzes+OSKahzt0Kncyp3Qxc+xqk+6/KbDgyRdmBcnBBnSRrPOp1r9VNltP/sP5GPeC0G9atWqIvq1m5QjwCW6b9DfyWX8kRcMvXWnRwS93mvWxNh4dfxgNZta7Apc/KDJwWfJJ4npRgpdkRMuA1NLp0h9dTKz3o3rx4gE/J4QmlgjZZ9p6+9lG37E2jsbTgyXd2555GZXX/U2KaiQi/zWy++8uRp8oHxka+W8iNJEiGMw+UU7i1gXD4fR4g0Ew5/Zo4dYWn1RrTElcOyQg23xPlhadWORmVfvfzEjEvbdGvpVvh1zL/H/1pwqey/1TqHPo/Kjpg0P76fbKLYMfVqFd67ECs4LJiFKGW+sqwKMjImnXXEYEBMWtWi8ra4g5/Jbufpu4Dq7Jejvr8l7fXzquFhFpdsLYmRMWnzXmZHwy1xfkxauzM6uN9SNrtisgI1ZGRM2nBStrsvbYnzY9K6TWnLPov7v9+tIevZnh3n3ySlbE+ovzvU+wZ7YBg35qPdT15P+DSkHZ9eX4DhHsMPvp5LbOsMaNXJCRFsDOPHDF13I89MURRlyr68olcIG0MIvZ0BTab/0dcHR7hvxwVn0gteInKvrOgVwsYw93YrXpdOpK5sy0UIYwX2WHZVTlIURZnT9w4PZSGEME7EoI33CgbMdA9WdpLhiFVtcqLRptZZmAGNEMJ41T/cmfzqc9pHv/fywxHuOfzQqxuWnq1oy8dwj3YLL+YWjJ8QikvftHTHsLJmhqv+HCDBuE2LvqHIDGgi/a8J8UIMlzSefdr6uc8FTftrpCeOeO+telnsc4bj4/xxxG35c0op9SJSfm7JRRhPJGQXyeBibrVG73pSzgCWOXVzLx8csSImndWV/c7CrNs01rG/4cXpr3xRm8vyH7TH4sMG1X8OcMe4zX6ydeUZAAAAFVbWdBX12cnRbITY8V+W/GPB3TvlTsew8m2v3/18ZVseLhu8r/CEneL3MxFpBz+pKcRwSaNZNp3QTTfn1WIjdo3ZV4pWhczb2I2PYZJBezWWP0ik/rVoyqSpPx5NL3aaMpyZGMZC7Ng5VwtK1B8a7oGxgsfvv7H3+8kj+3Zu37HHoAnfbEx8YcctPvrbyzr4sDCEcSTBsfUa1osLlXExhDBB/MxzJR/nVSb7G/5kSQsuYkVMOV/O5CHd+ek1OBgrsPeaO6/ul6QML49OrS/EcM8eGx29BIddYWn1RrTApcOyIg0viQlhad2ORqQsbclFuNeow8X3Ps2uviIMcVNybZwS5/hDpdmg0ag1+mIvKw5/FMzCuI0WlbW2KUNj0hlHDGbEpHUtKmeL23aZRtF3+iZz/x4XyWEFDd6TThpPTwi2aiIwM2PStr3MroaXxISYtHpndGS/haIlJu2vITNj0q6Tsm196ZKYEJPWbkqb9lnTtc/j2KyIqf++ivOqnIAmUndP7tmt56RdzwtHlunWvFpsxOu8/nV025aAJrO39HTHMG7dedeLbKX8o2NDWYUS0OZHPzTlYbh3vx1FFn4gFYc/CmYVCpeCjDDm1nV9oRUWCp5NiXsN2J339kXVzr5iDHMfnKC3qXUWE9Cs8E9PFw5LY+KUcBbidfq9IDdpPDU+iIW4bX8p1Psg8/79fd4XcxcfeFxKV8x8+6s6HEwyOKHImfvt8UWfcfjTWiIMlzSZ80+uzYu+aXb2EWCI32NL8TvCjP9OjWQhTr1v/yulXoZTnwTiCOGSeuM2XHgq1xu1WQ9O/DKqrgRHmLDhNzdKvbeOVNz4fVicCMPYoUP/TLehxlZuGuvY3/BilXryy3tuuKDZD6Us2WG6PrcmG/MYfggW4QAAgMpm8WrBrMl6fGnPvM7BHAxh/IbfWXhQLC0JaIYOJ1tWYpy4QqPOxTBiONlwYlwAjrjtfnny9NgPo96LC5AI+GLvyCZ9Zmy4mlP0I/pHf4yrJ8Mxjmd00w5dO7epEyTCMEH4Bz/+a3u3i6JoD8u3RVoz2O/aYVmhtxXDiLC0ckfTHvnID0fsmBkXivYuFYdGBbIQYidn2pjuozUmSUXK9Yvnju9b/+2IBp44Jqoz9WSZew4zY9IZRwxmxKTtLbK0xW2qLEXRFZNk5r5hISxW2MgD2SRFWZ2HZWZMFmlYOXuZnQ0vgRExae3O6Mh+C0XREZMVqCHzY7KQsk/KFUxAMyIm7diUVpwZi01krMpLcOBBfZbsO7hvad/gN7+COT/55M4TKRW4u8Z45XSimuI0GTGyNq/w6+5th/et9vYmEUrx75mbRkzWeUh3nyL3AUneG9wjgGV+nJj4otBke1ZovbqFVljAZZ4yDLHjmjWWvH2R6+nphqE3890r0jrcp0OPZoXvN8AlUnccIfSqeFZ49SgeZjr33YjPt5xLlpsQQgiTNf1o/jdfz+geXsqtMMTLZy8I3Nvfx9LficyjU9/vu/K2BokaDh/T0uNts8yXZkSzsTJwGy16QCBEvWp5KQthkERpzcYCOs9esuzXvYlnVo1oEirlcQTeMe99svbv9QMDce21ZT8dVlmobs7V9RNbxzYes/keFT3otyNrevvZsACHdZuG9oYXoTr5/ff/aPz6zx4dbXn7sXz9fXBK8+K59Te9AAAAcKSCgdw32CKfiMZ9vjqSauaG9FiyYXJcJdyaiRAiUu4+0CJBeGSg5S4kkXlkUqd+v/zHaTxr/+EFbaxeSquAWa3SUggTuYmKfQ4TiUQYojRqrdVnISr/5tpR73+ckI2HDvp+ZouCRfrMKY+emBFlYlf/aH3hUWd3ze21I/ovumm0vq6k3OzTqusHn3zzZe9qrxeu4vq3GdItikVqsrI1Np0u7W44pczPpxCVve+jZp1nbDj3AvePCHHTPb205/tRLRoP3/m8UCeAIw2KDPcRIFPuowvH/zryz80XGsSWhVYP9xbatpWK1pzWsLS4ES1w8bC0+20lMSMsrdzRBK1HDoliE49Wjp3852Ptq09m/bt02Meb0wiEKJKyq9NJU0waT81p1bRlh16jvth4TRs9Yv3ehe08yggkhsakE44YDIlJ21tkaYvbUtfC1XZoTJIvd0z4ZFtatdGrf+rmZcO2YGhMFlb2XmZvw0tgRkxauzOWczjNsC9z5ciYtL9n5QIx+YrdJ2UrMSMm7diUVpwZedWiQlimB7cfFKzlWjlXK8xFKu4e2rb7+KVb95OepKQ8Tc1SmygKIcQr95OWUcq0NBWJe9SI9S+2F3Fia8Vy0JPX35v5Is1MscJiIot/EzuiegQLpaWlphEo7E0ZLBZeYn/DuEUXsSrJ3tbhXr7eZQ1N4KEfrlh+qd+U7ScXDTuxmCXyq16/SbOW73Xt269rbe/SQorUqLUU5i8QWKgz8XjTvFWYe1g1r2cpp76asavnjgGvM7q4b9OBY8dllb70DSu0rgxDLLGYj5BWq9FSyL3wN1BajYZCmEhcfP97jRPTbXxMiVcxn+6f9A/bseTp+TO3TD1bvF2TiMi++NvsiV9uuppDiKK6fbHwh5m9Y8S2nwHL3zS0N7xwbZ5v/X7Lc6zGnAmdJKW9WyAUYIhUq9QkQhVYbgsAAICdMK7UP0DKfft/jM33CKnT6cPZMwfGu1fkWswW5Q8nL151W4Pc2pcYTo5t/kNS6ddJnIYLb1+YFeKYUVUi5+qmr6fMXZOYZhLEDPpt39txYiyg8+wlMaywdkN61Cw4exeMOvsZ6vXbdm3ZT4c/29LTrayi38KD+izZ16fIS5aHk2ltuEmvJyhkunPyUu0xW44tHhgnwREyZyYuGdFvzt/bxn3cptnBD4NxhKi845PbfrDiPq/uh798N6Fro0gPw8vbpzd9Nf2H7/u2/O/Xs/tGR9l3TUBbWJa+ES292bXD0p63lYIZYWntjiZo9uWm+Ze6fpn4a9+Yzd7VIgM4OU+S01S8+A4tyJPnMnHMrgCiKSY59cet2dBerUi/d27Ptv0bBzV8eGfPwa/blJaEZmhMOuGIwZCYtL1Flrb4mW/a2HOkdGRMEinrx078Myfq022LOsps+ihDY7JIUWXsZfY3vARmxKS1O2M5h9Pzj6b/r4btuStHxqT9PSsXiMmKnpStxIyYtGNTWnFmLJjImPTieS6FArAqnYCm8i9817Pn/DPZlFtogxbNmvXqNDQiKq6Ox9lPPlh8395Ccby0zC1PKCiURC4ICkv9qoISCLKCj4OpUOvw8np8grgPt9zqNefU/oS/T507f+HSpYS1Z/etXfh57XGbDq34wOIQFsbhchAymSw9xY6iMFmLLw8mfPhkdL0R+/6cOeevDuu6FQxx4WG9vvqlV7nNNQeGBLHQ/fQXaQTyKxzVuvQ0OYXxAoN9bJztzw6LDGOjJ/I8+ZstQeWdXzSw/7zjaZR3o49Wfj9vdKtAbllFlMK6TVOJDTffXvfrGS23yYejyng+pMlkRgjjcrmVleMAAABQBKv6Z4evza/t5J4bU4eT39Sh7HFiG0edy+P84WQ2j8fCEMZtPHfHysGvn3/D9m0xfePC8zEjD5xYtytl5NQI3HTtp0mr7hn8Bmw+8lufV/feRTcfuGB/NLt5828Oz5qzp/fuAZ5Wt7tw/WkIS9sH+108LO1vuEXOD0vrdzS3xp8fvVxvxcKlW49cTrr/UOAf1236Z/OnBa1tcPIcjrPsulWXpkMlHtJq0PBWCCH02czP1vZqNPbQorGLu91d3NjyAYOhMem4I8auATbMRnR+TNrRIktbPH3Wg2Ar5vaUqLzDYtL8aNVH04+o4qYlfNu21GlDpWBoTBZW+l5WkYZb5PyYtHJnLO9w+vxpBqoRanP7HXmctL9nxfSYdNBJ2UrOj0k7NqU1Z8aiExmrcAKauLfy06/P5Pp88Mvfm8a9Hech7l6vQFBhbkFBMpzMe3A/g2wfUrjXRL5IeW5+u0CGb6A/G7v57NETI6ohKFwCkZL0hEAs/0C/Ck0zpaV1RbE9anQcWaPjyNkIUdq0a4eWT5vww5nV47/t1enX9hbuSsC9fL1wUpGnsLDH4AFDNuz/srkH1uTHr7eeHn98y5T5Q1qtaOduQ2UiasWKsLspN24rqHqF7skx3b1x10Sx42rFCSx+jlLcPXb8P6VbbPtO8UXHUsl8uYJEuPebyeDaa9916zL3oiHsgx+3/vZZM297t49jN429DS/EeGnztntmXqv+/wsrvZ9PKvIUJMb28vGoysv2AABAlcfk4eQKjBNbGHUuDzOGk1kyTxmGDNEd348s0qfHvFu3q8U5cP7Rfw/NKIL9/MzpZDPm+f6QbkVWfkOCOoP711544+q5U9eoAR2ZMMRs30Z8B8LyXZ3lUJSlHU0Q3nnG751nFG5E3qaULBITcrnWDwbRgzQbzQTCOVx2kYayqw0e23XW4U1PL1/NJBsHWfwRGBqTjjtimAZ0tC5CGRGTpJUtKm+LazQmJLJnz3QU1YVj5xWIKzk+rcPZ169RyqeZJDJf/+mD5lu57OrjtqwbbvGajqExad1eVpGGl2wtE2LSyp2x9Gh7dTjV6fTl1tFJyu9ZMTQmC77fMSdlKzEjJktVdFPaemYsOpGxCieTdHeu3zMh9w4fjSpyl4Eu9VlmBdaA5tRr09wdM13YuPFOkSVSjHe2/3Ht7a6FyZq2qsWhco9s+yunyAosqn+2JaQS7LCWLa07fpaGntYVIO7+1DGqWuR7i2+ZX72CCQMa9Pt67v/8cDIn5anK4poy7PDocDYlT01Vlvwz7ubv744hhFjhHy79vKmQSP5t0sKLWoSsXwpZ3KZLazHSndtzMKNQ+YbLew8+I9hR73cuZWljjJ20Zdyg/j0/WvPAXOQP5of7D9w1494t29biIIQQ8WDlhAUX1V7dVp3cPcX+7DOyetPQ3PC3jBd27n1Kchv36mG5A12AePHsBcEKjo4Ulv4eAAAA7zwrhpM9gwb9+HV7KZW6Zcr800qbSi8YVSVSbtxWFOksvBpVjS5rVFV77btuXT4/nhP0wY9n7p7/bbyFSwVKcffo7p27/74jL94VKTHqXK63w8k3Up9c/Gvb6h/nT/94cJdGwXZNjrG74eyYuBgOhswlL99IkkQIcXk8hBBFkiSFEE8oKN4pwHgCPvb6zc5nxUa0yKXD0oa3lYsZYWn1jkZo5VmZWbnqYtGru3T2ihHx6lmcFVeZzNe+qCXiu7Va+rh4YLFFYgGGKJ1WV9rKnAyNyco/YjAkJq1rUblbnCSYcKgkVc9uXHzr0r0MI4XI/JTrFy9evHQ3rbSgZGZM2rKX2dnw4pgRk9bujOUdTkViJ1+dV6RnxcyYRMhxJ2UrMSMmrdyUtp4Zi01krMIJaK6PnwdGqS4eOZf3+gfSPTn8bf9xm9JJhMxGSwMx5cM8e4wfGs4y3Vg0aNzmu0oSIYQo9YM/xg9ZfMNUaBkWVtSQCV09UdauicN/upBdkHgkFTdWfzhm3TPSrcWE0Q0qNjmdnta9qntIuI/8+eMzvyzYdE/9qnQy/86W349kkuzQ2vFSi/sJ5lW/YQTLfP/2fbOlP7/Gif10+fS6PNPdZROX3DK+vtGgDGN615VhCGFevT8bFoYr/54/aevjgtw/lXtu/uQ1yaT7e5+NqfPm5zQ9PbNj27btOxNTSYQQErcfNSicZbzy7eDJe5M1rxqjvLd9wsBvLxuFjSZN7iBECCHzrW2br+pYceO+Hlat7C1TUP62HWefltJOKzcN3Q1/zXz3+MmXBDuuQ7tSFv8v+Eky793LpsT1GsVW4ZsmAAAAMHQ42cpxYqtHna3AkOFkzK9T1wZcIvlQwk1D4dfJ53//ddOECeo1jucgxAqKr+mJkxmnj94o8i5EZZw6dsuEceLqxDJg+rP9g/0uHZbv3iwHq3c07ZFPov39gj/4vXDflErfsyYhmxK37u/u7E4nK7J2nBAz3Tn5T0bRwDI/TPw3k8Cl1WsElLa1GBqTjjtiWLtxmBGTVrao3C0uEDhz+jNCSDb8oJ4qxnh6QjALcduuTCUoynhldo1SNj4zY9LKvawiDS+OGTFp5c5Y7uE0tJqfdc2mS0V6VsyMSUeelK3EjJi0clPaemYsNpHR2Sd2J+K2GPNpk62z/13VOfpk08YxEv3LB7fvPDHFDunTcPeOK2e+6z8ie+bCOV0CbC1X1ObrDbMud//u0obhtbZ+FhITzE5/9CTP5NV+yuj8FWvTXr8NDxi0cu25h4N+PzyjRehP1eNDOVkP7z9TGBEvvP+qtR9HVjDO6WodQggh964zZ7c8POPM7tG1jsyrHhvmTuSmPHiUqaH4sR8vndqolCMMu2b7tv6Lf7t08SnRMqqM5vHqTVs2YVe7n64unvhL35OTY6y60QAhJG77zbpJid2X7B5R+/Kq1nW8NQ/On38oR4G9fl81qtBqKLrEJSOHHjAI++/u2SKYh5Bb2wVbv7rTde7ZlX1iNwdGRgYItc/vP8rUUvzoIWu3Ta3JRgghKufKpWQzIu7/0FK21FLb4ucknpsdx3pTvp7/wdaurcIsLbdv7aax7g4L+xtegEg5eTLJzPJv3qLMqdKaK//eNAubdWghsqZGAAAA3lUFw8mn7t++b0YtS0/WcmI/XT79j+Zf3Vg2ccmAxC9qs61bt65gVHX+X7/8PX/S1lZbhkZwC42qdiw2qvrn+RckO7Rl3xbB+Jtx4mlljxOL248aFL7zlyvfDp4cvWtR70gRQohU3tsxY+C3l43Cxq9Hnd+UT7CCm/dpFWapxILh5MyLR87ldWlf8LQV3ZPDP3368aZ0EnGLDSfT13CEVxs+a9DSnht/HDTMb8uqTxp74ghpk/6cM+Tz01o8bOzE3j4YQkjQduyHNbd8d2fZsNHRO5ePqC3FEUL6Z38vGD7jSD7mM+CTfsGl/2qVxcqNaIlrh6X1DXeVsLR2RxO3H9TTb9f6l8MOAAAgAElEQVSmf775ZEWTLZ/Wk+LInHlm4eCpB+Wc2OlfDnX6ZSom6zKit3/CpmNzRy+J2/hZE282QojSPE74fOQPN83sqCEftiu1Y8zQmHTcEQMvXD7zY9LKFpW3xb3cXXj2HjNjsiJ7mWWuEpNW7ozlHU6bRTh7qSLre1YlMDMmK9IbscxVYtK6TWnjPvtqImOrNxMZi48kVSlk3pXfPu1SO0jC4/IlgbU6jv7hyBMtIT/9ZdsQMZfn1XFFkpmizA8XNeIgbrMfkwmKKvHfUqgf7v1mWJtYfwmfJ/KKaDpgfkKyOuXnllw8aPwpY6EKyG//8eXgNrEBUgGX7+4X06LfzI1Xss2FCiJSV7blInbt+bcKvWq+Nb82G/E6rE4n375oODHOH8fcBie8Hh20rnX/fVuf87Yoi19HUeY7X9fhIF6n3zNffyGpurd7/tB28cEyIYfNEXqG1ukw4qudtxUkVQbtiY+DWYIOq1++fReZs74zD7FjZl4yFd4wimMfh7MxXPb+mpSyfuYSyPybm2f8r3G4l4gnkAbGdxyz9NRLU9G35G/pwUcIE/bfU2gY1fjyzKopfZrH+EsFXIEsKP694V/tvFOoMaarc8oc6C/0ixWUj/gfbFWWXk1rNo1N7G04mba6Ax/DhN035Za16bTHxgayxJ3XppW5fQEAANDCcHS0L47YtebdNJX/5kKIpB+achAravrFMj9n5dte058aH8ziNPn+UaFTlcWzufrctFgOholbLXlgS73JvFNTa4swDBeFNenSs3vr6h5sDGMH9d7wuHApRU9qZPrqDjyEMDZfbJG06Xd3C6pL5l9c0NoTxxDGcQ+qUa9R/ep+QhxDmCB66LbCX1D+2dxwc1EzdwxhbM/qLbt80K1dg0gvHi6pO2xgIwGGcUNaDfvmr5e29WHsaHjBB3NPTq0jwhCG8WRhNWvH+IlYGMJY3m2+u6B8e97W3VnVI5iLIQznyULi6taK8BGyMIRwaaOZJ3LsOb07Oiyt34iWuHBY2tBw1wlLa3c04sXuoeEcDGFs96C4+vWq+wowhHECu6+6q7Ollq9b7/hDJZl56OMaQgxhGN8rsk7jJg3jgtzYGMJYvu99f0VVZqlMjMmCDzryiOE6MWlliyqwxS22nt7TN0VRxSYCl4mhMWnvb15Kw10oJq3bGa09nFqJjuOk/TVkYkza1xspa591nZi0clPass8q/xwoxUVd1r9OJFbtBDSoZMaLM2PYwg6rX9i0+7ge9R+9Pfru0ji7Gg6jOTY2iO3Zf1eZSWoAAAA0YVYCmonDyTaME1Pljzq/Ld9VhpMpUnl3xxcDW0T7uvN5Is+wBt0/XXHqeYn7lc3ZVzbNGdQmLlAq4PLE3hGNeoz/+ViKPYk+inJ8WNq2EUtw3bB8Z2c5WLOjURRlSj+z/ONujasHuAvdfCMb9576+4UsW6v4Cj2HSjL/9o75I9rXCvVx53MFEv8aLftNW5OYZrTw1qIYGJNvPuiwI4ZrxaR1x0C7t7gFzEpAMzcm7frN7U5AMykmrdwZrTycWoOmmLS3hgyMSft6IxVLQDMpJq3blNbusyUmMmIUZeVq7QBUHPns1041J6u/vJ04vdyH47kuIumH1v+T/3z9uwou5M0QlPzPwdEDb4w6d3NxY175bwcAAPCOM12aFd9iRcjKR3+PLevxAS5Ps+N/IXsHpO7qC8/fdQUQloBpICYB00BMAqaBmHynaY+Pi+myp/n2R3/0LVhapCo/hBA4AR46fP648BurV5zVOLsqdDFcWz18yCavzz6s+05knxEiHm/8+QDe88vJjSD7DAAAACHEafjxZ23wsxu3JxPlv9l1EWmpmYGR1Zz8yClgLQhLwDQQk4BpICYB00BMvsMo+ZENf2ZGfji5h8ebZytCAhpULmGz2UtGYFu/2fD4HT3EsHwbjd3wz54PI96NGd6U/Mh3Pz9o+fWifn5Y+e8GAABQFcBwMmAgCEvANBCTgGkgJgHTQEy+syxOZIQlOEClo5S3D+xOCu7du54McppMZ0w6uu2yqNPAFgEwWAUAAOANKu/vjxsNfDTp6vEJ78iIa1HmF9cvKEOaxnpVrYsFVwdhCZgGYhIwDcQkYBqIyXcRJT/0YZ2R6XMuHRobXmirQgIaAAAAAADYCIaTAQNBWAKmgZgETAMxCZgGYvLdU8pERkhAAwAAAAAAAAAAAAAAAKAF3FYPAAAAAAAAAAAAAAAAgBaQgAYAAAAAAAAAAAAAAABAC0hAAwAAAAAAAAAAAAAAAKAFJKABAAAAAAAAAAAAAAAA0AIS0AAAAAAAAAAAAAAAAABoAQloAAAAAAAAAAAAAAAAALSABDQAAAAAAAAAAAAAAAAAWrCdXQGnGT9+vFKpdHYtbEAQBEKIxWI5uyJMR1EUSZIYhuE4jK+Uw+V+K4qiTCbTwIEDe/bs6ey6VJIDBw7s3r2bvt2foiiKougIAJIkC0rGMMzhhRMEQdPBEH7qYuCnLsymn9rb23vJkiUOrwMAAAAAAAAAuJyqm4BOSkpav349HZfrNFEoFAghqVTq7IowHUEQSqWSy+WKRCJn14XpjEajRqMRCAR8Pt/ZdSmfyWR6+fLliRMntFqts+tSeXJycpo1a9ayZUscxyUSicPLN5lMRqORjp1Fp9Pp9XqRSMTlch1euFKpFIvFdGQY5XI5i8Vyd3d3eMkmk8lkMgmFQoeXrNVqDQaDWCzmcDgOLzw/P9/Nzc3hPzVFUQqFgqaf2mg0ms1m+n5qNzc3Nruc7pNOp5s6dapDvlSpVKpUKocUVS5aBzPo43KDqW8U/OCVM7eAJEmEUHBwcMWLgpi0BkEQEJPlfhdJkqGhoRUvSq1W5+fnV7wcaxQccCAmK01lxiRFUWazOTQ0tOIbV6vVyuVyh9SqXBCTlazyYzI4OLjiX6fT6fLy8hxSq3JBTFayyuwsFcRkUFBQuVdDFlXdBDRCKDAw0IV2CT6fj2GYh4eHsyvCdARBCIVCHo/n5ubm7LowncFgUKlUIpFIIBA4uy7lUKvVqamp4eHhQUFBLrTbOoREIvHz82OxWDKZzOGFG43GgoSaw0vWarVardbNzY3H4zm8cJFI5O7uTkfngMfjsdlsOob6jEaj0WgUi8UOL1mj0eh0Ond3dzpy/UKhUCKR0JGA5vP5NP3UBoPBbDbTMaxS8FNLJJJyc/0OHCfbuHHjiRMn6Bh/KqkgH8RisVzrMEtRFEEQOI673AUDQRAURdnXg7f1i0wmU25u7qlTpype2s6dOxMSEiqnR+rSMYlhmMvduVjJMZmenp6YmFjx0g4cOLBlyxYvL6+KF1UuiMlKVskx+fz583PnzlW8Q3X8+PFVq1b5+Pg4pG5lc9GYRAiZzWbXjclK+MFJkjSZTKmpqYcPH674ZeD58+cXL17s5+fnkLqVrSAmXbFjBjFZtoKYfPny5Y4dO+yb01ClE9AAAJeQl5eXkZEREBAAdwAAAKqg0aNHd+/evRK+SK1W6/V6qVRaCZf6DmQymfLz8/l8Ph0DPLSSy+UEQdCaNdPpdOnp6SaTydfXt2/fvo4qdtiwYf3793dUaWWwftSHUcxms0KhcMXJEAqFwmw2e3p60ncRazAY0tPT9Xq9n5+fA2Oyb9++o0aNclRpZSgYX6dp0Jc+BEHI5XIul0vHjUe0ys/PN5lMHh4e9GWyDAZDRkaGVqv18fEZOnSoo4K/e/fuEyZMcEhRZdPpdBqNhqY5H/ShKCo3N5fD4VTOELsDKZVKo9Eok8noS1MajcbMzEy1Wu3j4zN27FhHBX/79u1nzpzpkKLKptfr1Wq1WCx2idusC8vJyaFpfgytVCqVwWCgtQNvMpkyMzOVSqWXl9f06dPtDn5XusAAAFQ1FEVlZGTk5+dXq1aN+dO0AQAAAIYgCCIrK0sul3t5eXl5ebncLCTw7nkTkzKZLCQkBGISOB1BEDk5Obm5uTKZLCgoyOWmPYJ3D0mSOTk5OTk57u7uUVFRrjUhALyTSJLMzc3Nzs52d3ePjo6uYExCQAMAGIogiOfPnxMEERER4VpTnwAAgF6EiY5SxQKeWMBDiKKpfITRcm3PYbG8CpaDIEk6yke0pcnoWFgJIURRVF5eXlZWllAojIyMrKR5mrlpdJQqQkiEIaTMpqNwhBCSetNRKhtDXjIJQnTtqohFV6eIvmlfCoUiIyNDIBBUXkwaaHlkiJCFhG5CRJmRwUxH+chkoKNUFkJefBZCBFLTszDxiR20FIsQfZNjFW6+GV7V+BJZREREJc0dpueAIOCyBVw6DzjXHbB2U0kYQrQvmpN8h45S6buJIF/il+Efw5V6hYeH/5+9+w6PomgDAD57ez25y/X0XiAEpPcSAkpXSpBeBIEgCEhHivIhKiqIQEQQkKgoBJAm0msChBZ6h/RyJZe7y11yfXe+P6KQhDQgyd4l83vyPMreZPPe3Ozs7buzM3U0dvjpjdrYKxsANgCg9mZBd6mtD0ECALACYFTX0v7BjXO1sVceALX0vJWBK5SLAnCeICAgoEbW10EJaARBHJHZbM7MzORwOP7+/miMDIIgCIJUR2FhoVwuxzDMz88PrcaMOIKioiK5XA4h9Pb2dro5SZB6ycTmySXBdpzumffMrXmNzQODIK/NxObLvcJtLK674omgZVuqw0EQYGFw5CJ/M5Mr02aLWrSuqd2iBDSCIA7HYDBkZ2eLRCJ3d3eqY6kUVPz92cq8EesmRpQ3rI/U3P4rbte5WxkGV/8WPUZMiG4uxCrbjiAIgiCvq+SUkSKRyOlWo0Lqn+IpIw0GQ/E8MKhNIpSz05kqkb/OVSrR5Uh1WVgtPTeDINVG4AyVe4hW6CPOz5SmX6eRBNURIQ0dQaOrBD5ankxoUPnlPa3ZNokS0BVQplMdQVni4v8o9dSGUQ4HO3PjxY9O2AAorLUHNl/bjbNUR1AKCwAHXKsin++hFAf6+Pg4+jIp0Jxz9vcD94ztyj8CiIx9X325l4icMHOEOC9hx/YvV+Frvhrsi1e0vY6jRxAEQeoJNGUk4mhKThmJ2iTiCCCGady8VCJ/V6M2NDOZYa+VqU4QpPogwLQib6V7GNeoC3l6gWk1UR0R0uBhmM5FohD6sW3G4Ny7LFvNt0n0bQBBEEcBMVqOKKCI4+bwSw7CvDPff749KUdvhRVNX2a9c/hwmk/0D1P7+OIANJXons37+5/7/ac2vl/+9recaS31KkEIc3Nz5XJ5YGCgj48P1eEgCILUWwUFBQqFgslk1t2UkQhSKYPBIJfLcRyvqSkjEeQNFXIEcmkwDZL+8vtcUwHV4SAIKHIVy73CIcB8s++4GmptxmEEqbYiFk8uDiQxzFudwjPpaumvoAQ0giAOwY4zM6ShGIDB8nv05q2oDqdymKDV8Ll+A6H+0qYvz5Vbgsi6/7DQo0Nrr+KRzbhf65ayv24+kNtcyt9OvuVfPya61uv1q1evjouLy8rKKt4SHh4+ffr0KVOmoJUkEQRBapDJZJLL5Tabzd3dvfbWjkOQ6rNYLHK53Gw2F88DQ3U4CAKsTI5cHGRk82TaLJEuB80Cg1DOxmArPcIMPKlM9UykzsQApDoipKGz4Uyl0E/PFUr0cmlBLgZrcYYDlIBGEIR6ZiY3QxrmYi30VqfWapdXUxgCn2ABgNqnnAq+yZJqlRqKpaL/sso0kVQE1ao8ewXbSfBvAjozM3PVqlXP98PhcCIiIgAAJEkWFNT8kA2SJCGENbXnZ8+eDRs2LDU1teTGhw8ffvzxxzt27Pjzzz9r6nKUIAi9Xl9Ls0kSBOH4VV0SQRAAAKPRaDLV/HNSzlvVdru9NvYMACgqKqqyQkwmE+lg81Mh9QlBECqVSqvVisViqVSKlupFKPe8TQqFQj8/P9QmEcqRGK4W+qiF3sICpY/yEY6m1kWoRmK4WhaolgbyC5ShTxLpdivVESENHcQwDc9DKfDhG7VhObfohK22/yJKQCMIQrECrihHHCQtyJHq5VTHUmMIq8WOcTjP89MYh8PGrBarvYLtz+99FxUVXb169fl+WrRoUZxehBDabLV1SqiRTJlGoxkyZEhmZma5r16+fHn06NH79u2rqYkgayO9WMzxq7pctVchqKrLqE6F1N77Qho4CKFGo1GpVFwuNyQkhMmsV9M3IU5Kp9MpFAo2mx0cHMxiOeDyIkiDo+O5K8QBLKsxKOsW22qkOhwEAQa+LNcznGkzBz27zDYbqA4HQYCBK5SLAnDCHqB8xLXUUZtECWgEQaiUx/fMc/P2zU/hGbVUx1KTcCYLhwUmMwRsDAAAoMlkhgwes6Ltz38xODj44MGDz/958ODB4umwcRyvjVUZbTab1Wp1cXF5812tWLGiouxzsaSkpIMHD06aNOnN/5Zer3d1da2NAVZarbb2qtpms9XGbJgmk8lsNru6utbGJCcFBQU8Hq/GqxpCqNPpaqmqrVar3W6vvarm8XhV3kdhsVhoACBS44qKiuRyOYTQ19fX1dWV6nAQ5N82SZKkt7c3j8ejOhwEASaWq1waYqMzPfLTBQYl1eEgCDBz+HKvcCuT6654ItDmUB0OggALg60QBZiYXJk2W1SUB2DdzQODEtAIglADYrQcSZCR6RKsuF8bS6xSiyaWSrC0fC0JBDgAAJC6fB0mjhDTK9j+PFPFZDK9vb2f74fNZj9PY+E4XuNxEgSBYdib79lisfz6669VFtu8eXNMTMwb/i0AQHHMtZTgq5EKeVlNVfXLiqeDoNFotbTz2qhqCCGotaqm0Wi1VxugelVdG38dachsNptSqTQYDMVT69bSrDgIUn3FbVKv10skEqlUitokQjk7nakS+etcpRJdjlSXhaGJsBCqEThD5R6iFfkKNVn+6ck0oraeKUSQaiJouFrgnc/zEBpUvnlPaXU+NxFKQCMIQgEbzsiUNaJBMkh+n07Ww5Mx7hcR7nLw1u28kYEeGACk4vYdBa9JhDezgu3Onqy6ffu2Xq+vstitW7cKCwvRwD0EQZBqIklSrVar1Wo+nx8aGlpTsxghyGsjSTI/Pz8vL4/P54eFhaE2iVAOYpjGzUsp8nMx6UOzbjBsZqojQho6CDCtyFvpHsY16kKeJDKt9W2sFeJ8MEznIlEI/dg2Y7D8LouiNomeD0UQpK4ZWa4pns041qIAxcP6lX22p5yK+yX+ipIEgPlWv35+6Xs2/Hk1JetZ0o7YfVnBA/o1ZVa43cmp1erqFIMQVrMkgiB1yfj00IpxPcN9pRwXN0lo5+jF8fcKnWhZdvOlb94fsf5mfTqdFDMYDE+fPi0qKgoKCvLx8WkAmT7LpXVTRmy+V/FHWWUBijn5oVQ1g8Hw7NkzvV4fEBDQMNpkeaBq/7R2ft1X3XDYhggAAIB48kM7kQjjlfNDb/H5FYcNHur3b1zp9+mRGyVH5llujRw1HRs8rdTPsI1xhbCQI3jm20rLk/nn3veX329Q2Wcn6XDs2Vf2TPhoilfUe6yuQ/3HfjZj36P80sPToeHpL+u+jBo5it99eNiUNd9dy6d+JQ3L3ZETF2Cj5pf6Gf9LXIkahkXZv/zxe9TCL/gTl4etiP/uXkFx2EWu4pTQzvmSQN/su/4ZN+p39tmYfm7FvMnhnSM5TTtJeoyLXn3snrHcRmi9tHnBiF8fO1jHY7kU+/GIrQ/KRmU6MbJRGOYdWuoncHKczmGOL6jfH7vcb8HhUv0kILJvHZuw5DOv4dNY0bP8Z22YcSwtHwIAgInlmuLRROXm7Z2fGqB4SFX2GaAR0AiC1LECF0mOKMBdly02KKiOpcbZc64dPpRGdBza3h3Qg4Z+usC2+dfYRfvMXO8WAxbGDPbHAahwu3MTiUQ1XhJBkLphe7w5uvus43rPTkMnDvWzpZzd99d3489czDp3Yl5zZ1hODOb9E7v+UMLAj+rT49Zms1kul1utVnd3d4FAQHU4dQTmn4rdfDyh37iKPsoqC1DL2Q+lylksFrlcbjabi+eBoTocCpHZu2ZPi7ufF/QO9TmySmG8Rr2ihwSXyawQiqtHLiu9vKUOOg4NZifGTzuVm+cRUbJ6CU1euhVzD2kW5fFi0AbJDOT6NM0S8mXaTJEup6HNAuMkHQ7Mv7Qxat7RTEGj6PeGhjJ0yQlnN36z8KLqmwtTG/+7WIflycqZC5c/Yrd7J2pGp6Irp88umv0g7du1P3biU/iZEtr8dBvmHtQkyr3ECit070D6f0FZs1eu2rQ8ndmuQ8sZLcxXLt9c9F16yvx5S/q2LORJJXmpEnUGBh3zZFVjbGl7o0d+c7xQ2qnvoKGe9pQrZ/7asuxMsvLcr+Oblx5eBTUJsb+dS3h7qEPVCMw/G7vtVELvUWWiIhSZ6Waae/OoqAD2i62MJoEMB+lmYPb5P6adyMnzbFqin4T5yTujViZk8gOj3+kdyjAkX76ycePqC5pFu2dG2bhCiV4uLcilvE2iBDSCIHVHJfDJd3X3z3vqYi6gOpYagAn7frG3b4kN7G6f7u32/F+4tM2YpW3GvPRrFW13Zs2bN3dxcSkqKqq8WNOmTWtj0TkEQV4f1B1csfyE1n/C3oQtA9xpAABy8ak5Pfv9uGrprjGHxns4yHft8hAmdfr962d2fL0sXkG6Ux1NTSEIQqVSabVasVjs7+/fMFazJEz52fdvJu744dt4VbkfZZUFHIATH0pVIAhCrVbn5+cLhUI/P7+G0SYrRKT9GjPvkBJijl8LNM++K7f0Lb2NTI8b0eZkm6XffRDkkG+AUF6K2XZLCcpWL6FSp0NWz6Ef/tGeAQAgMVwt9FELvQWGPPfM6zjh4PcCaoGzdDikPO6Xk6n8TnFxS8bKaAAA8OHb8z9YsCZ+z4FRS0fxMQBgxuHt3z7EImd9e2ykLxMAclSbseO+3rp+/4ftxremLllF5OWnQ2bPQaP/aFPuEt8wI+HIt6lY5Jipx/rKmADY+4UPX/b7tvhnA99p+c6TRLrdWtcR1z1oOLh+44kCzwk/xm3pIaIBAMjJp76c3G/HtqWHBxwaIsYAAIA0aXPv372646eN8XnQYU7fhEmTc//WpR0b1saryomKyMpIh9yeM9f+0Yddzm9TjVBciNlys2w/SebFxV9MdW0ZtyZmrIQGAIAjOs2Y993GQxePTewxVXeb4Rht0iHPPAiC1DskDc+UhRW4iIMU9+tH9hkpicPhjB49uspiU6ZMqYNgEAR5BfY7CUk6/K0Jc/u6//ulkCbpMXdKJ4Yh8cx1C7WxVQqq4gb7hbXtP3XdhTyHGlDz2iCEGo3myZMnVqs1JCTE3d29gWT6oDp+cLNObUcsXHc5v9yPssoCDsFpD6XK6XS6p0+fmkym4OBgT0/PBtImK2R7Ejt1SULgyBHNnHIUF5kT/8nyS0FzVs+JcMjJ3whF7I/7EmTtR/iXaWZQq1RrMVGoOw4AKHCVPPVvXcThB2Xd9lI9bYjZZ+A8HY7xUeJjO69tz2jZf58pJ2xQRynNnHU/lwQAAFJ18MQ9o6DL3IG+xY2SJu40711fmJ4Q/4jC2RqgNk+jxYSh0goeU4W6g5fSjPxmc6NkTAAMfFlq+6kfvOcP0g6dTbzZILLPAADiScJNAx4+aG6k6L9GKOgxKboT3ZiYdK+4EcL8Q4O7Dmw76ct1yVrHOX1D9V+DW/dsO3bZuqua8qKC2sxsLeYd6lfuvQeq2RWxG/YmuHccEVC6nzSlJaYQvOYdoiU0AICBK3waPLBbZ3ea+bHi3mMHyT4DNAIaQZA6YKWzMqRhDMIalHsPh3W91ipSN/73v/8dPnw4Nze3ogJt27aNiYmpy5CQOpCdnX3z5s3CwkIPD48OHTpwOByqI0Jeka0ICEObRbYOLnGRhXG4HAzYLVbHuVp4GSZ6b935pjoSwPz9M4esyaY6njdUVFQkl8shhL6+vg1tpVZM0HvdP+E6EkDNkZnjNr38UVZZwCE47aFUEZPJlJubSxCEt7c3j8ejOhxHYLm9duqyW82Wn55NfLR7t5HqcF4VzD+4fOUx6Ydnpzvm2iP22wd2LEvxXv7VO8TGa7tL5VBhuiKfwD18Rcadj3UPNenuLs8GhLmx2Y4yzJcCztLh4CFTFn4ywr9xiXGkpKHIDGkiKZ8GAAC2lKtP7czmzTq8+P6IN2nZRBx3MvlRAdlUTNEtL5iu1BK4LNhVc/5K2j2tjSvx7tHMz5/1X5Oz5VzNJJhhQS0F/DSvcAuT46F86i+TieH15LRCMsStQdyps5mBm3+ztk1KNUI2m4MBu9VW3AgxQeS6nSE6EkDtmZnTfneQ0zcmeHvd/kY6CKDm+MyJ216KikzPyCHowcGCrPP/JN9TmLjeET26tfDnOkKHY7+9P25Zis/yVb2J2Cul+kncd8q0cSO8gzA6O0McYGS6ygrSeHmFEJNKeY4Q+b9QAhpBkNplZPMypaFuRfkemgwH6vyQmubh4XHkyJH+/fvn5OS8/GrLli0PHjzIZDrkJQ/yWpKTkxcsWHD27FkI/12Rw8XFZerUqZ999hmaaMWZcPuuTy77jHb2gf1JNmaL9i0c8cnD5+jSRm2lAAAov8V35ks9m82mVCoNBoNEIpFIJBjW8E6VdHGjlmIAAFTeK3/KzyoLOALnPZReYrfbFQqFXq+XSCRSqbQhtsnyGK99O3HV4/ZfnZ8VDtZSHcxrMF5e++k+IvqXmR24VIdSHuPTYxP3KNqPXzDL9+XqtaUqCwhoXTxrcZ7ODgEAAJsjDFs0e+LyZo6UWalLztLhcPz6DfADAAAAzUUGjTbvbtL+ecf1Xj0+GuaBAQDIfEW6BYg9S6XI6O4evjQyM0dFAKoS0LZ0ZQEBTYsWr5YbiOImxxQEL5o+enmEKwYAWaBJswJBwFt5IR1kmiz/jGQaYSfEIl8azFTpCNAwEtCczusPdi69icw+eSbJzmjR4r9bDriwUTMhAADmPXKgr2p0UaMWIgAAVD0oLypLevVmFkAAACAASURBVIaCIPWLeveVa/7tcJiyDoti1y7vLKa2wzE++WdivLz9hCWz/F7qJ9levd/xVQu803gyriLFNeP09eTj888bvDqNGCZzoG4SJaARBKlFGleZQujnqUkXFqmpjgWpdc2bN7958+aKFSt27Nih0+mKN3p6ek6bNm3u3LlobGx9snv37nHjxlkspUYoFRUVrVmz5tixYydOnPDy8qIqtnqGIAiLxVJmgnUXdu3dy7Gk/71k2IITRQEfLv0g0HEuFuolkiTVarVarebz+aGhoXR6DX8tL9Nsnt8rekMEQVit1rJtskZ2Xa845aFUPA+MUqnk8/lhYWHO3SbpNXrJbbjwWcwPmd3W7J0cQgfPanLPdYNM2/bFrxnN5u4bQHECpXymZ5/FnsxsOmxvbxkdqEq+AjFMw2Ne1RGQIEPennr23dAAoEu+cmJm3KWV3+3wXzN1ovSN3lAttUmSJG02Gzp3v0BmrZ02bfFDOwCYsMW4I5929aIBAAA0moogzdWFWzJmjMNxxWC2yVwzH8ZrIAtS8ghoJwO7jzk5oFEAKEi+fm7mH1dXrtvt/9WEiVKalsnSABqXJwx9ksi1mv4Nm81yxWC22fqGYZdpNiRJ1kizJAiinDb55vt9wZp+esOwVUlF3oOXDvF2xEZYTYQ8JcsG7UTgyPUnp3YNAMrkY1tmrtizMuZT/+ObJlL4zkxPPlt3PLPZyL19y/aTAACdq1Qh9GPbTME5J7+f+enipwQAmLDJwCMft/Z6406/BtskSkAjCFIrIMBUQl+Ni8Q/77GL2UB1OEgdkUqlGzZs+P7772/fvp2bmxsYGBgREdHQp4ysd65du/Zy9vm5+/fvDxo06NKlSzWeuWiYii9iTSZTyY21dBFrzT6zbuGclXseWoOGbtq3uo/QEdMU9YbBYMjNzaXT6YGBgbV0f65Ms6kp5bdJ1FhKcNJDyWAwyOVyHMcDAgK43FoZJVum2dRgss9ut5dtk7yaewtQd3zJtA3qXlsPjQvEAXDCyeSKEn9am8R6b+u48AqmtKUSNB7/7fcN+oityzoF0gAoMX9EIUcglwZhZMGYcbN7AX5kIzEXAACkXd8Z9TdW0HTj/fVncscP936T91RLbZIgiHLaZEM+d2PSITM+DZDnpzy4tPXv3wfMoR35fng7Liiu8nIjJknqphLBXAeN+qAlUxYZKuICAICka1T031hB0y2Pf0gydZ7zDkx5zIAAFDxiWn3L/Cr5xk2o9vpJgiDKtska2TUAVsXVdd+sXnk01er7zqaf5vZxc8hGWE00yaClP7Vkh0S29uECAIB/11Er/saUTecnrI9/Mn5OY2o6UWg8HvfrBn3Trf/rUqafNLFc5aIAO43umZ/mZtQAyBnywZQAlS7l6a2tpw4NWIEd+bxfuzd7LKJMsyFJ8rUPT3RxiCBIzSNo9CxpqJ1GD1HcZ9gdaCUMpG4wGIwmTZoEBATweDyUfa5/5s6dW1H2udi1a9d+/fXXDz/8sM5CqsfodDqHw3Fzc6vdPwO11zbPmbRk512LT8/Zv65dMryp48504PTMZrNcLrdYLB4eHgKBoPb+UJlmU1MTKeA4zmazy7ZJfV6N7NzpOeehZLFYFAqF0WiUyWRisbj2/lCZZlNT3xDodDqLxSrbJsmaWpsO6k4sjdluHLx97Wgf5/xKA/P2b9qT5Rm9pZ/I8Zoj1N3cH3PSOnj28NGSEtFhdKVHON9VINNminQ5WKPA0r+Febdr0fHn++dScwqB95ucIGupnyy/TdY4J+pwME6jNp0bAQDeHTAqaHHzNTuXHX/76GAxxuG60qCm9GBnaDIVQsyVS90k3xi3SUTjJqU3ydq3arn9cZIcp+tyA5RKPgYzSw92hmZLIcRc2cw3DPvlfrJGmiWdTmcymWXbpPaN9wv113aunrTm6F2re88JK9dO793U1VEbYTVhbk06dy/96dO8e/XquPj8ubuPC0HjWj6qywV1N/bGnLAOnju6VD8JcLUkKI0nlujl0oJcDJIAAICxG73VqhEA4O3uo/x+aL75yLJznY72EbzJ2atMs8Fx/LVP3ygBjSBIDbMy2BnSMJbNFKR6TIMOtAwGgiBvLjU1NTExscpiKAFdUzAMw3GcwSi9EjdRU4mV4r1l7Z3ab1xcurTXpwfWzX8vxCHnB60XCIJQqVRarVYoFPr7+9f2/bmyzaaG0Gi0ctokApzyUCIIQq1W5+fnC4VCHx8fHK/doV211GzK7yctNdVPkqq7d3Nt8vgxwfFjSm7/oYPrD3jIJxdvfdnesS+pyawD204XBUwZ3s0R50KDqvScXKIgfvWn8atLbj86sMtR3Kv3xfUD25fXKjEOV4ADSJAEBOUPoK2eMs2mphLQGIbRaDR07rZm39p9R+vfqntXj+cVS/Pv0KYp7c6jlFwCiBliDz8mTM5R6iF4PjsMkafKIWmNvGQOMl6fxGj5Ev88N4yP7wQFD4QqFs4X+jFgcp62VNhaXQ6JNZIJ3jDsOm2Tb4hQ7F02fdxfudKuEw8sm/CevwNNP16zMJ6bgA6gnXjDDud1QVVadq5dF//NvPhvSm4/MqDLEdy738UfBwtUD3c/1Ps3a9dVWuJYaxXRFH/8KFNFgDdKQL/cJl+7WTr22RJBEGdTyBFkSYJFhXnuuixQQ08MIQjiOJKTk6tT7Pr167UdCVJD7A/XjZv4a27E3AP/fNVT5pzD+xwfhFCr1SqVSi6XGxISglZkrY+c71DS6XQKhYLNZgcHB7NYLKrDcVg0Ucdxiz/t+WLiDahN+m3bWXOb8ZO7+0o6Ofxcp2T63/uTrL7TBjR3yLtGmKhxx8XvhxdXr4XJLeTQbh/867I5aHzvUF9+sDcN2FNPDd50U9h7YlzPF0vSEUrlMxvm6SlpqKsQOkmHk31uzopTjT9pcm6E+/MYYVGRAWKc4pHCzJAOYfT4ezcTTe8M+jeFTj6991gNZKObCKl6W/a084N/uSt8e1RcpKiIL5N7heM2q+/VP3JtmKe7gIcBwPTu4I/HP32aaGkziP1f2M8y1ZhwdBDPYT+NmkY8/HXJxH2qiA9/+Gdee8dthK/Ifnfr4EXHhePWxg1/8cwLkZH6zErzDPKjqMPBROGdFw9vUtxPWunsQjZ26+99l00h4/uG+vJDvWkAyK/N+SGp8aSQc++96Ceh0WSAgMNiOE43iRLQCILUmOIlB7006QK05CDyKpKTk7dv33758mWtViuVSrt16zZ58uTQ0FCq40LKodfrq1PMZDJZrVaUZXMC5vPr11+2tF7+20oHvoJ1ckVFRXK5HELo4+PD4/GoDgepHU51KJlMJrlcbrfbPT09a32WAKeHSTp/uLxziQ3Es+9Obz+n7Riz7DMHH/sMAABQffrkLZt4aK8WjnlGxiRNui5vAkwsV7kk2MZguedd3pKw74ohMGbEu/+OffaQCVXpf+45OqzN6AHFc8vaNXv2JN4E0jldAhwyq177nKTDYYS3jHQ5fujQkasDJ3QoHoBPao/uPfcICie1DaADAGjS996OWLzm6sZ/cvq/780AABbd+elwKggYNrwxZUcX3UMizMv888D57u+t7OTJ81A+FeTd27Xz3E0gntPRlwEAwATvdQhY/OvDjQl5/XtJGQBAU8pP5+XAK2p4oIOM2659luvr4+5Ymk77bW79yT4DAOgBAcLsO3+u2zis55cDiue7sOXsWb/rJvCb895bFHU4mCQicnkEsDI4cpG/kekq017bdmH/FXpgzKhBxf0kDA2PdLlw6OT5q72GdCi+KULqj/5z9RF0m9Tc23HOVI4TCYIgTgxiWK4o0MB2C1Q94lgKqQ4HcRpWq3XWrFmbNm16viU1NfXKlSs//PDD0qVLly1bVlPPnSE1xcPDozrFxGIxyj47BeJZ0mUlyeRfXBUzqfTlA8bv+smaDyLQN8U3YbPZlEqlwWCQSCQSiQR1aPWYsxxKdrtdoVDo9XqJRCKVSlGbrP8KL5++bmV36tTOUce4EzhDJfTT8t3FerlUnkmzvzSKhdt06eiIk5uShs5Vvt85LJBmuHPr5uEMe7OBHy0Oc5ADq645S4eDuXX6fELTk7G7+36QPiKykSfU3L164cCjQp9e85e0LW6RWMCACfP+WfjFuqUD0nv19yOS/zm4Q+45efWQ1tS9B8L1rZgpbY5+n/TR+I/f7+ATBPR37t45nEk06z9hcQj937Aj+81L3PTFH9sG5Lbt70EkJ17coRZNntu1dYPJPxMZdy6rIdP15qolGWUbYdsxa6KDHaQRvjJe1NIF3U5+undo77T332sXiGvunD96+KGt2dTNi1tRdmlDYjS1m5fazUtoUPmonuJEXpmTN8Zr+fmw0JPbj/WdkzOiQ6AnLLh7O/nAM6NP1w+XNHegKzJnbRUIgjgOAmdkSkIgjRaiuE8nrFSHgzgNCOGYMWP27Nnz8ks2m+3zzz83GAzfffdd3QeGVKJLly5MJtNqreJI79GjR93Eg7whe2Z6ph0WPjj224Myr9Bk9Pe/+yCCkqjqAZIk8/Pz8/Ly+Hx+aGgonY6+ctdzjn8oQQg1Go1KpXJ1dQ0NDUWzeDcQluSECwZaSItmDrg6HcQwjZuXSuTPNRWEZCYzK1y3nBb2zuQkybkvD145evrUbhvT2z9s3sy+iyJ9BI73puqG43c4/2E0Hb3ignTXit2J+/bc1NmZHgHhU+YOWxrdzPN5zpLT6LN1X0t/jNtwKn6BkeEd1mbl9x/O60BRg8UwncBL4dnI26/pRfam7w4mHT3zdI+d4e0bPG/q24u6eL1ocizfzxZOke46uuHymQVmurd/o5Xz+897y6XhNEl7bk4mAQufXfztWZlXaDK813fRwZREVRPwsNGxSV6/f/nzgaO7ftltZXk37jDvh48XRTemqsPRuUoVQj+W1RiUe5dtM1VQit500MwL4n9W/J2875+HOjvDwyd4ypQ+S/uGeTpSo0TfhhEEeSNmJjdT1ohjNnirUmho0mfkVcTFxZWbfX5u9erV/fv37969e11FhFTNzc1t/PjxW7ZsqbzYrFmz6iYe5A2x+m3Nt22lOoo3gnnGnDLGUB1FKQaDQS6X4zgeEBDA5TriwlCOCXMfeyp37JsUoJCDH0qFhYVyuZxGo/n7+6M2+abwkPmJuvlUR1FNrO6rswtWV12uzhVxBXJJMASYr+Khq1H74gWabP43G16qXkZAy3e2tHynLiN0ZA7e4ZSCcZr2nrC794RKitDcwqcv/mb64jqLqXxFLiK5Vzik4d5Zd3mGPNCk45YmHSspT3P1nz5p6vRJdRagY2F1X57/eHk1C2PSoafuDa3NcF4HJht5Km1kea+wAqImbYmi/qM1MV3k4kAbzvTQZgoK8168QJPNX72pbD+JsZp2G7K725A6DfEVoQQ0giCvz8ARZEtDxHqFTJdNdSxIXSgsLDx27Nj9+/ctFouXl1efPn1CQkJee2+rVq2qsszXX3+NEtCO5quvvjp16lRaWlpFBT7++OPOnTtX9CqC1GMWi0Uul5vNZg8PD4FAQHU4CAIsFotCoTAajTKZTCQSoTk3EMpZGWylOLCQK5BpMkW6XAyg8SsIxWx0ltKzkZ7vLlGnSVWpGCSpjghp6Ow4UyX00XHFEr1cWpBbb9okSkAjCPKa8vieeW7ePuoUfslhC0g9BSHcsGHD8uXLtdpSH3d0dHRsbGw15wUu6dmzZ0+ePKmy2NmzZ00mE4fDedX9I7VHIpGcPHnyvffee/Cg7JOfAIDp06evXbu27qNCEGoRBKFSqbRarVAo9PPzo9Hq0Yo8iHMiSVKtVqvVaqFQ6OPjg+MNZmpSxFGRGE0t9FULffiF6tCM63TCRnVESENHYrR8iX+eNJhvUIU9Pk+3o8kkEYpBgGn4HkqBj4tZH5p7h1Hh3EROCSWgEQR5ZRCj5YgDi1j8IOVDtrWI6nCQuhATE1PurAt//fXX1atXExISAgICXmmHmZmZ1Slms9nkcnlQUNAr7RypbcHBwTdu3Pjpp59+++2327dvkyTp4uLy9ttvz549OzIykuroEKSu6XQ6hULB4XBCQkLQ8puIIyhukywWKygoiM1mUx0OggCDizhXGsy0mYOyb7Et6PIBoZ6BL5N7huOENSD9OteoozocBAGFbDe5KACDpL/ykYvFQHU4NQ8loBEEeTV2OjNDEooBGCy/RyfRyIUGYePGjZXM+ZuVlTVkyJBr16690ugqFqu6y7FXvyRSl1gs1ieffPLJJ5/Y7Xaj0cjn86mOCEEoUFRUJJfLIYTe3t48Ho/qcBAEmEwmuVxut9s9PT3d3NyoDgdBgJnlmisJsjE57up0gUFJdTgIAiwsF7lnYzObL1M9FWlzAFrHCKGalcGRC/2MbJ5MlyPSy+vrbFkoAY0gyCswM10ypGGuZp2XJh1Dp+qGwWw2f/7555WXuXnz5p9//jl27CusDdW4cWMcxwmCqLyYWCx+jfk9kLpEp9NR9hlpgGw2m1Kp1Ov1EolEKpWiqXURytntdpVKpdPpUJtEHASB01VCfy3fXayXS+X3aWQV3/oQpLYROF0tDc4X+wm12X5Zt2mEneqIkIaOxGhqNy+1m5egSB2Wcxuv13MToQQ0giDVVeAizhEFSgtypHo51bEgdef06dNqtbrKYvHx8a+UgBaLxW+//fbx48crL/b++++jaSsRBHEoJEnm5+fn5eXx+fywsDA6HX2dRigGIdRoNEql0sXFJTQ0lMFgUB0R0tBBgGn57kpxANdsCMm8wbSbqY4IafAwTCfwUng0YpsNwSlJLHMh1QEhCNC5ShVCP5bNFJR7j20zUh1OrUPfmBEEqRaVwEfN8/BVp/BMaMnBhqXcheZedv/+/Vfd85dffnn27FmrtcLlPtzc3JYsWfKqu0UQBKk9BoNBLpfjOB4QEMDlcqkOB0FAYWGhXC7HMAy1ScRBFHEEcmkQBDRf1RPXIg3V4SAIMHEFuZ6NCZzhnXOPp1dRHQ6CABPTRS4OsOEsD22moDCP6nDqCEpAIwhSBZKGZ4uDzQxOsOI+y2aiOhykrpnN1Rq0Us1iJbVu3fqnn36aOnWqzVbOo0YcDic+Pt7Hx+dVd4sgCFIbLBaLXC43m80ymUwkElEdDoIAq9Uql8uNRmNxm0RzbiCUs9FZSnGAwUUk02SKdLkYQPP1IRSzM9gKjzA9312iTpOqUjFIUh0R0tAROF3l5qN1lUr0cmlBboNqkygBjSBIZWw4M1PWCCdswYr7OIkmyWqI/Pz8qlPM39//NXY+ceJEHx+fGTNmPHnypOT2Nm3abNq0qXXr1q+xTwRBkJpFEIRKpdJqtUKh0M/Pj0ajUR0R0tCRJKlWq9VqtUAgCAsLQ3NVIZQjMZpa6KsW+vAL1aEZ1+n1ehpTxClAjKYR+yploXyDKuxxAt1uoToipKGDANPwPVRCH65JH5p7h9Hw2iRKQCMIUiEji5cpDeWbtJ756WgIQ4PVu3fv6qwW2K9fv9fbf69evR48eHD+/PmkpKTipZO6d+/erl07NJILQRBHoNPpFAoFm80ODg5msVhUh4Mg/7ZJFosVFBTEZrOpDgdBgMFFnCsJohO2wJw7HLOB6nAQBBhwtjysK07YAtKvc406qsNBEFBoI+RezTAA/RSPXCwNtJ9ECWgEQcqndZXKRQEe2iyRQUF1LA0XSZLFmV8IYbnzVLwhu91OkmTlexaLxePGjdu+fXslZdzc3CZPnlxyPyRJAgAIgqhm2F27du3atWvJwCopDCG02+21lKGupaomCKLKqn49r1rVr6S4Nmp8vCeEEDhtVVfeOIvZbLbi94iUsnYW1RG8GpObLDe8MyH18fb25vF4VIeD1ILUu1RH8GpMJCYn6Dac6eHhIRAIqA7HsdGdcyXGw9uojuDVmNk8uSzU6vuWu0gg4LkC0IzqiBwY6ZwP2vPFVEfwaiwQU5AMI4nJ3N3FIiFo1ZbqiBxYcAuqI3gtzraApNVmV2p1hUarzC9IJBRiWMNtkygBjSBIWRAAldBP4yL1Vz12MeupDqdBK860Fv/Pa0yyXKXiBHeVe16xYsXFixfLzJJR0saNG11dXUvupzhvbrVaqxw6/RpIkrRYKnxkSaPR/PXXX5cvX1ar1WKxuEOHDtHR0WJxdb89115VkyRZG3subiFWq7U6idFXBSG0WCy1lOuvpQpxhKq2WCwoAe3UbCwXZVg7vXugJP2OtFMUeiADoZwdYioC1xE0CZ2QhoWhNolQjsAZKnGAVuAl1OX6N3mLRkNtEqEYAYEaMvIJXEgjfOhWXCSkOiKkoSNJqC7Qqwv0AleXMD8vnMunOiKKoQS0g7Bc2jB7PXv6jskRFX4kUL1//phZj/sf2D+j1YtC9uzz25at33v8Tla+je0R2vq9sTOWj2khrs+TE1ouxc5Zz56+Y1KTUnVlOj6y+fRdhaUv+JlR229t+UDw0vchqN6/YNysx/0O7Pu4Vf0+CKB+f+z3szLbHFg1oNXz6QEtN0aO+WmXqXRdMd7a/tuMD3iYLedY2+l7b5eXXcG9+lz8aWh7NM1gHcJxvPiJbxqNVhvj76xWq8ViqXLPPB4vMTFx+PDh586dK/OSUCjcvn37wIEDy2w3Go12u53D4dTGE+s6nc7FxaXcYblbtmyZP39+QUHB8y179+5dsWLFqlWrPvrooyr3bLFYaq+qrVarq6trje+5qKjIZDJxOBwmk1njO9dqta6urrUxAtpiseA4XhtVbbFY7Ha7i4tLje+5uKq5XC6DUcXAOhzH0TTBTgrSaBrfCGVIG74qPSxxF91iBNh4qoNCGjQIgIbAlXaaCw2GMm0MDAKUfUYoBQGmdfNUSgK5ZkNI2lWmzQRoXagOCmnodCSuIOhsGgxmWFnAOQebI/VLQaFRodEy6fQgLw820zkfyqlpzpB7I579NnP+X0WdF/wwt/OLTCLxePu0JY/6xa4a6PF8m/HS6snfJBj9Rqz5YVSQMyXJYP6Z2C0nEvqOrrinJLP3fTbtz8d5AZG2Ur/3edT4nZmiFtEjp4Qy85OPHdy4MOmi/M8LC1tw6yBuKsD8M7FbTyb0KVtXhCIz3UJzbx4VFVBiLjxGRCDj5e/oZPb+z6ftfJzn362+r44Bs8//Me1Edp5n05LvlMhXpdsw99DmUZ4l0lV0v0AGZmWw0wI6dH1H27iosNSkz6Tu6pWnSrFQijIqDZVMJjtz5szhw4f//PPPu3fvWq1Wb2/vPn36TJkyRSh0lPEFX3/99eLFi1/ertfrp02bplKpPv/882ruymaznT17NikpSavVSiSSbt26denS5VVTinfu3Dlx4kR2djaPxwsPD+/Zs2dtJKARBKkpBpm/vHEn3GYNSD7C1SmpDgdBQCGJye10DAB/ht2Fhp6rQKhXxBXKZSEQo/koHvKKNFSHgyDABGlygmGHwBO3udFQ6hmhnsliledrbXa7u0ggcK35MTHOyxkS0AAAAKDmwra4bs1mteNXeMsfGq4nJBs5XGb2hQupw4NCnSEDTZg02fdvXdqxbnW8CrpXUi5jd8yy40qIlUp+EJlxa/emCnrHHYsd64kDAMCcIfP7jFizdfOBmI2jXh7269wIkybn/q1LO9avKbeuiKyMdJLbc9a6P/pUsRgLkbE75rMTZSuzPiIUiTE/31CCsu+UUOalk6yew6f80aHUeMlCtluKNERQ5L7hYyEo9fA4TD++vk1y0NKYyKB61qyQV4Fh2Lvvvvvuu+9SHUj5Ll68WG72+bnly5dHRkZ27969yl0dOXJkxowZqampJTc2a9Zs8+bNHTt2rE4waWlpMTExJ0+eLLlRKBR+8cUX06dPr84eEASpSxYXN0XjziaeWPbsuijnEUAzqCBUs0JMSeCFBCajkyIagQY9I5Sz0VlKaZDBRSLRZEi02RhEmT6EYnaAKQi6nsQluF1Ks6NuEqEcQZIqbYHWUCjm86QCGZqbqAxnScHRPJpF0BK3/H6jsMILAqi/lnDT1mTouI48+cULT2t+0tGaB9V7B7fo3nbU4nVXNJWdwG0psXO+TvAbPKJJ6aR60c3EuzZe18HRnv9t5zYfFOVFM6Xcz6xvXwigeu/gVlFtxyxZd7XcuoLazGwt5h3qV9WjDbaU2HnfJPgNGhHuDHco3oRdEbt+b4J7xxEBZQ5zqFWqtZg41L3U/SeNqyxTGuqpzfDUZJS58CbVSZ/8+iRo6Jg5AU5zywppgL744osqyyxfvrzKMr/99lv//v3LZJ8BAHfv3o2Kivr777+r3MODBw/at29fJvsMANBqtR9//PGMGTOq3IMTSUlJ2blz588//3zo0CGNBo2EQpwPQWcqw9qndBzKLCoIuxAvyn6Iss8ItUgAVAT+zMrAAQhj2cU4yj4jFCMxmkoS+DSoAwAgNO2yVJOJss8ItSAA+ST9qZ0FARZKt8hQ9hmhGoQwv8DwJDPXarOHeHu6iwQo+/wyZ0knYa5vjR7h8f03P//RZe2U5txyPkiovZxwhwif0L27OHvn+UuJj8Y0jnD0aVYwwTvrDjXSkQBqjs2csCW7/FLW2z8tWHa38fKDU4i5B3ebSrxCj5jyzaoRwS1KjPi1GwpNEJNJ69vwZ4AJ3ll3oLiujs/8cOtLdUWmp2cT9OBgQdb5w9fvKU1c76Y9urXwL9tUrLc3LVx2t/Hy/VOI+YdKVWZ9Y7+9f/uyFJ/l3/QhNlzZXWq1NpguVxO4ZzAv7/zFZ/fyrRyZf7OoKJ5AFKh6xLG8tKQsLDz46/5jgqizg3xrfn5ZBKkhBoPhzJkzVRZLSEjQaDQikaiiAjdv3pw3b15Fr1osllGjRt27d8/f37+SMgMHDszLy6uoQGxsbKtWrSZMmFBltA7u2rVrc+bMuXDhwvMtdDp9zJgx33zzjUwmozAwBKkuDNN5hioadWAbNMGX97EKtVQHhCCggKApCJyJwSCmjY2heyEIW8NthwAAIABJREFU9QyuErl7KG63BmTe5KLFyREHYIC4nKDjAPjjVi6G7oUg1Cs0mRX5Ogihr7vElVPFE/kNmbMkoAHAeK3HTeoy+7vNO7t8/2HESx8pVCcl3INNJrUTc7kdW7qcT0p4MD6iecl8WW5ubsllqQAAdru9oiWk66he6KJGLUQAAKi8X9HUIsabsRPXprT/7MCsMLC2zGvc0H7DQwEAAJBmQ4EmP/fu2V/m7dN4Dfh8mI+zjG2vthd19aC8urKkZygJUr+oV2+5xg4BAABjundYtGHd8i7iF5OE3/xx4g+p7ZfuK6cy6xfjk8MTd8nbT1gyy+/ld2pLV+gIaFw08zO5niiuK8amEwvnTVjRtJzF4owPj3yaSEbP79Oh5leSq5DdXt4aiAAAAEiShGhsGvKSzMxMm63qSd0hhFeuXOnbt29FBb7++uvK91NYWPjFF19s3bq1ogJbt2599uxZ5WEsXbp07NixdLrznIJfsnfv3jFjxlgspe5u2e32uLi4M2fOnDx5MiwsjKrYEKQ6TG6y3MadCCbb88EFN2XZJx4QpO6ZSExux22A5k63C9A0pogDsDBd5LIQM8vFQ50qKFBQHQ6CAAvEFCTDSGIynBBhdvR0CEI5q82u1OoKjWaZ0E3Ed60owYgUc6arX8yt/QcTOnyyblN859XjG5eOHCovJjyiRUxtL8IA1qxjS27C5cR7E5u3KpEy27x58z///PP8n3w+X6fTVdQ+JLXyDl5d4dXPPvk5s9P/9o4LoIP0CosRqWuH9l182w4ATdh+9pHv+nnVu/xzFYjclCwrtDMDR8ae/KhrAFAmH/t55ordK2MW+Z/YPNGbBgAAhVc/m7Mls9PnVVRmPWB68tkPxzObjdrbz50OXlpDidSkKO3QzgjsNfWfYa1pUsHTk7+sXPfPV19aA9fPmCgtfUTAvG2/n88IHLCvo2tddqU6na6il8xmM4tVh7lwxElU/2R/7ty5ihLQ+fn5CQkJVe5h3759mzZtqih9vHv37ir3kJubm5iYGBUVVWVJx3Tz5s2xY8eWyT4/l5mZ+e677966dYvD4dRxYAhSHXa2iyK0nd49UJJ+R5p6EyOdYdY2pF4jAKay07QELqETEpoVPbOLUI7A6SpxoFbgJdTl+uXep5EVDg1BkLpBAqAm6WqCLqQRPnQrjvpJhGokCdUFenWBns/lhvp60vH6PsVrTXCmBDQAmLDLhA8uzN64aW/nb0eUfIHMuZD4FAQM9dBnZRoAEAYGMROuJNye1Krdi6HSERERJa+Wr1+/zmKxKsxZGF+aiKDuwYLjKxds0HTfuvP9QByASq6PaJ5Dlm0IyFal3DqxdecPA8bSjuyY1q5BLbZJkwxaurklJziytS8XAAD8u4764m9M0XTe+fW7noyf2xiHBce/XLRBE7n1j6oq09lB4/HtcRv0zbau6BJIA+DlATQYf9CEj1uyPFu3CM6XhooKVW91Gti+MKPphnvrT+aMH+VTsuMsunNi7QPGe/O6htftLY1KUsw4jtNoDe0GC1I1Pz8/DMOqMzperVZX9NKTJ08IoureQavVyuVyX1/fcl99+PBhlXsAADx48MB5E9ALFy40m82VFHjy5ElsbOz8+fPrLCQEqQ5Io2l8I5QhbXj52aEXdjPMDvBlD2nYIAAaAlcROBcjQ5hWJkqpIJTDMB3fXSEN4Zj0IWlXmbb6PGUh4ix0JK4g6GwaDGZYWeVc3yJIXTMYTblqDZPBCPLyYDMdfe5fx+FcCWgAMEn3D8cmzt760/52H7zYSmZduJBqtxG7lszY9aLotcSbxnYduf/9e9iwYcOGDXv+cq9evXg8XsUJ6Pwaj/0VQd3ZVTF/mAf/uGJ0leOZMZdGXfo0AgCMGD2q0fjmS35ctm/I0bEeDShLhwmadOnepNQmmnev3h0Z58/dfVQIGsGz38b8aR684X9VV6Zzg7rkvTEnrIPnjh4tqaBtYy5Nmjdz53so3Xx88lP5Rg0AmHf7Vh1/uncuJbsQ+Li92Jlh/99XskTttrSv0+HPAAAej1fRSywWC0d3F5GXuLq6CgQCrfaNpnCtaEjvK5Ws5k6q/7ccTW5u7unTp6ss9vvvv6MENOJQDDJ/eeNOuM0acOMoV4ueJUeoV0hicjsdAOBLt7uiOTcQB1DEFchloZCGe8sf8ooovxxGEGCCNDlBtwPME7e5oX4ScQBmqy1XrbHZCXeRQODaoEZ91gDnS8ZhsrenjG6c+9emQxn/PQpEpCYkZjBafRx38NB/di2J4hclJyQXOu9csaTqwcNcmzJ+SnvcIxDzCMS8oxbcsBOpP3fwCaR3+vqKHVjTL+7YfTAxp2RHjPt3j2yKWx49yqjHY3yrCeO5CegAEgQBSdXDh7k2ZfzUjrhXMOYVjPn2XHDDTqRt6eAXTO+86kr9eaoMqtKzcu26+G/m4gMmYQMmYe8tWfCYIHKPdRg4iT5l7xUCQIyWIwlW870ClQ/5Rk3xr2FcFwFeXFcv9kXmXdt2wxzQtWM3tPgg4gzatm1bnWIBAQEVvVTJ0oIlMRgMb2/vN9xJJWE4uNu3b5Nk1RcA9+7ds1qtdRAPUiOMTw+tGNcz3FfKcXGThHaOXhx/zzG/QUHztauJ766NEy7+2fObv0afzkyv6AwOjfv37PSLvXaDBBauW0brvtkR3cUZ94KS9qHsswOzXFo3ZcTmexV/L6uyQF0zpp9bMW9yeOdITtNOkh7jolcfu2cs99ixXtq8YMSvj4sjt0Isy07PsjNEOBnCsKHss1Nwmn7yOWjYv2mV35JjN/67LCRyTrYbPhMbWs4Pfebhv2Xhmd7N3PTKkLSr1GefjYdGuvMxLq/Uj3BonNax67xO2bJPrZnQq4WXRMBy8/RvN3jGlmv5DtmXGDPOrZg/JbxrFOetLpK3P4hec7xMP1luATvAcglGmp3pSiND6VZHyD47XydAGfOlb94fsf6m45ysq0Bqr/366budmghlPp4teo/+7lR6eY96EiQpz9em5ipc2KxQH09Hyj47TYU72whoAACgefSeMvLC3G03THg4AAAQzy5czOW2GdlR+GKUJrdlj06i8+cTrxu6dK9oeT8HRxO1HbZ4dtcXeWRYkBT/51lT8/HjO/mK23rTAEj7e84n+xr/r/W5yS/WHISFegMEHA7bOd/1a7Lf3TJ40XHhuLVxw32fVwWRkfrMRvMM9ONhNLLN+4s/6VK6MneeNb81flwnX3Ebb+e7EVMRTBTeZfGIiBLvtCjp1Pmz1sDxfcN93UI9GIwUzbWYBd979frg156C56UIheKZHfP0kvFetBuYnnQtyS6e1sEfPVKCOIUxY8acOHGiymL9+/ev6KXAwMBGjRo9fvy48j1ERUVVMrtxv3797t69W/ke2Gx2z549Ky/jsAwGQ3WKQQgNBoNYLK7teJA3Z3u8Obr7rON6z05DJw71s6Wc3ffXd+PPXMw6d2Jec4each+aju3fPzjJ4BHgP6oTz5yTsuvY3wny3ldGh3iV/dIDs2+en3Y1P08SqAxtzw5sKsx+5HP7NG5HN0UcGsw/Fbv5eEK/cRWlGaosUMdsaXujR35zvFDaqe+goZ72lCtn/tqy7Eyy8tyv45uXvnkPNQmxv51LeHuoHQINiasJnE8jQxlWeoP6vu7MnKaffAFmX9gz7XRunkf487WVMY5Hr86tgksPU4JQf/laisqrpRgDoalX6IRD9JNEblq6mebeqk9UcIlvXIzmgQx0zBSD+cdmR0Vvy5S0jf5gTihLlXwofuPHvS/mHL+wvC236l+vO7a0vdGjvzteKOnUp7ifPP3X1s/O3FCe2z6uuJ8st8Dp5Ly4rZNas8hQhoUBHCLJ64SdAGVg3j+x6w8lDPzIQU7WVYDqY3P7D96a6dGh96jJvubbh3b9b1jC/W1Xfhn8/OF5CKHWUKTU6LhsVoi3J5PhWHlUJ6pwx6q46sJ9+scMuzD/t2cAAGB7lHBB6dZxShteydMRM6JHN88TRxKuFkS+LXDK8xQmaT9qefsSG4j07xJ2ntO1iZk/tz0dAABgi86RvD2H/vzz6ugFHYrPM4T66C+HHkHppK5hzvnRviZ6QKAw6/afP2wc1vOrAcVTT9hy9qzbeRP6zxnYnAEwSfuRZSszcdc5bZuYeXPa16uawiQRkcsjSmwgld/dSjhnCI0ZPag5h5shDeOysrxy7u/ceXB463EDio8Ne/6e+PM3oWxOt8AXuWaoP309w8Zv3yukXlUQUo8NHz58+fLlqamplZTp06dPq1atKikwa9asadOmVf6HFi9eXPkeYmNji4qKKikzffp0Nze3Sgo4Mi8vr+oU43A4IpGotoNBagDUHVyx/ITWf8LehC0D3GkAAHLxqTk9+/24aumuMYfGezjOd6iCx5djLhc07j7oXD9PNwwA2Ord+PihN65siAz62rfUnWQi/0HMwVQlwGiccIubNPjyflahhqqwkWogTPnZ928m7vjh23gV6f46BagADQfXbzxR4Dnhx7gtPUQ0AAA5+dSXk/vt2Lb08IBDQ8QYAACQJm3u/btXd/y0MT4PyiDtmY3hgoEgho2NOURKBakW5+knnyOUSTG/3FYCrGTnSBM1WzmzWcliBlfx9Qs/Hr/F+fSD0E7Kai1iUTeIjNR00qXnwu1/vIsWNC4PkRr39e+pooFxl/4Y640DAMDiMfM7vbMmds2BmTtHiRymSULDwdhNJwo8J8T+siWquJ/88NRXU/r98cvSf/ofGizGXipQaJ/c++spk/7c9vOx/v8METrKO3HCToAKhEmdfv/6mR1fL4tXOMzJugqw4NSKmG3pjWcdOPdFRzcMADjz3SmRQ3d/tWHGu1+3pgMAiswWuVoLIfR1l7hy2FXusQ45X4U7Q2oJDxn3495xZbb5R3+7O7r4/z0mb90/+aXfojf64Kf9H9R+dBTChL0/n9Xm5MrNffs8HtGnhSfMu5tw5MCdAp9B3y/p2sBO1byopQsjTy7aM7RX6vsD2wfi+XfOHTv80Nrsoy2LW6H5IwAAoMhFnCoNlBbkSE2yZWObnfrxwtBZive7NgrE9XduJB9OtzcbMmNxoxIdgunZ6Sc2dkRoOzT+GXESTCZz165dkZGRJlP5C+Z4eXlt3bq18p0MHTr03Llzu3fvrqjAokWLIiMjK9mDp6fn1q1bR44cWVGBNm3afPHFF5WH4cjatm3L5/P1en3lxXr27FnhKguIQ7HfSUjS4W/NmtvX/d88BU3SY+6UTj/PSTxz3TJ+gKN80Ybmg0lPs9lBa3p4uhW3LIzzbq8eP/roZAyy1JxyhHbt/qRzfu/0t585asj2vH6YVX+ec6qfoDp+8Fvzj/877LKcT6vKAtQgniTcNODhY+ZGiv47dgQ9JkV32rU6MemeZUgkGwCYf2hw5BfPIydIXEYnZA7wIDnyapyln3yOUMb+dDDBve0IcfLuCpacsDC5clmoUXf2uw3JoYNmL/Qw1m2IlYPajAwt5hcagK5DKlB4NfGWlTdwVLT3f0vjuLQe1Mtn7Y+P76cTQOQwSR7iacINA9549NxuJfrJD6M7xa9JTLpvGdyNXaKAHdDkBN0Ipf0+HNp597eXLt+1DOnmKAeX03UCVICquMEBU47/2+c4zMm6clBzcMtf2W7918zv8N/XS+m7S2J/bPlMxrHZ7JhSozMYTTKhm4jv6miXNs5Y4Q7TNyGvg9n0o+0XPGNXbDuyb/tFnY3tEdpqypdTl45r5+kcza8G4WGjf0zy+u3LzfuP7ty228r2Du8wb93Hi6LDnXP8e02jueSJA9vmp/CMWgBoYb0/SpKc/vLA5aMnT+y2MbwDGs+bPWBRlG/JurI8fXjBiIWE+DnpFDZIw9S2bduzZ88OHz48IyOjzEtt2rTZs2dPJXM3F8Mw7Mcff/T29l6/fj1BlHpIlclk/u9//1u4cGGVYYwYMYJOp0+ZMuXlRRHfe++93377rZIZPBwfi8WaNm3aqlWrKi82e/bsuokHeVO2IiAMbRbZOrjE8q4Yh8vBgN1idaA8GaE4m2Zj+vtFlbjIw0V+MV38Spays1jnkq8tz26y4MtI9venjtoL6jpO5NVhgt7r/gnXkQBqjswctyn71QtQw2YGbv7N2jYpdeyw2RwM2K224mMHE0R+vzM0zYbp889+OytOidsEKPvsjJyln/yX/fbBP5elei1f2ZP4qZwENIHTVeJArcBLqH104+sfzvC6nO3v5WADdoj01AyC0ShYmHF+f9I9uZHr26JHj7b+Luiy5D/0FlM2bBoR1q7EKdFuMBghzVMqcqREgN0EBP7N2oVX2E/+V4CP0Z/Z6AIaEcaw0TiMkh2pQ3CyToAamOi9deeb6kgA8/fPHLLGUU7WlbNeP5tkZLbtGVUi64EH9Jg8NUpdoH+areZzuaG+nnQcr2QfVHHGCkcJaIeAuY8+lTm6ikJ4wPwjT+eX/U1u08ELdg9eUFuROR7MfdSp9FHlvcIKiJq8JerlwfDlwQPmH35ctjLrI4h7jvz19ECWi7/qPsv2fFgoI6B1ny2t+1Tyi6zmY7L/HlMHESJIzWrfvv2jR49+//33Q4cOpaWl0Wi0iIiI6OjoIUOG0GjV+kZOp9O///77iRMnbt++PSkpSa1Wu7u7d+vWbdKkSYGBgdUMY+jQoT169Ni2bduJEyeys7NdXFzeeuutoUOH9uvX7w3enKNYsmTJ0aNHb9++XVGBjz76qEePHnUZEvL6uH3XJ/ctvYnMPrA/ycZs0b6F44zoIQ0FqRYgE7FTriWOSXx2UW1zE0s6hkcse7tRMxYAAECMpvGLyDRfm70zt8PA0UssD9eiGQ6cBV3cqKUYAACV98q/7V1lAUpwOq8/2Ln0JjL75JkkO6NFi8ZsACAAWiDGwmRNadBD+2AbDSipCRR5Y07STxYzPjsx8S9l+7FzZ/mAtWVewzAd310hDWFbCoPTrxN3diy+SEZ/8nYHh5vB1pKemkuQBYs6tpXn2yAAAGBMj26Lftm+vLvUcfoAKrmE9xsXDgAAgDTrtRp11t3jG+btyvcavGaYnyMloNmd1++voJ9s3ogNAGB3XvFXNwVBt5EwiG5hYxAAMqtkAQfhVJ0AZejSRm2lAAAov8V3pGZYCVKZllqIyQIFKb8vHBN74GKa0S2gWdueoyaM796ETw/0dOewHOz2XElOWOEoAY0g9ZYNZ2TKGtEgGSS/Tycdf01UBKkZbDZ78uTJkydX73ZUBZo2bbpmzZo32YNIJJo/f/78+f/e6rJarVarQyzs8+ZcXV2PHz8+ZMiQS5cuvfzqxx9/vHZt2Wte5LURBGE2m8us/cjj1t7FjiX97yXDFpwoCvhw6QeBjvNtFlqsBgAK7p/vdZkICQ+OaUyTp6f9de7UyYyic1NaBbt7y8M70ww348bHKYK6HWrjYKvDUKRMs4GwZlLydrvdYrGUbZM1smvnZk0/vWHYqqQi78FLh3ibIE1uxyEEvgzClUZClDMDANRamyQIopw22fD6SQAAMKV89uPpzIihe3tJ6SCv5CtFHDe5exiJ0bzlD3lF+QCqN+y8lBHQa187xxtXTGSnZNigjQj84LeTn/QMAPLkv9fOXPTbyjHT/JPiJ/rWZJXXXpu0Wq1l2yS7FjJZxJO1vdsuTrYBQBN2XnZkY7SXY7XIMqzpZ2KHfXu5yHvQ0mhvC6TJCboNYB64XUD7P3v3HdhE2QYA/L3LaHabNEn3blqWDGWjVFmiDNlD9hYRUIYoAoICIkOg8gkqKntvlCVbNirIECwUSldGkyZtdnLj+6OCpZS2lKSXtM/vL7i8d/f0+vbN3XPvIJ8s4MM/ihcbgRLVhqIoj1RLkiTdbnfJOikUPv+R/RptKTTTdMHPUzr86E7s2HlEO/b9c78cWDH++O/TT/08le9zL+eYUaLakCRJUZXs9w/35wBUTzauKFOZJLEbwwwZmG+sHQwAeE737t07f/680WgMDg5+5ZVXIiMjmYokJCTkt99+27Bhw5o1ay5dumS1WhUKRZs2bSZMmNCyZUumoqqWKIoqyvcV3+ilxIor+/jyaZPmbr/liu+1atfijj6z9g9CiKYogqYLzZzRQ/v8r7aAhRCimw7ataPzhT8m57+b2j45JP3M5WWzV5mjVw+vHYcjBANiESpRbTyFpulS6qQPVRYGuDSXln+5eO7Be66o9v/7Zko9ISfTjStZpIxF1uwLU1KJauOpZB9FUUU56OIba2A7iWjb4Q2bvjbXXv1J8+LNIMEOyA6NLxQp5MYsheEBRlMIIeuNE0tvs7tOaFnbB5N8uLLbvM2N+LVSmsUIEEIo/pWhy/cjdb1xR1PX/T3kk3oeHAxfpXXSGwloPKLH/PWxmer03/etXju3c3fWgT0fNhV5/jzPz6W5vHzR4rkH77si233zzeT6Qu59giVnEQqcLHpWLV5g1TeTOvrQgJfHeLsRqNI6CQlogiBoqlArHLX555lNAwrNVukH7/41t1eXH5bP2DF438AQH62FVevJOlnpagkJaACqoQJhcI4sLsSUHWzWMB0LAMADrl+//v777x8/fvzRFgzDOnfuvHTp0tDQUEZCwnF88ODBgwcPRghRFFXBGU7As+JwOAKBQCqVPr7Z0+lV2nj520kjP9l83RnZ9oO1Sz/pW8/HHvwwDoePIW5c/Zm1BEWpB4otajDszQa/b7504Y/I8D+pG4ffuUh0fztlACz+8FCJauOpxXPYbDafzy9ZJ001dXoJuvDy5sUjlxy87gppM2zurHfelPPZCFEqjosNNfEJJaqNp7442Gw2j8er8e0kbbq6b8xRV/eJfQbI/w2MRgjh4qzYpjEOfdL9C2zi4Ugs2rz74O9Z0pe+b+J73Z8RQpi0zquv13lsEx7RuWuLD46cvHrDguoFeu5UVVonvTEgFRMnv9YtGSE0ZPTbdTo3+ODLmVsGHhzpY92g6cLLW5aM/OrQdVdI26GfffpOJxmf7aYpFcfJKeom9XiBpe++Xk/kixWzahqBEtWGxWJ55OubzWYHBAQ80U7WdBhfwMcwbrNh/ZMJ0s1KjAjlctghk0a2WDf99NGLtoFda3qGHiFUWp1kVXZSbEhAA1Dd6IIiDeKQ6Lw0kaOQ6VgAAB5w5MiRHj16WK3W4htpmt6/f//Zs2d37NjxwgsvMBVbEcg+exWO4yXv80iPJlbIrB3vvDl4TYaiw8d7lk/tmijw5ME9hCUWhuPYnSCxHEMIYaZwlSapWYDxl3icvqH7y+mubVTrc0nr1vU/bV1ffL8/m3/4J0v+4tkPWzareZW00o8HZcMwrJQ6WTORmh0zxw3emat4ZfjmGSMahgm5OApju3kYjDwrXZXWyRrXTtK6Bzm5ZMHWr2Zs/ar49j39X9rDCmt7dtlbzR5eIUp/5YerztiOTVr78OymJWDioCA2ogmSpBHyXNLPe3USw7CSB/dcAtp178S2c9qYlD6v/DchCSumQ4d6rNO3b6aTyJcS0KRmx6zxg3flKl4evuWTYY0iRRhCYbhLiNNPFtgzc0jXaF+dUbmqGoGqrZM1fbyYI1ARyMJ4clm90GC54N9V4vHQqAgOumQy2Wjkk+/oqlqJavM8b0QgAQ1A9UHhrGx5gpPDj1ffDCAcTIcDAPCA9PT03r17l8g+P5Kfn9+vX79Tp05JJJIqDgxUF8St5YOHr82tO3nPL/PbKn3omfVxXEVjJXYgz3hH3ERQp5WbJwxNuyi+djSLwAIDRRIMw2JrT28XTf63g+P85Rsn3CFDWkRFicIi4PkBeB55a+0nw3fpao9I/XZiSzGGhbCJILymP8xXU37RTmKy5ObTe9UiESJZHLNASrIcN/fsPOOIGdIhKUoSX2w+XTrj4p/nCdm7TaM5DMb7dMTV5d0n7JWO/GnN4JhHUZP379x14WGJcTV8wp9/3d02aeTGWotanBz/3yWiCwvNNMYX8HzpCpG31s0cvltXZ/iy7ya25GO4DCdlGFEsf/VvgbrDl/4yuamv/nEhP2kEwDNwE6Q232Q2RzRW4afUeSYeX/7wIzLrXoYLC4yI8K1RLtUCJKABqCZc7IAHiiQO6YpX32BRZPk7AACehcFgoGlaLpeXX9SjZs2aVVhY1mgGnU63dOnSr7/+uspCAtWK41Rq6gXnS7PXzfXtBypc2q1J6Of70j4yTv/WkB13/yrmLth19MZlWjC0XmgAQgFx9WbHFStPmRal3TxpCx/zerMa2PcZVAXn78vXXHPUHTdnfKsIFhnCJqGiVVv+0U5i8tqtZtZl64NjDEER0gJ1SN7FJad2nbXEj+nbqVnx7mu0+diVLLekcYcEHx3HwI5PlD74Y9OXC/u8saKzAkMIIVfm9oU/XqHjJ/V6yTeT5lWM89JrKYFr9/20+tLwz5sXzRFA6g6u3HKbDhn5Wl0fSvE4/1i+9pqj7rjZ418JZZEhLBerxNJEzj9S115z1hu7bpIvZ5/9pREAFUJRtL6gUF9QKBEIVLEtB/drtHTWd5/u7L6mdxQHIUTk7l34w2UqdGjXprAGocf5UOsEAKg0G0+cqVAFWg2h+Q/gRR0AHnTnzp0vvvhi7969+fn5CCGZTPbWW29Nnz49MTGxCs5utVp3795dbrGdO3cuW7asCuIB1Q959/wFLcWVnF0wZuTjj1SY5JX3lwz1iedYGsPzo+tizV8acXPsyum9u9ZL6CDH79+9syvLGf1i+zm1/GcMOaguaIT0966f0tNc4ZWtc6bvfOxDTNJk4JKeCb7wtwM8wi/aSYRhJkmIRpHIc1oSMv8IcFrR0/qjOO4du0vwaic09Ym4SyN5fcbs9r9OWN+rxZ3evV6JY+VdO7rn5xuuF97fNh0yQgghhLDgtz6d1vLX6UveaHmzX9fGYbT2+rFde/40Rfb54ZM2PjQ/TP7966f1NEd4Zcuc6TsfSz1jkiYDlvRIwB5cu6CnuaIrC2Y8KPmpOVNqAAAgAElEQVTH1WTAkh6+0pD6RyMAKsBss6sNRhaOx4WF8AO4CKFaI+d+sK3bghGv3t7TvUMi6/7J3bv+MEb3Wz2nvZjpYKsh+EsBwO8ZxUp1UHSY8YHUksd0LABUK+vXrx81alTxlX/z8/N/+umnTZs2ff/994MGDfJ2AP/884/dbi+3mMFgyM3NTUhI8HY8oPohMjMyCdry96F1f5f4BFeyey8aWpeRqIqzBEeoa7XCKDLm9tnUAZ3rHL608sY/S/+mpfLQYV0bz24VEQbvXUHVslK4mmA5c3K1JG1NP7MhvcTnuJLVYVFPaJCrD99vJ+18Sa4ikWRxIjS3xBZD2YWdd9PO2LDE+EgfHl3OThq24Xzkt/NSNx9c+/U2Fy+ibusp30/7qP8LsMrsQwH1PthzJuLLz/63a9fK4yY3PzS52eilU2aMfjnMN/rn2mlMTXKsuWoNSdvSz2x8sp1kt1/UI4HOzckkacvdc+vull6gquIth+83AqBcTrdbrTc6XO7Q4KAgUbHFBUXNP9+3N+Lz+Sv3b156kJbGNxn25dTZY3zlT6magQQ0AH6MRkgnjc4XymPy/hE6zEyHA0C1snfv3sGDB5f6kdPpHDx4cGBgYNeuXb0ag8ViqWDJESNGpKen22y2sLCwdu3ajR8/HvLRoCIC3lxtcK9mOorSuYSB6uQWtqBQZfofsgc3MEQjUdi4nm+N61mBnfGgqRPener1GIEnYSGDjuaW9WKv3ALe5qaRlmSbKVyOE/J2s/L/mVXBHTFFr6M3enk1NuA9vtxOEuwAjSK+UKSQG7MUhgcYXWwWclwx9YulTzaDAS/0yd7epwpjrBxebPuJ37efyHQYPgwT1ev7+ba+nzMdR0kkwnQk20ix5Cwi9rUZ+bdmlFX61U8Ntz6tqtAqz5cbAR+EhY05ahvDdBT/ISlKZywwmq1SsTA6VIE/sYYeS95s3PK945YzEp0H+NoFLwMkoAHwVyTOzlKoCJydoL7BJV1Mh1PDUPl/7Vyz5eTVB2ZRTMM2/Yb1bCB97JvMffGrgfNP2h+f5QwP77Hwf0MUR2aNXPmX+9FWVkTPL1cMSfLRafhqLKvVOnbs2LLLjB07tl27dgKBF4c6RkREVLDkqVOniv6Rn59/8+bNlStXLliw4IMPPvBaaAB4EcVi6+Ma6mMbBKnvJJ3ZynKVPw4AAK+iaKSnWHqSJcEpFcfFhm6YgGk0hucHhWuD48Q2o+r+RQ7hLH8fALyJRiifYusotgCRiWwnF6PL3wcALzNZrBqDiR/ATYwI5XIg/8kw+AUA4JdcHN4DRRKXcMZr/8ZhycGqRj7YNX/eDjJl2IR+wXmnN/w0bwFryfzuUcVyyGxVl8kfNSce3XfR5r92/Hgl8YUwnMrV6LCkLpN61P131lKMHxEOI3x8zs6dO9VqddllcnNzd+7c6dWJOBISEuLi4u7fv/+sO7pcrkmTJlEUNXnyZG8EBoDXYKZwlSapWYDVFH9hN8+Sz3Q8ACAzhasJNgtRcRyCj1Hl7wCAl5lFcrUykUUSsTnXBPYCpsMBAFkoXE2yEYZFsVwiaCeBD7DaHWqDkUYoQiETC/hMhwMQggQ0AP7Iwg/MkifKLHkhpixEw7vlKue69vPP9yN7LnunYxQLoXpy090p+3+52emd+v8thIXJVE1bqB7+j7b8+c1a+6tjh74oxpw6rVGiav5Kyxegz7MvO3nyZAWLeXsm6EmTJo0fP75y+3700UedOnWqVauWZ0MCwEvsErm69stunig07WJQbhrT4QCAHDSmJthOCoVyiCAcUiqAeU4OXxOisvEkSkOGzJgNffEB41wI05IcC4UrWYQMI56Y3gCAquYmSG2+yWyzy4Mk8kAxBpXSZ0C3OwD8TL5ImSlXheU/CDFmQvaZEWTWzVuW0BdfCi/KILOiX2qkLLz1t/qpD6aOm1t+uFJ76ICGQgxReVodrQxTUnajTm92wy/QV+l0uooU02q13o7knXfeadeuXeX2JQhi6dKlno0HAG8guTx1rVb3m3YVGbKTzmyB7DNgHIkwNcG65+bwMCopALLPgHkkztYqEtJjm3Bd9qR754Mh+wyYRiGko9h33QEYolVsRzAO2WfAMIqi8kyFd7JyEUKqqDBFkASyzz4FekAD4DdoDMuVxZl5gXG623xnRZcmAx5H6XV6Olghe/gCD5cpZLRel0ehmNLe6ZEP9v10KrjnkmYSDCFE5anziLzjXwz/6X4Bidji2FZvjx/7ZqLg4TdjTk7O119/XXz/5ORkhBBFUWaz59eZpCjKS0cmSRIhZLfbXS7PT1BOUZTFYvHS/UTRBREKheUXRUgoFFbw6j3PpV63bt2oUaN++eWXSux78ODB5/n9evVSkyTpvVpNUZ7PFhEEgRCy2Ww4Xs77e7vd7o0AqiUaw/Oj6+oSGwuMatXZ7Rw7LKgLmGeicA3B5mNUIscN05gCX2AKDNUoEnhOa0LmHwFOK9PhAIAKKFxDcrgYHc928qCdBD7AbLOrDUYWjseGKQW8AKbDAaWABDQA/oFksTPlKhJnJWhvcghYcpBJpMtJYHw+/2FKDuPzeZjL6Sr1zosuOLt5v6X1R22VGEII0Wa90c0XJXSZOOeVCKT96+dVX6+ev1qROr6pqOhwhYWFR48efbR7w4YNExISEEI0TTud3lpepihZ7A0EQRTl7DzOG3ntIhRFOZ3Ohg0bbtu2rdzCDRs2fKbfS+UuNYfDWbNmzeHDhzdu3Hj58mWDwaBQKEJDQ69du1buvmq12uFwPE8G2XuX2k9rtdvtLreM936uasYii1DXbolRVPSfh4TGcmZdB6AKWClcTbBohEWwCTH0egY+wM6TqENUBM4J06YFmvOYDgcAZKcxNclxIyyERQThsBYRYJ7T7VbrjQ6XWykNlElETIcDngoS0AD4AQeHnxlSi+8wx+hu4zDtBtNY3AAWXWB30IhXlFS22x00R8wtrSyV/evePxXtltR+uOKgtMOsLR0efhrVtP97Pa6O23rqr1FNWxWtjJCQkLB3795H++/du5fP5yOEWCyWRCLx+M/idrtdLlcFe/s+E4fDYbfbhUIhl1vqlXkuhYWFIpGo3F6olWA0Gosu9eDBg+fNm2e1ltXJSCgUDhkyRCqVVuTIbrfb7XYLBIJKx9avX79+/fo9+u+6deuGDx9e7l58Pl8mk1X6pAUFBWKx2OOXmqZpk8nkpVrtcrkIgnieS/00drvd4XCIxWI2u5zbp4CAAG/Uz+rEJQjUJjW1yCKU6X/IHtzAEHy1AYa5aaQl2WYKl+OEnE3BkF3AOIIdoFHEF4oUcmOWIv8BBgNrANNIhOlItpFiBbNIBe6CGx3AOJKidMYCo9kqFQujQxU4TLjh2yABDYCvM/ODshWJwYUapSmb6VgAQgjhwQo5dt9gpFAQCyGEKJPBhAXXDS7lJoxMP3EiK/71qZFPu0HD5RHhAW6j2UGjoh7VXC43IiLi0ec8Hu9RGovF8vyyhSRJYhjmjSMXdbk1mUzp6elWqzUyMrJOnTqemsmhKGYvJfiKDh4REfHpp59++OGHZZScPXt2eHh4BQ/7nJf67t279+/f53K5iYmJRTWkYcOGFdmxfv36z/P79dKlpmn60cE9e2SEEI7jOI57r1ZX5ODeOHu1QbHY+riG+tgGQeo7SWe2slx2piMCNR1FIwOJ55EsCYtWcdxsGEsOmEZjWH5QhE4eL7LmqzIucdwOpiMCNR2NUD7F1lFsASIT2U6Ymwj4ApPFqjGYeFxOQkRIAIfDdDigfJCABsCn5UnC8gIjIvXpEpuR6VjAv1jRdWsL9179K69/XCiGEKX565pGXKduxJMJJ+L2ydNaVfeWIY/SrrbzKyavJwZ8MfHlQAwhhMic9Acuad0ocbV7WXvjxo2ZM2ceP3780RQcERERU6ZMee+998rtPeojpkyZkpWVVWJK7kcmTJgwefLkKghj48aNc+fOvX37dtF/MQxr2bLl3LlzU1JSateufevWrbJ3f/vtt70fIwAVhBWExGmSW3DthfEX9/DMBqbjAQCZKVxNsFmIjuUQAhxSKoB5FoFUHaLCaTom55rAZmI6HACQlcbVJIdGKIrlEmHQEx8wz2p3qA1GiqYjFDKxgM90OKCiYNgEAD6KxvBseUK+ODRO+zdkn30Lt/6bb0ZnbP9606X0rLvnN6zYlZXQ+c16XISI9KNrftx6UfvvjRn54MpVU1id2tL/ssv8F5rXc//2/aL1J6+l3bl5fs/yxXvy6vboVNs/MrIVtn379pSUlCNHjhSfADonJ+eDDz7o2LGjxeIfS2hiGJaamrp9+/Y6deoU316nTp0dO3YsX77c26sqkyQ5dOjQgQMHPso+I4Romj579uxrr722ZMmSxYsXl32EunXrjhw50qtBAlBBdofjXtOumlotQ+5ejru8H7LPgHFOgsxws3PcLCWbSOC6IfsMGOd0uh5E1s8Krysz5cZnXIbsM2CcmyCySU4mwZXiZCLbCdlnwDi3252tMzzQ5kmEAlVkGGSf/Us1S3oAUE0QbO4DuQpDdIL6Bpsqf8ErULXY8b0+/tD97doVH+1yCCIadp42pnsMCyFE5Fz+ed99skWvZiEIITrv+jUNP6l2ZLGu0Zio8ejPPwxau23DF/sKWbLIpMajPh/YNrxavQs8f/78oEGDnrYI27FjxwYPHrxr164qjqrSevXq1atXrzt37qSlpSGEkpKSVCpV1Zz6k08+Wbt27dM+nTp16qZNmxYuXPi0eUKioqL27NnjjTm4AfNM/rQOFUnROovdaHMGi4UKtxFPSEQJiUwHBTzt7M9MR/AMSJytk0YZJSFSFh3NceOIRpBUqX5Y/jQcm6IovV6v1+ul0UmRSiWL1YjpiJ4RzE9dEZwApiN4Bo/qpEQsVSkV/jJ+8TF+1Qgwo0DHdATPgKZRvtWuLbRJhPykiFA2C0c05WdriNgKmI6gUkQVWvGoIvywHQGgunNwhQ8UKpGjIDw/A4MlB30TS9F44IzGA0ts5bX+eEfrR//DQrst3NntiV05oc0GTGs2wMsBMmjixIlPyz4X2b1796FDhzp27FhlIT0/lUpVZXnnInfu3FmyZEnZZSZNmpSenh4TEzNt2rSMjIxH2zEM69ev39KlS0NCQrwbJQBlommUb3PoLHYBh50ol3AfZDIdEajxMMwkUmiCY3lOa0LOXwFxtZkOCABkMpk0Gk1AQEB8fDyPx2M6HACQ2WzOzc3lcrnx8fE8DixrAZhndrjUBVYWjsXKJQKhiOlwQCV5LgFNmHPS0nLMRMlsGR6sapwoq3bTmwLgJQUCWU5wvKIgR1GoZjoWAJ7ZtWvXLl++XG6xH3/8sWoS0ARBbNy4cePGjdevX7dYLJGRkR06dJgwYUJCQkIVnP15rFu3rvgEJqXSaDS//PJLp06dXn311Zs3b964ccNqtYaHh7dt27b4UpYAMMLqItSFNpqmo4JEogDohQSYZ+VJ1PI4GmNF6O6IYXIz4APsdrtarSYIIiwsLDAwkOlwAEAOh0OtVrtcrpCQkKCgIIQQImEwLmCSkyDVJovDTSolApkQXtH5N88koB03vhvUbeLOdEcpfTV5vbebtvXyp+EmADBGFxSpF4dG6dPFdnguAn7p4sWLFSl24cIFb0eCEMrKynrrrbeuXLnyaMvt27dv3769atWqRYsWTZgwoQpiqLQKXqILFy68+eabOI63atXqtdde83ZUAFSEi6S0ZpvF6VaK+DJBgLdnSwegXG4WVxscUyiQyQtyFaYcjIbpAgDDCILQ6XQmk0kulysUCmgnAeNIktTpdEajMTg4OCYmBser1QyBwB+RFK232A0Wu1TIiw6W4NBO+j9PJKCp7LWTJu3MkrcZP7FvkzBBiZaKFdMUer0AUB4KZ2UHJzg4/ATNzQC3nelwAKgkk6lCC+YYjV5/xaLX61977bX09PQnP3K5XBMnTsQwbPz48d4OowSSJHfs2LFv376MjAwMw1QqVc+ePTt16vTkk6fvXEkAKo6iab3Vobc4JDyuShHIhsdXwDQKww2SsDxphMRmTMr6kw1d+QDTaJrOz8/XarVCoVClUnE48KgMGEbTtNFo1Gq1AoEgMTERlg8BvsBkc2oKrTw2O0EZFMCGeWCqCU8koN1Xz112Rg37YU9qB5iLBYBKcLO4mcokFkUkaG6yqHIG3QPgyxQKRUWKKZVKb0cyderUUrPPj0yZMqVTp07x8fHejuSRW7duDR069O+//3605ezZs2vWrGnZsuXWrVsjIyOLF67glYRZnoHvMDvduQVWLosVHyyBKSOBLzALZergOBbpjlXfEjjNTIcDALJYLGq1GsOw2NhYgUDAdDgAIKvVqlaraZqOiooSiSCdA5hndxO5RgtJ0xFBIjEPXodUK55IQDsLChx4wgt14CsUgEqwBYgzFSqJ3RhmyMD8bBlXAEpKSUnxYLFK0+l069evL7uMy+VKTU1dtmzZoy3nz5/ftWtXTk5OUFBQ3bp1u3fvHh4e7qmQbt261b59+4KCUtY+PnfuXMuWLS9evBgWFvZoY0pKysGDB8s9rLevJAAV4SDI3AKrm6RCxIIgPjwqAOY5OXx1cKyDK1Qas2QWHYIlnQHTXC6XWq222WxKpVImk8GcG4Bxbrdbq9WazWa5XC6Xy6FOAsYRFKUpsBbaXXIxXyESQJWsfjwxNJKfmBxN/33+cgHc2gHwjEzC4AxlsrIgN9xwH7LPoBqIi4t74403yi327rvvejWMY8eOkSRZbrEjR44U/ePevXutW7du2bLl4sWLN2/evHLlyvfeey8+Pv7jjz8udyXAiiBJcuDAgaVmn4tkZWUNHz68+JYhQ4YIhcKyD5ucnNyuXbvnDw+ASiMpWl1ou6cvFHI5KkUgZJ8B40icpQ2OSY9sEOB2JGVflZm1kH0GzKIoSqfT3b17l8PhJCUlBQcHQ6YPMKuoTt65cwchpFKpYBZywDiaRgaLPU1jpGmkCpEqxZB9rp48kYDmNJ22akrMofd6Td9x3eCCWzwAKoJGSCuNVktjY/LSZGYN0+EA4DHLly+XSqVlFHj//fcbN27s1RhycnIqUiw7OxshdOvWrWbNmv32228lPnU6nQsWLOjRo0dFctll27dv340bN8ouc+jQod9///3Rf0NDQxctWlRGeS6X+91337HZnllMGIBnRdN0vs2RlmdyEWSiXBIi5sPiMIBhGGYSK+9EvWjnihJyroUZ7uMwrRlgmslkSktLs1qt8fHx4eHhLBZMTwQYZjab79y5Yzab4+LiIiMj4U4SMM7scN3RGU12Z6xcEiUTc1iwgki15YlfrevEV3NOuISFJxb0rq8QSuShYcXFjf7Z6YGTAFCdUDgrU5Fk5gclaG4IHYVMh1PzuI59/Eqb2WeeXImI1u989+VOC/+AJ9bnoFKpDh48+LS5iceMGVN2XtUjyu07/KiY2+3u0aOHXq9/Wpn9+/fPnz//OePZv39/JYqNHTt2wYIFpZYUCoVbtmxp3br1cwYGQOVYXUS6odBgdUYFiWJkYi4sDgOYZueJ08Pq6YIiIvLuxqpvBrhsTEcEajq73X7v3j2tVhsaGhoXF8fj8ZiOCNR0Dofj/v37OTk5ISEhCQkJfD6f6YhATeckyAeGwmyjOVjIS1AECbiwKGs154n3XRgvKCQ0Vhoa+2Jpn3KTZPACA4BiXBzeA0USl3TFqW+y6OftWQmeBWnKTMsxU8h17crvf/Cu3bwpffxLjnb+c+L0pbPmHBK9BL0BnkOzZs1+//33BQsW7N69Ozc3FyHEZrNTUlKmTp36+uuvV0EA9evXr0ixhg0bbtiw4fbt22UXW7hw4YQJEwIDAysdT0ZGRkWK3bt3r8SWadOmtW3bdv78+YcOHbLb7QghmUzWo0ePGTNmxMTEVDoeACrNTVJas93sdClFfJkgAAbtAsYRbK5GFlMokMkLchWmHIymmI4I1HQkSep0OqPRKJfLYXID4Ase1UmpVBoTE4PjkKABDCMpWm+xGyx2qZAXKRWxoE7WDJ5IsXBaTtm6e4oHDgRA9WcNEGcpkwKt+jBjJkxKWNVo0+53Gg0/+HBQxrhGe0sphPFfHl4bss/PTSaTzZ49e8mSJQUFBXa7PSQkpCr7/rRo0SIhISE9Pb3sYgMGDNi8eXO5R7NYLIcPH+7Tp0+l46ng8EYOp5TX/o0bN961a1fRQjEsFiskJAQeG4CHOM8tH5/Km7BhTL2nVNDHClA0rbc69BaHhMdVKQLZDNRDIvvSnplrfj18W2sguKGxdbp27z/7reTgUgJxnVu7KJXXb0PfBGjO/QxduPubZRMzX9ozv9OLpXasL1agERvLl4RqpVESmzEp6wqbdFV1tAjZHpxcvGLT5gt3MgrcQmViyhv954ztUE+AVbwAqE5oms7Pz9fpdAKBQKVSlfq1Dp6R49yXg1L50zdMaATteSXQNG00GrVarUAgSExM5HKZX6rBdmff4s+Xbz5xLSPfJQyvl9J7wpzpfeqJoFX0a85zy8al8t7f8E7JW0radO2nJSvWH7/0RyYRWr/tqA8/fj8l1GpzagqsPC47QRkUwOgoOjJtWYvmn11+clw0QqyE8Wd/n9PMV9sdP43cJ4MCoJrKFyk10uhw44MgSx7TsdRImOjl91et7kki4o9VE9Zy3/lqeP0SbSCG85Qvvv6GCkaTe45Sqaz6k+I4vnjx4u7du5dRpmnTpv37958zZ05FDlhuL+lHdDpd0XrixXtMJycn//rrr+XuW6tWrad9xOFwIiMjKxgDABVBG46u+Pbw6TcHP62/aPECZqc7t8DKxrG4YAmfw0gTSRvOrXpt6sHMoOSeXXqquAV/nD7xzZd/ndUtODMmWVCiqPHSiq0XTqd0gq6w/obOPr353V9z8sLqlvZI9ViBAqHsjjKWRZKxmlsCh7lq4/yX+/6OngMWHbbIW3bs1iuMSL94bOfqWcf/1J78aXADboUKgOrEYrGo1WoMw6Kjoys4FRgoF533y4rUfaffGgvteSVYrVa1Wk3TdGRkpFgsZjochBBy//Ntz1cnHi4Ma9lreK9od/qJXTsXDTl+NuvkkSkNApgODlQWrf91xarDpzsNKfl36vhrbq9es68JmnbvPr69+eLeXR/1vfzX/zbPfFkSFiQM5DP/K8fEyR169kgoMf0mqbl04II2PELhw31+/DRyjySgbfrMPOvTunJiQkW0XPCUDwGoIWgaaWyugqCION1tvtPCdDg1VoCqw1AVQsidmL07O6Df8BEtoGdKtdWtW7f58+dPnz691E9VKtXOnTtZLBZBVGjC73LXIbRYLEuXLv3pp5/u379ftOXFF1987733Bg8ezGKxevXqtWLFirKPgGGYt9dmBAAhhBBpN2TfvPLbhmULt+qo0iZrf6yAkqYyDGaaJEPEgiA+czkzSr3mp1/vSVqu+enjQUocIYSGt506bNqSrTv29J/+tqSo5xRlN2lv/n11w5p1Ww2l/mjAp5GaM2NWX9Ei7GnPTf8VYAXr5An1C7KDCzWMjSejzXtXrDpSEDZsxY/fvybDEULUiKPzR7+58ccZv3Ta1z0YK7cAM3EDz3O5XFqt1mKxKJVKmUwGc254AmnXZ9z8/fiGL2Zu1UB7/syKRs4VdYmQy+W+Uidp097PZh8xxgzbcfr7ziE4QoiafnRS2zf/t2DGloH7hoT6RpSg4ki7IevmlTMbvlpQ2i0l9WDT/IVXsZTPdx4am4hTVO7bzd7t+sG2Revf7zoj2TeewvGwN+Z+/8bj26iMNf0a/9p4xqKh8b6axkV+G7knEtDOA+8m997ueMqnvN7bTdt6Mf9u4xnpspiOwH/Uh1WwykEGBmYuWUIGBiZ06sSp+wLT4QCEOCmfHkphOgjgdR9//HHt2rWnTJlSfC4ONps9dOjQhQsXSqVShFB8fHxFJmiOj48v49O7d+926tQpLS2t+MY///xz+PDhW7Zs2b59e0pKSvv27cvuBE3TdJcuXdavX9+jR49y4wGg0mj91u71px7+d66CUu5PSxQg7VYehxUpE+HMPr7a/vntH0L8apueyocx81XdmsuXbsu6mUshCQshRBt/7d51+cPI4THW35CaFSt2nQ5p3i/40rZSFzAnNan/23Uqot0b1InDViI660owxuiSweSd03+aWbUGTG79cL0bPKjNiJ4tty757fxNZ/fWvHILMBc78BSKovR6vV6vDwoKSkpKYrFgDJ1n0Lo13WNHH/63KfDVVIpPoijKYDDk5eVJJBKVSlXBWeCqCHHt9HkTq/7EyW+EPGwV5W0mj2753aTfjv/uHNIZWkX/Qudt6V5/ylP/Tqmcvbsu2IJ7TBqUYLbYdWa7SN7h04Gqw8sPbvtrWuPGvpGBfgKVs/X92efiJx2aVNfPRir5ReSeaI/Y9QcvWNys+B0gZdPdvXxg2y9/480mLpnaykerFgBVwRkTk7liBS8tLea993BzIdPhgGIIc05aWo6ZKNl1Cg9WNU6UQe6iWujWrVvXrl0vXrx49epVm80WERHRrl07uVz+qECXLl2OHz9e9kE4HE7Hjh2f9qnBYHj99defXD+wyJEjR/r06XPgwIGffvrp1VdfvXv3bhknstls/fv3P3LkSEoKvCAB3oIFvb78l9omCtH5ByYMXpVdWoFlP9fKsrsMOb8smLBGyxeGSgTMP/2zEkZ/OLFfTHKxp1PKbHPSeLBC8m90mKT58m9jTTSiTWcnfLjzyR8N+DDir91rZ6ZHzF7QgVxRWgIaI88c2DTzXq2J3w0Wzjl+mCrAKQIxm+sj7Cgo5oWmtROKhYHxeHwMES43VZECwM8VFBRoNBoulxsfH1+VC13UBJis6/JT9UwUog27J/RYAu15BZnNZrVazWKxYmNjBQLfG4XutiKp6oWUlx5rFfkCPoYIpwtaRb+DSTsuP1DbRCHacJQyb/MAACAASURBVGDCoJUl/05dNy/dcHObNA6xmEwsLCZYIuCyla0aBy/b9sdfBqpxKPP3lk+iDXtnzz2kGHFiXD3fTeKWyk8i90QCmpXUeeLkzk9snjtz56jW/Vb/8NuogU3CfLFyAeB1lpdfzlq4ULZ9e8jy5YiCb1Uf4rjx3aBuE3emO0oZuOun4zbAU+A43qJFixYtWpT66ciRI7/88kuNRlPGEUaPHh0S8tTRn5999tnTss9FDh8+vGnTpj59+hw/fnzcuHH79+8vo7DL5RozZsyNGzd8q8cKqE7YwcmNghFCtPaGpLQ3bVYqkB2dEEujZlG3VuNI99TpEKoWP/rNztEIIYRoh9Wcb8y7fmHPlMOF4a+90+fRmF1WYHKdQIQQrU+X+EbUoIJsdw4M36ZpNvTjiVFo6ROf2gNE97TH3tmgbjJq3hx+xlIfWcKZ1yp1d6vHN1HZvx4/T3AaNkjmVaQA8Ft2u12tVrvd7pCQkKCgIKbDqY7YiuQmCoQQrb4K7XlFOJ1OtVrtcDhCQ0N9t04K3kj9o+SkAdl7dp93cxs2awitov8pfkv5xN+pPTfjHzsWqJRGinihQl7RPDDsiOgoFpWZkU0iX0xA2y4s/XgX2fPHCc197/VN2fwlci8+33Iiu300quGm2Tt+yXi/dqIP1i4AvMswcKB23LjIWbMkFVh8DFQpKnvtpEk7s+Rtxk/s2ySsZNc+VkxTGLdRY4hEorVr13bs2JF++iyiZUyc53A4fvzxx3LP8s033/Tp00cqlTZr1qzsBDRC6J9//jl+/HiHDh3KPSyoCQiCsFqtRqOx+Eapd87lJimt2W52uuRCnlzIRzqffAtCZS8dN276LQIhTNpg4IGPXw6He8ynKFFtymjlnonb7bbZbJ6sk/Y7s1KPZNbrt6Ojko10xT8h2FyNLKaQvv+/sRu09frtb8P1yUpZxJVxfEWfhResEd1m9IworVaWW6D681KdJAjCbreXrJNSr7SUJEnqdDqj0RgcHKxQKHC8Zv4mq48S1YbyUIchgiAcDkcV10mpVBodHe1XddKZsf+TPh8escaOmDE0zo/i9qoS1YYkSY80lQRBOJ3OqrmfpGhab7Frs/R2GgtShipE/EePUphQJMLobKvNR14lP4a6/8Pnax+8MHlXZ39bpMHLkZeoNgRBVLqp9OpdHCYQCTGWROlvvz4AnhPN5ebOmmVp0SJuxAj+338zHQ54gvvqucvOqGE/7EntIGI6FsC4U6dOlX1jt2LFir59+7788stPfvTnn39aLOUvK3rx4kWn04lh2OnTpysYEiSgQRGapmmaLrkMpqdvrCia1lsdeotDwuOqFIFsHEcI+eKzAUIIk/d4b1qsJj/97/Or92/sPJl14Ks+TflMR+WTyl09tdJKqZOVP5bt8Np1XxfWW/1pqzgcoYdPNDSGGQJDtdIosS37/rzpPxjrrp7RsngBn+LSXF6+aPHcg/ddke1WfTOp4xODC8otUEOUqDaeSkCX3k56Gk3T+fn5Op1OIBAkJiZyub48yhlUlJeqTdXUSYSQyWTSaDR8Pt/v6qQr+/jyaZPmbr/liu+1atfijtIa2io+qUrrpBdmsjLZnJoCawCHFR8UwEYYWdpAOoryxXtM628rl54P6Lp6cG1/m8zf25E/WScr/fXtxQQ0Xfj7DxsvkyGj4kTQmoAahJRKM5cupdnshL592Xo90+GA0jgLChx4wgt1fHuECqgKTqdzxYoV5RZbsmRJqQlofcX+xosWhJHL5Xl5eRUpr9Ppyi8EagYOhyMSiYpPXI4QQoZcD57C7HQbCm0sDIsLlvA5Pn/TjfGTG7dKRgh17vR2/IwGS7bMPNz2YLdg6Dn1pBLVpozBHM+Ew+EIhcKSdbKSaNOfu8YccXWf1H+AvFh4GC8rspECJ2M1t1xnV4475CxZwHfQhZe3LBn51aHrrpC2Qz9b+u7r9Uo8+JRboCYpUW081VWTw+EIBAIP1cnSWSwWtVqNEIqKihKJoPdC9eG9Osnn871aJ61Wq1qtpmk6IiJCLBZ770SeRxsvfztp5Cebrzsj236wduknfevV1HdypSpRbVgslke+vjkcDo/HK1knjWVNQvisaIq8n1eAUVRYkDCQH0BZJCKczn+8szNttVhoTCQU+NyvnM7bvWp7VljP79/0t6WgvB95iWrDZrMrveKuJxLQrmMft/noaInVQiiH/n7aAxPWcNaQZjCYHdQYjuTkB6mpgqtXI2bNwp2lLuIOfAA/MTmaXnv+csG7kfC6vYa7dOlSYWH5q4P++uuvNE0/ef9X8Vn2ikpWcPSlTCar4GEBeB4UQqTTlmuyREmEQXyf7jnlyr667Zop5sWUVx7N+IzwmOYv1cOv3U7PJREkoP0UrcvIyiVNWxd9uHVR8e37+jTZxwrvcHZFd2npBY4073GEFd7h7IqezRh8aUJqdswaP3hXruLl4XtmDuka/cQUpuUWAD7P5XJptVqLxaJUKmUymade5ABQaW63W6vVFhYWyuVyhULhZ3WSzNrxzpuD12QoOny8Z/nUronQHag6ICjaSSPSbhXxOOHif5PLeEh0dAD1x4OsQho9mhOBVOfkkHhybISv9Xegsvb8cMwaO7pva38bVOdfkXukBzTGYrPZJTtliyNe7PR6x3dnvt/Ipx9oAPCcwg4dsj/7TPHdd4oKzAkLmMRpOm3VlJO93+s1nVw2pWu9YK5f3bgBT8rNrVBPUqvVWlBQ8GS6uVGjRgEBAc7y3jY1aNBAIBC4XK7mzZsfP3683NM1b968IlEBUGkkRWvNLjtCGI6rlEE83398zT416fNjtd6vfbJvyKNcM221mWmMz4M23H9hstqtpvepQyJEY7gtQGwPoG7s2X7OETekY3KUJDECx3gPC/yLtp0/fvqEM3bIG7WiJImMTqVM3lo3c/huXd3hS3+Z3FRZSiTlFgA+jaIovV6v1+slEolKpYLFgQHjikbU5eXlSSSSpKQkP6yTxK3lg4evza07ec8v89tCq1gN0DSdb3VodDYaIbZArBAX69oc8ELzFzhbfz/9m61vN2HRJvLO71f0WOSARgof++VTGft3n3dFvdu5gb/1nvWzyD3RZrGaT9n1yzShVBwA9/+gpsKwvGHD8kaNivr4Y/GJE0xHA8rjOvHVnBMuYeGJBb3rf8kWyYJFnGLNF6/L97e/6xzAXHigCgmFwooUw3FcICilj4ZYLO7Tp8/69evL3n3EiBFF/xgyZMjChQsJgiijcERERMeOHSsSFQCVY7K7NIU2HknxEcI5PNz3s88IcWo3TBEe2bf34KWuQ5sXdfGgTAe3n7hNS0c2ifW7R3DwECav03p2HWQSKzWyGJ7bFqY7n3pqx3lLwpj+b/3btblO69l1iu1B6Rb99dtJS+J/BZji/CN17TVnvbHrJj0luVxuAeDDCgoKNBoNl8uNj4/n8aDrOmCe2WxWq9UsFis2NrbUm1I/4DiVmnrB+dLsdXMh+1wdWJwutcmKYShWxuNhCJW4n8TDu3ZrOv2jY99svtdpZDwHIdp8buXmv5Hqvb6+liyl9cd+veoO7tWhob/1nvW3yD1xx27/eXTMIO28tBMTYqAZATUQHRCQM2eOrX79hEGDAu7eZTocUAEYLygkNFYaGvtiaZ9yk2TQltUYDRo0wDCs3IUU6tSp87SlXebNm3fo0KEyJndu3LjxmDFjiv6dlJQ0derUL774ooxzpaam8vn+MIYK+CGry60utNE0iggSihDPj5o6LLDlp8Pq/rpi+xvDMvq1Tg5DxuuXzuy5bYlsP/mTxvDC0I/ZA0RqeRyBc8L09wKtBkQ5mI6oosgH1y7oaa7oyoIZDx7/U8IkTQYs6ZGAlVcAXpz4JofDkZub63a7Q0JCKj7RFgDe43Q61Wq1w+EomgeG6XAqj7x7/oKW4krOLhgzsmSr+Mr7S4bWhVbRX7gIUl1gtbncSrFAJuQhXakvhPHYt6dP2dzr85lvd07r3ynB/cfWHzZkxYzaOPolH8s/I8uFY7+7eC1bNvW7O0p/i9wTf+OCZm1b8mecv1wwPgZmUwU1jVupzExNxZ3O+AED2EYj0+GAiuG0nLJ19xSmo6gImqYpiir6R9ndZiuHJEkvHbkobJIkvXHwopg9slBMWFhY69atT506VXaxAQMGPO0HCQsL27NnT/fu3UtdObB+/fo7d+7EcdztdlMURRDE7Nmz1Wr1mjVrnizM4XAWLlzYtWvXZ7po/nKpSxwWebNWF11qjx/50aUud75Fb5z9OblJSmu2m50uuZAnF/IxDPniAuRl4dR7e84ZxdbPtp3ZteOqieCGxtYePbn3jB71wvwojw6KIdhcnTTKJJTLC3IVphyMppiO6NkQuTmZJG25e25dyb4HuJLdflGPBLq8AlUVKagokiR1Op3RaAwODlYoFB7/7gPgWT2qk1KpNDo62t/rJJGZkUnQlr8Prfu7xCe4kt170dC6jEQFnglF03qLXW+2BwkCkkJkLBxD6Om3lIJGs7ZvVXy24Ou9qR+auREvtJm7ecaUNj63yp/zj9NnzHhiwxf8bjlMv4vcEwloPGbkj+tv9fxkyELJ0rFtEyS+Np84AN5iq18/c/lyycmTYfPmYb6XbgDVAEmSLpcLIUTTtNVq9fjxKYry3pERQk6n0+12e+PgdrvdU0f79NNPO3bsWHSdSxUfHz906NAyrlLdunVPnz49b968nTt32my2oo1yuXzkyJETJkwQCARWq7XoXULRQZYtW9a6detFixbdunWrqDCO461atZo5c2bTpk2f9ddBkiRCyOl0lvEjVBpN0zabzUvr2zy6IB4/LELIe0d2OBzlXhC73V5U2BdQNG2wOvIsDgmPq1IEsh8+vmIhg47mDipjx3ILVDWMX6/D0G0dhpZfUP7m0d/e9H5AoJJoDMuXhOqk0SK7SZV9lUMUm0YfV05d9M3UMnYut0BVCXj1U8OtT8sqUW4B4DNomjYajVqtViAQJCYmPm3ME6h6WNiYo7YxTEfBDJPJpNFoeDxeQkJCQICf9G8sU8Cbqw3u1UxHASrPZHNqCqwBHFa8IpDH+S+XiIUMPqoeXOouuKzxuGU7xi2rqhArJeDVxdkFi5mOojL8LnJPJKDdp+YO/+ov3HF1ekfVJ7xAuVTEKfZqjtd51Y2VnapDgwnAYwreeCPn009hyUE/Rltu//zDuoN/3tORLab9NE56/ldr7XYNFD41JIjNZhfNPIjjeGBgoMeP73K5nE6nWCz2+JFtNpvNZhMIBN64YzaZTGKx2FPdQF577bUffvhhxIgRpSZwIyIifv7559DQ0LIPEhgYuG7dum+//fbGjRsFBQUhISF16tRhsf57I+tyuVwul0gkKvrvsGHDhg0bdv/+/czMTBaLlZSUpFQqKxe/1Wq12+0CgcAbD8xGo1EikXijB7TBYGCxWN6o1U6nkyCICs7u/UyKLrVQKORwymknOByOj3RTMjvd6kIbC8NiZWIBF8a2AuZZ+IHq4HgcUTGaWwJHIdPhAICsVqtaraZpOioq6tHXNAAMstvtubm5JElGRER44y4dgGdldxHqAqubJEMDhUECyO6BSvLIowibJxKJuMkvv5lcyofc2CCfeAQDwHMwTDd2rOHtt6MnThRdvMh0NKBSiPsbh3YYtemunUYIk/KGUq57qT36H4od9O3+7wckQseXGmbgwIFxcXEffPDB5cuXH23Ecbx///6LFi0KCwur4HH4fH6TJk0qft64uLi4uLhnixWAinESpLrQ5nATSjFfJoAVtADzXBy+OjjWFiBWmrJkBWo/GS0KqjO3263Vas1mc9HUul4a7gNAxRXVycLCQrlcrlAooE4CxhEUpSu0mWxOuZivEAdCjQTPwxMJaE6raTv3T/PAgQDwA5RAkL1ggSM+Pn7QoID795kOB1QOdW/ViHe2GBtN2vq/cbbP605CCPFfn/n9u5nvrRwztH7jU5OTYS6haslgMCxbtmzXrl3p6ek0TcfGxnbr1m3SpEkhISGtWrW6dOnSmTNnrl+/7nK5wsLCXn311Ur3SgaAQSRF6yx2o80pFQRES0U4PL4CplEYrg+K0AdFBFnykrKvsEjPT80EwDOhKEqv1+v1eolEolKp2GwYIAIYRtN0fn6+VquVSCRJSUlQJwHjaJrOtzq0hTZhAEcVIuWwoGMpeF7QrgHwDFyRkQ++/pqj1Sb0788ym5kOB1QWeXPDD2folKUbF/aJde8oyjVjQQ0Gpu603a373rrNNybObgCtY7Vz9OjRvn375ufnP9qSlpa2cOHCVatWbdiwoUuXLgihWrVq1atXD1a9B/7LZHdpCm08DitBLglgw6s0wDyTWKmRRQe47PHZ13huG9PhAIDMZnNubi6Xy42Pjy+a6AwAZpnNZrVazWKxYmNjBQIB0+EAgCxOl9pkxTAUEywRBvjUFJXAj0GKBYCKsr34YubSpZLjx8PmzsVIkulwwHMg0v9JR6oeKVEl3uPi4S1bJaLFdzNIBAlor8rIyPjxxx9PnTql0+lkMlnz5s2HDh36wgsveO+M58+f79Kli8PhePKjwsLCnj17HjhwoF27dt4LAABvs7rc6gIbRdMRQUIxPCoAH2APEKmD49xsbmh+ZpBZx3Q4ACCHw6FWq10uV0hICLxsBr7A6XRqNBq73V40DwzT4QCAXASpLbRZnC6lWCAT8mAeGOBBkGIBoEKMvXqpp04N++IL6Z49TMcCnhsWGCRB+To9idDj/QPdWnUeLRKL4HvWmxYuXDhr1iyn0/loy7lz55YvXz5u3LglS5Z4Y8ghQRDDhg0rNftcxO12Dx8+PC0tzeOnBqAKuElKa7YXOlxyEU8h4kMDBhhHsLk6aZRJKJcX5CpMORhNMR0RqOlIktTpdEajUSqVxsTE+Mg6saAmI0lSr9cbDAapVBoVFQV1EjCOomm9xa4324MEAUkhMhYOd5TAw6CZA6AcNI5rP/hAM2FCzLhxkH2uJrgvtn8tKGfTl6vvOItvtt9YuWCLWvJymxeh76DXzJgxY9q0acWzz0VIkkxNTR00aBBN0x4/6YEDB/7555+yy2RlZW3fvt3jpwbAq2gaGayOO3kFCKEkZaASss+AaTSGGQLD0iIbullcVfZVpTELss+AWUVT66alpblcrsTExLCwMMj0AcaZTKY7d+7Y7faEhASok8AXFNidd7RGq9MdrwgMDxJB9hl4A/SABqAspESStWQJIZMl9OvHzc1lOhzgKYGdZ37W/vC4CS2aH+8b9w/hFB9YMffwyY3rDqSxU5bM6iaFL1zvOHPmzLx588oosGXLlo4dOw4ZMsSz5z169GgFi73xxhuePTUA3mN2utWFNhaGxcrEAi7c0QHmWfiB6uA4jKZiNLeEDlgqAzDParWq1WqapqOiokQiEdPhAIDsdntubi5JkmFhYYGBgUyHAwCyuwh1gcVNUiESYZAggOlwQHUGjysAPJUrJubB119zs7LihwzBLRamwwGexE56Z8cJ8YyJM79ftcdK0WjllAsscXybCT8t+WxQXej/7C0LFiwot8z8+fM9noBWq9UVKZaTk+PZ8wLgJU6CVBfaHG5CKebLBLCCFmCei8NTB8fZAsRKU5asQA2vcQHj3G63Vqs1m81yuVwul8M0poBxBEFoNJrCwkK5XK5QKKBOAsaRFK0z24xWh1zMl4v4ONRJ4GWVTUBTmWe2/fagIsuwsWJe6fNyNIwpAf7G0rJl1qJFsh07QpYvRxSMHq2GhHUHLD369hd56bfv6ewsSVhCcqwUUs9e5HQ6K9ITOS0t7c6dOyqVyoOnrmCnJ7FY7MGTAuAN/04ZqS+UCgKipSJ4VACMoyhKr9frIxsGWfKSsq+wSDfTEYGa7t86qddLJBKVSuWNtSUAeCZF88BotVqxWKxSqTgceOIADCuqkzqtUcBlJyqDuGxW+fsA8Nwq+33svpQ6bOD2p67nVAyv9/buL0dDR37gV/J79dJMnRr++edBP//MdCzAqzCeIrGhIpHpMGoEjUbz5NTPpcrIyPBsArpRo0Zr1qwpt9iLL77owZMC4HEmk0mj0fB4vITExIAAz99aWSwWh8MRFBTkrXxNcLg3jup2uwsKCng8nt+NrzcajSRJyuVypgOpvIKCAo1Gw+Vy41VJPF59jx/farXa7fbAwED/ytcQBGEymQICAvzuvabJZCIIIjg42H/7ZprNZrVazWKx4uLi+Hy+x49vs9lsNptEIuFyuR4/uPeQJGk0GrlcrkQi8coJvDaFcUFBgdvtlslk/jtL8qM6GRsbKxAIPH58u91utVrFYrE3bgwQQojlleaXpmmDwcDhcPxuHpLCwkKXyyWVSlksf03aWiyWouGhUdHR3rh3cjgcFotFJBLxeH42Sk+v17PZ7KCgIKYDeTZms9npdHrxBt5zKhsft92Cc79Pe9grlDZdWDx68m5744HjhndtnqxgF2T+dXTNsu9+D5+0fefMFMg+A/9Bczi5M2eaW7WKGzGCf+MG0+EA76FMaaePn/9HYyFKrnnHTuw48vUEf72j8F0Vvy32+A10r169pk2b5nCU9daUzWb369fPs+cFwFMeTRkZERHhdyktUC3Z7Xa1Wu12u0NCQvzuUQ1US06nU61WOxyO0NBQqJPAFzidTo1GY7PZlEqlTCbz3/c6oNpwuVxardZisUCdBIyobAIaC4pv9NLD/9hOjO+929V97aUN/SL/zdm0THmz79ttRzfrMWxO65vftBN6IFQAvI4MCsr86itSJEoYMICj0TAdDvAe8u6PvV4buzfbVTL5jBBCvN7bh0IC2vOUSmVwcLDBYCi7GI7jtWrV8uypw8PDP/roo9mzZ5dRZsKECSqVSq/Xe/bUADwniqIuXbpkMBgCAwNFIlFmZqb3zuVwONxut0Ag8K9OPSRJ2mw2Dofjdx1trFYrRVF+90aBoqgrV67Y7XaxWCyRSLKysrx3LqfT6XK5/LROstlsb/TA9aqiOikSiaomK0GSFZnPsXwURV2/fn3z5s1FdTI7O9sjhy1VUZ3k8/m+39GsOIqirFarP9ZJm81GkmSV1cmyOytUHEVRt2/f3rx5s0gkkkgkXl1lxOVyOZ1OHo/nXyNFaJq2WCwsFssbvcK9ym63EwQhFAqrple+zWbzyHFomk5PT9+0aZNQKAwMDPRqnXS73Q6Hw+/qJELIbDbjOC4U+ln+sqhOVtnNUmFhYaX39cQXp/vSrr3ZkX3W94x87KfF5K+P6h23bsPui8vatfGnIUqghnKoVJlff82/fj1m7Fi8YhMFAH/lvvzdgv25QSkfLZnVs4GSX+LmAQ+MgibLC3Ac79Wr17ffflt2sVdffVWpVHr87DNnzkxPT1+/fn2pn3bv3v3LL7/0+EkBeH5F70Wys7Nzc3O9fS6SJCmKYrPZ/tUjhqZpgiBwHPevHCVCiCAImqar7PGsU6dOHjlOfHx8VlZWdnZ2FTx7Q52sYlVcJzt27OiR40RFRd2+fbtq6iRFUSRJslgsv5sRwu12YxjmX3lzVOV1sl27dh75zYaHhwcFBWVlZVVBIwB1sopV8RfTyy+/7JEJfxQKhVKphDpZNqiTFdGkSZNKvzfyxJWlzAWFNEJP/qg0RVGU1WItrYshAD7F/Mor2QsXBq9fr1y5EtFQZas7SpOjwRt+uGLuwLp+9mjo56ZPn75p0yaz2fy0AhwOZ968ed44NY7ja9eubdWq1Zw5c4pmPSsil8tnzJgxfvx4v7tDAjVEp06dPJU3BMAj2rdv3759e6ajAOA/KSkpKSkpTEcBwH+aNWvWrFkzpqMA4D8NGzZs2LAh01GAms4Tz9vs5HrJ2IOd3x/MeyxtR+uPrN5xD0uum+xn7w9AjWMYODBr4cKITz5RfvMNZJ9rBFZUbBQL97d+SdVAdHT05s2by5jiefny5c2bN/fGqfV6/SeffPLVV1/pdDoMw+Ryedu2bbds2ZKbmztx4kTIPgMAAAAAAAAAAF7iiUdulmrwpB7KrLVvv9Jz1o8//3bl1q0rZ35ZM7t3634/PlB0e3+QCpI8wFfRXG72vHn6oUPjhg+XHD/OdDigqrAbjpjwasaKj1ffsjIdSo3TqVOnkydP1q9fv8T22NjYffv2jR071hsnPXr0aFJS0hdffJGWlkaSJE3Ter3+2LFjw4cP37lzpzfOCAAAAAAAAAAAgCIe6ZyMhfb5/ud8bOC0bXNH7P784UZcXKtv6vpv+4b505xtoCYhlMoHy5ZhBJHQty+7vIXRQPXCih/+1bQNTd59MfF/zRur5LzH3sVxW0xeM6m5ny2Z4E+aN29+5cqVM2fOnDp1SqvVBgcHN2/evG3bth6Z4OxJFy5c6NKlS6mrythstv79+wuFwi5dunjj1AAAAAAAAAAAAPDQ7BiY+MWxm6/3+/TU4ZN/puvsuDg0sVFK+1eSgqDzM/BRjlq1HqSmis6dC583D3O7mQ4HVDH7uZl9Zpy10sh1/9oFdYmhILzAQRQzYdUcOI63bt26devW3j4RSZIjRowoe03zUaNG3b17VyQSeTsYAAAAAAAAAACgBvLk9Mwsaa02/Wq18eARAfCOgtdfz5kzR/Hdd4off2Q6FsAE1/mNG27hDSb+su/LN6KeOh8xqAaOHDny999/l11Gq9Vu2rRp9OjRVRMSAAAAAAAAAABQo3guAU2Yc9LScsxEyRXc8GBV40QZTMMBfASG5Q0bph81KmraNPGpU0xHAxji1OQaWC9Nef91yD5Xd8eOHatgMUhAAwAAAAAAAAAA3uCZBLTjxneDuk3cme4omX1GCPF6bzdt6wVJHuADKD4/+4svHCpV/IABAffuMR0OYA5bGhxI/52V40KxPKZjAV6l0WgqUiw3N9fbkQAAAAAAAAAAADWTJxLQVPbaSZN2ZsnbjJ/Yt0mYoMRsqqyYprCW19PZMn9bvHLb5kt3MwoIoSI+EAjY1gAAIABJREFU5fXec0a3rSfAEELk/Y0ten57mShlL1Z0/7N7xzYrmmGbKry8Z+1nW06deWDlhcS36Tp43qBmsdUr438OoVSENjy9vj5ZgESoBUKXS5Sz29H777Nw7lnK1QwhhBCN0E8IrUfoD4RCERqF0PsIVcsKa7u7b/HnyzefuJaR7xKG1UvpPWHO9D71RI/GJrizjy6f+eW6w39mGNz80OQWXUdPnz2iaTBe1jH9GL/9R/9n7y7Dm8i6AACfiVvdjXqRosXdi1vRAlvcF1ncYXHYxbvA4k5x/XCKLxQtUKy0pUrdG8/MfD+KVNNJmjRJe9+nPyCZ3Jw7OXMnObm5s6bHjRmTZzQ9+deAGkaVtZsIgJGREZXNjI2NtR0JgiAIgiAIgiAIglRNmihAy0P/ey51GrXvwjZfdAknlcijL/QfseWG0KKFb88Btnjk8/tnD6wKfp1yb8/QeizABC6+XTu6FylAE2nP7r1LtrG2yq8cklnX107rdzrJtl7zoYNtJJ8eBG2f9yB8Wci69vaVpaZGAgQCPAAo7bJwJW6AAfgCuP/4L25mJmzQgJkU+e5DTDIhs/px+yqA5QBNAKYChADMB/gK8A9AJVszRh7+b/9202/k2LUYMHqAkzzy3rmzf48I/i/u3o3Z9dgAQKZfn9Heb2+sZZP+I2d5slNeXgraMcX3cfzNR3824ek6eK2QPTh4KI5FD9s9uNZ+gYWFoPBIyOm159PunpXrW5wqy8fHR4ObIQiCIAiCIAiCIAiiKk0UoKXZ2RKae51a+lKoIpMuL12VOmTraG+6rkNRisy7uGPvzRzbUVt27mlrRgMAYsTtDVO7nziy+FrXS33MaVYtV61pWfgxRPTZ+Y0e11o8v7cbDQDI7P/2TDj9rcaITfdm1DXBAEj/XovHDbi6b3tAm7W19bv7FIgB3gMcBTgJYKPiBjSAVT/+ndW9+7dly2y2bM4NDm4EsBjADQAAYgA2ALQFuA7AAiAAfgPYCzAGoKEWu1XhyKyLK5bfzHQedfrBnp42NAAgFt6e2bH7jnWLTw6/FGCL4VEH1xyOMu9z8L8TvznSAQAWDZ/TvNPGwL8vTD85tFKu4I5xTG2d6po71S3xXpaXeZnf3xAZb84eDLoXGpMrcK7fYcio/vXMiuwoMvPa0rE738h/3kB36L8+cIQXncJjEY3p16/fzJkz8/LylGzDYDCGDRtWYSEhCIIgCIIgCIIgSJWiiQI016N6NfLQk+fZkx11X0UhJQl3j1wIEzUpbbqs/sAjHrzJo1cfPKu12fdiF82kw8g+LU5vexjyUdqnZfGlaYnkmzO2hrqN3jHTkwkAQOZcPHkn3rj1xrF1TPL3PGbWa/K8f2rFWXPkAIZdgCYB+gHcKMcGAEDSaCnTp2f4+TlPncp99mwMgBvAzB/3XgQQAcwCYAEAAA1gNsApgJOVrACtePvgSRa97vRZ3Wx+ZJplh1njW+yZ+TD4hTSgJyfv2cNQmVHf4f0df+QMv1FfX8fN/3x+H42DueYuVao/mC1mnzw/W/3H4zHn1qw+g7cdNW2IReqDowdWr6NvXNPPqdAxR6QkpWBevWb6eecnGGBcB3satcdWFTiOR0RE5OXlWVhYuLi4aOMpLC0tly1bNmfOHCXbTJkypUaNGtp4dgRBEARBEARBEARBNFFaYjaZt2v2vYG/D1iIb5ndu7YFS0dVaDI1eNOyA08ScmQkWOomBJUoJGDiVKdRDfcCcy0xDoeLgUImL6F+TmZf3LrnukW/u795fK9nyT/cDZWw6jRp/2slX6A7NJ4wrLGWQ68IGMBWgCwAEmAaQLzqGxB8fty6dXJHR/chQ1gJCecBrgPc/VFuBoBnACyAZgUeUgvAAuAlAAFQWZYwAZALwcyzTpuG7gVKnBiXx8VAIZURAMCoPz7w3yFejQt856HIzRWTNHursmcCV0myt1eufHXsv2ViVyc6QG3LrIjZl//3vsfEuqwCG8lTkjONPZu1blGHrvJjK7/09PQ1a9YcPnw4LS0t/xYXF5cpU6ZMnTqVzdbw6iezZs2KiorauXNniff27dv3r7/+0uwzIgiCIAiCIAiCIAjykyYK0LK7m/68K+Pn3F03sO56hsDcQsAsUIKuuNVUMVOfwbOq9SFz/tu1+l4FPF95cZptO9Ws8E1E/J37TxSM+nU9i09/FoUeXXAD779+aLMf9xFpCVFCsHY0irywbfjRu4/jJCaOHs1b914yvlMdvs7nomtAdQAAIAFKuzqYkg1kTk4x27ezEhNdf/uNnpcnAlgA0L9AuZkAiAawACh4hTIGgBNALABemQrQvG7bXnQrfBMRf/H8EzmrftP6HADg1+weUDP/dklORkZa/Lsb22YHpdn7bRpUrfLshhKQeZ+u7Dt87VVUCt583oEpZk9uCWt2qmdV5lUo8bj3H/NsmzW0z68s06s1bGB99vWHRKKu86/9RaQmp5DWtawJcWa6kGFmYZQ/LlJ6bGUXFhbWvXv3uLi4gjdGR0fPmTPnzJkzly9ftrKyKu2xasAwbMeOHc2bN1+yZElMTMzP262trRcvXjxlyhQarersewRBEARBEARBEASpaJooQGMcUxtbFzNblxKv4URlNVUNYZo6upsCmfmFW1L19dSpU69evfr5X4IgcnNzMazkQq1Ribdqlzz63q5BG58J7Xsu7lvsCoJEwr7ASzHVA851MPkZMSkS5pKQfXez7xmFR5vWE1oxE988Ontw9a23afd2+derwpdQE/r4xG3ZYnL1qt2GDUAQALAPIAbgXIGrC5IAQgBB4UIzBiAAiAcgKz7oiiONvrxo0NybQucxi0e4Fso0PHyzb8OFL+UANLOWS6/u6K+rS1nm5uaWdpdUKtXMDFnF12MjfccdjxCTAJgZZyQhi9rm53/d5bd/L+8Z5qF0OjKRlpJGWvyaHk4ztzIn01JSCShUgE5MVaQGrx194Gs2Dgwjl5ZDp07q7sEs67EJCQnbt28v+HTVq1eHH0OWBjpepC8EoaWWcRwHALFYLJPJCt6ekpLStWvXhISEEh8VEhLSq1eva9euMRjKTk8EQeTl5ZU2gJeob9++ffr0CQ0NDQ8PJwjC1dW1cePGdDpdKBQWb9ywdrVCoQAAsVgslUo13rgau5o6HMe1t6sJQvNLceXvapFIVOaXFmKxWBsBIAiCIAiCIAiCGCKNLMFRztVUK8j79+9v377987/GxsZSqVRPCtCy5JdbN25bdTNa5th+19apXY2LRiV8cWrzK2bvtb1qFvjMSypwBUnkpHHHb9n2TxtzOgAQo35bM7Hn6cOLr3e51KdSXjyubBkDBiTNmWO/Zo3pxYv5twgBNgP0BqhZeEuyQD26oEpcM5DFB2+dP3PV6Y8y1wG7zv/dtciq7TQHv7XHXGK/RT6/tPfQyp596Vcvzmsi0EGcSupoOI5roqxDRO0aMzEos8HMk/9MEa30ngkA3C5L9kyO/X3nhJF1G92fVV3Jmsy4TKrAuNyf33RhXC4Hk0llBb+3IHPTMuVcgXuv6X+2doDkN1d2bd+7Zq/VtnFlPTYnJ6fgSFW/fn13d3cAIElSG+XF7z3CcS21rFAo8mt2P61YsaK06nO+kJCQffv2jRw5UnnLReraFNWqVatWrVqlxZaPIAhD3NVyubzsjdSi3q6mwkCzmsqu1l6/EARBEARBEARBDE5lvLxYKSZMmDBkyJCf/50+fbqpqWmps7oSKygqIHOfn942dsutd3LrjgFLNo/vWFtQLCQy8/zxW3HWnfa0L1SZxjhsLoaxfPovaWX+vVhGM+48ul/z84EPHr8T9WnLr6A+6AuSTk+cOze7c2fXceO4b9/+vP08QBzAnsLl5vzJzhmFJzuTAHkAglIK04aNzHy+e+bYRSfeSR07zji0edHg2sW+5wDMqHr7vtUBYMSEod496s1YtyTot2tjdTAN2tTUtLS7OByO8rmxlODvj+57RLbdfGzDIBf5mfzDBzOtN3zbWVGE9++HT4RNX16v9Cehs9h0MlssIYGDAQCQYrGEZBoVmjWNmfkuDfL98T+nJv6/+4VOOXn/zcg2ZTzW1dX1yJEjP/9769YtLpcLADQazdi4tNVo1CeXy+VyOY/H03jLEolEIpHweDwW61fvRCLRmTNnynzssWPHZsyYoWSD3NxcPp+vjaUzsrKy6HS6kZHmv4XU3q7On/vM5/OZzDLXj1FZTk6OQCDQ+K4mSTI7O1tLu1omk+E4nn/gaFb+rhYIBGWOQiwWCy3tgiAIgiAIgiAIkq98dRxF6qtLp64+Do3MNXZv3meEfxunQksXK94fXfzvK6/RG0bX14NCt729vb29fcFbGAyGln5WTBWRfObPWQEXEq1a/HZhwbDe1Yqv/AwAQCTe3fdY7OLfpU3hhQfoltb2dOyLrY1lgQ+5NEsbBwY8y80TkVApFoKmjMWP2bGVZmrqPmwYM/HXFwgEwD4AF4A2hTenAVQDeAmQA2Dx40YcIAGgOoCS2a8GCY87M7F7wKFoK98FF7bO6e1eqAQmiwo+9TjFue2g1r9WfKY7+/rWpt//FBaBgw4K0EqKOzQaTQOHrSLycyR4+rV1KtI3mn2Llh7wd0Q0DkoK0DQLK0vsa3omAaZ0AAAiKz0Ls/C2ULajaJYO9mx5Zq7MvIzHcjicmjV/TdZ/8uRJfhkLwzANVN6LIQhCoVBoo+X8sOl0esHGw8LCRCJRmY998+aNTCZTUqvN3xtaKvBpb1fjOF5hu1pTtLSrSZIEre1qHMdJktTtrtbGsyMIgiAIgiAIghgo9T9Skrkhazt7Nxnw+5JNew/u2bRkdLsaDceeiir4Q10i+s6ewJ3XI7T1K1hDh388snL0xTTvEeuf/zOmtOozABEdHPxEbturvVfRuW08j0ZuNGFMbFyBBQnwpIRoOWZiY1V8emslRmCg6LiAkZ3tNnx4weozAEQDPAHoBVB8ZmAzABnAwwK3fAFIA2hUma5ACACg+LgtYPThb94zLzy/tKxI9RkAIOLUzLFjF10smEdA5uTkkhiXV+KC6oYPMzE1hoyUtGKDkzw5MZUUGBX/HUJB9GreNfmJoW9S86fPE0lv3iYZ1fJ2KPi9hehJ4KTJWx5l/5hhjydExsjMnJxMnct+bCWWnp5OZTOSJCluiSAIgiAIgiAIgiCInlO7ziZ9tmbUsgeSWgE77nxM+Pb5QdDaIa4xB0b4LfsvT5PxVWbS19uOhklrDT88vZG1kteBzLrz6LPcrL5vrWIVVJpz/27Vae/OLbuZ9H1BSjz14u4LzwmLXh29q841CPOaeIgZNFrCa8c5c2gSSZF77wDIAXxLemBvAC7ADoD8vUcC7AQAgMFaDbfiSe5v2/ZU2nDu4VUdS8w0ZsMObU0UIfv3PPt5MTY8+dqOE59Im3YdvCvnLD6WT+f2pgnH1+/9UmidVnHYznVBicatOvgoX8mAVbd792rRp7cffxYZF/HkaOC5OPee3WuzABSRtw/uPxmSTAC3TrPa8od7/jpy7234l/dPLmz9+0Kqt1+PmoxSH1slWFhYlL0RAIZhFLdEEARBEARBEARBEETPqVtcUoSeO/eF2WLdmb2TvBgAYD94fss27lgT/00TVvd9trap5lderHTw2LCn6SRL8Hbd8rWFq4KYccPBG/u6fn9thG/vvJNzfOo1KaFCRasxcPIfV2etmz/+0832vi70r0+Dz73PrdZzyZ8tq8r6z+nDhycNdWT3XE97e7bEDe4AcACalHSXC8BsgJUAPQF6ALwEOAowDqChNgOueHjEk6fJBMvo8boJY4tmWpsZG0d4Myz6LJvf8taCv7s1fz+kdyM7MvndnXMXXmU6Dj6wqIPm16vVDyY9l6zofGPKtObNgge7flZIja4Grrpx79jhq+GMthuX9jUrY+I3w23Agrnyfw8Fzj8n4TnU7zlvQj9nOgAoEp5fufQVbz6gqY2g0fiVc00PnTq69lIO3dzRq9G4lcM72tMAaKU8tkpo0KABn88XCoXKN/Px8aG4VnJYWNitW7fi4+MFAkGdOnW6devG51eV0Q9BEARBEARBEARBDIK6BWg8MT4R8xza2f1XAzS7ARv/On1neOCcXSOD/6ius3mTmFm3lWe66erZqVMkJsbiZF7k08ORRe6hWdM7/NXXNf8/0vevHgkxj1qeJS+pwa+z8t9NDv/s3xl8Y/MD0szJe9TcgOVD6ttVriUkSkSyWN+WLs1r3tx18nAGQZa4jRTgEYAHQGnXblsKYAWwHWAugAPAKoDZle4KhIrY6FgFmffx+uGPRe6hWTMG/jXCG4Bd+4+Lj+zXrfjn7Lmdd7LkXNvqzcZvmb14fOtKnEgMr4ln7hotnr5kz64LQoKEnbOf0o3cOkw7sHHFb94UruRGt2o0fHGj4UVu5bRZcObnauNM26bD5jUdRvWxVQKXyw0ICNi5c6fyzSZMmFBmU9HR0ZMnT75x40bBGy0sLFauXDlp0qRyRYkgCIIgCIIgCIIgiOaoWyammZqZkEnRsWKoK/h5I2Y7cP2KQ7cnr5q+t/f/JrpXmTl96mG3WZD+ZkHZmzWdGR86U8kGdLPaUxZvmrJYc5HpGQzgdrEbcTOz2M2bSQbDffBgRlpa8Q3ysQHilTZOA5gCMEUDYeovdve96bK9ZWyECWoPWXVqyKoKiUhf8L2Hbb49dG1q5KeoFDHd2M69uosZhdIzUj7Lly+/cuVKXFxcaRu0bt161KhRyhsJDw/v1atXSkpKkdvT09MnT5788ePHbdu2aSBWBEEQBEEQBEEQBEHKTd35jcwG7VsZp55asvj6N0WBm+muY3Zs6Eq7PXfIwuC0UialIkg5Sby8IoKCGMnJLmPGMNLSdB0OYtAwjpVH/aYtmjeqjarPFcPa2vratWsuLi4l3tuiRYtz584xGMq+HJVKpUOHDi1eff5p+/btBw8eLF+YCKJPZDfH29KxImh0tpGVW8Nu49Zd+SIq7ZFk6pOjgYcfJRGlbaA+MunscGfHoWdS9fLdnhY7jnyH0hLRNygnkXKSPF9Uz7LNxvcyTTWIclJlVfr0TSQ92L95y+lQbV5UTf2c1CL9zkkASi9NlU7dEpQynKr9A3uT3kuXd+C+3dbDy7VR1yELzsd939F019G7941z/vh31zpN/beF6CJ/kUotx9c36sgRs4sXnebNo0mlZT8AQUpD5n26vHXh5BFDBgzf+lyuiHhw7U2qXNdBVQXe3t6vXr2aO3eutbX1zxvd3d03bdp09+5dS0tL5Q/fu3dvZGTRpYuKWLRokUKhUL4NghgYjGVq7/KLgwVTkv711fW9C/o06bTiaW5JDyFigxaM+2PVpZjS3g1Lo29snNStgYulkcDSrUGHYUvPfipjifbvyLSLc6dfqDbzz35W2li3ShRxcfWI9jXtTHh8C5eGvWf8+yQVV+XxZXRcFPG/9eO71nc257M5xrbVWw6auz9EtSfQFnU7TqVH8vvTnBlFP3RiGIaxGq/9qHbvNZiW0ssBZrSSAqQcp36mpSz+7rbfezdxtzbmsnmmDrXa+i849CK9WGqSOR/OrBzZqY6TOZ8rsHJt2Ov37fcS9eM8pv7xSGmE0fTxqPmhshwR6mdOgiw+eNu0fs087c14HJ6pg3e74UuD3mbrQ+lHu8lW5lHGaTRrWdcvK6bsDNfoGUHjOVme4UJPc/IHZR3XzllMQ8rbcQDAv+4f23/czHk7H2cV7r2yjqeqV+5UISepDhfq7wE9z0lQ8tIUUOZb7gqnzeGUwsFY2nBKloPw4+lFg5q5mbGZdZa8lhe4g0h7tGmojxULAwDOwNOS8jyJtnTu3JkgiFLvfvsA/VH9A6igPwxLGT36/ZMn2e3bV9yTavZPLkN/lP5Kt3fv3uPHj2tgCJBHHR3mwc0/y2FmIy5LhEH9ORi/RsDRL1INNK8p+/btO3bsWGpqakZGhjbal0qlOTk52mhZKBSmpqZKJMpOADiOf/ny5cWLF7GxsdRbbtOmDVAQHBysRtipqamZmZlqPLBMUqk0NzdXGy3n5eWlpqZKpVpJ3IyMDBzHNd4sQRDa29USiSQvL08bLefvaplM2RiVTygU9u7dW2NPLL0xzoYGjLrLQgu+2SIJSeKzfaNr8zDAWA3+fCMv+jAi4860mkyM7jnnabH7SJIkMu4vbmZGwzCawK5GXW8XczYGQDNrvfalsMyIJE/m1mTZBlzMKv2NlNqIrMfLmpvSAKPxbWvUre1ixsIAY7oNPRGtoNqCso4TGfcWNDamAWAsE8cadbzdrHh0DDBmtf77w8t+ZbVJ3Y5T7BGRtr87B8MwGqMobtO1H6nu2wI0npaSyyMtmMWiYzAYDAadhgHGbrUpUulopI9pKfu0q6ctAwOMxrer0cCntos5B8MAY7sHnI4v0Bk8/ty4WnwMMIxlWs27bnVbPh0DjGHXc9dHHX+MUv94pDTCaPZ41MZQWb4I9TEnSdHrvztY0n8kZT0vWz4DA8B4NcadT9D8+V4FWk42ikeZ7PXSuizrwSdTNPKaaSMnyzdc6GVO/mpB6cGo6bOYxpS/4yRJyj5t7WBKAwBW+8C4Qkei0o6nqnrQqpaTFIeLcu0B/c5JUtlLU+CJlL/lrnDaPndTOxhLGk7LVYD++fxyqayEV0KeFf36/tWLT2J1eiorDSpAG1YBmmCz49au/XztmsTDQ/d1ZFSANvgCNB65vb2AbtFi1snXUQf8uGYjLkuIzNAjUxqb0Pgt//6ky/cwhVXuArR6rKysqBSgAwMD1WgcFaCLQAXogvStAE2SJEnKQpfVZwIw6i1/833kwjMj/rsetOPPCZ3ceBgAlPJBLunkEFsaxvLw3/smCydJkhR/PT+5LhfDuM02lPFBjkg62s+c4THzkTZKY8JHs2syMZpl+9WP0xQkSZKi8GMBniyMZtnnULzSXKTUccmjmR4MjGbRbumtWHH+wzJC9w3zYGKYSfe9yp9Au9TtONUeyZ8vqMHAuL2PaOqw00ZalohIvzbBncGu9ce9bGWfTvUxLfH4vd2MMYxVPeDw+5z84KUJd5a1s6ABzX70lR9nX/zrTl8TDGM69/77YVL+DhNFnJ/VwoKGcZuueafLL0bUPh6pjTDKs1flT/FayMlyjRj6mJOkOGRBbRaGsb2G7fv+ypDC8HOzWpjTgGbZ78g3LZSAKNJuslE/yvCv29px2Q1XhWmijKT5nCzfcKGXOUn1BKHxs5imqN/xXyRv1rYQ5E+MKlbl1GzHVclJqsNFefaAnubkL8pemvK8t9EqLZ+7KedkCcOpRgrQBgkVoA2oAC23to44cSLy0CG5ubnui8ioAF0JCtCKt3/WZ/I7BH7FSVJyeiDXbMRlCUmSJB77bxcjZolnZB1BBejijI2NqRSgN27cqEbjqABdBCpAF6SXBWhS9nCGCx0w4+EXvx9tucf7cQoeCyW+G5Y9m1+TgTGqz3xYcFeJg6c404FZ/8+3yirQeNSW1hxG9XkhWqiLERlBA0wxjNd2a8G5rjnXxjnRgVl/xTtlcVHpuPzZ/BoMoHvOflIweCJlXzcuhvH6Hs3SYF9UonbHKfco9+QAPkb3KLxdeWghLUtCpF4e7cLgNFgconxmvj6mJZG425eD0awDLhY6z8pfLvZmAM1h0p38YVv+fEFNBtCdJ94stBnx7VAfcxrNZuRlrZw6qFD/eKQ2wpSRvVkamtn3PSR1crJcI4Y+5iQpuTnejgZ0j+n3Cx1QeOwuXwGGsdttj9HR13BaTjZVjjI8fldnLt1txgMNvIXVeE6Wb7jQy5wkqZ4gNH4W04zydPwHYcgSHy7dqmtAT3t68SqnZjuuQk5SHC7KtQf0NSd/UP7SqP/eRqu0fe5WISeLD6dqrwGNIBVEVLduRFAQ99Mn1zFjGBkZug4HqRQUkZ8jwbNdW6ciQyDNvkVLD4iOiNb1OmKIEs7OzlQ2K+06hwhS2SjkCgAgiR+LznHbLjp/5cqVK1euXNo9ukbJV/SUvzh5JlzBaDh6QnN+gZs5bdc/j4qOuDTFg1768+GRZ4JC5I7dejb4deVWMv1Adw7GrDH/2c9FKPFvlyZ682h0k6bz76aTVDsjunfxdjawWw0d5FpgfDbqMLS3PV3+/sr/IpSMzlQ6DgRBAGBMFrPgOoMYi8OhARAKXNWV+6RxwYHT/VrWsDfjsdk8U4earQfO2RuixpKM6necYo/w2C9fZSTDvbqbsou8ao46aVkCMuPq/N8PJXrP3LmwCU/ZhnqZlorIjxFyklHdp27BwwzoTi5OdCBzsnNIAAAy9cWzKAXNtF3P1kYFN8PsevdvxSJTr19+ouIV0XSfllRHGOXZS1J+hShRKyfLMWLoZU4ScW/epRE06449mxU6oGj2bdvXZJCKiE9Rqr0FNpBkU+koo9l17dmYHnMm6LG2Lzakek6Wb7jQy5wEoHgwavgspvvU/Sn3wdLRG96Y9tuyY4RLCe++KvT0XTAnqQ4X5dkDepuT+cp4adR+b1My3eck1XM39ZwsPpxWzJtQBFFTdrduCcuWWe3ebbV/v65jQSoRzMTUGDJS0nCAwicTeXJiKikwEmjjCgiIhnTv3v3du3fKt2Gz2R07dqyYeBBEp4RPL91KwoHu4uH6fTij2zfsag8AAETEx7UljmZE/NOQWJxerWUr18JjII1vVY1f0iMKPPbbzWuvFcYD2hb4sFB8o8Qr07r47/7Eajz3wtU17SyojqmKiDfv80i6Z0Mfy0IPYdZrXI+JxX9++0EK1UurQ1LoODDq9enjufnvz4fW7Pc/OK62EQYAsm83V266IcLMew3oaEIxUAAAkL7b1qvTzNspBMPE0bNmPY405euXx2f+fvy/GxE3n6xrVcaOLET9jlPtkeLrl68KurWH9bcLf627/PxTXDbT2qux75BRQ1o6sFXpNSVqpWVxZPadJTMOJbj/fnhhU67SLfUzLZleKF6sAAAgAElEQVTN1r3LWQl0Nq/Q1905L56+V2DMenXzP6ySUomMBMDotKIBsThsOhAZHz98Izq7UJ00pA9pSXWEKSN7BUq+CFOZejlZjhFDP3MSOLX6TJ3Rwr5b7SJFADwlMZUAzNjESIW3wIaTbKodZTSHVq09scc3rr6Sd2iu5OUrJ3VyslzDhZ7mJFA8QWjyLKYPqfsdmXFj7phtn6yGnNzu7/jpSUnPUHGn7yI5SW24KM8e0N+cBCovjZrvbUqkDzlJ+dOBCjlZbDhFM6ARfYVhKZMnf1u0qNr06aj6jGgYy6dze9OE4+v3fik0t0EctnNdUKJxqw4+2nu3iZTbtGnTeDylM+EApkyZYmKiUiUJQQwNLkqNenZ2+cBhgV8UGKeB/yBv6pMKFFHhUQqgO7vbfbv195hOtR1MeVwja8/mA+cdfJlexlQL0fNHr2SMGg3qlFoQJJKuTu8yeOcHZpN5Kn1UAAAiITaBALq9k33ht74Y38HRDCPFcbEp5by6OKfFyouHJ9QTXZjo41qjhW/P7u0buHt13fTBtveGywcCHFR5Xyy8tv7P26l0r7GnPifGvn/57GVYdFL0zTkNOZL3e/belagUVjk6Tq1HRGJEVB5JpBz0b9x/7uYDp6/dvnnpeOCSka1rNhl/+quilLZVV560LEb68u/Ze79aDVqzsHVZH730NC3pLB6Pz2MzAIDMjn4d8uj2hQOrR3X6bX88p97UteOq0wEAaDY1qpvTiKzH914Xnm+Zfff6fxISiIzUDOpprxdpSXmEUZ69mpknVb6cVH/E0M+cpDl2n7dx89+zfG0LhY7Hn9wSFIvTnX27qrB7DCjZVDzKGNV96vCIuCdPYst5xilZOXKyXMOFfuYk5SfQ4FlML1IXAADIlIt/jN/z1SFgxxY/25J3d4WcvkvMSYrDRXn2gB7nJIWXRpP0IiepnrtVysmiwykqQCP6iODxYrdsyere3e233wQhIboOB6l8THouWdGZfnNa82YDZh7/qJCGXw1cNbWXT8vZwVibJUv7mqEZ0NoRGho6f/78Xr16de7cedSoUSdPnpTL5ao2Ym9vv23bNiUb+Pj4rFy5shxhIoheUrz9sz4T+4nBt3ZvOuDPa3EKVrXemw78oUpRhczJziaBTD0/tkW3uQcextPs3KsZiaNDzmwY3arpiJOxyn4t+TXskwi4bh6lVF7w5Gszugz65z2z6fyLV1er9FEBABR5uSISML4Rv8jjMD6fjwEpzBOV+0f5TFNHDzdrLsjTw5/c+t+1e6HxQmCYOddws+KpFCyRqbBu06PP5JVL/Vx/fHJi2bUb3tOTTghTUoUqBVqujlPpkeJreJQCSDmjxtj9T6IzJTJRyqfb/4xuYCx8u3fk4HWhKq7xUCByzaVlEcTXffO3vqM3nbm0r1VZr4wBpKUseGGb5q079xu9+OBLkdfI/efWdjD/3hy37ajhngw8PHDCH2cjRd+fM+W/zQGTDn/DAUiJREo5m/QjLVUYYTR1PBYMW7M5qWaEBpCT35HZoXtHd510IZXmPHTDvFacsh/xnUElm4pHGdvVsxpd/untJ5XfpJbcO83lZDmGC8PJyZKfQHNnMf1IXQAgEoJ+n3zsm+u4XRt7Wpa2v8voeJJ660aqmZMlDRfl2AP6m5OUXhoN0o+cpHruVu1gLDKcogI0ondkjo5Rx44RbLa7vz/761ddh4NUTgyviWfuHp5aP/v6rgthctGTnbOX7rwvbzrtwL2L073R/GfNEwqFAQEBDRo0WL9+/ZUrV27fvn3w4MEhQ4Z4e3s/e/ZM1db69+9/8uRJU1PT4nf17Nnzzp07ZU6RRhDDg7FM7V0KcHX1qNmwg//Co8/fnZ/kTb1oAAByiQQnQf7uTojV2CPvUjLiPr77/C0z/sH6rrbyyGMTJx2MK3VSCJ4QE4/TrOysS/pxPJ58Y1bXgYFvhcBvPGJ8a/Nf73wVIXO9GJgSrCbrPuEAPxZ9LeXdPoGXc4V+MuPWH+1955xLrj7mn+uh0Rl5OYmfHx1f0A57tGFg64F7vqgwl4jmOGDT+cvnNw/8dTUBRXbEnZO3vxaMUesdp9gjzL7bgk1bd557dH/HyGbOpmwm16p6x8l7r+/3d6CJXm7deDWXes8L0WBaFpZ7Z8OGe0LbwQvGeZW9EIMBpCWz4cR/D+z7d8uq6f3r8SMODm3cbsm9jO/tclssPbS8lbnk3c6B1a1tPOs3qOVo4dhqVrBZh1YOdMA4XDblj7/6kZZUR5gyslemXr1Kkzmp/ohhADkJgKe92D+tba2m4w9/IL2G7r72r0oT/Qwr2VQ7yug2dtY0UhgfS325WWU0mZPqDxcGkZOl0+BZTD9SF/Cv+ydMO5vmOWX3Ol8lc5/K6PjjcLWWKlc9J0sfLtR/6fU1Jym+NBqkHzlJdThV7WAsMpyqOy8Bj7p98FYklbfpDPfOIzu5aXINL6QyEzVoELtli3FwsN2qVVh5T1QIUgpclJUtoXsM3Xx76NrUyE9RKWK6sZ17dRczVHrWColE0qVLl8ePHxe/68uXL+3atbt161bLli1VanPAgAEdO3bcu3fvzZs34+PjeTxegwYNhg4d2qlTJw1FjSB6hl5j+tWXy+tp4lfpDDabjgHGarokKHDYj4umMGxazTm49nH1UZdu7zv1ddQs9xInKRDCPBGJ2XG5JbytxSMPLduBGbu4WsZ8Df5z7qm+QUN+fDyh2TT3nzBRyY8d6c4NzDCgCwQcAJFIKCLBuOAzkCKhkASMLyg6nUM18pcbZ+z4ILUdcvja7gHW+U15tfRffdGL0bLlyqvzF57xOzVEhSk2RFbYlWOnb4W8+fgl6uvX6LiUPDlJAsCvFfC03XGqPWJW7zmlerFHY9a9Jg92CdoU/fj+G7JvK3X2rQbTsiAi9uiGI7FYzYW/dzGhEJYBpCWtWpuhI9oAAEyfN31vvyYTrqybsL5n2PqmTAAAo6aLbjzz2b5289Frz758/My18+45Z/ry2Y57G915SDM2NVFpxpDu05LiCFNW9ibnjHYyUf0zpAZzshwjhr7nJJ76dPeCaUsPvUjD+Z49F6/9a55fdTWugGIwyQYqHmVcHhcDIi83jyh6uRh1aHacVHe40PecLEPZZzF531bUP8jpPHUV4TvGzrmW6z37wqr2Sk9zZXQ8NjoJalK6PHvh4FXJSeXDRTleev3MScovjYbpPCcpD6cqHoyFh1N1x0HFq92/TzxNZTESzsDTw1EBGqEks3//xLlz7datMzt/XtexIJWa+Mp459+SV4ffnebMsfKob+Wh64AqucWLF5dYfc4nFosHDRoUHh7O56tygQUACwuLefPmzZs3r9wBIkgVQzezMMNA6uXb1aPQG0HMqm2HusxLj8Pff1aAO6ukh2JMFhOg5MVzSBIza7X08oUxUeN8Rp4/O2/h/zrv65lfnKG59Pvzn35lBqZwqOZIh4+J8d9wsC0YmjjxWyaJsR2crMvz2z0i9v7dCAVm0XV4T+tCb7659YcNrrf29YuHwS/lQ3xL7HgxZPaTNX37Lr+fSho5N2rVokW/Lr+5e3rXN38wuc/6jz+30nLHy90jhouHCwOiMjMyy4yxIine7tt5X8RqNma0sgsT/aKnaUkoZAocaEwWo9D9DNdhE3rMv3oo+tmLZKKp4/f7uG7d5u7pNrdg5BmHvqYQGM/dk/ri5HqRlhRHGEZZ2SsSisFEQLXrWlCe40tPczL/+TMer/MfvOzWN9KqydjADcvGtXGgNuoVacaAku17/6gfZXK5AgBjsVj6uSifWsOFPudkOfw6i1FeY1ovUjf3yc3HWcAyuTW784OfgeVEJxOgeLWxT8ujLEaNiUf2jSj9+rPfOy4Wq7Y+sKrKHi7o6r/0+pmT5X5p1KAXOVmeTwcAUOrBWHg4LecXcRjHtn7nfgP8ujZ24pfyCtBt6qA5hUhZSBotZfr0jH79nKdM4b94oetwkMqO17RjC+7iJ8+zpzqj5Z61LT09PTAwUPk2375927Nnz4wZMyomJASp6hjVvaszsSRF8ff8BEEAAItd6oXVaZY2ljQiKyOrhE96NPvhBy4ubWmONft7xdG7U24dmbl8eJvtHYxVCMy9bi0+Fvb19dsssuDFu+Vhr8PkJMO7rnep16mhgiQIggRg87hFJ0ZgbC4H+9F9SvAPgVNX3E+37vPP9UMT6/ycYoKHvVLnrKJuxyn2iMwKu3nrfY5RrU5d6hQ+6xHZmVkE0KxsrNSIWmtkIYePfVCw2wzuT/EDnn6mpeLl4rot1n9t/PeHR0V+UMDgC7gY5IhFYhIAABdlpufK6XwzC0HBD03ikAfPZcBu0dyHcnVQP9KS4ghTZvbqXHlGDP3MSQAA0cs1PbsveSp16fP30d3TW1ipO03MoJJN1aOMyMrIIjCGpbW53q1Xqv5wob85SQGVsxjV10pPUhcAgMiNef00puit2V9fPf0KTEVvMVl2x/kCba46SGW4KMce0OOcLPul0SQ9yUmK524VD8Yiw6m6Yyq7x5YH57bN9W/Kj7q2a/HYYeOX7r76LpPv2ax9xyLa1dbSt11IpUEIBLHbt+e2auU+ZAiqPiMVgeY8dv+RYV9XjNhwMzIHrfSiXTdu3JBKy16e7OLFixUQDIIgAACYbZcejVh4xJULoYUOTiL2+v9C5RjXp2mpkwcYbl5uDDIzLi6n+JtvmpGdnTEGAHS3MZsXNefhEbtnrH0qAqC+bp2gXfe2AhA/PHM5qUD70mfnLsfgDM+u3SgsB6wE3bFObQsakXT3xuvCgxKZFHzzjRxjetevRXVqhvjdqw9yMO48dnSdgj9wFMfFJKuzYJ+aHafYI4zx5cjEoYP7jv33U+Hl8xSfL14KU9CsWrevqw/1vu9kT06eiyZYTfv1dqT4GUI/05LuUc+bh8nf3bmXVDgsxedH/yXjNNMaNfMvUS+6NtnLztapz56Ci6+TiWf+vZBKCtoO7m1P+aOUfqQlxRGmzOxlc0r9JqxilGfE0M+cBMA/Bf6++mmeZc8dd07PVL/6DAaWbKoeZXh8TDxOd/Ly0L8riqg/XOhrTlJC5SxGddKjfqSu2YjLErII2d3fnejAah8Yh5Ok7PmCmvSyO+7sakux36qjOFyo/9LrZ05SfGk0ST9ykuJwqurBWGQ4VXsGNNe+cb+pjftNXS9Jen3r/JkzZ84emHt68yyeY5Nu/QcMGNC/R3MXASo8I2WTVasWExjIiotzGzGClpen63CQqkF+f9XoTW9oktCFXT0XcUwszQTMAuMVp+eusJ09dPypp/KIioqisllkZKS2I0EQ5Aea64j5Qzf3Pfj30ADbIzsmN7WgAYi+nF04fNFdEc1lwjQ/69LKkZhlw8bu9OCPbz8qoHXpn/aYtaZum3Oi5Z+vt07bNOTR4noMauvWAWbpNz1g+f/+ub58xtE2R35zZwGQ6Q+X//FvBGHsO318/Z/vW+XR988+jicYzq0HtnKi/IaT237CmNpH1rzbGjDO6+S2kfVMaQAgibm+esTca9mY9ZDJg360ld8+TndqOaCNS0nvllnWtuYYmfz02sOM7p3yr40jjrq6ceqkQ4kEsBSy79NHKC7Yp3bHKfZI0Gn0ULeT/zxfNewPr1Pr/Dz4AEDkfAia67/qmYzXdMYfnfWozKIIu3UnAWfU7dyB8soT+pmWmFn3kX52Fw7dXDJuk/fB6c2sGABACiMvLBr1V6iC4Tl8TIf8hacEnYb2tT116N7KydubHZnqY0oDRfL9tcNmXc5k1pqz9LdfZXhDSUuKI0xZ2WturOtf0VIfMYrRz5wExZtjh1+I6d6zVwS4Ki8DVLJko36UAQAQyR8+pJKCNk0ofyVZcVTqSCF6mpOU+031LGYwqauZjrdw19o4SXW4oLwHSnikIeckdQaTk9SGU9XeUhYbTosW99UnTXl7dffS0b7eliwMo/Ecm/SbtuH4g8hsheaeQpM6d+5MEESpd799gP6o/gGo/ZfbosWHx4+T/viDpNHK047B/Mll6I/SX+n27t17/Pjx8h7/skfr/HqWym/dI2UhVKh9+/YdO3YsNTU1IyNDG+1LpdKcnBxttCwUClNTUyUSyerVq6mcmp2dnak3npmZieO4NsJOTU3NzMzURstSqTQ3N1cbLefl5aWmpkqlUm00npGRoY1dTRCE9na1RCLJy8vTRsv5u1omK3uAEAqFvXv31tgTS2+Ms6EBo+6yULlKj8O//NWcCXTPOU9LeByRfmdWfT4GGMY2c6ldr7otn44BRrdqt+ZJTulvj0iSlARPcaIzm20IL/AGj0jb340NjOrzQgo8U97D2bWYGCZos+mTKnETGcGz6vExjMZ3ada9b6+2NcwZGMZw9DsQWbCV7CO9OQAYb/CZYvNUlHdc/G5HbycWBhiNbVbNu0Fdd2seHQOgmTaZdzvtV8fz2wdOn6OljZDS0HUtjDHAGBY1Wnfv07NDIw9LNs2kQYB/Ey6Gsaq1CVj5vwSVjh11O06tR0T209VtLWgYYExjx5o+TRrWsOXRMMC4Xr8di1Qtr37sAG2kJUmSivANzZhArzb1niqnYj1NSyL5yqSaPAwwjGPpUb9ps8bejkYMDDC6TccNzwucEfD407+5MTHAGMaO3g19athwMcCYDr12hInJYu0bRFpSHGGUZq8qceb3Xgs5SXHEKIE+5iSRuKszGwBjcAQlMm2+JkxR8IGVKdkoHmUkSZI5Z/1Nafzu+5OVvsJUaCMnVehIEfqYk9Q7TvUsZkipW0ShabYqd5wiyjmpwnBBcQ+UwABykiTJ0l6agpQds4aUk5SGU1VysuhwqsECP8uqTrdxf+67EfYt8f2NvfO7W0WdXDqsrUe1UZfK/u01UhVlDBgQu3mz3bp1Nps3A/VVFxGk/Jgt5529XKqz81rqes5NZeLp6UllMy8vL21HgiBIAZh5h78ehJxYPKSlMysj4lO83KpBz6nbbr28vqCZkdLVGNjN+vW0J97cCk4uYwU8fsvFW8a60oWPVs7YH039LI+Ztf/rweNDc/rVpkXcv3b7Ta5Dh3GbboacHOmmkalonNqTzr16fHChfxsPXk7U+8/JpF3DXlO2XH99f11HC1WWoWDVm3vlzr9Tu3lzE5/dvvHws8yt36r/vX58YMf6Oe2cWEkhVx9GiVRaI1DdjlPrEWbcdOGtt3f/mdm/iR2e+DH0QzLDvX3An0HPnh0aqpk9qyFkSvCtUAXGrteojiph6WlaYtY9/nn69MTyER29+DlRb16FxeOOzQfO3nX/9bU5jQpcXo/mMGD/49tbJ/VoaE/EffySaVS336zdD16fn+TNoRwiAOhRWlIcYZRmr2pd1xL1Rwx9zEk8ITYBByAVkrySiWTUF6YztGSjfpSJn958kMtr49fVSo+WJvpF/eFCH3OSOs2dxfQndam1rqPTtyrDhdp7wLBzUnP0JycpDacq5GSx4RQjSc0uoA0AoMj8fO/iqdOnTp69/SGdPuB01qkB+vdjdl9f3xs3bmBYKeeVdw8rNhxDVreNqo8g6fTEefNyOnZ0nj6dGxamjaD0lFym6wgMBKPUAvC+fft4PJ6/v3/5nkCanZIlKT74YRidyebyBHy2Zhd2Ut/+/fs5HI6vry+dTjczM9N4+zKZTCqVGhkZabxlkUgkEomMjIwkEomDg4NQKFS+/c6dOydOnEix8aysLGNjYxpN8z+SSktLYzAYpqamGm9ZJpPJZDKBQFD2pioSCoVisdjY2JjFUucy9splZmaamJhofFeTJJmenq6lXS2VShUKBZ/P13jL+bvaxMSEySzjSyqRSOTv719pVzaXh8yv02p7tcDw6xMor5FgiIRB/audGxJ3aqAeLU+BlAqlJaJvDD4nq2iyiW5NrN79TMvj4ScGmutlBbocDD4nKaqiqWuQUE5WasWHU02+yIqs8OBDqyf2rO9gV7Pz6FVnYxz6Ltxz/cXOPvpXfUZ0CDc1jd6zR1S/vvuwYVWr+ozoD+nlcc62JbCxsTI3NeJyje292w1ddPhVOrpAYfmZmJjMmTNH+Tbu7u6jRo2qmHgQBCkvZuNJ09vRHhw8HlGpx0j8W1yyg4er5r/XQbQCpSWibww9J6tmspGZ1w6cTfYY80fvSld9BsPPSYqqZuoaKJSTlVhJw6kGCtB4dsS9I2sm92rgaFej46g/z3y16Tl/9/V3CYnvb+xdPqaLtwX6LTvyk8TTMzIoiJGe7hYQwExK0nU4SFXFbDJ11/JeTgyMZV23y7BJM+fNmz1lRA8fWzbdstlvM/6YMLCFVeL1DSNbdVj0uIx5uwgVixYt6t69e2n3mpqanj17ls1G31UiiKGgOY9YPtHt9a7tDyrtECl9uWvE8EOW08c00K9faSKlQ2mJ6BtDzsmqmmx45MEtl2h9l/7RpHK+LTXknKSoqqauwUI5WWmVOJyqX4DGcyLvH1s3pY+Po61X+xHLT0VadZ+7+9rbb4nvb+xbPraLtyWqOyNF5LZu/fXQIdNLl5zmzqVJJLoOB6nCaLaC6It3xO03PPkSev3ojo3r1v0VePDKyy/PNjaKeZTSbP6eM/c+ht+aVePLP+tO6zrWyoDBYFy4cGHmzJnFFy5o0qTJkydP6tWrp5PAEARRE6/Fgk0jsaMrD0RW0hkrdJsmEw7cOzPGXV8WZEIoQGmJ6BvDzcmqmWxk5rU1Wz61XrFukG0lnP6cz3BzkqKqmboGDeVkpVTKcKpuDV56aVS1vkezgW1br/Oo1QMH9u1U1zp/QnlOenqhLTG2kbmgis01R0qQPnx48pQpjosXG9+5o+tYkCpP/uzIoffWw25P8zEuOCAK6k5eOnR7+xW7ZvVb2cCy7eyJrQOXPQEYqaswAYAkSYIg8v+hUCg03j6O41pqOT9sHMfzG8cwbP369ZMnTz537lxYWJhUKnVwcOjatWu7du0wDFM1gPyYtbEGNGhzVxMEUQG7WrO0tKvzrz9huLu61AtI/KCNZ9czmHmXDecOnv6SnUOCWSX8oM5w9Gmt6xgQlaG0RPSNweZk1Uw2eRqz9ZrzXfzdKnOdyGBzkqKqmbqGDeVkZVTKcKr2JHCZREqSAJKk0Ms7Qy/vXFjqhpyB+nkRQqTCkCxWwrJlwqZNXUeP5n78qOtwEASAyEzPJHkCfrGiGsYT8Im4mHgcGjAwnoCHlXXpPG3DcVwmkwEASZJlXsdPDQRBaK9lAJBKpXK5/OeNlpaW48ePL7iZSCRSr3GxWFzOCJU0ro0dkv9dgjZaxnEcAKRSaX6qaBZJkiKRqMx6q3q0tEPyc097LUskkjJ3iFgszt+4MsOM6/YZU1fXUSBIISgtEX2DctKAsDy7jPLUdRDah3IS0TcoJyufUoZTdQvQdDffcRMt5GVvCMyGlforRKQMCiurmK1bMYXCffBgRpHZ8QiiK8zaPnXpx0/vu/tHg84WvwpJZOaDfac+0uuMrMUEIFKuXwnB3SboMEwAYDAYHA4HAGg0momJicbbl8lkUqnUyMhI4y2LRCKRSMTj8bSxuHNWVpaRkZE2ZkCnpaXR6XQt7WqZTCYQCDTeslAoFIvFPB6PxdL8z40yMzONjY21MQM6PT1dS7taKpUqFAo+n6/xlvN3NZ/PL76YTBFMJlNLM/QRBEEQBEEQBEEMjroFaIbP2G07x5a1lUKUlSNhCKrWWtvIL5IaNWK2bRM8eWK/ahUmp/J9BYJUCJrLqBW/7+u2qU+jTwGjB7SuZS+AvMSPj87uPxycUnvu7rEu0cfG+885/ELUZvtwXceKIAiCIAiCIAiCIAhiwLRaG5a/WNa4VWCDILQER5WU7eubsGKF1e7dVvv36zoWBCkCM267/vYN25nT1x9YFvwvmX8b3aSm3/rrO2a2MiKefXyV6jzor782TXTXcaQIgiAIgiAIgiAIgiCGDE1ORrQAw1JHjUobN85p3jyj+/d1HQ2ClIhm3XrW0VdTt0WEvv6UkI1zLF3qNqzjwKfJUt9/xhutehG1StcRIgiCIAiCIAiCIAiCGDxUgEY0jOBy49eskXh5uQ0bxo6K0nU4CKIcy9yjSUcPAMCzvtw/s/rPE0Hngr92OJ6JfrehFQRBvH//Pjk5mcfj1alTRxtrTyMIgiAIgiAIgiAIoldQARrRJLmNTey2bfTsbHd/f3pOjq7DQZAykaK4kCunTgSdOH3tVaKEBIzGtW9exwFdPEzTxGLxxo0bAwMDk5OT829hs9l+fn6rVq1yc3PTbWwIgiAIgiAIgiAIgmgPKkAjGiOqXz92yxbju3ftVq/GFApdh4MgyshS3tw8GxR04uSl/6JzcRIwhqlXp6H+Q4cN9WvraULXdXiVTFpaWvfu3Z8/f17wRqlUeuLEiatXr549e7Zjx466ig1BEARBEARBEARBEK1CBWhEM7K6d/+2bJnNli0WJ07oOhYEKRWeFX7/wskTQUHngz+my0nAGCburXxNwu+8b7M79NRAjq7jq4xwHPfz8ytSff4pOzvbz8/v2bNn1atXr+DAEARBEARBEARBEASpAOoWoImUsAfvknHlG+EfYsRqto8YDpJGS5k+PcPPz3naNH5IiK7DQZBSBQ5stOZK/kIbbCtv3zF+/f38enesZxmzvkXt94Bhuo6vkjp27NjDhw+VbJCTkzN79uzLly9XWEgIYkDCwsLCw8Mr5rlwHCcIgsFgYAY1IJIkqVAoaDQanW5gP19RKBQkSTKZzAp4LrlcTqPRBg4cWP6mPn369OHDh/K3QwXKyQpWkTmpUChwHPf39y9/UxEREW/fvi1/O1QQBIHjOJ1Op9EMab22/JzEMIzBMLD5Z/k5WTGDgEKhkEqlw4YNK/+LGxMT8/LlS41EVSaUkxWsIk9M+Tk5aNAgNru8lydKSEgIqahajYHmJADI5XKUk2U+l0Qi6devn0AgUOPh6u5Z+YMV3QaellDYEs0orNQIwOK2bpW5uO56OhsAACAASURBVLgNH86OidF1OAiizIMrLxNlRrWHrdi4dEQHL7Mfw18Z36Qh5bRv374yt7l69WpSUpKtrW0FxIMghiU4ODgyMtLDw6MCnksmk+E4zmazDesDA0EQUqmUTqezWCxdx6IaiURCkiSXy9XqsxAEIRKJJBLJo0ePNFKAfvjw4evXr2vWrFn+psokl8sVCgXKyQojlUoJgtB2TpIkKRQKJRLJ3bt3NVKAfvbs2b179+rUqVP+psqUn5MsFsuwvl0gSVIikdBotPKXsSpYfk5yOBytFlZIkhSJRGKxODg4eMiQIeUfcEJDQy9fvuzj46OR8JRTKBRyudzgchIAxGIxysnSkCQpFotFItGDBw969epV/r308ePHs2fPNmvWTCPhKZefk0wm0+AquQaakxX2Bl4kEolEov/++699+/YVW4Bm1Bq0eLk3lWV+Gd61DCzrEKpkQIvBBCwGw83fn56Xp+twEKQMFuYs7Ftu2PF5w9/e7u/v7z+kdytXI0P6RGuASJKk8mU7QRAhISF9+vSpgJAQxOB06tSpV69eFfBEeXl5EonE1NTUsD4wyOXy7OxsDoej3lthHcrMzMRx3NLSUkvtkySZmZmZnJzM4/Hs7Ox69OihqZbbtm07ePBgTbWmhFAoFIvFJiYmFTMnV1MUCkVWVhabzTYyMtJ1LKrJyspSKBQWFhbaK6xkZWUlJSVxOBw7O7v//vtPU802a9Zs9OjRmmpNifyP38bGxob17QKO45mZmSwWy9jYWNexqCY7O1sul5ubm2uvsJKdnZ2UlMRisezs7EpbMk4NDRs2/P333zXVmhJisVgoFBoZGRlW1YwkyfT0dCaTaWJioutYVJOTkyOTyczMzLRX8c/NzU1MTKTT6fb29u/fv9fUgFy3bt2pU6dqpCnlJBJJXl6eQCDgcAxsOmpaWhqDwTA1NdV1IKrJzc2VSqVafQP/Myft7OwmTZqk9oCsbnz0WgMWLRug5oMNQdR7XUeg74Qc4zjbmiZ5yXatasOTa7oOB0HKtjM6YfLN08ePnwi6dO3fhf/7dzHPsUnPQf6DGiVLdR1apSUWi6VSSrs3MzNT28EgCIJUHUKhMDExkSRJJycngyvNI5WSWCz+9u0bjuMODg4GV5pHKiWxWJyYmCiXy21sbAyu5IRUSlKpNDExUSKR2NraopxE9IFUKk1KShKJRNbW1ubm5uX8OkS7M1wUoqwcCUNgLjCkL4gRCjKMbZMsXO3Tokxzk8Gktq7DQRBqmJZ1ekxa22PSGmHMf5eCjh8/cebW6Y1PTwEAMEQnt56uNrxXY3uOIS0zqfd4PJ5AIMij8AsJa2vrCogHQSoJUY42WhXQQMBjgUwEMm00ry1MAEseC4DQ0m6Bwa200iyAmXaalZuYJ3cZnFvDx9LFzdLSsoJWT07/po1W+QB8DCAnVRuNAwCwtbLWBAPAkkMHUECedr5bFWgpd0BL9Q6FQpGUlJSTk2NpaWllZVVBOSkVaaNVHh14RjwgFSCl8ltg1eWka6NVOoAlAEjFkJqtjfbBXFurqJkIeAAAJA64JhfNw3E8JS09Myu7QnPy6f+00SoXQLuL5tRrq41WMQBLPgcAQKy1H1KztDIl3JjPBT4XgACc0GCzP3PSzMysWrVqFbTwlFwr07A4dIxjYqS99rU0TgKAJQaAyyBdK6cPAIAvr7XRqhGANr7UxTFaGssknWlkZmHp6OiokSn/Wk1r+Ytlja0dRl9CkwsrERKwREu3FHNn58T3prnJug4HQdSB8Z1b+s/753JofMK7q7sWDm/rZkxGnJk3qJmzfa0u41YdfZFK6jrESqRNmzZlbsNkMlu0aFEBwSAIglRiBJOV0qn/l1mbAMBz46yKq6ogSCnyf2UfHh5OkqSnp6e1tTXKSUS3SJJMz8gMj/wqk8k9XF1QTiL6ICs750tUdH5O2tnZGdZlD5BKKYsp+MKzF9NY7qIkOzs7TS04Y0hr/CE6h9MZcTY1FTSGe8IbppzKNSgRRK8xLby7TVjdbcIqUdzTy0HHj584fePW3iUPsmsMPDXAkFZR02uTJ0++evWq8m2GDRuGfmWGIAhSHrk1fRJ7j6TnZrvuXcWNjdB1OAjya8lIFxcXHo+n63AQBPKEwsSkFAzDqjna81FOInpAKBIlJqWQQDrY2Rih9bIQPSCmsxPZ5gqg2UkzTBQangyOCtAIVVImJ9bOmy0VuiW+p5Ga/L0JgugaxnNqPnhO88FzNmd8vHP2TKIL+tZZc3r06DFkyJCgoKDSNnBwcFi7dm1FhoQgCFKZSOxdEnsGSC1sbG8Emb5+BCT6FQ+iY5pdMhJByk8mkyenpuYJRdaWFuZmpignEZ2TyxXJqam5eUJLczNLCzROIrqnwOgpbNMsOs9Snmslz8a08H4SFaARSvJ4ZnE21c1zkmwyYtAHG6TyYpjX7DJuia6jqHT279+vUCjOnDlT/C5XV9fLly/b2mpr6UAEQZBKDOcJUjr6ZTbpaPbsjvOhv2hSsa4jQqo6HMfT0tLS09PNzMw0tWQkgpQHQRBpGZlp6RnGRgJPNxcGAxVAEB0jCCI9IzMV5SSiN0iADKZxCttUoBB7ihOZhHYucoAK0AgV6Sb2yRYu9ilfTPO0dhEYBEEqLy6Xe+rUqdOnT2/ZsiUkJIQgCABwdnYOCAiYPXu2sbGxrgNEEAQxNBgtq0HLpO7DuXFfPDbPYWWk6DogBIGsrKykpCQOh+Pu7s5mo7XMEN3LzslNSklhMVluLtU4KCcRPZCbJ0xMTqbT6C7VHHlc7V4/EkGoyKNzEtnmNCCdxSk8XLsL7aICNKIMidG+WXnk8UxdE95ypVq7QC2CIJUdhmGDBg0aNGiQUChMSUnh8/nW1ta6DgpBEMQgCd1qJfYKIBksh1M7jMLf6DocBAGxWJyYmKhQKOzs7ExMTHQdDoKAWCJJTEqRK+Q2VlamJmiuA6J7UqksMTlFIpXmrwOj63AQBGQ0ZiLbTERjWctyzOU5FbAKjLoFaCIl7MG7ZFz5RviHGPRLQAOG05mxNjVIGs09LpSBy3QdDoIglQGfz3d1ddV1FAiCIAZJbmKe3GVwbs2GlvcuWj66huHa+o0kglCkUCiSkpJycnIsLS2trKzQMqaIzuE4npKWnpmVbWFuZmVhTqOhS7sgOvYzJ81MTao52qOcRHSOACyNZZLGMjaT5zmKU+lQQavsqluAlj9Y0W3gaSqzszlqPgOiWxIWP8a2Jk+S65D6BV1yEEEQBEEQRIcIBjO9ZdfU9n2NP7zw3DiLkZet64iQqo4kyYyMjJSUFIFA4OnpyWQydR0RUtWRJJmRmZWSls7jcj1cXVgslJOI7mVl5ySlpHLYbHcXZzabpetwEASymIIklimbkLuJEjmEvCKfWt0CNKPWoMXLvanMumB410LrfBiaHIFlvJWnZXaCdUasrmNBEARBEASp0nJr+iT2HknPy3bZt5YXF6HrcBAE8vLyEhMTaTSas7Mzj8fTdTgIAkKRKDEphQTSycFOwOfrOhwE+Z6TBEk42NkYCQS6DgdBQExjJbLN5TS6rSzLVK6DJXbVrQ3Taw1YtGyARkNB9ESqqWOqmaNj8mdjUYauY0EQBEEQBKm6pFb2iT0DJLZOtjeCTF8/ArKCfiOJIKWRSqVJSUkikcja2trc3BytuYHonFyuSE5Nzc0T5i+ti3IS0bn8nMzJzbO0MLeyQOMkonsKjJ7CNs2i8yzluVaSbExH7yfR6jPILyRGi7f2yjS2dU94h6rPCIIgCFJVEJnPDy3o1aKWmbWjXf0uw/66Ha3di2BriIGEnZObteBlhNuN99zrH73+i1uTIpcWup+MT00d9STc/noY+9oH54fRU2NE6STgXH5ir4DIaWvZad+8Ns8xffWwClSfpf9tHT/k37DSf2NZ5gY6g4dvaWJujhmV8MeovyxEDyNWHUEQKSkpkZGRLBbLy8vLwsKiilZVyJTzk5tUa7fulV6/rNL/tk0csvt98RhFUTdWTB5Ys44319HLslHv/isvhgn1cWwRfbm0IqBjTScrLt/E0rNl/4Unw/KKxkkQREpa+peorwDg6eZiYW5WeXNSEf/s7KjfJ9l38mO3G+I84s+pFz6nF14mUxT3dMXy+TV7Dea28bPsP7P/jvthYv17ZUWX/G2MMZ5RoT+zAQcz9S/UYijmZOqPnPRyd7W2rFLjpDz+9sZRvvXtLU3ZJnbOTfpN3fM8Xa8XczWsdx1qDgIkQDrTOJxnLwe6pzjRWpalq+ozqD8DGql0FAx2jG0NjCDdEt4w8ApdCAZBDA+R8ebswaB7oTG5Auf6HYaM6l/PrOh7C1IcHXz04IVHHxPFLAuXep39R/ZtYMkAMvPa0rE73/w6xugO/dcHjvCiV2wHEARBfiDTrs/q0W9vrG2zLkPHOUneXAr6c9CD9/tC9vez1+eJCgYSdl5mim9I8nNgd7O3GEyX/5eUvfi5MKyB+1F7Zn6Y6Snf2j/PiGXx+jtZedIUL5Ozdrz7+sC036Els0wTY9y3L2SnJOi4DxWFTL8d+O+NB90DSvu4WuYGOoQZVfft7+de5EMqnvTs6tNkewcrfcpJ9WRlZSUlJbHZbDc3Nw6nKl/kh4gP+mPywfepbp31+fMSmX4ncPfNB91+K3KwyCOO9O+15EauTYve/gMc5ZGPrp0NnB787Nu9s5Pq6dPitPLP//ZvN/1Gjl2LAf9n7z4Doyj2AIDP7l5vyfX0dilAgrTQBaRKFwQBFQERAfUJCKhIEZ6ggIhUCwIPBJQOAaRXgRAkIL0HSL/ecv1uy/sQaqhijt1L5vcJrkz+Nzc3O/vf2ZnBveMCNw5u2jhr4IHsokN7xtbh3n6Nw+kq1ek4bE5SQhyPy31ieaGOMucsav3ZrsLwtF5dX0/h2E8dPvTjt+OzDd8cHZpWvgJOoHBHr2E/7XbJm7Xt0FtN3DiVvXHVdwfOmQ4t6FWHSUthE6W38r2oun7H1hr+vUfZdRLZTM/SPmOb1Or1GIolxMUI+Pwnllf1UOZdn7TutbRQ0bDXoNEpXMOprWt//M+r2SW7j05pyMx1mkJq1PGcncD+87aViz+oyaLiPQYh6XvKHwk+mICGAADAyxUVRNQUu62Rphs0Xg+BoBBBFGz65usNRKt3R/STGw+vWvb1DGz2Nz1j788hU/ZjP0xeeCGuxzufZkZS+Qd+WzltctlXswensw06A5LabfTr6bfH+Qg/mlHJEgiCqhfKvu+rYUvza4zMOjS1aRgCADWi29BWvdd9s+DjbtMbMHagGCJhU74FFwy5iOj7ZvEjxSgAgEyRfXb81tzLxsHqqHYYAJR/+XXrTY5keYu4d3gIAMDVvu6onYeXntL/vfKnwQVn6P4ALwbhMRdfPH1k1dxv1xpI9fO8gH5oZKdpizs9+BiZv7xf5t7MibMGJYXycd7j8Wi1WhzHIyMjw8LC6A6HZsStX4eN3aqnEKZ+pYTHUnzxdPaqubMe8WOhyrbM+m6PPebdZVmLX1WgAABy5L6Jb3ReumDipt5b+ymZkgKkbFu+mrLHGv/uhsOLu6pRAAA5ft/otp1/mDFxTf+tAyN8Pp9WZ/AH/GqlMjxMQne4wUfqli/bd1PSdPnSce+oUAAAeLfNp+99MXvdxqx+X7wlQQDl2rJk5R6H+t0Z3y1+ORwFAJD99s0d13nD2ol72mzt8tA0GfoQBTfzSWHbz5f91i2k8rNPa5N+n1+rN3h9vvJ1YOgOlw7EzeXTV96Uvbb82G/vRGMAADC+/6fN2s9eODtrxOq3ZMxpgyAkRx3/vBPwg/5d5n0+aO3vC//osrMjiyHHLMYM0CH62EXKEmWy0lqktBXTHQsEhQL/uT/+uBXTa+7wjrEYABkKW97Ybdsvdhn+0r2pI5Q1Z/dfeJMRnw1oIUYASK8R4b41Mmvv+f7ptQ16qySlSYtmteGcZwiC6EdZtizeWBzWZfanTcLKzw4QZbcJC3+ol6fiB5g7UAyRsAlX2eYyEBOvGi6+PfJHOcIJyZIlp+2/myPaqVBAuI+UUeIIaS8eEpBI9R37laXXe+1K52WFJ2+cs4EwRp2wBQtlWtvzpU93+8v/94hTpKe+gJnIkrWjphxLGr1rdDqTZpb+EziOGwwGm82mUCiUSmV1upH8MQLXFg6fcDjxzX7R69a56Q7mUSjTup51P3/sjwW/dDi3DEt/f0w7xZ0uSdbmo/7NVkw5cviMr197psxsx88dzrFhL40c00l9J05FmzFDm/0y+sj+vwo6NnXb7HKZNF4ejaIh0yH8K+6rR67h4lZteqnufF5+So/Gijnriy+WkkCCAeLW4XMuLKXnmGbhd2pM0ubtTs2yfjly8pqvS2OmfLOAshYUWJG4lAQmzcp+Fk9sk0WdmzstVml4WFxMVHVpkw9znjhyxi9+7a1e0XfOcYUNenSImfPD1Yv5BJAxZWAGQnTU8U86AQAQAyfMxIlrNbBns41z/vrrlL8jUzoBBrUDiBYGWZxZEhWnuyzy2OiOBYJCA1F08bIzokmDqPKjKxbXoJ5q4+lLWvKl+LsHKMoR4MZnNqwhun2uhikj1Sy/x42TRr2BUtVSkR6r2cWSysWMv+EMgqAqzX/yYI6b07Bta8m9zghLaDPswzY0BvV0IRI24fWXAKARsu8/1RYLubGg7G+bn1DxMIQ/NCOmb5jE0aqb+ZXXJJdPpc4aU3jTQSFcZbU5PCDhr87bXtNGAsqyY8SAnx+eDfHUFzARZd4yZdou5XsHP8oIxfQzRVEWi0Wv1wuFwpSUFDY71LJFQeE7O2f4pDO1p+z/hPiAoQloJLzDvG01bBSgzLtGDFpU8ceCu0F4Yu1mL2numwSB8Pl8AHB/gAH3mN8RcAFpSu1WDe6PE/D4LAD85hKvP5CcmMDhVKc2iSUN/XREv/jU+1JIpMPto1CZUoICAADuBZLo2vVSNPflyhAulw8A7scZ9M0CIv9mAcFO00gL/tycc0HrFsTWbdOmYbyQ8ce7R7VJhC9gIcBvKXF5vJqEeC43FDv7ysOqO3TBz/1SG93XSnGHw02hkUoZM3K4d4TkqOOZOwEFR3CdK+WQeJJbywW4gGGdAExAV18kihWrUr0cQVLJWW7AQ3c4EBQySJPBRMnvHUpRmVJGmQxGEtxLQKPx3SZ8d+8thOHwgXMguW8anyzVGnHjgemDl92yE4AlTmj+1scfdE4W3Bl3lZSULFiw4P4/l5aWBgAgSdLhcFT+ZyHJIJVMEAQAwOPx+P3+Si+cJEmn0xmkqVghV9U4jgMAPB6Pz1f5C3sFtaoJggheVZNk5Y+1yqva7XY/dXqLx+MJRgDBQOpv3XQiqsTwGys/778wK/uWOyyhdtNXB00a90ZtEXNPCEMlbJSNhQFQ6sFxwLl7Yur3BQyAIj0BAvAwjNuiQ1Ntt4FOV1nEoqnem1f2G8xjS4ioSHmfkLo7+V9hydPqyQEAlP6C5JHf3lNfwDzu43O+2ET0+t+IJsxc+fKJnE6nVqtFECQhIUEgCMEPEBzu3G8Hz7ja+Js/R9YEc+gO5rHu/VguPuLHwm8z/0CFq3Rk8fadOTi7boN0hsyPAwAAQaf5px5Y0Mbldv699PcTOLtOy5apsdHMyma9APy4zl3iAAAAUF6Xw2Izns/ZMnZPWdQrQ/tEIAAAwMucvyLzwfdQxX8eyyFYdTOSGPTNAl/+zVKCtI9r2lBrDlAAAIBwIlqO+9+yKa8wZgWYR3qoTXq87lNLfj8RYNdp0SItLqbatcmHCWt2HlATAAAA6S2zWkxF53cvGLvGHNVzdp84hlVPKI46nqETmLmqmZYrs6Istd8WHnACQBUxrxOACehqKsDiFkTUZBEBTfFZjGTGrp4QFCIIvw9H+Hz+ncMRwufzEL/P/5jV0326Ext/XrTpRlL/r16NAI5z1gBfpOk28r8tooH+7B8/L1jyzRLl/I8b3U6ZlJWV7du37+6b69atq9FoAAAURQUjvXj7ExFEkErGcbw8Z1fpgpHXLkeSZChWdSAQrM2QglfVIdqqn6WqK/Fz4TjudrtttgfuUgrnVNpQnnKWOSjK/sfYDv8LJHfsOqwDR3ti+8a5w/bmag9tGVmHOSPWB4VK2CyxuA3P9FOx8ffEuEHlRw3cM/+G3UgBAUF5FZGlXQd4I+NU+zfKTuyafuTaeDsFAJDK1Dtqh0X963OeCs2GqqRNPnAc93g8FdtkpRRdZZC3lk79taD2mE1d5Qw5dX1Gfr9fq9W63W6VSiWTySr96mPw2qTX663YJvmVOhvRcfTLYXMLW87e8H4yC+RVZsl08ufvmt5nyp+u2Dcnvsm0FNFtgQCuN5Zc2Tb1s5lHPfHvTR6aXrlxVmg2lXXx+NFt8t+XSxbP+fjj8ZdxABBpnbd3jHv5MfvIBPKPLO+z4JQrsuPErhEM+maJ4hsFASpAJA5asXdU2wSgPbVtzohxK6b1/zA+Z+3gWAZF+gQ4TugMxZe3Tv1s5hFP/HuTh2YEtU0SBFEpXSVBED6fr2KbFAbhWjdxbc6rDcefCgCASptP2vFjL7jbUWV6VCdAIJiBE2ZlCRUBh9JrRyiqcjuBh9vkc3eVMAFdHbl5ksKImhKXOdJ4AwFwy0EI+mcwDhej7B4vBXgIAABQHo+XYosfcZ4T0Oeu+/mXrAugdo/PZ/dpqGIDwO3w5ZoOd56PbfTmf14/89HaP8++36h5+fE/MTFx5cqVd0vYu3cvn88HAKAoKpFU/i4rgUAgEAgEY36T1+v1er0CgYDDqfz70RwOh1AoDMYiazabDcMwsVhc6SUHr6rL5z4LhcJg3CJdVlYmEokqvaopirLb7UGqar/fTxAEPwibj5dXtUgkYrGeMnzicDiVVWkURZEkWfFCTuX9rCgcxymyTC8cumb7Dx3VGACAHPfOJ+26Lp01cUO/rf3VzEyfhUzYqHBcDcmWM/b3j97YGSlKQfHjOnsuYKkRvyu29c2RI9Qn9setWYB63QCwXq8Zl+AJ3LCVLSkydM1FdjRUNvp34/QgXf97dJtkSo0zguvIT3NyuN2XDKgZOrs9kCRpMplMJlN4eHhqaiqGBSX0Cs2mshLQj26ToPKGH5Rt94QPF5g6LNk6IBEDIFjXN18of2n2vP9Onrbluj++688rJncMZ9xvmCRJk8WqvbRj/dyZC/647k/q/fOm7zpW9nZ6wesnKYqq/MIRxesffpags9y4nLPkj9+7jsV2zH6j0YPjHb/h7LyFi6btL/JHvfzzt+93FDPpm0VVPb5eXY9fo1XjeAEAACS1GDRvG9BmfLRv/opLAydkMLzLpCjKYrUVX/gjFNskSZJBaZMPQ6Nf/2ZlQqH2xsmtS36d1rUntiPrs0aioP/Z6uKhTmD1vPdipOEC3JvsLuVQBAhCJ/Dwsfu5D98wAV3tWCURWnlipOmm1KGnOxYICkmoXKlAbpmtJAjHAACAtJltiDxd/mC2iXJfWTd12gZjaq/PF76eqX7MWRCqiI7iBqwOLwXK58bxeLyaNWvefT4nJ6c8jYUgyFNzXs+h/IQtGCWXh41hWDAKL6+NIO3yEbyqJggCVnW58lFLkKq6fKoIvVVdiX+dzWYLhUK5XP7Ao55KW7oE4Qv4CMJpNnxSB/XtEz9U1n70kKYrxh/e95e7f3dhZf2lShVCYcdExx5h8ybmWXcVmbah7PqRUVs6xo1edlwri9EsmCA23F1aEE1TSNIAALGyt8T5dS4aJpWG74xj/5vfXoVmU1mzWVkslkAgqNgmLdpKKbwqoIybf15fFNlrcWcZkxI/T2Kz2XQ6HZfLTUpK4vGCeAdBhWZTWQcXFovF5/Mrtkl/ZS0wSNn2TBy2zN1z2Zy3q8Z99pQ999fJQ6ZlnfdFth0+b86Y1zIYlaMEAADgcLpKtdcurZv+5eytF/0xbT/5dc6EvhlBuBn+hbbJfz91HuGnZTZLAwB07fxW4qQ6c9ZO2t1mZ4875yCUM3fzL0N+Onjer2z75pg577bKYNrayoi01iuv1nrgITS6a/emn+w5dOaCE2SE0RTXs3A4XVrd9Ytrv3nBbRLDsEo5fLPZbB6PV7FN4kG4zRERp7XukQYAGDj0rVpd63wyc9Ka/juHwGnQleS+TqCHZnLj2eu+2ttvRzefmPABEKxOoEKzYbFYz32VGiagqxEKAIM8wSJWx+suCT12usOBoFCFxaXXFG45c9b4ZmIEAgCpO3tOJ66VHv1AN+w9v/L79WXNx383vP79c0rcOQvHrMTfnj7y5TAEAACIkhsFfml6LPNG/hAEMQWCIEFahhsAgKmjoljI9ZgYxX1nBmhEbDQbnLDZ3BRg2tlruZAKG0lQqVapVAAAT6ymtNsg75X/GXCQXLheiHH8buc6Cx4vD29xbwobEq8UZwDXlTI/Af5VAjpIzQa5IxiFVwFkUdbS/a6EoX1bhsIq3h6PR6vVBgKBiIiI8PCgr6QSmm2SNJw/XxrQru2vWdv//sfnNhHNxZJHZZ/5unEInVITJRvG9B+wukjZ+uOs6R92T2RcM/X6fFqdwefJ/2v68A9+L1R2+CJr3qfdk4O1Fnnw2mQlFu4vObvunDW+fqsW927vQeObNMhAz1+5qSWAHAUAkMYN0ycN2K5XNu6bNeaN7jHcSvnTLwAiDg9nAQonCIqhN9P4fH6dweh23jw+ffhHq0O1TQa7cP/Ng+uO6eNb9WlxbykVLL5Dhwzs8JWLNwgAE9D/SoVOwI+y9Zxw0Kp1rTlnC6+c5XXOACCInUAlNpsQOlpC/wqJsopUqQE2T1N8hoMHa81NCKoWOC917hw3bv2C36MGt5QZDi7dVKR5/eMMDgD4jX2r/jTX7PJGY9mlP4+aIpukEHmnTt59HyrT1K3dJCMwffEsGd6nSTRmvrj7tyxj+sAuNWFfDEEQPYS1M9OwHXnXisiOyXdODoiim/l+JCw6milbrzwsTNUVyQAAIABJREFUVMKmAodKHHls4RspEY6O/crSGyqObLX+vEcP2ANlbBQA4LKPPmutUUtwKPHewt4UTjgA4GMwxRuKyPxtm3P8sR92rVP5iyJVKoIgDAaD1WpVKBRKpRJeUXg8VNZ0wPgv2t5beIOy5qxYetCbOfD9V2IVzUJqRzz88qIRg9fo0z9cvn3SyyqGRU4QhMFkttrs0nChe8Okj1fr0sdkbf+mLdPipEHx4dHT9tcYUfNQX/W9I4XL7aAQPo9TPqXl8ppZg3eY09+avP3DuoytMfzMvJ4jtkiHLFs+4N7O7cSt63l+NDI5kYHTcQiCMFmsZotVGi507Jg0cg1sk4+Xt270kN9qzGp66ON7Xy5VVuagEL6Ax7zvNtTc6QQO9I2wcMJMHIkEdyebtZ5Q6wRg0qNa8LP5BRE1Obg3qeQcCrcchKB/i5XU+4vPAot+XThuk1cQXbfr58N6xmMAALwk94+tt4imvRuhJaUuvGD3/Km7770L4bUY99unTYdO/Sz813Wrpm8tw2QxqZnvT+3fFl4ShiCILlhqrzfqTvvyl8kbey5/I5YNAMBLt3y7NJeMGNS9EXMnUIVO2BeLtSOc8UUTZ75vP5363WhKf/O9fB9XGjFIggAA2GHCVizL1kLLibiIJuX30VD4znzbFcAaouDBYXrooUz7954JyHt3qFv5+x9UFoqiLBaLwWAQCAQpKSnB2D+gakEUzd+b0vy+B4i8WfuXHbI2HTbpy1Ca+wwA8B2f/8vfvrpjV0xgVvaZoiirza43mgR8fnJiAoc8/NWCv3wNpqyYBjN9AADArlGnlXDP1m27TnQf2KR8zjpp27nh0BVKOiQzngUA8J+fv/aKr8Y7Kz5gbuIJAMBKSpYWnPp95rd9Oi3sqkQAAMBfuP7b/52mkkb3bsC0nshmL9MZjDwuV5MYzyWPwDb5ZOwGrVuF/bp12ZITg6c2KV8HjTDs/GnNFUo9pHV6aPWUDHS7E/hj36Z+nzXE8CS3jocbtq0/GHqdAN0BQEHnFEiL1GmyMp3aUgAqaa8PCKruMGVm/4mZ/Ss8ymv5xYaW5f/sNn1Tt8e8N6Lx2583fjuY0UEQBD0zrMaQaZ+s6zHjvVeuZPXskIzdOrR50ylrXL8l/21f+VtEVp7QCNtRq3HTDhmaTzfOfKtbfgSqDnj36BwXgGhubXkKAgAACCdscrJl7xVjp6PefmpBJMDPG+1ZdiImOmaCgsEnENDjOI/vP+nnNWvGrMsg93E6nVqtFkGQuLg4oZA5i6VDLwJx8+RxI8kRn5gx+uaD/Qsiafr+7DfTaEkNuNxurc5AASomKkIsEgEAiAs5x/UkR5I9Y9iQinG2GDV7ULVLZiFhTScPTN/744ZO7xX0a5EaCaznc7Ozrjhj2o2ekMkFABBFl49bKI7w4ozpJRWOHJK6PWd3jWdKjUlenTil/d4RK3s3vf5G7xaJmPHcvqw/Lvhrj1o3nkmdpsfr1eoMOIFHqlVhEjGAbfIZIPLXJn/ebO/42Z2aXezXPTOS0p/fvynrb1tMn6UT2gRruZLqwytt9d6QfbvnrR36Vv6bL2tCtxNgSBhQsFgkETp5YpTpRrjDQHcsEARBEAQxj6jJ1K1boqd+89O21XN2UtKkhu/O/HTKsJcjGZ7/ZHbYPkWkrtsAT2R8wr71RxtGTbpq3lHotyHsekpVVpqyq+Du3ahIhibhKM/wVb59U77TRqERIsHQDOXEeGEkvGE1BPlOHT7qQJPr1mbQOjB3+P1+vV7vdDpVKpVMJoNrblRDeHFRIU45rx5ccbXCM6iK1W3Wm2kvOJ5AANcbjQ6nSyGTKuT32iRemF+IU85Lu1ZcejjON2YNSn/BcTIAO+OtKUdVa79ad3TTxjM2nBMRX2Po6N4Te2aUH/Jwnb6QoJy3Tq64VeGNiAprOatrPA0hPxor9d1VOTGLvp6/euevC9b5edHpLccu/nzcm7XDmdEh4TihMxjKHE6FXKaEbfKf4WZ8knU0euZXP2za9NMBW4AfkdZ46JyxE4cyZWAWoggEM3DCrCxhvf7fHpX+Mm3dkU0bT4VuJwAT0FUWBRCtIrFMKE/UXuB7HXSHA0EQBEEQQ2GKxh/N2/LRPLrj+IeYGTbBE5heec3ctIP05MHY1QtQrxtIZYuayB7/DjQjOmJddMSLC5GpEPU7+0rf+TcvoB33le+K7d/RHUVFJEmaTCaTyRQeHp6amvrcm9dDt2HJnx6xfUp3FE+GqPvvK654px63/WyzfjYt8VRAkqTZYjWaLRKxKCUpgcV6ICnB7bzEHFhCV2wMhfAy2g9c137gI5/kNh9lPjbqBUf0vHgJ7Ucubj+S7jAqoijKYrUZTGaRUJCSlMhmwzb5zyGijL5T1/WdSnccz4rhow4KAAtbYuCGC3BvsruUQxHq9gPWtR/wyBeHSicAE9BVE4GxC9VpBMrSlJxjwy0HIQiCIAiCgg1BbfWa6zq/zdMWan6cxNUX0x0QBAG73a7T6TgcTlJSEo/HozscCAIOp0ur12MolhAXI+Dz6Q4HgoDT5dLqDSiCxsdGwzYJMYEL42m5MgqAWK9RhHvoDqfSwAR0FeTlCAoj0/leR7z2EkqRdIcDQRAEQRBUxXliNNruA3GBKHLLsrDzf9EdDgQBj8ej1WoDgYBarQ4PD6c7HAgCPp9fqzd4fd4IlSo8TEJ3OBAEfD6/zmB0ezwqhVwmDYdrE0G086MsPUfqxHgqv10WKKtiLRImoKsah0BarE6T20tVlkK6Y4EgCIIgCKricIlU17FfWXpDxZHtykNbETxAd0RQdUcQhMFgsFqtcrlcqVSiKFyAE6IZQRAGk9lqs0vDw+JiomCbhGhHkqTJYjWZLdLwsJioCLg2EUQ7EiAmTpiJI5Hg7hR3CasqziWFCegqxRwWpZfFxRiuS1xmumOBIAiCIAiqyigMszRpr2/XW3z9fMr3n7LtcPQF0YyiKIvFYjAYBAJBcnIyh8OhOyIIAjZ7mc5g5PN4yYkJHA6b7nAg6Hab5HI4SQlxPC6X7nAgCDhYglKOlEPhSW4dj/TTHU6wwAR0FUEhaIky2cUPTyw5z/e76A4HgiAIgiCoKnPUrK/t8g7m8yQsnyUouEp3OBAEnE6nVqsFAMTGxopEIrrDgSDgcru1OgMFqOhItRi2SYgBPF6vVmfACTxSrQqTiOkOB4KAF+OUcqQBlK3228IDTrrDCS6YgK4KcBanQF0TAZSm+DSLgDd+QhAEQRAEBYtPEaHrOsAdq1Ed2Cw7thuhKLojgqo7v9+v1+udTqdKpZLJZHAZU4h2gQCuNxrLHE6FXKaUwzYJ0Q/HcYPJbLOXwTYJMQSBoAZOuJUllONOpddYHfZvgwnokOfligoiaorctihTHjwFgiAIgiAIChKSwzO17GJq0VV68mDMmgWYt+rsSw6FKJIkTSaTyWSSSCQpKSksFjy5g2hGkqTZYjWaLRKxKFWTCNskRDuKoixWm95oEgoEKUmJbDZskxDNKACsLJGeGy4g/MluLYfC6Y7oBYG/Pcagyjb/NH9kYf2srzvXxwAAgCje3XRkVi7xiNdiUe2zF7zeGAN2ofy6M/+3MTMPXLh108mOjY1r17bjl+0TFVXxep674Mh3P61dfSIv344LlUmtXu3z32FtMwQIAIC4tarp64tyH/WzxeLfzN7yYWPsKSVUee68rd9Nnbf64Ll8i18YmdHqjRH/Hd8nQ/Soz07pN3/QaeSlXlkHJtSHPQQEQRAEAQAQxFbvZV2nt3j6Ys2Pk7j6YroDgiBgt9t1Oh2Hw0lKSuLxeHSHA0HA4XRp9XoMxRLiYgR8Pt3hQBBwulxavQEBCGyTEEO4MJ6WK6MAEuszi/DqNZWhaqWXSMvZjcvXHDpT4BDF123T791edaShklukig+v+XBviTGy1t0VNBBBZIeXMzUVpuGT9hMn8vQyqRIFxvAYrfnQ6IHfZxOqDs2bdhH7r5w99dNPcw6Vfnx0UIrkRX+E4ArkZ/UaMGe3S96sQ7fekfiNE39uXDb1wBnDocVv1eEARJjQoWNbTYVkPWE6cei8XqVWIk8voWoLXFvU65WRu8sim/Ue3Ds2cOPQpo3fDTxwrOjQ7rF1Km66QBavHvHhsgvGpFfhYi4QBEEQBADwxGi03QbgQknk1uVh5/+iOxwIAl6vt7S0NBAIqNXq8PBwusOBIODz+bV6g9fnUynkMilskxD9/P6AVm9wezzlbRKuuQHRLoCw9NxwB8ZX+e2yQFk1bJFVKQFNFGz65usNRKt3R/STGw+vWvb1DGz2Nz1jMbrjegaEPnvY0jN6gKD3PYjKXpr2yUsPvpDK3/ND5t+JE4a2YkXWtHLA1a9+yfZEjP3m85lpXAAAINrM+XL6mB07fus24gN5FWrPlHPLj0v2lEW8O/enxa/IUAAAOWjfzP90Xr1i4s6OW1+ToaqXp01/+cH3kPkbPs/MrjXxi+5J6NNLqEKV9RDKtuWrKXus8e+uP7y4qxoFAJDj941u2/nHGRPX9t86IOL+z07cWjZszBY99UBThCAIgqDqCScIQ88htrrNFEe2K//chgSq7L7kUKggSNKg1VqtVrlcrlQqURQO2SCaESRl0BusNrs0PCwuJgq2SYh2JEmZ7HaTrSw8TJIalYhhoZASgqo0kqJMLq9JGCXB3SnuElY1WO75kapQAtp/7o8/bsX0mju8YywGQIbCljd22/aLXYa/xPjZrYRu4cJNh9WN+8ly1z3xvIY0/zVqVV5i7y96NqtPUGRS0aHNRW4QVq+D5s4sVkzZsV7E55cNl3UkkFehfpbIO3zGgaX1HdNSdntEg4a1ebdHs/Xzjhy/5Hvt5YfvOST1u0fNP5M0+KfRKeznK6HqwM8dzrFhL40c00l957Mr2owZ2mzx6CMHTvoGdL332QNXFw794nDC2/2i1qxz0xQtBEEQ9FQ8Ed0RVH0URVmsVoPRKGr3WopKxa5TB/xnPN1BMVi4ku4InsuiSXRH8A9QCGJVa/SJ9QQyRXJyMofD+HMcenmcdEfwXBZOoDuCfwJBbPHpupde4clVGo2Gy614ZyX0gLQGdEfwXMyldEfwz9j8pM6DczEkKUkD1yZ6CoxNdwTP5e+DdEfwzzh4klJJNIvAExMS+JzQrPNKUnWuTxJFFy87I+o3iCpPu2JxDeqpyi5f0jL+ygJ+dvPKSTdipvynQ90nDyMp55YVW3aFtxvzUTeJz5lQep5F8VMieaCs4FjJncWPKftfV00ES5GqqjrfLAAA4B4QFls7M01z38dCuFw+AnA//oivmLJvmbt4l6znvAHJnOcroSoJuIA0pXbLBpr7LkkgfAEfAbjPf99n9539/v1Jp2tPWTymLjxSQxAEQdWY0+XKu3nTZrfHx8bGRkfBDYsg2rnCI2406GqOqRV7NTs+Ph5mnyHaeWSRN9r0N9RoEp27MyEhAWafIdp5COqmM6D3EhF8VqKIDbPPEO28bP4teXKJJEbt0GvM16t59hlUpRnQpMlgouTKO9NbASpTyiiTwUiC+PKHLBaLx/PACt8EQTxuJaAXNnnYfX3n4PW6xgM/HxkL5jz5lVd2f54N2s38tJ2nSGHXAgAA4Hfv32/AjZXTpszJa1unrsh/9fTxlRfZnd59Y7Cyai0pwWs6f33TBx8ii/f/mYOz6tZJefjA4j698ovdRK+Zbze5+9w/LKFKEXSaf7LTgw+RxVs25wQ4dRvfSzW7c2cM/uZq4xnZI2s+pSm+AATxqM03AQAAkCRJUdSLDAaCIAiqPvx+v1anc3s8KqVSJpUiCAKoxx6SIOgFCHAF+oS6DnmMquCcrPQqAkdBEN0CfJG+dquy6BTFtVzllePI48ftEPRi4BQweAmbn1BwMSUPq1qpECgkEShmEEVYhXKpyxxvvYWSsJ8EoColoAm/D0f4fP6d3gbh83mI3+e/O0abN2/e9u3b775eIpFYrdbHJaAVQY31Ls/1LxfsLczou6GjigUMT3ghRRnnrssuTBuyupZWYbfdfZylrDG0jWbHqssrNtxcAQAAiDil7X8aRwiCHTnNAvkHf+4z+4QrqtvEHlEVJ3uTJUsXbi1IG7Cpbdjjjz1PLKGK8+Vvm9Dnsz2u+PcmDky8/dkdR74cMruw1dwNQ5NZII/e+AAAVqv1cU95vV44wwKCIAiqdCRJmsxmk9kcHhaWGh0Nl4yEaEeimCk23RSbLjEWpORuZQW8dEcEVXcUilk09fTpzSWleak7F7O8Lrojgqo7CgCLj9R7cCEbTRFz2NXsxB5iIAoAq0CmF0cK/O5kwxUOAbcPuafqJKAxDhej7B4vBXgIAABQHo+XYovv3Z6Wnp7u8/nu/vfkyZNcLpfOvVAp9+5fVy4oS1/yZbNEFIDHLwNBotjVwtM/neN0G5tW32e7rwTv0d/md9xkeanLwC3da2eI/NfPZo9bsrP7BOeaGQNel1bNK39+/al5s+dN253vj2nz8/yPO0oqfkxX7ro5f3O6z+hW8zGHn6eWUIX5iw/MGzd62vrL/sTeP2/+rmN5I6Gsu78YusD86pI/BiViADDg4twTUswYhsG9TSAIgqDKZbPbdXo9l8NJSkiAN+1CTOCQx5RqMjk+d9KZXTznYy/MQ9AL44hK1tZtg/l9CUc2CMwldIcDQcAZILUeAkFAvIglZMEzRIh+Lo5IGxZNASTGVij2OegOh3GqTgIalSsVyC2zlQThGAAAkDazDZGny+/2Q3369OnTp8/d13fo0EEsFtOXgKZspzcP2+vvObrf24onxeBn8wrUkbtn79XJGgxv8MDtJKTlxFfbijkNB25+r7EaAQAI6zXtuoHvqP3V0UnbW3fvH1d1vt1ylCN33bwhc/eeD6jaDpg0Z1i7DNFDVUdZN/++p0jVbnHrR01/fpYSqirKmvvL6CETVp/3xbQd9eucCX0zbmfeKdvu8cP+5+756/y3Y5ly2BaLxY97isvlwllpEARBUGXxeDxavT4QCESo1eFhYXSHA0HAK5JpkzP9PLH61ulw/S0A4JobEM18YpmubltPmFJ1KVt26xyA68BAdPOTlN5LOAOkiseScRA6pxVCEAAAgADG1osjHVyJwqlXuE1wvaxHqjopSiwuvaZwy5mzxjcTIxAASN3ZczpxrfRopmaqKEN+cSlhXztr3NpZ9z++t0mvvVhU++wFrzfGgIsnKYqoKc5buiXHndC5UcsHtxvBi0su+LGMjJT7F3wW10xrxD6yNb+kjIqTVaV+mNRvmDJmQFapsvmArC/e7h736NlJpPbA0mxPwpuvtnx4Bu2zlVA1EUUbhnce8Gu+ssMXWfM+7a65f40W0nD+XGlAu/at+LVv3f+e2U34s7HkMdnnpzeuOv0EBEEQBN2G47jBaLTZ7Qq5XKlQwNNXiHYEi2uIr22NTJFqr8efP4gSAbojgqo7gs011Wxi1tSX3joXe3wrGvA9/T0QFEwkBUw+wuQjwjlYqoQD13uGaEcCxCxUGEVqia8sxXiFReJ0R8RcVSixxHmpc+e4cesX/B41uKXMcHDppiLN6x9nMHaHaERWo9n4PjXvrXZAuXMOHDnoSxjYMS02LDkaBRZJhE6eGGnKs+7cnYPLP2wcV2HLTITHFSGk1eEiwd29FwHldlpJwOHxuFWqLyYur/xq8BZj+qBvt4/KVD12ni6Zv/9ATiDiwzZpD20v+owlVEn45fkDBq8oTR+dtf2btg99dlTWdND48e3va4qWnBWLD3oaDhzaJlbZLLp61RUEQRBU9VEUZbFa9QaDUCBI0WjY7Oq+KTlEOwpBrGqNPrGuoMyUfHIbx+ukOyKo2kMQW3y67qVXeHajZv9KbpmJ7oAgCNj9pM5LcFCQJGLDvQYhJnDwJFpJDEYGEiw3BQE33eEwXRVKQANWUu8vPgss+nXhuE1eQXTdrp8P6xnP1PnPACCKWi2m1LrvAdIw6+zRQ07NsDe7N8IQnSJRL1LGay8KPcUbThUEJI06aCp+WezEjA7y/T8f2Luh/cB+SgwAACjXoc2Hj+D8jpmaKrUPoe/0/JUXfOlDVox8Yu6Ysu0/ejUgbd+h1kNnks9YQpXk/XP+/OO+BlNWTHs4+wwAQBQvvz/l5fseIPJm7V96yNJ82OQpcO4zBEEQVMU4XS6tTocgSHxsrFAopDscCAKu8AitJpNC0Zgrx8TWUrrDgSDgkUWW1m1LcPmRf+8NK75KdzgQBDw4qfUSARKoeVg4p7qdz0NM5GNxtZJoL4sX4dCFeyx0hxMaqlZ6CVNm9p+Y2Z/uMP4dEmMVRNXEUVZyyVl2wAs8efuv47xayY0enp3DSZkwpMnu73L6f6Jd83Ktl0T+a+dPb77mkDboO7NFldpZjyi8cNxMcUTnZkz+5sGjDSLJ7Du7R9Ltduw6t/98gNegTqOHJr4/awlVEZGXc1xPcsTZM4YNqfjZW46aPTC9Cn92CIIgCLrL7/drdTq3x6NSKmVSKVxzA6JdgCvQJ9R1yGMUhRcUJVcQ6vGbkkPQC4HzxbraLcuiUxTXcpVXjiMEA3Ynh6o3ggIGL2H1EwoupuCiKDx2Q3QjUMwgirAK5VKXOc5WgJKwn3xWMPXENKyS6DrRuCtJexGlSACAL+/qUTeSrIl9VEYZiWz8dvbU+K83ZGcdPbjDhykjE94ZMHBSt5oMnvr9PHBtaSFBOW8cX3GjwjOoitV2Vo+k8v/4Lp466kKSa6Y8XFfPWEKVhBfmF+KU8/KuFZcrPIOqWG/MGphOS1TQM6IoiiTJ8n/geOWvJ0UQRJBKLg+bIIhgFF4eM4oGZfpD8KqaJElY1XeLBaFc1U9NXAbjr0P/BkmSJrPZZDaHh4WlRkfDzWwh2pEoZopNN8WmS4wFKblbWQEv3RFB1R2FYhZNPX16c7E+P2X3UrbbQXdEUHVHAWDxkQYvIWAhyWI2B4WpZ4huCGLjSXWSKL7flWy4wiH8dAcUYmACmjFQ1QcLf+uqTpOV6dSWgrubC3NferN485tPeluNlvMmtpz3YoKkCbflePO58U9/WeMxxWfH/JsSqiRu5yVm/5J/8AYs+dNs16dBiwf6RwiC8Pv9AACKolwuV6WXT5Jk8EoGAPh8vkCg8vdQIknS4/FUerF3Cw9GhZRfSwhGyQRBAAB8Pl95U6lcFEW53e4gTRQNUoWUt73glez1ep9aIR6Pp/zFocZ7bOY78/njV42oF1IDxKeEbS8r0+n1HDY7KSGBx2PEFsTu61u/mzpv9cFz+Ra/MCqj1Rsj/ju+T4YInlrfExpV5L/25heb11RIHbM0y77pPejO4i5lpZembz+59rpJi7NjYxIGvdpqTLrEL4/RJjfE/J7Ec3v5cGnd0ECVXdo8feaitUeuav2C2NqvDBo9fkz7mId3PacRYbrQ9OfTuY86+GCy9OwP6zd+4GoycSz76HxW7VWNZSwAHFHJ2rptML8v4egGgankBUUMPQ/fsbkfzeeNWjU8o8Ihj7KdWzZ74coDJ04V4hEvtX3/sy9GtYpg0hYHvmM/fDqfN3zVe7UqHqxJe+66H776dc/Rmw5eZGqbXh9+PbSFAiW1HgIAECvERCy45kZoYfh4kij+e+ek1Yd3XzeaCU5EbEr3Lj2ndNbI7w0xqLJbOdNX7Vp7pliL82I1tQf1e2NMIwXOEWrDYigEibYViH00X6Ijrs1t2uSr3EedZ2Oaj7NP/peZi6kyMqhqqXzLwShjXrjTSHcsEAQxBYvFKk+XoCgaFhZW6eX7/X6fzycWiyu9ZLfb7Xa7BQIBl1v5Z2c2m00sFgdjBrTJZMIwLEhV7ff7RSJRpZfscrk8Ho9AIOBwKn/fXavVKpFIgjED2mw2B6mqfT4fjuPBWNu3vKqFQuFT96xjs9lBmqEfVJRx+8L5Ww+/9kFo5c6fELbH49Hq9YFAQK1ShQehsT2fwNVFvV4Zubssslnvwb3jAjcObto4a+CB7KJDe8bWYVQ2iz6hUkWEzZofQNRxya2V951SYerEO/9z3sru8EN2LpB3ql+/L8d57OzViT+X/jX5x+mNNVH5Z8L1twCgaIkc+qecJ2d36DU7FyR36jm4r0B/7I9tE986fuGXP1b1jGJOX49wwzukJ2gqdIWU58RVg14iUD54+YZyFy/8q+hwWppHJLXUa+uWRqou58jyTiEUbJOMRpn2Lvx59+EuAyse8rxnp/XuPeWcoFHPnh+3d/y1ZdO4fidvrfzjh3ZShly4o8yHFi7dd7jjmxUjpyy7Jr3Tc1VJRINX3hoQ5b24Z82sYQcvfrt6eocMAUvGQeB6WSGH2eNJypz7a+vJBwslml4du6Swy04dO/bj/K+zjROODrq9j5rz8uYO4zfngqhOrdr35dmOZZ+YOPnqiamLpnVNUrmMSqeeCf0kIk7r0Ot1TYVbLgndiR3H9VHRSuYcmR4EE9D0oxC0VKlxCqSJpef5PrjnNQRBEARBLxLhMeVfPHlg1fRJa3Wkmu5ontmTwiYIwmA0Wm02hVyukMsZdD2Asm35asoea/y7Gw4v7qpGAQDk+H2j23b+YcbENf23DoyA59khVEWExZZPcdp27P5bnUedUpGmBetyctGE7z/pOTKSTbA4ug+wiZOmr/xh+X/CG9ViVf7tQVCwENcWfDYvF2v5/Y7lI2vwAQDk2Lc/69Fv7uR5g1+d2Y4xO7+j4phpPWMefIzK//tgZp5iYsfUpNu/HMrjdl4s1a06ematEyjlL91s/7bq1rmY49uwgO/Fxww9M8JjLrp4+uiq72esNTx8pCYLfv/m2zNIq6kbd32QzAGA/PCVd1p/sOTLRe+1GteA5lnQhMdScvFszqoFc9caqYcip+x/zhn2W1GNYcsOfdFADCiT9926Y3t/sn3hjmEdW9VjzLEbeiahMJ4kDct/O3JTnLl84cfvKFAAAHi7xacfT5ud9UdWrxFviRFAliz4YVsumvH995/dYxU7AAAgAElEQVSMjOeQADEO6THuk4krF6z84KV+GRymLLKHRnaatrjTg4+R+cv7Ze7NnDhrUBJTfzpMjavaIDB2fmS6jyPQFJ2B2WcIgiAIgl4wyrC8Z1xqwy7D5x01MnKuyqM9LmyKoswWy7W8PL/fn5yUpFIqGZR9BgDg5w7n2LCX3h3TSX07LFTRZszQZmzHkQMnYfoHgFCqIqvJbgWSFMWjGxhhzNtcQsZkNhkexbGpk643fA1XNZrxSrLIlL36qvsFhwr9G8TNXZsvEDG9Rw6vwS9/BJU1nTCqg6h0++/ZwVoQrFKQZTdHHdAnNW88WnW7lVKuGz3nZDX8/fi8Qi8JEIorSzqwMvLMfph9ZjjKuKZnRtOGfT6dd9z8iCM1WbJl03G3vMuYAcnld8Ohqk5j306mrm9be5bma12UaVPPhu0bDvhyXq7lEZFTti0rthdL2k34T30QIK87cBchHfzp1z982b+JAF6lCzGhMZ705B25gYvrvdzr7rGbl9SjgRz1lV7UkQAAouTvzTeJmDbdh8dzHDxJnqqGM6LF133qi/QH155h9LGbLFk7asqxpNHfjU6v/JtiKwucAU0nL0dYGFmL7y2L1l5H4bbXEARBEAS9cIis+7w/M2wkoMybR7w+u5jueJ7RI8N2ulxanQ5BkLiYmGAsw1IJAi4gTandqoHmvn0QEb6AjwDc54djQQBCqIrIfJOdwOQagf3P08UX7AGBVN2mZnT8nfM+wlZWQqIJcZqC+h0QlBV9NVtsKcWlYbHA83eBjUhXwq0wQwVRWlxCoJrE2PsmkiLi5JRYZNffp/OJ9jWZ+lX6tuw/s0uYdrCJ9G42AuHHzBz5ztCUTNz118zPV2tLD3HtETSGCD0jRNpx3o6aNhJQ5h0j3vmp4pHaf/HEhQCncZMm9+bjs2o1zZR/v+7UWTOZGUHjZVgkvO28Tak2ElCWPSOG/K9i5IGzB096OHWbJwFc5wVqHhbOQYHo5WGDX6YlWujfCI3xJJYw9OMh/WI0920JQjg8PgqRKsUoAIAwmUoINDEmukSW5GfxVE6dzGPFI9WxyIm/r+mJRrEM7fAp85Yp03Yp3zv4UQZz088wAU0jh0BWrE6T20tUlkK6Y4EgCIIgqLpiKdMaKgEAlPaMhElzhZ/iwbApMlBcXOxzuVRKpUwqZe6SkYJO809VvGWyOGtzToBTt3FdRuyQSLuQqSI83+ggKO+4GUu0TrJ8PUhOWPy4gd2npAkQAAiJSIBSRSBJqL8VVXIFoUgAgN/uMFAUaXEQACagQwYqCQ9DydISHQ5i757Y+3WlBpIgi7QEYGgC2l144YtLVK/X05vcSZzjfJGh1qvsuJovX8tV3Lj1CwBaWiOE/gGWPK2eHABA6S88fKQm9YX5XkQeFy2+79DHio6LxcjC/GIC0JmABixZWh0ZAIAyXHo48oCh8IoTkUaKDFtnzP1197ECb1hcjaZt+k4a0bU203adhZ4qJMaTvOjOHaIBAABQXrfTYjOfP7lr7AFnVIsOfdQIAIASi4QoWegQsXBfgq0AJQkAgN9sMZAkqbcSgKEJaPfxOV9sInr9b0QTxqwK9UgwAU0PY3iMURoTo78qcVvojgWCIAiCIIYKBAJOp9NsNt//oFwqpSseBiJJyk8BokyLIBkpGg2LFVqDW1/+tgl9PtvjSnhv4qDEyj1fq9BsqEraMycQCLhcroptMlxSKYU/ShCr6F8hHTcsBEWwEpv12Ns2MQE4Tp37a8Smc9OW7ogb36d7Rg1jZlLzxdkrs77dm9ptkAwFAACffv6+a0aKEvhx+jcwokOQ2iSO4263u2KbrLwkAatWqzaRC39a+8Pvw5YMimUBAIDr/Pz5240kJXB7GPpVUo6lh64VqGtvqsFFAKBQ1KKpb0hvLtLnp+z+H9tdRpFMup2APhWaDVlJ1YLjuMfjqdgmg9Z/US6ni0JFYtH9fwERikQIVexyM7OJUhSw+olSnd1BUe5D3/RbH0hu235Ya7b21P6NP3+292/9od+GMGrX2RemQrMhCKJSukocx71eLxxP3kNq53z2xfhrBACINKPXjlGNolDExpPqMrs0VW1btXXhgfYfDVJjAADgyZ+/PtdIAYHPx8xfEyBvLZ36a0HtMZu6yoNx3aZCs8Fx/Lm7ytAao1cFFIKWKJPdPImm5DzX76I7HAiCIAiCoFBlLyvTFhgJADBxRHR0dGiNa/3FB+Z9Pnra+sv+pN4/b/quoxTO9qqI0VWECHv0eL0eR9EqMUwAAADSFs1e3Qac6b/f+q6gVovWsQlXT0zrnLb/18vvf2vf2SA+BXMdP3s1FwjVqM+NMSiRDj0dt+m4yV23DN/6frsuO3u0SmHrj+/YlgtUaszpZuoVL1f+5TmFWPeeKTUR4FTFa+u1Q0k8/uhGgYmht8VD/wpFURR4ZP9IkkzMmLlwSuvBKQBiOBQKyDIDf+iSjT+0VWAAAPI/70zs03XVTxO39tj6hoJJnT5UtSCy14f8J0Fvu3Ht5JLdm7p8yVv8w4gMIRpdFvh6UKMD3/71/oj/7myVkYLZjuecyAVhatTrxpg5+xm4jvw0J4fbfckAht6Pcx+GHjKrKpzFLYiogZBUUslZFgGX1YcgCIIg6EnYbLZIJJLL5Q88CmeuAeDxeLR6fSAQUCvEfAQgGJOXvHsIZc1dNHrIhNXnfTFtP/l1zoS+GZLKP8uu0Gwqa1kSNpstFAortslKH9a+kCr6VxBerTRNrfse8AnCAn2611k/98TpQ+q6SgFFCTK7HOErJu46vys7dxtHXL9O6wOt/CNmHSrgsRn2YV6QILVJFoslEAgqtkmboVIKBwAAgMb0+uGIpObE2Wt2rfhxGz+qftf/HnjfOaLdVwViISO/Su/m3FtF4oSfGkQWZrZ2y6JUl3NkeaeQSppyXpVUaDaVtWkti8Xi8/kV26RVVymFPwwRikQoZXlwsjPlcjopRCQUMKuJUlSJG/cGSBWPJeOgpJDPBwin8YBJrRW3U2doePsP3266ZvrhQ6fcb7zKyM0cgqtCs8EwrFK6ShaLxePx4HjyHoSXVrdhGgCBTh3b1Piu/eyNC7Z13deOwChK3Hr4EWHMxNVHdu3csY0jq9/8rQOveUd8vLpAwGPWr6kcZdz88/qiyF6LO8uCFF6FZsNisZ67q4QJ6BfHyxUVRNQUua1Rphvw8A9BEARBEPQcCIIwGI1Wm00ukykVCkTPpzuif4go2jC884Dl+coOX2TN+7R7MrOX66NFqFURweIY4l+yRqZIC1dFIRRwawlSARAAAJaQ3mxVerO7r/Rf21NIoImqcHgOFmrYCe0/WdX+k7v/9x8ZV4hjiZo4Bn6VpL1gyQ08tmOPyE79OLfOxfz1Bxbw0R0UFESoOi6OS54qKCqjwN078AltSQmBpiVEM2ROJEkBPwC4nwAApIjZLBQBAGCqiCgWcj0qUnFfOgtVRUWzwYkyh5sCzLzCA4Uuf+nFdRft8XWatlAhFIJYBAq9SB3dpHFt9PTNq+fJtuVziFkJjXqsatTj3rvOLi8ksMRoJRM7/KKspftdCUP7tgyF4TC8/+sFsYsUN6Nqy+zaaGMezD5DEARBEAT9UxRFmS2Wa3l5fr8/OSlJrVJV1my1Fwi/PG/A4F9L08dk5W6bzPzUKh1Co4rwohPdZq0ccNxuUSddb/iaTxiu+XuH6kTuDRyJVEnFCABU2aHjZ5ZcMLnvvYk8f6VIh0hbasQh13CrNbL00OqVS3Zfu++rDJw/lK1DE1s2jWLcV4mAcwZDDhHZul2z1P0rI8/sh9nnqo9bu0lttv/k4SP32ihx/eRpExKTWU/JhCbqCJDXnQQBAMbGogWs8uwzAAAIamSmoK6bN4vum4lLlBTk+5GwyAim3fcCVQWlOaO/+2VCtsnOk1xX1rDxwxOst6L1pU4K4XM5CACAMh/ae2DJXyX3dfjE+b8v61B1y9oyJvyaHkTmb9uc44/t1rUO++kvph/zKrAqMsjiShXJcbrLShtcdQuCIAiCIOgfc7ndN27dslitsTEx8XFxHE5Irblxl/fP+fOP+xp8tmJaWxUchj9SiFQRSykVW7S/HyhaL06Pvnos4dw+blnR+l2nT1PSNxpElp8HXjqxf9jyAyvMt6eeBEznp2SbuUl1BsUw+INBj0BdWjNx2LAvVxQQ5f8P3Fo3ZcUNbqMBg2ozaz6cRxpx85Uu225qcVHUG/qNvDIT3RFBLwQa1b1HI75t/4+rb5Yvh0Q5jv20+hJI6d6X7qyUl6BuOfFSD6HmonwAEPTBpDKW1Kt7Bnpm1eQ/Sm8v5ITrtyxYnUspu3WsWy33IISCi52a3kJEHN/79y52jMKp15jzBN7SnVuOXaHCXqlXvsksuLR31bCZv63Q3b4qEig9MmWHllurzSANQ24nuA9l2r/3TEDevEPd0BgVM+uQWfWQKFasSvVyBEklZ7kBD93hQBAEQRAEhZhAIKA3GBxOp0qplEmllbVuLC2IvJzjepIjyZ4xbMiDOUhE0mLU7EHpcGgeElUU4PD1af37jzLun7ZjZN9zRxvEJiLuc5ev/FFK1m7ba3wCBgAAiKR/p3o//pA76vvfczJj1W7jnnM3L4CEuf3qpcD8c2hBo/t/NujHXotGdeqZ07up2n5pz44DF0DLud8PTGFMOgLniwy1mtviairOLrp41s+L4zRiwk8FekHQhLfGj13de+qkt7pee7OLJnBq7dJVRfHv/za0AX35Z4ICBi9h9ZNSDhovZCHeRx67sRr9P/9ky+AZI3pd2d6pQxJ26+iOTWftca/P/u8rohcdMVTVEQhmiuk+4P3j++auGt7vYr+mSZHAdv7vE1nXXTGvDJ9QjwMAAIi8f/+2P47fNWr01zmta6idRXuOnb0AMuaOaMPEY7fz+P6Tfl6zZo1C5HINPC4FUYDFLYysheF+TfFZjMTpDgeCIAiCICiUkCRpMptNZrNELE7RaFiskB+44oX5hTjlvLRrxaUKz6Aq1huzBqXTEhWjMLyKSBQzR6UZ42pLzEUdYlv99QH29f6LO4+dWIezoqPjxw5oNq6hKvxOmkWS0vrACOmkP07vyD5pw0T1ajbP6taoq5wxOUvomUmaf3lga8Kkb5bvWLHIxo6s13ps1oQPu8YzYsYZhaIWTX19enOhqThlzzLywqGjPpAcKZXQHRj0Qgnqfbl+rfKrGQu2zP/MwYmu3Wba6olj2wRrU7Inoyhg9RN6LyFgocliFgdFAACPXYRUVH/qqmXRs+f/tCtrzj5KmlD33ckfTBnYKJKByT4odCGIjSfVSSJ5uLdjl0+yuWu/2nJi09bzNoITEZsy9MOuE7vWiLx77H7pzQPfqif9um/Hzp02TFavQc+sQV26RjBxiQvfqcNHHWhy3dqhsl5NyI/jGcvNkxRG1JS4zJHGG8jj+1sIgiAIgiAmQCKH7XMPozuKexxOZ6lWy+FwkhISeDze417GtLCfjNt5iTmwhO4oGI3JVeSQx2g1mVjAl3Bhv6DMBABIqNV4ca3Gj38Hokqqt2hEvRcWIRQ0mKrRu4uy3qU7jIqcqnhtvbYIQcQf3Sg0FQMAQGLj4klPaJO3IaLUfRNSgx4fVNkQ9YB92gGPfAqVZX40d8NHc19wRBW5cErrwSkAYoVsEeteVgxRvbnvxpuPfAsmr/fRN8s++uZFhQgFGdMGZh6OoFQcRaCsaHuR2FsGAMho3Xdd676PfweqqtVu0cx2LyzC58Z95bti+3d0R/EPwAR0UFglEVp5YqTpptShpzsWCIIgCIKgUOL1erV6vd/vV6tU4WFhdIcDQcDHl2g1mV6RVJV/Vqa/AeCO4hDd/GKZtk5rtzxademYLO8U3OUeol2ApPRewhEgFVxMwcNCZEYmVJXhGFsnjizjhSlcRqVTD/tJ2sEEdCWjADDIEyxidbzuktBjpzscCIIgCIKgkEEQhMFotNpscpksPjYWReEtuBDNCBbHFJdhjkyV6vLirhxB8QDdEUHVHclim9IamVIbhRdeSt21BPO56Y4Iqu5IijL5SJOPlLCRFDGbhcLkM0QzCkEsAoVepBb7nSnGK2wCHrsZASagKxOJsopUqQE2T1N8hoP76A4HgiAIgiAoNFAUZbXZ9AaDgM9PTkricBixuCpUrSGITZWoS6rPc9k0p3dy3XBmCUQ3BLFHp+rqtOE4rUkHVvHsRroDgiDgCJBaD4EhIFHE4sN5zxADOHgSrSQaI4kE6y2B30V3ONA9MAFdafxsfkFETQ7uSyo5h8ItByEIgiAIgp6Ny+3W6nQURcXGxIiEQrrDgSDgEStKNZkEmxN97bjYXEx3OBAEPFK1tl67gECivnAkPP8C3eFAEPASlNZD+Agygs8K58A7liD6+TCuLizazearnAaZywivhzANTEBXDic/vCiihqxMp7YUwFXhIAiCIAiCnkUgENAbDA6nUyGXK+RyBIEnCxDNcK5Al1C3TBGnKL6kLLqIkATdEUHVHcHlG2o2sybWVlzLVV75CyHgVCeIZgQFDF7C6ielHDReyIFLbkC0IxDMJFabBXKp2xJjzccoku6IoEeACehKYJFE6OSJUaYb4Q4D3bFAEARBEASFAJIkTWazyWyWiMUpGg2LBQelEM0oBLVEperj60jMRam5W1h+D90RQdUdhaIWTX1DenOBqThlzzK2C64DA9HP5id1XoKPIcliFsw9Q0xg48t0kkge7tWYr3MDXrrDgR4LjvX/FQogOmWSXSBP1F7gex10hwNBEARBEBQCHE5nqVbLYrES4+P5fD7d4UAQcMhjtJpMDPcnXDggKINL60L0c6ritXXbIhQZd3Sj0ATXgYHo58IprQenAIjmY2I2XHMDop+HLdCGReMIFmkvDvPCS3RMBxPQz4/A2IXqNAJlaUrOsuGWgxAEQRAEQU/j9Xq1er3P54tQq8PDwugOB4KAjy/WJTd0i+SqwvPy0qtwMT2Idn6RVF+7pVMVr7p0TJZ3CoFtEqJbgKT0XsIRoBRcVMGDWw1C9MMxtkEUYeOHK1xGpdOAwDU3QgFMQD8nL0dQGJnO9zritZdQ2NYhCIIgCIKeiCAIg9Fotdmk4eHxsbEoCidPQTQjWBxTXIY5MlWqy4u5dAQjAnRHBFV3JIttSmtkSmssKb6asmsxywfXgYFoRlKU2UcafYSEjaZIWCy4VQNENwogFqHCII4Q+Rwpxqtswk93RNCzggno5+EQSIvVabIyndqcT3csEARBEARBjEZRlNVm0xsMAj4/OSmJw+HQHREEAZu9TJfZnee2ac7s4rpsdIcDQcDu9upefY/jsiXtX8mzw3VgIPo5vH6tA8cQkCBkCVjwsjFEP6fLpVWmohQVb7kp8LvoDgf6Z2AC+h8zh/2fvbsObOJsAwD+3l08lSR191JkuBUfDC/Dhw4bNr7hzmAwZxsMGTMcxnDX4W4DhrsUaGnS1FKJnrzfH0XqTSXNBZ7ff03vLs/dPffe3ZP33vNNVAX6ax+66FPsHQsAwE641OvbVm88ce1ZplNQzZa9B3evoczXHaCwaayZFwAAiuBQfYf1er1arcYY+/t6Ozs5IYQQZu0dVElQQntH4AhePLZ3BCVgZLHaxDEY+6icXb0VKDTY3hEBG5A62TuCEjCazOqkFJphvPz9FbJwVKuuvSMCNnD/ir0jKAEzKVSLlCZS6O0qV4ihagTsz2KxqDUag9Ho6eOncnUhiKr2jqjkdI75y6KTsryW5Eg3MHaHCTLeMyJZ4R+ScAuqzwC8w9hn27/7dmucf6cxU0d38n22+du5O+PyllMKm8aaeQEA4G1A03R8fPzz589dXV3Dw8NfVp8BsB8Go3gjG2tgnQREhJPAVUTZOyLwrmM5Tp2UEvtCLZdJIoL8FTKJvSMC7zqWINVi1WOZjxgzkUY1VJ+B3XEcp01KevTkiUgkigwPd1O4EjAUjGOC1sRajED0zKsygXBY/FUBjBAHwLvMcmPv3lj/7gtHtgugEKrmrns0ac++2x1HVhcVP03U7eLnBQAAB8dxXEpKSlJSkouLS0REhEAAF5zAzjBCqRZOa8ZOAiLCiRLCrSuwN4xxanqGNjVNJpGEB/qJhPCwBbA7QieUa0RKCWcJM6jFHBQ9gP3p0tM1iYlikSg0OFgikSCEEGSmw4L7AauYxE7PvCvLTRl+2ofwek0A3nFs3O27Wd4N6/hm95uiAuvU8tx29Y6aqx5EFjcNLS9+XgAAcGiZmZlqtZqiqODgYJlMZu9wAEBZDFabOJJAQTJSRkHtGdif3mhSJyVjjAO8vZxkUnuHAwDSUxK1WIkJ0s+U7MzC2y+B/RmNRnViIk3T3l5eCldXe4cDygEUoIuXLnd/4RnhkRbnoYu3dywAAPvjkrXJ2M1D9apiTKo8VDhZm8ShN0XkwqZhiptXo9GsXLny9Xfp9frw8HCEEMdxWVlZ5b8uHMeyrC2WzDAMQshkMtF0+f9GzXGcXq+30bNXDreps7ewyWSyWMr/HdA23dQ22iAsy2KMbZfVRqPRbDYXPaXRaMQYl3sA/Gc2m9Vqtclk8vb2VigU9g4HAGRmscbMGVjsKSZVQgIe2gV2Z6HpxJS0LIPBU6VUubpATgK7owkqUazMoKTudKYHnU68kxcwgFcYhtEmJenS093d3Dzc3aGdfGtAAboYSQr/ZGVAgPa+sz7V3rEAAHiBtZgZQiqVvjoRElKphLCYLdiKaZji5k1LS9u+ffvr5dSsWTM4OBghhDE2mUy2WiPWVqNQ0zRtiwI0QqjYCmCpcRzniJvaFtXnbLbb1DbN6uxisS1Ys6lNJtO7VoBmWVar1aalpSmVysDAQNKhXpMI3kocRskWLtnCKYWkv5Sk4PYV2BvHccm69OS0dBe5LCIoQEDBEOTAzjhEpAidk0SuLqwx0pAgcKxXBIO3EcY4NS0tUauVy2QRYWFCGJvo7QIF6EJxBBnvGWkSO4W+uC62GOwdDgCALyiRmMLpRhNGEgIhhLDRaMJCZ5E10xQ7b0hIyF9//fX6z8OHD0ulUoQQSZIuLi7lvi7ZBWJbPCNvMplMJpNMJhOJyn9468zMTLlcbosKl06noyjK2dm53Jdsu02d3SFXLpfb4hItIyPDycmp3Dc1xjg9Pd1Gm9pisbAsm33glK/sTe3k5FTsiMYikeidqsDqdDqNRiOVSsPDw21xyANQUjoaa0ysmCRCZZQExtwAPJCpNyRok0VCYai/r0QM7SSwv0yBTC1WUpgLNmllrK16GwBgvSy9Xq3REAQRFBAgl8vtHQ4of1CALhhNiZ77VCExF/riOrxyEACQE+nm4U7EpqRxSEEhhBCnS9ERblXdSCumERQ3r0QiqVy58uvlnD9/PruMRRCELd7ixXEcwzC2WHJ22BRF2WLh2VvDRgU+221qlmVhU2fL7h1so02dPQSHfTf1u/POPb1er1arMcZ+fn62+DkBgJIyslht4hiMfCSkq/Ad+h0I8JbJbEnQJtMM4+WuUjg72TscAJCZFKhFKhMl8jTrVIweoXfrmS3AQxaLRa3RGIxGTw8PlVIJY268reCyrAAGg+FxQE2pOSs44SZUnwEAeVCBVSvL1deuJ2VfrHGa6zc0zlWq+lFWTCOyYl4AAOA/mqbj4+OfPXvm4uISHh4O1WdgdwxGCSYu1sA6CYgIJwqqz8DuWJZTJ6U8iU+QyyQRQf5QfQZ2xxJkolj5WOYrxkykIUHFZEH1GdgXx3HapKRHT54IhcLI8HA3lQqqz2+xd6WHjvXS09NfvHjh5R/k5lYboQ/sHc4bKSkpBEGoVCp7B8J3LMumpaWJxWK4GS6W2WzOHsrAFs+qv81E1Tt0CJy25Zf1vkOaqbTHV2yPC+s2upoIIebxkXUnUyp37NnAq7BpqMLmBQAAx8BxXEpKSlJSkouLS2Rk5LvT3RvwFkYo1cIlmji5gIhwEgjh1hXYG8Y4LSMzMTlVJpWEB/qJYBhTYH+ETijXiJQSzhJmUIs56GYH7E+Xnq5JTBSLRKHBwRKJxN7hAJuDe4Y3MMZarTY1NTUoKAhGnAEAFE4Q2mP6FPrPNUumbTfJ/GrGTB3RNYhCCDEvLu3dHctG92jgVeg0hX0OAAAOIDMzU61WUxQVHBxsizHNASipLAarTSyBULCcksFwz4AH9EaTOikZYxzg4+Ukg04ewP6MlDhBpGQJ0s+c7MwY7R0OAMhoNKoTE2ma9vbyUri62jscUEGgAP0Sx3FxcXEWiyU0NFQsFts7HAAAv1EedfvPrNs/z6eSZtO3NitmmsI/BwAAHjObzWq12mQyeXp68uR5LMPD3fO+XrTh+I2nqRa5b7XmPcd8OeOjak5QgnRc5nO/TVksGbluSOXXtyjs42XRbX6+xBQwNRX8yba94yMR9hSTKiFh14d2zeeWTFwsGbVuaJVcN1fGQ31qfrYxK/cT7qIWq64uHaSARHVYWLvjfzFj73TbeWRa7dw30zTDJCanZhoMniqlytWFBw+S44w7O77/4c9Np++rLbKA91oMmjBjYmt/uNd1QEz8v7tmrT1y8F5iCiPyDqr8Ydfecz6slPMVNIa4C/NW7NxwJfZpOi33CG7eqvOXg5tFyYUakSKDkrrTmR50OoHtOOCG+dwv4xdL/rduWNVCi1A4ecfkj8c+6LBz++jaUKlyYKZzP3y8WDpj3Zha+Xcjy7LapKQ0nc7dzc3D3Z0H7WQOhTfvfGI+98u4xZLP8h1KTPzJ5bMWbz14Iy6FlnhH1Pnw4zFz+td049OAZPzdqBXJYrE8e/ZMKBSGhoZSFPRFBAAAAAB4iWVZrVablpamVCoDAwNt9P7PkqLv/9m9xdiDGT6NegzpEUg/Pr59208Dj52NO3FoUg0orjgmnHJiycqjp9r24XJ8SDiFtenUIYzNPSWrvXD4P62HpydFREopu/d7xinHl6w4cqptXy7356zm+VMT6VXj/b3lPDMAACAASURBVPeDczxZLKwSAqOEODAufuP4UatvJ4W2zjmEAcdxybr05LR0F7ksIihAwI87yqzL89t0n38JhbfvOqSXLPHc3j0z+164tXTvuq6+vGjHgbVwyvk/35/yz3NFpe4x3SJE6VdOnfjtxxlntd+dGV4p+1kk+vn+7iN+P6h3a9SqTQ8v9vGVs9vWzTt6M3PV8k/rIWOkIUGA2WK+xObrcGzJ8sOn2vXnCp2Ei9/xxagN95OCm8P4IA4NJ+1bsnj3qc6f5tnXGOPUtDRtUpJMKo0ICxPybmyigpt3vsEpR5csO3yqfZ5DCacc++L9gRueq2p27zMiQpR85Z9dv03tc1a94czUmvx5YhEK0Eiv18fFxbm6unp7e/Pr5xcAAAAAALvS6XQajUYikYSFhfHoETGs2/XVnENpQYO3nloW40UihLgZRya06vDr3Jkb++8e6A3Xcw6FNaa+uH3jwrolizYlYa/c/yO9Wn6zsGXOT3Q0e2XdyEMnqs/4qne0zL5lNNaY+uL2tXPrflmwSZs3coQQG/fsKZa1GrPg73YwtOVbgo1dM2LS7kRM5My8TL0hQZssEFAhfj5SCW/aSfbBL1MWXaKa/bx/9dgoKUKIm9RvSpfeC2cvGtL2hw/4U5AAxeI0q1cdeeISvXrFtI89SYQQGtxy8ifT52/etrP39L4uBML6Xcv/OpTpNXjuvGVNFCRCmeTgNosmDtvw17Ld73dpL7frOTG7nTy7btH8AtvJN9M92zxi1qE8BxdwKKwx+enty8fWfT9rk4bLs6+z9Hq1RkMQRKC/Pz8HvC2weecT1pgaf/va2XWL5m3S5t28iH22esHWJ4q2q//59WMfCiGEJnSf3K7X/OV/7Bzxe1/ePHT1rhegU1NTNRqNj4+PUqm0dywAAAAAAHxhNBoTEhJYlvXz8+Pde32ZG6fO66jqYye293p5n0C6t5w4vNHSCaePXTYPjIFqnwPBKTu6Npx10JL9V1H3fUYWq02cWbPz50VXwj9dP6WKnV/hi5O3da33eeGR47Tn8WmEX0Qg3zp5gdKiHywZ+fmpkD69/TZvNiCEkMlsUSelWGjay12lcHayd3y5sE/+2XGL9R80dmTUy3GoSVX05+PaLB++b/3ZOR+0hsGpHYfh/ukHjHPzlt09X7Uz0oguDdwXbIm/ncAhFwqxsadu6KmIrhMbKWhSoBG7GUhhx36dGm9ZfO7fW+b2Dex4TsTJW7vWmV58C08/XjJx7qnArr19dm2GQaodE9au7ho8/KA5+683+9pisSRqtVl6vaeHh0qp5Gmnz3zNO9/g5C1da08r9FDSXzt9k3bu0K27z6vnb2Q1urzvu2DF49vPWaTgS+GXL3HYRWJiYlpaGrxyEAAAAADgNZqmExMTMzIy3N3dPTw8+HirQOuRMuK95nXCcjzmTkhlUgIxZkvhj/cCPiJcWy7aGqnjEE47NGbYqviCpmEw0po5Hc25C9Ov/fLLUfe+x4dG2bn8jBCh+GDRjko6jHDqwTFDVuSLnHv67AUrCAtTxJ3cd+WWxijzq9qyWc0gGf8OKGAV8/UFI2dde2/O0fHsp5s3G3ByUsoTQ6bSxTnI15skebdb2YT4FywZFhKQ4wcQwjk8IoD457+rT9nWlXkxSgiwBhU6fPKY3kGROerIXKbBjEmVhwuJEEKMCbn4VasV6SxVPhY6K+ksf6OWJLEUIcbC2PecSChaL9pVScdlt5PLCmzhEbJc/33qrJtRc3YOZydBAdpREaoPF52spuMQTtkxptv8eIQ4jtOmpCSnpChcXSPDw3k82m2e5t3e4RSEULRZtDtKxyGc+s+YwUvzHkqCqsN/+KF3WM0crQSTmWXEhJeHgkddut/dAjTLsgsXLnRycuLJUIbFMplMBEHw6OlXvsIYm81miqL4N6gQ77AsS9O0QCAQCBymKbh371779u3tHUWFOnLkyL1792x0+HMcx7KsLQ4WhmEYhhEKhba41LBYLEKh0BZFMZPJRJKkSFT+ZQ1bb2qRSGSL05nZbBaJRI61qVmWxRjbolmzflMzTEFvTCstjDHO/dYg21WEMcapqamJiYkuLi6RkZH8PTvI2i++kudcwMXv3HGeFtVsUBO6P2fDtnnZFH4l54dlykiBqlINFUIIa++45Du2MEKpFi7RxMkFRISTgL68fMZetvsvnzTkQ/dNgapSzUIjR8j89JmG5TKmtW2vTmUwQggRIs+G05YsmNPYjXfVygrhMDlZEMOlH4fMvd/gu5NjotB3LEJ0JsPQ4YF+Ir7ecZAuCleSS3ihYVDA63OtRZOg5VguTs0iKEAjZMuczL/w0uekNLBDx8DsBZv0mam6pJvnd006lOHbYvhH2SNOSep9taGFRqRkOUuYQSPmLAjhuJPnzrOCmtVC7XxOfN1OJt52KWQTGK7+OmTh4wazdoyNRAsqNDg+slFOFrjwcm4nBR6V6nkghLD6mguJsEX/6PFjuVAYGhwskfD60ux18z62Mo8zsOhDSRbRoVcEQgghzpSpS01R3zy+ctL2NN+Y2R/5l/UOsRxzkq/3FbY3ZcoUkiT52KmnEBs3bhSLxV27drV3IHyn0+n27t0bEBDQuHFje8fCd0+ePDl37lzNmjWrVatm71isVb9+/cjISHtHUXHef//9wMDAv//+28nJqXPnzuW+fIwxx3G2qBFfv3795s2bTZo0CQ4OLveFsyxriwYcY/z3338rlcqOHTuW75KRLTf1lStXnjx50qJFC39//3JfOMMwFEWV+6amaXrTpk3u7u7t2rUr3yUjW27qf//998mTJ61atfLx8Sl24latWpXLl9I0rdfrU1JScn7o7u5eLgvPIzMzU61WUxQVHBwskznW+KDmp3s+/2jKIX3wJzMHhThGzwLby5M25XX/wDCMwWDIm5Plsuh8shisNrEEQkEySi4gEPf8j3mbn1UZub2N0gGu4Fn14zgaM2xIn8WHRzYNRolX/lk25qst34yYHnTwjyF+72Ke5kkbjiufrpkMwxiNxrw56VyujVjmmS9GLHzebP7a/v7P4q4YWIwombePt4jHN9OCKs1b+iz5fdOv60csHxQgQAgh/c3Fi/clcVhmMNqwxOVQKjQny75cLn7B6NEz7jIIEcoa/fZPa+JLIiMlVotVDCJ8zCmuTHbXTfrp6dUf/XJF79NuZow339uarH+/GL/0eaM5WwcEC9BTe0djf3nSJrtfRdkXS9O0yWTKm5MqVdmXnJ/RZDFixBrTPD09PV1dbfEV5elV8751WLgAPbJ3NGXGPlnQo92M6wxCpLLB+P0/dSz7O2fzpA3DMCxbypea8vicaWNt27a1dwgl8+WXXyoUig8++MDegfBdbGzs3LlzPT09YVsVa//+/bdu3WrevDlsK94KCQkJCQmZOXOmr6+vY+2mJ0+e3Lp1q1+/fg4UNsuy06dPj4iIcKCYEUJ37969devWkCFDmjVrZu9YrGUwGGbNmlWtWjXH2tTXrl27devWqFGj6tevX2FfShAESZK27olsNps1Go3RaPT09FTZ5m7EdizxxxZNnfDNlruW0B5/bJ/XzhEqkxXDRmlTMTlp4VCimctiOE8xqRIS2T+D6S+sWXBZ9OHCno7RdZN07zLz91qS8OZ1/GUIIRTUtO9Xe4jEapNPLd70YOCEKIdYifKVJ23K69dNm+ck1h38fNQvya1/XNGO1GpcnWVuIgKRvL+PFkdPmx2za+TuYR90PNCleYQw8cL+PZeQpxeVZeDt0y0VznbtJEEQ5b9wwr3bqCnBmtTHd88v37s+ZrJw9S8jQuVSdzrTg04nMEYIWbTXFy3585ujcRbfJn/8OKydM7/PiTj94DdTf0ltsXx9zxAKoVIWtd4qNsrJ7L47tj53syyrTUpKjU+lEBK4+Cr4X31+2by3Wb57wFuSgaRPt1lLguMTH187tHzDwpiPqf3rRtUv25DD+c/dpT59w7kHAAAAAICnBAKBTCZTKBQ2Wj7LssnJySkpKUqlMiAgwFHGJXsJp136c8LQzzfcNPu3Gr9mwee9qhX2fO87KU/alFexTyAQSKXSvDmZoSmXhSOEEEZJZi7dwimEZKSTgHodNU7ZsXpPnGfMsta8eZt70QjXKo1bVMn1EenXpk30jJMnbt7PQlG8vy8vf7bLSYlEkjcnzeU1iidOPfj50FVZreZO7OpD+noECBDjGBmISP/uv552qTxz/sZ/1v62R+pbO+bLY8Oyxnzw1TNnuYOsgs3lSZvyOgkWnJNlR0gr1W1UCSEc06FD+JdN52386UD3QzECMWYQQghnXdqxdOjvx29aPFr1mbhgcPNqfN/PWHf8hxHrTV2XfNmv7L003xZ50qa8nkSkKEosFufNyXLq8o+yx3BLS9MmJcmk0vAgdxGBEMH/fYp1h2aOWGXoumpBvzKPU8EXhLxSk3aVEEK9+/etNKDG50tmbe924OMyPQmRPydL3VRCARoAAAAA4F2k0+k0Go1EIgkLC3O8l0ywcVtHdhiw+qlHm+k7F03+MNyxxgwBBWMQYhhWz+BQGSWhct1ycwn/rDhpCB7wYTNejyRZDMLZVSFAmGFZbINRioENZOqzLp/+T0Mnxk9sETQx538WNnRaSIWPO3vt2wb8vaUWBrcev671+Nd/W05Pe85QIWGB/A0Z5GN5cX3zjbSg2s2behEIoUyBTC1SOjVtWu3nq0/v3yI7VkMIIS5p6/ezBuxL9GjQa+fEnh/6O8Q5ndPeuZtAJ24a0XDTiJyfL20YsJQKHX725DQeH1zgDb3BoNZoMMYB/v5OcjlWO8pu47Q3bybQ6k39wzb1z/m5QzTvuVient38b3JQ405N3wzwRQW1aF6NunDv3jMW8WUoHgfZnAAAAAAAoJwYjcaEhASWZX18fFz5/4BkAZi7iwYMWZNQdeLOfd+18uTJZTUoAyOLEwzYghBJkcFyKt/7Sbmn/xw4T/uNaluVp298y4e5ubzrtIPKAQtW93rTsYp99uSRhfQJDeT5Y/EAIWS20OqkZJPZHNbi489FyW+ezMZp59euOG6qO3BYiwD3RvwdzZtLOLHp6CNVg75tI1/9QEffPHFWQ4YMiIbupg4l/tSEb45Gjal8sLefVqIykCJPS4ZLikaPCalERCCEEHt3409D9qdU7Tt736iajnNOJFX1es4Y1zTHwaU7v2nDcVONgQMbBbjV5e/BBV6xWCyJWm2WXu/p4aFSKh3oFWsIIYRIVfSAGdNbOV7znl/sngnjtkV9WefEsDeXHDgrMxMTUqmEP3sFCtAO4/Tp0/YOwTGEhIRcvnzZ3lE4hg4dOnTo0MHeUYDiXbhwwd4hlNjw4cOHDx9u7yhKhqIoR2w9Ro8ePXr0aHtHUTIymcwRN/WkSZMmTZpk7yjKimEYjUaTkZHh7u7u4eHhaLcKr5hOLl58wVxnztpvoPrs8FiMtGYujebcBEiKEEkWlJM49eiJ27SyY5v3HKX+jATBwcr4G+sX/fZRq29j3AmEEKJfbFm88SoKnPBhdYdZjXcSy3La1LS0jEyli3OgjzcZOmpO65z/fvTT0VUn0qJHzPqC353j8J2NM0dfj2ZO/j0yiEII0bGb56x9LK7/5aD3eB03yEMYVaOZ/NDuvcd39p3SgsvyNyZRXNqerSfuYeXQukEChJDl5uJN98xRH6/91IGqzwghwr1B3zkNcnzAPv3p9MYTurojJk3g98EFEMdxySkpySkpLs7OEWFhth5d2jYI98afzGmc4wOHad7zEtZs3Nx58+71f//bb2rD7J8c2eQDK3fdwx5Dm0byZ1X4EwkAAAAAALAVjHFqampiYqKzs3NERIRQ6MAVMPbR+QuJnMjl7NwRQ3PfaxMuTcfNH1QVLnAdAkYo1cJpzVhGoXA5JTQW/nuI/srRaxZJ/Xr183WN5i/n92dOaXZ4+tYebWN7flg/hEq9cfLA3rv0eyP/nFHbgVbjnaPLzNIkpUgl4vBAP5Ejt5OI9Os/ZdBv3f8c177r+R7RXul3Du0/dgs1W/jzwIh38A2YjizdvfXAYUcPLVw/qtfD3k0jfFDazUtnd97L8v9gwud1xQghNu7uhVQskt+e+/2LPPVnl5pd58cEwTkRlK/MrKwEtVokEoUGB0skjjww1tuCULadPbbu4W/+bN/uQe92NXxw0s1T+3feSPfvsuDzplJ7R/cGtEUAAAAAAG+5zMxMtVpNUVRwcLBM5vDDJTPPnz5ncNadf9beyfMf0lPQ86dBVe0SFSiRLAarTSxCRICUdBIQCCFc+MTm6xfPZBHh1aIc6jWTVGS/Jed9//p26c4DG1dutoj9ohpOWvjZtO5RDvIWxXeO3mhUJ6VgjPy8PJzlDt9OIoRcGn9xbHfwrO9W71/7p07oU+v9STs/HxUTBL9/OAwjKVKLVQxBNev91TnF6q82n9m+7aqOEXkHRQ2f0GNm12o+JEIIMZrE5yzOir28NjbPAghPqtlPMUF2CB28pUwmU4JGQ9O0l6enwiHHcHtbiap9uuqMz5KvVhzYvuqMjpZ4R9Qe/u2nMwfU9+HTUxFQgAYAAAAAeGuZzWaNRmMwGDw9PVUqlaOOuZGbuMPyFHq5vaMApWThcKIZZzGcp5hUCYnXOUl49j7ysHeBs4gbfxEf+0UFxlgyhGefI7F9CvqPOPj9ocveH1rRAYESohkmMTk1Q29wV7p6KBXFtJNU+OTTuskVFVvZUJ71B/+5c7C9wwAlxhCUVqzQUTJ3OtODTicwdm09cHPrgQVOLG48LuXcuAqOsKQIr35HnvUrZiIqePK+Bw5ycL1zWJbVJiWl6XRuKpWHuztJFlrXJHxGHDGMKOy/vOYIzTvh1e/I84IOJUJerevUzV2nVnhEJQAFaEfApV7ftnrjiWvPMp2CarbsPbh7DeXbcPdoQ1iz54tvknovGlIVHjBDiH20dszkbfrGUxZObPymyw17f9Woz+91WDK3s/frzwzn5g374ZQhsPf8hX1DYdNVLCsOc2x8emzd6p1n7qqNIrfgGq37DOpSy12AcNqBL4b+fp1+PR3l1/2HJQMjbbkHrWmUCpvGjg2aY21ka2MuPDYeb2r64s/9vzthzN3dkfTt9uOvAz0O2WlTZyv69MHDrC4Sy7LJyckpKSlKpdLf35+ioGEHdsZhlGzhki2ci4CIkFOCAod7BqACcRyXostISktzkcsjgwME0E4Ce8MIpQpdtGKFE2OMMKqFHGPviMC7DmOcptMlarUyqTQ8NFQkgqcoQClBAZr/2Gfbv/t2K9t88Jjebkmn1q36di41/7uuAXB1VBhsenH8r523DPU5e0fCJzj1zIrVzd4bW7/wZ1dx5uVTVwxSmSj+zJknvUJhdLiKZMVhjtPP/Tp7ya3ALh9PruuDnx77+69vZmd8NX9IVaFWoyUiO03oVvXltQAh9bPtu82taZQKm8aODZpjbWSrY0ZcIbHxelMLIjpNnNaQeV2AxpnXt668Gv6eD8kl2GdTZ4dR9OmDh1ldFJ1Op9FoJBJJWFiYWCy2czQAIJROcxoTJ6KIUBkloaD0DOwvU29QJ6VQFBns5yODYUwBD2RRErVYRSIcZNTKWJO9wwEA6Q0GtUaDMQ7w93eSy+0dDnBsUIDmPcuNvXtj/bsvHNkugEKomrvu0aQ9+253HFkdfnfKDycd+3n2qvMvMiwYuds7GF4hvd+L4k4v+6tplVF1nAq+58MZl05dpav0HOKxe9nZMw/7RUTZu3ryDrHiMMdp5w9eZBqOmTKgqTOBUNUob0Ps2J2Hb/av+p42Mc0lomHTRu9V0B6zplEqbJqo23Zr0BxrI1sdM0J0wbHZ8dxhxVcTqoj60RGv/sJZ//22xtji00G1nQmzfTa1NacPHmZ1IYxGo1qtZhjGx8fHFYbnAzxgZLHaxNEYeUkohRBKz8D+zBZanZRsMls83ZQqVxd7hwMAspBCtVhpIMWelnQVnQENJbA7mqYTtdrMrCxPDw+VUvl2jOEG7ItP41GDgrBxt+9medeu45t9K04F1qnlmXH3jhp69xaEUNTuNXH23Pmze0TCbyu5EE7V+w1vgY8t/fuGoeB3/OC0C6dusJWbtGjRqLaT9tzpe3SBkwFbsOYwx5m0OKhuvahXvx9QHj5eAovRwHBJiVrs6ePJGdO0yZl0Ea9wqsBoC5uGtl+D5lgb2fqYUSGx2fHcUeKvNt3euOJq5UH9asqJwlbH9oo/ffAwq/NjGCYhISE2NtbJySkiIgKqz8DuWIzUJi7WwMoFRIQcqs/A/liWUyelPI57IRaJIoMDofoM7I5DhFakeCTzEWI20pDgBtVnYG8cx2mTkh4+fowQiggLc3tb3iAC7A6qdHzHJWuTsZuH6tVPBaTKQ4WTtUkcCoJfD/ITKvzDFAinPZRCC5kH4VxnwNAm43/6c0OTnz+pmu8hQ5x8/tQtXGVofTeZLLqW/OT5U3cGVq0B3ewrhjWHORnU6fN5b2ZhtaeO3UDhvSpJuQR1EpN07Pshq2LTWSRwDm7cd/SnHcJlNjsErIm2sGkY+zVojrWRrY8ZcUkFxibk96bOgX22e9VJt+7zG7gQha+OrTc1suL0wcOszgljnJqaqtVqs0vPQqGwAr8cgAJgjNJoLtHMySgiXE6JYLhnwAO6zCxNUopELAoL8BOLoJ0E9qcTOmlECjFHhxrUEg46AAH7y8zKSlCrBQJBSFCQVCq1dzjgrQI1TL5jLWaGkEpf3xATUqmEsJgtFdctDLwtCNcGgwY31B/4Y9M9c97/4cSzp+6RVZs2UBFI+l50LVnqhdO38k0FbKSEh7lZ8+/6r6cvfRjad3hbb5SZnEZLncI6fbl6y5a/lkzr4HRt+XfLL2XZromwJtrCpmHs16A51ka2PmZcSGyOsqlx+tkNe7Ka9WrlSRS1Onw45fEwq1/Lysp69OiRTqcLCgoKCAiA6jOwOz2LHxvYFAsOkFJBMqg+A/vTG42PnsdrU9L8vDyC/Xyg+gzszkiKnki9E0Wu3hZdiDERqs/A7kwmU+yzZwlqtZenZ1hICFSfQbmDHtB8R4nEFE43mjCSZN+dG40mLHSGnqmgFAhlk8GDzoz/7Y+tjX/snfMf3Iszpx+i4B7eGXHPMxFShoSKTl08dX1o7frwPhaboC/+3P+7E0aMEOHUcuaa/1l9mNOJlzb/sXTnLfRel6nzP6rnKURI3OaLjW1e/T+gfp/Pul3736aT14fVb2yjSwZrGqXCprFjg2b9V/NhI1sfM6EsOLZBzRxgUyPExR/e9Z/HB/Mrv3rjYCGrY+tNbQ0eZjVCyGKxqNVqg8Hg6empggckAQ/QHEo0s5kM9hSTKiEJKQnsjmaYxOTUDL3BXenqoVRAOwnsjiEorViho2TudKaHKZ3AfPidHbzTWJbVJiWl6XRKhSIoIIAkoaMqsAkoQPMd6ebhTsSmpHFIQSGEEKdL0RFuVd2gSQClQbi3+OTj0+OX/76j/qA3n3JxZ848YWh24+ejN76Z9NLpq4b60bKKD/IdIKw9cunaIRgjRBAimZB8Zs1hjg33Nn/9zdakyO5Tl3Sr61VIeYt09/MV02mZJoxsNBCNNY1SYdMI7NegWdeW8mUjlyTmgmOzqHi+qRFCCLGPjx+PC2072b+wsCpqU1uDb1nNcVxycnJycrJSqfT396coeG8ssDMOo2QLl2zhXAREhBMlgDIfsDeMcWp6RmJKqotcHhkcIIB2EtgbRihV6JIocpWz5gijWsgx9o4IvOswxmk6XaJWK5NKw0NDRSLo6QhsCMqYfEcFVq0sV1+7npT9wyinuX5D41ylqh9cQIHSITw/GN4vKmHbH7ufvbriYZ+cOv1MWPuz1bt2v7Lx8/dd9FdOXeHFg+9vI6HM1VWhUCgUrq4yoXWHuenmXz9vyWg8fd6s3jkLo4bzSz4dtfBM+ut3z714/MyiDAhwttmNvzXRFjaNyH4NmmNtZOtjLiw2RRC/NzVCCCHm3olTiRFNG3m93pD22tTW4FVW63S6Bw8e6PX60NBQHx8fqD4Du8tk8MMsRs/iUDnlL4XqM7C/TL3h4bN4XWZWsJ+Pv7cnVJ+B3WVRkkcy3zSBPMioDTJpofoM7E5vMDyOjU1JTfX38wsKDITqM7A16AHNe6LqHToETtvyy3rfIc1U2uMrtseFdRtdDZoGUGqkd9vhfc5MXPGfkaqMEELsozNnE2R1+0Qr39wtymq1bKQ6efL05cwmLVzgJtLmCj3MmcdH1p1MqdyxZwPVnZNnkn0aRrCPrlx+PR+pCqv5XsNq9PfLflIxHzX0o1JuH/x7Z1LVgR0r27BxtyJar8KmoezXoDnWRrY6Zs/CYhNxfN7UXiRCiH129ZrOp1HlHE2P1F6bulC8y2qj0ahWq2ma9vb2VigUNvoWAKxnMpnUarXFxHlJKIUQLhmA/ZnNZrVabTIaPd2UKlcXe4cDwKvxsiQenpZ0FZ0BDSWwO5qmExMTMzMz3d3c3N3cYGwiUDGgAM1/gtAe06fQf65ZMm27SeZXM2bqiK5B8BM+KAvKv+OIj85MXvsIIYToe6fOJLpGD6+bq4uhqGrLZj6H9p/6N735Bwo4H9lcYYc58+LS3t2xbHSP+uSLBD3z7ODirw++mYuQNJ329+To4V9PUazZvO773RmUyj+y7rCv+7fytenTLcVG28Cr0Gns2KA51ka2MuYGXk51C4mN5PGmbuCFEMJJN29opJGV/XNERRS6OvbCo6xmGEar1ep0Ond3dw8PD1vcKmRlZZlMJoVCIRDY5vqQsslbv2iaTk9Pl0gkTk5Otli+7aSlpbEs6+7ubu9ASollWa1Wm5aWplQqg4KCbDFkpF6vNxqNrq6ujvVqTYZhdDqdWCx2dna2dywlo9PpGIZxc9hiBMuyycnJKSkpSqUyMDDQFjlpMBgMBoOLi4utugqKbTL6HcuyaWlpIpHIxcXBKvLp6ek0XWr79gAAIABJREFUTatUKgcdlPb1eFkKhSKySlVbPLFkNBr1er2zs7NYLC73hdsOxjglJUUoFLq6uto7lpLJyMiwWCxKpdJBnz97nZMuLi4RERG2uOQzmUxZWVlOTk4SiW1eKGWbdhIhlJycLBAIbNjDwyvIFkvNzMw0m802vIAvPwSGMe8BAAAAAHhp8eLFwcHBjRs3TkxMlMvlvr6+tqvE2bwAbRtQgLZS69atDx8+XPblLFu2zNnZuU2bNomJiTKZzMfHx3YP7UIBuoJVcAG6vHJy/fr1JpOpW7duGo1GIpH4+PjYrhJn8wK0bUAB2kodOnTYtWtX2RucXbt2xcXFffzxxxqNRiQS+fj42KoSBwXoClfBBegePXqsWLGi7FvpyJEjV65cGTVqlFqtpijK19dXKrXVG75tXoC2GZsXoG2jggvQAwcO/P777319fUsxryPdYAAAAAAAvFNomt69e/f169flcrmta3AWi4VlWbFY7FgdzTiOM5vNFEU5Vj0IIWQymTDGtrsDtBGapv/5558HDx7I5XJbb3OaphmGgZysMGazmeO4CstJi8VSLsthGOb48ePx8fEVlpMikcixOj9ijE0mE0mSjlWjRK9yUiKRVMyPIllZWeWyHIZhzp07l5KSIpfLbb3NGYahadrhchIhZDQaISeLlZaWVi7LYVn28uXLP//8c4XlpFAodKwODchhc7KCL+ATExNLPS/0gAYAAAAA4KkrV67cv3+/YrqQsCzLcZxAIHCsp+8xxgzDkCTpcPfeDMNgjCusb69YLO7YsWPZl3P9+vVbt25VzL035GQFq+CcpCiqc+fOZV/O7du3r169KpVKKyBPOI5jWZaiKMf6USQ7JwmCcLh6UHZOVmQj0KVLl7Lv3IcPH168eBFysgiOm5MVf2KKiYkp+09rT58+PXPmDORk0Wiahpy0Rrt27WSy0gyEAgVoAAAAAAAAAAAAAAAAADbhYL9IAAAAAAAAAAAAAAAAAHAUUIAGAAAAAAAAAAAAAAAAYBNQgAYAAAAAAAAAAAAAAABgE1CABgAAAAAAAAAAAAAAAGATUIAGAAAAAAAAAAAAAAAAYBNQgH4XcM8WNROT8t7bzPn+RZ8YHSgQVp35H2OHuMrCGHto0ZhujSr5KmViibNHaJ0Ow3/a/9ho77AAAG+zq7OqCamAz47TuT+2PFrbK1hEOteecEjL2ScyAAAAAAAAAACAr6AADRwPpz4wvmnN9uP/OKXzb9JtwKCPWtdSJp1cMbVT3Q++PJ+B7R0eAOBdwjzd+Em7YVuSK4/ecmBeG084qwIAAAAAAAAAALkI7B0AACVE3/v1436Lb7h1/2370hE1FUT2p0zCP5M6dl/87ZBv21z9IVpi3xABAO8INn77yHaD1qsjP918cEE7L6g+AwAAAAAAAAAAecHdMigt1mJmyre3MUvTxT69jlN2ffn1cX3VSRvWjHxdfUYICXzbzV00LIR7sHrZMYNtvrrUbLpwAIC9cOp9o9v1X/U8bNiGg4s7epf8fFps2wCNBwAAAAAAAAAAxwcFaJAD92RBE7Go4U8P2TcfPZ7fWCxqNO9RdhUka0M3qbjxd3tXDK7t5SQVieRe1TrO2POcNj3aPP6DKE8nqYtPVIvhK27o3yzUHLv/+8GtqvkppCKxk0dovc4T11x/M05G1oZuUnGT+ReOft0pQiUVCyWqwBptR6+5mVVwhDhl75rdydKWY0bXl+b9n6TRuOUrl83t7Gd5tXQu5dKycR/WCVbJJXJVcJ0Pxy27lPKmmmPFVxvub/uid+MILyexWO4eFv3RFzsfm17/0/h4zzcDmlf2dpE6eYTUjhnz2xkNWx4LL34vFBMYAMD2OO2hiR16/fk4aMj6g79+6Evl+FeRjZ55R19ncYNvD++c0jpEIRULJYrAOp0nr7tp/QTFfgUAAAAAAAAAAMAnMAQHKDHm9vwBY13rDZo9P8Tw71+/bp7bu/2Z93SPyLbDpnak7mxZsmb5px/71LnyZU0BQjhx6yfNem/QhbbuNbx7oNTw7PzOzQuG/KtxvrWum9ur/svss1VDesaTzYbMGRXA3tm5dM2vn3zI+d/6tZU833fTl09fNAmqtmjqSeT7HxIEvz9gyOu/cPqJqS07zr8lqtKhx6i+irTr+7f9MqLF8Qf7Tv3YwtWar+YS1g9sMWC7ucqHvcf082DiTm/Z8M1H1zOPXF3QTIYsd5Z0aTH2iKVSu54jenjST8/sWPbZB/vOrz255iN/smwLL3b8kCIDAwDYHpdyYlZMj0U3ZB+u+Of3Lv45q8/WNHrso98G9EmkIzoMHl9JFH929675A09f1p48OOE9kTUTWNWuAgAAAAAAAAAAfIHB2499urCpqIgkEFT5/AqNMcbs458bi4QNfnzAvJn30bxGImH0Tw9ZjDHGmeu7ShDp02tjQvbfbOzCpiKCkDf+8ZYZY4wxl7SuqyshbrNUw2GMcfqGbnJS2fWvRO7V8uJ/aymh/EYdzZ48e4GEtN6si5kvp9CfGBtOCaKmX6LzrwmXvLKDGEm6/J1R7ErT1+fUFJIeHX69Y3i14NuL27mRolpf3aCt+WpO/WdrMened5vu5X8t179v6u1VZ+YFGrPP/2jjTHl0/OOB+VVk6edm1JFS3oP2ZJR54cXshaLmBQDY0n8zqwpI375fTWukIEViEUEFfLz9deuWrbhGz7S9jxOBSO8uyx8YX06QeGhsdTHpErMygbNmguLbVQAAAAAAAAAAgEegB/Q7gxBEdvy0QziV+1Mu/viqbbdLtiTSvePgLj7Z3XxJ36pVVMS/NQcPqpJd4iYUVaoGUPtoC40RIpBTl1XPk7DU9U2XY7OZQ5ihmZyhSVuOGlPP6eVfspp1KgvxHYuloMfJOS57EIpiO/mx93fvvs2Fjvl8aOVXY3XIqoyY8fGCw7/u3vtwxnuVqWK/WiAWUzjrzsmTT9p2CpUTSFh92in1NIQQwgn7tp40ho6Z9UnEq8I+4dJw9PAm80cdPXiFjmkhLMPCUbFDvhYxLwDA1rB64+wfXaJnHf4tcF7rYetHj41p+PdHPq/Hs7Kq0RNUGTZ7YMTLpx1Izw9mT++0pt/+HYfTBg1QFTsBYdVXAAAAAAAAAAAAPAEF6HeHqNagnxZ0F+f+kD4xeseOEhagCYlU8mbwcJKkEOHk4vy6JExSOUYWJyUuLhlX9y7bf+7G/SdPnz99ePvW42Qz4ZVrgaQqOMiVyLHEQocmJ1y8vGQEmxCfwKJIKt+/mReXj1xLcq3SPDqEevr4KSNsWrNazq7fovdqVRWyFx49Y9HLAnQRX02495jzzdabM37pErHMq0r96IbRTd7v0K1zk2A5wTx9GMswj39qKPwpb4CypBQWIWEZFl7YupfLvACAssKEc8MZu/fObqrEIfP21B28eeyYTo039fV7eXxb1ejJatSJynH6JVzq1I+idj55+JRFqmInEFj1FQAAAAAAAAAAAE/ASwhBMTDGpX+zFU47MaNxZN1es7fcMbpXa9l73Pzt55f2dMlbKC2i5JyHqG6jemLm1tETmgL6CTM3fh/UqVOvhVe47MBRvp7SJEkizHFs7k8KI68zfs/9p1d2/zGzdy3Zi2N/TOvfPKpyl99vmxFJkUhQbcSqPXvz2LNtcrSgjAsvSO69ULJ5AQDlifTu++2spkoCITKg/5Kfu3pqt4//31/PXzZJVjZ6eRongqRIAnEsZ80EVn8FAAAAAAAAAADAB9ADGuSDuRxFEEYdr+aQT+mWxD1fN2fBZUmP9dc29PJ+WYs1bv+NK31Fm/Dq1K/NtCMHFi0413deE6dc/zP/t2XHfVb2QevGcoS4oLBgAX3n2m26X7Tw1RT07et3aEFQaFD+ztMFBJ/68MqjdGVEnZhhtWKGIYQsL/aNa93lz6+XnBkyJzJUiO9Lwtp0fDO4NtbdOnj4rtDJxZqDqoiFf/JrCEJF7YWi5v29VVGDfQMAygFJEq+KvaRfn8ULdp/rt3XSqFXNd30STFnZ6BluXr3PdK7+urHIvHb5HiOoFxpAIcQWM0H5t6sAAAAAAAAAAIAtQQ9okJNQKERs7PVb6S9LGWz8ll82P2eLnqlwXKo2mSFVYWFurxLN8nTHljPGMkRI+PSaM6m++O6i3n1+vpD8JjJL3N5JwxffxQF9xvT0JhCiojp1iiIfr/1+5QPTy0lM91d8t+YJWblTpyhrCtDM1QVdoqO7zf/vVb9ikXdUhBuFGJomPNp2bSZ9/tdXv99+tXCcevyLjz7sM21fkrCwBVq58GL3QpHzAgAqFOnba9GiXj5pB6aMXPaYtbbRY24v+/rvJ5bsP7jkE99+tzNN2rhzGw+i+Als0K4CAAAAAAAAAAA2BD2gQQ6kT5MWVYQnN49sL77Zr55ryn87lv911eAkKO2j3YLK7dqF/rDglwG9uaGtg4jEO8c3bbyKFc5Ie37TqiPB/VpFOhW/kLzEtaZuXPmkw+CVk5qE/96kdfP3fMX6uGvHDl14bnSpN23tj+2yh10W1Bi/4H/bOy0aFd3wYK8O77nqbuzftPumqeqEheNrWJX2ouh+/aJWzvuhQ5P7PVtX9xHp7h/dvOUcVX36J81EpGzQT3M2vj9lQuOaezu1jw6Xqs9u2nA0zr//hsmNxMUvupiFi4reC0XNW/LNCQAoG8K7x8Jf9pzp+ff0Eb+3/GdocY2eECGEJL7icyOjo3f3aF1JGH9mx7Yz8eLor38cFPj6N+EiJiCLb1dhNA4AAAAAAAAAAHyCwduPfbqwqYiQ9dpqyvcvy/HPAihBlc+v0C8/MD/ePq1znRAPmYBAhMCz8dRdy/orRdE/PWQxxhhnru8qoQJHn7C8WoD56Kd+pKTHZuOrD+hrs6sLRO8vicuewXh/8+ROdUI8nJy9KjWI+ezPSykZ575q5iMVKdr89pQtYIEYZ6zrLKHCJp7N8VE+XPrtbd8MaVsryM1JLBQ7e4TW7Tjyp32PDHlWXHv+99Edavq7SkQSRUCtmLFLLyazr/9b/Fdbnh347uNmlbycRAKhzC247ofj/ryQ9GoBXObtTTN6NghRycROnqE1W38y70i8pZwWXsxeKDowAICt/DezqoD0/9+xvK0Tp901KJAiXJr/fMdSTKNn2t7HifQcuvfx/i86V/d1Foudfat3GLfyvzTu5bKKnaD4dhUAAAAAAAAAAOARApfhDXPgLYbNaepU0sPH1aoRJYBtwF4A4G1j3tHXvcfR3vvjlrUt+JGFYicAAAAAAAAAAAAcCgzBAQpGiJW+pXz1ICg3sBcAAAAAAAAAAAAAgEODlxACAAAAAAAAAAAAAAAAsAkoQAMAAAAVhfSu3S6mdXWPQs++xU4A3kGWQ8O9KSIPkhI7e4TWaT9s7t6HhjJ+AU46v27J2jMariTzaLb1D/LvuzWJt0O5cZpTKxcs3HIty96B8FBp9nheNk/L0uB/Wr6zKuJ4hJwssfJoCt52ZUrdCsnJkkbI75y00jubumVecWgngQ0U0AqZLn1ew73Z/NuWPJPaexBqAAAAAABQOPPBYV4kIkQK3+A3/D3kAgIhhBCpiP7yfEauGeKOLhrdpUG4j0Iqlrr6Vmneb9aG6zqusOWzTxc3lwgiJl+gC5siHy5px8d+8ibzHzBlWK/C6R/u/GZAiyhvF6lMFVS709g/zmlL+kXMk2Ud3Un05q3IuZhi/5k3sl3NIDcnuVtIzff7ztp6N6tcIi+jEq+4affHCqKIWwJh3e/u5F9CKfZ4frZKyxJmb058TUsrZrScGB1IWb8HK5Ztj0cu/faWrwa2quavlEnk7sG1Y/63+HhC6TLTRjlpjju26H+d6oV6OEtEUlffys16T1t9Kdm6V/7yNSdfKqYp0D/cO3dY2xqBSplI7OwV2ajn5BUXSrzvbaK0K17yNSr6VFIsW5++SxEhX3OyZDOWy1msXDnM6dsmOVm2UxhPc9Lqg/GtuaR8raRrVHArxKVs6+ft0nzh/VzfCgVoAAAAAAAey75bEFSffS3XDQdnUv+7Ykg1GYEIUa0vr7/6n+HqvJbuFIEIUu4TVatGpLdcQCBEyKKG7XhR0N0pl3p0TGUhQZXkfsZ0fkplkfeAXdaVBUuG052dHa0gEUHKvaOqVwtWighECEP7bnhagjsTy71FLRUkQgXdk3OpJ2c2VJIEQTr5RFWvGqwSEwiRyqbfX9GX75qUUKlW3LRnkJtQUCCKJBAhbvLz43wFv1Ls8QLYJC1Lmr25NwYf09K6GbnklR0kBEGQ+XajtMH3d+1Z8bPx8cjGbx9WRU4gghApAqtWr+QtpwhECHxi/rhrKnmwtshJy70/YrwFr6aqXS1YJSEIRIjDBmyJL77cx8ucfLOEopoCLvXE9HouJEKEyNU/6r2qoR4yikCEMLD7ygeW8l2TEirtipdmjYo6lVjFtqfv0kTIy5ws6YzldBYrNw51+rZFTpbtFMbLnLT2YHyrLimz5yzxGhXeClmuflFd5NlrkzbHroUCNAAAAAAAjxVyt4AxxthybXZNIUKCGnOuMxhjbLw4vZqIIMSR/VZc12VfBuofbJ/YSEUi0r3rXwmvrwHZtEfn/tn425cjPgiVEQihEtzPcJp1XVWC8AlnSlEhKpb+zKTKQoJ0f//bs8kMxhgbHvw9IEJEkO6d11hR78EYY2y6/n0jp+y+PPmuhjnNpt7eJCEK77P85QYyxu4YVV1KENKGP9qz0lceK/4Gl3JgRJhAXGX8ifRXu7wMe7xANkhLq7O3wFXmZVpaOSN9aXqUgJB++FeaDYIvC9sej2zs721cCUIY9OG805rsg8/waMfERm4kIW3w3c0SFyPKPyfZ+OXtXQhCVGnA2tsZ2R+ZXxyd3cKNRKTvkL0Z+b4mF37mpHVNgenMhHABQbq1+OLwc2P2bKnXVvQLFxKEa4flJW+Syk9pV7wUa1TUqcRKNjl9lyFCfuaktTOW91msvDjW6dsWOVmWUxgvc9LaFX/7LilLvkZFtkJs7OIWUnGdb269STYoQAMAAAAA8FhRdwvYcnpcMIUIl/67TBhj06HhPiSiwseezNVRgX3+RxsnghC3+OXZq0vDzPVdJTkfk7T+foZ9srCpRFBp6kUb9ILjUjf2UBCErPminB1/Mg4MC6CQsOZXN625mtdfnFVbSnm0GxDjS+W7Grb8O62ygBBUmnA659OExmP/C6KQsOaXN+x1u1AeK55jaUl7hgQLJLVmXsyRBqXf4wUr/7S0PnsLwMu0tHrGzE095AQVPum8fbuW5mXj45G+NL2yAFFBIw/lKuRyCWs6q0jSa1BGSSs35Z6TnHppGwlBeg7YlStC+srMqgJE+n161FxUOLzMSWxdU0D/Oy1KgKiI3CnJaVe0lxKErMs6XTmuS4mUesVLvkZFnkqsZZPTd+kj5GVOWj9jeZ/Fyoejnb5tkZNlOIXxMietXfG375KyxGtUXCvExv/RWkqFjjv1+vcFeMsRAAAAAIDDYmgGIYQ5DiHExV2/mcyRnq1iGspyTkP6Nn+/sgAzj+49YV9+JG3++Y69e/fu3bt399IhUQLrv499vHXjRdq/fUwt4evPcMqqDhJCGDXtX+b1ZAm7R1aVkZRrg2nHU6x+q4zhxK4j6UjcpO9HITkuUZ1b9v3Ql6Jv7933iC183myZp74Y8uN1RdeFvw0Mzj8gIX1509YHjKDOkBHR8hwfS5r/cOnJ00e7/xde4BiGhTPHHVsytlvjKF+lTCyWKfwqN+05efnFpJK/HKjsK/4GTt0/7bM16qoTfp9RP0calHqPl0op0rIE2ZsfP9PS2hnZ5w9jLVgQVim0XPYLj9KyqOMRJ13+9wlDKlrENHXO+Tnh82H3JiKc9E+WsVzfR1WKnGQe331EY0Gl2tVztheICggOoBDOSM8oKkB+5iSysingOA4hQigS5hyklhBJJCRCHMOWNJl4kJMlXKOiTyXlpJSn71JHyM+ctH7Gcj2L8SAn87P/6btUOVmGUxgvc9LaFX/7LilLukbFt0KkT7uYetSzrRvPml9+YuvLTwAAAAAAYCP6C7sPa1hEBYeHUAghSZXOo8c18m1fLc8FHqtVJ3GIcHF1fnXvTfnWaeeLEEKIe3T3+6JehJMbl3DowFXGpUfzHDcL+SdS7x3Tts/Se6J6U3bu/66Fm7WLZx5dv52FqYg6td1zzSKsUa+GkIi/f+OOGVWSFTY3Qjj14JRPFt/z6L3plz7+987njyv+wsXnLBXYuElI7itlUu4RKM83eTHMNxd3+mDCES0ncPWPqFxDYtbGPjy7dd7ZfQcfHTo/t0lJllfWFc8Bpx+dNW7Ni7DP1s5oIM35j9Lu8dIoXVpan7358DMtrZ6RiX0Yy1Ce4Z4JO3+au+fSvbh0oWdkvTa9B/du7Ce2MspXeJSWxRyP2GyyYIQIisy7J0QSMYW4VLOZQfIidmiJlConhQ3n3sz4GlFiWa4+WxmXL9xmCGGN6kVVgviZkwhZ1xQIanTuHLFg3v01363ss3pYNWcCIWRJOPT1zwcNhKpTj1auVgaKEOJJTpZojYo7lZSPUp++SxshP3OyBDOW31mMFzmZj/1P36XMydKfwviZk1au+Nt3SVmyNbKuFSL9mjSNIM4e3P8f3TJaiBCCITgAAAAAAHiswOclGb328cWts9sHCAlESOp9d6uIxzGZuLVdPUlEhY07Zcz/X/bhT9FCq5/ozNzW25UQRc97lOslLMkr24uRoNLUizTGrHrfZ+/JCNK1wfTjySUbxdW8b7AbicStfnuRZz7z4ZE+JBI1XRhbxCPGXOKOAYEUFTx4dxKHseX4ZwF5nwc0HxnpSyJRy1+fPD3005BWVX1dpRInj/CGPaasupxc0sers3b0UxGEqNLQLU8Mr5afcHhyHSlBqgbuKWBDF6FsK56T6dLMGiLKp+9WbeGbvmR7vNCYbZuWJZuMn2lp7Yxs7MKmIkSI5TJBrptFwrn6sM1PSraT+JOWxR+PhgNDvUkkqDTlfO6xP3V7h/hRCAkeJZYsXtvmJKeL/e/C6cM7Vn4zqK4bSchrTjyaUlQi8TMncyuyKTA92DCytpIkhG6R0a07tm9R019OENLQzvPOFbne+fEmJ61do+JTtwQB2yQnSxkhP3OyVDOW8SzGm5zMpYJO3+Wfk2U4hfEzJwuRd8XfvkvKkqyR9a1Q1rbeLoSo0fyXOxmG4AAAAAAA4D3mxpc1hcRrArlnWIMeXx6IY0SBH/68anzVQrri4fRry4e0+3RnEhnU98epTSQFT2U1NvbWPQOShob7FXwJySYeGNf2o19vCxtM27X/W+s7qmRjsjINGBFyZ3me+Qi5XE4grM8yFProJfdi42ej/k4IGfbH/Bj3Qr4WZ6SnY4STdgxt1H7KqtPxpE9YoLPx6cWtPw5p0mDgpucleFAWcWmMZ7OOnUd9/UW3kFddlUQ+LfrHRFCcXpukL9HgAWVZ8VxBxa6Ytugm1WDCF108bNvH+RXbpqW12cvTtLR2Rib2wRMGYVoQNXTl+adpJotBe+/Ir0NquehvLB/Ua+41i/Wx8iYtrTkepc0H948QsA+WjBi/7bHh5Xdqzy0Y8OnaBBYhzOFSDcFho5y0HJvRLLpp665DZq6+YogctHL79y1VRSQST3OyBIQK//BQTymiUx6cP7zvwIlr8XokUAZFhXrIShQsb3LSyjWyJnVLqnxzsrQR8jQnKyKZ8+BPTuYMqmJP3+WZk6U/hfE0JwtQ0Iq/fZeU1q9RSVohcUhEIEXfu3GPRgghBAVoAAAAAADeI0QK3+AcQkLCK9dp2WfGuks3d3xataDSHJt8eeWY5lUaDF97B0f2XXrgz27eZb6rYV88i2dJDx/PggZ7YxMPTmzXc8kNPZLXGzi8aY7qDHNxSqSAKIKo/tx7LEKvCk6FxMmxhV3Ps7ErR4zZlhzxv6Vz2ygLXUvaZGIxom8evegx9K+b2tS4uzfvJ6TFn/qhnTf9+O+Rn66Os36oPdK/x8879uxY0DPg9cU0k/7o6KYjsTljtPmK55J59McfT+i9e00fFmmzQUvzsFlalih7+ZqWVs5I+Laf/vOi37efOfnboIZBCrFQ6lGp1ajl/6zs40cariyavz+z0DXPiydpad3xiKSNvlgzp4nKdPP3npU8vSJq1qri7+bfZOIxZcsmfhQiSKJUDZaNclJYZ+Sfq1b8ufCbsd1ryB+t7luvxawTqYUXBfiak1bCqYfHv99m8vbESp/8+s+1p6lZGer7Z9ZPb0Gc+bFn057LHjLFL+IVnuSklWtkZeqWUHnmZOkj5GtO2jqZ8+NJTuZS0afv8szJ0p/C+JqT1q3423dJae0alawVorx8PEmsj3+ePXo3jAENAAAAAMB7VNTY/Vfm1LDuyo1NurB0+pgv1lxOZuURMTO//2lqt0pO5XEzzemzDJjwkUoLWBj7eM3s3wiX4BD3Z7HHvpyyucvG3q9uT0iv6D4jRmoLvxangmopCUQ5OUkQMhj0Boxccn4DNuj1GBFyp7zdObIxD34bOvlAZtVJO79537WI1RSIxRSBCFGDWRuX9Hs1fKvAq8nk1d+frTR495EVm2MHTwyzvncGp7u19+8thy9ev/vwSWzs0zhtFo0xQujNmIc2XvHc0Txf9+Nfz4nKMz5rW9RGKF+2SMuSZy8/09LqGYWVYv5XKd/chGenUb2CN/789OzJ63SXJtaPhWz3tLT2eEQIOTf4/OC/tX/5fsG6A/8+vHtf6lM1ZvLYOZP8l9c9epokqVL1lLJRU0kGNus7sBlCCI2dOnZ51/oj9s4d8UPMrR8aFLxneJqTVqKvzB/32x2zd++1B5b28MxeVGTjPt/uihQ0bvz1/mkztnbb3LsEvRHtnpNWrhFrfeqWSPnlZAkOrnx4mpO2TuZC2D8nc0VT4afv8mwnS38K42lOWrnib98lpXVrxJW0FZLKpATisjKzOISN3HqGAAAgAElEQVQoKEADAAAAALxFcOrZuX16zT6cgD3qD13y4+xhzfxE5bZwQigSIkTTdEFfjAllky/27PzkybDag3ZsmzpjX+sVMdk1CjK465e/di126YxfoD+F7qrjE1jknfMa1ahOSMOE2C/As8BL+czzh87qkMj18KTWp15Hk/E0kUPMf/M7N14nEkSN/GvFwGBK6aYkkDmyTbvwXFfAhEfzltWFu88+uH2fQWHWba3/s3ffcU2cbwDA37vLJgQICYQ9w3ThFkfdA617a5211Wp/tVVrHbVqrdphrbO2tnW2jjrrrnvvuhdbREIgkEBCQsbd/f7AAQgSRrgAz/fTTz8fj7s3z3v35HJ58t57dM7lxX37zj+bSTv6NW0THd2v23tB8shG4nMf9fn20au1bNzxIm3c/f3ns3pOy/Hj3vYwH8ZYmZYVy177TEtEVPKwsvyD/VkoUZ2ttnoYlV2kpbXvx4KN+YE9Pl/f4/PCncjelJRBYQIOx7aZXHayURaThUQ4m8Mq0lFWwIgPe35xeFPytRtKqoV3iTvBTnPSOlTK2dPxFsy1+8hebkXKC/xGI4Y0XHLrxvlTN81Du9agU6WVPcorK3X/+OtAeIDEqn5XSJk5Wb43V1F2mpOVPU9WgF3kZJE27PjjuxKXlGV/hNlpTha8fpkdr32XlNb1qMzzZPGzkNlsQQjjcDgYQjACGgAAAACg9tDfXNwr5ssrRv8+P2z99ZNoaRXfy4lL3CU4pcnWlPB1AvccuWH/vNZirOUPC7eennx8y2fzR7Zb1VFkfeusoAYRDtj9pFt3NXThh3eb79+6b6ZZkQ0i+aVvTGmf3rrytPjSnKT/riQhtqW3gUaIFRoZysbSLW9+2aEoCiHE4b79ee2FkA9Xf7zwbJZbnzVHN02s/2qICXn/v4qMXqpUxwuYrm7+86GF227IgBJLDwyzMi0rmr12mpbWbUhr7v97/EGuY0TnbvWL3stK5ag1FMKl7lJrD6kdpaUV70dE6tVZWjPh4OIqLFx1MVw9d92EuNEljoqrMlYkm+Xm3AbR3yY1++HhhWLD2FgOQj6Gcg16Q2mTcNhpTlqHpiiKRogr4BffKxiXz8NenjCtYh85WZ4evS11dfpyzMhebtaeAK15c5XATnPSxslcAvvIyULs+OPbipyszEeYneYksu7NWPsuKcvRo3KchShNtobCWBI3MY4QzAENAAAAAFBbkI9XT/nmik7Sa+3Jvz+r8uozQogVGBLIotXPnuW++RUXd/TwEGEIISJw/PI5rQRk/K9Tl1zRI2T9vHXC9jHvCJHh/K4D6YXaN17bc+ApyZJ371HK3Iguow/kF3/sdpFHcpuuzwonEMJk3Xo25ZDxB/fdNhbenko5eui2GeM3blHf2tFHhnv/PTQjUZf3x9UvfIOj4dlTZUUm7Ktgx18zXd6xJ5nitOjXu+TxmIyyMi0rnr32mZZWboix4rZMHD6k7/u/PC46sa7lyf5/7ltwadsODWpWWlr7fkT6Ix+FeMh8+qwvPFMmrdj1y75MWvjOEJENB0pZlWxEcMNIAWa+d/JMetHEsjy5cElJ4s5h4Z6lHXt7zUmrEN7167niVPrpY7eKnCkRnX7q3ztmjB3ZKMLag2MfOWllj8pM3WaRnlb2u/ysykmr31wlsNectG0yl8A+cvI1+/34tionK/MRZq85ad3VSO27pLSuR+U9C5GpT1NJwickWIAQghHQAAAAAAC1hOXOn5tvGIjI6QtHBdjmEg+TNGkWRJx6dPeRBbUt/cqaHfHxyhnbWi+4teJ/Pw69MLchy7p56xAm6f/JqPmH1hydP3Vruy3vBXEQorPOz//0l3hK1PWTDxq96pQ5+ezui6kUy6/toDY+1n9lwwNGfzF8ed+NPwwfJduy9qMWrjhC+rjds0fOOa3H/T/8X/+Xd2cXtE8SPq0HtvMvaVdy3GRijFZeOXI+O6ZzwbNxDImHl308aZOCQhyL6cXwESsn7Kt0xy33j598TrIadOlYyrPkmWRlWlYie+01La3bUNh53PDAHWuuLxrxacjOpf2DHRBCVO7D7Z8PW3TNJGgx9dMugiLt15y0LIuw8/C+sp2bznz90aqWWz5u7Iwji/LskhHTDqjZETPmvWfDr6nWJRvmEjOmv8e+Tf9+OeHHyI2ftJSyEEJ0XsK+OWO/v21hyUeO7+hQ6rZ2mpPW4Xf4cHy9LYvvrRg1IWTHyjENnXGEUP7To9+M/vxIDuY29KPBL9uqKTlpfY+YUnc/vq3e0Eo1JSdfst+Pbytz0vqPsDfYaU5a+2asfZeUVveoHCjlw4eZtLBd85c/WxYvXgMAAAAAAPthPDbBHUesBl/dNr99RUqxrgsXIYzFE5bIudXi+5Y3tiLjvm/FRoR8xpUymi+Qf2qyD8Fu+V1soZYo1R89uIgVOvNqoSZ056dHsDFM2O7Hx1Y1/LKt7FPTGjpgGO7g3zKm77vvhIlZGMby7r8hoXArOVt68xDCBEN2vTEO44UiwzEKt591clojBwxhGNfFv17DUJkDgSGMkLZffDmXKtY+4vXZmltK+8bbS6NFGMJYrmFtY/r06tg0WMLFnaJGDWvOxzCOb7tRXx96TpaybZV33BL7XUs2Inw/PmOy4pXKecRLUdVpWbHsfclu09KqDamcK9+844pjCGOLvMMbN28SJhPgGML4Ie/9WXi9GpaWhZXyfiRT/34vkI0hjCXyjmzSOMydjyGM7fXu2vuG8kT5gg1OlZTy4KRwAYYwjCcJbtSiZbNIb0cWhjDCvdN317VvfRG7zcnX3nYqMNxb29uHgyEM57r4RkY1CHITEBhCuHPzmSdUNfJUaWWPiivto8Q6Nv74LmeEdpuT1m1YyNtStwblJE0z8PFti/OklR9hJbDHnCzPm7H2XVJa16Pi3nIWyt09zBl3iPlD+WJrO/uZBQAAAAAAVAj5POU5iRBtydeVTG8iy26lDNyW/Xp5UneOn1KWNvnpCw6t5/70fgCRd+HrqX8kWz1hKMJcOnx/7uKmGf3q4fFnj5y4o/XqOOHHf6/uGBNYNYPCMHHH789d3TZ3aGs/Tnb841SzNKrXxyuP3zw6q6VjeUZ2cBp+fvDkLx/3iOQrrp04dv6JKbDfokO3Lm5Y++2M9j6c9KuHzyfqy9hDxQKreMfpjFPHb1swbsOm9e3w3kYr07Jy2Wu3aWnVhpioxezjd0+v+WxAcw9S8ej2QyUrqMOoBduvXds0vHx5b09paQ3ca+AfF0+smNSziSf17FGc2rFBv2m/nru1d1IkryqaL431yYa59Vxz5cq2+aM7hTjkJt75734q6d1q0PR1Z28dmdFU+NYXsductA6v3qQ9/13cOHtYu2BBbuKDJ0rao8m7k386euvs0k6uNfJUWWU9som6/fFt68/9YuwmJ5Fdf3yX4zxZ8Y8we8zJ8rwZa98lZVX16CXDlX/PaQXt+neXvtgao+ly9QQAAAAAANRh5qtf1G+zynd17NEP7e2G0SqVt32A756hz3YOKvXuUWBHIC2BvYGcBPYGchLYG8jJWk1/fGJozK7Wf8VuG1QwtQg8hBAAAAAAAFiP3WzSJ+3xcxv/iq/8gCw7RqY9U3oFB3CYjgNYB9IS2BvISWBvICeBvYGcrMVo9ZENu5XB4z/tLX41ehoK0AAAAAAAwHq43+j5EwNvrVt1Lo/pUGzFeHPd6JGbJJ+Mj7K3m2JBaSAtgb2BnAT2BnIS2BvIyVqLTNj40z9433mfNue+XlinC9B3FzRiY7yuv6RXxSwkxn/ec8IJnymnC55RSZazcSvXL/YqVYuM/bYFB+O2XpZg/bQ6FUclLm/DxbhtfypjEp9iUZV3x1ZYtb1QiYya9LTnacock61fiNluvg2dvnukn/fwXZm2D4zOvLx19eYL6WXkfeVWy78+p6Gk3bIHNj+kAABQDQTRs34cg239ekNCLR2xQrg3/3DDmV3jgwimIwHWg7QE9gZyEtgbyElgbyAnayVafWTxT4/bLlw6WFZ48ug6XYAG4DXT81unT56+/lTPdCAIIWS6OLupj7dv669vVPUvDXbVzbegVfs//2Sf72cL+klt/lQQKmX7rAmfLvrn6dsry5Vcjdd02lfd4xZO/jm2ln6yAgDqFkzc7bs9G0d45OTa2++XVYPl3bhthKRuDVWpBSAtgb2BnAT2BnIS2BvIydrIrGK3Xbz39wmBRcvudW03FOHTe/6v3hqPNk42qHDh5Wy8vOvXWbbaUXTWgRk9Jp2rv/jOlVnhhA1fiFk1pZvGq9/P3kEO+Ht8sM1/J6TVZ378+ZKR9rf1apj43ekf+LdYPG/38G2DbV9WBwAAG8NEDfqMb8B0FAAUAWkJ7A3kJLA3kJPA3kBO1j4cebex8jcX1+kCtEtU37FRNmobK2fj5V2/zqq2HcXoEcF4fB724v82fiV7TDxaueu73+J8x6zvZruyOKVJuHr1xu2rp/ds2nIy0UyXUuiu0tXYDca+H/39jO9+fdh/TmSdPvcCAAAAAAAAAACg7oAiSGksJiNic1kwTrE0tMVkwTlsmMTlbSqaRazwRpFcLDOygdy6dyipzc0XihyqPFuZeRdQydt/OZIb9MmQwtPVF1X5wPRHZnQcvje/elfDffsPbTNz8h+/XZ6+vG2pnQMAAAAAAAAAAACoRep0+fDhN005rx+/RqWu6cjFHYbu0sTv+qxTgFjA57C4jh7hHcctO51mKbqlPu6fxWM6Rno5C/hOHuHtRy85nJxfdMIaslDj+mMfeBEYO3LOzWLNGI5P9C74g5ksGoyVr2K5PiucjfH7/qktstj07wcygpCMO1L4eWfGZ6dWf9K/dZini4DLFTh7hbcdNOO3q5nleN4glbi8DRd3GbU/7fJP7zX1FPG4LI5QGtSi/4w/bmQVmte2PFEhhKic2xun9W7i7+rAF0oCmrz78ZpzitJnPi5pR1Hq21tnD20b5uHE5zt5hLUdOnvLLXWxjr2t+7pt/fm456STRmS+MTuChXHbr0qhSnohOvfBzgWjOtX3FjvwBC5eEe8MnbXphqrwlL7WZxGtfbhr4ehO9X1cBByug6t/45iJP516/qLjmCiqaQgvvElDQclH4umKdlxcNHK/0ZSwe3q3MFeh//9Om6qim+V5F1BZ13+b2ivK10UgcPZp1Gv6tke5976O4hDeH516fYjf2s1SDnHCru1Xzd49ekWxK7JjrcR/Z87egwcPHjx48J9fx4WVWuev2tUQ7tG9VzPi6a7tF40ViBkAAAAAAAAAAACgBqLrsAeLmrARt8s6BUXTNE0+W92Bg/E6jH0vmI1xXYObd+7WoZGXAEMI49X7/Lzu5VaU5sJX0S44QghjOXqFhnoJCQwjZF3ebSnAcO/Jp0w0TdO0pXDjhhOTfAjEipx701z49fOOvO+BY5xmix9Ziq5v9auYr30RxkK8Pltzi3TMeGyCO467jj1sfLkk/+6KLm4EhjC2k09E42aNI/1cOBhCGL/+zNc9szxZ2pyNONE/xJMl7i8y4cfWHEzQuENLZxxhON8tOCxAzMUwhDCufPTfKS+3si4qMuHH1hzEbjBweGMhhuECd3m4vwsHwxDC2D59f3tiKjmq4juKtqTsGhvKwxBGiHzqNYkK8xASGMK4oeP3Pn/VjTK6b7y1cdb0iV38CETI2o6bNv2LtRfU1BsvRCoOfFTfAUMI47oGNWraONSdj2MI4wQO3RL/6rham0W5F+Y0ccQQhgvc5A2bNg73FBIYwtgB4/ZnFLyc6fE/aw/GFsmXQkci+ae2HMxx2LrtYwM4XGl46+7DVtwwV0U3rY2fJtP2TwjjYQjD+W4hjRoFS7gYLm7et6MvgXtNOvky8crsZkmdS1ndgYu7jNirK7LU2sDKj4z7vhUbEfIZV0rZ3VW6mvnmnEgWETTtkqnEPwMAAAAAAAAAAADUMlCALlp6Qwhh3LDxO+L1BavoY9f3k+EIdx190FCwRHtyShALw3ih7/1+K9tC0zRtzry2qp8vC0MIlVKApvNPf+xHIFb9L28VKkrpDo2T4Ri//apk8o26qpWvYm0BWrd3hBjDOKHv/52of7lO2vEZTfgYLh594EXPrCtAI4QQLu244ERqPk3TNKVPOjSrjRhHuKTPplSyHFG9bs2tyzdn0ow0TdNUXuLBma3FOMIc26+Is5QUVfGCadKvPVxwjBc2essjbcES9a3Vfb0IjPCZcCTH+u5TaT934iJ208UPLXQJR5CmFNsGueEId+/6zVlFwd4ns66v6ufLwjBRx1Uvd5l1WUQ+XdWBh+HijkuuZBW8HKm5+nVbEYaVvveLHInkn9pyMLabh0/U5H1JL49fVXTTyncBpdw5VIZj3LCxf8XmUTRN06bUozNaiDCE0OsCdMW6qd091AnjtCq2gpWBVUT1FqBp3e6hIowTvSy+4hEDAAAAAAAAAAAA1Bx1egqOEhEBH/y8cnAQv+BffPnoacP9CUqXrtDSCCFatW/V5kSS3WjmtvXjGrkQCCHEkjSbsnH9eN9SHk+GEELc6MH9/QjLo/37HryaLUB3aufBDFrYafQg3+JHoYKvUipKbXFr17PPR1/P6x/womOI49F+ZC85QeVlZObRb926ONy197KtX3by4iKEEMb3j1m048deYpR1ZPWWWLKsjd9sTTpgxdZZ73hwEEIIEwT0XLzjx15iTHvhlw23y55ZwXJr/U/H1XjI5N9+HhkmxBBCCHduNGn13A48Ku3oof/MCFVN98n4rSv/yUTSgSu2zGonK5gaAhc3nbxh3RhvPPfc2t//KxLs27MIkQmP48w0q+GA95qJCw4o7tRs8rfL5s2Z2ScEs/Jw0OZsx8Grl/Xx5xX8uyqPchnxU4l/rtyrxPzGr145TC7AEEKI7dVt8frpjdiFZ2WuUDfJpPuP9YgfGOxV0smpjMBqAm6A3JcwP777mOlAAAAAAAAAAAAAAKoDFKCLwd269I4uPPEu7uQswhFCiEYIIdP10xd0NLvlmLENizxCTNRh9KCAt9SGOS0GDwgkLI/273/0okabe2LnIRUSx4zu4/bGk9Qq+iqldsp74I97D+xdPsjn1fG25MSf3HEiqfwFY4Q5dRvV36NwzLjnwPE9XTDzvTMXVOUtA+LimFG9i+wB3Gvg+J4uuCX+4qW0siaoJpNOnYqzsOT9h7bgF1qMe43Z/jj+ydm5TVkIVUn3ac2ls7dNmEuPke8WCRZz6jSitydhSbhwIbVQsGVkESICw+RczHx+8Zg5W87Hq80IIYS5tHp//tcLP3830NojjLt17NH0dYJU4VEuI346+9yJmybMvXv/NsJCK7Ei+vSJKBx8hbpJPn+aSuJSD7eS/l7WjrVc/TyEhb0Fp/nSxxVI+qpEuHu44XReagqzYQAAAAAAAAAAAABUj9KfllVH4RJ3aelVeTo3LU1L4eLwCI9iK7EjGkSwUWKpW7KbDhogX770wb79j+bUr0egnBM7j2Qj2djRPVzeqD9X/FXegtLcP/jn38ev3nkUl5iUlPwsQ2emaYQQt8wti2H5h8l5xZbxwiKDCPq/50/TSORerpwiAsKCi4fAC4sMItB/yjQlhd4YHV4E+Sz5GYmIoNCgYi/Kc/UNdC28oJLdp5SpaRaa8A99I1hWUFgQgdLSnqWRyP9lsG/PIoRwv/GrVl4d/NlfJ5eOOvEt4SALa9Iyum2nnoMG92wotXr/ETIvWbEqbRUd5TLiJ1OTn5lpwjfQt2ishF+QHwvde91MRbpJ5en0NObB57/xvig7MIS7txr24cSM0n+4IPyi3nzDVTO+gI8hSqcte00AAAAAAAAAAACAmg8K0MXhOPaWAhWOl1b+4gr4+NsqW6yowQPDflh0f9/+J7PqhWv/3XlUjfl9PKqjQ5W+yitFRiLTOZcX9+07/2wm7ejXtE10dL9u7wXJIxuJz33U59tH1rRWVAkB4ASOECLJMgaXWjk+uqA1Fptd5pqkhUQII4i3Dhquiu4XRF5SahQcLJKiii58WxYhhPiR47fc6Tf71P59R0+dv3j56tV9v53b+9uSOQ0nbjq4qk+Js0+8qegeqsqjXEb8pMWCUAm7442tKtBNjM1hI2Q2mysSGO7fb8Gafm9ZwR6YzRaEMA6H6TgAADXDqVOnrly5Uj2vRZIkRVEsFgsr40PMvtA0bbFYcBwv43LA/lgsFpqm2VZc71Se0WjkcDhz5sypfFMXLlw4d+5c5duxBuRkNavmnEQILViwoPJNXbt27cSJE5VvxxoURZEkSRBE6d/X7JTZbMYwjMWqYV//qzMnTSaTxWKZP39+5ffSnTt3Dh06VCVRlQlysppV5wdTQU7OmjXLwaGkslF5PHr0aO/evVUSVZkgJ6tZdeak2Ww2m82ffvqpq6tr2Wu/oYbtWaZhjt7eLjiV/fhROtW5yOBcKjUpxfLW+iqrweBBkd9+dXff/tiZsjs7jmnwsI9GRZc0NLUyr4IQQsiYnZ1Ho1fDlMmHqz9eeDbLrc+ao5sm1he9zEny/n8VSU/L08fx+ahekTOgKfZhIolwmZfsLWeYYlG9CCLpcbwRhRWeVQGZnjxMIDG2j79XWRfthIe3jEBZTxOfkqh+oZXp3PuH99/MFjfuHVPfiaqC7uPuXh4s7PbT2EQTCi882wcik+ISSUR4vDEYuWwscXjXseFdx85CiNan3Ty4cvqU78+um7yoX7efOxcfY162qj3Kb4W7e8pw9ORZUgqJggt1m0x9mvrmTxDl7CYucZfglCZbU9b8KzUVpcnWUBhL4sZ0IACAmuH+/fsEQTRp0qQaXis/P99sNgsEgppVNSNJUq/Xs9lsHq/8n56MysvLoyjK0dHRpq9iNBrVajVN05s2baqSAvSjR48sFkt0dHTlmyqT0Wg0mUw1NCdZLBafzy97bXtSkJNCodCmX2JNJpNaraYo6o8//qiSBuPj43U6XceOHauktbcryEk+n1+zKhQUReXl5dXEnNTr9SRJ2jonzWZzdnY2SZIbNmyg6Sp4tExycnJ2dnb37t0r31SZTCaT0Wjk8XjVU6avKjRN63Q6giAEAkHZa9sTg8FgsVgcHBxsWl01m80ajcZkMm3bts1iKfvZWGV6/vx5Wlpa3759K99Umcxmc35+fo3LSYSQVqvFcbzy5f5qVpCTtr5YslgsarXaZDLt3r07Pz+/Yo3UpA9Oe8Bu3L61aP2eyxs33vtwXsPXYxhN9/7adrPkMZuvEBEDBzVYNPfO3n1Xva6fyGFHzRzZsOT9X85XoXVaHY0cX34m05pThy8aCpV6Dff+e2hGoi7vj3tdl0QIGZ49VVZgOlxac3TLvvQ+I2SvmqLT9/x+QEWx6rVrU6gAXVZUBajsI1sOZPQc8npmZVqx+/d/smhOq87tXMu6zCBC2rX1JO482P333S/qR73aUbRq/9zho/+h+/31bs/6VdJ9zKVVuwbsw9eP/HlIFTNQ8roZ7Zk/9z0jWUFt2/pb//lD3l/Wo9/qRN+Ju4/NLEgBTODZdPDCL09vOb9OlZSspRGv3FdYVXuU3wr3aNc+gn3m3tF9l/Qd27+6YiDj9u+/V+jDsWLdZAWGBLLoc8+e5dJIUt69YLn6eUTr7+NK7zC72ZK7l78IY/JLLJn6NJUkfEKCGYwBAFCzREREdO7cuRpeSKfT5efnOzs716zCitlszsnJ4fF4QqGw7LXtiVqtJklSIpHYqH2z2axUKnNzc5s1ayaVSjdv3lxVLYeGhlZPTubl5RkMBicnp5r1JdZisWg0Gi6Xa+tfF6qcRqOxWCyurq42KvZZLJaMjAyNRtO0adOqzcng4ODqyUm9Xq/X60UiEadG3c1GkqRareZwOCKRiOlYyicnJ8dsNovFYhsV+0iSzMjIUKvVjRo1cnd33759e1W17O/vXz05aTAY8vLyHB0dudxyT67JIJqms7Ky2Gy2k5MT07GUT25urslkcnFxsVGxjyRJlUqVlZVVkJMHDhyoqpZ9fHyqJyfz8/N1Op1QKKxxIwNUKhWLxXJ2dmY6kPLRarVGo9F2F/AURalUKpVK1aBBA3d391OnTlX4IqGGDYlnHObae/J7gYT51tLhEzffz6UQQojWPd42eeS3t8wlzU1RGBE6cFAUx3J745Tv/83ltR49LKSUU5bVr4JLZVIcmS7+svxc9osBo3mPNk78dJuy8PBRjptMjNHaK0fOZ7/8PdeQeHjRkImbFBRCFlMZhfPiqKx9n7235Fx6wWbGZ/9+NXTqPhVy7jxlbH2W9VG9bC1z99TR31/MKChc5qccnTtk6v4sJOs/dWRQ2dnJaTNxcnOB5d6yMZ/sSjAghBCitQ9+nzz3oBaT9hrWxamc3aeN+cYSf/Mm5COn9HRFGTv/N3rZ5cyCAielubVu/Ae/P6Uc20yZ0LQcb3XCN9BNnZJwds03mx7qXrwclXNvy/ojSorl17C+c0XezVXSTWs7EPn+tHeldNJvUz7bk2xECCFkST/91fvf3Sh40OCLtSrUTUzSpFkQYXl091EFfugtmAP6LT7oz/Qc0JTy4cNMWti4eQSjYQAAAKjNCr7Yx8XFIYRCQkLc3Nxq1hQWoPYpyMnY2Fiz2SyXyyEnAeNoms7Ozo6NjTWZTMHBwR4eHjVuugBQ+2g0mri4OIPBEBQUBDkJ7EFOTk5cXFxeXl5gYKCnp2clf3epSSNc7IND+4Ubvrj27uKrG0Y32PqJb6gPSxGbmG2WdP5sQs6q39Leui0hHzC46bzrl27fxxzfHT3wLQ/Ys/JVcN8BH/RacnHP7R+6hB5o1TyYm/no5p1EjSCyvt/j+7qXa3HafPBxy62zLq3tEXKyVYtQp/znj+/eSzRHjBzY7O/t188uHjImc+aS2TGe1u0AVlCHDsSFue29l3iEBAqz4uIzDRTiBA5b+/M4P7wcUSGEEMKE8ki31GMz23ot8gzxF2TGJ6gMFHJoMOX35abb76AAACAASURBVAPcrLkqJSI+2bDictdJ+9YNDt/hXy9UalHEPk7RWNgBw1cu7eeKWd99R7GYg5EP1ox690FEkzErv+5R9IVwz+Grfzv/ZPj6w5+38VsWVt+PnfHk0VONCXEDh6z9bVJwud6Gop4zZ7U9/PnZvyc0OPJVWIS/iMxKehyrzKN5EZOWT2teoTE+VdNNK+GeI9ZuuBI7aO0vA4P/9AgLcdUmPE61NJj6cZc1K05yeVysEt1k1evcwePbX69eSSbbyst5dqsBc0DnXb902yKI7tKmht3XAwCwL0a9LVoVsnEhW4BIEyJNtmgfJd23RatshGw1hLjALVvNd+xim2a1IjeFRzhBmvwjo6rv1ubrx2zRqgNCtv28FMts0SrrVU5m2KJ5hG6ctE27yEaDvnQOYoVHGEZRfhENq+/W5twsW7QqQEjAwVC+FlXw/mNmEAhJOBhCZhvtFjS2q02aRchGg2PzAsIVPUbSLJZPk5Y17u6ZYvh8fo2bWQUhhGGY7W4Asikb3UZgMBjS0tJIkvTw8Khxo8KL4fF4NW7sc4EampOOjo62uOPKYDAoFAqz2ezu7l5Vo8LhF5Vyw5zbfn3y2q6vR7UPl9DKuMQc58ZDvtpzee+UiLLvecED+w9uycEQLu45qs9bC6xWvgruPXLz6W2z+jf1IpMvHjl0/Hpinqzbwj1bPygyepjT8PODJ3/5uEckX3HtxLHzT0yB/RYdunVxw9pvZ7T34aRfPXw+UW/1gFjMLWbVuTM/T+4ahCvinuoEvk36TP3l7JXNw/xfFQutiwohhDCnzssvX9k6Z0hLT0tqXIrBMSh6yJw/L59f0cPd2kERnNDxO6+d+XlqnygXbex/txN04ka9p647c2XTEF+iPN137DX726FRMtOTE4dPP1SVMNM27tln3cUrf80b3i4AT7t360k2L6D14JkbLlzdOjKovD/kcOp/dvDijvnvdYhw0SfdunrjUSZX3mn0gu1XL62OsarwXlKbVdNNK2HuMSvPnPn1swFt/KiUJwpe1NjVp/6d1YiFECZ0FGKV6Sa3Zb9entSd46eUVTABm70xXPn3nFbQrn93KYz6AQAAUMWMXIdk/ybPPSMlmQlBCVdq3MSaoPYxcQRPfaOe+TQUq58HJV6pcRNrgtrHLBKn9v8gZcjHTncvBa+ZU9Orz6AWsFgsqampSUlJjo6Ocrm8plefQS1AkqRCoUhKShIKhXK5vArnJMGqZJZ9YA/IvIwUJSn18xDaaIZbKnF5u/DPrjX5/uGF6cHW/nRh86gAAyy6zIwcM9vJXVr4sFpufdmo+TcJPTam/TOqUqO6zFe/qN9mle/q2KMfetWu38j0xyeGxuxq/VfstkFiqEADAKyxcuXKgICAd999t8hS24yAtjnbjIC2OZuNgK5CJMFSSYOyXH1d1KnuyjictCCE0LDphdfp0qXL8ePHK/9a69evF4lEQ4YMKbLUNiOgbc42I6BtzmYjoKsQhRMqib/K1d85R+GeEU9YTAghNOSzwutUVU7+9ddf+fn548aNK7LURkN9QYlsNgK6ClFsjqpNT1XrGNHD67Jj21l5uQghtPtm4XViYmL2799f+Unn9+/f/+zZsylTplSyHVC7FcwDo1QqHR0dZTJZiYk3cODA33//vfJV6RMnTty8eXPmzJmVbAfUbgU5mZGRIRAIPDw8SnzawejRo5csWeLpaeUUCkXAFBy1B+HgFhDIdBBvsM+oQKXQ6r/HBI8/6jTuYMJvPV6NrjI//OdgLMlu2i66snclsZtN+qT9mk83/hX//ozSJkqviWj1kQ27lcHjP+0N1WcAAABVBMM0zp7pslBevjYo4TI3X1f2JgDYWI7IPV0WyjHpAxOv8oyQk4B52tAoRcxIQpcbsHEpPzWB6XAAQFqtVqFQEATh7+8PdywBe6DT6RQKBULIx8fHRneHQAEaAFBOmKTHiBjXo3v+nDaxhWjhoCbefEPK1Z0LP/ruDinp99HwwErXjHG/0fMnruq0btW5j1Z1qDX3apIJG3/6B++7/tPmNekJ1QAAAOyXQeCc5hFGEmyv5/cdc2003zAA5WDgiRQeYWY2zz0j3lnz9qfjAFAd8j38FD1GGF3cZCd3Od+5iOD+b8A0o9GYnp6u1+vd3NzEYjE8kRUwzmQyKZVKnU5n65yEAjQAoLww2dDVW249H7l86wdttnzwciHbvd2srT8P96yKWTME0bN+HLN32NcbprabElQrBkHT6iOLf3rcduGmwTK4xAAAAFBJFjYvXRaSK3KXqJKkGYkYTTEdEajrSIKdIQ1Su3hJspIlmUk45CRgGsl3yGjfT920vcuNM35//ogba9SDI0FtRJKkSqXKyspycXHx9vYmiFrxPRfUZBRFqVQqlUolEonkcjmLZdsSMRSggdUwSftPlv2kdGsLz08DuKz79+djxxzfe/DiwzQtcpAGNGwXE9M20LGqcgMTd/tuz8a/43JyaeRSGxLOrGK3Xby327DKjw8HAABQl9EYnu3qo3STO+pU8tjzbDOUVADDaAzLFvtmuAUJ8tTB8Rc5kJOAcRiuaRid3m0o/1lC8OpZHHUm0wEBgDQaTXp6Oo/HCwoK4nLhlljAvJycnPT0dA6HExgYyOPxquEVoQANrIaJogZNiWI6CmA3WOLIHuMje9iqeUzUoM/4BrZqvdpx5N3GypkOAgAAQM2mFbkpPMIJ0uyffEOg1zAdDgBI5yBWyMIwRPs+veWgVzMdDgAozz9METOSZrG99vzqGHeX6XAAQAaDQaFQWCwWDw+Pyj9OEIDKK8hJs9ns7u7u7Oxcba8LBWgAAAAAAADsmpEjSPcM1/Od3DITXLNSYBpTwDgTR6B0l+scxG6ZieKsp7XhfjVQw5lFYmXngdrQKMn5g5LLxzDSwnREoK6zWCwZGRkajUYikUilUpjuGTCOJMmMjAy1Wu3q6iqVSnG8KiZQtRoUoAEAAAAAALBTJMFSSYOyXH1d1KneKXcICkoqgGEUTqgk/ipJgCgnXR53gUWamY4I1HUUi53Vsmtmu96ixzflq2aydLlMRwTqOpqms7OzMzIyhEKhXC5ns9lMRwTqOpqm1Wq1UqkUCATBwcEcDqf6Y4ACNAAAAAAAAPZI4+KVLgvlGXVBCVe4+VqmwwEA5Yjc02WhHJM+MPEqD3IS2AFtaJQiZiSRl+u/+TtBagLT4QCAdDqdQqHAcdzPz08gEDAdDgAoLy9PoVDQNO3j4yMUCpkKAwrQAAAAAAAAIYQQnbF3cq9PHvbfd+KLxvZ3kah/evaHNdu2XYlLzjE7uAW/033ogkld6gle3dBqSb207ctfDx57kJZl4coCGvQeMn7+oEjXar258A3Ge8MmbdmeX3TGDHb4hjVjxwhfRE7npW7Yd3rL3eSbmaTMP3xC/+5T6zlZ+E4KzwgLwfZIe+iUk85A5NXHknp175cbjx97nJ5l4cj8I3r3Gz6/b1jhA0dr4zb8sXPLlQc3FaQspPmECWOmNnO1h+Fk+uTTP6zauu3yk2SN2cFN/k7PEQsmdy+Uk4jOebhh7YYt52/dTCVlkW0mfPzx1Gg3e4j8BVq797dfPnnWcN9XXRq/fk4ynZtya8nuczseKBUWjo9/yJg+MdOiXCieo8Ij3MzmuWfEO2vSGIyaCbTu8f4l3/5+8MaTRA3XJ7Rh55GfzhvVRMLs6aVsNSbs3NzsJY8ydmTmKyjcx0k0JtRzmoxT0mPaqEtPklcSsq3BAhZCRomHoseIfDdv2cldzncuwtxEgHEmk0mhUOj1ejc3N7FYDHNuAMaZzWalUqnVau0hJ+3vuwUAAAAAAGAAlbr90482PsgM7GKHd9Sbk3YPGPnDMZ0kunufgR6WhKundv/+1albyjN/vNeQgxCis8790GHyvhSXyAH935Nzsm+eOrZ2wUcXlWsv/C+SwdFHpDor2Yy5B0Z0cC9UdWR5BbBefgEwpS5aum5+Mqd5y6iPG+VfvXLri++f3lu8dmZXuVSVJM1MwiiSkcirC511aW2H6UdSnEMH9B4oZ2tunju99tuZFzO+vTAx7MWBM8Yu+t/M+Y95zbt0+Dg67+rJ0198+jDpu+VrokXMfrM3J+4cMHTpMZ00ukf/gZ6WhCsndv8659RN5ZnNYxoW3Nia/3DRuAnz7/Ob9+rxcXvd1cOHv3j/TtLPW9a842QfNQk69eKej04pMt3DCr/ldXHHuy759zpy69Gq9RBu7qVrd+b+kHR97k9f928ozX4mzUzAa3lOlsD08Od3e8w/Zwns2n9oT7Hh8an9P0/tcybh7wtftxIxHdtb1JSwddmKrhcV1xGvh5d0CMt8KU0z97LufrPQrd7sYqVy2pi7OiHnnIfUzHfIbN9P3bS9y40zvjvX4EYDM6ED8BJFUSqVSqVSubi4eHt7EwRR9jYA2NKrnBSJRHK5nMVivvzLfAQAAAAAAIBxZNKmD6f/o6Qx+xsbhxCt3b/6l39zPMau+m19BzGOEKLGnVgyMebPDXMPxfzTzxUjn29cdyjRqf3GnYvfk+EIIfRRzIxBk5Zt2bJv9JLhzJX7yMysZJrTqe+IP5uWOOyVfnru8HeJ2DsjJx7t4cbGMNWI1uP+t2Lb2r2TfaIjqTpQUqEUG/84niiK3rhxzntuOEIIje88Y8zny3b8vW/43OEiDCH66cEN3z3C3vnku6PDfDgIUcObvjdqyW8r945vProJg19laO3+lWv+zfEc+/Om9R1dcYQQ9cGJReNitqyfe6DXPwMkGKKe7l7x3T30zqz1R8cGcBCixka/13fmb0u3jG89hcnIXyIzrn646Z4SFX3LU8pVG05ex0N+nD/mE28OjTDV+N4zZ3+z+ZfdH4bq6uH5TEXLKN3hn1ac04VMP/Lvt80FCCE098PlfTpNW//9n5N2TfK0x1MmQqjGhE3nr7qTfh0T/dgu8BMRjhCiwrSfn0/46X76OJlP5xfvFNpgMj1Qa7c+TtuRT0sl9eL/N8MxPSVo3TxuZl0bjA/skUajSU9P53K5gYGBPB6P6XAAQFqtNi0tjcPh2FVO2s0HDwAAAAAAYIo5dvXEOecChg2tbweFsTeRceduaYmw3tPaiV9cvOLOHcf3j2bpz195aEQI6e+ff2R2bNVjgOzlxS0/om8bd9yQ/CCVYipqhGh1ZrYac5FLSxkJRWv2X0rSi+pP6+BmErrGy1vnBvWb3V6Gnv67O1ZXvaEyRP/4/BOLY7NOA9xeHbiQvq2keP6zB2kUQghRGfv/va93bjOtj0/BqGLcNXr6uz508rkdjxl9HiMZe+4/LRHed9o7rq9zcsKgaJb+/KX7RoQQlb7/4C29uPO0IQEvIpd2nD4wgE78d8d9O3iSJJmx+peD59yaDvUt8n2QTH+w9ynl3brTRG9OntA1IbiVxq/rwj4NhRmnd96pqw92I5VP4nORtFXXRi/vpmAHdO8sZ5kSHyXa8WDwGhI2qdPszUHePu4TRS/fSRzHOaEioUHzl+rF2Zs2ZvU7/KDZxZQVWRYKYZRHK8+96/03fQfVZ8A4g8GQmJioVCplMllAQID9VPpAnZWfn5+UlJSWlubu7m5vOQkFaAAAAACAOs54Z/nEL2/Xn7/u00YlTbrJPEs+cvKt3yw8qFAhF+Py+BiymMwUQogV+sG8OetGRBa6yia1efk0LpIyOdsBnaxUk4Q4SJh99ur1NUcvbbjx9Kmx0Cyl5ufXUkhOUJhXaJNnPg3F2c8C4642DvRxpdU3k3QMFs6rDxH8wcyp6waHFTpwlDYvn8YdpQXVKHPCtTgLJ7x+S/7rbSKiIlyR8ubjHCZ3kdmAnPzqN48skpO8QjlpenLtsZlTr0mRyJs1dKUVNx9kM31wLXcO7PgyyWP+h+0bFR2aT2arn1OYr6dM6VUvxbuBi/p5cPxlmdjZB9P/l5hlR2XL6kRI5YGOKOvWpTjTiyWU8uq1FJLjF+Jnx3fZ15CwSYPpOY38HLiFM9FRyPdBlv/UxoKUwzjOy3o0+2fBzL9WjGpEINaDDY6xd5gJF4CXLBZLWlpaUlKSUCgMCQlxdnZmOiJQ15EkqVAoEhMTeTyeXC63w5y0y0Eu1SI2NpYk7fQiiqZpiqIwDMNx+IWg3CiKQgjBrqsAiqJomsZxHJ6WUAEkScJUXxUAp7vKgNNdhVXD6Y7D4QQFBdmo8Sqnv/7duKVPWiw++0k4Ws50MCXjRa/cG110EZV64vRlC7tRwxAeQogfENMvoGB5vi43O1t578L26Qc1nl0/G8zknebmZGUOSRu+mP2DQkvSCCGEcZyDvpg8Yn6kEEPIkquJMyEneVuxWe/15A5BWRBCLFexD06nZGhI5FT7395835hevgghhOj8PG22OvPe5b3Tj+V6dpw0WIYhhKis9GQjcvWQOhZ6s7LcZT44lfI8g0TMPWOS32blgTZFF1Gp/568bGE3igrjIUSpnifnY65esiKRe3j54GRKSjqJ3Bg8uPr4E+P2KluMmPqJ9xtveQeBA04/Jf1IhORxF1ikGSFkUmsyKIpS5ZDIo05e64h6z/t21O3/LerXJ35ETCMXw5OT27dc4vZYtHicjz2/R2tG2Dib5YRQmsFsQRzOy4WmfFMGoimDmUR8jMXOatkTa/tu1JP/3Pfv/Z2mlZQd3EMA6jCaprOzs5VKpYODg1wuZ7Pt6MmyoG6iaVqtViuVSoFAEBwczHl9NrUvdbcAPWXKlODgYKajKBlN0xaLBcMwe5gmvMaBikyFkSRJURSLxYICdAWYzWa4+KiAgtMdjuNQvq8AON1VmMVioWnadqc7iqIUCsX+/fsr35TZbNbpdCqVqvBCiWOVPlRPe2Hehz+ltFu2a0IwC8VXZcs2ZEo+tWbwd1fyvPrM7e9VdAaBlOVjR8y+b0EId2ky4fCCTkzWn6mchEyStlAB7Uce7xXqj3Ju3jjzvz+vLVqx02/x2P5y7+csDx3CnUyJnmk5r06CGI8rxOjUfBP9tqbLVixtaLqS7b1gNpvz8vKK52Tl26WeLf/oo9mPLAhhLo1GHZ7VtuDA0XpDHo0LHQSFDyPG5wsxOtWQXzVdqhqm5JMrBi+5lOfVf+4AbxwhMi8vj8aEjg5FIhc4CDGUqjcwGbkhcd660ykR/Xd1lrBQkeOodZSmtR/QUnrqz33LzzYfMUaCI4RQ/vOVB+5l0khgNFdtThZ8ilWe2WzW6/XFc5JTlad3lne7D0a0OLzwzOYfr29GCCHMscmkKb3kDD7g1Bo1ImyWyLEjX/lzivKvoIAxAgwhhCz6lbGaTBoJLFRuaFR2zAhCr/Pf+oPgWTydX8WzkNsuJw0GQ/GclFTBmRIwTqfTKRQKDMP8/PwcHByqvP1iaUOSZJV8fJvN5vz8fMjJWikvL0+hUNA07ePjIxQKq7z9YmljsVgqPJa3Ttc316xZY5+FNpIk1Wo1h8MRiezqAcU1g8FgQAjx+fwy1wTFaLVao9Ho4uICpcAKyM7OFovFTEdR8xSc7rhcrqOjI9Ox1Dxwuquw3Nxck8lku9OdXq8fNmxYlTRVcH+ADX+QpjXH5ny0StX1t39GBRAI2em9YUWY0q+v+P7HRUeTTN6d1639tLuo6LUc7tZ/2iL/NFXC/bO/7VnfaxJxeN3o5kyVWzBh3+Fjojhu78jFAoQQkrTtMOAAlhO5/skP99xatQ7ySNjFpmmK1CPkWmxTqtJfOG2UNrbKSUza/+NZ/oqshIeXfjuwpddn+OEfhzQXoILKeYnX61VVKqo8U/rVFUu/W3Q40eTTdd0vM7oXzPpC22XktOHYXztWacN/m9U8AEfoZSAmvijJK8zE4bsrYxcPanB67Z0Jc7KOtAqRE7lXbty9jhzdcaOeqOyPOcXSpqq+iJWSk1V3OqO1F74e2H3F8wYfrNk/uWs9Z0Pc2S1ffL68d0z29mMr+8vs9WfgmhI24fhFpPP+G+oJp58c8RbJcfOVNPV1xHbDyLygfmnv9vU+vVf83zlE2+RdY7vzJAwmq31MJpNCodDr9W5ubmKx2EalJBulTcFtf5CTtYzZbFYqlVqtViKRSCSS6snJgvNbBZuqingAAAAAAEDVY7FYAoGg+CRuRn0VNU9r/p374QZ9vw3LR3jbTTHiLWjt9e3L3l9+7J7JrdOYBcsnda0nfOMKGBOEtuwQihDqP2B48P8afrPhy4MxRwZLmekeJoiIDIsotMDC5mE9uzfY+OT6g9secdkii1mIoeyig53pfKOOxoS8yg7gLJY2VfW1hMVi8fn8qp9YEOOHNm0dihB6t9fwwNkNl2378ljnI/1cMb5AiNPZRQc70waDjsaEAh7zA0no3Ot/fff+D4fvmdw7jVu8fEr3VzmJOTgIcTo7r8hgZ1qfp6ORUMBnKHJac+fgh6dM/ab0H+H6IgQKQ4glfu7fLCTnmd/TmzhFOrcefl4gm7vv+tFTZw5wnBs3632qW/7/5h58yufabU7yeLziOZmbVSWNI4Qoxe6FPz/gdF+9d+lgdwwh5BL17sxdwsz6A7Z++euE3vMa2uc36hoUtreP/3k2f+6TrKPJygMEJ8oncNfQ0M+/O5KO6UNWfcEzGmz30sXSpqruKis5J0GNRVGUSqVSqVTOzs4hISE2Ha1VLG0IgqiSUyVBEFwuF3Ky1niVkyKRSC6X2/SnhTdzssKnSvv53AEAAAAAANWJyrh3L82s2DEyaMfIwst/ain8iQieevH2Ny3s51KRTN/11Sej9qRJ24zdN3dUb98iD/U2pVzfeSvbr3mXth6vrolxvzat6uE3H8c9IxFDBehCaAzLdvVVuskdNNmeGEJ6BUV64U5iXzZ9M1OdS6OX9UBEqjXPKSzUzbku3I5kSr29867ar3H7trJXX7Bxv5ZN6+F3HyekkciV7Srz5dA3nyuL7KLMjOcUHurpxvAuItN3zZ00atdzadv39301rrdfkZzEJV6+XPpmalqRyJXpzyki1FfGUOR0RkpaGpm7Y8WCHSsKL989rPFuQtbh4rJeLQiEEOEf1WVrVJdXfzY92JNC4gEysf2cD6qTJfb+fSOrXttW0kJVIMeWbZtzNv1z/2Eu3VDM/C8hJahRYWP+MtlWmQxhuKZhdHrXIcSJBZkWFJx9niO205lMQd2Rk5OTnp7O4XACAwN5PF7ZGwBgY1qtVqFQEAQREBBQs+6FrZtXEQAAAAAAABe3GjV7VqfXd6rT6subfz+d33T0hPY+kmgvxqu2r5GPNs8btzcjctyyQ581L+HxbSnHP5t9OGxmgzOjXlegaZ1OS2N8XmWHbVaYJelsvz/uuXQevrqnXOkRjtGU/9Ob3NiriRbMQ+bqiCHE8WrpR+yIiztvbNr3xbdaKi4+RYW5jAh0tKPdbzupZz5beCJsasSZoe6vD1xenpbG+AVjwDnBLUNYO+7fOm/o0vfFVCpU3P0nKuQ2IsKF0V1EPto4a9zujMj3Vx2a0aKEnOSGtwxn77h15byh9+vIb99XYbIR9SUMRY6JQ5rP7h9KImRm87RCCULah/v2nDP6ju4s9xEFeOEI0Zoz5x7HOwYMb+z+cuoa8t69+HRcMirMuU7k5BswB6EQo9TZGgq9fngfnaNWU4jjIGTs/FKWGhM2bTqTkhvPFfZrGqHpMZLkO3jtXx+755wScUZL2HUz5YCdMBgMCoXCbDa7u7vD2GFgD/Lz8xUKhdFolMlkNTEn4ZQOAAAAAFA3YZLW4+d/Ne/rV/99ObmbF46JW3345bwFH3e2o2k5jDdXbr5nrDdm86clVZ8RYtdr9o6QvLp777VX92qT2Uf+OvYYubZvFcTUgAuWTOKkSvnrwO0/hQ3F6mdB8ZcEOYl/77tyC7kOauXDRghhzr1b+vPzHq09l2lGCCFEGxJ+PqtAng2HBNSFAdCIHR71jgN59Z/Drw8cpT6y68xj2qV9M38WQgiX9u4cyddeW3vo+YtdlHf354OJyL/dkDBGR9IYb6zccMdYf9zm6SVVnxFCuHvvno34uRfW7nn6InLd9Z93P0GB3YbUYypyTBLWas6Ivh9+On30rAXzh/Va3TkkxgXDhAEfDuq+ICbUG0MI0Q/P7ftwzf7NGS+m3DUrb8w/lckNaTXG337OCNWKXa9zV0/60Z+rdqWaXyyiss+s/OO82aljt5Z29UC/wmpQ2PfTUj+8jVZ2nuEYf0++di7vv1Pzk41cV8kYJ/spk4O6hSRJhUKRlJQkFApDQkJqYqUP1DIFOZmYmMjj8WpuTtrrCGg6/cC8RZlDV4yLLOnim8q+s3vj9jO3n2qFfo06Dh07oKEL9rblAAAAAACgxiKf3ruiojkOt5d+mVKsBiZqOnxZ/yCW8ztffdjw+LItPQYlDO0U4UFn37t8ct8DrXfM/DktmblhlsIJlX+v4Z8kHF909NOBTy61DAzAdXfv3T2YQtbvOXZ2cMFFOOb/Tsz08+u+/vP3XmnNesrIm+cvblWJJ0xr26RO1J8R5hT91dh6x1fv7DEmeeg7oR509r1rF/Y91nl3nTGnGbdgFf9eY6cfmvn1irm9krv29CVvHtq/VeEx4Yf+TRj9HkMm376iojnCW0tnzyuak5io2XvLBgazEO4/4H/T90z4esnkXvF9ewZYbu7dtvW594RfRjIVOYXhKmmAShIgykmXx19kWUzozWddYi4jB0SvXXJu6vy1l6OD3PWKf288uo/kP41vJa+j9WeE+NFzlg49Nu6vkW2ebO/XsYGzIfb8wb03Ml26fvvtAKn9ftusCWHTBCu7Wdfm3RsET9n27dCuyV58d7PhX0XufeT4UyOp3E6iBHUJTdPZ2dkZGRkCgSA4OJjDgUlgAPM0Gk16ejqfz6/pOWmXBWg6//npLfvu65uX/Khb8umexd/sIt8Z+7+hrpnntm74ZimxbHE/H6K05dUcPQAAAAAAqEoWRVoKSesSLm1OKPYX3I3o8n3/IIQ49cYuv+C+YeHWk3v+G6yYXQAAIABJREFUuqaxcGUB9T+YM2ru0CgPJqpmGhevdFkIN1/XsdGgqzNE3xz+78iZszstbC+foOkTO3/RxtP5VWGF6zNv5gfS7UdWXTn1eT7Lyy900Yye0xs41JnCC7veiIUXpNsX7jy/5+9bGgtH5h/+wbTBcwfUf33g+KHzViyRrtm46sSOz/Vsr5Cmi34cP72liNldZEl7nkLSuvgLm+OL/QV3I7p9PzAYIYT49eb98Yv0+1Wrjvz+eR7HKzx60fqp09s6MxK51lGaJgtjkaaA5Bt8veYta4oiep360vXLnZcOnz6nIURRDbruG9yhl5tdfm2sJrhHrx8vHoj65sfN+/b8etjAkQZGvbdg1ZeTOvixmQ7tbew9bG1olKLHCMKQV+9w4vlo7y8fqQ4nazU4O8rNY1+EW6+6cxYEdkOn0ykUCgzDfH19HRwcmA4HAJSXl6dQKGia9vLycnR0ZDqcyrK3Kwk689SPX224/DzXRCNJyauY7h48mOQ94KeJ3X0IhOpJNPHTDxx60HNi2IOSlzeowb8PAAAAAABUHyJ4xnnNDKajeBP3nS+zHn5ZxkoYv17Pj3b2/KhaIiqVgS9SeEaY2TxZeqyz+jlCyL9h+/UN279lE1zoN/n9iZPfr6YI7Q7Gr9dt7M5uY9+yCu4UPnn2t5NnV1tMZeN2WJgVt7DM1XDnBpO/WT/5m2qIqFT5PEeFR5iRzZdlxDtr0or8DZfMWPTdG2953C2k9S9zW1dbhDUB4dZizIodY1aUvaZdsdOwja6y9B4j9F6Bbmf3u149gWhK4Cr9pY20zA0xnuRE31KqBABUgslkUiqVOp3Ozc1NLBZjGPz+ARhmNpuVSqVWq5VIJBKJpHbkpL0VoDHnxkOm+fahcy+t++ZMiWuQzx480slaNvEsGNlM+DaJctt966HC7FDycqqBX529XQwAAAAAAFQPksXJcAtSu3hLVEnSzCSMIsveBgBbIgl2hjRILfZ2yU71e3oLpyxMRwTqOpInULXtldWis8vNc95/ryWMhrK3AcCWKIpSqVQqlUokEsnlchbL3kpkoM6hKCorKyszM7P25aTd9YTt7B3kjGh1HL+U+j6lylDRrlLxy6oyLpaKaVVGpqWU5RR6UYA2GAxms7lwU/Sbs57Zh1eB2W2E9g92XYXRNA17r2Jgv1UAnO4qD3ZdhdnudAcHpa6hMSzb1TfDXS7QZcvjLrBNUFIBDKMRpnbxUroFCww5wfEXOZCTgHEYrmkYnd5lCC/jWdCvC7kZqUwHBADKyclJT0/ncDiBgYE8HjNPjACgMK1Wq1AoCILw9/cXCOzqebFVwO4K0GUiTUYLxue/qk9jfD4PMxlNllKWv/oKuHTp0kOHDr1qRyQSZWVl2fM4dpPJlJWVxXQUNVVeXh7TIdRUGs3bpgUEbwFv2AozGo1Go5HpKGoqON1VmO1OdwaDgaJKfpAFqH10QleFRxhG075JNx30aqbDAQDlOYgVslAaJ7yf33fUqZgOBwBk8ApUxIy0CIQehzc7PbjOdDgAIIPBoFAozGazu7u7s7Mz0+EAgIxGo0KhyM/Pl8lktTUna14BmuBwCTrHkE8jHoYQQrTBkE+zHTmlLX+1YVBQUPPmzV/9MzY2ls1m22cBmqZpi8WCYVhtGmxfbQq+8+M4zLxSbiRJUhTFZtvHc0lqGrPZDLuuYsxmM47jBAFPjC03ON1VmMVioWmaxWLZ6DLAYoH73OsEE1egdA/RCV3dMuLFqqf2eE0J6hgzm6d0C9aK3CSZiZKsFIyGX8IAwywil/TOg3LDm0guHZWeP4hZzGVvA4AtkSSZkZGhVqtdXV2lUilcSAPGvcpJFxcXX1/fWpyTNa++ibtKJVhSlppCzgRCCFGaLA3mGunKKmX5q0M3atSoUaNGvWqna9euTk5O9lmAJklSrVaz2WyRSMR0LDWPwWBACPH5fKYDqXm0Wq3RaBQKhVAKrIDs7GwnJyemo6h5Xp3uasFTfasfnO4qLDc312QyOTo62uh0x2aza/G1I0AIUTihkgaoJAHOGkVI7HnCYmI6IlDXURie5eqbKQ0U5WbI4y6wICcB02icyG7eKaNjf2H8ffnq2ewcuFMQMIym6ezs7IyMDIFAEBwczOFwyt4GABvTaDTp6ek8Hi8oKIjL5TIdjm3VvAI04RsZ7rD/9p3MYQEyDCEq/c7ddMeISC9OKcuhkAYAAAAAAKpKjpMs3SOMY9IHJlzh5WuZDgcApHWUKjzCCYvRP/mmwJDDdDgAIG1olKL7cMJo8Nu6TJASx3Q4AKC8vDyFQkHTtI+Pj1AoZDocAF7npJeXVx0ZjFVTCtCWhBNbz2aF9xzUwp3TICbG94u/V/3lOa6dOOP073ueBfX/uB4HEaUsBwAAAAAAoNIMPJHCM9zM4bsr45zVz5kOBwBk5DooZGH5XAdZRryzJo3pcABARldZeo8Req9At7P7xVePY/BUXsA0k8mkVCp1Op2bm5tYLLbPm+BBnWI2m5VKZW5urkQikUqldScna0wB+vn1g/8kka0GtnBHrMCBsz43/7Jp9Rd78gVejXrN/LCfH4FQqcsBAAAAAACoOJLFyXALUrt4u2alSJNv4BTJdESgriMJdoY0SC32dslO9X12B6dg6nnAMIrDU7XuoWrdw+XmOe+/1xJGA9MRgbqOoiiVSqVSqUQikVwuhydsAcZRFJWVlZWZmSkSiUJCQupaTtppbzGXHl/v6lFoAa/drF3tXv2LkDYdObfpyDc2K205AAAAAAAA5UdjWLarb4a7XKDLDo69wDFDSQUwDcM0Th7pslC+XhMcf4lj0jMdEKjzMEzTsHV6lyG8zNTAXxfwMuAGEcA8rVablpbG4XACAwN5PB7T4QCAtFqtQqEgCMLf318gEDAdDgPstAANAAAAAAAAs3Q0rgiORhjm8/S2UKdiOhwAUB6FKQJb0jjhlXrPEXIS2AGDyawYP9fiIPI4vNnpwXWmwwEA5efnp6Wlmc1md3d3Z2dnpsMBABmNRoVCkZ+fXzAPDNPhMAYK0AAAAAAANQqLzXQEFWLQMR1BOZgwQkkIdRjHzc9X7OKMNWrCdET2rVk3piOoEIpiOoJyMJvNyoyMXK1W4hMolUiwRk2Zjsi+iVyZjqBCSDPTEZSDxWLJUGVpcnIljVtJJRKsTXumI7JvCXeYjqBC1n3NdATlQHL5GQ3bq4OjXJ9clw4Yg+N4zXpPIYQQUY3XeFcOVd9rVaGEB0xHUA4kwVK5B2e5+rlkP/NtF4PjONMRMQkK0AAAAAAAALxAIUxFCFS4QEQZ5RYVSxzGdESgrqMoKis7O1OlEjk6hgQH17UpI4Edomk6W63JUGUJHQTywAA2h8t0RKCuozFcLY9SRnUSqFKD/1nL0WnQoHFMBwXqNgzTuHime4Tz8rVBcRe5+TqE92I6JobB5QsAAAAAAAAIIZSDcdMJIQdRgRY1j4anugHmaXU6RXo6QRD+vr51c8pIYG90eXkKZQaGMD8fLwGfz3Q4AKA8WYCieQ8ax30u7BU+j2M6HACQQeCc5hVBEmyvZ3cdczOYDsdeQAEaAAAAAK+ZTKbc3FyRSMThcJiOBYDqY8BYClxoxlnupM6Zymc6HACQ0WhUpKfn/5+9+4yPolobAH6mbO81ZdMrJXQMiChVlCKCWLCDBfGiXikqongtqKCignpR4V6xoKAUUUFBpPcaagIphLTtvU99P8xLbgghhJhkNuH8P/ALu7Ozz86cPTPz7JnnRKNGg0Gr0fAdDgQBgiDNVlsoHDbqdVqNGkEQviOCrnekTGXtNdSfnGs8vl1beBBh21NhJahDogRiS0KuTxWnt583WEthm6wLJqAhCIIgCAIURa1bt279+vVFRUWFhYVdu3bNy8ubMGHCyJEjr/NqZVCHRwPUhsncqFjHhA2kFwUs3xFB1zuapm12u9vj0ajVKcnJsBOGeMcwjMPldjhdapUyJzEdwzC+I4KudwwmcHS7yZF3k7L8TPa6T/BIkO+IoOsdi6AufYo1Lkfps+YU7cDJKN8RxRyYgIYgCIKg653T6ZwxY8bPP/+s0WjkcnlWVlYwGPzrr79Wr1790EMPLViwQKFQ8B0jBLU8FgA3KraicilLZpEuIaD5jgiCgMfrtVitYpEoMz1dJIKldSH+ebw+i80uEgoz0lLEsE1CMcCfnFuTPxKPBNP/WC5xVPMdDgQBvzLObOqM0WTa+UPSoJvvcGIUTEBDEARB0HUtEon885//3LRpU0ZGRu2YJoFAIJFINBrNqlWrWJb99NNP4XAnqIMJokIzpmBZkMz45AzBdzgQBMLhcI3FQtO0KTFRIZfzHQ4EgXAkYrbYSIqMNxrUKiXf4UAQiGjjzf1GEXJN3NEt6rITgIU3LUE8i4pkFlOXkERltJXoHBdgm2wETEBDEARB0HVtxYoVv/32W0ZGxuV3eeM4npycvGLFiltvvfWuu+7iJTwIanEkgllRmR8VGemglgnBIqYQ70iStNpsPr9fr9MZ9HpYWhfiHUVRNofT4/XpdVqDTgvbJMQ7WiSx9RjszumjOXckdcsKFNY3gPhGY7gjLsupS9W4KpPKj2EMnLz6KmACGoIgCIKuXwzD/PTTT3q9/ko1RnEc1+l0q1atggloqANgAOLApA5UqmSi2aQTB3BmGIhnLMu63G6rzaZUKHKysnAcXp1BPGNZ1uX2WO0OmVSanZEuEMA2CfGMRVB3di9rr2FSR1XW+s+EfljfAOIbgng0iZaETuJIILN4ryji5zug9gEeTiAIgiDo+lVRUbFr166cnJxGlpHL5aWlpR6PR61Wt1lgENTi/KioBpULAZNBucUsHKUC8c8fCJgtFgzD0lJSpFIp3+FAEAgEg2arDQFIarJJBtskFAOC8enm/NtZDE/avVZRXcJ3OBAEwlK12dSFwgQJVadVXgvf4bQnMAENQRAEQdcvl8uFIEjj9Z0FAkFhYaHL5YIJaKidiiACMyYnECyODqiZCN/hQBCIRqMWqzUciRgNBq1Gw3c4EAQIgrTa7YFgyKjXaTVqWHMD4h0pVVp7D/Mn5+pP7tKf2Y8wcKJgiGeUQGxJyPWp4vT28wZrKcLCG+muDUxAQxAEQdD1Sy6XsyzLMMyVSnAAAGia7ty5sxzOiNVxhYp/+eCtRT9sO1HuImSJeYPuee6NOffmyWMu+xCq2PPBl6t/OFha7qNkhvRBt05444khedLaONlA2Y53v1z/26nyMp8wOT1n+J0PvDKuKyOQuVGJhgmnUh4UxMTMMO1lg0PNFdm74OHFkjnfPdfr8mstmqYdTqfT5dKo1clJSY30vXxoLHKoPWpKb8MwjMPldjhdapUyJzM9xuYchm3y/4XKt33wyXc/7Dtb7iFlxuxBox98Y9rtdY6AgPWe+erfX32769iRKjq+68Ann332+QFGAY8RA0C7zt64/NShhnJ0mCZnz+Ru/bj+jyUOnSp881j1bjclViiHdu38Vr5J0a2fvfstyoqi7HWf4JFg2wbeMHjsvgxVdXD93G+2bCqyOilhfGrnseMnvj42V1fnsBaq3P/Bf37+4cj5ci8pM6QNGnbnG5NvyZPwutGIU/f/47uVkUtPCAWdvvpk0qT6e5Pa++vKxcKh392WiCGIS59qi8+R+x3ZRTsFJBzN0BzXeTcOQRAEQdeRQCBgsVhYlo2Li1MqlTabLRKJ5OXleTwehUJRd0mWZQmCIEmSYZhgMJidnS2TyfgKG2pV5NkvJgz+5yZfwoC7H7s7hSzdtnbN+49u3VO5ffOsHiK+g6uDLP9lwuOLNwX1A4aPujuBLj20c83X72wtsG///L4eQgAAIErW3PHE5zvppBG33jZaFS06sH3J2zM3VS1ZO717NuUUsrEycqq9bHCo2Vj7hk8X/7Lzzqcvz7p4vF6L1SoWiTLT00WimNvfjUQOtUdN6W28Pr/FZhMKhBlpKWLYJmMVWfbjhInzNwUMA0bedXciVbp/y5ovX9l6xLr9m0ncERBEzsx77MnXT0nyx4x8dnDgwMaNs584fn7Jt58NUvGY6kOEyhGdkjPr7Tw2fLDEaZVLDf8fWfSPv3aOPx6KT4x/oKc0Yqv+YfeereLX147u0uPPb6X2qrYPu0Hw2H0Z1rnviyEv/lGhzp0w5q5soffIzu3/fm/OHts7u6fkcuV7yIqNE55asimoGzBsxN1xdOmRPWu++2DrCcf2Tyb04O+3EdrlLCeRuPTOQ+LrBIGZ0vH63xXWV/jpH6d39u3vVcY5TZ0xmkotOyQNwhLkzQcT0BAEQRDU8Z08eXLp0qUHDhw4deoUACAxMZFhmJqaGhRFSZIEABiNRr1ej+M4QRAOh8Ptdkci//tt32w2d+3adcyYMc8++2xubi5vHwNqcaxn/Zuvb3anTl69c+mYOBQAwMzZMmPYqM/mv7ryoV8ejY+VgT1sYP0XX232xU9e+MnSWzQoAIB5aMsH00et+u7VP279ZawWAaGNy7/fGUyd9Z/PFnQXBxGhmZ3c6ckH5//w2c77FnSNi5XP0W42ONQcdNhRfvrw1u/enbvKwsRd+lw4HK6xWGiaToiPVymV/AR4RY1FDrVXV+ttIpGI2WIjKTLOYFCrYJuMYax//eLPNnsTJy/5eulQHQoAYKZsmffYqG+XvvrrmF8m6BHAXFiz6L2TYNDLS/+YnC4EgJk84OFxLy2b/+3jNz3Th7+UDypPmDcq4dLH2PITe/ue1746LD0DAQAA7/nTTx0Pdrph4PZb9GKVwXzDjb0Xv/DPPz75Jf7EjbGz4+Gx+3KMZflXW8qUNy7/z+yHjSgAAEwe+sLjLy/8cc3PE19+QIkANrh+2beb/XGT53+wdKAaBQAwE7d8PHvU6lWvbh76y2gNXxuNdjjLWeGwcQ+s6HOlLDgT9rtPl5V898umVV5Wr8ytTu5mspVo7eXX445uUTF1zxcEQRAEQS3v+++/f/LJJ9esWRMIBHJycmQyWVlZ2YULFwiCMBgMubm5AoHAbDafP3/e6XSWlZVZrda62WcEQViWraioWLZs2X333bdu3ToePwvUwqgTO/d5sO6TZ46M+/+TQlQ/dOaUAQL/rq2Ho/zGVhdduvN4AMsZNXOg5mKcqqGP3jEAD+86WBQFADCusxVBoO0+tLO0ClNW4CoVanzoxmScrCysipWxzwC0nw0OXTvWtnx8Ss4No6cu2m2vO+CPoqiq6urzFy4o5PLszMzYyz5fMXKofWukt/nrwAWr7fyFSrlclp2RHnvZZ9gmL0Wf23nUj3UeN3PQxdoGqHrok/cMwEO79p6KAgAYy/rfjoW0w2fel86Nh0YNQ2fdnc6WbV51KrZm3GX8Fc/vcmTk95qh5z5KdH1BZZU48eWBSaH8kaV3PCXykVNSu342OCkfg8fu2BY6u+scpeg7dILxYlJRkj2unx6NVJ2uYQAAgD6/80QQyx4xc4D64kZTDn1w5AA8vOvwOf42Guu2ud2IJttwxVpDrO/w+Ofeu+H9tYvOBhmAIHQku3C7DmafWwIcAQ1BEARBHdnGjRunTJmSlJSUkJAAAKisrHS5XCKRCEEQhmEqKyvT09PT09MrKysDgUAgEOAer305chHLshRFlZSUPPTQQxs3bhw0aBB/nwlqOWQQaLK7DeqTWec8HJFIJQigokQMXfZTEaBK6tYnJ7PO2AlEJJYggCIpBgCAarKSpeBs8YZqZddMJpt04ox1wwkzLUjPSYyleqbtZYND1w7Rjl20I8/DANa57rm7FlYBwLKs0+222mxc6lkg4Lcc6xVdHjnUETTU2wCxBAeAcFZHCDIrPU0ohG2yPSDDQJXaLb/rJQcOsViCAIogGQAAcfZgESns06e/pPZ5rMsNPXRLfj1y2sX0NMbMqMPo+l2n/5BmbOuj4hLlgHZvq6EFmX1T7n+OcFRlrf+30O8CMu1TvbX8BlofPHZfDsuY8sJzE1NzxP97iPGHoiyqNShRAACgIkBp6tYr+9IzN5EEAIqg+NtobLnNRWPGTJlrx8HyU25Sqk8cmpeSKvpfehmRdX3r/e6PaVMFtk3vvLSyOngBY7J4i7djgQloCIIgCOqwgsHghx9+GBcXx00h6Pf7HQ4Hl30GAKAoKhAIbDZbZmZmenp6cXFxKBSq+3Iu9Vz7N03TkUhEoVAsWLDgxhtvFAqFbf+JrkMMw9D0JeOAWjKfKh25+MjIem9Y9fO6faSwZ7+e4oZfwwdxv8U/9Lv0IbZq6859FN6zW5YYAD+q7fL8q+MLX/tiyiPesTf1VEbO7tv87VHhyOnTHkuIpTErbbjB6zWblsJNW1q/TcbWrGU8wQ25NxgAAKy5QIkClgyXlJaKMSwtJUUqlfIdXKMujbz1wDbZpi7rbQJB/9Fl3x+kBD1uuSUn2RQzScmGtP82ybJsix27JQMX/zrw0oeYqs1/7aMEPXt1EgPAOKrLI4jOFK+oc7jDE0zJKF1RYaFBrCSgQ9VnXz7LThid0//iDx9+ifA0hehy+0YWTpu65dQeL61SqW7MSJ/bP6VbTJ1jdohjd0u2SQCAJGXU6BRu3ZGg3+Wxn9y3ftZmX+LgKfdyJUnEfRd/07deFFU79u6j8Z55GfydYVLlVh/NRma/+qHZT7MAAIAI1Rmz//HA613kCABhqcpsGqDChbfVFCl9kc9QUM1bqLGiXrNh2eZP6A0T0BAEQRDUYW3duvXw4cOZmZncf91uN47jtTllAACGYaFQyOfzSaXSSCSCoih3VlF3mVpcPpqiqN27d+/evXvo0KFt8ymuZyRJhkIht/uSCU/0GlWrvWG0/NdX7n1xczDt8VcnpcfIJWtDyPIdS+/96FAwYfRLdyZX4IoIwBIMeTPv6LrrsyPf/Pf0NwAAgCjy7n5mSGpsZ/5acYPXazZ/54KhLoqiwuFw/Tap17fIyjuGKEFFWEAHHVrtjfEaTYPd6fWpXrOpe7fN30FRVCQSgW2yEQRBWu3VZ3+b9+J7u8Opj/9rStcY7t7bVJu2yRZZNQAAEOV/Lbr33b1B012vTkhCAaCDwSCLyBWyursVkcrkCKgKhVum6//72OB/dp+/YOi0NluEAEBKFdbew93EngizPbh53rgQk5VheioDMdeY1xw8/GdNZPvdOT1iN1nVdsdumqZb5PBNUVQ0Gm2VNslUffTss3MKKQAQTY8HN84emNjwFiHLdy2/95MjwYTbXx0Tz1sXxHhKHTRLMemDH/xzVE4a8B05sv257w/NW7w6ecFTo/JyPOoEvf28wVaGMHSsfHf4dnmbbPbPJLH7nYYgCIIg6G8qKCiQyWS16Y9wOIyi9U/5UBTlBj5zdTZYlm0kXcKybCgU0mg0BQUFMAHdBlAUxXFcJGqLGdaJqq2LXpox76dCIuPuz9d+cDtv08NcBWE9uujjz+b9eYEwDV6w+KVMrVrEhFMo897Pnr99ua37fS+tf/DGPGWk+OCG2e9/P/YJ78qvXrxLH4ufpbU3eCs1GwRB2qxNtjs0TTucTkeFAwEAVyXqtNpYbHn8qddsWio1j6IohmGwTTaIYRiHy20+s/Gnjxd88ltxjHfvba/dtUnCcmDR/PfmbSwjkkd8/sULt6sQALjRraDB0Fsqpf73BSuLP6pGx45Kz8Vxe+d+9m63KCuLsv/cC1jWF8SnjLvlswwxBgBguzy8ZduY40WvFqX8kieOwZbaxsfu2G+TANHf9Y8X0yyu0sJ9y377fswsbOPCe/IllyxC2I4v+vSLeX9VEokDP3/vydsV/O1YRD7u/kd6CYyDsrVSAADQ3Tz4rl8QX96ycx+cShzeQ5B9dpeACPMWXky6vE02u1nCBDQEQRAEdVg+n6/2NmTuJuXLzxi42ho0TXN/NLI27rXcaYfH42mlmKG6MAwTi8UKheKSR2myhd+GdR/6YsYTr/xwMpo0bPrXH71yX54yBi/6AGD9h1Z/9sQnW04SxkEPvzZj6l3dpWQC5RSyNGPb8ub3pcJbXlo369Y4BACg6DV00mqpp9szG+euGj92Wk5snfK2yQav12xa6iKWyz7Xb5MQAB6v12K1ikWizBS9CAEAue5LQFymldokl1WBbfJyXp/fYi0p+mn+3A/WnyJiu3vnSeu1SaFQWL9N2v7eSlnfoe/fe+KDjSeJuGGPvfPRM7fnyS8WSZPJ5CjrCl4y2JkNBQMskEslsbG/o+uOVlTKkxcN7lZ600gsEkzb8q3UXkXTtAQAYVLm3HTx//eYiPDW/MwbTx3fWe4M5Zlk/EZdDx/HbhRFW6RZYhgmEAhapZ9EJLl9B+QCAMaMeiB9bo+PVs3dNPT3cRcnzGQDh9Z9+cSSbScJw7D7Z340eVCejNcmiUi7dOnUpc4DAbk+fM9dPb9+9+CRTZqbcmK0Lj6v6jUbDMMuH8/URLF1Ng5BEARBUAtSqVS1OWUEQVAUpSiq3oksy7IYhmEYxrIsiqKNDJbhBkdzo6TVanXrhg61Gbpy9dRRjywvN4x4+edFL4zNitWSFYxt9VsvPfKLWX/jo0vmPDU0VRJP+RQ0wT1JlZeeIrC8vt0NdVq3omevfOFvv5w772NzYmgkanvZ4FCThcNhs9VKUVRCfLxKqWTN8AoL4lk4EjFbbGS0Yv87Tz39fQXsbdo92rL61acfWV1tuPmJn//12NjUSyroonpTiog9UlXjY4Hu4sGOtlqqGSw3JT4WfgpjfFVLL9CmO6ek33yL/vh2bfFRwLIAAEwmSUSRYoW07n1KqFxqQsHBKBkCIIYS0PDYfSmi+viPJ9ypvQfdHFe789DU/n3y0JNFZWYa6FAAAGNf/e7cRzZYDf3u+3nmPWOTYus+FUIkMyd2Dsk0xqrCRASwhI9mQcO3EkAtBJ4eQRAEQVB7EolECgsLuWpcXL5Yp9N16tRJIBCUlJRYLBaBQJCZmWk0GgEAPXr0CAaDtVU1JBKJ1+ut96s1wzBSqVQqlTZS/bneYXH+AAAgAElEQVQWgiASiYQgiJ49e7bih4TaDlW46JHHvq7pOvPnDe8Mi5WJihpAF654+7FfHdmPfvzv6TfnsEE96ULA/wZ7IVKpHLBur58BcbUfgg343AwQSiSiGLqcaC8bHGoSiqJsdrvH69XrdAa9HpZ7hnhH07TN4XR7vDqtwrHm1Wd/sMDepv2jC5e//NgaW9cnPtnwQr8GdqWoc//OglXH9u8Kjx33/3lRprjglAOJf7Cbnvc9TwtFh6LB/XTipB7qLus/RYno/54TqvvqkI1ufyWbkFWbOvcFymlEJZcoeQm3YfDYfZmqnTPm/dXpuc7b76tz3hUM+VlEIhYiAABAF658/7GNzq4P/GvDP3rGyEajyneO/+qkevhD79/T12XIUHtqcop2gIrTJRSSEKfjsTTIdeL6TUCzLBsIBGLzNJFLAVAUFQgE+I6l/eEG97XS7LEdG0VRAIBQKBSb34sYx3UpfEfR/sDu7pq4XK5ly5Zt3rz55MmTNE2TJAkAEAgEGIaZTCYAQFVVFY7jLMvm5OTk5eVNnTq1X79+vXr1Ki8v12g0AACVSuV0OjEMq/2a0zQtkUjkcjmGYWq1mstrc8OcL+8KuLHPOI7369evR48e7XevtXZ3Fw6HW2rCt1YX2bF48f5on9e/mRfTF1QMcXzB92ciXZ5Z9Fx+P9qJg/rj9AU5+SPifvr8l1Wrx780MR4HAADGt/3r9bso+e03d4uhcUrtZINDV8WyrMvtttntcpksOzNTIIC37UI8Y1nW5fbYHE6pRJKVniZkdr7+yQHY23QE0cOLvzoe7Tbtm1kNZZ8BAGjc2NE957y5+99rL4x+KFUAABs4tGTNWZDx2H15vCZ8EMST0d3Sp8/2p1dT0ozxzj/ReuEgigmd1PN2lv7rbNLyTlIBAIAJr99fdogVT8rWxtBwWXjsvoygU49Bss2//PrHwbGP9ucqPjOe31dvL2I1T/RNxQEAxMnFq4qinR7+5ulYyT4DAPA4vcxZ+cNvpwePHf5g8R5xJAAo98r1B44B3Yz+yfBA3tqu3wQ0giAikSg2E20Mw0SjURRF4WQazQY3XTNwRWCFQmGza/pczwiCgK2uGWB313RlZWXPP//8oUOHFAoFhmEEQQiFQgAARVEsy5aWlgIA5HJ5SkqKUCgkCGLLli1FRUUzZsyYMWPG/fffLxQK5XK5UqnU6/VOp1MoFCIIwjAMSZImkwnHcQCAQCBQKpUURXH50wYrdYhEIoIgXnzxRaUylgamXCOKohiGab3urh39CEqX7NtvZYTKPfOfeuLSbYEob35+4aSusXCm6EdFVTXnDzpZkezAV6+f/fqSJxFl77sXjk3HRT1emXXbppf/eOj+Cytv7dtdGT13aNe6U27NwOcW3BZD8221iw0OXVUgGDRbLCiKpiYnS6Ux9AMHdN0KhkJmi40FbLIpQS6TAQDoU7C36SDo8oL9DlYoPzZ/zmv1d+UNDy+8OwsHaNqE52atffKtd6eNKRk3Op06su6H76qTnvzioT787eZgXKo5fySDC0xbFxWcIsVJ8vwGgkE69eg+vXDX/A1bi84ljdAg5yuq1pqJlC75b6THUDIQHrsvh6hu/NejXf/89+qRj1+YeHNOAnCfPLTn56JA0vAZr/QVAQDoysL9LlYoOz3/3ep6Z9vKnuMXjklt+40WlqjMWZMmP1O67Z1fpj10fHv/zHQ0cOLkyd8qqW6jJs3Jug53Y1u7rjexQCCIzQQ0d+GKoigcTNEM3Lg2uOmagUvE4DheO2UZdE1gq2sG2N01kc/nmzlz5vHjx00m0/nz5yORCJd9BgAgCEIQBJcaDofDVVVV6enpIpEoISHB4/E8/vjjmzZt+vLLL6dMmaJUKjUaTWJiIsuyTqeTG+acnJysVCoDgYDT6ezdu/fDDz+8ZMmSY8eOEQTBzVhYW/QZQRAcx3Nzc+fOnTt06FB+N8jf1NrdXcyeYFyOqiivoNjAmT++OVPvGdSI3/P+pK68RFUrimBmVBFBcHV1uZVmA2UHvimrtwhixAa/PzYdACRhyIw9X+S+/d8NP29etzGCG5I7Pfzci3Mf6MvDJc6VxfgGh66KIAizxRIKh40Gg1ajaS/fdKgDI0nKarf7A0GjXqfVqGvbJOxtOgyqprqCZgMlu78pqfcMasRue//uLAAAkOS99t8vDO9/8snv/3kxKDR1HjBv6fOzblbz0kORUoW193BfSmf9mb2Gk7uJ88d3EyArTt3wyAWh7q27bzbtObOk5MJHpUCj0U4e2un1noaEWOpc4bepIYK8B17fbVz15o+7164p8FDC+NROU2bc/er4vAQUAAAoi7WCZgPnD39zvt4LESN2y/tjUtsyVkogtsVne9QJevv5EV3GHJilfHvj0d937PyREpiSM2c9NWz2TQn8fFuuM7F0Sg5BEARBUEP++9//7tu3Ly0tzWKxhMPh2uwzN4SZqwRNUZRAIPD7/S6XS6/XAwAUCoVOp/vggw9Wr17dvXv3L7/88uDBgydPngQAZGRkMAxTU1Njt9vtdnu/fv0ef/zxJ554QqvVDh069PPPP//pp5+Ki4sZhuFKSaAompKSMnr06Oeeey4nJ4fHTQG1LNGoZU5yGd9RNIAGiA2Tu1GJhgmn0D70ppnOIzOv9iLU2OOORYvuWNQWATZTzG5w6KoYhnE4nQ6nU6NWJ5lMjfx8hSQ8tSX0VFvG1lLab+TXJ4ZhHC63w+lSKuTZGWnczUy1OkZvA9skAEA05E1n8ZtXXQxVd5/29tJpb7dBRFfEopir0w3WHkOUlUU56xbj4QAAQJTSq2pmr0ZehUl10269edqtbRXltesY36aWh4jzbn30x1sfbfBJ0U3PO/c+38YRXY5FEJc+1RqXIwu6ss/uEhBhAJC07oOWdh901dci6v5bvurf+jFeR2ACGoIgCIJiGsMwGzZs0Ol0LMv6fL66V5g0Tdet5ozjOI7jXq+XS0ADAHQ63Z9//nns2LG+ffsuXrw4EAhYLBaWZePj4xUKhc1mczqdEokkOTm5NpliMpneeuutuXPnVlVV1dTURKNRrsa0yWSCd5pDbQLxoCILphCzZCblErEU3/FAEPB4vRarVSQUZqSlicVivsOBIOAPBGssFqFAmJGWIoZ1zKAY4E/ONeePxKKhtC3fSu1VfIcDQSAg15lNXRGWTj1/SBZ08x0OBBPQEARBEBTbampq9u7dm52dHY1GQ6FQ3dwHw/z/VGzc5Kssy6IoShAETdNcQhlFUYlEcurUqb59+wIA5HJ5VlZW7cuNRqPRaGzwTYVCYUZGRkZGRit+MAi6TBARmDEFA4CJ8ipYgu9wIAiEw2Gz1UqSZHxcnFql4jscCAKRaNRssREkEWcwqFXteD4GqMOIKnXm/Nsjmnjj8e3a4qOgvczDDHVchEhmTcgNyHVGa7HWXg6ra8QImICGIAiCoJgWCAQAABiGRaPRxpfkKjVHIpHaBDT3Qr/f3+pRQtDfQwLUisl9qEjPhAx0CAHw8hXiGUVRNrvd4/XqdTqDXg/LPUO8o2na5nC6PV6dVpOqM8FpwyHe0UKxo9vNzk75muKjKTtXo8RVzlQhqLUxKOYwZjgMGWpPTU7RDoyCoxliCExAQxAEQVBM02q1AACKoi4vOVovIcJNGCgWi+uW6SBJUqfTtUGcENQ8DABOVGpHpUqWyCGdOGD4jgi63rEs63K7rTabTCrNzsyE0+RCvGNZ1u3xWu0OqUSSlZ4mFMI2CfENQTwZ3S19R4jd1swNX4o8dr4DgiDgVcVbTF2E0WBG8V5xBI6/iTkwAQ1BENQYl8t19OhRt9stk8ny8vJSUlL4jqgdMJvNJ06c8Pl8SqWyZ8+ecXFxLbLaRvaF1WotKCjg3rF79+4qlero0aNms1ksFmdkZHTp0uVKI9ccDsfRo0e9Xq9MJuvevXtSUlLdZ4uKikpKSsLhcFxcXO/eveVyeYMrOX/+fGFhYTAY1Gq1eXl55eXl1dXVGIYlJyf37NmzdoASy7JnzpwpKyuLRCIJCQm5ubknTpzYt2+f2Wy22+0SiSQxMVGv11+4cMFqtUql0gEDBtx///1yudxoNI4YMeL48eNarVYmkxEEUZuJRlGUpmlu5RiGcYU4ZDJZ7ZuSJBmNRrn6GxAUg/yoyIzJMZZNo71SluQ7HAgCgWDQbLEgCJKanCyTyfgOB4JAMBQyW2wsYJNNCXLYJqEYENabavJH0iKpac96RdU5vsOBIBCWqMymLqRQEmc5q3ZV8x0O1DCYgIYgCGqYzWb7+OOPt2zZcvbsWRzHGYYhCGLixIkzZ87s0qUL39HFqLKysg8//HD//v0lJSUYhtE0nZ2dfdNNN82YMePv5O6tVuvHH3/8119/1d0X999//8yZM6VS6cKFC/ft21dcXIxhGEVRSqWSpmmfzycSiViWJQji1ltvffbZZ4cOHVp3nTU1NR999NGOHTu4ddI0nZWV1adPn5kzZ+bk5OzevXvRokW///67UChEEIQkyby8vHHjxk2bNq1uPuLEiRMLFy5cvXq1UChEUTQcDuM4Ho1GpVIpgiAEQQwcOHDKlCnjx4/ftm3b4sWLt2zZIhQKAQChUIhboLaI8+WWL18+Y8aMCRMmfP755/fee+/WrVtVKpVGo+Gy29wy3EdmWRYAgOM4y7IURWk0mtqV2Gy2+++/Pycnp9kbH4JaSRRgZkweQQRGOqBlogDW3ID4RhCE2WIJhcNGg0Gr0cCaGxDvSJKy2u3+QFCv1eh1WtgmId5RUqWl9zBfSmf9mb2Gk7sRGk4UDPGMxoW2uCy3NklvP6+3lqIsvJEudsEENARBUANKSkqmTZt29OhRo9GYnZ3NPUiS5B9//FFYWDhv3rx62UwIAHD48OEZM2acO3fOYDDUznQXiURWrlx5/Pjxjz76qGfPns1YbXFx8bRp0woKCgwGQ9198fvvvx86dAhBEIvFwr0jTdMVFRVmsxlBELFYHBcXJ5VKaZo+duzY2LFjP/zwwylTpnAvLywsfPbZZ0+cOFF3/xIE8euvv54+fXrIkCEfffSRTqfLysqqrWXhcrnmz59/+PDhJUuWcBUt/vjjjzfeeKOyspJbrKqqipv9j2EYlmWTk5NxHC8uLp40adJXX321bds2vV6fnZ3NsmxFRQVBEGyjM7RwF5mBQOCbb745fPjwjh077rnnnp9//jkxMTEQCPh8PoFAgCAIgiA4jnNjornpB/V6veriNFk2my07O/vll19uxmaHoNZDA8SByZyoRMNEUmgXvFSAeMcwjMPpdDidapUqx2S6vN4RBLUxhmEcLrfD6VIq5NkZaXUra0EQL1gUc3W6wdpjiMJcmr3+M0HQy3dE0PWORRCXPtUWnyMNuLKKdgnJMN8RQVcBj2QQBEH1BYPB6dOnnzx5MjU1te7jAoEgISHBarXOnTs3JSWlNscKAQDMZvMLL7xw4cKFelUsRCJRUlJSaWnprFmzVq5cqdfrr2m1gUBg+vTpp0+frjeAWiAQGAyGc+fOMQyTnZ0tEokAANXV1dzAZwAAQRBVVVXp6ekCgUCv10ul0hkzZqSmpt52220+n2/GjBlFRUX11ikUChMTE0tLS/fv35+WlqZWq+s+K5fLpVLptm3bXnzxxaVLlxYVFb3xxht2uz0+Pp77+E6nkxsuDQAIhUKVlZUZGRkajYam6Q0bNsTHx3Of/cKFC17v1U/ZuekEURRlGObMmTNc9hnDsB9++EGlUtE07ff7uRQJwzBSqTQcDkciEbVabTQao9FoOBx2u929e/d+//33MzIyrmmbQ1BrQjyoyILJxSyVSblFLBw5BfHP6/NZrFahQJCRliYWi/kOB4KAPxA0W60YiqWnJktgm4RigD8513zD7RgRSfvrO6mtku9wIAgE5DqzqQsASHL5UbnfwXc4UJPABDQEQVB9K1as2L1795XSdhqNpqysbPHixYsXL27jwGLZl19+eerUqXop+1pGo7GgoGDZsmWzZ8++ptWuWLFiz549De4Lh8NBkiSCIDabLTk5ORAIOJ1OLvsMAMBxPBwOOxyOhIQEAIBUKjUYDIsWLRo6dOjy5csPHjyYlpbW4DtGIhGWZQOBQL0ENAAARVGTyfTjjz/ed999q1evrqio4FYejUa9Xi83JJlbUiAQ+P1+l8ul1WrdbjeGYX6/n6KocDjscrkYhmnKXbRcDpqzbdu2/fv3L1myZPTo0WvWrDl9+vSpU6e4YiDBYLBr167JyckoiprN5kgkAgBISUm57bbbHnnkkcs/BQTxJYwIalA5jSAm2q9gonyHA0EgHA6brVaSJOOMRvXFe0cgiEeRaNRssUWJaLzRqFYp+Q4HgkBUqbPk3x7Sm4wndmoLDyCN3sAHQW2AEMmsCbkBuc5oLdbay2FlonYEJqAhCILq+/3337Xaxgrt6XS6/fv3c+nFtgwsZhEE8ddff3GFKa5Ep9Nt3rz5hRdeuKZbmzdu3NjgvmBZ1ufzcXUngsEgTdNer5ebha92GRzHfT5ffHw896BGo9m1a9ehQ4f++OOPK+3fcDjs8/mEQmEgEGAYpnYqv7rrVKvVq1evPnbsWO3e9/l80WiUK+5cC8Mwbjh2IBAQi8XhcNjv9weDQS6h3Hj9jbofE0EQLpIlS5aMGDFi7NixY8eOJQiCq8IBACBJUqVScX+zLOtyucRiMZw4C4opFEVbbDYfrtYzIQMVQmC5Z4hvNE3bbDa3263X6Qx6PSytC/Gutk1q1KrUZNPlZyAQ1MZoFjho1HnHVE3x0aQdqzES/nIM8YwBiEOocuQMVHot2YU7cJrgOyLo2sAENARB0CW44glSqbSRZcRicWFhYUlJSX5+fpsFFssqKyuPHDmSm5vbyDJSqfTAgQM1NTXJyclNXG0wGKyurm5wX5AkGQwGRSIRgiBc9YloNFrvag1F0VAoRBAENywaRVGxWFxQUGCz2SQSSYPvGIlEUBTlphOMRqMNLiaVSk+cOHH27Nnamf24V9VbDEXRaDRa+1Ttf5v42eviMiPFxcW1jwiFQr1eHw6HAQCqOqP2EARp/GcAqINA2k2BWpZlXW631WZTKhQ5ObntsowpTAM1RTTEdwRNxbKsy+uzudxSsTgrLUUoEAAGloJpK6iI7whilMfjsVgsEokkKyOj3u/Z7QPsJ5sipRPfEVwDj89vsdvFIlGmViRKHQ2Gj+Y7omuHCfiOIOYZkq6+TMzw0oiFRIQIyIgziNOSQI++fEcEXbN2eBkAQRDUmrik3lUHnnDJzTaJqB0IhUJcweJGluGe5TZv01dbWFjYYK1thmHAxcwsN6CYe+RKS9bG4PF4CgsLaycebGThK62QS0/X/bANLlkvKm4g85XWeVUIgjQveQ1BPPIHAmaLBcOwtJSUxn/Vg6C2EQiFzXYHgiApCXEyiQSg7ea3HKijCgaDZrOZZVmTyaRQKEBzzxMgqKWEIxGzzU5RdILRoFIoQMDNd0TQ9S7MADOJkiwSJ2DUGAsE8KeF9gomoCEIgi6hVqsFAkEoFBJc+djGMAxN00ajsS0Di2VGo5FlWZIkG9loBEF07tzZYDA0fbUajaZbt261tSbq4sZRchUqWJbFcRzH8Xp1Lbj/1n0tSZLp6eldu3YNBoMNjsSsu5IrDdUkCIKbVpF793qvqvvuGIYJBALuKYZhuCCb/vHrrQ3We4HakWg0arFaQ+Gw0WDQwaYLxQCCJK1OdyAUMmo1WpUS1tyAeEeSpNVq9fv9er1eD+vAQDGAommLze4LBPVajUGrgW0S4h0NgI1E3RSiE7AGnIa3WrR3MAENQRB0CQzD+vbtu27dukbG6/n9/v79+zdeceK6EhcXd/vttx89erRe/YdQKOR2u8PhME3TNE3n5uaeO3euT58+TczD4jjep0+f9evXX74vcBxXqVRcSWWpVMrNHEhRFIIgtTWmaZpWqVRcdjgUCnElmJ1OZ1pa2v79++uW16AoKhAIkCTJMIxAIKAoSqFQiEQihmGCwWA0GiVJkqIohmGi0Sj3caRSaXV1tcFgEAqFDMNQFEXTNAAAwzAcxxEE4d5dJpOxLMsNheb+9vl84OL46CZuXm7JW265pYnLQxCPaJp2OJ1Ol0ujVieZTNdU8x2CWgPDMA6P1+H2KmXS7NRkHLZJiG8MwzidTrvdrlQqs7Oz22VtIqhjYVnW5fHanC65VJqdniqAbRLiGwuAi0JsFCpF2SwxLYS/hnQIsGeBIAiq78EHH/zqq6/UarVYLL78WZqm7Xb77NmzYWKlrgcffPDPP/9UKpXciONwOFxRUREMBuumWQsKCgYOHDh06NCXX3558ODBTVzt119/3eC+0Ol0Xq+X+7u8vJxL6RIEgSAIjuMYhtE0rdVq/X4/N8IIACAWi//1r3+FQiGapiUSiUKhYBjGarV6vd5IJMIN9KBpmmVZpVLpcrkcDkcoFLq8vseFCxe4P2w2G7iYIK4d6UySJIZh3Jhlrlizw+FQq9UymUwoFHIZ+SZmn7kPhaKoRqOZPXt2U14CQTzyeL0Wq1UsEmWmp3O11yGIX15/wOJwCQV4RlKiWNQOS+tCHY7f7zebzRiGpaWlwdpEUCwIBENmmx1F0VRTolTSwLUPBLWxIIOYSZQFIFnIyFE4c3XHAcewQxAE1de/f/85c+ZUVlZeXrCYoqjKyspx48Y9/PDDvMQWs8aNGzdp0qTKykqCIAKBQElJSSAQqJtmRRCEGxe8ffv20aNHr1ixoimrHTBgwOzZs6uqqi6vgCwWi7nCygAAkUgkFAqFQiE33JgkyUgkotPpGIYpKSkJh8MYhsnl8qysrPT09JycHJFIVFZW5na7y8vLrVYrTdPcGgQCAYqiOI47nc7y8vJoNMqt8ErhXelZmqZxHJdIJFx5EKVSiWEYN7yaq9xSW76jESiK1ia133jjDb1e35QtBkG8CIfDZeXlNrs9IT4+LTUVZp8h3oUj0bLKGovDFafXpsPsMxQDotFoeXl5dXW10WjMzMyE2WeId1GCuFBdU2k2a9WqjJQkmH2GeEeyoIpAKwhUgzFZIhpmnzsYOAIagiCoAS+99BKO42+++aZCoVAoFAKBgKbpYDDo8Xgefvjh+fPnt8s5ylsTiqILFiwQi8WfffYZQRAURdV9lss+AwBqS0U/9dRT2dnZffr0ueqaX375ZYFA8NZbbymVSrlcXrsvrFarQCDQ6XQOh4NhGBRFEQThCmhw6V2api9cuMANhVYoFElJSdzobIFAkJOTU1JScv78eQRBuF3J1fWmaVqv1wuFwurqai5UcHFo87UiCKK4uBjDsPz8/H/+85/Lli3bunWrWq2WSCQJCQl2u50giEZeXptbVygUr7322rRp05oRAwS1AYqiLFarz+/X63QGWMYUigE0w9icbrfPr1MrDRr1VWcVhqDWRtO0zWZzu90ajSYlJQW2SYh3DMM43B6Hy61RKZPi4+BtnRDvGBY4aNRBIUqUzRbRODyd7IhgAhqCIKgBGIa9+OKLt99++6pVq44ePepwOBQKRV5e3tixY4cNGwYzLA2SSCTvvfee3W7/9ttvudoR3Iaqu7m4x0OhkFar/eSTT5YvX37V1WIY9tJLL40cOXLVqlVHjhxxOp0KhcJoNK5fvz4nJ0cgEGi1Wq6uBUVR3DhoBEHC4bDP58NxXKFQKJVKjUZTLwyTyVRUVCSTyRAEoSgKwzClUskVyigpKREKhVxZ52va17ULcznrcDg8f/78qVOnymSy4cOHr127dvPmzcXFxSqVqkuXLjRNV1VVmc3mcDjMMAxyEZd3RlFULpcPGjRowYIFOTk5TY8BgtoMy7Iut9tmt8tlsuzMzEbmIIWgtsGyrMvrs7ncUrE4K8UkhG0SigEej8disYjF4szMTHh3CBQLPD6/xW4XCYUZKUli2CahGOBnkBoCESIgQ8iI4ajnjgsmoCEIgq6oe/fu3bt35zuK9oQkyYKCAq5sMZdUvXwZLgfNsuzatWu5MeZNWXO9ffHOO+/s2LGDS3jJZDKZTHZ5JCdPnkxJSblS5Qqfz4eiKIZhmZmZdR/3+/2hUEgkEnFTGjYlttrPVbs89xkpikJRlItNKBROnDhx4sSJTV8hBMUyfyBgtlgwDEtNToY3kkOxIBiOmO0OlmWT4+PkUsnVXwBBrSwYDJrNZpZlTSZTE892IKhVhSMRs81OUXSC0aCCbRKKAREWMZMowYA4AaPGYOq5g4MJaAiCIKjFWK3WwsLCusOfG8TNFojj+Pnz55uX4i8tLZVIGssvRKNRAABN040sgGEYQRD1Qo1Go7XVQsC11N+otx7u76NHjzbx5RDUXkSjUYvVGgqHjQaD9tJ7CyCIFwRJWp3uQChk1Gq0KiVskxDvSJK0Wq0+n0+v1xsMBtgmId5RFG1zOj0+v16rMWjhsRviH80CG4W6KUQnYFOFDKxMdD2ACWgIgiCoxdTmc6+at+UW49LEzXujxk+dr5o+5ipdcH/UrXzXxPibKBQKtch6ICgWMAzjcDodTqdGrU4ymWDJSIh3DMM4PF6H26uUSbNTk3HYJiG+MQzjdDrtdrtSqczJycFxeLkN8YxlWZfHa3U4ZVJJdnqqALZJiG8sAG4KsZKIFANZYloIfw25bsTezwyM6/hPH7487ZEHHvnHyx+uPu6unwIgD3x4351j6xk3dfk5mnX/PndC3UfHP/31uSuOfYMgCIJanMFgSEtLu2oOt3a2wISEhOa9UXx8fOOT+HGXfI0kyAQCAVcqpN4yOI7XLR7S9BEi9ZbkyozUq+8BQbEtsnfBPRMXH6Maes7j9Z4rKQmFQhlpaQnx8bGUfW4sbKjdY23r/pGfMnj+0ct2sD8YKr5QFQxFMpISk+KNMZB9Jqu2LJw8omeiXi1SJaTmj3926SEnw3dQTdJ+I48tfr+/pKTE5/OlpaUlJSXFUvYZ9pMdT5O+toFgqKS8whCNFzQAACAASURBVO31pZoSU02JvGafo3s/fmLi56cub4Ss58R/504ZclNPZXJezuh/vr/DQvIQHtQcofJtb858vPOAgZIu/fSDH5rw/u+nQpdcALLeM/9994Uho4Yruw/JuX/u+3ttHgYpjWJOGk0WsalCJgayz2yg6OdXJt/Ro1uOIrlbl+EPPbf8iAMeAVtH7BwUOfSFte+8vZoeNPm5iTr7zu++ens+tvCd8cl1zifx7Dtmzu5P1bZq1n989X+PZXVLQJkaiw3JuWPGXV2F3FOIxJQYexl2CIL+nnPnzu3atauqqgrDsLS0tCFDhphMJr6DujZOp3Pbtm2lpaXBYDA+Pr5///69evVq3q1wLMsePXp0//79VqtVJpNlZWUNGTJEq9X+/SDPnj27a9euoqKiiooKAEBycnJubu7AgQO7dOlSuwxFUfv37z98+LDL5VIoFF27dh00aFB+fn55eXnt+GLQ0DBkbh5Co9FYUFCAomh6evq1hjdgwIClS5cajcYrbTcMwxqZZZ5lWYZhSJIEAJw6dQoAgOO4UCiUy+UAABRFuex244VErgpBkAkTJjT75RDUxlj7hk8X/7LzzqfrnXWHw2Gz1UpRVEJ8vEqp5Ce4K7tS2FCHwFStnP6P5aftGbfWzUdEokSNzUFSVJxeq1bIeYvuEqzzj+lDJvynQn/DhEkzskW2I7+s+vczt+2p3rT79Rtiu0p6+408hkSjUbPZHIlEjEZji5yGtSzYT3Y4V//aEiRpttlD4YhRp9WqVbzX3GAdf376+aadox+t3wgjx+fdfffrJ6T548c/e6v/wPq1sycePv/tb58N1/CfmYQaRZb9OGHi/E0Bw4CRd92dSJXu37Lmy1e2HrFu/2ZSDy4lFzkz77EnXz8lyR8z8tnBgf0bN85+4vjRRSsWDVYaBGyM7F/izJI7Rr6+k8oYcdfE0dpw0db1S56/c3vpT7vfujHmTnnbvxhLQBMnfvvtfNKEj6fenowBkKf3lMz6dcPp0VO7C2sXQbTZ+TdmX/wfGzj676/Dg5+e1FuBRG1WtzK7/80DuvE+/gGCoNbgdDrfeuutZcuWSSQSkUjEsmwkEsnMzLzzzjtnzpwpFov5DvDqGIZZunTpN998c+bMGYlEwiU6Q6HQ3Xff/a9//eta87ClpaVvvPHG2rVrpVKpUChkGCYcDnft2nXSpEmPPfZYI+nXxjmdzjfffPM///kPAIAkSYqiAAA4jnNDhidPnvzaa68ZjcYjR468/fbbf/75p0wmw3GcpulQKNS3b99hw4Zxn7R2ssEG34UgiOrq6qlTp2ZnZ48fP37OnDnXtAdHjRo1YMCAU6dOGY3GBhewWCxDhw49cOCARqOpNwTJ4/FUVlZyKWYuBw0AiEajwWDQ7XaDi1MIco83vRZH3TN77oP36dMnPz+/6R8KgnhChx3lpw9v/e7duassTFydJyiKstntHq9Xr9MZ9HreL18vdcWwoQ6DPv/1U7N+sbJI7fGMphmby+32+XVqpUGjbvaRruXRZcvf/bZMe+fyvSseNmEAADDnoRcG3Lrw04U/P/fDA9qY+u5cqv1GHhtomrbZbG63W6PRpKSkxFCbBAD2kx1Wo1/biWrW4fY4XG61UpGTnoZh/LZJOuysPH1s93cfzl9lu7wRMhe+f+e9AmTQW2v+eDpLCADzj8EPD3l62WtfPD5odh8BH/FCTcT61y/+bLM3cfKSr5cO1aEAAGbKlnmPjfp26au/jvllgh4BzIU1i947CQa9vHTjpHQfjd7/wMC5972w5sOvZw15puHrNx4ENn68aGcgZ9bvmxfkSwEA4NWnPrpz2Myl7694evXTcDxrS4utDUpXni4MxPfuk8hlkLGUPr2MvsIz5iv+VBs5vfI/xzpPerCnDAGM3WpjjQlGJuy2OfwknD8TgjoWm802adKkFStWZGRkpKamxsfHJyQkpKenB4PBhQsXTp06NRKJ8B3jVTAM8+qrr7744osOhyMzMzMxMTE+Pj4lJSUrK2vTpk2TJ08+e/Zs09d25syZyZMnb9myJSsrKyUlJT4+PjExMTMz0263z5w587XXXmteFWObzfboo49+//33IpEoEomgKCoWi8ViMYqikUhEJBL9+OOPjz766Jo1a5555pnDhw9nZ2cnJSXFx8ebTKbs7OwLFy68++67I0aMQFG0kewzAADHcbFYzDBMWVnZokWLrnUPikSiefPmJSUl2e32eu9C03RVVVXv3r2XL1/+4IMPVlRU1K007XQ6y8vLa/PODapdYfPqb3AfXK1W//jjjzGWsIOgBrC25eNTcm4YPXXRbnvtGRfLsk6Xq7i0lKbp7MxMY+xNotVg2FCHQp77dOorO9Pvn9gNB1wZU6/vXHkFQZJZKaY4nTa2Mn2Bg7sKCMWQByaYLo6EkfUZNyIJDZ09XR7bJQHbb+QxwOPxFBcXR6PRzMzMhISE2GqTsJ/swK78tT1y2nPufHkwFMpISUqMM/KdfQasfeX4vBtvuPeFRfsbquvDVK9fuz+kGz3zkSxuyCFqHDnrwSy2+NdVx2EdjthGn9t51I91HjdzkO7/GxmqHvrkPQPw0K69p6IAAMay/rdjIe3wf9yTcSGK+mmQaRry2t3pbNnmVQ0UYuEJbT1b4gOGG0f0vHjDjyD99uHZOFFWWAaPgC0vtkZAMw6bg9UZtBd7SVRr0LIOm50BqQ11nPSFX77aoZuwsJ8SAQAwdrOdsm9997GvzntpgCvSbnrg2adHZUkvXi6Fw+F6GYeWmmOqxTVj5B1UD9x0zdZ40pBHr7zyyoEDB1JSUuolQSQSSWpq6vr167Ozs+fMmcNXeKAJre7777//9NNP09LShEJh3cdxHDeZTCUlJS+88MKPP/4oEomu+l7hcHjWrFllZWWJiYn1nlIoFCKRaPHixXl5effdd9+1foQ5c+YcPHhQLBabzWahUFi7tVEUFYlEPp8vPj7+8OHDR48elclkl48+VqvVQqFw27Zt3bt3LygoaHybcJWgCYLAcbwZe7BXr16LFy/mGoZKpeK2ajgc9vl8Y8aMWbBgQUJCwsKFCzUazaJFixQKhUwmo2m6oqKibonnRmAYRtP0VYtZ1+uxuX8TEhI2b96cnp7eBt+m2PzCtgut1921r52CaMcu2pHnYQDrXPfcXQurAAgEg06LBUGQ1ORkqTRGb8G/PGyoY4ke/2jq3IJur/81nX76xx+DdHVVtQ5lkxPi5FIJ37E1BO855ZPPJ+bk17mXh/L7Qyya8L9Lm9jUfiPnVTgcrqmpoWnaZDIpFAq+w2kY7Cc7rIa+tk5PiEV0IsYVbzCqlbHSJhHN7Ys2dvYwgHVufO7hJfUbIXH64ClS2K9///+da+Bdbuyr+/DHI8edTN942AfFLjIMVKnd8rtm1qk/gIjFEgRQBMkAAIiz+4pIQa8bklAkTsCqMRYAtMsNPXRLfj1y2sX0NMbEzsUM2RkKcPLY3mJiGFfKl7EeOFhBCzvnpMLCCi0vthLQNBGlEIlEcjEvgEgkYoSIEg1exrHePT/8Grhl9jAjAgAArN/hJiXyzDv++cbNJmA9/tvnnyx7Z5lh8bP5cm518+fP37BhQ+3LlUql0+mMteE8dREE4XQ6+Y6ivQoGg3yH0F55PB6+Q2jAoUOHfvjhh7S0NJpu+KdIo9G4Zs2asWPHNntSu7+v8S8sQRBffPGFXq9HUZQralGPTqfbsWPHt99+O378+Ku+108//bRnz560tLQGV4WiqE6nW7JkyS233FIv2d24Q4cOrVy5Mjk5uaKigitbUS+PJhAI3G63TCaz2+0KhaLBdxcKhQqF4sSJE+np6V6v1+/3EwRRd0wx1/FSFIXjOJeDDgQC8fHxzdiDaWlpy5Yt27hx4/79+81ms0AgSEpKGjx48JAhQ1AU5fbI9OnThw8fvmnTpqKiov379zMMw81/2JT1i0Qimqa5gtEYhnF/oCiK47hUKs3JyRk/frxSqfz888/LyspIkkRR1GAwTJw4cfr06TiOt00fDru7Zmu97i4cDtctg/53sCxL03S9X9AFLTvZGm7IvcEAAGDNBXIU0AFrVVWVyWDQajSxfJpUN2xlTFzExJzGb/VoNoZhGmiTLf0uoUPvPTb/bL93dvwjm36bZAEVVCgUWTpl7LZJWedRj3QGAADARHxul6Py5KZPZq10Jo5feG9KbDfQNoy8ldpkw/2koLXu3idJ0mq1+nw+vV5viL27Qy4B+8mraaUBanXnGqnVki3y0q+t3Vqxe93C11Y54se8MW1ghhqLpTaJ63J76QAArPXU5Y2QsVaURxBdiklRJ2TclJKMMRXlVTS4HhPQ7aZNSgYu/nXgpQ8xVZv/2kcJevbqJGBBtbnmbATRmOJ7SpnaX0rwBFMySldUWGgQGwlooBz72oJHCp6bN/7OkgdH9dSEz/618tu9opHz3nksOTYCjAGXt8lmN8vYSkBjQhHGesMRFoi5pHI4HGEFigazJ0zVn+uPGoYv7HxxxkHNiNdWjrj4bHL+/c/cVTBt1Y7jT+bfxA2TyMzMrFuL89y5cwKBIDbPGFiWpSgKQZBYmjq53eCu+WPtDrh2gaZpLjfHdyAN2Lt3r1wubyQ2qVRaXl6+f//+e++9ty0Dq0WSZOOb7siRIwUFBZmZmVfqdhAEUalUe/bsacpH2LNnj0qlaqSdq1SqI0eOnDlz5oYbbrjq2mrt3r1bLpdHo9FoNNrgQGwEQaLRKJeNDQQCVxryg6IoTdNisVihUPj9/vLyci7tXvezIwhC0zRXVxrDMJIkm7cHBQLBxIkTJ06c2MgyvXv37t27NwAgNzeX6/mbctTkcs0YhgEASJJUq9Umk8nn82VmZv700091l3zggQeuKeaWAru7ZqMoimVZ7ieQVlp/C64qHA57vd66D+pbYYYrhmHsTn+YBQDFs7OyJC2b44b4UK/ZtNRFLE3TkUikfptUtOhIef/u1576uOLmD76YoDt/4QQAAAgUKrUqJk/bL0Of++i2G+YcIQFANTfN3fjvCe2mhmTrR16v2bTUD3UURUWj0fptUq9vkZXXxbKsy+WyWq1KpTInJwdeqXUArdRPNtwmVS0/Kpmlzr49PH9eAQkAqhnwysZlj5piKvt8NWwwEGRRuUJet7NBZHI5wlYFQ+3pbrKWc3k/2SLNkqIogiDqt8m/v97/Icr/WnTvu3uDprumj08uiaCiYJBhEZVKUrejRKQyOQKqQuHY2bl40i1THuy38c3t33x46BsAAEAUfZ5+Zkx2jN4AyId6zYbLGjVvVbF11ER1Bj1y3ulmgBoDAADG4/Qguq66Bk5+6NJt2yozbnsh6UonRqjelCgi3f4IC7gR1Y888sgjjzxS+/yIESNUKv5ng20QTdNut1sgEChjb6752BcOhwEAEklM3p4Z2/x+fzQalcvlWOzlHaxWq0QiaTwwiURit9tVKlWbRVWXy+Vq/K2dTqdIJGr8WkUikdTU1DTlI5jNZqlU2vgGEYvFTqfzmjaIzWaTSCQURTWS0+SSyyiKkiR5pQBYlkUQhKIosVjM5Z0bPHOqfZBbm1QqbdU9GIlEAoEAV1ijKcvXjbn280qlUpfLJRQKY6GTgd1ds/l8PoIgFApFK3V3AoGgpX4YQFFUIBC09l72eL0Wq1UYIiQIwKS6GDwKQM3QSs2m1dsk69n0yj8+sQ9767Mhmkgo0WRQCRAAYvGMvWGo6a53vk2rMJce/mXZ1/PGjMc2/vxivpzvqJqi9SOv12xa6kKMuzOptftJv99vNpsxDEtLS4vZ2kTQtWqlNolhWBu0yUAwZLayt8z46Ct/qOrE78u+fmfMeEG76XA4LMuyDffvDBM7Kco21Xr9JIZh9duk9wpLXyPCcmDR/PfmbSwjkke8+cns7lIsHqelOAOuuHNjpig969/91t23L6ruPuWz9dNG5KnDxTu+nf3iR2NHuVZuWnzX9TgEvwH1mg2Kos2+zImtBDSW0rWzbH3Bcfv96fEIAIzl+AmLoktX0+WXQVTR9p3W7PED4mobdGjfpzO/pR58958DVQgAANDVpRcITddkRfs5X4Ug6Eq4UrxNWawNgmmepnwEblBwU9bWxCrG17pBrlryuPVwb9qqe7AFB6XGckuDOhgMw0QikUwmu+TRljtxD4fDZquVJMn4uDiVoqGf/KF2q16zacHEilAorN8mo6EWWTkArHXDnMf/6x/+3ktP5Om1Cjmgwy205raCKHKHjMsFADw65YEuY3pMXzB35UO/P9EehkG3fuRt2iZbTjQatVgs4XDYaDRqW+EGFIhHrdQmuR/q6rdJMnqFxa8ZQZJWuzMQChl1iVn3PY4gCADT2lmHAwDgBjujrOvSwc5sMBBgEblMen0mcuo1GxRFW6RZYhjWQJv8+1jfoe/fe+KD/2PvvgOjKNYAgM/uXu+X5NJ7oRcpUkMVaSKioAgCD1EQQUERBBF4SJEiYEGfAoKCiICAgIo0UZpU6T0hBZJcruV629vy/lg9QxqXcGn4/f6Cvd3Z2Z25yd13s9/suUxGpP9n0dRX+ndUsmF8GkOIkUplOFvkvGeyM+tyOlgkk4jrSOMy2u3zPr8q6PvpD4ufi8AQQupWT07fJjM0H7xx9uqxA+e0rFsB01oSxD5Zx4YmQYv+/eNzvl+56fTtu5knNn66427KgP7NBAhRtw9+vW7LKd1fX7jo3PMXLFFNGqv/uWxx8w7NfEfXfPDN75duZVw9sfPjZTsNTZ95ojH0GAAeAjExMV7vfT60eb3emJiYmqlPFQR4CbGxsYGUFh0dXXFpLMuSJBlgaX5cJQUCQQW/S3MZMyrO1sKlS+Z24JJslPlXyr+RZVmBQFDdLSiTySQSSYA/ZqBi6aq5GnKX4/V6VSqVTFaP5pYAUDaKogq02uzcXJlU2iA1VVVLj48A4EfTjNZg+POPc3pKv2dK11BNBCaSYtKWb5/x0ZkfdZBJec3ePRW0XxKDjMz6bePGzUfvFv/rSST07t2M8Ny4ersu/2hZf2teA2ia1ul0t2/fFggEDRo0gOgzqHUMw+hNRdePbt35w249Lz5Urfr7w2q9fNviEfHxQsaQe9dWLEhJa/PzaTw+sYxpiKBuoQu3zfxPt7n7ix55eeWO3Zum9e8fymj4LNcj8bCYeCFryCu4p3F1hfkMER8fWUcal7p15YqX16xLR02xb4fyDl3aCejbV67Z/qWz8KtRXQvP8pKHvPO2b9X6T2fs8EhiHhkw/ZWnEwiEEJV/5qfd2XTHIe0jEEKs4fKlQnGDxrHFF9yUtR03/23V+q0bF+22ESGxDdqOnT/isXrz4x8AoCJdu3b96KOPwsPDy3sw3Ov1ejyerl271nDFAte+ffvmzZsbjcYKlkq3Wq0BXkLXrl337t3r/yLE5e2xWCwkSSKEBAKBSCRq1qxZ27ZtK1XJLl26fPzxx2q1WiQScXk20N9pnvxBZIZhZDKZyWQq80JYlrXZbFyiqMLCQolEIpVKRSIRVzFumrN/hjW3FAa3dhBFUVwLZmVlff3110ePHuUyXTRq1GjkyJGPPfZYiaa/c+fOJ598cuLECavVymXIdTqd3Fn4fH58fPzo0aOnTp1aYg3G1q1bHzhwQCgUBjLRu/izRTRNc9cbeBsBUGexLFtkNuv0eqlEkpaSUjdT/4N/FZZlzTa7zlgkEQsf6TNmprDwnwAKaz6xYe1vnrb/Gds9LqxTTJ39aJ+5dcrL3zb6oOPvryf468jabHYWE0tEdWSqV9nqb82rmcViKSwsFIlEKSkpZS6MAUANs9rthXqjQMBPch95/K3vGjF96v3bVti8Q3P+lrNHjrqGDvprkiWdcfa8EYt9oZWmzo73ACGEEH3963de3K5PefGztW+2byZkJPi9E5iEjTs05m85f/Koe+Cgv7IWMRkXrhixyBeah9WRxsWkMhnGmIssDPpnzUHWajYzSCCVCevTe6l+qGsBaIQITdsRs9qOKLFV1PWdbf9848ciBy3dPqjUofzI9i9Mb/9CNVcQAFDzevbs2bdv32PHjkVHR5d+lWVZrVY7YcKE1NTUmq9bgKRS6fDhw999993ycjcbjcZWrVo9++yzgZQ2dOjQzZs35+TkhIaG2my2u3fver1ef4yYWx4Kw7DDhw/369cv8Eo+9thj3H1WKBQGg4HH4/l8vuKzobmJwNws4NKHO51OrVZrt9tZlhWJREVFRRaLhct87fF4UKmlXWia5uYjYxhmtVrDw8NfeeWVa9eu6XQ67tEelmX//PPPzZs3d+3a9X//+1/Dhg0RQgzDzJ0797PPPjObzTiOl16aw+v1ZmRkvPvuuytWrNi4cWPfvn39Ly1atOiPP/7weDwEQdw3I4c/KkdRlEwmUyqVVqs1OTl59OjRgd9SAOoah9OpLSzEMCwhLq76nlgHIHBOt0drMLIsGxsZLpdKUPS4ud2KvUxnfvDrV7+bO74ye077uvfFxY/fpkc35frdX315esz8Dtwbi9b/8vnmG2zEyz2a1uGK1+OaVx+3263VaimKioqKqq3FRQAozu3xaPUGn4+K0ISpFHJW8lg35TcPw9sWjx44qN3MGb/+77usJ15O5iPE2v/4/LtrKO21oS3h1/E6zes+u3DdRW/T19ZObddOUNazs3jEwCcemTnv2P925D4xIoGPEOs48/n2myh5zNBmdaWT8pv16h39+Rffrtz2n8+ej+UjhBBT9Psn6476lH37dIBk/0FXVxoeAAAqgOP44sWLX3rppZs3b0ZERBQP4Pp8voKCgvT09JkzZ9ZiDQMxduzYCxcubN++PTo6WiQS+bezLGswGGJiYhYuXBjg0qMqlWrBggVvvfXW7du3TSYTy7LFkzFxWTL0ev2gQYM2bdo0ePDgAGtIEMTixYvHjBlz8+ZNkUjkcDhKpKHgcmu4XK7u3bufPHmSYRi1Ws296nA48vLySJLEMCwiIiI8PDwnJ8fpdFIU5Xa7WZYtb8YxFzeXy+Vut/vQoUMYholEouJZMiiKOnbs2HPPPffdd981adLk9ddfX7VqFbebx+OpYCKzyWR65plntmzZ8uSTT3JbWrVq9dZbb82dO5fH43HB6/KO5XZACPl8PqFQGBMTY7FY9Hr9smXL4uPjA7yfANQpJEnq9HqH0xmu0YSo1XVzHWbwr+KjKJ2xyO5yhalUYeo6ujZ4gLDQp/47vdOBmcv7dbr6/MC2Uazu8q87dp6zxD639t2edfo7bP2teXWgKKqwsNBms4WFhWk0mnrdJ8HDgaYZvclkttpC1SpNiJr7dPoQvW3xxOEzp343ZP7s4QNuDXsixffnlrUb7yaM/XZcG4g/11U0i/QUbsy8dMHECuXnPpud8/k9r2OKR0cuH5LKQ3ji4ElTd4ydv2jigMxBTyRRf/7w3cb82LGrRrSpO2FIcad3Fz+/b8ymEek3Nz/ds4XKfevoTz+cNah7L1kyWAN/AIKu7rQ8AABUJDk5ee3atTNnztyzZ49MJhMKhSzLejweh8MxatSoBQsWlDknt04RCAQrV66MiopasWKFRCKRSCQ4jpMkabfb09PT582b16ZNm8BL69y58/Tp00eNGsUFcP1xWG6SMpd52ePxzJo1q1WrVsnJyQEWm5ycvG7duilTpvz0009csf7ycRxnWVahUGg0mtOnT0+aNOnkyZPnz5+XyWQEQRQWFlIUJRKJQkNDNRoNQigxMTE/P7+oqKiC6DMHwzCZTKbVarlvejRN83j//Hni8XgURd28efOtt956+eWXV61axS3tUnH0mePxeMaMGZOdne3P2vzf//5XJpO9//77ZrO5RCIO/2VyGUi4WdsikUgqlRYUFLRu3fqLL77o3bt3gHcSgLqDYRijyWQ0mVRKZYPU1PJyGQFQYxiGMVlsBrNZIZWmJcTxHoY+KWz25s5jMUvmfbZjx+eHLD5xZMP24z6cOmtcelQdedK4XPW35sHEsmxRUZFOp5PL5WlpaZCbCNQ6lmWLLFa9qUgiFqUmxgvu6ZMP0dtW0mrO91s08xav3PXJ23ZBTPOeC76bNbVnCMT+6iYLjRX6cBHOJhjztDTryDy2IbPELng40eeDIakIISRuNmfdKs0HK1f+svZtpyCmcacFa96Y2kVVlxoXjxqw4viPrRau2LBzx+o9boEmudXI91bOfrVHAvwRqAYQgAYA1BvJycmbNm36/fffjx49mpeXRxBEUlLSY489VtlMx7VIJBLNmzdv+PDh+/bty8jIcLlckZGRHTt27NOnT4lsxYE4d+6cz+fj8Xj+QCqO4wRBcGFcDMP4fH5OTs66desWLFgQeLHJycmdOnX6/fffpVKpy+Xy+XwIIT6fLxaLZTKZXC7HMIyiqHPnzu3YsWPfvn1nz549evSoTqeLjY1VKBT+C+HxeAkJCTwer7CwkKsSN4Gapv/K7emfWMQwjMFgQH+HgCmKKh6A5oryer2HDx/OyMjgIuxcZur7XgvLskajcd68eUuXLvVvfOutt0aOHLl06dKjR4/m5+c7nU6EkEwmi4mJadKkSWJiYmFhoclkcjgcfD5fqVRGRES0bdu2X79+FeTvBqDOstpshTqdgM9PTkws/uxFaVjUKwddr9RYxYKlnlb738zudGkNJoLAE2OiJBX2SYQQIlKnHbVMq5GKPShM1mzo/K1D59d2PSqv/tY8SOx2u1arJQgiMTFRIqlfE0gDAuNkveNwurR6A0IoLipSJi2rT9a3ty0WMeqgdlSZL+EhbSd+tG3iRzVcI1A5TgbT+jAWYTF8Rk6wqMd7poz37nsUrmoxceGaiQtroIJVRoS3H/3xltEf13Y9/g0gAA0AqE9wHO/Zs2fPnj1ruyIPpFGjRo0aNXrAQhiGOXDgAJcgorxHRAmC8Hq9Bw4cmDdvXvEl9e7ryJEjGo2mgryHSqXy2LFjd+7cGTp06NChQ4cMGWIwGPzpOIpzuVwIl6jZFQAAIABJREFUIQzDGIbhkkoXT+vhvxYuzM29xDAMwzAlKsyFpLOzs7nJm/4o9n1hGLZ///7iAWiEUHh4+LJlywIsAYB6yu12a3U6n88XER6ugjSmoA7wkj6twejxkpGaUJVcVtvVAQB5vd7CwkKXyxUeHh4SEgI5N0CtI30+ncHkcLnCQ0NCVPU7NxF4OPhYpPPhNhoL47MaHg09ElQZBKABAKBeslgsFosFFZtHXJp/fT+z2RwaGhpgyRRF6XS6ihd855Jg5OXltWjRgmXZgoKC8vbnIs7o79nN/pUSK1AiM4Z/I03TXIoMVGo9w4rpdLrAdwbgIUDTtN5gMFssYaGhYaGhlfr9CYDqQNOMvshsttnVCnl8VCSOwxdYUMsYhjEajUajUa1Wx8bGQm4iUOsYhjGaLcYis0ImTUtM4PGgT4JaxrDIRGEGClMQqIGI5sGfbvBgIAANAAD1UvFVB++rUrMnuLB1IBHevxZCqWThlYodlzi2agdC9A38e7AsW2Q26w0GiVicmpxchdw+AASdxe4oNJjEImFqfIwAUuuCOsBisRQWFopEopSUlIp/cQegZljt9kK9USDgJ8fHiqBPgjrAzmBaEicwNlHISvAqfn0DoDgIQAMAQL2kVCq5Sc0VzClmWZZhmNDQ0Eqt0EgQRExMzOXLl8VicXn70DTt8/kSEhK4/yYkJBQWFpaZNlEgELjdbi7u7M+wUXEoucwrYhiGS2/t/0fgVxQVFRX4zgDUXw6nU1tYiBCKi42VSaW1XR0AkNPt1hpMLItiIjTyMtOYAlCz3G63VqulKCoqKqqCVGMA1BiP11ug0/t8VIQmTKWA5UZA7fMySOvDPSwK5zEhPAg9g6AJRgCa/PWdxxYKF+2bm15iRgNr3D5x0LrEj3e93QYC3QA8jBiG2b9//6FDh3Jzc1mWjYqK6tat24ABA+rmnDuSJH/++ecjR47k5+djGJaQkNCjR4/evXvX04cuT548yd1nr9eL4zi3/CC3NJ8/1IsQEggEffv29U8Bdrlcu3btOn78eGFhIUVRJEniOG61Wi0WC4ZhkZGRjRo1Sk9PT09PP3LkSAVha4vF0rNnT38m6x49euzbty8kJKTEbhRFcevIc0FnkiRRsewZXA252goEAp/Px72EYRiXuIMgCH/r0DSN43jDhg1v3rzJ5/MJgqAoKpAbxbLsgAEDAryrANRTJEnq9HqH0xmu0YSo1ZAyEtQ6H0XpjEU2pytMrdSoVdAnQa2jKEqv11sslrCwMI1GA30S1DqapvWmIrPVFqpWaULU8MQeqHU0i/QUbqYxNcHG81kcQfQZBNODBIZpy51b+XYGkZfOn/1TdOnqVfW9AWjWe/O3I6eP2/NpBAFoAB4+d+/enTZt2p49exQKhUgkwjDsxIkTX3/9dbdu3RYvXtykSZParuA9rl27NmPGjMOHD3O1ZVn2+PHjX3zxRf/+/ZcuXRofH1/bFawEm8327rvvfvXVVzKZjMfjkSTJsixFUaW/SrEsGxYWNnToUO6/p06dmj179pkzZxQKBUmSFouFJEkuNEwQBMuyV65cOXXq1IYNG9q2bZucnGwwGMLCwkpXwOPxGI3G8ePH+8/4/PPPb926NSMjQ6PR+HezWq2FhYX+6c8cf8W4f3AvicXi0NDQ/Px8fwCaYRj0d9BZIBDQNM3j8fr37z9+/Ph+/fqRJCkQCLiA+31vV1RU1MyZMyt1hwGoRxiGMZpMRpNJIZenpaRwy3UCUIsYhjFZbAazWSGVNkiM49XPX3nBw4Rl2aKiIr1eL5PJ0tLS+JAHBtQ2lmXNVpvOaJSIxamJ8ZCbCNQFFhor9OEinE0RMkIMQs8g+B7gWwpr+WF8qzG/eP/678RWu8rYCROnj2kMX4UAeOhotdqXXnrp8uXLKSkp/jmqSqUyPDz83Llz48aN+/LLL/3TY2vdzZs3X3nllezs7JSUlOKTCzQazeHDh1966aX169dHR0fXYg0D53K5xo8fv3///pSUFD6fr1AocnNzi88s9mdwZllWIBB4vd4FCxasWbPmwoULb7zxhlarTU5ONpvNer2ez+f7J0pzOyOEnE5nSEjIrVu3lEqlUqnU6XQajab4TbPZbIWFhe+8807//v39GxUKxZIlSyZNmpSbm6vRaAiCsFgs2dnZ3FRlLppcGldJHo8XHR2t1+v96aGLR9IZhvF4PDwe75FHHlm2bFlSUtLMmTPff/99r9fL5/O56d4V3C6ZTLZ169a6OSUfgAdntdkKdTqBQJCcmCgSiWq7OgAgu9OlNZgIAk+MiZJAnwR1gMPh0Gq1OI4nJCSUmSsMgBrmdLm1egPLsnFRUTLITQTqADeDFfgwmkUxfEZOQOgZVJcHiA1jsvQ3vvhyMI2oP7+YtF4wfsWYFiVKw3BReOs+/dJg3gMAD525c+devHgxLi6uxHYujUNOTs7MmTO3bt1aF+bi0TQ9c+bMrKys0omAuWTHly5dmjt37urVq2ulepX12Wef7d27NzExkQsKKxSK+Pj4rKwsf5CXi+piGCaRSOLj40Ui0Y8//rhy5cr9+/drtdqwsDCv16vX67lpxf50zAzDcOkyBAJBUVFRfHy81WpNSEhITk4+ePCgVCrl9ne5XM2aNZs1a9bIkSNLVKxNmzZr1qyZO3fuL7/8IhaLrVYrjuPcvGxuFrPX6y0zEs3j8bRardvtlkgkQqHQ4XBwuTj8kXGEUHh4+NatW7mU0/PmzQsPD1+wYAEXs0bF5lOXEBcXt3379kcffTRYNx+AusPtdmt1Op/PFxEeroI0pqAO8JI+rcHo8ZLhoeoQpaK2qwMAIklSq9W6XK7w8PCQkBDIuQFqnY+idAaj3ekKDw0JUSmhT4Ja52ORzofbaCyMz2p4DPRIUK0eJDYkTOs9Og0h5EvN+yFP+PyYlzrCkyMA/CtcunTp22+/TUlJKW+H8PDwgwcPHjp0qHfv3jVZsTIdOnTowIEDqamp5e0QGRm5adOmiRMntmzZsiYrVgU2m23Hjh0RERHFpyRzOaD5fL4/AbREIomMjFQq//pcGx4evmbNGp1OxzWZyWQiSZLH4/l8Pn85GIZxaS4wDOPxeCaTKTU19fLly19++eWbb7555swZo9EoFoubNGnSs2fP0rmeOU2aNNm8efOJEycWL1586NAhlUrFsqxOp+MmZopEIpqm/ZUkCCIiIoJhGIPBgBCKi4tTq9U8Ho+iKLPZbLPZuOC1WCxWq9UFBQWZmZn+NQ9fe+21kSNHrl69+rfffjObzSRJms1ms9nscrm4hB5NmjR59dVXR40aVZ2tAUDtoGlar9OZLZbQkBBNWBikjAS1jqZpvcFkttnVCnl8VCSOwxdYUMsYhjEajUajUaVSNWjQoJ6u9gEeJgzDGE1FxiKzQiZNS0zg8aBPglrGsmwRhel8mIJADUQ0D/50g+oXjMmJ/G7/3dstCOUAAOqJ48ePSySSCjLo4Tgul8uPHTtWFwLQx48fl8lkFcRo+Hy+RCI5fvx43Q9Anzp16tq1a2lpacU3OhwO4m8IIYqihEJh8fUDZTLZ5cuX/XN/uP1pmi4x7YJlWYZhuHIcDofH45HL5SdOnFi+fHnXrl0DrCGO4507d8ZxPCoqSqVSabXa4t/6ii8q6PF4ZDKZVCq12+0IIX/yaB6Pp9FoiueS5i7h+PHjjz32mH+LUqmcNm3atGnTAqwYAA8BfxpTiVicmpwMuWVAXWCxWAoLC0UCfkpcjFAAk1FA7eP6pFAoTE5OhtxEoC6w2+0FBQUCPi85PlYkFNZ2dQBAdrtdq9USNJ4oZCQ45NwANSR4T8dT9vxbt/LtVMnOi4emtU0NgZ9TAHiIFBYW3jfwIRAItFptzdSnYtyXkIr3EQqFBQUFNVOfB1Hmnff5fMVDyTiO+3y+4jv4Ez0jhBiG4ULPZaatKL42oM/nEwqFVWhEbtYzV88SdStRK66e5VWmuPrSQABUH6fTqdVqWZaNi4uTyWTVcQrulyeVSlUXsicFzufzWa1WkUhUTbel+pjNZpqmy1zrtV7g+iTDMDExMXK5vJpO4Xa7lUpl/Vo1jqIoi8UiFAqr6bZUH4vFQlFUaGhoPc0M4Ha7tVqtz+eLjIws/kt8ELlcLpfLpVAoqusnwOp5qIWmabPZLBAIFIp6lh7HarX6fL6QkJB6+riPx+PRarUkSUZERFRTn3S73U6nUy6X3/f7ThWpI6ujVJZlTSYTn89X1rc0YjabjSRJtVpdTx+t8Hq93CrxXG6i6jiFx+NxOBwymaze/QRoNBp5PF41vVWrj91u93q99eIDfHDq57myeuSgydtve8oIIYie/d6ydQj8zgfAQ4TP5983YsiybB35uigQCAKpbb2YS1jmnS89kbnM743cRv9L9/1uiWEYwzBVaEQMw/z1rPgsgVemvjQQANWBpum8vDy73Q5pTEEdwfVJm80WFham0WigT4JaxzBMQUGBxWKBPgnqCJZltVqt2WxWq9UJCQn1NIAOHibcJCGTyaRWq+Pi4qBPgpoXjAA0k7d+ypTtd8N6vj556KNRkhLdmEhoVydiUACAoElOTna73RXv43a7K0gSXZMSExMDqW1ycnLN1OdBJCcnc0v5Ff/EIBQKuTTQ3H9Zli0xA4LLuUzTNEIIwzCBQOB2uysIUnPLGAqFQpvNVrVGTEpKysvLk0qlQqGwzIUH/adACJVOBlJafWkgAILO6/WuWrVq8+bNXIr2aj0XwzBcHp76Fbvhxjccx+vdVymaplmWrfvTVUrwer3ff//97t27oU+Wh+uTGIbVu/lxNdwnPR5PUMrxer1btmw5cOAAn8+HPlkm6JMBKioqCko5JEnu3Lnz2LFj0CcrwC33Uk/7ZI3d8GA9A0qS5P79+8+fP19jfbI+fjCDPhmInJycKh8bjKHcd+GPM964F9fu/KR3PXv0EQBQJT169GjQoIHNZpNIJGXuQJKk0+l8/PHHa7hiZXr88cfnzJlDkmR5U2hdLldqamrPnj0f/Fy3b9/esmXL6dOnTSaTRCJp1KjRgAEDevXqFcgfA4Zhfvnll19++eXWrVt5eXkej4d7AigxMbFDhw7Dhg2Liopq3bp1p06dMjMz1Wq1/0C5XG42m/0fzbkvGDk5OSRJchOHMQxr2bLl9evXdTqdy+Vyu90kSZb4E8XNm+Y+JdA0rVKpMAyz2+29evWquNrXrl3btm3b2bNnzWYzQRBcuFmn0+Xl5TmdTrFYzIW/S9wBmqYVCoVYLHY6nSkpKRiGuVyu8rqT1+utO90JgBr28ssvDx06tGY+CnPvVhzH69eXWC5/vX8Eq0f8K7LWzOmCdX9eeOGFgQMHQp+sGPe3GPpkxYLVrM8880zPnj1rJkbJDTjQJ2tMDfdJhFBQOlK/fv3atWsHfbJi0CcDFJRsTt26dWvatCn0yYrV6z5Zkzc8IiKiagcGo/95rVYPntK8SdmRAwDAQycqKurZZ5+dP39+YmJi6T9jDMPk5+e/+uqrLVq0qJXqldC8efMJEyasXbu2zMffKIoqKCiYNWtWdHT0g5yFZdlVq1atXbs2NzdXLpfz+XyGYa5du7Zu3bphw4YtWbKkeMi4NL1eP3Xq1J07d8rlcrvd7nQ6cRznwsc5OTm//fbbtm3bpk2b9vTTT7/66qsjR44Ui8X+pFpqtdpsNjudTj6fT5IkjuMmk4kgCO5iSZL0+XxKpZJLo8yl1MAwjPulFBULSXBz2RiGoShKo9EUFBSMGjWqU6dO5dWZYZiPPvpozpw5MplMLpc7HA6LxUKSJEJIoVAIhUJuFolQKCRJsvikbP8pKIrSarWTJ08mCOLDDz9MSEgoszsVFBS89tprTZs2rXyzAFDvqdXqikcPAGoY9ElQ1yiVynqXRhY83GQyWb1blgA83KRSqVQqre1agH+7YIT2xakN49lrJ85YYfFMAP41Jk2aNHz48JycHIfDUXy7y+XKycnp3bv3nDlzaqtupc2ZM6dPnz45OTkul6v4dofDkZOTM2zYsEmTJj3gKdatWzdt2jS73R4XF6dSqaRSqVwuj4iISElJ+eGHHyZOnFhBGhCbzTZ+/Pi9e/cmJCQ4nU6PxyMSiQQCgVAo5BbokMlkBoNh5MiRu3fvHjRo0KxZs3Jzcy0Wiz/PcmxsrFAo9Hg83BahUMjj8bgQNkVRYWFh+fn5DodDIpFwD6pz06K530i5h6R4PB6Px6MoiiTJqKgog8HQpUuXBQsWVHDJH3zwwXvvvZeQkBAbG+vz+fR6PUJIJBIJhUKHwyEQCCQSCbfSIEEQXOYQhBBN0yRJxsTE4Diek5MzdOjQV155ZeLEic8991x53alv376zZ89+wAYCAAAAAAAAAABArSDmzp37wGXEtGnm+WnRop2WhNatUsMlRL2YZ//NN9+MHDmybj4UwLKsx+MhCKK6lrJ9qFEUhRCqI8vf1S8kSdI0LRaLA3nqhCCIPn36yOXy27dv37x50+Vy2Ww2g8EQFRX14osvLlq0qE797C8QCPr164fjeHZ2dmZmJldbvV4fHx8/adKk2bNnP+ACd9evXx8+fHh8fHzpH5ZxHFcoFGfOnFEoFO3bty/z8OXLl3/33XcJCQk6nc5qtRavDPcQELdOsVAovHjx4oABA/r06ZOampqRkXHlyhWXy2W3261WK0mSUqnU4/Fws5hpmqYoSiwWR0dH2+12//tCqVTabDZ/Fml/CJublczj8UQiUXJy8vDhw5cuXVrBEsCnT59+6aWXEhISxGKx1+stKCjw5/ni6uxyucLCwvh8vsvlommax+MxDMNN0JbJZF6vNz4+/vXXX581axZN00KhcODAgTKZLCsrq3h3io6OHjNmzKJFi8rLzvEvB8NdlXm93sCHuyrw+Xzbt28fNmxYdRQOAAAAAAAAAPULxkUfHgh5aFbvd3/OvnLxjoPFeLKQUBm/WFRX9OSaG6sH1L04au/evfft21c3A9A0TZvNZoFAoFAoarsu9Q83z1QsFtd2Reofu93u9XrVanWlclqZzeZjx47l5ubSNB0XF9e5c+cqpwSqAXq9/tixY3l5eTiOx8fHd+nSJSjPEc+aNWvNmjVxcXHl7WC328PDww8ePFj6VyWbzda7d28u7pyZmVk6XTJCiCTJiIiIyMjInJycefPmTZgwASHkcrn++OOP27dvO53OyMhIgUDw4osvxsXFeTwen8+H47hIJJJKpVarNTc3lzuv1+tNSkriMi9zsWAuF4derx88eHBUVFRUVFRCQkLnzp3vm5Bk0qRJO3bsiIyMRAhptVqDwVAiDMqFldPS0jweT1FRkVAoHDt2LE3TUqlUIBDEx8enp6eHhIRww51QKOSymxUVFR07duzOnTsMw8TGxqanp4eHhwfaDP8+MNxVmc1mI0myssNd4Fwu17Bhw3bt2lUdhQMAAAAAAABA/RKMHNCYSBURmaiOTGxd1quCBiH1LIU3AKAS1Gr1k08+Wdu1CFR4ePgzzzwT9GJPnjxZ8eoQMpnswoULFy9ebNeuXYmXzp49e/369bS0NIvF4vV6y3zugSAIp9OJEJLL5SdPnuQC0BKJpFevXv5FAlesWCGVSiUSSYnJwk6n0x9iw3Hc6XQqlcoSM749Hk/37t3HjRsX4PUyDHP27Fn/JXMZq0vX2eFwcOlEoqOjb926lZ6e3rVr14pLDgkJGThwYIDVAAAAAAAAAAAAQN0XjAA0v9PULT9MDUJBAABQ/5AkabFYKk6DgGEYn8/X6XSlX/LPHaYoqrxnMrhMygghgUDApVquoJwSiheLYRiXtKGECootE7fYoD+KXV7NuWpziyXy+fxKnQIAAAAAAAAAAAAPh2AEoOsnlmUdDkfdTMHB5UWhKKrEelwgEFwsjKbp2q5I/cOFJl0uV918X9RZLMviOM4t5VfBbjRNYxhW+k3NddeKj0V/p2mmaZrP55c5MhAEUV4diqda4sopXTccxwMfcCiK4nJGc3Ory+swXDoR/9qDZV4+DHcPgqZplmVhuKuC6h7u3G53EFKcAQAAAAAAAMBDIXgBaNZx46e1G345l6WnO07/aqL6xAFn414tNXV5aSQ+n183A20Mw3i9XhzHYWmpKuC+88OtqwKaprnF4qppVa6HWGpq6rFjxypYd9Hn81EU1ahRo9I9s2HDhiRJMgwjEonKC0Nzr2IY5na7GzZsWGb3btCggcvl4qLhxbeLRCKr1eovRygUlh733G53mXUrj1KpjImJuXbtGje7WSgUchmlS9eZOx1FUT6fr8xTwHD3IGC4qzLuR5TqG+64RxYAAAAAAAAAAKCgBaCp7G9H9x67KdPNIoSpRaMZMuuTZ4btTRy56sc1L6QK7l9AzcMwrMxATF1A0zSXU7XMbLCgYlwID25dFZAkiRASCATVtCrXQ2zAgAE//fRTWFhYecGsoqKiZ599NjU1tfRLLVq06Nev35kzZ8LCwuRyudvt5vFKjsw0TSuVSpqmbTbbgAEDSnRvrVa7YcOGvXv3+ny+GzduCAQCuVweGhrKxSWVSqVWq2VZlmVZoVCoVCpLjHs2m61ly5a9evWq1LvmiSeeOH78uEqlwjBMqVRaLJYS1aZpWqFQcHUoKioaOHBg06ZNS5cDw92DgOGuyrxeL6rO4Y6b8l8dJQMAAAAAAABAvROUiT9M1hcvjd9sbjVly/msr54RIYSQuM/sNROaaDe+MnrlTXg2GADwcBsyZEjXrl25OG/pV202W2xs7BtvvFHmsRiGvfnmmyaTyel0ajQabmJm8R1IklQqlXK5PD8//4UXXujWrVvxV3/99ddnn3122bJleXl5SqXS5/N5vV6dTnf79m2bzYYQEovF4eHhJEn6fD6VSlUiWOn1egsLC8eOHatQKCp1ySNGjOjQoUNhYSFCSKVSKRSK4lM+aZoWCAQajQYhZLfbzWbzm2++WanyAQAAAAAAAAAA8HAIRgCavrpx7TG223vfLn3ukWgZN5UIU7Uc8cn2pY/jpzd8d6WMJa8AAODhIRAIFi5c2KpVqzt37rjdbv92iqJ0Ol1ISMj06dMfeeSR8g7v3LnzF198kZeXR5JkdHQ0SZJcglqGYUiSlMlkISEhubm5PXv2XLRoUfFplSdOnHj33Xe1Wm1CQoJSqYyKiuJC2ARBUBRVUFDgcDhYlpXJZDiOEwQhkUj8IXKGYcxmc05OztSpU0eMGFHZS5bJZB9++GGTJk3u3Lnj9Xrj4uIkEglJkjRN+3w+Ho8XHR3NLTyYn5+/du3adu3aVfYUAAAAAAAAAAAAeAgEIwBN3b55G6V17xZXojA8ulPnVJSTmQNToAEAD7u4uLgNGzaMGzdOKpVmZmbm5uZmZWVlZmZ27tz5008/ffrppys+fMSIEXv37m3Tpo3ZbJZIJAght9tNUZRAIKBpOiwsbMaMGV999ZVarfYfQpLkwoULtVpt8Y0xMTHx8fECgcDn87nd7qysrFu3bkVFRX366afLly8PDw/PyMjIycnJzs7OyMhISUlZv379nDlzqpYroGHDhuvXrx81apRYLM7NzSUIgsfjcfOg+Xy+0WjMyMho3779gQMHhg4dWoXyAQAAAAAAAAAA8BAIRg5oTKlSoCK9kUbo3kyKPp3WwMrkMsiCCAD4FwgLC1u4cOGbb7559uxZo9EolUobN27cqFGjAA9PT0/v3LnztWvXbt686XQ6nU6nWCzm8/kRERGPPvpo6RQZv//++5EjR9LS0kpsDwkJUavVLpeLS68xe/bsSZMmcasFjhkz5syZM/n5+TweLykpqVWrVqXzTVdKdHT0smXLdDrdn3/+aTQalUplbGys0Wg0GAwSiaRRo0aNGzeGTLgAAAAAAAAAAMC/WTAC0ILWj/dQrdq05MtJHSfE/7PZfeXzxZu1isd7tuYH4SQAAFAvhIWF9e3bt2rHYhjWtGnTMhfrK+3s2bMymazM8C6GYVKpVCqVer1el8vFRZ8RQhKJpEQK6aCIiIjo379/0IsFAAAAAAAAAADAQyAYAWikHDB73uP7Jk7q2OHQ0KSblFe+59MF+37/dsOeW7xuy+cMUsPsNwAACDaTyXTf+ct8Pt9kMtVMfQAAAAAAAAAAAABKC0oAGvEajN/2m3zW5NlrvtjpZFj0+dSThDy556Svls8b2RTmPwMAQPDJZDKGYSreh6ZpmUxWM/UBAAAAAAAAAAAAKC04AWiEkLTpCx8eHL7IcPtGlt5NKKJSGiaqIfQMAKgKg8FgNptVKlV4eHjNnJGmaZ1O53K5NBqNUqksbzev16vValmWjYqK8ue1qAKfz6fVaimKioiIIAiisLCwdJl6vd5isajVao1GU2YhTZo0cTqd5V0ORVEYhjmdziZNmnAbWZY1GAwWiyU0NDQ0NLTKlQcAAAAAAAAAAAAIXNAC0AghhDCRJvURTWpQywQA/Ft4vd7Nmzdv3769oKDg+vXrjRs3joqKevrpp4cPH/4g0d6KGY3GdevW7du37+TJkwghbtnAESNG9OnTp3h65evXr69Zs+bkyZMXL15ECLVo0aJdu3bjxo0LMF+zX05OzurVq48cOXL+/HmGYbhgt9VqxXG8RYsWHTp0GDly5Pnz53fu3KnVarmbEBMTM3jw4Oeff14gEBQvqlevXs2aNdPpdMXXJ7Tb7SaTye12ezwehJBMJrt69Wp2dva+fft27959+PBh7hrj4+OfffbZIUOG8PnwSyEAAAAAAAAAAACqEcaybDDKYSy3jhw6cbPQQZUsjpfa9+U+KUQwThJUvXv33rdvX5nrd9U6mqbNZrNAICgeVwIBcrvdCCGxWFzbFal/7Ha71+tVq9UEUQvvWIPBMHny5D179oSGhspkMoIgaJp2OBwmk6lfv34fffRRRERE0E966dKlKVOmXLhwISQkRCKR4Dju8/lsNltRUdGECRPmz5/PxXy3bt26YsWKO3fuqFQqoVCIYZjH47FYLHEOFkbLAAAgAElEQVRxca+//vqIESMQQkVFRSEhIRWfbv/+/XPnzs3KylKr1W6322AwkCSJEGIYJjo6Wi6XFxUV+Xw+j8cTFRUllUqL34Qnn3zyww8/DAsLK17ghg0bXnvttfj4eJFIxLKsVqvV6XQ8Ho9rQa/Xq9FofD4fjuNerzc8PJwrk6IorszBgwevWLFCpVIF/cYGjhvuhEKhXC6vxWrUUzDcVZnNZiNJsvqGO5fLNWzYsF27dlVH4QAAAAAAAABQvwRlBjSduW5Ij1d35ZFlxbJFz34/ui4GoAEAdYfX6508efLBgweTk5NxHOc24jiuVquVSuWhQ4cmT5781VdfBTfQdufOncmTJ2dmZiYmJvo3CoVCLgvH6tWrhULhvHnz9u3bN2bMmJiYmOjoaP9uEolEIpFYrdbx48erVKoBAwbc93SnT5+eM2eO0WiMjY21Wq13794VCARcgJthGK1Wi+M4SZI2m41lWQzDuLnJ3E1QKBR79+5FCK1du7b4POiRI0dqtdoFCxaEhoaSJKnX64VCIfo7BUdkZGR4eHhOTo7VahWLxSKRiCtTIBCEhIQolcrdu3djGLZq1ar7LmYIAAAAAAAAAAAAUDV4EMrwnVm9+McCVbcZ3xw6c+lKSedW9BbcvwwAwL/Zpk2b9uzZExsb648+++E4HhMTs2/fvo0bNwb3pMuXL79+/XqZE6sFAkFsbOyKFSuOHDmybNmy8PDwMufnymSyiIiIFStW2Gy2is9F0/TixYsLCgpUKhXDMDqdjs/nFw+18/l8nU5ns9mEQiH37+ILDBIEERsb++OPP27ZsqV4sRiGTZ8+ffv27WlpaVxyapIkvV6vRCJJTk6OiooyGo12u10oFHq9Xp1OV/xYgiDi4uK2bdu2c+fOAO8YAAAAAAAAAAAAQGUFIwDNFOYX4o+8/umCET3aNm9aUuNYRV3McgEAqCtYlt2xY0doaGjp6DMHx/HQ0NAffvghSCmDEEKosLDwjz/+KG99P4SQUChUKpWffPLJmTNn1Gp1ebup1epz584dPHiw4tOdOXPmwIEDXAINm83mcrlKPPjPTX/mkgIRBOFyuUoEtQmCCAkJ2b59e+nCe/fu3b1797CwsNTU1JSUlMaNG6ekpCiVSpZlrVYrN7uZx+MVFRV5vd4AywQAAAAAAAAAAAAIimAEoIm4xDgCr42ksQCAh4BOpzt06JBMJqtgH5lMdvjw4by8vGCd9MKFCxkZGVzCigpOeuHCBalUWnGyeJlMdv78+YpPd/78eS7HNELI5XKVDrWzLFs8vI7juMvlKrGPXC7Py8szGAxlXo5SqZTL5XK53L9go9frdTqdXKQbwzAMw0qXKZPJMjIyHA5HxfUHAAAAAAAAAAAAqJpgBKB5j7w0qXvOp+98ed0ZhNIAAP8yFosFIVRxGmIej4dhGLdnsE5638THPB7PH8CteDez2VzxPlar1V8OTdOlI9pc9Nkfg8YwjKbp0ie6fv16mTehzMspUUJlywQA1BXk/nGRBFYCTgjlmuQ2/cYu/imj5E9LNYEt3D4iIXb4NkPQnkwB9Qt0S1AzPGfebRnWdflVsrYrAgAAAIAHEYwANCKSx6yYnnxgQuvUFj2eHPzsvV5YcdIXjJMAAB5SCoUClYqWlkBRFMuySqUyiCelKKrifSiKkkqlFVeM2+2+FVMoFP5yCIIonUuEC0n7A9Msy5YOfFMU1bhx4zLPVebllC6hvDK5JgAA1GmYQBWd+I+YUL7HlH1u75fvPNWu17yT9uK7knmHPpn0dIe0aLVEJFHFNO0+Ys7mS9YyQnLenH3LX+3XKjFMLgtLbtXzhTnbbwQ2mYA17np78s74Ke89ranJRGuuzF0L/9OjcZRSIg1NbDPwjVUnDPcZoQM/0Hd4UgKvZDwVwzBM8Oii64GdpfpU9cJdmT8vGdf3kYQQqVCkiGzY+bm3150qfSRru7ZtvrEwvyo1C2K39P44So2X1QIBN0Q1d8uqtkJg70fWdm3b/NG9mseFSMUyTVKbJ19b+bv2Pp9TakilL7yyTVnxQCRq+9Z/+2bMm/j5rdp+HwIAAADgAQQlAO3+Y/Zzs447Wa8p+9LJI7/f68g1PXP/IgAA/1pRUVHdunWrOAuE0+ns3LlzbGxssE7asmVLn89HkhXNp3E4HM2bN3c67xOOcTqdLVu2RAgVFRWdP3/+xIkTOTk5pU/ncrm4dQXFYrF/gUHmb9xXMv/+DMOIxeIShVgsFpFIlJ+fX3rCcsuWLUvXUygUSiQS7lwsy5ZZptPpTE5OhgA0APUA0Wjynoxsv7t6u6Pg9NoxzSSs5eTCCR9e+jtU5b6wvF+r3m+s3HVGiyIbNYoTW28d+Xb+8I4dXtlZUPwTGWs+Mrt76/7TVu3PJDXJiXLr9d83zX+uU7/F5+4/c9V76oOZW+jB015KrbkEbKz1j7m9Hn1m1jdH7qLotGSF7cpPH7/arcOozbn3iUoFdiBry7qtZzAM55VCVJiGqdpV9cJZ8+GZ3dsMnLFm/3WrNL5hqobJO7Xtg5e7tB36VUaxuSFM/g+vdGz33ByHp0oTRoLZLTGCKH33uSbAMYThIpGwwpaozm5Z5e4X2Pvx71bYcOiWQ57UIJZnuPjzZ5Mfb/P0qhveCgqvAVW78Eo0ZQADERby5NRxiSfen7MdZrYDAAAA9VcwAtDkiW83XsdbTv451243GUq6++XAipKsAgD+7TAMGzRokMlk8odlS2BZ1mg0Dho0qLxVCqsgJibmP//5T5n5lDkkSVqt1gkTJrRu3bqCDBUWi6VFixaxsbHTpk3r27dvly5devfu3bRp04EDB+7YscN/Re3atevRo4fJZEIIKRQKsVhMkqTH4/F4PF6vl/sHjuPczGiapiUSiT8ozLJsUVFRRkbG3bt3z549y51i8uTJt27d8ldj0KBBdrvd4/EUrxuGYUqlkpsZTVGUWq32p4fm0DRtMpkGDRpU2bsHAKgLMGHko2O+2DitJZ8lL+/44RqNEEKe0/NHzvzNxEt74cvz+XnXz124qdVf2/5WJ7Xnxtqxr23S/h2/YXXfTxj6/iln8vNrzuflXb94JTv/xo4JLYSWY/MmfnbjPpFN3balX2bEDx/XR1lzkVnXHwtefv+kLaTHgqO5edcvXs7Ov7JxVCqWvfn1yd/mVzTVIcAD6eyMLAqJnlxv8JXgOjmjUS0udFLVC/f+seDlD8461N3n7M8svHv90pXbhXl/fvlCCrq74803Nvx9JJOzesyLX14n4weqo+KCUt+qd0vhgK+MZMm77/P5SN2PLycRwsYTFryUVMGngGrtllVthcDej/+0wgdH7hhzr1y8oTXc3PFWR6Xu5zdHr7hSm4+SVu3CA2/KAAcifosXX+5k37l09bW6MSccAAAAAFXAPjjbt4NEgvQPs+kglFVzHn/8cYZharsWZaMoymAwWK3W2q5IveRyuVwuV23Xol6y2WwGg4FLdlHDnE7nkCFDIiIiWrVq1eZerVu3joiIePrppx0OR3BPevv27S5duiQkJLQppUWLFmq1+u2332ZZdteuXVKptFGjRqV3a9y4sUwme/vtt9u3bx8ZGdm0aVNue8uWLZOSkuRy+ZQpU7xeL3e6o0ePSqXStLS05s2bSyQShBCGYfjfEEI4jvP5fIIgcBxPSUnhimrVqpVGoyEIgiAIlUrF3Z+mTZtGRkZ27Nhx7969/st57733lEpl8+bNi9ewZcuWSqWSIAipVOqvXvGSR4wYQZJkcG9spXDDnc1mq8U61F8w3FWZ1Wqt1uHO6XQOHDgwaMV5942NwBGvxX8v+Eq/SB59I5FAmGLELg/Lsp7946JwRKROPuwsvhN954veMgwTdl+Zy31aI0/PaMzDeA2nHC0+sroPTUwgEP+R9y5VdGforI+6iHgNp5+qwbGDKdo8RIVhkm4f3y72cdP2y9g4AvEfmXe53PoGfKB9yxApRqROPVGbI2JpVb5w3+kZjXiISLv3ghj92n5iDJMM2mjh9jrzTmMeIhLG76/8IFwN3bIsjOHHMYk8UatZp5zl7sOy1dstq9wKgV14Oa3AFKx/KgTHI0b/aA/y9QSsyhdedmmlmzLwgYjO++JxMZH8xhFPla8GAAAAALUqKIsQqkOVrP5uPiwNAQCoGolE8vHHH6enp2dnZ1utVi5dMk3TVqs1Ozu7U6dOH3/8sVQqDe5Jk5OTly1blpiYeOfOHYfDwc1W9vl8JpMpOzt7xIgRc+fORQgNHDhw5cqVd+/eLSws9Hj++uLj8XgKCwvv3LkzYcKEw4cPFxUVRURE+OcX83i8kJCQpKSktWvXLlmyhNuYnp7+7bffqlSqW7dukSQpEAj8AzHDMHw+XyAQ0DTNMIxIJMJxnLsJ+fn5/nnT8fHxXKhaJBLFxMTo9fq5c+deuHCBK3/GjBnjxo3LyckxGo1cahGWZb1eL4/HUygUOI6TJMldI0VRFoslKyurV69eK1as4PP5wb2xAIAaRfkohBDLMAgh5u7Fy0YGD39sQAdJ8X3w6G49GvNYKvNGFo0QQr6zW7bdonhtxrzSsfjIKuq25ExWTubuiRWlMKBvb9t8yhfbb0Crf8YO1vRVfxHGbzTjtH9+Il2we3xTCU4o28/4zfTAz827ft910IqE6cOfKz4HVt5z+MBownf1p58zy5uzHeiB9J2MbJLlpTRMvs/ytIHx3j306eRnOjeKVkuEQokqpnGXZ6d9ecpQ+aR0Vb5wxDAMQhhfwC8+HRgTiEQ4QgxFMwghxBrOns6icFX3AV3kla5axarSLcvAFu2Z8dp6bdMpn89sJylnH4RQNXfLqrZCYBdeXitgUQMHpwtYw94fT1TyO1Yd6H6lldWUlRiI8Ki+Ax4lcrdtPl7LOUkAAAAAUEXBCECLH5/x/hOuNRPe2HrDDumeAQBVEh0dvWHDhoULFyYlJd26devGjRu3bt1KTEycP3/+N998ExcXnEeDS2jXrt2mTZteffXVsLCwmzdv3rhxIzMzs1WrVl9//fVHH33kz5j84osvHjlyZMCAARKJ5MaNGzdv3pRIJP379z906FBGRoZWqy0zhzKfz4+NjV2yZMnVq1e5LU899VS/fv0QQkKhkKIoHMe5qc1cuJkgiJCQELlc3rt37/j4+Fu3bl29elWv10skkpiYmMTExBKRYpVKdffu3aVLl7IsixASCARLliz57rvv2rVrd/v27Rs3bty4cUOtVo8bN+7o0aNz586NjY3lrjEjIyMtLW3FihXr1q3TaDTVcWMBADXFeXL3gUIaEYmpSQRCSNTkqdffePOtZ5qVCKPSeq2BQZhCKccQQkzeyVN3aCK+c3rSvZFmXKqJT4iPCy2ZLr4YpmD/L+cpRedurSr47YrR/jSpz7DVNwSPvr1rz6IeoQ+aEoHKvHjVwRJJbVqH3VMUv+WjLfkYdfPStXKCUgEfSGVnZFNEeGp4wc4Ppox5rv/jfZ564fUF64/nVyHa5b38yZNte0/6ZOeZQl5045bNklXurOPblo3r8djMY4Gt8Vj5+pfCa/nUU2l8+ub699ddsf8VaSUL9s9fsc+FhfQe8pgSIYRYr4dkEcIIPMhJK6rULUtjrb/OfmN9fsqrn8xsX0GfRNXcLaveCgFdePmtIBAJCcQUXb9WUIkvWHWi+5VSZlNWaiDCY9K7pGHafXvOwer2AAAAQL0UjGke5JGv198VEFdWD22yThYaKru3TNGTa26sHgBpoAEA9yORSCZMmDB+/Pg7d+6YzWaVSpWQkBDEvM9lio6Ofu+992bOnHn37l273R4REREdHV16t9atW3/xxRc2m+3u3bssy8bFxSmVyrNnz+7fv79BgwblFS4SiWQy2a5du5o2bYoQYhjm1KlTcXFxcrmcS3zB5/MxDOMmLAsEAoIgbDabzWbbu3dvXl7ewoULf/zxxwqC72FhYbt3775x40bjxo0RQhiGPfHEE0888YROpyssLBSLxXFxcVwYvWnTppMnT87NzbVaraGhoXFxcVjtrqoFAHhAtMuQe+XIhrlvfppBYaJHhz3XlIcQiu0/fXn/0vvmbflo8x2aSOrdtykPIURl3cqiEJGQElVwYNm8JV/vPZtVRMtim3V75pUZb49qE1rRsOs6c+wcyWvSqnm5AUGmcM/kPkM/v8ZvN33nzwu7P3D0GSHE5N/JZxARHRd9b5wKk8bEqjHWdPeOnkGJZVQ70AMZbWaWg2WcXw979H8u6q947f7dmz5buuLltTv/92xSJT4wO39Z8t5BA9Hg5c2/fDIkSYwQQqT24KwnBy47v+bL3+amDxDdr4QgXDhCok7zd22wPz9h9fjWScvbtk5T+fIvn7mYzyQNXLpx3agYHCGE8IhGDUPwo8bjv5/39usQjA/rD9ItS/H+uWzql9ma57bM7HK/R6CqtVtWuRXwwC68vFaw/rb3Dw+LsCJDUXmtXFod6X4llN2UlRuIeA1bN5cwO06cuMN0TKnej4YAAAAAqAbBCEBjIlVkXIuQuBZlvipoEFKpzwhM0cXtX2/+/UKuXZbwSM/nXxzcUl3iIyJr/mXOy59f/OfnbyJm8JJP/9OACOBYAEBdh+N4YmJiYmJiTZ5UKBSmpqbedzeFQsGFkjlXrlwRi8UVh8ilUumVK1e4f+t0uqNHj6alpeE4Xnw9QP9Ua27/kydP5uXlJSUlGQyGMudW+/F4PKFQePnyZS4A7RcREREREVFiZ4IgkpOT73eJAIC6irr03iP890pvx4TxA1d89WbZITyEWOuFtZNGvLHTgCeMWDo9XYQQQqzNamURa/jh5U6//aYlFDHJKfHWnKxT25ae+mn7r18f+npofHk5OOjsKzdcSJycGlP2yEfrfpnS57nPrvLbz9j184JuIcH5HEY57C4WYVK5tER5mFQqxZDR6XCVnU4h0AOp7FtZFGIRr9G4dZ/NGNQqWmjL+uP7pdNmfn3+y9FD49OOzXpEEGBdGTMV3vWJpxJHzXkm6e+xXRDVfcSAtA//vKk3OFkkCvymVPnCEUKIr4pNTQ4Xnzebbp04wK1ai/GjExolayR/lybu9uKItK+X3/r0lTfn/PmZlFf55gpityyByV474+PLRPslcwZp7lev6u2WD9QKJZR14cVaod2OZYNTJAghSv/HyrGvbiigESI8Hm/A5ded7le8UuU0ZSUHImFSWjzhu3Hphg+lwNQmAAAAoN4JRgCa32nqlh+mBqEghBCdu+P9hdvobi9Oej7UcGTjVwsXE8vffzrunq9BjL5QjzV4csozTf/6LoCJY6LxwI4FAICgsdvtBHGfIYab1Ozfn9tS8f4YhnF7Blg+tzMA4CGHCVRR0ap/wqAYxhOFxD/S56V3pg9rrigrqEQbz66fN2X2qmMFPnHD4at/WPVMJLebz+OhWeS7/OupluO+2b9kWFMljhClO7Zi9HMz9347/tXunX58Ka6cSF5+bh6Na6LCyxqbaN2+t/ou+d8lJ5L3+s+4LsXCfNSpt5t0/iCj/Iyx/EcXXToxo1F5Ix77V5yrnNgZQ5ebQziwA7Hofu+saEgk9hwxsJkMQwghTcPHJny5N9Lb+rlv//x4+Z7J3wwKMEsyHjtkxQ9D7tlEWTN/3XIwu3gdA7wh8VW/8KIDb/Z4auV1YauXPnv/tSfapYZ48y/9tv69aR8sfbbL1c+P/DA2jYcQEneas37uqSfmHPvckDddmpgQ2DUWE8RueS/7r0uX/u6MHPnO2Ab3/yhfvd2y6q1wbz3KvfB/WuHZhhs0SanRfGNWZoFd2PzxdObXozqRWBhw0LiOdL97lNuUlRyIiIiocJzNyLtjYlE0TDECAAAA6pugrLQSPOSln37Kjh380fi+cQRCzcIsmVN//PnqE+NbFJ924tPrzIq0Dl06NScqfSwAAASNWq2mKKrifSiKCgkJ8e/Pbalg3T+KoliW5fYMCQm5c+dO4OUDAB5mRKPJe/6c2zKwT2604eTqdybNWX/WSEvTBsxa9MH0ZxrK/CEbnlBIYAgTtJ+9+dMXGv1VIi8ifdrXi443fHH3wbVbs198q+yH3Bmnw8ViUWJxGfEf+vb6//4PUyQmheVmH3rv7a2DNj//d4QNj+g47JXx+vIz2RIJrdQY8v44KvKpbyz+WZWCTsuuHX0rBSdkMhFCLpfTxaJ7gpqsy+lkESaVlZyi+XexAR7IbzhgYsNSR2PhT04Ymrh5Rc7xwxd9g9IDX7CVsVz56dvvD5y6eD0jKzs7567e4WNZhNA/0zYDvCFVvnDfn8vf+N81b+TzG35ZPSSc26dB52ELdzXgde48f8+Mmdue2fp8KIYQkrd/d9/p1isXifhVymoQxG5ZHHNn49Jv7mCNZ77WRxlAqLF6u2WVW+GfOtzvwv9uhQ83/nI64/pNcVTTAdMmz50a+2XbX4/iCpWyck+T1nr3u6c25TdlZQcisUSMIcZhdzAIwQQjAAAAoL4JXgCaddz4ae2GX85l6emO07+aqD5xwNm4V0tN4B/WEUL03avXHZEd2vyVaYyIb9MqfPv5a1qmRcI/Hz4Yg07PhjcJZ9xmk5OnDpVzy3sHdCwAoJ4wm82XLl0ymUwqlapZs2bh4eEPXqbX6z1//rxer2dZ1uv1ikQigUDQsGHDpKQk/z65ublc/mWFQpGent6+ffsKMmy0bt3a4/FQFMXjlTuW2u32Nm3acP/WaDR9+vS5cOFCBSFjh8PRvXv32NhYrvxjx46pVKrydiZJ0uv1+ssHAACEEFt0fPGwof89UMBq2r386dL/ju0aU+K3eEIdqsaQt0Hvvqn3DF6YplvPFvzdx29dvUmhlDJ/wMf4Aj5CPl9Z64CxLKZOn/PjzpeyxrYe/cP26TN/fnztAC7XLp749HufPX3fqlOxnZ8bwf7zWD8vrYkcQwgRMfGxBLquzSugUWTxKru1BWYWE8bEhZc9Ulf5wL8rkJiayENZ5iJzwKvAsdYT7w8aNPewgZUntE3v1OnpPiNT0po+EnJkwlNLrvv3CvSGVLH+zJ3Dv2VSWGjfEQPC7wn6iR95YWjLRefPHj30p+/53n81sTi539trAr2+qrp/tyyGurT288MuQYeXxlS0qOA/qrlbPlAvCvTCxcn93l7T7+17jlyfrWcwSUpaOZlFyjpbXeh+95RRQVNWdiDy+SiEMIFAANOfAQAAgHooSAFoKvvb0b3Hbsp0swhhatFohsz65JlhexNHrvpxzQupAU9BZox6Ixuq8SeNxkM0IaxRb2DQPQForYEyHFo05qtsK4148sTOw19/tX8q/37Hut3uEh9MWTbgjGo1y1+xOlvDug9uXZWxLFu7d6+wsHDlypUHDx68efMmj8ejKKpBgwYdO3acPHlylVMYezyeNWvWfP/99xcuXKBp2ufzURQlEAgEAgHDMIMGDZo8ebJAIJgyZcqRI0cY5q84A4ZhycnJ77777qhRo8pcsq9Ro0ZDhgzZv39/mesWIoQcDkdKSsqgQYP8t3Tw4MG//vqrUqksM7cGTdNGo/Hdd99FCLEsO3jw4J07dzocDolEUmb5er1+9OjRcXFx9bfDw3D34ODWVVn1DXe12SiuP98f0H/2SW/iU8s2rp7cSVPWREFew6YN+VghVTpexw2AAmG5GVbxsIgwnLEUWcoIyOLRI77aNadzCNZh2byNv0088M2UuSO6ruxZUSb7khVr9cqqDa+UsT2lRRMpdiX7/CUL2zrsn+HYd+X8FR/La9qiaTlrzwV2IGu5sv/AVZu8Sa8+ze9dPYSxmi0MwjURmkAjgPS1T1+fd9gU/tRne9eP/ycHBX3lXFWCZlW9cJZhGBYhoUT8f/buO76J+v8D+Ody2U3SJk13S0vbFNl7iYCAFJGhbAEFXKyvgBMUUREFHD8Hwz2QIUMQ2Vs2AqIIsqEsoU2Tpk3a7OTG748KlFKgLQlJyOv58A+b3H3ufblPjrt3Pvf+lD/+lEQmpa4caEJYh7nQ6qUj1NGKKo0ZqarKdMtrPPvn/XSckbQb0KeSU+/5uVtWt/uRSu74TY6Cc//OAx4iub91k0rfSgVH9yvjloeyiicizlJk4SihNrZq0wsBAABAcPBJApo799UzIxebG7+05PP/Od6t+xIhRNblzW9H//v8lyOGNWi24+ValXxMivW4GUp27fk5SiaTUh63p+xtHG81mb0yRUaPce+0TSKGw2u+mvXdtO9iZj53u3Xff//9tWvXXm1HpVIVFhZWmFQKEh6Pp7CwMNBRhCq73R7oEEKVxWIJ4NZzcnJef/31I0eOaLXaqwOTbTbbkiVLDhw4MHny5GqM9rVarRMmTNi0aZNGoxEKhU6nUygUikQihmEcDkdCQsL27dv/+OOPwsJCi8UiFArF4v/u9DiOO3fu3HPPPbd79+5p06ZVOBR61KhRJ0+ezM3NjY6OLleOw+l05uXljRo1KiIi4up3uUOHDt26ddu4cWNiYmK5HDTLsnq9Pjs7u0uXLqXLR0dH9+rVa/r06YmJiWUnLSxVUFCQmZn57LPP3gMnCrfb7Xa7Ax1FqMLprtr8d7pzOp1Xf8q6u9iTs5+fus+m7f7tb0ufrnmzqzwqvku3ZuKtf6xZcejtZs2u5Xi4fzesPeSlZE1a1r9ZNlKYnpUu5HdeulTCE225ayiBMiFBRRFC6PRnPn1jQYvxv3/zwvTB+6a3kt9xDWjFg4+0V/y8etey1flDn0q4sl33H8tXX2SFtR7uetMywZVakRKemT9y0EJ7s2l/73mtdplPjTm1ctVRRhDTtkODyqZnnUcOHvcSVednn76uArLz0kVDNYrw3lfNHaeT69eLFuzP37bxb3eHFmWyeHz+1k2HvZSobqM6QkIIcawfndVviafD7FO/jU6p5C5WXeW65VWevUuWX+DED/TqmVzJTKOfu2W1u18ld/zaUdg8+mrNY16/7OsVBbyi84CeiZVOuAZH97vm1oeyiici9vLFy5teIU8AACAASURBVCydkpVZ8W/yAAAAENx8kYBmjy34fjff/tOfPuyf5l1WeiVCRTV8YuYvjpy6z89bdHRcZUvD0WIJzRc7XVdmaOadThcvUl73sz+lzn5rcfaVv1JaDHy+96H/LdlxeFi726ybmJhYu3btq3/q9XqhUBi0CWiGYSiKuu38Y3Cj0nv+W5RNgJvhOI7juFtUk/A3q9X65ptvnjp1KiXluttgqVSamJiYm5s7ZcqU7777LiEhoUrNTps27bfffktNTc3NzbXZbJIrA2pEIpFAINDr9UlJSRcuXCgdE11292mapmna4/HMnTs3PT199OjRNzZeq1atqVOnvvPOO8eOHVOr1VKplKIoj8dTUlJSUlLy9ttvlxs9LRQKp02bRtP0ypUr1Wp1RERE6Shvu91uNpu7des2derUsuOdR4wY4fF4PvroI5VKpVKpRCIRz/NOp9NsNjdq1Ojdd98tWz8kRDEMIxAI8J2tBpzuqo1lWZ7n/Xe6C9iJlDn807w/nXTdV6YMuWWaT1Bz6GuDPn3sx/8bNCR+/hejW0YLCHGc+WXiE29scwjSRoztHXuzyyNK27R5Br31xD8nGNL25klZUZ0xM19d1Oadv2eM/eTx3ZMaCitXc/amKG3vcUMmr/18w+QXFrSb/2SGmBC+cNfkF7/O4VTZ44Y3urqz3gs7ftlzmROmtu33QIqgsisqHnp6UPqSzw+8N/jFrJ/f750ZQQjhSo4vHj/wvT888pYvvNhZfl37LJ3Spm+7tIo+YnFsvIbiDfvW7yp65KHS+e6c59Z9PGbUXD1HxIznv7GelSzCW+0dl3UY8Uy9+dOOzBjyXNaSmcMaRgkIIa6LG6YOHb++mIp9fHT/0kSn4qFBj8X/PHf7u6NLnl2pEvvnZFLZbnll8aObf8tlhQ06d6x05Qk/d8vqHoXK7vi1ozCr1fwxTaIEhDHsmD745dVmUZ1X33ryWu42VLrfFbc7lFU6EXGG48cLeEW7FnWCbAojAAAAqBz+zrl+HaQUNZpyhOF53rW0n0w9dLWL53meZ45MaSxSDV7hqmxLzJl5o/s8/9M55urfc6/7u0Ke/Z883vvN9QWnq7Zu586dOY6rbGR3F8MwBQUFxcXFgQ4kJDkcDofDEegoQlJJSUlBQUHpJHgBMXPmTLVa3aRJk6Y3ERMTM3HixCq1uWPHDoVC0aBBA51OJxAIZDKZ/HpisVgkElEUVfqTj7wiAoFAp9Pl5ubebCsFBQWTJ0/u3Llz06ZN5XJ569atx4wZc/DgwZst7/V6ly5dOnDgwNLlmzZtOmDAgMWLF3s8ngqX37dv3+jRo1u2bFm6cJcuXT755BOz2VyljyI4lZ7uSkpKAh1ISMLprtqKi4v9erqz2+09e/b0WXPujc/FCYiwwduHvLdekNN/1VlCCCWUKioU1Xra0Sv7zBX+9nKjCIpQlESdVq9hrfgImiIUHfPgtL0lt7w8cm39XwotavXh6TKfHmf6oauECGtN2F8mQtuuV+qIKErR7pOTt4m7UriirS83jKAoQURaq0ce69H+Po2QooTJveecLdt68fyeUkIo+YBlriqtyBXvm9o+WkARSqRKrt2kRdP74uUCilCyrCd/KrtcaftE+uiCm5213Ifev19FEUoYfV/bRx7t3rFZplYiiGw8ZGALGUWJa7Qb8u7aXPZu7LjzyBc9U8QUoQQSdY26jRtkxMppihBBVIsJW0zXDjF7eemT6SKKnD9/oSpR+alb8jzPnP6wlYjQNcZsr/hfxIr5u1tW5yhUYcevHAVKqEqu27TJfXEyilCipB5fHHXyN7QfEt2P5yt3KCt/Iir5ZWCUIOKRHwxBevsGAAAAt+aLkQ5UZJSKFBlNNzzH5TXoC3iFsuLprStC16hbO0J/6HBBad0MLv/wP/nKOnWTyg4DduydPWr0Z7uLr5TWYHPPXvSoU1KiUm+/LgAELZ7n169fHx0dfYvnEqKjo7dt2+ZwOCrf7Lp160oHDhcXF9M0fWPjNE2XVoenKIpl2QqfmhcKhf/+++/GjRtvthWtVjtmzJiNGzdu3Ljx3Llz27dvnzlzZuPGjW+2vFAo7Nu378KFC3fu3Hn69OkdO3YsXrx4wIABIlHFA7datmz5+eef79y58+zZs5s2bdqwYcOLL754i8kJASA8sbn/5rKE8IzLVjGH5+rFGqXp+NHO/YsmPd4mVVyUc/KyN6Zx9zEzN/+14fVWylteuEla9eqeyB3evNVwm0LXEW0mffZsTdq++90Xfrhw5wVJKHWHj3bumftqr3qCnB3rtxy2JnV87pNN+5cMS7/NeMhKrUipWk7c/M+2z1/q0yKB1Z84dNwgzOgw5J3Ff/wxd9DtNnA9ccPxa377ekzXujL9H1s27jrlSe/13tq/98z54oNXH0wR5+9ft+uco0olwqu749J6o5Yf3PPjxIHtMuUl546dMvAJTXv877MNf+94v1P0tUMsSOr7w54tM0bJJP4aV1qVbkkIb9y6+RBDSRo2q1+VgPzdLatzFKqw41eOQremidylE2fMyga9Xv5m59+/jqpbvvzWbQRN9yOVPJSVPhE5923aaZW36/1wTJA+vQoAAAC3RvE+mCeneMWTur7rms7ct2J0jdX91cPlP+t/7C5xHv20Z7tXD3ZelLO4362eqrwOc27J+NdWyR4d93Q7jXHb97PXsr0/nN4nlWbOblmwo7B2t34tYx1/fvHi9D/iHn2qf6skuvDYxp8W/aUZ+tHkRxK5m6xb8Zays7M3btwYnCU4WJY1m81isVilqsIUKVDK6XQSQmSy286LAuVZrVa3261WqwNS+6WoqCg7O9vr9d4sCUsI4Xn+1KlT+/btq1evXiWb7dWr19GjRyMjI8+cOeN2u2/cNY7jXC5X6QhonufFYnGFy3Ac98ILL3zwwQe3iF+j0VQyKriq9HQnkUiUSmWgYwk9ON1VW0lJicfj8d/pzuFwDBw4cOXKlf5oPPC8+1+r/8CsGrNPbxhR6RoJ9xL74j41lj9+6ed+KEUbTMKlW4Zp93NsHlnrkWVtFp5e1E8TjDdvAAAAcDs+uUCL7P7mlM70prGtW/V9aeEJxn163ez3xvRo0uaVrVS7N996rNLZZ0KIML3v6+O7yvbNfu2FiV/9qew+YUKvVJoQwuQeWLPqt6NFPKEUzYa/Oz5beXjB9IlvTJ+z09bguXdf65oouPm6ABAC7Hb7iRMnbl3NtjRNXKUR0Ha7vbRNjuMq/MGp3I9wFf4mV7piSUlJ5bcLAHDPEjUfNe5Bwc4fF+bcfBKzexibd8mQlFlTfPsl4W4Kk24Znt2PN6+f84sh85kXeyL7DAAAEKp887SdMGvksm3KSePe/ParFXaOJ1++so9WpnccO+fjKU/Wrey04f+hY5o9ManZE+VelbZ7fVm7K3+I4lsOntBycGXXBYAQEB0dXbduXYfDcYsBiaUlMrRabeWb1Wq1OTk5hBChUFhaaqOcclnpCpPUpcnr+Pj4ym8XAODeJUgdOnnkrE5fzdo5elaHiEBHc1e5//rqmdFzteNWNsZEaMEmDLpluHY/9uyPn60SPPbtiy0kgQ4FAAAAqstnly8RdQd/umXQ9IKzJ88ZnbQqIaNWmrqKqWcACEocxx05cuTYsWNWq1Wj0TRt2jQ9Pd0nLRuNxn379uXn50ul0oyMjDp16mzdulUqvWnBw5KSkvbt29esWbPym2jZsuXmzZs1Gk1ERITNZivNbvM8XzoHaWm6WSAQlKaYKYqqcAg2x3ECgaBFixZV30UAgHuR/P7XPxn268B357zQ7vmMcHrcjI5rMWLO9tZ1tOG00yHjnu+W4dn9ePP6aZ+dbDtlbv94DH8GAAAIXb79/ZySxmQ2isn0aZsAEEj79+//6KOPNmzYIJVKS+frc7vdQ4YMmTBhQlpaWrWbLS4u/vjjjzds2HD69GmJRFJaiDkrK6ugoCAqKkosruDZUpZlTSbT5MmTq1S6vV+/fosXLy4qKlKr1RaLhWEYlmUZhrnaCM/zQqGwNCUtEolubJzjOIZh2rZt26lTp2rvLwDAvYXSdPlw+Y9LzxSX8KQqtdZCnTC5SdtAxwA3da93y/Dsfl6TqO20X7sMTA+rtDsAAMA9x3cJaN52cs3389YfPGdkW0+Y8z/13s322g81jMEoaIDQtWrVqmnTpuXl5el0uquVMTwez6+//nry5MkZM2Y0aNCgGs0WFBQMHz58165dcXFxmZn//WTF87zFYuE4LicnJyMjQyK57jFLhmEuXbrUr1+/xx9/vErbSkxMHDNmzIgRI5KSklQqlV6vLzvMmed5mqZLk86lI6DLrc5xnMfjqVGjxkcffVRhWhwAIExRqgaPPlOdfwMA/Afd8t4j1nV5ShfoIAAAAOBO+SgBzZz/aVj2cwtznDwhlFo6jPOcm9l74Ia0J79e/e3gTCRtAELQ0aNHp02bVlRUFBsbW/Z1sVicnJyck5PzyiuvLF26NDIyskrNchw3fvz4PXv2pKamlk34UhSlVqulUmlOTk5OTo5Go1EqlUKhkGVZm81msViGDBkyffp0kajKv2oNGjSIZdlPP/30/PnzpannqzMNUhRF0zTLsnK5nKZpu93OMIxQKKQoiuf50pLT6enp3333HepvAAAAAAAAAABUQwXVTquOO/fVMyMXmxu/tOTvc3N6SwkhRNblzW9H19EvGDFs1ql7ei5qgHvWrFmzLl26pFKpKnw3Li7ur7/+mjdvXlWb3bp167Jly5KSkiqspCGTyZKTkxs0aNCvX7+EhASpVBoTE9OzZ8/ly5fPnj37ZsHc1pNPPvnQQw8JhUKlUimRSIRCoVAoFIvFMplMqVSmpqbWqlVLJpN17ty5ZcuWCoVCKBSWlqWeMGHC/v37H3zwweptFwAAAAAAAAAgzPliBDR7bMH3u/n2n/70Yf8077LSp/SpqIZPzPzFkVP3+XmLjo6b3DC85moGCHkFBQUHDx7UaDS3WEatVm/cuHHMmDFVannjxo2RkZFXC3rcKCoq6vjx4x9//PFnn31WOh65Su1XiOO4v/76q7QKx9W5B6/+T6no6Giz2bx582alUunxeIRCYYUTEgIAAAAAAAAAQOX5Ir3CnD11lugebJ9SrjFB4v1tMsmFnAsYAg0Qas6dO3fy5MlyhZjLkclk+fn5NputSi2fPXtWJpPdYgGKokoLcRBCfJJ9JoSYTKZ9+/bJ5fLS9q9uqOwyUqn06NGjFy5cIISIxWJknwEAAAAAAAAA7pwvMixUZJSKFBlNN+SZvQZ9Aa9QKu7BWagB7nFut/u2GdjSBdxud5VadrlclWnZ5XJVqdnbbpTckHEup3QSwqruDgAAAAAAAAAA3IIvEtDiJp07ROUu/OC7M9clbpxHv3x/sV71QMcmVZ4zDAACLC4ujmVZlr3V8wsej0csFqvV6iq1HB8f7/F4br2Mx+OJj4+vUrO3FhMTU7du3Vtv1+v1chzn2+0CAAAAAAAAAIQ5nzzeHtn9zSmdN/5vbOtWWwfUPMW4letmv7dx+0/z1p0Wtv/4rcfUGAENEGp0Ot0DDzxw5syZW+SXi4uLu3btWtVSFa1bt165cmV0dPTNFnA6nTqdrlWrVgaDYfv27f/++29pXrht27bp6elV2hYh5NSpU3v27DEYDDRNGwyG5OTkm5X1KCkp6dKlS3JyclU3AQAAAAAAAAAAN+Ob+qrCrJHLtiknjXvz269W2DmefPnKPlqZ3nHsnI+nPFkX458BQo9AIHjyySdHjx6tVCorzNg6HI6SkpKhQ4dWteU+ffrMnz8/Nze3wtQ2z/MGg2H48OHz5s1bvnz56dOnpVIpIcTj8bhcrtGjR0+cODEqKqoyGzIYDFOmTJk7d65MJhOLxW63u6ioyOl0arVarVZbrhyH1+stLCysxu4AAAAAAAAAAMAt+CIBzTosxS46c9CnWwZNLzh78pzRSasSMmqlqZF6Bghhjz/++O+//75o0aLk5GSxWFz2LZvNlpeXN3369IYNG1a1WY1GM2nSpN69exNCyuWgWZbNy8tr3bp1bm7ul19+mZCQUHbIs9vt/uGHH06fPv3999/fYgB1qcuXLz/zzDOHDh1KT0+/GrxUKtXr9ZcvX3a73WVHOrtcrtzc3OHDh/fo0aOquwMA4FeLFi1at27d3dkWx3E8zwsEgltXzA82PM9zHEdRVMhNHlta54qmaX9viOd5hmHkcvkPP/xw562tWLHil19+ufN2KgN98i67y32SpumffvrJ39sCAACAYOCLBLRzzfDUJw1TT28bmyqNyWwUk+mDNgEg0Gia/r//+7/IyMiZM2eqVCq5XE7TNMMwVqu1Zs2aL7/88rPPPlu9lrOzs5cvX/7ee+8dO3ZMpVKJxWKO45xOZ0lJSa9evWrUqDF79uy0tLRy9z8SiSQ1NXXPnj2TJk368ssvb9E+x3Gvvvrq4cOHU1JSyr4eHx8vEAgKCwuNRiPHcWq1mmVZu91utVrHjx//2muvhdyNIgDc8woKCnr27NmlS5e7sC273e5yuSIjI29Wqig4eb3ekpISqVQaERER6FiqxmKxsCx7259U7wTP82az2WQyRUREjB071idtFhQUdO7c+bHHHvNJa7fmcDicTqdKpRKJQmlcC8MwxcXFEolEoVAEOpaqKS4uZhhGo9H4L+PP87zFYikoKJDJZOPGjfPTVgAAACDY+OIGQ96y0/2ySXsPFI9JRblngHuJTCabNm1anz59Vq5cefz48eLiYq1W27Rp0759+6alpd1Jy9nZ2c2aNVu2bNnvv/+u1+ulUmlmZmaXLl3q1KnTp0+fhISECkffUBSVmJg4f/78p556qkWLFjdrfNOmTWvXrs3IyLjxrdjY2MjIyPz8fJ7nExMTtVpt/fr1H3vssQYNGtzJ7gAA+I9UKlWpVHdhQwKBQCQSqVSqkEtA8zwvlUpDLtlXOtmv/w6uzWbT6/UCgaBOnTpyudyHLUskkrvTJ2maFgqFoZiA5jhOIpEolcpAx1I1HMcxDKNSqfyUgLbb7Xq9nuf5++67T6FQhNbAdgAAALgTvrjBEKQ++8P8E33eGPqh6tNRnTJUfn9oCwDupqZNmzZt2tTnzWo0muHDhw8fPrzsiwsXLjxz5swtJhsUiURKpXLLli23SEBv2bJFpVLd7AHS0pHUZ86cmTBhwsMPP1zt+AEAAIKTx+PR6/UOhyM2Ntavo1kBKsnr9RoMBqvVij4JAAAQnnyRgPbueO/pTw4LXIcmPqx7QxqpVStEZR5jl3b/6uiX3SQ+2A4A3PMuXrxYOuvgLUil0gsXLvi7EQCAcKNQKEJuEDEhRCQSabXaQEdRHRVOxnuHOI4zmUwmk0mtVicnJ9+FYr7/Yb3+aDVCKo6Qiv3XPqH88vkIBQKtRkMIIRznj/aJ3yqGVXKe5yq52idVKpVOpwutBywAAADAV3xyBSCUKhQKca0HHqlVwZvitChUVQWAymFZ9raDYiiKYhjG340AAACEFovFkp+fL5FI0tPTb/tDLMBdYLVa8/LyxGIx+iQAAECY80UCWtRmwi+rJ/igIQAId4mJiW63+9bLuN3upKSkWzfy119/3WEjAAAAocLpdOr1eq/XGx8f749BrABV5XK59Hq9x+OJi4tDnwQAAACfjIB2FxstLv6GlymKFklkckWEBFWhAaBSHnjgAZfL5fF4xGJxhQtwHGe1Wtu2bXuLRtq2bbtgwQKtVnuzcdAOh0On07Vp08YHEQMAAAQOwzBGo9FisWi12piYGJTWhYBjWdZoNJrNZrVanZqaKvBbwRAAAAAIIb64IHCvfi41vgJxcTGaKKVMpkqs++CgN+YdLGR9sDEAuJdlZWUNHz68dIb0ChcwGAxdunTp1KnTLRrp2bNnq1atCgoKKnyX4ziDwdCzZ8/Y2FgfRAwAABAIPM8XFhaePn3a6/XqdLrY2FhknyGweJ4vKio6ffq0x+PJzMxMSEhA9hkAAABK+aQER4sxX012vfneGoOmfofObeomqwS2/BN7N245zDQe9OT9kcUXj+ze8OGwFWuOb/79/TYRPtgiANy7Jk2adObMmf379ycmJpadqaY0cZyRkTFt2rRbz6okk8mmTZv2/PPPX758udxwMK/Xm5ub+9BDD7344ot+3AcAAAB/stlser2eoqjU1NSICFxdQ+DZ7fbSAQQpKSmhOJ0pAAAA+JUvEtCCeMWFlb85O3y4d9nLTVRXMz22f2b0e3iG8aVd8z5OIqbtE7If+fz9pe+vHuaDLQLAvUuj0Xz//fcTJ05csmSJQqGQyWSEEI/HU1JSkp2dPX36dJ1Od9tGmjRp8sUXX0yaNGnXrl0qlUosFvM873A4bDbbs88+O2XKFNyuAwBAKPJ4PHq93uFwxMbGajQajHqGgPN6vQaDwWq1arXaWxRAAwAAgHDmiwS094/5c4/FDt4ytkz2mRCiaDD6rUGzOkz56uVe7zbWtn9lZNvZb+8lZJgPtggA97TY2Nhvv/32qaee+u233y5cuMDzfEJCQrt27Tp37nzrsc9lNWrUaPny5evXr9+zZ4/BYBCJROnp6V26dGnatKlfgwcAAPAHjuNMJpPJZIqKisrKyqr8P4gAfnK1T6pUKp1OV/bBNQAAAICyfHGVwJkLzbxcEXFDiS9KrojgLl28zJLGQkqukFN2uw825yM8z9tstuD8ib60+i3DMDabLdCxhB6GYSiKYlmUHK8yhmEIIQ6HI0i+Fw0bNmzYsGHZV5xOZ1Ub6dSpU7mC0X76WpWeUvzR8r0Np7s7wbIsz/M43VWDv093TqfzZoXsAarHYrHk5+dLJJL09HSpVBrocACI1WrV6/U0TdesWbP0eTUAAACAm/FJDeh6TRrQC5d+v+3Fxp2jr93I8ead3/98gq4/rI6IEM64Yc1+Nn2EDzbnOyKRKEgSbeVwHOd2uwUCgUgkCnQsoaf0nh8fXTWwLMuyrFAoxIwx1eB2u9HrqgGnuzuB0121MQzDcZz/Tnder9cfzUJ4cjqder3e6/XGx8dHRUUFOhwA4nK59Hq92+1GnwQAAIBK8kkN6LSnpjz/fddPHm12csjTfdvWSVQQm/7E7l9+mLfVWG/8N8+mXfhp+MBX5/3paDfrCR9szkcoipJIJMGZgGZZ1m63CwQCiUQS6FhCD8dxhBB8dNXg8XgIIWKxGE/1VoPdbkevqwac7u4ETnfV5na7iT9PdyzLBucFBoQWlmWNRqPZbNZqteXm1AUIiKt9Uq1Wp6amYsgCAAAAVJJPCnVRqvYfbNkY/9K4D+a8vfXr0kdOKTqydu8PNnzx0gNK7o8TBwtS+3/00ScjM3yxOQAAAACAexbP80VFRUajUS6X63S6MHzQwXFm1f+9O2PRtn8uFHkiEuu17zf2nYn96ylCJQXv+v2DJ2fKJi4Y2/heKopcWgdGJpNlZmaKxeJAhwMAAAChxFcXRYLYti8vODhmZs6hv0/mFrNSbVqDpvWTIgSegmOn2Gbv/XnuPR9tCAAAAADgnmWz2fR6PUVRNWrUiIiICHQ4AeA99XWfB8dtLEm4v+/TfWt4z25b/stHQ7fuubR90ysNQ+GRD75g7eyZq3Y+OooLdCS+Yrfb9Xo9z/NJSUlKpTLQ4QAAAEDo8e2v8mJNZotOmYQQ1nJmx7Kp7yxavHzr+Y4LzT/3DYWLRQAAAACAQPF4PAaDwWazxcbGajSaMK25wVtWTpm8yZz61LKd33aPExBCuIlbXur0yOfvT1r8xKqh8UH8obBO04Vjf25dMP3NJflcXKCj8Qmv12swGKxWq1ar1Wq1YdonAQAA4I75NgHNOy7tX/PzosWLlq4/qHfxhBLIElvXT0JxMAAAAACAm+A4zmQymUwmlUqVlZUV1pMxMP/s3GuhG4x7uWvcf/cQAm3Hl4ff/81Lu7b+6R7aXRrY8G6ON/7YK234RnfpXyF//8NxXGFhYUFBgUql0ul0QuG9VE0EAAAA7jbfXEl4jIc3/bJ48aIlq36/YGV5Qgmjsh4aNHDQ4EG92+siw/gKGgAAAADgVoqLi/Pz88VicXp6ulQatPnVu8VrJ2pd/fZNM8rcQlAyuYwijNsTzEUtKE3PGTvqWTjCF/46tvfHlwMdz52wWq16vZ6m6bS0NLlcHuhwAAAAIOTdUQKatZzesWLJosWLf916otDLE0oYmfFAduTp3461++bQz/3C/voZAAAA4E7wPM9xHMMwZV/EUMR7htPp1Ov1Xq83Li4uKirKt42X6za+UnGf9GFhBnnXmX91vf4l7vKKX/d6xY1aNgrq2wthTK3mMYQQXn9IFbIDoN1ut16vd7lc8fHxodInAQAAIPhV/wZmdr9m09aUFtqQxNTNfqZ3n969e3ZqqL34wf31jhHUBwMAAAC4QwzDOBwOi8VS9kWtVhuoeMBXWJY1Go1mszk6OjomJkYg8H3Csly34XneJ80yDON0Osv3SXWkTxqviPvC6jf6j99kT3tm0rCaIZvXDQFX+6Rara5Ro8Zd6JMcF8wj2gEAAMCXqp+A3rnmL71HWW/wlI/fGtoxS32lIdY3cQEAAACEPYFAIBKJUJbhXsLzfFFRkdFolMvlmZmZYrHYTxvyU7cRCARCofDu9EnP5a0zJrz03tITnvS+Xy3/v4fVGOHiLxaLJT8/XyqVZmRkSCT+mj6+XLfBlIYAAADho/oJ6GiNmMqzHl044Yl/tvQZOHDg4z0fqKnEqAQAAAAAX6FpWiKRKBSKQAcCvmG32/V6Pc/zKSkp/j6s5dr3VbKv4j7Jen3S+DW8+cDXLz37xqIj7uROL8799I0B9VRIVvrF1T6ZlJSkVCr9ui0/9UkAAAAIftVPQH95IXf0pqULFy5avGr91xPXfj1Jntyie/+B/ZsZ3D6MDwAAAAAg1Hk8HoPBYLPZYmNjNRoNUm+3wl5aNvKRIT9eiMl+fcWMV3tmYhI8v/B621dF7wAAIABJREFUvQaDoaSkRKvVxsTEoE8CAACA/9zBJDYibf1uo6Z3GzXNfvH3VYsXLly0bPPSj/f9TAghQseSGUtrPNGjeaIUFzIAAAAAELY4jjOZTCaTSaVS6XQ6zCF5O8yJGUOenptX9+UVa6d1isXzlX7AcVxhYWFBQYFKpcrKykKfBAAAAH/zwTUdFZHaZuCEz1cfupx7ZN1XE59on67ic5ZN6N8qNbFOl+feW/BngW+mPAEAAAAACCVWq/XMmTN2uz09PT05ORmZvttz7Zg5c5+76fh57yH77BdWqzUnJ6ekpCQtLQ19EgAAAO4OX15wiKLrdh0xteuI9xyX9q1evHDhoqUbN3/35s7i+/r93NdfU1kAAAAAAAQdl8uVl5fn9Xrj4uKioqICHU7IYHP27jNwYtWe90c8e33+mVK1feHjYXWRLq02t9ut1+tdLldpHZhAhwMAAABhxB+XcJQ8pfWAV1sPePXTohO//bJMn4bBCwAAAAAQHliWNRqNZrM5Ojo6JiZGIMClcBUw/174l+FtxzfMO17uHUGssN9Hw+oGJKpQd7VPqtXqGjVqoE8CAADAXebXMQRCTe0uz73pzy0AAAAAAAQHnufNZrPBYJDL5ZmZmWKxONARhR7JI98Ver8LdBR3hEoYscUxItBRXGOxWPLz86VSaUZGhkSC51IBAAAgAPAQGwAAAADAnbLb7Xq9nuf5lJQUhUIR6HAAiNPpzMvLY1k2KSlJqVQGOhwAAAAIX0hAAwAAAABUn9frNRgMVqu1tLQuRVGBjgjCHcMw+fn5JSUlWq02JiYGfRIAAAACCwloAAAAAIDq4DjOZDKZTCaVSqXT6YRCXFpDgPE8X1RUZDAYVCpVVlYW+iQAAAAEA1yRAAAAAABUmdVqzcvLEwqFNWvWlMlkgQ4HgFitVr1eT9N0WlqaXC4PdDgAAAAA/0ECGgAAAACgClwul16v93g8cXFxUVFRgQ4HgLjd7vz8fIfDERsbGx0dHehwAAAAAK6DBDQAAAAAQKWwLGs0Gs1ms1qtTk1NFQgEgY4Iwh3LsiaTqbCwUK1Wp6SkoE8CAABAEEICGgAAAADgNnieN5vNBoNBLpdnZmaKxeJARwRALBZLfn6+VCrNyMiQSCSBDgcAAACgYsGXgOaKDv/y4+Lthy5aFamNOj7+VJ+G6vKzNvPOC1sX/Lhi9wm9Uxyd1rDzwGGPNdYKCW9e/9azXx72Xl2OTurzweyhWfTd3QEAAAAAuKfY7Xa9Xs/zfHJyslKpDHQ4AMTpdOr1eoZhEhISIiMjAx0OAAAAwK0EWwKavbh82tRlbPunxj4eXbBzwZyp79MfT+uVUjaHzBf//vnbs4/WeOzJV5sl8Be2/jT/vbdLpnz8dF2RMd9IZfV4qXfd/0akULKkRDyDBgAAAADV5PV6DQaD1WrVarVarZaiyg+MALjLGIbJz88vKSnRarUxMTHokwAAABD8giwB7flnzZrzyX0+G/lwCk1IPa0l55XVa491G9ng2kOOvHnvxv1Mq7Hjh7RVUoTUvS/ecX7cis1Hnqhb32gwq3St2t5fH2OeAQAAAOBOcBxnMplMJpNKpdLpdEJhkF02Q/jheb7IbDYYjUqlUqfTiUSiQEcEAAAAUCnBdSXNXjp2whbfqmliaQaZrtG0cewvfx/Xcw1Sr45k5q1eSWqz5vcp/vutn45JiBN6nA6GKzAY+dg6sZzTXGgXqqOVIowGAAAAgHuP2xHoCKqlU51AR1AF1gYt9QNG0FZLzU5dZTJZoMMJeh53oCOolpD6KlldHr3FSgsEaWlpcrk80OEAAAAAVEFwJaA5k9HER8dormSbBZoYDW8yFnDkWgJakNrjjf+7tgpr3Ln1H5I5oJaMy9MXMAVbpz8953wxS4TKtDaDxox6JFOONDQAAAAAVI47IUXfb7grsUb8inlR+7eS7r0DHRGEO7eXyS+2OzyeWJVCEyGlkH0GAACAUBNcCWjW42YomUx2JWdMyWRSyuP28BUv7s7/45evvl5+Nv2JKV3iifUfs1emyOgx7p22ScRweM1Xs76b9l3MzDEt/hsr/fbbb69du/bqyiqVymQyBXPRNI/HYzKZAh1FqLLb7YEOIVSZzeZAhxCq8IWtNrfb7XaH5ui5IIDTXbX573TndDo5jvNT4+A/rFxh7D7I3PZh9a4NNb6ZJnA5Ax0RhDuO501Wh8nqUEfIkjXRtADT2wAAAEBICq4ENC2W0Hyx08UTKUUIIbzT6eJFSvGNS3oNB37+6psVR0n9xyZ83L95rIgQSfZbi7OvvJ/SYuDzvQ/9b8mOw8+1aFP62GRiYmLt2rWvtqDX64VCYdAmoBmGoSiKplHOuspK7/kFuECvOo7jOI5DjcvqYRgGH131MAwjEAjwna0GnO6qjWVZnuf9953F2SD0CASWFh3y+z4jO38y853RYlN+oAMCIBaHK7/YJhUJM+I0EiFuCgAAACCEBdcNkiA6RkudLzRzJIomhBDOUmihoutGX39vzTtO/vzue8sKsvpMmN27WVwF6WlCCBFokxIlXrPVxZPSEdUjRowYMWLE1fezs7OjoqKCMwHNsqzZbBaJRCqVKtCxhB6n00kIQbnGarBarW63W6lU4pePaigqKoqKigp0FKHn6ulOqVQGOpbQg9NdtZWUlHg8Hv+d7sRiMX4YCCF2XT394yN5kTjpx0+UR/8MdDgAxOlh9BYrw3EJkYpIuTTQ4QAAAADcqeBKQNM16taOWHnocMHAmvEUIVz+4X/ylXXqJl13d+g6Mv+TpSVtJv7fyCZRZbLHjr2zX57PDJ4+7oFIihBC2NyzFz3quinKYMwwAwAAAECAeaOiDb2GWhu01K5fqt26gmKYQEcE4Y7hOGOJ3WJ3aZXyGGVEUA6VAQAAAKiy4EpAE3GDRx6p8drSWQsTn26nMW77fvmljN5j6okJYc5uWbCjsHa3fi01x3fsNiW00rE5f10boiLQZDSq36qed/q3H2mY/q2S6MJjG39aUVB3aLfaQbaHAAAAABBgnEhc2KFnQdf+qn/26d4eISyxBDoiCHc8zxfZXcYSu0Iq1sVHi2g8RQEAAAD3jmBLzwrT+74+3vv13NmvLXfJkxp1nzCiVypNCGFyD6xZdZ5t3beFIDfPzlzcOPPdjdfWoqRtX/vp1dbD3x0fNffnBdNXldCa5Kxmz737RKdEXLoBAAAAwDXWBi31A4bT1uK0mW/Kz58KdDgAxOby6C1WgUCQqo2Ui0WBDgcAAADAx4ItAU0IHdPsiUnNnij3qrTd68valf5vj+nLe9xk3fiWgye0HOzP6AAAAAAgRLnjk/X9hruS02JXL9T8volwXKAjgnDnYVi9xebweGJVCk2ENDjnpwEAAAC4Q8GXgAYAAAAA8ClWrjB2H2Ru+7B614Ya370vcDoCHRGEO47nTVaHyeqIipBmabS0AKlnAAAAuGchAQ0AAAAA9y6BwNKiQ37fZ6SXz2VMGyfRXwp0QADE4nDlW2wSEZ0eq5aKcEcGAAAA9ziUSAYAAAAAQgghvPHX0S1qPPj+QSbQkVSkxGF//aQ+ff+/sn2Xs46YppkZ9+0WKNLVzZk4w/hI/6S5n6Z9NgnZ59DgWDUwTkXJldf9p+77o5kPdGS3xpccX/760C7p6Wmy5DpZXUdP23zZfcNCTo/3nNFsKLbFRylqxiD7DAAAAGEBVzwAAAAAQAjhLi9+cfSPxwrSO3sDHcqNbNbi7GOWA0TUVascQLO/FzomnXAfzYpfoKUFFS2wx+ycdFK858nR3x/aE7dhKcUE4T5Bxdi88xdcgrgmD3fIkF17VdSwpiioi1TY/vw4u8/HB0hm115PD5Abfl+zetKgfUe/WbOg13+zojMcZyyxW+wurVIeo4xAtWcAAAAIH0hAAwAAAABhz88d8coqA08F4/NxvHfWueIDlOyT+jHj5BQhhEtxjT9q/OxC8dNqzUP0dQuMVYmK2nUb3K72rKfHfj9l2NGGEfF0oOOHqmAvnrvARXSaMOenHrLbLx0k2NOzxs84QLf7ZN2P4+6TEUK4VwaPf+zxz96e8XSXDzrJ+CK7y1Bsi5CIdPHRIjoYv2QAAAAA/oOrHwAAAICw5z09e+QbO2sOfLx+MI5OYF2OX+18coxqpPy/UaMCofSNZJnC41hYwpddYHCrVmfe+drS8sH0eSvel4sULnPpAhA6ePPFi2aqhi5NFOhIqoA9t+HXo2xy33Ej7/svaS7QtH7jhWxF3tq524pzDEVmuzNVG5mqjUL2GQAAAMJQMN5jAAAAAMBd5D786cg3D9Wf/NuL7Kiff3YEOpwbsG42l6cypMKyKUmlTJRCnAdtDKsWsW72MqGSO79qHNw8fvVCze+bCMeJyyyAMdChg71w7iIrqpWhvrjj171H9Q55SqOOHZunRgR1xQo273IuK8iomVKmi1KSmpnxZP2Bfcci2zeOiZBSKLoBAAAA4QoJaAAAAIAgxXGc1+t1uVxlX5T6OovlOPDh0++fajltx7ja5FMft+0bAqEgkuLz3CxDhOIrL3o8rJHnOTfjkUUVNU+Rnfy94NKZ9MnfS52OcguwJBwT0OW6Dc/7ZiR4xX3SJ03/x33hXB7LFb/Wurm+0MsTQggljm/32g9zJj8YE7QZXIEqKlLA5eXmMyRFTAjH8yar4/LJ84U8R8zOKIUsaCO/m/zUJwEAACD44REwAAAAgCDFsqzb7bZdz8fbsO5+a8Rn/7ab+s1zmUE7MEEol3YUk/MFJQvdV15iPTNzHQWEONT1zkz5xtuibbaE/3f3/MUWR7kFnGyYZrn81G1YlvV4PH7sk+zlsxe9vJetOWze0UtG+6XDO78YWsex670nRs+5xPlyQz4lrNO+YwI5v+TzhZeYYofrTH6h3Xxo3YLfCjne6XSFZw+8UblugwQ0AABA+AjaGw0AAACAcEfTtFgsjoiIuP5l32VteMvGN0bPMmV/t2pITZoQ1mcN+5hA+lpqxMoz9ucO69drZTqK3VdkPyCSaQVOZ3K7xHkztEf+eCNZvqbcAoSOozhHuNY9uKHb+IZAIKioT/qu6whiH5u6qLHsvvYtU+WEEJLedtiM1URf739bZs47PvSNekE6mF3S+rW3u68YuerZjg//3KV1nQjzoc3rDpDYONrmEOKG6z/lug1qkgAAAIQPjIAGAAAACFKlyT7Z9XzXPG/ZNGnEHEevTz4dnBzs14TJMdG7akcNkHG/GUo+KfCWNO//3dfPpVEk8vi3qiN/lF/A6HJFarbep0wnRCkM0yxXuW7jq2QfTdMikchvfZIQSl3nwS5d/8s+lxIkde/ZWsyeOnTU1+P/fYblKLrTB3NmPv9YWvEfv8z5Yukfrgfe2Tp3aDpNKZXBXb76LvJTnwQAAIDghx/kAQAAAMITZzxyJM+rX/JExpInyr7+WSvFZ3TmC3sOTW0ZRJeKVJo6cn5MdFG7boYeg5UnDmpmvfUSS2pKrl7OUmnqyAXqyKsreIqL/uWpmlIMQA15lDIqSkh4hmV5QoIsacnzfJHdZSyxy8XC9v1e7zxw0tW3PLte+5eha2bUQA8EAACAMIfLIQAAAIDwJNC0HjLx9U7Xqifw5r3zvt/majb0uQdTtPcnBdGoaGa70XVU17ztqy8rHLa02W/Lzx7/65IlnxIOUQkFVxbIEUoGaURXRs7yRyyuMgtAaGAOzeg1dqX62Tk/Dkm9euDY82dyPIKEzJrKIMs+21wevcVKUVQNte3Ail2bNS0Hdcm60gO9R7bvyRfUHNI6ET0QAAAAwhwS0AAAAADhidK2eWZymzIvsDkf/TZnu7n1iDffCqaxz8QdE7fbcvTtneYPM1a9fGgN4Tivyz7Z4JUoNcOuFJU9biwaY5cyDWNHSgkh5MYFICQI0zPVF/9a+MGH/bvO7h5DEUKI59+lH/7wN5/+Ut+mokCHd5WHYQ0ldpvLHatSaCKkFO88vnjSmMOtmR0/jUylCSHe8z9PnndW0uKdYfWD6bsEAAAAEAi4HgIAAACAIMXKIkxd+xU+2L3/jy8s+nzPG18f+idGGsd4NhU5jxLZZxkK3X9DYoVPpCi/OF7ywpH8vRUvACFC1WXS5M6bx87v2/pMv75ta9IF/2xZseaop/4LP09sIQl0cIQQwvG8yeowWR0qmUQXFy2kBYQQQiU9MX7YF32+fqFrr719W8cVH9+0butR0u6zT4bqgnTaRAAAAIC7BwloAAAAAAg+FGVp2TG/91PSvIsZ778sybu8rZ7mzX+t6wwlFopuHBW1ooaqu/RadlkVqd5aT3iLBSBECLOeWrA3+eupMxetnzvrZ480qW67V76d8NrA+lFBcDCLHa78YptYSKfHqqWi6+6kVG3e2roq7c1pP66b97VFlNC4wysr3hjdPVUcqFABAAAAggcS0AAAAABACCGEznx1l+XVQEdBCHGmZekHjGAilAmLv4o8uLv0xVil8uu6ylusddsFIERI0zqP+7bzuECHcR2nx6u32LwsFxepiJJLK1qEjm3x1NcrnrrbkQEAAAAEPSSgAQAAACBYMFHR+b2GljS+X7tpeczGZZTXE+iIINyxHG8ssZvtzmilPEYpF1BBMBIbAAAAIKQgAQ0AAAAAgcfTdFH77sYegxUnDuomjxIVFQQ6Igh3PM8X2V3GErtcLMyM04iFKOcMAAAAUB1IQAMAAABAgNnua6QfMELAeFJnT5afPR7ocACI3e3VW6w8T1I0KoUUpZwBAAAAqg8JaAAAAAAIGHdsYn7/4Y60rNh1SzTbVlM8F+iIINx5WdZQbLe6PLGqCE2ElELNDQAAAIA7gwQ0AAAAAAQAJ5aasnubsnurd29K/v5D2ukIdEQQ7jieN1kdJqtDJZPo4jRCWhDoiAAAAADuBUhAAwAAAMDdRVGWlh3zez8lybuY/v7L0ryLgQ4IgFhdnjxziVgoTI9VS0W4SwIAAADwmfC9tOJ53m63B+cjdTzPE0IYhrHb7YGOJfQwDEMI4Tg8wFtlpR+d0+kMzu9FkCs9pQQ6itCD092dwOmu2vx9unM6naV9GyrkTNXpB4xglJEJi7+KPLg70OEAEJeX0VtsHoaNi1REyaWBDgcAAADgXhO+CWhCiFAoDM5EW2k2QSAQCIVhfYCqp/TTw0dXDQzDsCxL07RAgAdOqwO9rhpwursTON1Vm9fr5TjOf6c7mqb90ew9gInUGHsMsjRvr938a8zGZZTXE+iIINyxHG8ssZvtzmilPFUbKQjKWwMAAACAUBe+d60URUkkkuBMQLMsa7fbBQKBRCIJdCyhpzQjg4+uGjweDyFELBYjdVINdrsdva4acLq7EzjdVZvb7Sb+PN2xLBucFxgBxPN8UcdHDT0GR+Qc1b0zWlRUEOiIINzxPG+2OQ0lNrlYlBmnEQtx8QMAAADgL+GbgAYAAAAISRJ5oCOoGpvNptfrqcGj0jSR8loZpNujgY4IfG3y04GOoGrs8Wn65g/zmtgUMVHQbmJ1BzqiqoiKDXQEAAAAAFWDBDQAAAAA+IXH49Hr9Q6HIzY2ViPkMTAcAs4boTI06mhNztIe3a1N6oQeCQAAAHAXIAENAAAAAD7GcZzJZDKZTFFRUVlZWTRNk5LCQAcFYY2jRaZ695vq3q+6eEK38nOhy07adgp0UAAAAABhAQloAAAAAPAli8WSn58vkUjS09OlUmmgwwEg1uSsvOYPC132mpvnywouBzocAAAAgPCCBDQAAAAA+IbT6dTr9V6vNz4+PioqKtDhABCXJl7f/GG3Qh3/99ao8/8Qng90RAAAAABhBwloAAAAALhTDMMYjUaLxaLVamNiYlDuGQKOlciMDdqbdU3UZw6mbl0k8IbUTIMAAAAA9xAkoAEAAACg+nieLyoqMhgMEREROp1OJBIFOiIIdzwlMGc2MjTqKDddzlz1pdhmDnREAAAAAGENCWgAAAAAqCabzabX6ymKSk1NjYiICHQ4AMQel6Zv3oWnhcl7VijzcgIdDgAAAAAgAQ0AAAAAVefxeAwGg81mi42N1Wg0qLkBAeeVqwyNO1qTs7RHd2tP7Kc4NtARAQAAAAAhSEADAAAAQJVwHGcymUwmU1RUVFZWFk3TgY4Iwh1HCwvva1FQv63q0indys+FLnugIwIAAACAa5CABgAAAIDKKi4uzs/PF4vF6enpUqk00OEAEGtylr5FV9plT9uyQG7KDXQ4AAAAAFAeEtAAAAAAcHtOp1Ov13u93ri4uKioqECHw9tOrpz+wfdr/jx1ziJJqdXwoSdefGtIU60g0HFBVbCFJ1vPOXKAq+AtWl1rzzMNWgoI8eYO/Pz3xZ5ybyfM+d8DA2O1+uZdXFGx8X9vjTr/D+H5uxL1jdy/f/X6TMnwBU/dd/3NFV9yav30GQuW7MvRe2Qpde4fNnrMyw8mSgIUJQAAAECgIAENAAAAALfCsqzRaDSbzdHR0TExMQJB4LO8nuNf9ug6eSeTnt378W4a58mtK7984dHtZ5fufre1KtCxQeVRElV27ZSMcglozvVHjsmglMdQhBDC2mwXGCouPqGD+lqxF14Yo2r+8Nn6TdRnDtbYuUzgdd/VuK/HF+2cPWfbzuwB5fbD9vdX2cO+PkBqdu32+AC56feNmyc9d/DoZ/MWdIsL/FcIAAAA4C5CAhoAAAAAKsbzfFFRkdFolMvlmZmZYrE40BGVsq37bMZOW9Yr6zd90EJOCCGTRnz6aKeXv/3op1HLRiUiuRcyBIrE97olXv8af+Hw7mbnNZM6paeXJqCLbRd4YafWrX7S0YQQQlGWmg3ym3WWFVxOWP2l2Gq++2FfwTnNuccO71/wxawlBXxcuTfZs7Mmf3+AbvXJks/G6aSEEO5/vcY/Ofqz9799usOkh+SBiBcAAAAgQJCABgAAAIAK2Gw2vV5PCElJSVEoFIEOpwzWcCqnhMT0zG50JY0nqvnwQ7oJ+86dOMcSJKBDGWe9+MJOU3rLDi/F/HcczcV2MyXXRQoIIfa4VH3zh3mhKGnPCmVuTkAjJXzhil5tJm/8rzZI+V7HXtj+6wkmedAzI3X/lUoXqJu9MaLddy/9tvCPVx56EPXTAQAAIIwgAQ0AAAAA1/F4PAaDwWazxcbGajQaiqICHdH16BhdupIc+fv3M55OdcWEEMIZ9v/xLyuunZVK325lCGbulTuPbpBnbGsWdWWwPX/B4mAFyjQ1WUapDxto7a/rH6XzlAImoHESQggV1WHGzzoLR3jzlrEj5l6+/l3WoM/l6IwaSaIyayjT01PItoP/XGIf1KGnAgAAQPhAAhoAAAAA/sNxnMlkMplMKpVKp9MJhcF5rajq+dYHQw6Nfa/XozmDH2mkdp76bfH83yVd35v2dAqGP4cwx+WTr5/k+/So1epa1pY9b3GyhJ8wZ0WBhSmdZHC8Iva1bq0mp0oC/MMIra7VQE0I4Y0nVDf0O4FSFUmxeXojQxKvVq7xGPONPMflGlmCBDQAAACEkeC8qQAAAAAAwrKs2+222+1lX4yIiPDT5oqLi/Pz88VicXp6ulQa1CUChMnthg9uuW7K9nmfHJhHCCGUsumo57vrUFn3qnLdhud5nzTLsqzH4ynfJ33SNG/7fve5i7G1l+uuZZatibF/UITnBBmNH9lWT5hGnH+dOTV22/n3Vh1IHdrmaVWQjc0vQ5jVqmP8D1/++uPCYR8PS6IJIcRxcuY3vxVwvNzl9M3BCDV+6pMAAAAQ/JCABgAAAAhSHMd5vV6n01n2RX8koJ1Op16v93q9cXFxUVFRPm/fx3jr7nf7Pjwjt8Hwz1f+L7telPPMjvmvjf+05yNFizfO7B2PQdCEEFKu2/hKxX3SFy3b/z3z6WVBz+7ptSlCCHGrtPrmXVxR0n6X3J2bFbRPlMgJIUTRtkGT1cRZb0P+zCMlQ9tEBu84Ykmz18Znr3xp43O9nlzfrZVOWLBv8+YDRBtH2x10mN6Cles2SEADAACEjzC9+gEAAAAIfjRNS6VSpVLpv02wLGs0Gs1mc3R0dExMjEAQAtlbTv/LlC+PiR+e/ev7/eMoQoi6cY8JyxQF9fssePOb53q+1RAXuISQct3GV4W8aZqWSCR+6JPuXw9evKSo8W2mmBNLjQ0fNOuaqM8crLFrm4B2k8SyQ9uppMyk1rR+u8FiI5GRvo7DdwTJPabuUmZO+nzlhiVzV0vjmmS/snWIfWyvTy8q5ME7ctufynWbkDjbAAAAgE/g+hwAAAAgSAkEAqFQKJFI/NE4z/Nms9lgMMjl8szMTLFYfPt1ggNz+uhRt7Be29YxZdJ4ylZtW4jnrjp6vIRvqAnP9N71/NRt/NQnuZJL359n0pqkNchqeKbpQ1KzMWPtN5JiU4ULUxJxlIDwHM/6NgjfE6U9OHzBg8Ov/u3ZO/Vflq6ZlhSe92B+6pMAAAAQ/MLz4gcAAAAgrNntdr1ez/N8SkqKQqEIdDhVQ0UoFBRnLrJw5Nqcg3yx2cwRcYQi0DPTQTXwF05f2supBj35orm+Iun3VcrcM6VvMIZTvTblqhu1/LF+xNVjzVqsOSyVoFb48dGAO8flb/91d4668aCOGVfGbzNH9vyZT9UY0gJlYgAAACC8BF8Cmis6/MuPi7cfumhVpDbq+PhTfRqqb7iNuNkylVkXAAAAIIx5vV6DwWC1WmNjYzUaja8qM9xNonoPZSd++dVPs5YN/fzxZBEhhHBF22f+sMsb+XCXVpiHMOR4ZaJl5hKv+pFs5QXdmj0Uy1x9S6hWqouLFu490T+jWffSQ8s6lu49+zdRvFRbIwpUxJXCH1/+wZhjTZnVX4xMERBCvP+umrz4vKTpq8NqB2/lagAAAAB/CLYENHtx+bSpy9j2T419PLpg54I5U9+nP57WK4WuzDKVWRcAAAAgTHEcZzKZTCaTSqXS6XRCYbBdB1aa7P433n9849MLn3jg1OJeHRtEOU/vWvPrnwUcVzUoAAARh0lEQVTq7A8+6BMTegn1MMYL6KJazQwZ7O7/WyxNKsw+vqP84RMnTGobv3nT+b4/WvvVjqlJuf+5cHmNkavfos3ExOAeRixIeGLsgC+GzX9hwFN7ezSLKzm9afPuo6TVZ+/20+H2BAAAAMJMkN14eP5Zs+Z8cp/PRj6cQhNST2vJeWX12mPdRjYQ336Z+47dfl0AAACAsGS1WvPy8sRicXp6ulQqDXQ4d0iQ0P2TPasbT/1k3orl36xzimPSGz/5zqw3R3VIDe4xsVCWNTlL37wL7XElLHj1oINkxshUFSxFZTVsvVeVM/XAxfX/nP6ZpZNiYl/pVvu1ulFRdz3gqlK1fGnrTylvfrJk3ZL5FmFs47ajVrw0tHsK7k0AAAAg7ARXApq9dOyELb5V08TSYQF0jaaNY3/5+7iea5AquN0y3ojbrwsAAAAQblwul16v93g8cXFxUSGQtaskOrblsBlLhs0IdBxQDW5VdH7zLk51XOzhHZqcv0lU1uVXs26+OJ1Ws9a3NWvdvfiqiIrtv+Vk/4reEcQ2GfD1ggF3OyAAAACAIBNcCWjOZDTx0TGaKxljgSZGw5uMBRy5lkS+2TJMJdYFAAAACB8syxqNRrPZrFarU1NTBQJcE0GAsWKpqd4DhbWaq3P+Ttn1i8DjDnREAAAAAOB3wZWAZj1uhpLJZFeKv1EymZTyuD18JZZhbrfu22+/vXbt2qvtqFQqk8kUzBPveDwek8kU6ChCld1uD3QIocpsNgc6hFCFL2y1ud1utxs5iGrC6a7a/He6czqdHMf5qfFK4nnebDYbDAa5XJ6ZmSkW46l/CDSKstRskN/0IanZmLH+O4mlINABAQAAAMBdElwJaFosoflip4snUooQQnin08WLlOLKLHPbdRMTE2vXrn31T71eLxQKgzYBzTAMRVE0jTlKqqz0nh+DvKqB4ziO40J4TqqAYhgGH131MAwjEAjwna0GnO7+v737j5KyrvcA/swMu+xuO8vA7iK/F8QFEbNEkbyU3YtBHPwZ4gHNm4kZpJmmXa50r2Gn1LLUTK5eMy9pohKIBCoZBXqlOJlHWVPKhAB/tMsssCsL7s+ZuX+gBF1hZ8nZWWZfr//22c88z+ccvnzOzvv5zjOHLZFIpFKpzP2fzfo02LNnT3V1dSqVGjx4cHFxcXabgSAIGksH/HXs5ERBUf/nVvbauiHb7QAA0Km6VlwSLi0vC23eUZcMYpEgCIJk/Y76UOno0nAaNT3ae+2sWbNmzZq17zyTJk2KxWJdM4BOJBJ1dXV5eXklJe/3XSwcUmNjYxAEhYWF2W7kyNPQ0NDc3ByNRt35OAw7d+7MoSerdp594y4ajWa7lyOPcXfYdu3a1dLSkrlxl5+fn60bA62trdu2bWtoaCgrKysrK+uaf+fQrbQVRWtOPH3XkGPLNqwrf/k3oURbtjsCAKCzda1tU5Eho0d9qHp9Ve3e52Yka6peqokeN3pgJI2a/DReCwCQk5LJZDwef+2114IgqKysLC8vlz6TXalwZMeocX8+6/JUpEfl8rv6Vj0jfQYA6J661g7oIP+EKVOGXLf4zocGzDytT3zNfUvfGD71yuPzg6Bt068efGbHqDPOH3fUwWoiB3stAEAua2hoqK6ujkQiw4YNsymerqBh0IjqsZ+OtDQNXfNQUfyNbLcDAEA2dbEAOuhx9LS5c1rvuX/+dUubigZ+9Mx/n/WZikgQBG1v/f7x5ZsTp04bd9RBaw52HAAgNzU1NVVXVzc3N/fr18+DgOgKmqN9asZOfqdsQN8/PNvnT8+FUqn2XwMAQE7ragF0EETKT77oP0++6O+OFpw2d8lp7dQc/DgAQG5JJBLxeLyurq53794VFRW+jpKsS+QXbD/+4ztGju298cVBzz4aaW3OdkcAAHQJXS+ABgDgkOrr62tqagoLC4855pj8fA8cI9tCofphJ9Sc9KmC+vjwlff1rI9nuyEAALoQATQAwBFjz5491dXVqVRq4MCB0Wg02+1A0NjYWD15ZlvPwv7Prey1dUO22wEAoMsRQAMAHAFaW1u3bdvW0NBQVlZWVlYWCoU+2PPv3r27qakpFov16JGZvw9LSjNx1tbW1rfffrugoKC4uDgT58+curq6RCJRVlaW7UYOX1tbWzwer6+vLzvuxPLy8tCpp7X/mo7Ys2dPY2Njr1698vLyPtgzZ1RbW1t9fX3Pnj2PuFtE9fX1bW1tpaWlH/h4AQC6OQE0AECXlkwmd+zYUVtbW1JSUllZmamAGNKWSqV27twZj8eLi4srKyuPrIAYAIBO5g0MAEDX1dTUtHHjxkgkMnTo0KKiomy3A0Fzc/PGjRvD4XBFRYU1CQBAu7pvAF1cXHz66adnu4uDSiaTQRD4RvvDkEqlgiDwycHDYNX9I1KplFV3eCy8w2bcHbZOWHX9+/f/QM6TSCTmz58fDoc74R/6yF1RR2jnndx2LBb7QM6TTCbvu+++BQsWWJOHcIR23slt2zgPAN1HaO/fGXQpW7ZsmTZt2oQJE2655ZZs90I3Mnfu3FWrVi1atGj48OHZ7oXuYtOmTdOnT584ceLNN9+c7V7oRubMmbN69eolS5YMHTo0270AAADkODvOAAAAAADICAE0AAAAAAAZIYAGAAAAACAjuu+XEHZl0Wh06tSpI0eOzHYjdC9jx46NRqMlJSXZboRupKSkZOrUqccee2y2G6F7GTduXCwWi0aj2W4EAAAg9/kSQgAAAAAAMsIjOAAAAAAAyAgBNAAAAAAAGeEZ0F1DcmfVoz955On1WxuKKz46YcYl532kd+jAilTdym984e6q1n0HIgPP++78i0dEOrlTckH76y29GugQg45sSdWs+Ma3a2fcMXP0+60l4w4AACCTBNBdQWLr0ptuXJL45CVfmVFa+78PLrjxO5Fbb/rM4APeJifjNfHQiLOumTo6f++BUOHAATawcxjSWW/p1ECHGHRkSarprTU/XfbyO6ck3/fXxh0AAEBmCaC7gJaXHn9886DzfjB78uBIEBxfVr/xayueeOWM2Sfk71fUGt9WV1L5sU/804e9KeYfks56S2tNQkcYdGRBqnb1bfMWrHtrV0sqKHv/EuMOAAAgw+wsy77EG6/8cXe/MScN2Bu4RIacdGLfXX/cUH3AVq1k7bZ4qm//vsnGuvj2htZUVjolF6Sz3tJak9ARBh3ZEIqNmX7tvO/cOm/aiIPccDfuAAAAMs0O6OxLbo9vT5WW93nvZkC4T3mf1PZ4bTKo+Nv9gWRtdW1b7eqbZy7Y/HYi6BEdOv7CK7805Zgij6mkg9JZb2mtSegIg46syIsNGh4LUnWvFR5kFRl3AAAAmebtVfYlWprbQoWF+94chwoLC0ItzS37b/5LNWyvay0sHn7WN3+yePFP5183pXj9j2/68e932yBIR6Wz3tKpgQ4x6OiajDsAAIBMswM6C1p/d9tFNz3dmAqCUPGE/7z/ivyekdTbjU2poCAUBEGQamxsSuVFD3j6ZKj3pG88Mum9nwafcsGXp66/YtEzVZedMr6ws9vnyBZJY72lUwMdks6iMujofMYdAABApgmgsyBvzOwfPTAzlQqCUCi/KC+8tbwstHlHXTKIRYIgCJL1O+pDpaNLD7U7PVw2cEDP1rqGplRwsI8Vw/sKl7a/3tKpgQ45nEVl0JF5xh0AAECmeYeVDXlFvXrFYrFYrFevorwgMmT0qA9Vr6+q3fuB32RN1Us10eNGD4zs94p31s3/0uU/WPv2e58JTry1aWtL78GDo0IZOiid9ZZODXSIQUfXZNwBAABkWuSGG27Idg/dXqS8rOW5JY+90Dp4aO/GV5ffc//zsXMuv/DDsXDbpl89sOz3zQOOGxTrE9765MIVVc29ywpbt//52YX3LNlYccEV548UzNBRaay34h4Hq8l28xy5DDqyqGnjmhUbSv757JOP2jvFjDsAAIDOI4DuCsK9R40Z1lT1xMMLFz9VtbtiypevmjbqQ6EgaHl50Xd+8kKv8WeMKS8YcOIpQ5v+uHr5kqUrf/NqXfTEGVdfPmlIvlSGjktjvYUPVgOHzaAje/4+gDbuAAAAOk8olfJN7wAAAAAAfPB8xBQAAAAAgIwQQAMAAAAAkBECaAAAAAAAMkIADQAAAABARgigAQAAAADICAE0AAAAAAAZIYAGAAAAACAjBNAAAAAAAGSEABrITS9ef3xeZPCX17QeeLhl4wPTh+aHo2Ou+WU8mZ3OAAAAALqNHtluAKDTtG155NLJly3ePurKJSu/P6mvO3AAAAAAmSWABrqJxJtLZ0/+/EPVI770s6dun3yU9BkAAAAg40QwQHeQrH7iyskXLXh9+GUPP/XDM/p1fPQlWlsP/cSOdgsAAAAAuh8BNJDzkvFfXjtl+j2bKmY+9NR/nT0gst+vmjc/efMlpx8/MFaY37O4/Oix51x7f9Wu1Hu/fOzCaM9xN65aNmfisFhhz7yC2JCTzvm3B/+QfkG7lwAAAADIaR7BAeS25I6nrz9z2h0vFZ193y/uPnfQ/ulzatuSS0+b8XD90ROnf/G8IYXvbF237Ge3z3yuJvryg1NLQ3trEhvv+twF21orp1zy1ZH5b/5m+c9vvfjZ5+PPPHXNh/PTKUjnEgAAAAA5SwAN5LBk3dobzr7te1Uteal3Xlj9ws6LK/rul/o2rHl42V9Lzrl/7aMX7T2cvPrkicdc+cyvq1qnTng3X07urAnO/dG6hy+tLAiCIDlv1TUTz7rzm19feMHyS/qH2i9I5xIAAAAAOcsjOIDclap+ZN4tG467ftXv7j6zz1sPXXnV4ur9n9NcfO6C12s3L7xgXyidaG5OBqm21rb9inocd9m8iysL9v4Q7vupeXPPKtm9+rFVdal0CtK6BAAAAECusgMayF2pUPRjX1/++LxP9E4N+/6Kky/52VVfOWv8ogsHvnvrLVxQUrLrxcfvffK3L736ly2vb3ntlZc3bW8OHXXAOYo+ctKx+03KUMlJpxwbWfaX17Ykgj7tFvRI6xIAAAAAucoOaCB3hftdeOP1n+gdCoLw4Ivm3/aZvvGlX73ip6+/uws6Vff018ePOHn6vMUbGsuOnzDj6luXrvvR+SX//8nMBxwJhSPhUJBMJNMpSPsSAAAAADnJDmggh4XDoffC3vDAC354+/LffnbJ1y5f8MmfXzo0knz9wRtuf75g2kPrH57e792bcY1L70qmDjzFO3948dW2c07YNywb1j//p7YeY48eHAmCRDsFaV4CAAAAIFfZAQ10F+EB0++4Y3r/upVzZt+7KREkd8a3t4X7DB9e+t4gbNny2OK1jX/3qrZX7v3Wwr+07P0huf3pG29aVlc4/pxJ5aH2C9K8BAAAAECusgMa6D5C/ab94M4Va89fOHfW3RN+8YXJk4/+7u13fm5G8gsTK0LbNqxZ9MiLqVg0iK9btOBXQz97+oi8IAiCggE9fzv71FOXT5s4Mu/NtY89uvbNnqd+65bPD9l3++4QBeFR7V2i2NM4AAAAgFxmBzTQnYT6nnvr/H8d1LD6P7545+ZTvr1i4bX/UvTi/8yb8817Vm6puHpl1XMPXPPx0k0PXve9X+/Y+5yMUMmn73x26ezBG5fdddt/L98Um3DVj9c8MXdM4d/OeKiCgvFpXAIAAAAgZ4VSKQkIwPtpfuzCsmm/nvHkG/d+Ov/wCgAAAAC6NzugAQAAAADICAE0AAAAAAAZ4UsIAQ4i3G/M5DPDJ5Qf9E5duwUAAAAA3ZtnQAMAAAAAkBH27QEAAAAAkBECaAAAAAAAMkIADQAAAABARgigAQAAAADICAE0AAAAAAAZIYAGAAAAACAjBNAAAAAAAGSEABoAAAAAgIwQQAMAAAAAkBECaAAAAAAAMkIADQAAAABARgigAQAAAADICAE0AAAAAAAZIYAGAAAAACAjBNAAAAAAAGSEABoAAAAAgIwQQAMAAAAAkBECaAAAAAAAMkIADQAAAABARvwf+u1BLqkiMzUAAAAASUVORK5CYII=" width="1536"></p>
</div>
</div>
<div id="column-1" class="section level2 tabset" data-width="45">
<h2 class="tabset">Column</h2>
<div id="individual-results" class="section level3">
<h3>Individual results</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><a name='61'></a></p>
<div id="aikenhead-2011" class="section level4">
<h4><a href='https://doi.org/10.1111/J.1758-8111.2010.00003.X' title='Open publication'>Aikenhead
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

AMSTAR
A1. Was an 'a priori' design provided? [No]
No protocol mentioned. 
A2. Was there duplicate study selection and data extraction? [No]
Not reported.
A3. Was a comprehensive literature search performed? [Yes] 
Searched PubMed, Embase, Web of Science, Cochrane Library. Handsearched references. 
A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
Grey literature excluded.
A5. Was a list of studies (included and excluded) provided? [No]
Included studies described but not excluded.
A6. Were the characteristics of the included studies provided? [Yes]
Table 3 provides characteristics of included studies.
A7. Was the scientific quality of the included studies assessed and documented? [No]
Study limitations discussed but quality not assessed.
A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Quality not assessed.
A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No meta-analysis attempted.
A10. Was the likelihood of publication bias assessed? [No]
Not assessed.
A11. Was the conflict of interest included? [No]
Not reported for individual studies.

PRISMA
P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Identified as systematic review in title.
P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]  
Structured abstract provided.
P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Introduction reviews evidence and need for review.
P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]   
No PICOS stated.
P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.
P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]  
Eligibility criteria described in methods. 
P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Databases and dates described. Handsearch of references.  
P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [Yes]  
Search strategy provided in appendix.
P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Selection process described and flow diagram provided.
P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]  
Data extraction process not described.
P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Outcomes described but no full list of variables.
P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
Risk of bias not assessed.
P13. State the principal summary measures (e.g., risk ratio, difference in means). [No]  
Not applicable.
P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No meta-analysis.
P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No]  
Not assessed.
P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.
P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes] 
Flow diagram provided.
P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]  
Study characteristics presented in tables.
P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). [No]
Risk of bias not assessed.
P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]  
No forest plots. Simple summary data presented.
P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis.
P22. Present results of any assessment of risk of bias across studies (see Item 15). [NA] 
No assessment of risk of bias.
P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). [NA]
No additional analyses.
P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in discussion and conclusion.
P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]  
Limitations discussed.
P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted and future research implications discussed.
P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [Yes]
Funding source described.
</pre>
<p><a name='62'></a></p>
</div>
<div id="al-hozaim-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2009.12.001' title='Open publication'>Al-Hozaim
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search was limited to studies reported in English and performed in humans.&quot;</span>
No protocol, ethics approval, or predetermined objectives mentioned.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):

A systematic search of the MEDLINE, PUBMED, and
Cochrane databases (June 2000 to April 2008) was
conducted. The search terms used were “laparoscopic,”
“pull-through,” “anorectal malformation,” and “imperforate
anus.” In addition, a manual search of 4 surgical journals
from the same period was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic search of the MEDLINE, PUBMED, and Cochrane databases (June 2000 to April 2008) was conducted." "In addition, a manual search of 4 surgical journals from the same period was performed.&quot;</span> 
At least two databases searched along with supplementary strategies.

A4. Was the status of publication used as an inclusion criterion? [No]  
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [Yes] 
Table 1 provides a list of included studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of included studies such as sample size, study period, and procedure details. Table 2 provides patient demographics.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed. 

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic-assisted anorectal pull-through for anorectal malformations: a systematic review...&quot;</span>

P2. Provide a structured summary. [No] 
No structured abstract provided.

P3. Describe the rationale for the review. [Yes]  
Introduction provides rationale and background.

P4. Provide an explicit statement of questions addressed. [No]
No explicit review questions stated.

P5. Indicate if a review protocol exists. [No] 
No mention of a review protocol.

P6. Specify study characteristics used as eligibility criteria. [Yes]  
Methods section describes eligibility criteria. 

P7. Describe information sources and dates searched. [Yes]
Methods describe databases searched along with date ranges.

P8. Present full electronic search strategy. [No]
Search strategy not provided.

P9. State process for selecting studies. [Yes] 
Methods describe study selection process.

P10. Describe method of data extraction. [No]  
No details provided on data extraction process.

P11. List and define all variables extracted. [No] 
No list of extracted variables provided.

P12. Describe methods for assessing risk of bias. [No]
No risk of bias assessment mentioned. 

P13-P23. [NA] 
No quantitative synthesis performed.

P24. Summarize the main findings. [Yes] 
Discussion summarizes main findings.

P25. Discuss limitations at study and outcome level. [No]
Does not discuss limitations at study or outcome level.

P26. Provide a general interpretation of results. [Yes]
Discussion provides general interpretation of findings.

P27. Describe sources of funding and support. [No]
No mention of sources of funding or support.
</pre>
<p><a name='63'></a></p>
</div>
<div id="allen-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2014.10.042' title='Open publication'>Allen
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the assessments for each AMSTAR and PRISMA item:

A1. 
Quotes:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.8%):

thoracotomy (EDT) is rarely utilized in children, and is thus
difficult to identify survival factors. We reviewed our experience and performed a systematic review of reports
of EDT in pediatric patients' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A resuscitative thoracotomy (RT) is rarely utilized in children, and is thus difficult to identify survival factors. We reviewed our experience and performed a systematic review of reports of RT in pediatric patients.&quot;</span> (Introduction)

Reasoning: The objective is stated explicitly.

[Yes]

A2.  
Quotes:
No mention of duplicate data extraction.

Reasoning: Duplicate data extraction is not described. 

[No]

A3.  
Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

We reviewed
patient records for the presence of vital signs (VS) and/or signs of life
(SOL) in the field, time without VS in the field, presence of VS or SOL
upon arrival, MOI, location of injuries, return of spontaneous circulation
(ROSC), survival, and neurological function of the survivors upon dis-
charge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;</span> (Methods)

<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

For our systematic review of the published data, we obtained all case
series regarding pediatric EDT and combined the data from those
reports with the data from our institution (Table 1) [6–13]. These
reports were obtained from a Medline search for all publications
regarding EDT in the pediatric population for the past 40 year using
the keywords “thoracotomy”, “emergency”, “trauma”, “resuscitation”,
“pediatrics”, and “children”. Bibliographies of relevant publications
were reviewed to identify reports that were not initially located with
the Medline search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For our systematic review of the published data, we obtained all case series regarding pediatric RT and combined the data from those reports with the data from our institution (Table 1) [6–13]. These reports were obtained from a Medline search for all publications regarding RT in the pediatric population for the past 40 year using the keywords “thoracotomy”, “emergency”, “trauma”, “resuscitation”, “pediatrics”, and “children”. Bibliographies of relevant publications were reviewed to identify reports that were not initially located with the Medline search.&quot;</span> (Methods)

Reasoning: Searched Medline and reviewed references. Supplementary search with bibliography review.

[Yes]

A4.
Quotes: 
No mention of searching or including grey literature.

Reasoning: Searching for grey literature is not described.

[No]  

A5. 
Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Variables extracted from each report include demo-
graphics, MOI, injury location, presence of VS and/or SOL upon arrival,
ROSC, survival to discharge, and neurologic outcomes for survivors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variables extracted from each report include demographics, MOI, injury location, presence of VS and/or SOL upon arrival, ROSC, survival to discharge, and neurologic outcomes for survivors.&quot;</span> (Methods)

Table 1 shows the included studies.

Reasoning: The included studies are listed in Table 1.

[Yes]

A6. 
Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Demo-
graphics obtained from our trauma registry included age, sex, mecha-
nism of injury (MOI), and Injury Severity Score (ISS). We reviewed
patient records for the presence of vital signs (VS) and/or signs of life
(SOL) in the field, time without VS in the field, presence of VS or SOL
upon arrival, MOI, location of injuries, return of spontaneous circulation
(ROSC), survival, and neurological function of the survivors upon dis-
charge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Demographics obtained from our trauma registry included age, sex, mechanism of injury (MOI), and Injury Severity Score (ISS). We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;</span> (Methods)  

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Although each series differs in the specific data reported, the informa-
tion obtained was pooled and analyzed using the variables and
outcomes reported by each series' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Although each series differs in the specific data reported, the information obtained was pooled and analyzed using the variables and outcomes reported by each series.&quot;</span> (Methods)

Tables show characteristics of included studies.

Reasoning: Participant characteristics were extracted from studies and presented descriptively.

[Yes]

A7. 
Quotes: 
No mention of quality assessment of included studies.

Reasoning: Quality assessment of included studies is not described.

[No]

A8. 
Quotes:
No mention of incorporating quality assessment into conclusions.

Reasoning: Quality assessment was not performed. 

[NA]

A9.  
Quotes:
No quantitative synthesis performed.

Reasoning: The review did not include meta-analysis.

[NA]

A10. 
Quotes:
No assessment of publication bias mentioned. 

Reasoning: Publication bias was not assessed.

[No]

A11. 
Quotes:
No mention of conflicts of interest.

Reasoning: Conflicts of interest are not reported.

[No]

P1. 
Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pediatric emergency department thoracotomy: A large case series and systematic review&quot;</span> (Title)

Reasoning: Identified as a systematic review. 

[Yes]

P2.  
Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Background/purpose: The emergency department thoracotomy (EDT) is rarely utilized in children, and is thus
difficult to identify survival factors. We reviewed our experience and performed a systematic review of reports
of EDT in pediatric patients.
Methods: Patients age ≤18 years who received an EDT from 1991 to 2012 at our institution and all published case
series were reviewed. Data analyzed include age, sex, mechanism of injury (MOI), injury patterns, presence of
vital signs (VS) or signs of life (SOL) in the field/ED, return of spontaneous circulation (ROSC), and survival.
Results: A total of 252 patients were analyzed. 84% were male. 51% sustained penetrating injuries, and median age
was 15 years. Upon arrival, 17% had VS, and 35% had SOL. After EDT, 30% experienced ROSC. The survival rate was
1.6% for blunt trauma, 10.2% for penetrating injuries, and 6.0% overall.
Conclusion: Survival of pediatric patients following EDT is comparable to recent analyses in adults. Children who
sustain blunt injury and are without SOL have been uniformly unsalvageable. Children who sustain penetrating
trauma and have SOL or are without SOL for a short time prior to arrival have been salvageable. There are no
reported EDT survivors less than 14 years of age following blunt injury' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎a b s t r a c t [...] Background/purpose: The emergency department thoracotomy (EDT) is rarely utilized in children, and is thus difficult to identify survival factors. We reviewed our experience and performed a systematic review of reports of EDT in pediatric patients. Methods: Patients age ≤18 years who received an EDT from 1991 to 2012 at our institution and all published case series were reviewed. Data analyzed include age, sex, mechanism of injury (MOI), injury patterns, presence of vital signs (VS) or signs of life (SOL) in the field/ED, return of spontaneous circulation (ROSC), and survival. Results: A total of 252 patients were analyzed. 84% were male. 51% sustained penetrating injuries, and median age was 15 years. Upon arrival, 17% had VS, and 35% had SOL. After EDT, 30% experienced ROSC. The survival rate was 1.6% for blunt trauma, 10.2% for penetrating injuries, and 6.0% overall. Conclusion: Survival of pediatric patients following EDT is comparable to recent analyses in adults. Children who sustain blunt injury and are without SOL have been uniformly unsalvageable. Children who sustain penetrating trauma and have SOL or are without SOL for a short time prior to arrival have been salvageable. There are no reported EDT survivors less than 14 years of age following blunt injury.&quot;</span> (Abstract)

Reasoning: Provides structured summary.

[Yes]  

P3.  
Quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The emergency department thoracotomy (EDT) is rarely utilized in children, and is thus difficult to identify survival factors.&quot;</span> (Introduction)

<span title='Moderate quote deviation. Best match in fulltext (Similarity 87.2%):

With recent reports showing the
detrimental outcomes associated with a prolonged pre-hospital period,
there has been a push for emergency medical services in urban environ-
ments to “scoop and run” rather than “stay and play” [17,18]. Many of
these patients in the past would have been pronounced dead at the
scene or at their community hospital emergency department. During
this development, the resuscitative thoracotomy was also added as an
extension to ATLS techniques [19]. Now after 30 years, we are able to
Table 1
Systematic review of the published case series regarding pediatric' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎With recent reports showing the detrimental outcomes associated with a prolonged pre-hospital period, there has been a push for emergency medical services in urban environments to “scoop and run” rather than “stay and play” [17,18]. Many of these patients in the past would have been pronounced dead at the scene or at their community hospital emergency department. During this development, the resuscitative thoracotomy was also added as an extension to ATLS techniques [19]. Now after 30 years, we are able to systematically review the current literature with this relatively aggressive resuscitative measure in the pediatric population.&quot;</span> (Introduction) 

Reasoning: Provides context and rationale for the review.

[Yes]

P4.  
Quotes:  
No explicit PICOS statement.

Reasoning: PICOS is not explicitly stated.

[No]

P5.  
Quotes:
No mention of a review protocol.

Reasoning: A protocol is not mentioned.

[No]

P6.  
Quotes:  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Demo-
graphics obtained from our trauma registry included age, sex, mecha-
nism of injury (MOI), and Injury Severity Score (ISS). We reviewed
patient records for the presence of vital signs (VS) and/or signs of life
(SOL) in the field, time without VS in the field, presence of VS or SOL
upon arrival, MOI, location of injuries, return of spontaneous circulation
(ROSC), survival, and neurological function of the survivors upon dis-
charge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Demographics obtained from our trauma registry included age, sex, mechanism of injury (MOI), and Injury Severity Score (ISS). We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;</span> (Methods)

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Variables extracted from each report include demo-
graphics, MOI, injury location, presence of VS and/or SOL upon arrival,
ROSC, survival to discharge, and neurologic outcomes for survivors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variables extracted from each report include demographics, MOI, injury location, presence of VS and/or SOL upon arrival, ROSC, survival to discharge, and neurologic outcomes for survivors.&quot;</span> (Methods) 

Reasoning: Reported characteristics used as eligibility criteria.

[Yes]

P7.  
Quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For our systematic review of the published data, we obtained all case series regarding pediatric EDT and combined the data from those reports with the data from our institution (Table 1) [6–13]. These reports were obtained from a Medline search for all publications regarding EDT in the pediatric population for the past 40 year using the keywords “thoracotomy”, “emergency”, “trauma”, “resuscitation”, “pediatrics”, and “children”. Bibliographies of relevant publications were reviewed to identify reports that were not initially located with the Medline search.&quot;</span> (Methods)

Reasoning: Sources searched reported, but dates not provided.

[No]  

P8.  
Quotes:
No full search strategy provided.

Reasoning: Full search strategy not reported.  

[No]

P9.  
Quotes:  
No details on study selection process. 

Reasoning: Study selection process not described.

[No] 

P10.  
Quotes:
No details on data extraction process.

Reasoning: Data extraction process not described.

[No]

P11.  
Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Demo-
graphics obtained from our trauma registry included age, sex, mecha-
nism of injury (MOI), and Injury Severity Score (ISS). We reviewed
patient records for the presence of vital signs (VS) and/or signs of life
(SOL) in the field, time without VS in the field, presence of VS or SOL
upon arrival, MOI, location of injuries, return of spontaneous circulation
(ROSC), survival, and neurological function of the survivors upon dis-
charge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Demographics obtained from our trauma registry included age, sex, mechanism of injury (MOI), and Injury Severity Score (ISS). We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;</span> (Methods)

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Variables extracted from each report include demo-
graphics, MOI, injury location, presence of VS and/or SOL upon arrival,
ROSC, survival to discharge, and neurologic outcomes for survivors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variables extracted from each report include demographics, MOI, injury location, presence of VS and/or SOL upon arrival, ROSC, survival to discharge, and neurologic outcomes for survivors.&quot;</span> (Methods)

Reasoning: Variables sought are described.

[Yes]

P12.  
Quotes:
No details on risk of bias assessment.

Reasoning: Risk of bias assessment not described. 

[No]

P13.  
Quotes:  
Not applicable (no quantitative synthesis performed).

Reasoning: No meta-analysis done.

[NA]

P14.  
Quotes:  
Not applicable (no quantitative synthesis performed).

Reasoning: No meta-analysis done.

[NA] 

P15.  
Quotes:
Not applicable (no quantitative synthesis performed). 

Reasoning: No meta-analysis done.

[NA]

P16.  
Quotes:
Not applicable (no additional analyses done).

Reasoning: No additional analyses described.

[NA]

P17.  
Quotes: 
No flow diagram provided. Number of studies included reported in text and Table 1.

Reasoning: No flow diagram, but number of included studies reported.

[No]

P18.  
Quotes: 
Table 1 lists included studies. Table 2 shows characteristics of own case series. Tables 4 and 5 show summary participant characteristics.

Reasoning: Characteristics of included studies presented.

[Yes]

P19.  
Quotes:
No details on risk of bias of individual studies.

Reasoning: Risk of bias not assessed.

[No]

P20.  
Quotes: 
Not applicable (no quantitative synthesis performed).

Reasoning: No meta-analysis done.

[NA]

P21.  
Quotes:
Not applicable (no quantitative synthesis performed).

Reasoning: No meta-analysis done. 

[NA]

P22.  
Quotes:
Not applicable (no assessment of risk of bias performed).

Reasoning: No assessment of risk of bias.

[NA]

P23.  
Quotes:
Not applicable (no additional analyses done).

Reasoning: No additional analyses described.

[NA]

P24.  
Quotes:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.5%):

Overall, the mortality rates are
comparable between adults and pediatric patients following EDT' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Overall, the mortality rates are similar between adults and pediatric patients following EDT.&quot;</span> (Discussion)

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Children who sustain blunt force trauma and are without SOL at the scene of the injury have been uniformly unsalvageable.&quot;</span> (Discussion) 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Children who sustain penetrating trauma and have SOL in the emergency department or are without SOL for a short period of time prior to arrival have been salvageable.&quot;</span> (Discussion)

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There are no reported survivors in children less than the age of 14 years who required an EDT after sustaining blunt force trauma.&quot;</span> (Discussion)

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There are no reported survivors in children less than the age of 9 years who required an EDT after sustaining penetrating trauma.&quot;</span> (Discussion)

Reasoning: Main findings summarized including strength of evidence.

[Yes]

P25.  
Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There are limitations to this study. First, all of the data obtained from our institution were collected retrospectively, and thus not specifically collected for research purposes. As for all data reviewed, some of the variables may have been missing or misclassified.&quot;</span> (Discussion) 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Selection bias may have also affected results, as all EDT were performed at the discretion of the trauma physician.&quot;</span> (Discussion)

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Publication bias also exists. It is likely other institu-
tions have performed this procedure over the same time period,
however none were published' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Publication bias also exists. It is likely other institutions have performed this procedure over the same time period, however none were published.&quot;</span> (Discussion) 

Reasoning: Limitations discussed including risk of bias and publication bias.

[Yes]

P26.  
Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Our review allows considerable trends to be made regarding this contro-
versial topic. Overall, although outcomes appear similar to that of the
adult population, there may be less benefit in the younger pediatric
patient and in those who arrive without SOL after sustaining blunt
force injury' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our review allows considerable trends to be made regarding this controversial topic. Overall, although outcomes appear similar to that of the adult population, there may be less benefit in the younger pediatric patient and in those who arrive without SOL after sustaining blunt force injury.&quot;</span> (Discussion)

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Continued evaluation of this technique is warranted to develop adequate guidelines.&quot;</span> (Discussion)

Reasoning: Interpretation of findings and need for further research described.

[Yes] 

P27.  
Quotes:
No statement on funding or support.

Reasoning: Sources of funding not reported.

[No]

In summary, I have provided assessments for all AMSTAR and PRISMA items, highlighting relevant quotes and explaining the reasoning behind each decision. Let me know if you need any clarification or have additional questions!
</pre>
<p><a name='64'></a></p>
</div>
<div id="allin-2015" class="section level4">
<h4><a href='https://doi.org/10.1371/JOURNAL.PONE.0116908' title='Open publication'>Allin
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

The review was conducted according to a pre-specified protocol. The protocol was registered
on the Prospero International Prospective Register of Systematic Reviews' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[The review] was conducted according to a pre-specified protocol. The protocol was registered on the Prospero International Prospective Register of Systematic Reviews.&quot;</span> [Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Identified titles were assessed for inclusion by two investigators (BA and WT) acting indepen-
dently. Any conflicts were resolved by a third investigator (MK). Data from included articles
were extracted independently by the same two investigators (BA and WT), and any differences
resolved by discussion' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Identified titles were assessed for inclusion by two investigators (BA and WT) acting independently. Any conflicts were resolved by a third investigator (MK). Data from included articles were extracted independently by the same two investigators (BA and WT), and any differences resolved by discussion.&quot;</span> [Yes]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

Multiple search strategies were used to
identify relevant articles from Medline, Embase, Cinahl, the Cochrane library, and Google
scholar, published between 1
st 
January 2000 and 31
st 
December 2012' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Multiple search strategies were used to identify relevant articles from Medline, Embase, Cinahl, the Cochrane library, and Google scholar, published between 1st January 2000 and 31st December 2012.&quot;</span> [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
- No mention of searching for grey literature. [No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows a flow diagram of included and excluded studies. [Yes] 

A6. Were the characteristics of the included studies provided?
- Table 2 provides a summary of the characteristics of included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- The methodological quality and risk of bias were assessed using the STROBE checklist and GRADE criteria, as mentioned in the Methods. However, the quality assessment for each individual study was not presented. [No] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Cannot score <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.3%):

question if scored “no' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎yes" because question A7 was scored "no&quot;</span>. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

Using a conservative cut-off of p<0.01, no statisti-
cal heterogeneity was detected and therefore fixed-effect methods were used throughout' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using a conservative cut-off of p<0.01, no statistical heterogeneity was detected and therefore fixed-effect methods were used throughout.&quot;</span> [Yes]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
- No mention of conflicts of interest for the systematic review or included studies. [No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 
- Identified as a systematic review and meta-analysis in the title and abstract. [Yes]

P2. Provide a structured summary including applicable elements.
- Structured abstract provided with background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, limitations, and conclusions. [Yes]

P3. Describe the rationale for the review in the context of what is already known. 
- Rationale and context described in the Introduction. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to PICOS.
- Research aim stated in Introduction: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

The aim of this study, therefore, was to perform a systematic review of the literature com-
paring outcomes of infants with simple gastroschisis following either OPFC or SR' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of this study, therefore, was to perform a systematic review of the literature comparing outcomes of infants with simple gastroschisis following either OPFC or SR.&quot;</span> Participants, interventions, and outcomes described in Methods. [Yes]

P5. Indicate if a review protocol exists and provide registration information.
- Mentions protocol was registered with PROSPERO. [Yes]

P6. Specify study characteristics and report characteristics used as eligibility criteria. 
- Eligibility criteria on study design, participants, interventions, and outcomes described in Methods. [Yes]

P7. Describe all information sources and date last searched.
- Information sources and search dates described in Methods. [Yes]

P8. Present full electronic search strategy for at least one database.
- Search strategy not provided. [No]

P9. State the process for selecting studies.
- Study selection process described in Methods. [Yes] 

P10. Describe method of data extraction and confirmation.
- Data extraction process described in Methods. [Yes]

P11. List and define all variables for which data were sought.
- Outcomes described in Methods. [Yes] 

P12. Describe methods for assessing risk of bias. 
- Use of STROBE and GRADE mentioned but details not provided. [No]

P13. State the principal summary measures.
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Di-
chotomous outcomes were meta-analysed using Mantel–Haenszel fixed effects methods to
produce summary odds ratios with 95% confidence intervals. Continuous variables were meta-
analysed using the inverse-variance fixed-effect method to produce weighted mean differences
and 95% confidence intervals' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Dichotomous outcomes were meta-analysed using Mantel–Haenszel fixed effects methods to produce summary odds ratios with 95% confidence intervals. Continuous variables were meta-analysed using the inverse-variance fixed-effect method to produce weighted mean differences and 95% confidence intervals.&quot;</span> [Yes]

P14. Describe methods of handling and combining data.
- Fixed effect meta-analysis used due to lack of heterogeneity. Tests for heterogeneity mentioned. [Yes]

P15. Specify any assessment of risk of bias across studies.
- No assessment of publication bias mentioned. [No] 

P16. Describe methods of additional analyses, if done.
- No additional analyses mentioned. [NA]

P17. Give numbers of studies at each stage with reasons for exclusion. 
- Study flow diagram provided (Figure 1). [Yes]

P18. For each study, present pertinent characteristics and provide citations.
- Table 2 provides summary characteristics for each included study. [Yes]

P19. Present data on risk of bias for each study. 
- Risk of bias assessment for individual studies not provided. [No]

P20. Present results for each outcome, including summary data and effect estimates.
- Results provided in Table 3 and forest plots. [Yes]

P21. Present results of each meta-analysis, including confidence intervals and measures of consistency. 
- Results provided in Table 3 and forest plots. [Yes]

P22. Present results of any assessment of risk of bias across studies.
- No assessment of publication bias presented. [No] 

P23. Give results of additional analyses, if done.
- No additional analyses mentioned. [NA]

P24. Summarize main findings and discuss relevance.
- Main findings summarized in Discussion. [Yes]

P25. Discuss limitations at study and outcome level and at review level.
- Limitations discussed in Discussion. [Yes]

P26. Provide a general interpretation of results in context of other evidence.
- Results interpreted in context of previous study in Discussion. [Yes]

P27. Describe sources of funding and role of funders.
- Sources of funding described. [Yes]

In summary, for AMSTAR - yes: A1, A2, A3, A5, A6, A9. No: A4, A7, A10, A11. NA: A8.  

For PRISMA - yes: P1, P2, P3, P4, P5, P6, P7, P9, P10, P11, P13, P14, P17, P18, P20, P21, P24, P25, P26, P27. No: P8, P12, P15, P19, P22. NA: P16, P23.
</pre>
<p><a name='65'></a></p>
</div>
<div id="alzahem-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-010-2840-X' title='Open publication'>Alzahem
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the assessments for each AMSTAR and PRISMA item based on the systematic review full text:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Methods We searched MEDLINE, EMBASE, and The Cochrane Central Controlled Trials Registry for relevant randomized controlled trials and observational studies comparing laparoscopic with open inguinal hernia repair in children aged less than 19 years.&quot;</span>
No a priori design or protocol was mentioned.

A2. Was there duplicate study selection and data extraction? [No]  
"Methods Retrieved articles were assessed for eligibility and data on 
patients, intervention, control, outcomes and methodological 
quality were abstracted independently by two authors. Discrepancies 
were resolved by discussion and consensus."
Duplicate data extraction only. Duplicate study selection not mentioned.

A3. Was a comprehensive literature search performed? [Yes]
"Methods Initial electronic search yielded 290 Medline, 216 Embase, 
5 Cochrane Library (issue 2, 2010) and 7 ClinicalTrials.gov potentially relevant citations. After screening the abstracts, 48 articles were reviewed in full texts. Thirty-
four articles have met the predefined inclusion criteria (Fig. 1). Additional citations were sought using references in articles retrieved from searches. Content experts were 
contacted to identify unpublished and ongoing studies."
At least 2 databases searched plus supplementary strategies.

A4. Was the status of publication used as an inclusion criterion? [NA]  
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No] 
Included studies described in text and tables but no list of excluded studies provided. 

A6. Were the characteristics of the included studies provided? [Yes]
Characteristics of included studies provided in Table 1. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
Quality assessed using Cochrane risk of bias for RCTs and Newcastle-Ottawa scale for observational studies. Details provided in text.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
Studies limitations mentioned in discussion: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Our review’s conclusions are ham-
pered by the quality and the small sample size of the most
included studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our review’s conclusions are hampered by the quality and the small sample size of the most included studies.&quot;</span>

A9. Were the methods used to combine the findings of studies appropriate? [NA]
No meta-analysis performed for pooled results.

A10. Was the likelihood of publication bias assessed? [NA]  
No assessment of publication bias mentioned as no meta-analysis performed.

A11. Was the conflict of interest included? [No]
No statement about sources of support or conflict of interest.


P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Identified as systematic review and meta-analysis in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No] 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Rationale described in introduction: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Unresolved debate still exists regarding the benefit of using laparoscopy over conventional open inguinal hernia repair even among laparoscopic surgeons due to the concern about its higher recurrence rate [9].&quot;</span>

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned. 

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Study characteristics and eligibility criteria described in methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]  
Information sources described in methods.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Study selection process described in methods and Fig. 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]  
Data extraction described but no details on methods/forms used. No confirmation from investigators mentioned.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]  
Outcomes described but no complete list of variables provided.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes] 
Risk of bias assessment described for RCTs and observational studies. Limitations discussed.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]  
Summary measures described in analysis. 

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of bias across studies as no meta-analysis performed.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]  
Number of studies included reported but no flow diagram and no reasons for exclusions provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] 
Study characteristics presented in Table 1.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes]
Risk of bias details provided in text for each study.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [NA] 
Not applicable as no meta-analysis performed. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of bias across studies as no meta-analysis performed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]
Main findings summarized but strength of evidence not discussed.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]
Limitations discussed in context of quality of included studies.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes] 
Results interpreted and implications for future research discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] 
No statement about sources of support or conflict of interest.
</pre>
<p><a name='66'></a></p>
</div>
<div id="apelt-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.024' title='Open publication'>Apelt
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are my responses for assessing the methodological quality of this systematic review using the AMSTAR tool:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review.

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review of all publications on the laparoscopic treatment of pediatric intussusception from January 1990 to April 2012 was performed.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were non-English language articles, case reports, laparoscopic-assisted enema reduction and mixed pediatric and adult populations (age cutoff 18 years).&quot;</span>

Reasoning: The authors specified the research question, inclusion/exclusion criteria, and timeframe for study selection prior to conducting the review.

[Yes]

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. 

Relevant quotes: None provided.

Reasoning: The authors did not report on the process for study selection and data extraction.

[No]

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. 

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An online database search for all English language articles on pediatric small bowel obstruction, intussusception and laparoscopy in PubMed, Medline and Ovid from January 1990 to April 2012 was performed.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Results were confirmed by a second independent search by a different member of the team using matching search strings and databases.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Likewise, the bibliographies of identified studies were examined.&quot;</span>

Reasoning: The authors searched at least 2 databases, supplemented searches with bibliography review, but did not report search terms or strategies. 

[No]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. 

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were non-English language articles, case reports, laparoscopic-assisted enema reduction and mixed pediatric and adult populations (age cutoff 18 years).&quot;</span>

Reasoning: The authors excluded non-English studies, but did not report on inclusion/exclusion based on other publication types.

[No] 

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided.

Relevant quotes: Figure 1 shows included studies, but no excluded studies are listed. 

Reasoning: A list of included studies was provided, but not excluded studies.

[No]

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Table 1 provides specific details on the selected studies.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Overall, 10 studies were identified which included a total of 276 cases of laparoscopically treated intussusception.&quot;</span>

Reasoning: Table 1 and the results section provide aggregated details on the participants, interventions, and outcomes.

[Yes]

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.

Relevant quotes: None provided. 

Reasoning: The authors did not report assessing the quality of included studies.

[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.

Relevant quotes: None provided.

Reasoning: Study quality was not assessed.

[NA]

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).

Relevant quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Owing to the absence of any randomized controlled trials
and the heterogeneous nature of studies, a formal meta-
Fig. 1 Algorithm for the studies selection (based on PRISMA guidelines).
1790 N. Apelt et al.

analysis was not performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Owing to the absence of any randomized controlled trials and the heterogeneous nature of studies, a formal meta-analysis was not performed.&quot;</span>

Reasoning: The authors did not perform a meta-analysis due to heterogeneity.

[NA]

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). 

Relevant quotes: None provided.

Reasoning: Publication bias was not assessed.

[No]

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.

Relevant quotes: None provided.

Reasoning: Sources of support were not reported for the review or included studies. 

[No]

In summary, for the AMSTAR quality assessment, there were deficiencies in the reporting of the review methods, inclusion of grey literature, provision of excluded studies, assessment of study quality, assessment of publication bias, and reporting of conflicts of interest. However, the review did have strengths in its reporting of inclusion criteria, literature search methods, and aggregated characteristics of included studies.

Here are my responses for assessing the reporting quality of this systematic review using the PRISMA checklist:

P1. Identify the report as a systematic review, meta-analysis, or both. 

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎By reviewing available data we aimed to establish whether laparoscopy should be the primary technique in the surgical reduction of intussusception.&quot;</span>

Reasoning: The authors identified this as a systematic review. 

[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.

Relevant quotes: The abstract provides relevant information on background, objectives, eligibility criteria, participants, interventions, study selection process, results, and conclusions.

Reasoning: The abstract covers the key elements recommended for a structured summary.

[Yes]

P3. Describe the rationale for the review in the context of what is already known.

Relevant quotes: The introduction provides background and rationale on the use of laparoscopy vs laparotomy for intussusception.

Reasoning: The rationale and context are described.

[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We thus aimed to provide the data needed to challenge current clinical practice in favor of a method that allows for earlier discharge, reduced postoperative pain and decreased risk for postoperative SBO.&quot;</span>

Reasoning: The objectives relate to participants, interventions, and outcomes but comparisons and study designs are not explicitly specified.

[No] 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.

Relevant quotes: No protocol is mentioned.

Reasoning: The authors did not refer to a protocol.

[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.

Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Exclusion criteria were non-English language articles, case reports, laparoscopic-assisted enema reduction and mixed pediatric and adult populations (age cutoff 18 years).&quot;</span> 

Reasoning: Some eligibility criteria are described related to population, interventions, and publication characteristics.

[Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.

Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An online database search for all English language articles on pediatric small bowel obstruction, intussusception and laparoscopy in PubMed, Medline and Ovid from January 1990 to April 2012 was performed.&quot;</span>

Reasoning: Databases, date ranges, and last search date are reported.

[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 

Relevant quotes: A search strategy is not provided.

Reasoning: The search strategy is not presented. 

[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).

Relevant quotes: Study selection process is not described beyond the inclusion/exclusion criteria. 

Reasoning: The complete process for study screening and selection is not reported.

[No]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.

Relevant quotes: Data extraction methodology is not described.

Reasoning: The methods for data extraction are not reported.

[No] 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  

Relevant quotes: Extracted data variables are presented in Table 1 and the results section.

Reasoning: The extracted variables are not explicitly defined but are evident from the results.

[Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.

Relevant quotes: Risk of bias assessment is not described. 

Reasoning: Methods for risk of bias assessment are not reported.

[No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).

Relevant quotes: Main results are summarized as frequencies and percentages in Table 2. Mean values are provided for some variables.

Reasoning: Summary measures consist of frequencies, percentages, and means.

[Yes] 

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 

Relevant quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Owing to the absence of any randomized controlled trials
and the heterogeneous nature of studies, a formal meta-
Fig. 1 Algorithm for the studies selection (based on PRISMA guidelines).
1790 N. Apelt et al.

analysis was not performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Owing to the absence of any randomized controlled trials and the heterogeneous nature of studies, a formal meta-analysis was not performed.&quot;</span>

Reasoning: The authors did not perform a meta-analysis.

[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).

Relevant quotes: Risk of bias assessments are not described.

Reasoning: Assessment of risk of bias across studies was not performed.  

[No]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.

Relevant quotes: Additional analyses were not done.

Reasoning: No additional analyses were reported.

[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 

Relevant quotes: Figure 1 provides a flow diagram of studies screened and included. No numbers are provided for studies excluded.

Reasoning: A flow diagram tracked studies screened and included, but not reasons for exclusions.

[Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.

Relevant quotes: Table 1 presents selected characteristics and citations for the included studies.

Reasoning: Relevant extracted characteristics and citations are provided for each included study.

[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).

Relevant quotes: Risk of bias assessments are not presented.

Reasoning: Risk of bias results were not provided.

[No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 

Relevant quotes: Summary data are presented in Table 2, but not organized by intervention group or with effect estimates.

Reasoning: Outcome data are summarized for all studies together, not by intervention group with effect estimates. 

[No]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.

Relevant quotes: No meta-analysis was performed. 

Reasoning: The authors did not conduct a meta-analysis.

[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).

Relevant quotes: Assessment of risk of bias across studies was not performed.

Reasoning: Results for risk of bias assessments were not provided.

[NA] 

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).

Relevant quotes: No additional analyses were conducted.

Reasoning: Results for additional analyses were not applicable.

[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).

Relevant quotes: The discussion summarizes the main findings and contextualizes them for health providers.

Reasoning: A summary of main findings and their implications is provided.

[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).

Relevant quotes: Limitations are described in the discussion related to study design, heterogeneity, and lack of meta-analysis.

Reasoning: Limitations at the study and review level are discussed.

[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.

Relevant quotes: The discussion contextualizes findings based on other pediatric laparoscopy evidence and suggests implications for clinical practice.

Reasoning: Results are interpreted in the context of other evidence with implications described.

[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.

Relevant quotes: Sources of funding and support are not reported.

Reasoning: Funding sources were not provided.

[No]

In summary, the PRISMA reporting checklist shows strengths in the reporting of background, objectives, eligibility criteria, information sources, study characteristics, summary measures, limitations, interpretation of results, and study funding. However, deficiencies existed in reporting of the review protocol, search strategy, study selection process, data extraction process, individual study data, within-study risk of bias, across-study risk of bias, and details of any meta-analyses.

Thank you for this valuable assessment opportunity and experience. Please let me know if I can elaborate or explain any part of my review. I look forward to your feedback.
</pre>
<p><a name='67'></a></p>
</div>
<div id="aworanti-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0034-1370780' title='Open publication'>Aworanti
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
"[No]" No protocol, ethics approval, or pre-determined objectives referenced.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.  
"[NA]" The review did not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
"[Yes]" The authors searched Medline, Embase, Web of Science, and manually searched journals. This meets the criteria for at least 2 electronic sources plus supplementary searching.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit. 
"[No]" The review did not mention searching for or including grey literature.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
"[No]" No list of included/excluded studies was provided. 

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.
"[Yes]" Relevant characteristics of the included studies were provided in Tables 1 and 2.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
"[No]" The quality of included studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
"[No]" Study quality was not assessed or considered in formulating conclusions.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
"[NA]" The review did not conduct a quantitative synthesis or meta-analysis.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.  
"[NA]" Publication bias was not assessed, likely because no meta-analysis was conducted. 

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
"[No]" No conflicts of interest were reported for the review or the included studies.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]" The report is identified as a systematic review in the title.

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Management of Recurrent Tracheoesophageal Fistulas: A Systematic Review&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
"[No]" No structured abstract is provided.

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]" The introduction section provides background and rationale. 

Quotes:
"The spectrum of esophageal atresia (EA) and tracheoesopha-geal fistula (TEF) include an isolated EA, EA with a proximal and/or distal TEF and the “H” or “N” type fistula. Since the initial description of the open surgical repair1 and subsequent thoracoscopic approaches2,3 the outcomes have been very encouraging. Anastomotic leaks, esophageal strictures, gas-troesophageal reflux, and tracheomalacia are complications pediatric surgeons are familiar with. The incidence of a fistula recurrence range from 1.9 to 11% after open and thoraco-scopic repairs.2,4–8 The diagnosis of these recurrent trache-
oesophageal fistulas (RTEF) can often be elusive to the unsuspecting physician and the ideal approach to their management is still in debate. Proponents of an endoscopic approach to this problem frequently state that the morbidity, mortality, and second recurrence rate are too high with an open approach and majority directly or indirectly reference the only literature review of open surgery (OS) from 1970 by Kafrouni et al.7 Here, we reviewed the published treatment options, and their outcomes, for managing RTEF. This review will aid pediatric surgeons in making management decisions when faced with a recurrent TEF."

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
"[No]" The review does not provide an explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
"[No]" A protocol is not referenced.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
"[Yes]" The inclusion criteria specify including all English language articles published by August 2013, describing management of RTEF in children under 18 years. 

Quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

All English language articles pub-
lished by August 2013, irrespective of design, describing the
management of, and outcome after, RTEF in children under
18 years were reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All English language articles published by August 2013, irrespective of design, describing the management of, and outcome after, RTEF in children under 18 years were reviewed.&quot;</span>

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
"[Yes]" Sources searched included Medline, Embase, Web of Science. Journals were manually searched. The last search was conducted in August 2013.

Quotes:
<span title='Moderate quote deviation. Best match in fulltext (Similarity 82.4%):

A Medline, Embase, and web of science searches were performed
using the keywords recurrent tracheoesophageal fistula. The
index of all issues of the European Journal of Pediatric Surgery,
Journal of Pediatric Surgery, Pediatric Surgery International, and
the International Journal of Pediatric Otorhinolaryngology was
searched for relevant articles; the reference list of all relevant
articles was also searched. All English language articles pub-
lished by August 2013, irrespective of design, describing the
management of, and outcome after, RTEF in children under
18 years were reviewed. The' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A Medline, Embase, and web of science searches were performed using the keywords “recurrent tracheoesophageal fistula.” All English language articles published by August 2013, irrespective of design, describing the management of, and outcome after, RTEF in children under 18 years were reviewed. The reference list of all relevant articles was also searched.&quot;</span>

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
"[No]" The full search strategy is not presented for any database.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
"[No]" The study selection process is not described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  
"[No]" The data extraction process is not described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
"[No]" Variables extracted are not explicitly listed.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  
"[No]" Risk of bias or study quality assessment is not described.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
"[NA]" Summary measures are not applicable as no meta-analysis was conducted.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
"[NA]" Quantitative data synthesis methods are not described as no meta-analysis was conducted.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
"[NA]" Assessment of publication bias was not applicable as no meta-analysis was conducted.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
"[NA]" No additional analyses were reported.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
"[No]" The number of studies screened and assessed is not reported. No flow diagram is provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
"[Yes]" Study characteristics are presented in Tables 1 and 2. Citations are provided.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
"[NA]" Risk of bias was not assessed for individual studies.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
"[NA]" Outcome data and effect estimates are not presented for individual studies. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
"[NA]" No meta-analysis was conducted.

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
"[NA]" Assessment of risk of bias across studies was not done.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
"[NA]" No additional analyses were reported.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
"[Yes]" The main findings are summarized in the conclusion section.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In conclusion, based on our findings on 165 published cases, OS for the repair of recurrent TEF has a low morbidity, mortality, and re-fistulation rate particularly when an interposition tissue is placed between the trachea and esophagus. We recommend OS as the treatment of choice when faced with a recurrent TEF.&quot;</span>

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
"[No]" Limitations at the study or review level are not discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.  
"[Yes]" The results are discussed in the context of previous reviews of endoscopic treatment. Implications for future research are provided.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Further clinical trials and controlled experiments are necessary to devise the technique and ideal, preferably nonbiodegradable, sealant that guarantees a definitive endoscopic closure of a recurrent TEF after one attempt.&quot;</span>

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
"[No]" Sources of funding and support are not reported.

In summary, the review adequately addressed some PRISMA and AMSTAR items such as providing rationale (P3), specifying eligibility criteria (P6), searching multiple databases (A3), and providing study characteristics (P18, A6). However, several key items were not addressed including providing a protocol, search strategy, study selection process, data extraction process, study quality assessment, evaluation of publication bias, limitations, and conflicts of interest. Additional details should be reported to improve the transparency and reliability of the review methodology.
</pre>
<p><a name='68'></a></p>
</div>
<div id="baker-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.021' title='Open publication'>Baker
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the extracted quotes, reasoning, and responses for each AMSTAR and PRISMA item for the attached systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Reference lists from the re-
trieved articles were then hand searched to identify additional po-
tentially relevant articles' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References lists from the retrieved articles were then hand searched to identify additional potentially relevant articles.&quot;</span> (p. 719)
- The research question and inclusion criteria appear to have been established before conducting the review, based on the description of the systematic search strategy.
[Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Screening of eligible studies, data extraction, and assessment of methodological quality were conducted independently by two reviewers.&quot;</span> (p. 719)  
- Two independent reviewers performed study selection and data extraction.
[Yes]

A3. Was a comprehensive literature search performed?
- The search included two electronic databases (MEDLINE, EMBASE), plus CINAHL, Scopus, Cochrane Library, and hand searching references. No language or date restrictions. Search strategy provided. (p. 719)
- Search meets criteria for comprehensive.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding based on publication status.
[No]  

A5. Was a list of studies (included and excluded) provided?
- List of included studies provided in Table 1. No list of excluded studies.
[No]

A6. Were the characteristics of the included studies provided? 
- Study characteristics including number of patients, interventions, complications, and MINORS score provided in Table 1.
- Aggregate patient demographics described in the text.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- MINORS tool used to assess quality of included studies. Score provided for each study in Table 1.  
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Limitations due to retrospective nature of studies and potential for selection bias discussed.
- Quality assessment not explicitly discussed in relation to conclusions.
[No]

A9. Were the methods used to combine the findings of studies appropriate?  
- For meta-analysis, fixed effect and random effects models used. Heterogeneity assessed.
- Narrative synthesis used to summarize non-meta-analyzed data. 
[Yes]

A10. Was the likelihood of publication bias assessed?
- Funnel plot generated to assess publication bias for LAP vs PEG analysis. No evidence of asymmetry noted. (p. 722)
[Yes]

A11. Was the conflict of interest included?
- No statement about sources of support or conflicts of interest.
[No]


P1. Identify the report as a systematic review, meta-analysis, or both.
- Identified as systematic review and meta-analysis in title.
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Structured abstract provided with all relevant sections.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Rationale and context described in Introduction.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
- Research objective clearly stated to compare complication rates between gastrostomy techniques. Participants, interventions, comparisons, outcomes described. No mention of study designs.
[No]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No protocol mentioned.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Inclusion and exclusion criteria specified, including participants, interventions, comparisons, and outcomes. No exclusions based on languages or publication status.
[Yes] 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
- Databases, date ranges, and supplementary hand searching described. Date of last search provided.
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- Full search strategy provided for Ovid MEDLINE. 
[Yes]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Study selection process described.
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
- Independent duplicate data extraction mentioned. No details provided about forms or process.
[No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- Outcomes extracted described. No list of other variables extracted.
[No] 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- MINORS used to assess quality/risk of bias. Limitations discussed in interpretation of results.
[Yes]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- Odds ratios and mean differences reported where applicable. 
[Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
- Use of fixed and random effects models described. Heterogeneity assessed using I2.
[Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- Publication bias assessed through funnel plot.
[Yes]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses mentioned.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- Number of studies at each stage reported. Flow diagram provided. Reasons for exclusions not provided.
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
- Study characteristics presented in Table 1. Citations provided.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- MINORS score presented for each study in Table 1.
[Yes]  

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- Complication rates by study provided in Table 1. Forest plots provided for meta-analyses. 
[Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- Results of meta-analyses presented with CIs and I2 values.
[Yes]

P22. Present results of any assessment of risk of bias across studies (see Item P15).
- No assessment of risk of bias across studies besides funnel plot.
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses conducted.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Main findings summarized in Discussion. Importance and relevance described.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations discussed related to study design, heterogeneity, potential biases.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted in context of previous research. Implications for practice and future research described.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
- No statement about sources of funding or support.
[No]

In summary, I have provided the requested quotes, reasoning, and responses for each of the 11 AMSTAR and 27 PRISMA items for this systematic review. Let me know if you need anything else!
</pre>
<p><a name='69'></a></p>
</div>
<div id="berger-2012" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0032-1311695' title='Open publication'>Berger
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘missing-squared-brackets-in-numbered-list’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments based on the full text:

A1. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span> - No protocol mentioned.
A2. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 34.8%):

review), based on their publication status, language etc. Note: If review indicates that there' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎One reviewer extracted data from the original publications and a senior reviewer checked the data and the reliability of the analysis, including Independent reviews of the articles.&quot;</span>
A3. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 31.1%):

esophageal stenosis and
stricture with special emphasis on pediatric data. The screen
included the use of Mitomycin C' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Databases searched included: PubMed, Scopus, Web of Science, June 2011. Key words used in different cross-combinations: esophagus, esophageal, stenosis, stricture, corrosive, caustic, mitomycin C.&quot;</span>
A4. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span> - Grey literature not mentioned.
A5. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Review article. 
A6. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45%):

reened for publications regard-
ing the application of Mitomycin C in esophageal stenosis and
stricture with special emphasis on pediatric data. The screen
included the use of Mitomycin C in' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data extracted from the reports included patient demographics, indication for Mitomycin C application, stricture characteristics, dosage, regimen and technique of Mitomycin C administration, adverse events, and outcomes.&quot;</span> Tables 2 and 3 provide details on patients and outcomes.
A7. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Not assessing quality of individual studies.
A8. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Not assessing quality of individual studies.  
A9. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis.
A10. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis.
A11. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No primary studies, review article.

P1. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Identified as a systematic review in title.
P2. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Provides structured abstract with background, objectives, data sources, eligibility criteria, results, and conclusions.  
P3. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Describes rationale and need for review in introduction.
P4. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Research questions and inclusion criteria explained in methods.
P5. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span> - No protocol mentioned.
P6. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Inclusion criteria described, case reports and case series in English, German, Spanish included.
P7. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Databases and dates listed in methods. 
P8. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span> - Full search strategy not provided.
P9. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Process of screening and selecting studies not described because review article.
P10. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Data extraction process not described because review article.
P11. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Variables extracted described in methods.
P12. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Did not assess risk of bias, review article.
P13. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.
P14. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.
P15. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.  
P16. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.
P17. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Review article.
P18. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Key details of included cases provided in Tables 2 and 3.
P19. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - Did not assess risk of bias, review article.
P20. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.
P21. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.
P22. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.
P23. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No meta-analysis performed.
P24. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Main findings summarized in discussion and conclusion.
P25. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Limitations discussed.
P26. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span> - Interpretation of results and implications described in conclusion.
P27. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> - No funding sources for this review article.

In summary, this review article appropriately reported on most relevant PRISMA items but lacked some key components of AMSTAR like a protocol, search strategy, and assessment of publication bias. The overall quality of this review seems moderate. Let me know if you need any clarification or have additional questions!
</pre>
<p><a name='70'></a></p>
</div>
<div id="billingham-2010" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0029-1241871' title='Open publication'>Billingham
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are my responses to assessing the methodological quality of this systematic review using the AMSTAR tool:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review.
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

This review was con-
ducted to evaluate the clinical and cost-effective-
ness of this approach for a variety of different
surgical indications in pediatric populations' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This review was conducted to evaluate the clinical and cost-effectiveness of this approach for a variety of different surgical indications in pediatric populations.&quot;</span>
- Clearly stated objective and inclusion criteria before conducting the review.
[Yes]

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.  
- No mention of duplicate study selection or data extraction.
[No]

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.
- Searched multiple electronic databases, along with supplementary search methods. Provided keywords used.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. 
- No mention of searching for grey literature.
[No] 

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided.
- Included studies summarized in Table 1. No list of excluded studies.
[No]

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.
- Table 1 provides summary of study design and quality. Outcomes summarized in text and figures. Limited details on patient characteristics. 
[No]

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
- Assessed quality using established criteria, summarized in Table 1.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.
- Does not explicitly discuss limitations of included study quality when interpreting results.
[No]

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).
- Used appropriate statistical methods for meta-analysis (mean differences, tests for heterogeneity).
[Yes]

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).
- No assessment of publication bias.
[No]

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
- No statement on conflict of interest.
[No]

In summary, this systematic review adequately addressed some but not all key methodological criteria based on the AMSTAR quality assessment tool. Additional details on study selection methods, grey literature searching, included/excluded studies, and consideration of study limitations when interpreting results would improve confidence in the review findings.

Here are my responses for assessing the reporting quality using the PRISMA checklist:

P1. Identify the report as a systematic review, meta-analysis, or both. 
- Identified as a systematic review and meta-analysis in title.
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Abstract provides structured summary covering background, objectives, methods, results, and conclusions.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Introduces topic and rationale for review.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- Clear objective and inclusion criteria stated in methods section.
[Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No mention of a review protocol.
[No] 

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Inclusion and exclusion criteria specified.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
- Databases and search methods described. No dates provided.
[No]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- Did not provide full search strategy.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Study selection process described.
[Yes]  

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
- No details provided on data extraction process.
[No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- Outcomes of interest listed in methods. No other details on variables extracted.
[Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
- Assessed study quality/risk of bias using established criteria.
[Yes]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- Used mean differences as summary measures.
[Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
- Described statistical methods, including tests for heterogeneity.
[Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- No assessment of publication bias or other biases.
[No]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
- Number of included studies provided. No flow diagram or number screened/assessed/excluded.
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
- Table 1 presents summary data on study characteristics and citations provided.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- Study quality assessed in Table 1, but no outcome-level assessment.
[Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- Summary data and forest plots presented for main outcomes.
[Yes] 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- Meta-analysis results presented with CIs and measures of heterogeneity. 
[Yes]

P22. Present results of any assessment of risk of bias across studies (see Item P15).
- No assessment of risk of bias across studies.
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses done.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Conclusions summarize main findings and relevance.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations of review discussed.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted in context of other evidence and implications for future research discussed.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
- No statement on sources of funding or support.
[No]

In summary, this systematic review addressed many but not all of the PRISMA reporting criteria. Additional details on the review protocol, search dates, full search strategies, data extraction methods, study selection flow, and assessment of bias across studies would improve reporting per the PRISMA guideline.
</pre>
<p><a name='71'></a></p>
</div>
<div id="black-2013" class="section level4">
<h4><a href='https://doi.org/10.1111/OBR.12037' title='Open publication'>Black
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are the key AMSTAR items for the given systematic review:

A1. Was an 'a priori' design provided? 
[No] No mention of a protocol.

A2. Was there duplicate study selection and data extraction?
[No] Only states <span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Two
authors independently screened the abstracts and extrac-
tion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;</span> No mention of duplicate data extraction.

A3. Was a comprehensive literature search performed? 
[Yes] Searched EMBASE, Medline, Cochrane Library, reference lists, and hand searched Obesity Surgery. Search terms and inclusion/exclusion criteria provided. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
[No] No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided?
[Yes] Figure 1 shows flow of included and excluded studies. References list included studies.

A6. Were the characteristics of the included studies provided?
[Yes] Table 2 provides characteristics of included studies.  

A7. Was the scientific quality of the included studies assessed and documented?
[No] No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[NA] No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate?  
[Yes] Used random effects model meta-analysis with assessment of heterogeneity. 

A10. Was the likelihood of publication bias assessed?
[No] Publication bias not assessed.

A11. Was the conflict of interest included?
[No] No statement about conflicts of interest.

In summary, the key issues with this review are the lack of duplicate data extraction, lack of quality assessment of included studies, and no assessment of publication bias. The search and selection process seems adequate, and the meta-analysis methods appropriate. More rigor in data collection and assessment of bias/quality would strengthen the review.

For the PRISMA items:

P1. Identify the report as a systematic review, meta-analysis, or both. 
[Yes] Identified as systematic review and meta-analysis in title.

P2. Provide a structured summary including key elements.
[Yes] Abstract provides structured summary.

P3. Describe the rationale for the review in context of what is already known. 
[Yes] Introduction summarizes previous research and rationale.

P4. Provide an explicit statement of questions being addressed. 
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] Questions not explicitly stated but implicit in aims. 

P5. Indicate if a review protocol exists and provide registration information.
[No] No protocol mentioned.

P6. Specify study characteristics used as criteria for eligibility. 
[Yes] Inclusion criteria described in methods.

P7. Describe all information sources in the search and date last searched.
[Yes] Search strategy provided with databases and date ranges.

P8. Present full electronic search strategy for at least one database. 
[Yes] Search strategy provided for Embase and Medline.

P9. State the process for selecting studies.
[Yes] Study selection process described and shown in Figure 1.

P10. Describe method of data extraction and confirmation.
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] Data extraction described but no duplicate extraction.

P11. List and define all variables for which data were sought.
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] Extracted characteristics described but definitions not provided. 

P12. Describe methods for assessing risk of bias of individual studies. 
[No] No risk of bias assessment described.

P13. State the principal summary measures.
[Yes] Mean BMI difference was the summary measure. 

P14. Describe the methods of handling data and combining results.
[Yes] Describes use of random effects meta-analysis and assessment of heterogeneity.

P15. Specify any assessment of risk of bias across studies.
[No] No assessment of publication bias or other meta-biases.

P16. Describe methods of additional analyses, if done.
[NA] No additional analyses conducted.

P17. Give numbers of studies screened, assessed, and included with reasons for exclusion. 
[Yes] Screening and selection provided in Figure 1.

P18. For each study, present pertinent characteristics.
[Yes] Table 2 provides key characteristics of included studies.

P19. Present data on risk of bias for each study. 
[No] No assessment of bias for individual studies.

P20. Present results for each study and meta-analysis. 
[Yes] Table 2 and Figure 2 provide individual and meta-analysis results.

P21. Present results of any meta-analyses done, including heterogeneity. 
[Yes] Figure 2 shows meta-analysis results with heterogeneity metrics.

P22. Present results of any assessment of bias across studies.
[No] No assessment of publication bias or other meta-biases. 

P23. Give results of any additional analyses.
[NA] No additional analyses conducted.

P24. Summarize the main findings including strength of evidence.
[Yes] Provides summary of main findings and limitations in discussion.

P25. Discuss limitations at study and outcome level, and at review level.
[Yes] Limitations discussed.

P26. Provide a general interpretation of results in context of other evidence.
[Yes] Results discussed and compared to previous reviews.

P27. Describe sources of funding and role of funders.
[No] No statement about funding sources.

In summary, the key issues with reporting are lack of protocol registration, no assessment of risk of bias for individual studies, no assessment of publication bias or meta-biases, and no statement about funding sources. Otherwise, PRISMA items adequately addressed. More attention to bias assessment and transparent reporting would strengthen the review.
</pre>
<p><a name='72'></a></p>
</div>
<div id="borruto-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2010.07.007' title='Open publication'>Borruto
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. [No]
No mention of an a priori protocol.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. [No]
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A literature search was performed, using Medline and Pubmed database, on all articles published during the last 10 years (2000-2009), reporting on varicocele treatments.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. [No]
No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. [Yes]
Table 1 provides characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. [No] 
No quality assessment of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). [Yes]
Meta-analysis used with calculation of odds ratios.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). [No]
No assessment of publication bias. 

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. [No]
No statement on conflict of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [No]
Not identified as a systematic review or meta-analysis.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Background section describes rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No mention of protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [No]
Study eligibility criteria not explicitly specified.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Medline and PubMed searched from 2000-2009. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No]  
No details on study selection process.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No data extraction methodology described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Outcomes not pre-defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]  
Odds ratios reported.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Meta-analysis methods described. 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No] 
No assessment of publication bias or selective reporting.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
Number of studies included reported but not screened or assessed for eligibility. No flow diagram. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [No]
No detailed data extraction for each study.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA] 
No risk of bias assessment performed.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Forest plots presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes] 
Results of meta-analyses presented.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]  
No additional analyses done.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]
No summary of main findings.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]
No discussion of limitations.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [No]
No interpretation of results in context of other evidence.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]  
No statement on sources of funding or support.
</pre>
<p><a name='73'></a></p>
</div>
<div id="castagnetti-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JURO.2010.06.044' title='Open publication'>Castagnetti
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are my responses to the AMSTAR and PRISMA assessments:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Hypospadias&quot;</span> was the only search term mentioned. No protocol, ethics approval, or pre-determined objectives were referenced.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Three doctors reviewed the abstracts. Articles rel-
evant to the topic of the review were selected by consen-
sus. A second review was performed of these studies and
their bibliographies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three doctors reviewed the abstracts. A second review was performed of these studies and their bibliographies.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
Four databases were searched and supplementary strategies like checking references were used. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No] 
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table provides overview of studies included.

A7. Was the scientific quality of the included studies assessed and documented? [No]
Studies were categorized by level of evidence, but no quality assessment is described. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [No] 
No quality assessment was documented.

A9. Was the methods used to combine the findings of studies appropriate? [NA]
No quantitative synthesis done. 

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No] 
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60%):

N
The present review' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎In the present review study...&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
No structured summary provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Introduction provides context and rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion criteria focused on primary repair of severe hypospadias. Rationale provided in introduction. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]  
Four databases searched described. December 2009 stated as last search date.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
No full search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Screening process described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No data extraction process described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
No list of variables provided.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No] 
No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA] 
No quantitative synthesis performed.

P14-P23. [NA]
No quantitative synthesis performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings and conclusions summarized.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]  
Limitations of included studies and review discussed. 

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of field. Recommendations for future research provided.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No mention of funding sources.
</pre>
<p><a name='74'></a></p>
</div>
<div id="castagnetti-2016" class="section level4">
<h4><a href='https://doi.org/10.3389/FPED.2016.00041' title='Open publication'>Castagnetti
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the provided systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 82.8%):

A systematic search of the literature published after 06/1995
was performed in 06/2015 using the keyword “hypospadias' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎[We performed a systematic review of the literature published after 06/1995 was performed in 06/2015 using the keyword “hypospadias."]&quot;</span>
The review protocol was pre-determined. [Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction. [No] 

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Three databases, namely, MEDLINE/PubMed, Scopus,
and The Cochrane library, were searched for using the free text
“hypospadias repair,” in all fields of the records for MEDLINE/
PubMed search, and in the Title and Topic fields for the Web of
Science and Cochrane library searches' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Three databases, namely, MEDLINE/PubMed, Scopus, and The Cochrane library, were searched for using the free text “hypospadias repair,” in all fields of the records for MEDLINE/PubMed search, and in the Title and Topic fields for the Web of Science and Cochrane library searches.]&quot;</span>
At least two electronic databases were searched. [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
No mention of including or excluding grey literature. [No]

A5. Was a list of studies (included and excluded) provided?
Figure 1 provides a flow diagram of included and excluded studies. [Yes]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies. [Yes] 

A7. Was the scientific quality of the included studies assessed and documented?
The Oxford Level of Evidence was provided for each study in Table 1, but no quality assessment of individual studies. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]

A9. Were the methods used to combine the findings of studies appropriate?
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):

a meta-analysis
of case–control and randomized studies comparing PR vs.
circumcision was performed. Two different outcomes were used
for the meta-analysis, namely, “hypospadias fistula formation”
and “overall reoperation rate.” The analysis was conducted using
Review Manager v5.2 software designed for composing Cochrane
Reviews (Cochrane Collaboration, Oxford, UK). Statistical heter-
ogeneity was tested using the chi-square test' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[A meta-analysis of studies comparing PR vs. circumcision was performed for the outcomes “hypospadias fistula formation” and “reoperation rate.” The analysis was conducted using Review Manager v5.2 software designed for composing Cochrane Reviews (Cochrane Collaboration, Oxford, UK). Statistical heterogeneity was tested using the chi-square test.]&quot;</span> [Yes]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
No conflict of interest statement. [No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We performed a systematic review of the literature on PR during hypospadias repair to determine the cumulative risk of specific complications related to the procedure. Moreover, we performed a meta-analysis of studies comparing urethroplasty complications and reoperation rates in patients undergoing hypospadias repair associated with PR vs. circumcision to test the hypothesis that circumcision is associated with a lower rate of complications related to the urethroplasty, namely, fistula rate, and a lower reoperation rate.&quot;</span> [Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
The abstract provides a structured summary. [Yes]

P3. Describe the rationale for the review in the context of what is already known.
The introduction provides context and rationale. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
The objectives and inclusion criteria are specified in the methods section. [Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No] 

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Study selection criteria are described in the methods section. [Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Databases and date ranges are provided. [Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
The process for study screening and selection is described and shown in Figure 1. [Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 
Outcomes extracted are described in the data extraction section. [Yes] 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Odds Ratios (OR) and 95% confidence intervals (OR 95% CI) were calculated to determine the influence of PR on the selected outcome.&quot;</span> [Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA] 

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
A flow diagram of study selection is provided in Figure 1. [Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
Table 1 presents study characteristics. [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Table 2 and Figures 2 and 4 provide summary data and forest plots. [Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency (e.g., I2) for each meta-analysis. [NA] 

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
The conclusion summarizes the main findings. [Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Limitations are discussed in the final paragraph. [Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
The results are interpreted in the context of other evidence. [Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
</pre>
<p><a name='75'></a></p>
</div>
<div id="chan-2014-pediatr-surg-int" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-013-3429-Y' title='Open publication'>Chan
2014 (Pediatr Surg Int)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the provided full text:

A1. [NA]

A2. [NA] 

A3. [NA]

A4. [NA] 

A5. [NA]

A6. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.&quot;</span> [No] No quality assessment is reported.

A7. [NA] 

A8. [NA] 

A9. [NA]

A10. [NA] 

A11. [NA]

P1. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 82.5%):

Ideal timing of orchiopexy: a systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Abstract: Ideal timing of orchiopexy: a systematic review&quot;</span>

P2. [Yes] The abstract provides relevant background, objectives, data sources, eligibility criteria, methods, results, limitations and conclusions. 

P3. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.2%):

The ideal management of cryptorchidism is a
highly debated topic within the field of pediatric surgery.
The optimal timing of orchiopexy is particularly unclear, as
existing literature reports mixed recommendations' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The ideal timing of orchiopexy is a highly debated topic within the field of pediatric surgery. The optimal timing of orchiopexy is particularly unclear, as existing literature reports mixed recommendations.&quot;</span>

P4. [No] The review does not provide explicit PICOS criteria.

P5. [No] A protocol is not mentioned.

P6. [No] Study characteristics used as eligibility criteria are not explicitly specified.

P7. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), Embase (1980 onwards), and CINAHL (1982 onwards) to find relevant articles.&quot;</span>

P8. [No] A full electronic search strategy is not provided.

P9. [Yes] The process of study screening and selection is described and illustrated in a flow diagram. 

P10. [No] Methods for data extraction are not described. 

P11. [No] Variables extracted are not explicitly listed.

P12. [No] Methods for assessing risk of bias are not described.

P13. [NA] 

P14. [NA]

P15. [NA]

P16. [NA]

P17. [Yes] The number of studies screened, assessed for eligibility, and included is provided in a flow diagram. Reasons for exclusion are not explicitly stated.

P18. [No] Study characteristics are not presented for included studies.

P19. [No] Risk of bias is not presented for included studies. 

P20. [No] Study results are summarized narratively but not presented quantitatively. 

P21. [NA]

P22. [NA] 

P23. [NA]

P24. [Yes] The abstract summarizes the main findings and conclusions.

P25. [No] Limitations are not discussed.

P26. [No] Implications for future research are not explicitly discussed.

P27. [No] Sources of funding and support are not reported.

In summary, the review does not report on assessment of study quality, risk of bias, or sources of funding. The review methods and reporting are limited with respect to explicit documentation of eligibility criteria, search strategy, data extraction, variables extracted, and presentation of individual study characteristics and results. As a non-systematic narrative review, its methods do not adhere fully to PRISMA guidelines for systematic reviews. Caution should be exercised in interpreting the review findings.
</pre>
<p><a name='76'></a></p>
</div>
<div id="chan-2014-j-pediatr-surg" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2014.02.049' title='Open publication'>Chan
2014 (J Pediatr Surg)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and the reporting quality using PRISMA for the attached systematic review:

A1. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[We sought all publications describing both techniques through MEDLINE, Embase, and CENTRAL.]&quot;</span>
Clear statement of searching multiple databases. [Yes]

A2. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Two researchers independently assessed each study and compared their scores for each item to reach a consensus. If an agreement could not be reached, they consulted a third researcher.]&quot;</span>
Duplicate study selection and data extraction described. [Yes]

A3. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

Our initial search of MEDLINE, Embase and CENTRAL yielded 160
studies (Fig. 1). After applying our exclusion criteria, 9 studies
remained. We identified one additional relevant study through hand-
searching, thus we included 10 studies in total [8–17' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Our initial search of MEDLINE, Embase and CENTRAL yielded 160 studies (Fig. 1). After applying our exclusion criteria, 9 studies remained. We identified one additional relevant study through hand-searching, thus we included 10 studies in total [8–17].]&quot;</span>
Comprehensive search including ≥2 databases, supplementary search, and references screened. [Yes] 

A4.
No mention of searching for grey literature. [No]

A5. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fig. 1. Electronic search strategy and results.&quot;</span>
Flow diagram depicts included and excluded studies. [Yes]

A6. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Characteristics of studies included in the meta-analysis are detailed in Table 1.&quot;</span> 
Table 1 provides aggregated details on participants, interventions, and outcomes. [Yes]

A7.
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.7%):

Two researchers independently assessed each study for method-
ological quality using MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two researchers independently assessed each study for methodological quality using MINORS.]&quot;</span>
MINORS tool used to assess quality. [Yes]

A8.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Our results should be interpreted with caution owing to the nature of the included studies. All were retrospective and are thus vulnerable to selection bias.]&quot;</span>
Limitations due to study quality mentioned in conclusions. [Yes]

A9. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):

For
each outcome, we first assessed the heterogeneity of the studies (Chi 
2
test and I 
2 
statistic). When heterogeneity was low to moderate (Q test
p N 0.10, I 
2 
b 50%), we used a fixed-effects model. When heterogeneity
was moderate to high (Q test p b 0.10, I 
2 
N 50%), we used a random-
effects model [7]. We used weighted mean differences to analyze
continuous data and odds ratios to analyze categorical variables' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[For each outcome, we first assessed the heterogeneity of the studies (Chi2 test and I2 statistic)...We used weighted mean differences to analyze continuous data and odds ratios to analyze categorical variables.]&quot;</span>
Statistical tests for heterogeneity described. [Yes]

A10.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fig. 2. Funnel plot of included studies for recurrence of Bochdalek-type hernia.&quot;</span>
Funnel plot assessed publication bias. [Yes]

A11.
No mention of conflicts of interest. [No]

P1. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis&quot;</span>
Identified as a meta-analysis. [Yes]

P2.
Abstract provides structured summary. [Yes]

P3. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Controversy exists regarding which operative technique (MIS or open surgery) leads to the best outcomes, particularly with respect to recurrence of the CDH.&quot;</span>
Context and rationale described. [Yes]

P4.
No explicit PICOS statement. [No]  

P5.
No mention of a review protocol. [No]

P6.
Inclusion/exclusion criteria described. [Yes]

P7. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[We conducted an electronic search of MEDLINE (1966 onwards), Embase (1980 onwards), and the Cochrane Central Register of Controlled Trials (CENTRAL).]&quot;</span>
Information sources described. [Yes]

P8.
No full search strategy provided. [No]

P9. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fig. 1. Electronic search strategy and results.&quot;</span>
Study selection process shown in flow diagram. [Yes]

P10.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Two researchers independently assessed each study and compared their scores for each item to reach a consensus. If an agreement could not be reached, they consulted a third researcher.]&quot;</span>
Data extraction process described. [Yes] 

P11.
Outcomes described but no list of variables. [No]

P12.
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.7%):

Two researchers independently assessed each study for method-
ological quality using MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two researchers independently assessed each study for methodological quality using MINORS.]&quot;</span>
Individual study risk of bias assessed with MINORS tool. [Yes]

P13.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[We used weighted mean differences to analyze continuous data and odds ratios to analyze categorical variables.]&quot;</span> 
Summary measures described. [Yes]

P14.
Statistical tests for heterogeneity described. [Yes]

P15.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fig. 2. Funnel plot of included studies for recurrence of Bochdalek-type hernia.&quot;</span>
Publication bias assessed with funnel plot. [Yes]

P16.
No additional analyses described. [NA]

P17.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fig. 1. Electronic search strategy and results.&quot;</span>
Flow diagram shows numbers at each stage. [Yes] 

P18. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Characteristics of studies included in the meta-analysis are detailed in Table 1.&quot;</span>
Study characteristics presented. [Yes]

P19.
No individual study risk of bias results presented. [No]

P20.
Forest plots with effect sizes presented. [Yes] 

P21. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):

For
each outcome, we first assessed the heterogeneity of the studies (Chi 
2
test and I 
2 
statistic). When heterogeneity was low to moderate (Q test
p N 0.10, I 
2 
b 50%), we used a fixed-effects model. When heterogeneity
was moderate to high (Q test p b 0.10, I 
2 
N 50%), we used a random-
effects model [7]. We used weighted mean differences to analyze
continuous data and odds ratios to analyze categorical variables' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[For each outcome, we first assessed the heterogeneity of the studies (Chi2 test and I2 statistic)...We used weighted mean differences to analyze continuous data and odds ratios to analyze categorical variables.]&quot;</span>
Meta-analysis methods and heterogeneity described. [Yes]

P22.
No assessment of risk of bias across studies. [NA]  

P23. 
No additional analyses. [NA]

P24.
Main findings and limitations summarized. [Yes]

P25. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Our results should be interpreted with caution owing to the nature of the included studies. All were retrospective and are thus vulnerable to selection bias.]&quot;</span> 
Study and outcome limitations discussed. [Yes]

P26. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Surgeons should carefully consider the potential morbidity associated with MIS when deciding on a repair method.&quot;</span>
Results interpreted and implications described. [Yes]

P27.
No statement on sources of funding. [No]
</pre>
<p><a name='77'></a></p>
</div>
<div id="chang-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00345-015-1526-3' title='Open publication'>Chang
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my responses for the AMSTAR and PRISMA items based on the full text:

A1. "[No]": No protocol or pre-determined objectives mentioned.
A2. "[Yes]": Two authors independently did literature search and data extraction. 
A3. "[Yes]": Searched PubMed database, supplemented by reviewing references.
A4. "[No]": Did not search for or indicate inclusion of grey literature.  
A5. "[No]": Did not provide list of excluded studies.
A6. "[Yes]": Provided summary data on patient characteristics in Table 1.
A7. "[No]": Did not assess quality or risk of bias of included studies.
A8. "[NA]": Not applicable since did not assess quality/risk of bias (A7 is No).
A9. "[NA]": Not applicable since no meta-analysis done.
A10. "[NA]": Not applicable since no meta-analysis done.  
A11. "[No]": Did not report on conflicts of interest or study funding.

P1. "[Yes]": Identified as systematic review and meta-analysis in title.
P2. "[No]": Structured abstract but missing some key elements like study selection, risk of bias, conclusions.
P3. "[Yes]": Described rationale and existing evidence in introduction.
P4. "[No]": Did not provide focused question with PICOS elements.
P5. "[No]": Did not mention protocol or registration.
P6. "[Yes]": Reported eligibility criteria and study characteristics in methods.  
P7. "[Yes]": Described literature search strategy and databases searched.
P8. "[No]": Did not provide full search strategy for at least one database.
P9. "[Yes]": Described study selection process and numbers at each stage in Figure 1. 
P10. "[Yes]": Stated two authors independently extracted data.
P11. "[No]": Did not provide list of data items sought.
P12. "[No]": Did not describe risk of bias assessment methods.
P13. "[NA]": Not applicable since no meta-analysis done.
P14. "[NA]": Not applicable since no meta-analysis done.
P15. "[NA]": Not applicable since no meta-analysis done.
P16. "[NA]": Not applicable since no meta-analysis done.
P17. "[Yes]": Provided study flow diagram with numbers at each stage (Figure 1).
P18. "[No]": Did not provide citations for included studies.
P19. "[No]": Did not assess risk of bias of individual studies.
P20. "[NA]": Not applicable since no meta-analysis done.
P21. "[NA]": Not applicable since no meta-analysis done. 
P22. "[NA]": Not applicable since no meta-analysis done.
P23. "[NA]": Not applicable since no meta-analysis done.
P24. "[No]": Did not provide summary of main findings or certainty of evidence.
P25. "[No]": Did not discuss limitations at study or review level.
P26. "[No]": Did not provide general interpretation of results.
P27. "[No]": Did not report on sources of funding or support.
</pre>
<p><a name='78'></a></p>
</div>
<div id="chen-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2012.12.036' title='Open publication'>Chen
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the assessments for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 50.7%):

patients; 444 underwent
TERPT and 348 underwent' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎patients underwent TERPT and TAB between 1990 to 2008 at each centre.&quot;</span> [p.642]
- No protocol mentioned. 
[No]

A2. Was there duplicate study selection and data extraction?
- Reviewers independently selected studies and extracted data. Disagreements resolved by consensus. [p.642]
[Yes]  

A3. Was a comprehensive literature search performed?
- Searched Medline, Embase, Cochrane library from 1998 to 2012. Reference lists manually searched. [p.642]
[Yes]

A4. Was the status of publication used as an inclusion criterion?  
- No mention of including or excluding based on publication status.
[NA]

A5. Was a list of studies (included and excluded) provided?
- Provided a flow chart showing included and excluded studies. [Fig. 1, p.643]
[Yes]

A6. Were the characteristics of the included studies provided?
- Provided characteristics of included studies in tables. [Tables 1-2, pp.644-646]
[Yes]  

A7. Was the scientific quality of the included studies assessed and documented?
- No quality assessment mentioned.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
- Did not assess quality of studies. 
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
- Assessed heterogeneity with I2 statistic. Used fixed effects model for I2 < 50% and random effects model for I2 ≥ 50%. [p.642] 
[Yes]

A10. Was the likelihood of publication bias assessed?
- Did not assess publication bias.
[No]

A11. Was the conflict of interest included?
- No conflict of interest mentioned for included studies or review itself.
[No]


P1. Identify the report as a systematic review, meta-analysis, or both.
- Identified as systematic review and meta-analysis in title. [p.642]
[Yes]

P2. Provide a structured summary.
- Provided structured abstract with objectives, data sources, participants, interventions, results, and conclusions. [p.642]
[Yes] 

P3. Describe the rationale for the review.  
- Described rationale that benefits of TERPT over TAB are still unclear. [p.642]
[Yes]

P4. Provide objectives with reference to PICOS.
- Stated objective to compare clinical outcomes of TERPT and TAB. Participants, interventions, comparisons described. [p.642]
[Yes]

P5. Indicate if a protocol exists.
- No protocol mentioned.
[No]  

P6. Specify study characteristics used as eligibility criteria.
- Inclusion criteria were studies comparing TERPT and TAB. Excluded studies with different data types. [p.642]
[Yes]

P7. Describe information sources and dates last searched.
- Searched Medline, Embase, Cochrane library from 1998 to March 2012. Reference lists manually searched. [p.642]
[Yes]

P8. Present full electronic search strategy.
- Did not provide full search strategy.
[No]

P9. Describe process of screening and selecting studies.  
- Described process of screening, eligibility assessment, and selection in text and flow chart. [p.642, Fig. 1]
[Yes]

P10. Describe methods of data extraction.
- Stated data extracted by 3 independent reviewers. Disagreements resolved by consensus. [p.642]  
[Yes]

P11. List and define all variables extracted.
- Listed outcomes evaluated including operative time, hospital stay, incontinence, constipation, enterocolitis. [p.642]
[Yes]

P12. Describe methods for assessing risk of bias. 
- Did not assess risk of bias.
[NA]

P13. Describe principal summary measures.
- Stated pooled ORs calculated for dichotomous outcomes and pooled MDs for continuous outcomes. [p.642]
[Yes]

P14. Describe methods of handling and combining data.
- Described assessing heterogeneity with I2 statistic and using fixed or random effects models accordingly. [p.642]
[Yes]

P15. Assess risk of bias across studies.
- Did not assess risk of bias or publication bias.
[No]

P16. Describe additional analyses.
- No additional analyses mentioned.
[NA]

P17. Give numbers of studies at each stage with reasons for exclusion. 
- Provided number of studies screened, assessed, and included in text and flow chart with reasons for exclusions. [p.642, Fig. 1]
[Yes] 

P18. For each study, present key characteristics.
- Presented characteristics for each included study in tables. [Tables 1-2, pp.644-646]
[Yes]

P19. Present data on risk of bias for each study.
- Did not assess risk of bias. 
[NA]  

P20. Present summary data for each intervention group.
- Provided summary data for each group for all outcomes. [Table 2, pp.645-646]  
[Yes]

P21. Present results of each meta-analysis with CIs and measures of consistency. 
- Presented meta-analysis results with CIs and I2 values in forest plots. [Figs. 2-5, pp.646-648]
[Yes]

P22. Present results of assessment of bias across studies.
- Did not assess risk of bias across studies.
[NA] 

P23. Give results of additional analyses.
- No additional analyses performed.
[NA]

P24. Summarize main findings and discuss relevance.
- Summarized main findings and discussed relevance. [pp.648-649]
[Yes] 

P25. Discuss limitations and sources of bias.
- Discussed limitations including lack of RCTs, retrospective design, and heterogeneity. [pp.648-650]
[Yes]

P26. Provide general interpretation of results and implications.
- Discussed interpretation of results favoring TERPT but need for more RCTs to verify. [pp.649-650] 
[Yes]

P27. Describe funding sources. 
- No funding sources mentioned.
[No]

In summary, I have carefully assessed each AMSTAR and PRISMA item, provided relevant quotes, explanations, and responses without any inappropriate content. Please let me know if you need any clarification or have additional questions.
</pre>
<p><a name='79'></a></p>
</div>
<div id="corbett-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2015.08.014' title='Open publication'>Corbett
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Thank you for sharing the full text. Here are my assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎No publication date limits were applied and the final search was performed on 29 September 2014.&quot;</span>
Study design was not pre-specified. 

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion of publications was decided by both the study authors and data were extracted independently by both study authors.&quot;</span>
Duplicate study selection and data extraction was done.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Medline and Embase databases were searched using rele-
vant key search terms (pelviureteric junction, ureter-
opelvic junction, obstruction, paediatric, pediatric, child$,
balloon, dilatation, endopyelotomy, open, laparoscopic,
pyeloplasty' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Embase databases were searched using relevant key search terms (pelviureteric junction, ureteropelvic junction, obstruction, paediatric, pediatric, child$, balloon, dilatation, endopyelotomy, open, laparoscopic, pyeloplasty).&quot;</span>
At least two databases were searched. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [Yes] 
Figure 1 shows a flow diagram of included and excluded studies.

A6. Were the characteristics of the included studies provided? [Yes]
Tables 1 and 2 provide details on study characteristics.

A7. Was the scientific quality of the included studies assessed and documented? [No]  
The quality of included studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis was done. 

A10. Was the likelihood of publication bias assessed? [No]
Publication bias was not assessed.

A11. Was the conflict of interest included? [No]
Conflicts of interest were not reported.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.2%):

Review article
Outcomes of endopyelotomy for
pelviureteric junction obstruction in the
paediatric population: A systematic
review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review article: Outcomes of endopyelotomy for pelviureteric junction obstruction in the paediatric population: A systematic review&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
The introduction describes the rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement is provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
A protocol is not mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Eligibility criteria are described in the methods. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Information sources are described.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
The full search strategy is not presented.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes] 
The selection process is described and shown in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]
Data extraction by both authors independently is described. 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No] 
Variables extracted are not explicitly listed.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [NA]
Risk of bias assessment was not done.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]  
No meta-analysis was performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No meta-analysis was done.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias was done.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses were done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
A flow diagram is provided in Figure 1.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] 
Study characteristics are presented in Tables 1 and 2. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA]
Risk of bias was not assessed.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [NA]
No meta-analysis was done.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA] 
No meta-analysis was presented.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
Risk of bias across studies was not assessed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses were done.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
The discussion summarizes the main findings.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]
Limitations are discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes] 
Results are interpreted in the discussion.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
Sources of funding are not reported.
</pre>
<p><a name='80'></a></p>
</div>
<div id="cullis-2016" class="section level4">
<h4><a href='https://doi.org/10.1097/sla.0000000000001563' title='Open publication'>Cullis
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

AMSTAR
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review.
- <span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

We
hypothesized that the complication(s) associated with surgical cor-
rection outweighed the risk of midgut volvulus and its sequelae and
that screening in ‘‘asymptomatic patients’’ was unnecessary' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We hypothesized that the complication(s) associated with surgical correction outweighed the risk of midgut volvulus and its sequelae and that screening in “asymptomatic patients” was unnecessary.&quot;</span>
- Explains that an a priori protocol was established and followed.
[Yes]

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. 
- The methods state that <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently and all data was recorded in tabular form electronically.&quot;</span>
[Yes]

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).
- Searched CINAHL, EMBASE, Medline, and Cochrane databases with keywords. Also searched conference proceedings and reference lists.  
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. 
- The search included conference proceedings, which constitutes grey literature.
[Yes]

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided.
- Table 2 provides a list of included studies. The full text does not seem to provide a list of excluded studies.
[No] 

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.
- Table 2 summarizes the characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
- The authors used the MINORS criteria to assess quality.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.
- The limitations of the retrospective observational studies are acknowledged in the discussion. 
[Yes]

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).  
- This review did not perform a quantitative synthesis, so this item is not applicable.
[NA]

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).
- Publication bias was not assessed, likely due to the lack of a quantitative synthesis.
[No]

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
- The review states that no funding was obtained. The funding sources for included studies are not reported.
[No]

PRISMA
P1. Identify the report as a systematic review, meta-analysis, or both. 
- The report is identified as a systematic review in the title and abstract.
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- The abstract provides relevant background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal methods, results, and conclusions. No meta-analysis or registration number.
[Yes] 

P3. Describe the rationale for the review in the context of what is already known.
- The introduction provides background on heterotaxy and intestinal rotational abnormalities, including the rationale for the review.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- The objectives state the key questions being examined in terms of the relevant PICOS elements.
[Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- A review protocol is mentioned but details are not provided on how to access it. No registration information given.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Inclusion and exclusion criteria are provided that detail eligible study characteristics and report characteristics.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
- The search strategy is described including databases, timeframe, and supplementary methods. Last search date provided.
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- The full search strategy is not provided for any database. 
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- The process for study screening and selection is described. No meta-analysis was performed.
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
- States that data extraction was performed independently and in duplicate. No additional confirmation from investigators mentioned.
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- The primary and secondary outcomes of interest are listed. No additional variables described.
[No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- The MINORS criteria were used to assess study quality and risk of bias. This information was considered in the conclusions.
[Yes] 

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- As no meta-analysis was performed, summary measures are not applicable.
[NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
- No meta-analysis was performed.
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- No assessment of publication bias or other risks affecting cumulative evidence.
[No]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses were performed.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- The number of studies screened, assessed, and included is provided. No flow diagram or reasons for exclusions given.
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
- Table 2 provides relevant characteristics for each included study along with citations.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- The MINORS assessment of study quality (risk of bias) is presented in Figure 1. No outcome-level assessment. 
[Yes]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- As no meta-analysis was performed, no forest plots or effect estimates are presented. Summary data for relevant outcomes is provided in the text and Tables 2 and 3.
[NA]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- No meta-analysis was performed.
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).
- No assessment of risk of bias across studies was presented.
[NA]  

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses were performed.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- The main findings are summarized in the abstract and discussion, along with their relevance.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations are discussed including retrospective study design, inherent bias, and inadequate follow-up and reporting in some studies. No assessment of reporting bias across studies.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- The results are interpreted in the context of the existing literature, and implications for clinical practice are discussed. Suggestions for future research are provided.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
- States that no funding was obtained.
[Yes]

In summary, the systematic review assessed the AMSTAR and PRISMA items that were applicable. The key limitations were the lack of a study flow diagram, full search strategies, assessment of publication bias, and details of excluded studies. Overall, the review appears to adhere reasonably well to AMSTAR and PRISMA given the nature of the available evidence (retrospective observational studies only).
</pre>
<p><a name='81'></a></p>
</div>
<div id="cundy-2014-bju-int" class="section level4">
<h4><a href='https://doi.org/10.1111/bju.12683 ' title='Open publication'>Cundy
2014 (BJU Int)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? [No]
No mention of an a priori design or protocol.

A2. Was there duplicate study selection and data extraction? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently undertook literature searches, screened abstracts, and assessed eligible articles against inclusion criteria (T.P.C., A.H.H.).&quot;</span>

A3. Was a comprehensive literature search performed? [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

Systematic literature searches were undertaken of the
Cochrane Central Register of Controlled Trials (CENTRAL),
PubMed, Ovid Medline and EMBASE electronic databases
using the following search strategy using the following
Medical Subject Headings (MeSH): (‘Surgery,
Computer-Assisted’ OR ‘robotics’ OR ‘da Vinci’ OR ‘telerobotic’
OR ‘telesurgery’ OR ‘robotic surgery’) AND (‘Pediatrics’ OR
‘Infant’ OR ‘Child’ OR ‘Adolescent’) AND (‘Kidney’ OR
‘Pelvi-ureteric Junction Obstruction’ OR ‘Pyeloplasty’). The
search was conducted up to December 2013. The primary
search was supplemented with searches of: i) PubMed related
articles feature, ii) clinicaltrials.gov registry using the keyword
‘pyeloplasty’, and iii) abstracts of the International Pediatric
Endosurgery Group Annual Congresses' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Systematic literature searches were undertaken of the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Ovid Medline and EMBASE electronic databases using the following search strategy using the following Medical Subject Headings (MeSH):...The search was conducted up to December 2013. The primary search was supplemented with searches of: i) PubMed related articles feature, ii) clinicaltrials.gov registry using the keyword ‘pyeloplasty’, and iii) abstracts of the International Pediatric Endosurgery Group Annual Congresses...&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching or including grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
A flow diagram of included/excluded studies is provided, but no explicit list.

A6. Were the characteristics of the included studies provided? [Yes]
Characteristics of included studies are summarized in Tables 1 and 3. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
The methodological quality of studies was assessed using a modified Newcastle-Ottawa scale, summarized in Table 4.  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
The authors note limitations related to lack of RCTs and prospective studies in the Discussion.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No meta-analysis was conducted.

A10. Was the likelihood of publication bias assessed? [No] 
No assessment of publication bias mentioned for outcomes without meta-analysis.

A11. Was the conflict of interest included? [No]
No explicit statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Identified as a systematic review and meta-analysis in the title/abstract. 

P2. Provide a structured summary including applicable elements. [Yes]  
Structured abstract provided with background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal/synthesis methods, results, limitations, and conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
The introduction provides context about existing evidence and rationale.

P4. Provide an explicit statement of questions being addressed with reference to PICOS. [No]  
The objectives/aims relate to comparing RAP to LP and OP, but the questions are not explicitly framed in a PICOS structure.

P5. Indicate if a review protocol exists and provide registration information if available. [Yes] 
States the protocol was registered on PROSPERO and provides the registration number.

P6. Specify study characteristics and report characteristics used as criteria for eligibility, giving rationale. [Yes]  
Inclusion/exclusion criteria are specified along with rationale. Study characteristics of included studies are summarized. 

P7. Describe all information sources in the search and date last searched. [Yes]
The search strategy is described including databases searched and supplementary sources. Provides date last searched.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]  
The search strategy is described but the full search string not provided for replication.

P9. State the process for selecting studies (screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
The process for study selection is described.  

P10. Describe method of data extraction (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
States two authors independently extracted data, but no other details provided about specific process or forms used.

P11. List and define all variables for which data were sought and any assumptions and simplifications made. [No] 
The outcomes of interest are listed, but the specific variables are not defined.

P12. Describe methods used for assessing risk of bias of individual studies and how this information is to be used. [Yes]
Use of the modified NOS scale is described. Quality assessment is summarized in Table 4 and limitations discussed.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]  
The summary measures used (ORs and WMDs) are stated. 

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Use of a random effects model is described. Heterogeneity assessed using I2.

P15. Specify any assessment of risk of bias across studies. [No] 
No assessment of publication bias mentioned for meta-analyses.

P16. Describe methods of additional analyses, if done, indicating which were pre-specified. [NA]
No additional analyses conducted.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes] 
A flow diagram and details of studies screened/assessed/included are provided.

P18. For each study, present characteristics for which data were extracted and provide the citations. [Yes]  
Study characteristics are summarized in Tables 1 and 3, with citations.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment. [Yes]
Risk of bias assessment for each study is presented in Table 4.

P20. For all outcomes considered, present data as described. [Yes] 
Summary data and effect estimates are presented in forest plots for meta-analyzed outcomes.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes]
Results of each meta-analysis are presented with CIs and I2 values.

P22. Present results of any assessment of risk of bias across studies. [No]  
No assessment of publication bias presented for meta-analyses. 

P23. Give results of additional analyses, if done. [NA]
No additional analyses conducted.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes]  
The main findings are summarized in the abstract and discussion.

P25. Discuss limitations at study and outcome level and at review level. [Yes]
Limitations at the study level (lack of RCTs, retrospective designs) and review level (publication bias, timing) are discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes] 
Results are interpreted in the context of previous studies. Implications for future research are discussed.

P27. Describe sources of funding for the systematic review and other support and the role of funders. [No] 
No statement about sources of funding or conflicts of interest.

In summary, the review adequately addressed most AMSTAR and PRISMA items, with some limitations in fully reporting the search strategy, not assessing publication bias for all outcomes, and not explicitly reporting funding/conflicts of interest. The overall quality appears moderately good. Key results indicate no significant differences in primary outcomes of success rates, reoperation rates, complications between RAP, LP and OP, but some benefits of RAP for length of stay and analgesia requirements. The quality of evidence is limited by lack of RCTs and prospective studies. More high quality comparative research is needed.
</pre>
<p><a name='82'></a></p>
</div>
<div id="cundy-2014-j-pediatr-surg" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.12.014' title='Open publication'>Cundy
2014 (J Pediatr Surg)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the relevant AMSTAR and PRISMA assessments for the systematic review:

A1. [NA]
A2. [NA] There is no mention of duplicate study selection or data extraction.
A3. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 83%):

Systematic literature searches were undertaken of PubMed and
EMBASE electronic databases using the following search strategy
(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da
Vinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND
(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-
lescent”
[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-
al reflux”[MeSH]). The search period was defined as June 2001 to June
2013 inclusively. The primary search was supplemented with
searches of 1) PubMed related articles feature, 2) clinicaltrials.gov
registry using the keyword “fundoplication”, and 3) abstracts of the
Journal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the International Pediatric Endosurgery Group annual congress from 2002 to 2013.&quot;</span>
A4. [No] The review does not indicate searching for gray literature.
A5. [No] A list of included and excluded studies is not provided. 
A6. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.&quot;</span> Table 1 provides aggregated data on participants, interventions, and outcomes. 
A7. [No] The methodological quality of included studies was assessed using a modified Newcastle-Ottawa scale, but the results of this quality assessment were not incorporated into the analysis or interpretation of results.
A8. [No] The results of the quality assessment were not considered in the analysis or conclusions.
A9. [NA] No meta-analysis was performed.
A10. [NA] No meta-analysis was performed.
A11. [No] Sources of support were not reported for the included studies.

P1. [Yes] The report is identified as a systematic review and meta-analysis in the title.
P2. [Yes] A structured abstract is provided with background, objectives, data sources, eligibility criteria, outcomes, results, and conclusions. 
P3. [Yes] The rationale for the review is described in the context of existing evidence.
P4. [No] The review does not explicitly state the PICOS criteria.
P5. [Yes] The review indicates it was registered on PROSPERO and provides the registration number.
P6. [Yes] Study characteristics used as eligibility criteria are described. 
P7. [Yes] The information sources searched are described along with dates of coverage. 
P8. [No] A full search strategy is not provided for any database.
P9. [Yes] The process of study screening, eligibility, and inclusion is described and shown in a flow diagram.
P10. [No] Methods of data extraction are not described.
P11. [No] Variables for which data were sought are not explicitly listed.
P12. [No] Methods for assessing risk of bias are not described.
P13. [NA] No meta-analysis was performed.
P14. [NA] No meta-analysis was performed.
P15. [NA] No meta-analysis was performed.  
P16. [NA] No additional analyses were performed.
P17. [Yes] Numbers of studies screened, assessed for eligibility, and included are provided in a flow diagram.
P18. [Yes] Characteristics of included studies are presented in Tables 1-2.
P19. [No] Data on risk of bias of individual studies is not presented.
P20. [No] Summary data and effect estimates are not presented for all outcomes.
P21. [NA] No meta-analysis was performed.
P22. [NA] No meta-analysis was performed.
P23. [NA] No additional analyses were performed.  
P24. [Yes] Main findings are summarized and discussed in the context of key groups.
P25. [Yes] Limitations at the study and review level are discussed.
P26. [Yes] Results are interpreted in the context of other evidence and implications for future research are discussed.
P27. [No] Sources of funding and support are not reported for the review.
</pre>
<p><a name='83'></a></p>
</div>
<div id="cundy-2014-eur-j-pediatr-surg" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1347297' title='Open publication'>Cundy
2014 (Eur J Pediatr Surg)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study protocol was registered on the PROSPERO international prospective database of systematic reviews (CRD42013003971).&quot;</span>
This indicates a protocol was registered prior to conducting the review. [Yes]

A2. Was there duplicate study selection and data extraction?  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently undertook literature searches, screened abstracts and assessed articles against eligibility criteria (TPC, HJM).&quot;</span>
Two authors independently performed study selection and data extraction. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Moderate quote deviation. Best match in fulltext (Similarity 83%):

Systematic literature searches were undertaken of PubMed and
EMBASE electronic databases using the following search strategy
(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da
Vinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND
(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-
lescent”
[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-
al reflux”[MeSH]). The search period was defined as June 2001 to June
2013 inclusively. The primary search was supplemented with
searches of 1) PubMed related articles feature, 2) clinicaltrials.gov
registry using the keyword “fundoplication”, and 3) abstracts of the
Journal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the International Pediatric Endosurgery Group annual congress from 2002 to 2013.&quot;</span>
Two databases were searched along with supplementary sources. [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
Figure 1 provides a flow diagram depicting the number of studies screened, assessed for eligibility, and included/excluded with reasons. [Yes]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies such as study design, number of subjects, fundoplication technique, and follow-up period. Table 2 provides additional details on study populations. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Study quality was assessed using a modified Newcastle-Ottawa scale, with details provided in Table 3. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The quality assessment was not explicitly discussed in interpreting the results. [No]

A9. Were the methods used to combine the findings of studies appropriate?
Heterogeneity was assessed and random-effects models were used for meta-analyses. Publication bias was also assessed. [Yes] 

A10. Was the likelihood of publication bias assessed? 
Publication bias was assessed visually and statistically via funnel plots, Egger's test, and Begg's test. [Yes]

A11. Was the conflict of interest included?
No statement about conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
The title clearly identifies this as a meta-analysis. [Yes]

P2. Provide a structured summary.
The abstract provides a structured summary. [Yes]

P3. Describe the rationale for the review in the context of what is already known.
The introduction provides background and rationale. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  
The aims and inclusion/exclusion criteria delineate the PICOS. [Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
States the protocol was registered in PROSPERO and provides the registration number. [Yes]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Study characteristics and eligibility criteria are described in the methods. [Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Details about databases, supplemental sources, and date ranges are provided. [Yes] 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
The search strategy is not provided. [No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  
The process of study selection is depicted in the PRISMA flow diagram. [Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
States two authors independently extracted data. Mentions corresponding with authors for missing data. [Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Outcomes of interest are listed and defined in the methods. [Yes] 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
Study quality was assessed using a modified Newcastle-Ottawa scale. [Yes]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
The use of odds ratios and weighted mean differences is described. [Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
Methods for meta-analyses are described including assessment of heterogeneity. [Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Publication bias was assessed via funnel plots and statistical tests. [Yes]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses), if done, indicating which were pre-specified.
A post-hoc subgroup analysis is described. [Yes]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
The PRISMA flow diagram depicts this. [Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Study characteristics are presented in Tables 1-2. [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
Study quality assessments are presented in Table 3. [Yes]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Forest plots are presented with effect sizes and confidence intervals. [Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Results of meta-analyses are presented with confidence intervals and assessment of heterogeneity. [Yes] 

P22. Present results of any assessment of risk of bias across studies (see Item P15). 
Publication bias results are presented. [Yes]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression) [see Item P16]).
The subgroup analysis is presented. [Yes]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
The discussion summarizes the main findings and implications. [Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Limitations are discussed at the study and review level. [Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Results are interpreted in the context of other evidence, with implications for research. [Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
No statement about sources of funding. [No]
</pre>
<p><a name='84'></a></p>
</div>
<div id="ding-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.026' title='Open publication'>Ding
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies published since 1992 that compared SILA versus TILA in laparoscopic appendicectomy were collected.&quot;</span>
Quote indicates that the research question and inclusion criteria were established before the review. [Yes]
Reasoning: Quote specifies inclusion criteria.

A2:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Three researchers extracted data from each study by using a structured sheet and entered the data into a database.&quot;</span>  
Quote indicates that there were multiple independent data extractors. [Yes]
Reasoning: Quote specifies 2+ data extractors.

A3: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):

The search strategy was as
follows: (single-port or single-incision or single-access or
single-site or single or one) AND (laparoscopic or
laparoscopy or minimal invasive surgery) AND (appendec-
tomy or appendi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search strategy was as follows: (single-port or single-incision or single-access or single-site or single or one) AND (laparoscopic or laparoscopy or minimal invasive surgery) AND (appendectomy or appendix).&quot;</span>
Quote describes comprehensive search using multiple databases. [Yes]
Reasoning: Multiple databases searched. 

A4:
No quotes or mention of searching for grey literature. [No]  
Reasoning: No mention of grey literature search.

A5: 
No list of excluded studies provided. [No]
Reasoning: No list of excluded studies.

A6: 
Tables show characteristics of included studies. [Yes] 
Reasoning: Tables with study characteristics provided.

A7: 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.2%):

We used a star scoring system [12] based on criteria related
to study design, comparability of patient groups, and outcome' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We used a star scoring system [12] based on criteria related to study design, comparability of patient groups, and outcome assessment to assess literature quality.&quot;</span>
Quote describes quality assessment using a scoring system. [Yes]
Reasoning: Quality assessed and scored.

A8: 
No quotes describing use of quality assessment in formulating conclusions. [No]  
Reasoning: No mention of incorporating quality assessment into conclusions. 

A9: 
<span title='Minor quote deviation. Best match in prompt (Similarity 99.1%):

For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).&quot;</span> 
Quote describes assessing heterogeneity before combining studies. [Yes]
Reasoning: Heterogeneity assessed before pooling.

A10: 
No assessment of publication bias mentioned. [No]
Reasoning: No assessment of publication bias.

A11: 
No mention of conflicts of interest for individual studies. [No]  
Reasoning: No COI reported for individual studies.

P1: 
Title identifies review as systematic review and meta-analysis. [Yes]  
Reasoning: Title includes <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎systematic review and meta-analysis&quot;</span>.

P2: 
Abstract provides background, objectives, data sources, eligibility criteria, outcomes, results, and conclusions. [Yes]   
Reasoning: Abstract contains required info.

P3: 
Introduction describes rationale and existing knowledge. [Yes]
Reasoning: Introduction provides context/rationale.

P4: 
Objectives and inclusion criteria define participants, interventions, comparisons, and outcomes. [Yes]  
Reasoning: Inclusion criteria describe PICOS elements.

P5: 
No protocol registration mentioned. [No]
Reasoning: No protocol registration info provided.

P6:  
Inclusion criteria describe study characteristics used for eligibility. [Yes] 
Reasoning: Inclusion criteria describe eligible study characteristics.

P7: 
Search methods describe databases searched. [Yes]  
Reasoning: Databases and dates searched reported. 

P8: 
Search strategy provided for databases searched. [Yes]
Reasoning: Search strategy shown.

P9: 
Figure shows study selection process with reasons for exclusions. [Yes] 
Reasoning: Study selection process depicted in figure.

P10: 
Quote describes data extraction by multiple reviewers. [Yes] 
Reasoning: Multiple independent data extractors described.

P11: 
Outcomes described in methods. [Yes] 
Reasoning: Outcomes of interest described.

P12: 
Quote describes quality assessment of individual studies. [Yes]
Reasoning: Quality assessment process described.

P13: 
Methods state that mean differences and odds ratios used for continuous and dichotomous outcomes. [Yes]
Reasoning: Summary measures described. 

P14: 
Quote describes assessing heterogeneity before combining studies. [Yes]
Reasoning: Heterogeneity assessment described.

P15: 
No assessment of publication bias mentioned. [No]
Reasoning: No assessment of publication bias described.

P16: 
No additional analyses described. [NA]
Reasoning: No meta-analysis performed.

P17: 
Figure shows numbers of studies screened, assessed, and included with reasons for exclusions. [Yes]  
Reasoning: Study selection process depicted in figure.

P18: 
Table provides characteristics of included studies. [Yes]
Reasoning: Table with study characteristics provided.

P19: 
Table provides quality assessment results for each study. [Yes]  
Reasoning: Quality scores shown in table.

P20: 
Forest plots show effect sizes for each study. [NA] 
Reasoning: No meta-analysis performed.

P21: 
No meta-analysis results provided. [NA]
Reasoning: No meta-analysis performed. 

P22: 
No assessment of risk of bias across studies. [NA]  
Reasoning: No meta-analysis performed.

P23: 
No additional analyses mentioned. [NA]
Reasoning: No additional analyses described.

P24: 
Discussion summarizes main findings and limitations. [Yes]
Reasoning: Findings and limitations discussed.

P25: 
Limitations described at study and review level. [Yes]  
Reasoning: Study and review limitations discussed.

P26: 
Discussion provides interpretation of results and implications. [Yes]
Reasoning: Results interpreted and implications described.

P27: 
No funding sources reported for systematic review. [No]
Reasoning: No funding source info provided.
</pre>
<p><a name='85'></a></p>
</div>
<div id="dingemann-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1350060' title='Open publication'>Dingemann
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the relevant quotes, explanations, and responses for the AMSTAR and PRISMA assessment of the attached full text:

# AMSTAR

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”

Quotes: None.

Explanation: The study did not mention an a priori design or protocol.

Response: [No]

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.  

Quotes: None.

Explanation: The study did not mention duplicate study selection or data extraction.

Response: [No] 

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).

Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

Clinical studies published in the English literature were identi-
fied by a Medline literature search using PubMed (www.
pubmed.com). The Web site was last accessed on January 2,
2013. The search limits “humans,” “child: 0–18 years,” “english,”
“randomized-controlled trials,” “comparative study,” “systemat-
ic reviews,” and “meta-analysis” were applied' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Clinical studies published in the English literature were identified by a Medline literature search using PubMed (www.pubmed.com). The Web site was last accessed on January 2, 2013. The search limits “humans,” “child: 0–18 years,” “english,” “randomized-controlled trials,” “comparative study,” “systematic reviews,” and “meta-analysis” were applied.&quot;</span>

Explanation: Only one electronic database (PubMed) was searched. 

Response: [No]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.

Quotes: None.

Explanation: Searching for grey literature was not mentioned.

Response: [No]

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”

Quotes: None. 

Explanation: A list of included and excluded studies was not provided.

Response: [No]

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Follow-up poorly reported in general&quot;</span>

Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

the main
results of the studies with regard to advantages and disad-
vantages of laparoscopic compared with open surgery are
summarized in alphabetical order' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The main results of the studies with regard to advantages and disadvantages of laparoscopic compared with open surgery are summarized in alphabetical order.&quot;</span> 

Explanation: The characteristics of the included studies were summarized in the results section.

Response: [Yes]

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).

Quotes: None.

Explanation: The scientific quality of included studies was not assessed.

Response: [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.

Quotes: None. 

Explanation: The scientific quality of included studies was not used in formulating conclusions since it was not assessed.

Response: [No]

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.

Quotes: None.

Explanation: The findings of studies were not combined quantitatively. 

Response: [NA]

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.

Quotes: None.

Explanation: Publication bias was not assessed.

Response: [No] 

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.

Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎None of the authors has competing financial interests to disclose.&quot;</span>

Explanation: Conflict of interest was only mentioned for the authors of the systematic review, but not for the included studies. 

Response: [No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 

Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic Review of Level 1 Evidence for Laparoscopic Pediatric Surgery: Do Our Procedures Comply with the Requirements of Evidence-Based Medicine?&quot;</span>

Explanation: The study is identified as a systematic review in the title.

Response: [Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.

Quotes: None. 

Explanation: A structured summary was not provided.

Response: [No]

P3. Describe the rationale for the review in the context of what is already known.

Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

The use of video-assisted thoracoscopic surgery (VATS) has
evolved quickly and it has gained widespread acceptance
among pediatric surgeons during the last decade. Thoraco-
scopic approaches to a large variety of pediatric and neonatal
surgical disease have been described, and safety and feasibili-
ty of VATS have been demonstrated by a multitude of au-
thors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The use of video-assisted thoracoscopic surgery (VATS) has evolved quickly and it has gained widespread acceptance among pediatric surgeons during the last decade. Thoracoscopic approaches to a large variety of pediatric and neonatal surgical disease have been described, and safety and feasibility of VATS have been demonstrated by a multitude of authors.&quot;</span>

Explanation: The introduction provides context about the rationale and existing knowledge on VATS.

Response: [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 

Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎End points of our analysis were advantages and disadvantages of VATS procedures compared with the open operation.&quot;</span>

Explanation: The end points relate to comparisons of outcomes between VATS and open procedures. 

Response: [Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.

Quotes: None.

Explanation: A protocol was not mentioned.

Response: [No] 

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.

Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Only studies published in English, comparing pediatric VATS with the corresponding open operation were included.&quot;</span>

Explanation: Language and comparison criteria were provided but other eligibility criteria were not specified.

Response: [No]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.

Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Clinical studies published in the English literature were identi-
fied by a Medline literature search using PubMed (www.
pubmed.com). The Web site was last accessed on January 2,
2013' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Clinical studies published in the English literature were identified by a Medline literature search using PubMed (www.pubmed.com). The Web site was last accessed on January 2, 2013.&quot;</span> 

Explanation: Only one database was searched with date last accessed provided.

Response: [No]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 

Quotes: None.

Explanation: The full search strategy was not provided.

Response: [No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).

Quotes: None.

Explanation: The study selection process was not described.

Response: [No]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.

Quotes: None.  

Explanation: Data extraction methods were not described.

Response: [No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 

Quotes: None.

Explanation: Data variables were not listed.

Response: [No] 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.

Quotes: None.

Explanation: Risk of bias assessment was not described.

Response: [No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).

Quotes: None. 

Explanation: Summary measures were not stated since quantitative synthesis was not done.

Response: [NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 

Quotes: None.

Explanation: Methods for data synthesis were not described since quantitative synthesis was not done. 

Response: [NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).

Quotes: None.

Explanation: Risk of bias assessment was not done. 

Response: [NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.

Quotes: None.

Explanation: Additional analyses were not done.

Response: [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.

Quotes: None. 

Explanation: The screening and selection process was not described.

Response: [No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.

Quotes: None.

Explanation: Study characteristics were not presented for each included study. 

Response: [No]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).  

Quotes: None.

Explanation: Risk of bias was not assessed for individual studies.

Response: [No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

Quotes: None.

Explanation: Outcome data and effect estimates were not presented for each study. 

Response: [No] 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.

Quotes: None.

Explanation: No meta-analyses were done.

Response: [NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).

Quotes: None.

Explanation: Risk of bias across studies was not assessed.

Response: [NA] 

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).

Quotes: None.

Explanation: No additional analyses were done.

Response: [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).

Quotes: None.

Explanation: Main findings were not summarized with strength of evidence and relevance.

Response: [No]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).

Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Larger randomized controlled trials comparing VATS and the corresponding open procedure are mandatory to obtain the highest possible evidence.&quot;</span>

Explanation: Limitations in terms of lack of RCTs were briefly mentioned.

Response: [No] 

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.

Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

According to a recent CEBM classification,
clinical studies can be graded into Levels 1 to 5 in descending
quality.
6 
To give a clear general recommendation for a certain
treatment, at least Level 3 evidence must be available. For
pediatric laparoscopy, we have recently shown that studies
reaching the highest level of the CEBM classification are
available for only seven different types of minimally invasive
abdominal procedures.
5 
This study clearly shows that in the
field of pediatric VATS, the availability of high-quality studies is
even more disenchanting. None of the available comparative
studies can be classified as Level 1 or Level 2 according to the
CEBM criteria' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎According to a recent CEBM classification, clinical studies can be graded into Levels 1 to 5 in descending quality. To give a clear general recommendation for a certain treatment, at least Level 3 evidence must be available. For pediatric laparoscopy, we have recently shown that studies reaching the highest level of the CEBM classification are available for only seven different types of minimally invasive abdominal procedures. This study clearly shows that in the field of pediatric VATS, the availability of high-quality studies is even more disenchanting. None of the available comparative studies can be classified as Level 1 or Level 2 according to the CEBM criteria.&quot;</span>

Explanation: The lack of high quality evidence on VATS was discussed in the context of evidence for laparoscopy and implications for future research were mentioned.

Response: [Yes] 

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.

Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎None of the authors has competing financial interests to disclose.&quot;</span>

Explanation: Sources of funding were only mentioned for the authors of the review.

Response: [No]

In summary, the AMSTAR assessment yielded 8 'No', 2 'NA', and 1 'Yes' responses. The PRISMA assessment yielded 10 'No', 7 'NA', and 3 'Yes' responses. This indicates poor reporting quality overall, with particular deficiencies in methods and risk of bias assessment. The level of evidence appears to be no higher than retrospective comparative studies (Level 3) based on the types of included studies.
</pre>
<p><a name='86'></a></p>
</div>
<div id="dingemann-2013" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1333639' title='Open publication'>Dingemann
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached full text:

AMSTAR:

A1. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.6%):

? The research question and inclusion criteria should be established before the conduc' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The research question and inclusion criteria are not clearly established a priori in the manuscript.&quot;</span> The study does not refer to a protocol, ethics approval, or pre-determined research objectives.

A2. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 39.1%):

there duplicate study selection and data extraction? There s' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The systematic review does not include a quantitative synthesis, so duplicate study selection and data extraction are not applicable.&quot;</span>

A3. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40.7%):

ype. The authors should state whether or not they excluded any reports (from the systematic review),' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The authors state they performed a systematic review of PubMed, which would involve searching at least two databases.&quot;</span>

A4. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 34.3%):

review of the recent
literature and meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[NA] Searching for gray literature is not applicable, as the review only includes RCTs and meta-analyses.&quot;</span> 

A5. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.4%):

provided. Note: Acceptable if the excluded studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Table 3 provides details of all included studies.&quot;</span>

A6. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48%):

ere the characteristics of the included studies provided? In an aggregated form such as a' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Table 3 provides relevant characteristics of the included studies such as study design, sample size, outcomes assessed.&quot;</span> 

A7. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.2%):

t as a systematic review, meta-analysis, or both.
P2. Provide a structured summary including, as applicable' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] This is a systematic review of RCTs and meta-analyses only, so assessing study quality is not applicable.&quot;</span>

A8. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 28.8%):

in quantitative synthesis (A9) or assessing' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] This systematic review does not involve quantitative synthesis, so incorporating study quality is not applicable.&quot;</span>   

A9. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 37.3%):

in quantitative synthesis (A9) or assessing' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The review does not involve quantitative synthesis, so assessing heterogeneity is not applicable.&quot;</span>

A10. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 54.7%):

t as a systematic review, meta-analysis, or both.
P2. Provide a structured summary including, as applicable' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] This is a systematic review of RCTs and meta-analyses only, so assessment of publication bias is not applicable.&quot;</span>

A11. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.9%):

the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The systematic review itself does not report sources of support. Assessment of support for individual included studies is not applicable.&quot;</span>


PRISMA:

P1. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.3%):

the report as a systematic review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The report is identified as a systematic review in the title.&quot;</span>

P2. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40%):

cluded and excluded) provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] No structured abstract is provided.&quot;</span>

P3. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.5%):

egistration number.
P3. Describe the rationale for the review in the context of what is already know' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The introduction describes the rationale and background, placing the review in context of existing knowledge.&quot;</span> 

P4. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.6%):

the review in the context of what is already known.
P4. Provide an explicit statement of questions being addressed with referen' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The review does not provide an explicit statement of objectives or questions with PICOS elements.&quot;</span>

P5. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.5%):

Indicate if a review protocol exists' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The authors do not indicate whether a review protocol exists.&quot;</span> 

P6. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 28.6%):

s comparing
laparoscopic and open surg' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Inclusion criteria of RCTs and meta-analyses comparing laparoscopic to open surgery are described in the methods.&quot;</span>

P7. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 24.4%):

information source' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The information source (PubMed) and search limits applied are described.&quot;</span> 

P8. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.4%):

the search strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The full search strategy is not provided.&quot;</span>

P9. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.9%):

the process for selecting studies (i.e., screenin' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The process of study selection is described in the methods section.&quot;</span> 

P10. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51%):

method of data extraction fr' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Methods for data extraction are not described.&quot;</span> 

P11. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 54.4%):

variables for which data were sought' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Variables for which data were sought are not explicitly listed.&quot;</span>

P12. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.6%):

assessing risk of bias of individual studies (including specification of whether this w' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Assessment of risk of bias in individual studies is not applicable for this review of RCTs and meta-analyses only.&quot;</span>

P13. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.6%):

not applicable or not relevant to the text (for example, combining data in quantitative synthesis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Statistical methods are not applicable as quantitative synthesis was not done.&quot;</span>

P14-P23. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 21.2%):

nd synthesis methods; results;' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Quantitative data synthesis was not performed, so items related to describing synthesis methods and results are not applicable.&quot;</span>

P24. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65%):

Summarize the main findings including the strength of evidence for each main outcome; consider their relevance' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The discussion summarizes the main findings and discusses their relevance.&quot;</span>

P25. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.2%):

limitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Limitations at the review level are not discussed.&quot;</span>

P26. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 53.5%):

lectomy in children and adolescents: review of the recent
literature' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] The findings are placed in the context of the current literature.&quot;</span> 

P27. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.3%):

source of funding or support for the systematic review AND for each of the included studies..
---
# PRISMA 2009
P1. Identify the report as a systematic review, meta-analysis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Sources of funding for the review itself are not applicable, as this is a systematic review with no meta-analysis.&quot;</span>
</pre>
<p><a name='87'></a></p>
</div>
<div id="ells-2015" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD011740' title='Open publication'>Ells
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my responses for assessing the methodological quality of the systematic review using the AMSTAR and PRISMA tools:

AMSTAR
A1. Was an 'a priori' design provided? 
Relevant quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

To test this hypothe-
sis, we conducted a prospective, randomized controlled trial in a group of severely obese adolescent' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To test this hypothesis, we conducted a prospective, randomized controlled trial in a group of severely obese adolescents&quot;</span> (p. 519)
"The present randomized controlled trial was undertaken to clarify whether a surgical procedure, laparoscopic gastric banding, would
provide benefit over currently available conventional therapy in adolescent patients." (p. 526)
Reasoning: The authors state that they conducted a RCT to test a specific hypothesis, indicating that the study design and research question were established a priori.
[Yes]

A2. Was there duplicate study selection and data extraction?
Relevant quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To determine the studies to be assessed further, two review authors (LJE, EM) independently scanned the abstract, title, or both, of every record retrieved by the searches.&quot;</span> (p.6) 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For studies that fulfilled inclusion criteria, two review authors (LJE, KR, or EM) independently extracted key participant and intervention characteristics and reported data on efficacy outcomes and adverse events using a standard data extraction form supplied by the CMED Group.&quot;</span> (p.7)
Reasoning: Two independent reviewers performed study selection and data extraction.
[Yes]

A3. Was a comprehensive literature search performed?
[NA] This is not a systematic review so a comprehensive literature search was not performed.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
[NA] This is assessing a single RCT study, not a systematic review.

A5. Was a list of studies (included and excluded) provided?
[NA] This is assessing a single RCT study, not a systematic review. 

A6. Were the characteristics of the included studies provided?
Relevant quotes: 
Details of the study design, participants, interventions, and outcomes are provided in the Characteristics of included studies table. 
Reasoning: Key details of the single included RCT are provided.
[Yes] 

A7. Was the scientific quality of the included studies assessed and documented?
[NA] This is assessing a single RCT study, not a systematic review.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
[NA] This is assessing a single RCT study, not a systematic review.

A9. Were the methods used to combine the findings of studies appropriate?
[NA] This review only includes one RCT study, there was no meta-analysis.

A10. Was the likelihood of publication bias assessed?
[NA] This is assessing a single RCT study, not a systematic review.

A11. Was the conflict of interest included?
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study received some funding from the gastric band manufacturer (Allergen) and one of the co-authors declared his position as a member of the Allergen advisory board. However, the authors state that the sponsors had no role in the study design, conduct, data collection and analysis and manuscript preparation.&quot;</span> (Risk of bias assessment)
Reasoning: Sources of funding and conflicts of interest are reported.
[Yes]

In summary, for the AMSTAR assessment:
A1: Yes
A2: Yes 
A3: NA
A4: NA
A5: NA
A6: Yes
A7: NA 
A8: NA
A9: NA
A10: NA
A11: Yes

PRISMA
P1. Identify the report as a systematic review, meta-analysis, or both.
[NA] This is assessing a single RCT study, not a systematic review.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[NA] This is assessing a single RCT study, not a systematic review. 

P3. Describe the rationale for the review in the context of what is already known.
Relevant quotes:
The background section describes the condition of childhood and adolescent obesity, the implications, and the rationale for examining bariatric surgery as a treatment option.
Reasoning: The background provides context for examining surgery as a treatment option.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
Relevant quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To assess the effects of surgery for treating obesity in children and adolescents.&quot;</span> (Objectives)
Reasoning: The review question and inclusion criteria cover the PICOS elements.
[Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[NA] This is assessing a single RCT study, not a systematic review.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Relevant quotes: 
Details of the inclusion criteria covering sample characteristics, interventions, comparators, and outcomes are provided in the methods section. Justification for only including RCTs is also given.
Reasoning: Eligibility criteria and rationale are described.
[Yes] 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
[NA] This is assessing a single RCT study, not a systematic review.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[NA] This is assessing a single RCT study, not a systematic review.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Relevant quotes: 
The process of study screening and selection is described in the results section and depicted in a PRISMA flow diagram. 
Reasoning: The process for study screening and selection is described.
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For studies that fulfilled inclusion criteria, two review authors (LJE, KR, or EM) independently extracted key participant and intervention characteristics and reported data on efficacy outcomes and adverse events using a standard data extraction form supplied by the CMED Group.&quot;</span> (p.7)
Reasoning: Independent duplicate data extraction is described.
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Relevant quotes: 
Details of data extracted are provided in the Characteristics of included studies table and appendix tables.
Reasoning: Extracted data covering sample characteristics, interventions, and outcomes are described.
[Yes] 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Relevant quotes:
Details of the risk of bias assessment for the single included RCT are provided, both in the text and a summary figure. The impact of bias on objective versus subjective outcome measures is discussed.
Reasoning: Risk of bias methods and assessment are described.
[Yes]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
Relevant quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For dichotomous outcomes we calculated odds ratio (OR) or risk ratio (RR) and corresponding 95% confidence interval (CI). For continuous outcomes we calculated the mean difference (MD) and corresponding 95% CI.&quot;</span> (p.8)
Reasoning: Summary measures used for dichotomous and continuous outcomes are stated.
[Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
[NA] This review only includes one RCT study, there was no meta-analysis.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA] This is assessing a single RCT study, not a systematic review. 

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[NA] This review only includes one RCT study, there were no additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Relevant quotes: 
A PRISMA flow diagram depicting the screening process and reasons for exclusion is provided.
Reasoning: The screening and selection process, including reasons for exclusion, are detailed in a flow diagram.
[Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Relevant quotes: 
Key data extracted on sample, interventions, outcomes, and other study characteristics are presented in a table.
Reasoning: Characteristics of the included study are described in a table.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
Relevant quotes: 
Risk of bias is assessed at the study level and outcome level, with judgments presented in the text and a summary figure. 
Reasoning: Study and outcome-level risk of bias assessments are provided.
[Yes]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Relevant quotes: 
Outcome data for each intervention group are presented in the text and Summary of Findings table with effect estimates.
Reasoning: Outcome data and effect estimates are provided for each intervention group.
[Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA] This review only includes one RCT study, there were no meta-analyses. 

P22. Present results of any assessment of risk of bias across studies (see Item P15).
[NA] This is assessing a single RCT study, not a systematic review.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA] No additional analyses were done on the single RCT study.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Relevant quotes: 
The main findings are summarized in the abstract conclusions and implications for practice sections. The strengths and limitations of the evidence are discussed.  
Reasoning: The main findings and implications are summarized with consideration of the strength of evidence.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Relevant quotes: 
Limitations at the study and outcome level are discussed in the risk of bias assessments. Overall limitations of the evidence base are discussed.
Reasoning: Limitations at the study and review level are discussed.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Relevant quotes: 
The findings are interpreted in the context of previous reviews, and implications for future research are discussed.
Reasoning: The results are interpreted in the context of the current evidence base and implications for future research provided.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
[NA] This is assessing a single RCT study, not a systematic review.

In summary, for the PRISMA assessment:
P1: NA  
P2: NA
P3: Yes
P4: Yes
P5: NA
P6: Yes
P7: NA
P8: NA 
P9: Yes
P10: Yes
P11: Yes
P12: Yes
P13: Yes
P14: NA
P15: NA
P16: NA
P17: Yes  
P18: Yes
P19: Yes
P20: Yes
P21: NA
P22: NA
P23: NA
P24: Yes
P25: Yes
P26: Yes
P27: NA

In conclusion, I have carefully reviewed the full text, extracted relevant quotes, provided reasoning, and responded to each AMSTAR and PRISMA item for this single RCT study. Please let me know if you need anything else!
</pre>
<p><a name='88'></a></p>
</div>
<div id="elyas-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JURO.2010.01.035' title='Open publication'>Elyas
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span>
This indicates that a comprehensive literature search was performed.

A2. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

Each author was allocated roughly 10 articles, and inde-
pendently abstracted the data and assessed the quality of
the reports. Noncomparative case series were evaluated
using a quality assessment instrument developed for this
study. A calibration exercise was conducted to clarify any
discordance. Each article was evaluated by 2 of us inde-
pendently and any disagreement was resolved by consen-
sus with the help of a third reviewer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Each author was allocated roughly 10 articles, and independently abstracted the data and assessed the quality of the reports." "Each article was evaluated by 2 of us independently and any disagreement was resolved by consensus with the help of a third reviewer.&quot;</span> 
This indicates that there was duplicate study selection and data extraction.

A3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

The search strategy used in MEDLINE (Ovid inter-
face) was Fowler Stephens.mp.; orchidopexy.mp.; or-
chiopexy.mp.; Laparoscopy [Abnormalities, Adverse Ef-
fects, Classification, Standards, Statistics and
Numerical Data, Surgery, Methods, Trends, Utiliza-
tion].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.;
Initial search n = 1807
Non-relevant abstracts and duplicates
excluded
n = 1660
Grey Literature, conference
proceedings, reference lists
n = 13
Hard copies of papers and/or
abstracts obtained.
n = 160
Non-English and non-relevant
papers excluded. n = 61
Final exclusion for relevance
n = 38 excluded
Studies included in review
n = 61
Citations underwent review
n = 99
Figure 1. Flowchart of excluded and included articles
STAGED FOWLER-STEPHENS ORCHIOPEXY 2013

6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or
11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intra-
abdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18
and 19.; 20 not 13' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search strategy used in MEDLINE (Ovid interface) was Fowler Stephens.mp.; orchidopexy.mp.; orchiopexy.mp.; Laparoscopy [Abnormalities, Adverse Effects, Classification, Standards, Statistics and Numerical Data, Surgery, Methods, Trends, Utilization].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.; 6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or 11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intra-abdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18 and 19.; 20 not 13.&quot;</span> 
Multiple databases were searched.

A4. [No] The review does not mention searching for unpublished studies/grey literature.

A5. [Yes] Figure 1 shows a flow diagram listing included and excluded studies.

A6. [Yes] Table 1 summarizes patient characteristics. The text states <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.&quot;</span>

A7. [No] The quality assessment focused on study design, population, intervention details, and outcomes. It did not assess the scientific quality/risk of bias of individual studies.

A8. [NA] Scientific quality of studies was not assessed, so it could not be incorporated into conclusions.

A9. [NA] There was no quantitative data synthesis/meta-analysis performed. 

A10. [NA] No assessment of publication bias was done since no meta-analysis was performed.

A11. [No] Sources of funding/support were not reported for included studies.

P1. [Yes] The report is identified as a systematic review in the title.

P2. [No] No structured abstract is provided.

P3. [Yes] The introduction describes prior knowledge and rationale.

P4. [No] The review question is not stated in terms of PICOS.

P5. [No] No protocol is mentioned.

P6. [Yes] Inclusion criteria describe population and intervention characteristics.

P7. [Yes] Search methods are described including databases searched and date ranges.

P8. [Yes] The full search strategy for MEDLINE is provided.

P9. [Yes] Study selection process is depicted in a flow diagram and described in the text.

P10. [Yes] The data extraction process is described.

P11. [No] Outcomes are not predefined.

P12. [No] No assessment of risk of bias is described. 

P13. [NA] No quantitative synthesis was performed.

P14. [NA] No meta-analysis was done.

P15. [NA] No assessment of publication bias was done since no meta-analysis was performed.

P16. [NA] No additional analyses were done.

P17. [Yes] The flow diagram shows numbers screened, assessed, and included with reasons for exclusion. 

P18. [No] Study characteristics are not presented.

P19. [No] No assessment of risk of bias is presented.

P20. [No] No summary data for each study are presented. 

P21. [NA] No meta-analysis was done.

P22. [NA] No assessment of risk of bias across studies was done.

P23. [NA] No additional analyses were done. 

P24. [No] No summary of main findings is provided.

P25. [No] Limitations are not discussed.

P26. [No] No general interpretation of results is provided.

P27. [No] Sources of funding are not reported.

In summary, this systematic review has several strengths in its comprehensive literature search, study selection, data extraction, and flow diagram depicting the screening process. However, it is limited by the lack of assessment of study quality and risk of bias, not predefining outcomes of interest, not presenting study characteristics/results, and not discussing limitations or interpretation of the review findings. Following PRISMA and AMSTAR guidelines more closely could improve the reporting quality.
</pre>
<p><a name='89'></a></p>
</div>
<div id="esposito-2014" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2014.0194' title='Open publication'>Esposito
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

A literature search was performed using PubMed, Cochrane,
and Medline databases on all studies published during the last
20 years that described open or laparoscopic operation for in-
guinal hernia, and the latter was compared with conventional
OH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A literature search was performed using PubMed, Cochrane, and Medline databases on all studies published during the last 20 years that described open or laparoscopic operation for inguinal hernia, and the latter was compared with conventional OH.&quot;</span>
The review performed a comprehensive literature search using multiple databases.

A2. [No]
There is no mention of duplicate study selection or data extraction.

A3. [Yes]
"A literature search was performed using PubMed, Cochrane, and Medline databases on all studies published during the last 20 years that described open or laparoscopic operation for inguinal hernia, and the latter was compared with conventional OH. The following key words were used: ‘‘inguinal hernia,’’
‘‘herniorrhaphy,’’ ‘‘hernia repair,’’ ‘‘children,’’ ‘‘laparoscopic versus open herniorrhaphy,’’ ‘‘laparoscopic versus open hernia repair,’’ ‘‘contralateral patency,’’ ‘‘complications,’’ and ‘‘recurrence.’’ Searches were also performed using the following as 
limits: clinical trials, randomized controlled trials, multicenter
retrospective, prospective studies, and expert opinion."
The review searched multiple databases and supplemented with other sources.

A4. [No]  
The review did not mention searching for grey literature.

A5. [No]
The review did not provide a list of included and excluded studies.

A6. [Yes]  
"Data regarding the following factors were considered:
first author, publication date, study method, participant 
features, intervention characteristics, definition of compli-
cations, and outcome measures. Outcome parameters for 
inclusion were patients’ age, gender, affected side, opera-
tive time, time to resume full activity, duration of hospital
stay, recurrence, metachronic contralateral hernia, and
complications."
The review extracted relevant characteristics of the included studies.

A7. [No] 
The review did not assess the scientific quality of included studies.

A8. [NA]
The review did not assess quality, so using it in formulating conclusions is not applicable.

A9. [NA]  
The review did not perform meta-analysis, so heterogeneity assessment is not applicable.

A10. [NA]
The review did not assess publication bias since it did not perform meta-analysis.

A11. [No]
The review did not report on conflicts of interest.

P1. [Yes]
The review is identified as a systematic review in the title.

P2. [No]  
The abstract does not contain a structured summary.

P3. [Yes]
The introduction describes the rationale and existing knowledge on the topic.

P4. [No]
The review does not provide explicit PICOS criteria.

P5. [No] 
The review does not mention a protocol.

P6. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
The review describes some eligibility criteria such as study design, participants, and outcomes measured, but does not specify all inclusion/exclusion criteria.

P7. [Yes]
The methods section describes the literature sources and search strategy. 

P8. [No]
The full search strategy is not provided for any database.

P9. [No]  
The process of study selection is not described.

P10. [No]  
The methods of data extraction are not described. 

P11. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]  
The extracted variables are described but not defined.

P12. [No]
Risk of bias assessment is not described.

P13. [NA] 
Statistical methods are not applicable since no meta-analysis was performed.

P14. [NA]  
Combining results is not applicable since no meta-analysis was performed.

P15. [NA]
Assessment of publication bias is not applicable since no meta-analysis was performed.

P16. [NA]  
Additional analyses are not applicable since no meta-analysis was performed.

P17. [No]
The number of studies screened and excluded at each stage is not reported.

P18. [No] 
Study characteristics for included studies are not presented.

P19. [No]  
Risk of bias for individual studies is not presented. 

P20. [No]
Results for each study are not presented.

P21. [NA]
Meta-analysis results are not applicable.

P22. [NA]  
Assessment of bias across studies is not applicable.

P23. [NA]
Additional analyses are not applicable.

P24. [No] 
Main findings are presented but strength of evidence is not summarized.

P25. [Yes]
Limitations at the review level are discussed.

P26. [Yes] 
The findings are interpreted and implications are discussed.

P27. [No]
Sources of support are not reported.

In summary, this review is identified as a systematic review but has substantial reporting deficiencies based on AMSTAR and PRISMA guidelines. Main issues include lack of duplicate study selection/data extraction, study selection process, risk of bias assessment, included study details, and funding sources. The review would need significant additional information to meet quality standards for systematic reviews.
</pre>
<p><a name='90'></a></p>
</div>
<div id="feng-2016" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3845-2' title='Open publication'>Feng
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the assessments for AMSTAR and PRISMA:

AMSTAR

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Literature searches were conducted to identify studies having compared the laparoscopic splenectomy (LS) and open splenectomy (OS) for children.&quot;</span> The research question and inclusion criteria are established before the review is conducted.
Reasoning: The review had pre-defined objectives and inclusion criteria.

A2. [No] The review did not mention duplicate study selection or data extraction.
Reasoning: No details provided on study selection or data extraction process.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Published records were searched using the MEDLINE, EMBASE, and Web of Science from 1993 to 2015.&quot;</span> At least two electronic databases were searched. 
Reasoning: Searched MEDLINE, EMBASE and Web of Science.

A4. [No] The review did not mention searching for grey literature.
Reasoning: No mention of searching for grey literature. 

A5. [No] The review did not provide a list of included and excluded studies. 
Reasoning: No list of included/excluded studies provided.

A6. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):

Tables 2 and 3 outlines the primary
and secondary outcome results from each study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Tables 1 and 2 outlines the primary and secondary outcome results from each study.&quot;</span> Data from original studies provided in tables.
Reasoning: Study characteristics provided in Tables 1 and 2.

A7. [No] The review did not mention assessing quality of included studies.
Reasoning: No quality assessment of included studies mentioned.

A8. [NA] Not applicable since no quality assessment was performed.

A9. [NA] Not applicable as no meta-analysis was performed for heterogeneous data like operative time and blood loss. 

A10. [NA] Not applicable as no assessment of publication bias mentioned.

A11. [No] The review did not provide details on sources of support or conflicts of interest.
Reasoning: No mention of sources of support or conflicts of interest.

PRISMA

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic versus open splenectomy in children: a systematic review and meta-analysis&quot;</span> Review identified as systematic review and meta-analysis in title.
Reasoning: Identified as systematic review and meta-analysis in title.

P2. [No] No structured abstract provided summarizing objectives, data sources, eligibility criteria, etc.
Reasoning: No structured abstract provided.

P3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Splenectomy is occasionally performed in children with various hematologic disorders such as sickle cell disease, idiopathic thrombocytopenic purpura, and so on [1].&quot;</span> Provides context and rationale for the review.
Reasoning: Provided background and rationale in introduction.

P4. [No] No explicit PICOS statement provided. 
Reasoning: No PICOS statement given.

P5. [No] Does not mention if a review protocol exists.
Reasoning: No mention of a review protocol.

P6. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

Inclu-
sion criteria: (1) clinical trials that compared laparoscopic
versus open splenectomy between 1993 and 2015; (2)
children under 18 years old who suffered from benign or
malignant hematological diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria: (1) clinical trials that compared laparoscopic versus open splenectomy between 1993 and 2015; (2) children under 18 years old who suffered from benign or malignant hematological diseases&quot;</span> Specifies eligibility criteria. 
Reasoning: Specified eligibility criteria.

P7. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Published records were searched using the MEDLINE, EMBASE, and Web of Science from 1993 to 2015.&quot;</span> Mentions literature sources searched.
Reasoning: Stated databases searched with date ranges. 

P8. [No] Does not provide full search strategy.
Reasoning: Did not provide full search strategy.

P9. [No] Does not describe the process of study selection and reasons for exclusions. 
Reasoning: No details provided on study selection process.

P10. [No] Does not describe data extraction methods.
Reasoning: No description of data extraction process. 

P11. [No] Does not list variables extracted.
Reasoning: Did not list variables for which data extracted.

P12. [No] Does not describe methods for assessing risk of bias. 
Reasoning: No risk of bias assessment mentioned.

P13. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):

For continuous data, we pre-
sented mean differences (MDs) with 95 % confidence
intervals (CIs' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For continuous data, we presented mean differences (MDs) with 95% confidence intervals (CIs).&quot;</span> States summary measures used.
Reasoning: Stated use of mean differences and confidence intervals.

P14. [NA] Not applicable as no meta-analysis performed for heterogeneous data.

P15. [NA] Not applicable as no assessment of publication bias mentioned. 

P16. [NA] Not applicable as no additional analyses mentioned.

P17. [No] Does not provide a flow diagram or details on screening results.
Reasoning: No flow diagram or details on screening provided.

P18. [No] Does not provide study characteristics for each included study. 
Reasoning: Study characteristics not provided for each study.

P19. [NA] Not applicable as no risk of bias assessment performed.

P20. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Tables 2 and 3 outlines the primary and secondary outcome results from each study.&quot;</span> Presents summary data for each study. 
Reasoning: Outcome data for each study presented in tables.

P21. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

Meta-analysis revealed a statistically significant
decrease in mean length of hospital stay for LS compared
with OS (WMD -1.61, 95 % CI -2.19 to -1.02;
P = 0.001' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Meta-analysis revealed a statistically significant decrease in mean length of hospital stay for LS compared with OS (WMD -1.61, 95% CI -2.19 to -1.02; P = 0.001)&quot;</span> Presents results of meta-analyses with CIs.
Reasoning: Presented meta-analysis results with CIs. 

P22. [NA] Not applicable as no assessment of risk of bias across studies.

P23. [NA] Not applicable as no additional analyses mentioned.

P24. [No] Does not provide an overall interpretation of results or implications.
Reasoning: No overall discussion or interpretation of results provided.

P25. [No] Does not discuss limitations at study or outcome level.
Reasoning: Did not discuss limitations at study or outcome level.

P26. [No] Does not provide overall interpretation in context of other evidence. 
Reasoning: No overall interpretation in context of other evidence.

P27. [No] Does not describe sources of funding or support.
Reasoning: No mention of sources of funding or support.
</pre>
<p><a name='91'></a></p>
</div>
<div id="feng-2015" class="section level4">
<h4><a href='https://doi.org/10.1097/SLE.0000000000000161' title='Open publication'>Feng
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘missing-squared-brackets-na-with-slash’, ‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords “laparoscopic herniorrhaphy”, “pediatric inguinal hernia,” and “open herniorrhaphy."&quot;</span>
The research question and inclusion criteria were pre-determined. 

A2. Was there duplicate study selection and data extraction? [No] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The first author independently extracted data from the included studies.&quot;</span>
Only one author performed study selection and data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords “laparoscopic herniorrhaphy”, “pediatric inguinal hernia,” and “open herniorrhaphy.” Total reference lists of selected articles were also included.&quot;</span>
At least two databases were searched, and supplementary strategies were used.

A4. Was the status of publication used as an inclusion criterion? [No] 
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
A list of included studies is provided, but not excluded studies. 

A6. Were the characteristics of the included studies provided? [Yes]
Characteristics of included studies are provided in Table 1.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Quality of the RCTs was assessed, including randomization, method of blinding, and allocation concealment.&quot;</span> Details provided in Table 2.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
The quality assessment was considered in the discussion.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
Heterogeneity was assessed using I2. Random effects model used when I2>50%. 

A10. Was the likelihood of publication bias assessed? [No]
Publication bias was not assessed.

A11. Was the conflict of interest included? [No]
No conflict of interest statement.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Here, we per-
formed a meta-analysis on total published randomized
controlled trials (RCTs) to assess whether LH is superior to
open herniorrhaphy (OH) in repairing PIH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Here, we performed a meta-analysis on total published randomized controlled trials (RCTs) to assess whether LH is superior to OH in repairing PIH.&quot;</span>

P2. Provide a structured summary. [Yes] 
Structured abstract provided with background, objectives, data sources, eligibility criteria, results, conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Introduction describes the rationale and context.

P4. Provide an explicit statement of questions being addressed with reference to PICOS. [Yes]
Objectives and inclusion criteria cover PICOS.

P5. Indicate if a review protocol exists. [No]
No mention of a review protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
Inclusion criteria describe study characteristics. 

P7. Describe all information sources in the search and date last searched. [Yes] 
Search methods described.

P8. Present full electronic search strategy for at least one database, including any limits used. [No]
Search strategy not provided.

P9. State the process for selecting studies. [Yes] 
Study selection process described and shown in Figure 1.

P10. Describe method of data extraction from reports. [No] 
No details provided on data extraction process.

P11. List and define all variables for which data were sought. [Yes]
Outcomes analyzed were operative time, complications, and recurrence. 

P12-P16. N/A <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span> (no risk of bias assessment or meta-analysis)

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. [Yes]
Number of studies at each stage provided in Figure 1.

P18. For each study, present characteristics for which data were extracted. [Yes]
Study characteristics presented in Tables 1 and 2. 

P19-P23. N/A <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span> (no risk of bias assessment or meta-analysis)

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes] 
Main findings are summarized in the discussion.

P25. Discuss limitations at study and outcome level, and at review-level. [Yes]
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results interpreted in the discussion.

P27. Describe sources of funding for the systematic review. [No] 
No statement on sources of funding.
</pre>
<p><a name='92'></a></p>
</div>
<div id="friedmacher-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-011-2958-5' title='Open publication'>Friedmacher
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. "[PubMed
Ò 
and MEDLINE
Ò 
databases were searched for all studies that reported cases of patients with HD who had undergone redo PT operations for RA or TZB after initial operation between 1985 and 2011.]"  
Searched multiple databases. [Yes]

A2. No mention of duplicate study selection or data extraction. [No] 

A3. "PubMed
Ò 
and MEDLINE
Ò 
databases were searched for all studies that reported cases of patients with HD who had undergone redo PT operations for RA or TZB after initial operation between 1985 and 2011. The search terms were “residual aganglionosis”, “transition-zone bowel”, “redo and repeat pull-through”, “reoperation Hirschsprung’s disease” and “postoperative follow-up and outcome Hirschsprung’s disease”. The reference lists from retrieved articles were reviewed for additional cases."
Searched multiple databases and supplementary sources. [Yes]

A4. No mention of searching for unpublished or grey literature. [No]

A5. No list of included/excluded studies provided. [No]

A6. Table 1 provides characteristics of included studies. [Yes] 

A7. No quality assessment of included studies. [No]

A8. Not applicable since no quality assessment done. [NA]  

A9. Not applicable since no quantitative synthesis done. [NA]

A10. Not applicable since no quantitative synthesis done. [NA]

A11. No mention of conflicts of interest. [No]

P1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Residual aganglionosis after pull-through operation for Hirschsprung’s disease: a systematic review and meta-analysis&quot;</span> [Yes]

P2. Abstract provides background, objectives, eligibility criteria, participants, interventions, results, conclusions. [Yes]

P3. Introduction describes rationale and what is known. [Yes]

P4. Objectives refer to participants, interventions, outcomes. [Yes] 

P5. No protocol mentioned. [No]

P6. Inclusion criteria described. [Yes]

P7. Information sources described. [Yes]

P8. No full search strategy provided. [No]

P9. Inclusion/exclusion process described in methods. [Yes]

P10. No data extraction methods described. [No] 

P11. Outcomes sought described. [Yes]

P12. No risk of bias assessment. [No]

P13. Not applicable since no quantitative synthesis. [NA]

P14-P23. Not applicable since no quantitative synthesis. [NA]

P24. Main findings summarized in abstract and discussion. [Yes]

P25. Limitations not discussed. [No]

P26. Results interpreted in context of other evidence. [Yes] 

P27. No funding sources reported. [No]
</pre>
<p><a name='93'></a></p>
</div>
<div id="friedmacher-2012" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-012-3142-2' title='Open publication'>Friedmacher
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was performed to identify articles reporting cases of LGEA managed by DPA.&quot;</span> The review had predefined objectives to analyze cases of LGEA managed with DPA.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.5%):

Common electronic databases as MEDLINE
Ò
, EMBASE
Ò
,
ISI Web of Science 
SM 
and the Cochrane Library were
searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Common electronic databases as MEDLINE®, EMBASE®, ISI Web of ScienceSM and the Cochrane Library were searched.&quot;</span> Multiple databases were searched. 

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Characteristics of included studies provided in Table 1.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA] 
Study quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
Meta-analysis performed and relative risks calculated appropriately. 

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Article titled <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Delayed primary anastomosis for management of long-gap esophageal atresia: a meta-analysis of complications and long-term outcome.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]
Structured abstract provided with background, objectives, data sources, participants/interventions, analysis methods, results, and conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
Introduction provides context and rationale for examining DPA for LGEA.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No review protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Inclusion criteria broadly described but no explicit eligibility criteria stated regarding study characteristics.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [No]
Databases listed but no dates of coverage provided. Last search date not reported.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No] 
Study selection process not described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No data extraction process described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Outcomes of interest not pre-defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes] 
Used percentages and relative risks as summary measures.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [No]
No measures of consistency reported.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No] 
No assessment of risk of bias performed.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
No flow diagram, number screened, assessed, or reasons for exclusions given.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]  
Some study characteristics presented in Table 1 but not complete.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]
No risk of bias assessment presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
No forest plots presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [No]  
No measures of consistency reported for meta-analyses. 

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment of risk of bias performed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression), if done (see Item P16). [NA]
No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in discussion and conclusion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]  
No limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of other evidence on LGEA management.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of funding or support.
</pre>
<p><a name='94'></a></p>
</div>
<div id="frongia-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.018' title='Open publication'>Frongia
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. No quotes extracted. The inclusion criteria of the review did not specify an a priori design. [No]

A2. No quotes extracted. There is no mention of duplicate study selection or data extraction. [No]

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was carried out using the search terms “bowel lengthening”, “intestinal lengthening”, “longitudinal intestinal lengthening and tailoring”, “LILT”, “Bianchi procedure”, “serial transverse enteroplasty” and “step procedure”. The last search was done on December, 10th, 2012. The reference lists of retrieved relevant articles were also cross-screened for additional studies.&quot;</span> [Yes]

A4. No quotes extracted. The inclusion criteria did not specify inclusion or exclusion based on publication status. [No] 

A5. No quotes extracted. The review does not provide a list of included and excluded studies. [No]

A6. No quotes extracted. The review provides summary data on patient characteristics but not for each individual study. [No]

A7. No quotes extracted. The review does not assess the scientific quality of included studies. [No] 

A8. Not applicable. The review does not assess quality or use quality in formulating conclusions. [NA]

A9. Not applicable. The review does not perform quantitative synthesis. [NA]

A10. Not applicable. The review does not assess publication bias. [NA]

A11. No quotes extracted. The review does not report on conflicts of interest in the included studies. [No]

P1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Comparison of LILT and STEP procedures in children with short bowel syndrome — A systematic review of the literature&quot;</span> [Yes]

P2. The abstract provides background, objectives, data sources, eligibility criteria, outcomes, and conclusions. [Yes] 

P3. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

The first pivotal aim in the therapy of SBS is to ensure
alimentation of the child by parenteral nutrition (PN), which
results in significant improvements in mortality rates and
improved thrive and quality of life in paediatric SBS [65,66].
Nevertheless, the long-term application of parenteral nutri-
tion is associated with multiple complications, primarily
significant liver dysfunction. While first-line therapy is
always conservative, surgery should be taken into account in
cases of failed intestinal adaptation. LILT and STEP are both
accepted procedures potentially able to wean the child from
PN, therefore promoting intestinal autonomy and patient
outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The first pivotal aim in the therapy of SBS is to ensure alimentation of the child by parenteral nutrition (PN), which results in significant improvements in mortality rates and improved thrive and quality of life in paediatric SBS [65,66]. Nevertheless, the long-term application of parenteral nutrition is associated with multiple complications, primarily significant liver dysfunction. While first-line therapy is always conservative, surgery should be taken into account in cases of failed intestinal adaptation. LILT and STEP are both accepted procedures potentially able to wean the child from PN, therefore promoting intestinal autonomy and patient outcome.&quot;</span> [Yes]

P4. No explicit PICOS statement. The objectives, inclusion criteria, and outcomes imply a focus on patients (children with short bowel syndrome), interventions (LILT and STEP procedures), comparator (comparison between LILT and STEP), and outcomes (various clinical outcomes). [No] 

P5. No mention of a review protocol. [No]

P6. The inclusion criteria specify that studies must include humans aged 0-18 years undergoing LILT or STEP procedure. No other study characteristics are specified. [Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P7. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was carried out using the search terms “bowel lengthening”, “intestinal lengthening”, “longitudinal intestinal lengthening and tailoring”, “LILT”, “Bianchi procedure”, “serial transverse enteroplasty” and “step procedure”. The last search was done on December, 10th, 2012. The reference lists of retrieved relevant articles were also cross-screened for additional studies.&quot;</span> [Yes]

P8. The review does not provide a full electronic search strategy. [No]

P9. The screening and selection process is described and depicted in a flow diagram. Reasons for exclusion are provided. [Yes] 

P10. No description of data extraction methods. [No] 

P11. No explicit listing of all data sought. [No]

P12. The review does not assess risk of bias in individual studies. [No]

P13. No meta-analysis performed. [NA]

P14. No meta-analysis performed. [NA]

P15. No assessment of risk of bias across studies. [No] 

P16. No additional analyses performed. [NA]

P17. The flow diagram depicts records screened, assessed for eligibility, included, and reasons for exclusion. [Yes]

P18. A table lists author, year, procedure, and number of patients for included studies. No other study characteristics presented. [Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P19. The review does not assess risk of bias in individual studies. [No] 

P20. No quantitative synthesis performed. [NA]

P21. No meta-analysis performed. [NA]

P22. No assessment of risk of bias across studies. [No]

P23. No additional analyses performed. [NA]

P24. The discussion section summarizes the main findings and limitations. [Yes]

P25. Limitations are discussed related to lack of control group, retrospective data, heterogeneity, and limited number of cases. [Yes]

P26. The discussion provides interpretation of the results and suggestions for future research. [Yes]

P27. No statement about sources of funding or conflicts of interest. [No]

In summary, the AMSTAR assessment found that the review had a comprehensive literature search (A3) but was lacking in all other domains of methodological quality. The PRISMA assessment found that the review adequately reported on the title (P1), abstract (P2), rationale (P3), screening process (P9), flow diagram (P17), summary of findings (P24), limitations (P25), and interpretation of results (P26). However, the review was lacking in reporting of protocol (P5), search strategy (P8), data extraction (P10), individual study risk of bias (P12, P19), across study bias (P15, P22), and funding (P27). Overall, the review has significant methodological and reporting limitations based on AMSTAR and PRISMA.
</pre>
<p><a name='95'></a></p>
</div>
<div id="gallo-2012" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0032-1331459' title='Open publication'>Gallo
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Review of the English-language literature published in the past 5 years about esophageal replacement in children was done.&quot;</span> No mention of a protocol.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

A literature search (PubMed and Embase) was performed, and
all human studies published in the English-language literature
between 2006 and 2011 describing esophageal replacement for
LGEA were identified, using the medical subject headings
“Esophageal Atresia,” “Long-gap,” “Esophagoplasty,” “Replace-
ment,” “Interposition,” “Substitution,” “Graft,” and their combi-
nations. All titles and abstracts were scanned and appropriate
citations were reviewed. Also, a manual search of the bibliogra-
phies of relevant articles was done to identify publications for
possible inclusion' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A literature search (PubMed and Embase) was performed, and all human studies published in the English-language literature between 2006 and 2011 describing esophageal replacement for LGEA were identified, using the medical subject headings “Esophageal Atresia,” “Long-gap,” “Esophagoplasty,” “Replacement,” “Interposition,” “Substitution,” “Graft,” and their combinations. All titles and abstracts were scanned and appropriate citations were reviewed. Also, a manual search of the bibliographies of relevant articles was done to identify publications for possible inclusion.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [No]  
Included studies listed in Table 1 but no list of excluded studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides author, year, replacement type, number of patients, and study design. Additional details provided in text. 

A7. Was the scientific quality of the included studies assessed and documented? [No]  
No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
Used random effects model and weighted analysis to account for heterogeneity.

A10. Was the likelihood of publication bias assessed? [No]  
No assessment of publication bias mentioned. 

A11. Was the conflict of interest included? [No]  
No conflict of interest statement.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Identified as a meta-analysis in the title and abstract. 

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]  
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Introduction describes lack of consensus on optimal surgical approach and need for meta-analysis.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]  
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No] 
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion and exclusion criteria described in methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]  
Databases, date range, search terms, and supplementary strategies described.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]  
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No] 
No details provided on study screening and selection process.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No details on data extraction process. 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Outcomes defined in methods section.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]  
Used relative risk as summary measure.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Described use of random effects model and rationale.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No]   
No assessment of risk of bias across studies.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]  
Number of studies included given but not number screened or assessed for eligibility. No flow diagram. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] 
Table 1 presents key characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No] 
No risk of bias assessment presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]   
Summary data and effect estimates presented in tables. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes]
Results of meta-analyses presented with confidence intervals in tables.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]  
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses done.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]
Main findings summarized but strength of evidence not discussed.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]  
Limitations discussed in discussion section.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in discussion section.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] 
No statement on sources of funding or support.
</pre>
<p><a name='96'></a></p>
</div>
<div id="gosemann-2013" class="section level4">
<h4><a href='https://doi.org/10.1055/s-0033-1343085 ' title='Open publication'>Gosemann
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here is my assessment of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the given systematic review:

A1. "[No]"
- No protocol, ethics approval, or pre-determined objectives are mentioned.
- The research question and inclusion criteria are not explicitly stated before conducting the review.

A2. "[Yes]" 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span> (A2)
- The review had 2 authors who extracted data and analyzed the studies.

A3. "[Yes]"
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PubMed&quot;</span> database was searched, along with screening reference lists. (Methods)
- At least 2 sources were searched.

A4. "[No]"  
- The status of publication was not used as an inclusion criterion.
- It is not stated whether grey literature was searched.

A5. "[No]"
- A list of included and excluded studies is not provided.

A6. "[Yes]"
- Table 1 shows characteristics of included studies like author, year, surgical technique, number of patients etc.

A7. "[No]" 
- The methodological quality of included studies was not assessed.

A8. "[NA]"
- Since quality of studies was not assessed, this question is not applicable.

A9. "[Yes]"
- Odds ratios and tests for heterogeneity were calculated in the meta-analysis. 

A10. "[No]"
- Publication bias was not assessed.

A11. "[No]"
- Sources of support/funding are not reported.

P1. "[Yes]"
- Identified as a systematic review in title.

P2. "[Yes]" 
- Structured abstract provided with background, objectives, eligibility criteria, data sources, results, conclusions etc.

P3. "[Yes]"
- Rationale described in introduction, comparing surgical techniques.

P4. "[No]"
- PICOS not explicitly stated.

P5. "[No]"
- No protocol mentioned.

P6. "[Yes]"
- Inclusion/exclusion criteria described.

P7. "[Yes]"
- Database and years searched stated. 

P8. "[No]"
- Full search strategy not provided.

P9. "[Yes]" 
- Study selection process described and depicted in Figure 1.

P10. "[No]"
- Data extraction process not described.

P11. "[Yes]" 
- Outcomes described.

P12. "[No]" 
- Risk of bias not assessed.

P13. "[Yes]"
- Used odds ratios as summary measures.

P14. "[Yes]" 
- Meta-analysis methods described. 

P15. "[No]"
- Publication bias not assessed.

P16. "[NA]" 
- No additional analyses.

P17. "[Yes]"
- Study flow shown in Figure 1.

P18. "[Yes]"
- Study characteristics presented in Table 1. 

P19. "[No]"
- Risk of bias not presented.

P20. "[Yes]"
- Results presented for each outcome.

P21. "[Yes]"
- Meta-analysis results presented.

P22. "[NA]"
- No assessment of risk of bias across studies.

P23. "[NA]" 
- No additional analyses.

P24. "[Yes]" 
- Main findings summarized in discussion.

P25. "[Yes]"
- Limitations discussed.

P26. "[Yes]"
- Results interpreted and implications described.

P27. "[No]"
- No funding reported.
</pre>
<p><a name='97'></a></p>
</div>
<div id="graziano-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.06.019' title='Open publication'>Graziano
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Adhering to PRISMA guidelines, a broad-based search strategy was conducted with two separate authors and librarians involved.&quot;</span>
The review mentioned adhering to PRISMA guidelines and using multiple authors/librarians for the search, indicating an a priori protocol.  

A2. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Abstracts were then reviewed and relevant articles selected by two of the authors (KG and SI), who also then performed independent manual searches of the reference lists of these articles, bringing the total reviewed to 2545.&quot;</span>
Two authors independently selected studies, meeting criteria for duplicate study selection.

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

Databases searched includ-
ed MEDLINE (1980–April 2014), PubMed (1980–May 2014), EMBASE
(2000–May 2014), and the Cochrane collection' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Databases searched included MEDLINE (1980–April 2014), PubMed (1980–May 2014), EMBASE (2000–May 2014), and the Cochrane collection.&quot;</span> 
Multiple databases were searched, along with supplementary strategies like reference scanning.

A4. [No]
The review did not mention searching for grey literature.

A5. [No]
The review did not provide a list of included/excluded studies.

A6. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The evidence was graded and the recommendations classified based on the Oxford system.&quot;</span>
The evidence levels and recommendation grades for each study were provided. 

A7. [No]
The review did not assess the quality of individual studies.

A8. [NA]
Quality assessment was not performed, so using it to formulate conclusions is not applicable.

A9. [NA]  
The review did not perform quantitative synthesis/meta-analysis. 

A10. [NA]
Assessment of publication bias is not applicable without a meta-analysis.

A11. [No]
Sources of funding/support were not reported for the review or individual studies.

P1. [Yes]
The report is identified as a systematic review in the title.

P2. [Yes]  
The abstract provides relevant details on the background, objectives, eligibility criteria, data sources, study appraisal, results, and conclusions.

P3. [Yes]
The introduction describes the rationale and context of the review topic.

P4. [Yes]
Five specific questions are listed regarding participants, interventions, comparisons, and outcomes. 

P5. [No] 
The review did not mention a protocol.

P6. [Yes]
Inclusion criteria focusing on study characteristics and publication status are described.

P7. [Yes]
The data sources, search dates, and search terms are provided. 

P8. [No]
The full search strategy is not included for any database.

P9. [Yes]  
The process of screening and selecting studies is described. 

P10. [No] 
The method of data extraction is not described.

P11. [NA] 
Data variables were not defined since this is a qualitative synthesis without meta-analysis.

P12. [NA]
Assessment of risk of bias in individual studies is not applicable without a meta-analysis.

P13. [NA]
Principal summary measures are not applicable without quantitative synthesis.

P14. [NA] 
Methods for combining study results are not applicable without meta-analysis.

P15. [NA]
Assessment of risk of bias across studies is not applicable without meta-analysis.

P16. [NA]
Additional analyses are not applicable without meta-analysis.

P17. [No]
Details on the number of studies screened and excluded at each stage are not provided.

P18. [No] 
Study characteristics for included studies are not presented.

P19. [NA] 
Assessment of risk of bias for individual studies is not applicable without meta-analysis.

P20. [NA]
Study data and effect estimates are not applicable without quantitative synthesis. 

P21. [NA]  
Results of meta-analyses are not applicable.

P22. [NA]
Assessment of risk of bias across studies is not applicable without meta-analysis.

P23. [NA] 
Additional analyses are not applicable without meta-analysis.

P24. [Yes]
Main findings and conclusions are summarized, including their relevance to key groups.

P25. [No]
Limitations at the review level are not discussed.

P26. [Yes] 
The results are interpreted and implications for future research are described.

P27. [No]
Sources of funding are not reported.
</pre>
<p><a name='98'></a></p>
</div>
<div id="guo-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-011-2889-1' title='Open publication'>Guo
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Since the current study was a systemic review and meta-
analysis based on the published articles, the consents of
patients and approval of Internal Review Boards were not
included' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Since the current study was a systemic review and meta-analysis based on the published articles, the consents of patients and approval of Internal Review Boards were not included.&quot;</span>
The objectives and inclusion criteria were pre-determined.

A2. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The citations and/or abstracts or full text of all potentially relevant studies were independently evaluated and selected by three reviewers (GJ, LZL and TQS), and any disagreements were resolved by consensus.&quot;</span>
Study selection and data extraction were done independently by 3 reviewers. 

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Published studies until August 31, 2010 were searched with the terms ‘‘laparoscopic orchiopexy’’, ‘‘open orchiopexy’’, and ‘‘children’’ from Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span>
At least 2 databases were searched along with keywords.

A4. [No]
No mention of including or excluding grey literature.

A5. [No]
No list of included and excluded studies provided.

A6. [Yes] 
Table 1 provides characteristics of included studies.

A7. [No]  
No assessment of quality of included studies.

A8. [NA]
No assessment of study quality.

A9. [Yes]
Heterogeneity assessed using I2 statistic. Random effects model used for I2 > 50%. 

A10. [No]  
No assessment of publication bias.

A11. [No]
No statement about conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic versus open orchiopexy for non-palpable undescended testes in children: a systemic review and meta-analysis&quot;</span>
Identified as systematic review and meta-analysis.

P2. [Yes]
Abstract provides structured summary.

P3. [Yes]  
Rationale described in introduction.

P4. [Yes]
Objectives state comparing laparoscopic and open orchiopexy for non-palpable testes in children.

P5. [No] 
No mention of a review protocol.

P6. [Yes]
Inclusion criteria described.

P7. [Yes]
Information sources described.

P8. [No]
No full search strategy provided.

P9. [Yes]
Study selection process described and depicted in Figure 1.

P10. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Three reviewers (GJ, LZL and TQS) independently asses-
sed selected studies, extracted and tabulated data from each
article with a predefined data extraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three reviewers (GJ, LZL and TQS) independently assessed selected studies, extracted and tabulated data from each article with a predefined data extraction form.&quot;</span>

P11. [Yes]
Outcomes described in Methods.

P12. [No]
No assessment of risk of bias. 

P13. [Yes]
WMD and OR used as summary measures.

P14. [Yes]
Methods described for meta-analyses. 

P15. [No]
No assessment of publication bias.

P16. [NA]
No additional analyses.

P17. [Yes]  
Numbers at each stage provided in Figure 1.

P18. [Yes] 
Characteristics extracted into Table 1.

P19. [NA] 
No assessment of risk of bias.

P20. [Yes]
Forest plots provide data and effect sizes.

P21. [Yes] 
Results of meta-analyses presented.

P22. [NA]
No assessment of risk of bias across studies.

P23. [NA] 
No additional analyses.

P24. [Yes]
Main findings summarized in Discussion.

P25. [Yes]
Limitations discussed.

P26. [Yes]  
General interpretation of results provided.

P27. [No]
No statement about sources of funding.
</pre>
<p><a name='99'></a></p>
</div>
<div id="hall-2011" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2011.01.019' title='Open publication'>Hall
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are my responses for assessing the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? 
"[No]"
No mention of a protocol, ethics approval, or pre-determined research objectives.

A2. Was there duplicate study selection and data extraction?
"[No]" 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A Medline search was performed using the keywords appendix mass, interval appendicectomy, and children from January 1964 to July 2009 to identify reports of successful nonoperative treatment of AM in children.&quot;</span>

A4. Was the status of publication used as an inclusion criterion?
"[No]"
No mention of including or excluding studies based on publication status. 

A5. Was a list of studies (included and excluded) provided?
"[No]"
Included studies are referenced but no list of excluded studies.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
Characteristics of included studies provided in text and tables. 

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
No assessment of quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
"[NA]"
Did not assess quality of included studies.

A9. Were the methods used to combine the findings of studies appropriate?
"[NA]" 
No quantitative synthesis conducted.

A10. Was the likelihood of publication bias assessed?  
"[NA]"
No assessment of publication bias as no meta-analysis.

A11. Was the conflict of interest included?
"[No]"
No mention of funding sources or conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. 
"[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Systematic review&quot;</span> in title.

P2. Provide a structured summary.
"[Yes]" 
Structured abstract provided.

P3. Describe the rationale for the review.
"[Yes]"
Rationale described in introduction.

P4. Provide an explicit statement of questions being addressed. 
"[Yes]"
Objectives stated to evaluate evidence for interval appendectomy in children.

P5. Indicate if a review protocol exists.
"[No]"
No mention of a protocol.

P6. Specify study characteristics used as criteria for eligibility.
"[Yes]" 
Inclusion criteria described in methods.

P7. Describe all information sources in the search.
"[Yes]" 
Database, keywords, years searched reported. 

P8. Present full electronic search strategy.
"[No]"
Search strategy not provided.

P9. State the process for selecting studies.
"[Yes]"
Study selection process described.

P10. Describe method of data extraction.
"[No]" 
No details on data extraction process.

P11. List and define all variables for which data were sought.
"[Yes]"
Outcomes described.

P12. Describe methods for assessing risk of bias. 
"[No]"
No assessment of risk of bias.

P13. State the principal summary measures. 
"[NA]" 
No meta-analysis performed.

P14-P23. Synthesis methods.
"[NA]"
No meta-analysis performed.

P24. Summarize the main findings.
"[Yes]"
Main findings summarized in discussion.

P25. Discuss limitations at study and outcome level.
"[Yes]"
Limitations of included studies discussed.

P26. Provide a general interpretation of the results.
"[Yes]" 
Results interpreted in context of literature.

P27. Describe sources of funding for the review.
"[No]" 
No mention of sources of funding.
</pre>
<p><a name='100'></a></p>
</div>
<div id="healy-2015" class="section level4">
<h4><a href='https://doi.org/10.1097/MD.0000000000001352' title='Open publication'>Healy
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the provided systematic review:

A1. [Yes]  
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

This systematic article was conducted according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This systematic article was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.&quot;</span>
Reasoning: The study mentions following PRISMA guidelines which require an a priori design.

A2. [Yes]   
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.2%):

4).
Two authors (DD and DH) independently extracted data
from eligible studies using an electronic spreadsheet' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two authors searched Medline and Embase to identify relevant studies." "Two authors (DD and DH) independently extracted data from eligible studies using an electronic spreadsheet.&quot;</span>  
Reasoning: Two authors performed study selection and data extraction.

A3. [Yes]
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.6%):

2 authors (DD and MM) independently searched Medline and
EMBASE up to June 24, 2015 using the following search strategy
‘‘([paediatric surgery OR pediatric surgery OR pediatric surgeon
OR paediatric surgeon] AND (appendectomy OR appendicect-
omy)].’’ The search terms were inputted as free text. Titles and
abstracts were examined initially and then full manuscripts were
obtained to finalize eligibility. The reference lists of eligible
studies w' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two authors searched Medline and Embase up to June 24, 2015 using the following search strategy ‘‘([paediatric surgery OR pediatric surgery OR pediatric surgeon OR paediatric surgeon] AND (appendectomy OR appendicectomy)].’’" "All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span>
Reasoning: Searched two databases (Medline and Embase) and supplemented with reference list checking. 

A4. [No]
Quotes: No mention of searching for gray literature.
Reasoning: No mention of gray literature searching.

A5. [No]  
Quotes: No list of included and excluded studies provided.
Reasoning: No list of included/excluded studies.

A6. [Yes]   
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Table 1 and results from the studies are provided in Table 2.&quot;</span> 
Reasoning: Table 1 provides characteristics of included studies.

A7. [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Study quality was assessed using the Downs and Black tool.&quot;</span>
Reasoning: Used the Downs and Black quality assessment tool. 

A8. [Yes]  
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Despite this, our find-
ings must be interpreted with caution as our article is based
entirely upon observational data' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Despite this, our findings must be interpreted with caution as our article is based entirely upon observational data.&quot;</span>
Reasoning: Limitations of observational data acknowledged in conclusions.

A9. [Yes]
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):

We used Mantel Haenszel random effects models.
The potential for publication bias was evaluated by visually
inspecting funnel plots. Statistical heterogeneity was assessed
using the I 
2 
statistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We used Mantel Haenszel random effects models." "Statistical heterogeneity was assessed using the I2 statistic.&quot;</span>
Reasoning: Used random effects models and assessed heterogeneity using I2.

A10. [No] 
Quotes: No assessment of publication bias mentioned.
Reasoning: No graphical or statistical assessment of publication bias.

A11. [No]
Quotes: No mention of conflicts of interest or funding sources. 
Reasoning: No mention of conflicts of interest or funding sources.

P1. [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic Review and Meta-Analysis on the Influence of Surgeon Specialization on Outcomes Following Appendicectomy in Children&quot;</span>
Reasoning: Identified as a systematic review in the title.

P2. [Yes]
Quotes: The abstract provides background, objectives, eligibility criteria, outcomes, results, limitations, and conclusions.
Reasoning: Structured abstract provided with all necessary elements.

P3. [Yes]  
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

An expanding body of evidence suggests that surgeon
subspecialization affects outcomes; studies found that color-
ectal surgery subspecialization 
4 
and orthopedic surgery sub-
specialization 
5 
lead to improved results and that outcomes from
a variety of cancers are improved with subspecialization' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An expanding body of evidence suggests that surgeon subspecialization affects outcomes; studies found that colorectal surgery subspecialization and orthopedic surgery subspecialization lead to improved results and that outcomes from a variety of cancers are improved with subspecialization.&quot;</span>
Reasoning: Provided context about existing evidence on surgeon specialization and outcomes.

P4. [Yes]  
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

The aim of this study is to assess the influence of surgeon
specialization on outcomes following appendicectomy in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of this study is to assess the influence of surgeon specialty on outcomes following appendicectomy in children.&quot;</span> 
Reasoning: Clear objective stated relating to participants, intervention, and outcomes.

P5. [No]
Quotes: No mention of a review protocol.
Reasoning: Did not mention existence of a protocol.

P6. [Yes] 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eligible studies were comparative and provided data on children who had appendicectomy while under the care of general or pediatric surgical teams.&quot;</span>
Reasoning: Specified participant characteristics and comparators. 

P7. [Yes]
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 90.5%):

2 authors (DD and MM) independently searched Medline and
EMBASE up to June 24, 2015 using the following search strategy' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Two authors searched Medline and Embase up to June 24, 2015 using the following search strategy&quot;</span>
Reasoning: Described databases searched with date ranges.

P8. [Yes]
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 92.2%):

paediatric surgery OR pediatric surgery OR pediatric surgeon
OR paediatric surgeon] AND (appendectomy OR appendicect-
omy' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎‘‘([paediatric surgery OR pediatric surgery OR pediatric surgeon OR paediatric surgeon] AND (appendectomy OR appendicectomy)].’’&quot;</span>
Reasoning: Provided full search strategy for one database.

P9. [Yes]  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Titles and abstracts were examined initially and then full manuscripts were obtained to finalize eligibility.&quot;</span>
Reasoning: Described process of screening titles/abstracts and full texts.

P10. [Yes] 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors (DD and DH) independently extracted data from eligible studies using an electronic spreadsheet.&quot;</span>
Reasoning: Stated two authors independently extracted data.

P11. [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Extracted data comprised details on the following variables: lead author, publication date, study design, inclusion and exclusion criteria, outcomes reported, whether there was a specified primary endpoint, main results, numbers and characteristics of patients, surgical approach, rate of negative appendiceal histology, wound infections, intra-abdominal collections, readmissions, mortality, and length of stay.&quot;</span>
Reasoning: Listed variables extracted from studies.

P12. [Yes] 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Study quality was assessed using the Downs and Black tool.&quot;</span>
Reasoning: Specified use of Downs and Black tool for quality assessment.

P13. [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pooled risk ratios and pooled mean differences were used to evaluate the effect of treatment by general surgery units or pediatric surgery units on dichotomous and continuous outcomes, respectively.&quot;</span>
Reasoning: Specified summary measures used (risk ratios and mean differences).

P14. [NA]
Reasoning: No quantitative synthesis performed.

P15. [NA] 
Reasoning: No assessment of publication bias applicable without meta-analysis.

P16. [NA]
Reasoning: No additional analyses applicable without meta-analysis.

P17. [Yes]
Quotes: The search results flow diagram in Figure 1 shows numbers screened, assessed, and included with reasons for exclusions. 
Reasoning: Provided flow diagram with numbers at each stage.

P18. [Yes] 
Quotes: Table 1 provides characteristics of included studies.
Reasoning: Provided details on included studies in table.

P19. [No] 
Quotes: Quality assessment results not presented at study level.
Reasoning: Did not provide quality assessment results for each study.

P20. [Yes] 
Quotes: Table 2 provides summary data and results for each included study.
Reasoning: Presented summary data and effect estimates for each study. 

P21. [NA]
Reasoning: No meta-analysis performed.

P22. [NA]  
Reasoning: No assessment of publication bias without meta-analysis.

P23. [NA]
Reasoning: No additional analyses without meta-analysis.

P24. [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We found that children who were managed by specialized pediatric surgery teams had lower rates of negative appendicectomy although mean length of stay was longer.&quot;</span>  
Reasoning: Summarized main findings in results and conclusions.

P25. [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Regarding limitations, the main issue is the retrospective nature of most of the included studies.&quot;</span>
Reasoning: Discussed limitations including risk of bias.

P26. [Yes]  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We wish to encourage future research through the use of large-scale prospective multicenter registries.&quot;</span>
Reasoning: Discussed implications for future research.

P27. [No]
Quotes: No mention of sources of funding or support.
Reasoning: Did not describe sources of funding/support.
</pre>
<p><a name='101'></a></p>
</div>
<div id="healy-2016" class="section level4">
<h4><a href='https://doi.org/10.1007/s00383-015-3839-0' title='Open publication'>Healy
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In December 2014, a comprehensive literature search was performed using Ovid MEDLINE (1946–present) and Embase (1974–present) using the OvidSP interfaces.&quot;</span> (p.323)
The study performed a comprehensive literature search using at least two databases.

A2. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Citations
of retrieved results were manually reviewed for relevance to
the topic of IA by two independent reviewers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Citations of retrieved results were manually reviewed for relevance to the topic by two independent reviewers.&quot;</span> (p.323)  
There were two independent reviewers for study selection.

A3. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided.&quot;</span> (p.324)
The review searched two databases and provided the years. 

A4. [No]
No mention of including or searching for grey literature.

A5. [No]
No list of included or excluded studies provided.

A6. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data was collected to index the type of study, specialty, year, location, number of patients, and primary outcomes of each study.&quot;</span> (p.323)
Characteristics of included studies provided.

A7. [No] 
No quality assessment of included studies mentioned.

A8. [NA]
No quality assessment done so not applicable.

A9. [NA]  
No meta-analysis done so not applicable.

A10. [NA]
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest.

P1. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.3%):

W A RT I C L E
Pediatric incidental appendectomy: a systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎REVIEW ARTICLE Pediatric incidental appendectomy: a systematic review&quot;</span> (title)
Identified as a systematic review.

P2. [No] 
No structured summary provided.

P3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

A detailed review was
undertaken of the techniques, pathology, risks of appen-
dectomy, utility of the appendix, and incidental appen-
dectomy in the treatment of specific pediatric medical
conditions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A detailed review was undertaken of the techniques, pathology, risks of appendectomy, utility of the appendix, and incidental appendectomy in the treatment of specific pediatric medical conditions.&quot;</span> (p.322)
Provides rationale for review.

P4. [No] 
No explicit PICO statement provided.

P5. [No]
No mention of a review protocol.

P6. [No]
No explicit eligibility criteria described. 

P7. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In December 2014, a comprehensive literature search was performed using Ovid MEDLINE (1946–present) and Embase (1974–present) using the OvidSP interfaces.&quot;</span> (p.323)
Databases and date ranges provided.

P8. [No]
No full search strategy provided.

P9. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Citations
of retrieved results were manually reviewed for relevance to
the topic of IA by two independent reviewers. If adequate
information was not included in the abstract, the manuscript
was reviewed, by default, to determine relevance' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Citations of retrieved results were manually reviewed for relevance to the topic by two independent reviewers. If adequate information was not included in the abstract, the manuscript was reviewed, by default, to determine relevance.&quot;</span> (p.323)
Study selection process described.

P10. [No]  
No data extraction process described.

P11. [No]
No list of data extracted.

P12. [No]  
No assessment of risk of bias mentioned.

P13. [NA]
No meta-analysis performed.

P14. [NA] 
No meta-analysis performed.

P15. [NA]
No assessment of publication bias mentioned.

P16. [NA]
No additional analyses mentioned. 

P17. [No]  
Number screened and excluded not provided.

P18. [Yes]
Study characteristics presented in Tables 1-3. 

P19. [No] 
No assessment of risk of bias presented.

P20. [NA] 
No meta-analysis performed.

P21. [NA]
No meta-analysis performed. 

P22. [NA]
No assessment of risk of bias across studies performed.

P23. [NA]
No additional analyses performed.

P24. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The discus-
sion includes a variety of situations and comorbid condi-
tions that may influence a surgeon’s decision to perform
incidental appendectomy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The discussion includes a variety of situations and comorbid conditions that may influence a surgeon’s decision to perform incidental appendectomy.&quot;</span> (p.322)
Main findings summarized.

P25. [No]  
No limitations discussed.

P26. [No]
No general interpretation in context of other evidence.

P27. [No]
No mention of funding sources.
</pre>
<p><a name='102'></a></p>
</div>
<div id="heloury-2012" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2011.08.003' title='Open publication'>Heloury
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

conducted a systematic review of the pediatric and adult literature about MIA' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic review of the pediatric and adult literature about MIA&quot;</span>
The authors state they conducted a systematic review.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span>
The authors state they supplemented electronic searches with additional strategies. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The largest pediatric studies involving MIA demonstrate a low morbidity rate, ranging from 0% [5,7,10] to 10% [11,12].&quot;</span> 
Study characteristics like morbidity rates are described.

A7. Was the scientific quality of the included studies assessed and documented? [No]  
No mention of quality assessment of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment was performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed. 

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Based on an extensive review of the adult and pediatric literature, we attempted to answer the following questions:&quot;</span>
The report is identified as a systematic review.

P2. Provide a structured summary. [No]
No structured summary provided.

P3. Describe the rationale for the review. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Over the past 15 years, many studies have reported the use MIA for NB.&quot;</span> 
Rationale provided in introduction.

P4. Provide objectives with PICOS. [No]  
No explicitly stated objectives with PICOS.

P5. Indicate if a protocol exists. [No] 
No mention of a protocol.

P6. Specify study characteristics used as eligibility criteria. [No]
No mention of eligibility criteria regarding study characteristics.

P7. Describe information sources and dates searched. [No]  
No description of information sources or dates searched.  

P8. Present full search strategy. [No]  
No full search strategy presented.

P9. State process for selecting studies. [No] 
No description of study selection process.

P10. Describe data extraction methods. [No]
No description of data extraction methods. 

P11. List and define variables extracted. [No]  
No list or definition of extracted variables.

P12. Describe risk of bias assessment. [No]
No description of risk of bias assessment.

P13. State principal summary measures. [NA]
No meta-analysis performed.

P14-P23. [NA] 
Not applicable - no meta-analysis performed.

P24. Summarize main findings. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.5%):

is promising for removal of small adrenal tumors' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎MIA is promising for removal of small adrenal tumors.&quot;</span>
Main findings are summarized in the conclusion.

P25. Discuss limitations. [No]  
No discussion of limitations at study or review level.

P26. Provide general interpretation of results. [Yes] 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):

is superior to OA for
the removal of benign adrenal diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎MIA is superior to OA for the removal of benign adrenal diseases.&quot;</span>
Results interpreted in the context of existing evidence.  

P27. Describe sources of funding. [No] 
No description of sources of funding.
</pre>
<p><a name='103'></a></p>
</div>
<div id="huang-2015" class="section level4">
<h4><a href='https://doi.org/pmid:26131065' title='Open publication'>Huang
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

A
systematic literature search of electronic data-
bases including PUBMED, Web of science and
Cochrane library was carried out between Jan.
1966 and Oct. 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic literature search of electronic databases including PUBMED, Web of science and Cochrane library was carried out between Jan. 1966 and Oct. 2014&quot;</span>
The review had an a priori design with predefined research question and inclusion criteria.
[Yes]

A2. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Data abstraction was carried out independent-
ly by two authors (Yidong Huang, Yang Wu' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was carried out independently by two authors (Yidong Huang, Yang Wu)&quot;</span> 
There were two independent data extractors.
[Yes]

A3.  
<span title='Moderate quote deviation. Best match in prompt (Similarity 84.4%):

e search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎PUBMED, Web of science and Cochrane library were searched" "All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span>
At least two electronic databases were searched along with supplementary strategies.
[Yes]

A4.  
No mention of including or excluding studies based on publication status.
Publication status was not used as an inclusion criteria. 
[No]

A5.
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Among
these studies, 37 studies were finally leaved
behind for full-text assessment. Detailed steps
of literature search were shown in Figure 1.
After excluded 21 studies due to different rea-
sons, 16 studies including one RCT [2], eight
retrospective studies [5, 8, 9, 12-16], three pro-
spective studies [6, 17, 18] and four studies
from database [1, 4, 18, 19] were included in
the meta-analysi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Among these studies, 37 studies were finally leaved behind for full-text assessment. After excluded 21 studies due to different reasons, 16 studies including one RCT [2], eight retrospective studies [5, 8, 9, 12-16], three prospective studies [6, 17, 18] and four studies from database [1, 4, 18, 19] were included in the meta-analysis.&quot;</span>
A list of included and excluded studies was provided.
[Yes]

A6. 
Table 1 provides characteristics of included studies.
Characteristics of included studies were provided.
[Yes] 

A7.
No mention of quality assessment of included studies.
The scientific quality of included studies was not assessed.
[No]

A8. 
No quality assessment of included studies was performed.
[NA]

A9.  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

Heterogeneity was consid-
ered significant for P value < 0.05 or I
2 
> 50%.
Considering the heterogeneity of included stud-
ies, we conducted meta-analyses of all com-
paratives using random effects models' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Heterogeneity was considered significant for P value < 0.05 or I2 > 50%." "Considering the heterogeneity of included studies, we conducted meta-analyses of all comparatives using random effects models.&quot;</span>
Methods to combine findings were appropriate, including testing for heterogeneity. 
[Yes]

A10.
No assessment of publication bias was mentioned.
[No] 

A11. 
No disclosure of conflicts of interest.
[No]

P1. 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.1%):

alysis of laparoscopic versus open
pyeloplasty for ureteropelvic junction
obstruction in children' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Comparison of laparoscopic versus open pyeloplasty for ureteropelvic junction obstruction in children&quot;</span>
Identified as a systematic review and meta-analysis. 
[Yes]

P2.
Abstract provides structured summary.
[Yes]

P3. 
Introduction describes rationale and context.
[Yes]

P4. 
Objective clearly stated to compare laparoscopic versus open pyeloplasty in children.
[Yes]

P5.
No mention of a review protocol.
[No] 

P6.  
Inclusion criteria described including study design, participants, interventions. 
[Yes]

P7.  
Described databases searched and date ranges.
[Yes]

P8.  
Did not provide full search strategy.
[No]

P9.
Described process of study screening and selection. 
[Yes]

P10.  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data abstraction was carried out independently by two authors&quot;</span>
Described process of data extraction.
[Yes]

P11.  
Outcomes of interest described. 
[Yes] 

P12.
Did not describe risk of bias assessment.
[No]

P13. 
Described use of OR, WMD, RD for summary measures.
[Yes]

P14.
Described using random effects model and measuring heterogeneity with I2.
[Yes] 

P15.
Did not assess risk of bias across studies.
[No]

P16.
Did not conduct additional analyses. 
[NA]

P17.  
Figure 1 shows flow diagram of study selection.
[Yes]

P18. 
Table 1 provides characteristics of included studies.
[Yes]

P19.
Did not provide risk of bias assessments. 
[No]

P20. 
Forest plots provide effect estimates with CIs.
[Yes]

P21.
Provided results of meta-analyses with CIs. 
[Yes] 

P22. 
Did not assess risk of bias across studies.
[No] 

P23.
Did not conduct additional analyses.
[NA]

P24.
Summarized main findings and conclusions.
[Yes]

P25. 
Discussed limitations at review level.
[Yes]

P26. 
Discussed implications of findings.
[Yes]

P27.
No disclosure of funding sources.
[No]
</pre>
<p><a name='104'></a></p>
</div>
<div id="ishii-2014" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2014.08.003' title='Open publication'>Ishii
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search involved finding relevant studies from MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar and individual urological journals between January 1990 and March 2014.&quot;</span>

[Yes] The review had pre-determined inclusion/exclusion criteria.

A2. Was there duplicate study selection and data extraction?

[No] The review does not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The search terms included the following: ‘uretero-
scopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediat-
ric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’,
‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search terms included the following: ‘ureteroscopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediatric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’, ‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy’.&quot;</span>

[Yes] The search included multiple databases and supplementary search strategies.

A4. Was the status of publication used as an inclusion criterion?  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criteria were for studies written in the English language...&quot;</span>

[No] The review did not search for unpublished or grey literature.

A5. Was a list of studies (included and excluded) provided?

[No] The review did not provide a list of excluded studies. 

A6. Were the characteristics of the included studies provided?

[Yes] Table 1 provides aggregated characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented?

[No] The review did not assess the quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?

[NA] Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?

[NA] The results were not combined quantitatively. 

A10. Was the likelihood of publication bias assessed?

[NA] Publication bias assessment is not applicable without a meta-analysis.

A11. Was the conflict of interest included? 

[No] Potential conflicts of interest were not reported.

P1. Identify the report as a systematic review, meta-analysis, or both.

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎REVIEW ARTICLE Flexible ureteroscopy and lasertripsy (FURSL) for paediatric renal calculi: Results from a systematic review&quot;</span> 

[Yes] The report is identified as a systematic review.

P2. Provide a structured summary...

[Yes] An abstract with structured headings is provided. 

P3. Describe the rationale for the review... 

[Yes] Rationale is described in the Introduction.

P4. Provide an explicit statement of questions being addressed...

[No] Specific review questions are not provided.

P5. Indicate if a review protocol exists...

[No] A protocol is not mentioned. 

P6. Specify study characteristics...and report characteristics...

[Yes] Inclusion criteria specify study characteristics. 

P7. Describe all information sources...

[Yes] Information sources are described in the Methods.

P8. Present full electronic search strategy for at least one database...

[No] Full search strategies are not provided.

P9. State the process for selecting studies...

[Yes] The study selection process is outlined in Figure 1.

P10. Describe method of data extraction...

[No] The data extraction process is not described.

P11. List and define all variables for which data were sought...

[Yes] Extracted data variables are listed in the Results. 

P12. Describe methods used for assessing risk of bias...

[No] Risk of bias assessment is not described.

P13. State the principal summary measures...

[NA] Summary measures are not applicable without quantitative synthesis.

P14-P23. Describe methods of additional analyses...

[NA] No meta-analysis was performed.

P24. Summarize the main findings including the strength of evidence...

[Yes] Main findings are summarized in the Conclusion.

P25. Discuss limitations at study and outcome level... 

[Yes] Limitations are outlined in the Discussion.

P26. Provide a general interpretation of the results...

[Yes] Results are interpreted in the Conclusion.

P27. Describe sources of funding...

[No] Sources of funding are not reported.
</pre>
<p><a name='105'></a></p>
</div>
<div id="ishii-2015" class="section level4">
<h4><a href='https://doi.org/10.1111/BJU.12927' title='Open publication'>Ishii
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The aim of the present review was to look at the role of ureteroscopy (URS) for treatment of paediatric stone disease.&quot;</span>
The aim is stated but no mention of protocol or pre-determined objectives.  

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers independently extracted the data from each study.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review was conducted in accordance with the systematic review guidelines provided by the Cochrane Collaboration and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist.&quot;</span> 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search involved finding relevant studies from MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar and individual urological journals, published between January 1990 and May 2013.&quot;</span>

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No] 
Included studies listed in tables but no list of excluded studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics like country, number of cases, mean age etc. Table 2 provides details on interventions and outcomes.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No mention of quality assessment of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No meta-analysis performed.

A10. Was the likelihood of publication bias assessed? [NA]
No meta-analysis performed.

A11. Was the conflict of interest included? [No]
No statement on sources of support or conflict of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎systematic review&quot;</span> mentioned in abstract.

P2. Provide a structured summary including key elements. [Yes] 
Structured abstract provided with background, objectives, eligibility criteria, participants, interventions, results, conclusions.

P3. Describe the rationale for the review in context of what is already known. [Yes] 
Introduction describes rise in pediatric stone disease and advancements in ureteroscopy.

P4. Provide an explicit statement of questions being addressed. [No] 
No specific research questions stated relating to PICOS.

P5. Indicate if a review protocol exists and provide registration information. [No]
No mention of a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
Inclusion criteria specify population, intervention, outcomes, and study design. 

P7. Describe all information sources and date last searched. [Yes]
Describes databases searched from January 1990 to May 2013.

P8. Present full electronic search strategy for at least one database. [No]
Search terms listed but no full search strategy shown.

P9. State the process for selecting studies. [Yes]  
Process shown in Figure 1.

P10. Describe method of data extraction and obtaining data. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers independently extracted the data which was then put into an Excel spread sheet.&quot;</span>

P11. List and define all variables for which data were sought. [Yes] 
Outcomes of interest defined under <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion Criteria and Outcomes of Interest&quot;</span>. Table 2 shows data extracted.

P12. Describe methods for assessing risk of bias of individual studies. [No] 
No mention of risk of bias assessment.

P13. State the principal summary measures. [Yes]
Stone free rates summarized as percentages. Complications summarized by frequency and Clavien grade.

P14. Describe the methods of handling data and combining results of studies. [NA]
No meta-analysis performed.

P15. Specify any assessment of risk of bias across studies. [NA] 
No meta-analysis performed.

P16. Describe methods of additional analyses. [NA]
No additional analyses like sensitivity analysis performed.

P17. Give numbers of studies at each stage with reasons for exclusions. [Yes]
Figure 1 shows flow of studies with number included/excluded at each stage.

P18. For each study, present characteristics for which data were extracted. [Yes] 
Table 1 and 2 show characteristics extracted for each study.

P19. Present data on risk of bias for each study. [No]
No assessment of risk of bias for included studies.

P20. For all outcomes, present data for each study. [Yes] 
Table 2 shows stone free rates, failures, complications for each study.

P21. Present results of each meta-analysis done. [NA] 
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies. [NA]
No assessment of publication bias or other biases across studies.

P23. Give results of additional analyses. [NA]
No additional analyses performed. 

P24. Summarize the main findings and their relevance. [Yes]
Conclusions summarize the main results and their implications.

P25. Discuss limitations at study and outcome level. [No]  
Potential bias and confounding factors of included studies not discussed.

P26. Provide a general interpretation of results and implications for future research. [Yes]
Results interpreted in the context of other evidence. Future research implications mentioned.

P27. Describe sources of funding and role of funders. [No] 
No statement on sources of funding or conflicts of interest.
</pre>
<p><a name='106'></a></p>
</div>
<div id="ito-2014" class="section level4">
<h4><a href='https://doi.org/10.1111/PED.12429' title='Open publication'>Ito
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

A clinical question was structured according to patient, intervention, compari-
son, and outcome, as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (inter-
vention), compared to lactation support alone (comparison), improve feeding (outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A clinical question was structured according to patient, intervention, comparison, and outcome, as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (intervention), compared to lactation support alone (comparison), improve feeding (outcome)?&quot;</span>

A2. Was there duplicate study selection and data extraction? [No] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span> 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

An electronic literature search was systematically performed
using databases including PubMed (January1966–April 2013),
Japana Centra Revuo Medicina (Igaku Chuo Zasshi, January
1983–April 2013), CINAHL, and Cochrane Library using the key
words “ankyloglossia,” “tongue-tie,” frenotomy,” and/or
“breastfeeding” in English and the equivalent terms in Japanese' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An electronic literature search was systematically performed using databases including PubMed, Japana Centra Revuo Medicina (Igaku Chuo Zasshi), CINAHL, and Cochrane Library using the key words “ankyloglossia,” “tongue-tie,” “frenotomy,” and/or “breastfeeding” in English and equivalent terms in Japanese.&quot;</span>

A4. Was the status of publication used as an inclusion criterion? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
The included studies are listed in the results section but no list of excluded studies is provided.

A6. Were the characteristics of the included studies provided? [Yes] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
Tables 2-5 provide characteristics of the included RCTs and observational studies. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria).&quot;</span>
The included studies were divided into RCTs and observational studies and assessed for risk of bias in the results section.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review.&quot;</span> 
The evidence levels were rated using the GRADE system based on study design and risk of bias. This was considered in the conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>
Heterogeneity was assessed and meta-analysis was only done when studies were combinable. 

A10. Was the likelihood of publication bias assessed? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test).&quot;</span>
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
No conflict of interest statement provided for the systematic review or included studies.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This article is based on a study first reported in the Journal of the Japan Pediatric Society 2014; 118: 462–474, titled “Effectiveness of frenotomy in breastfeeding difficulties in infants with ankyloglossia: Systematic review” (in Japanese).&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes] 
The abstract provides background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, and conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
The introduction describes the background and controversy around ankyloglossia and breastfeeding.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

A clinical question was structured according to patient, intervention, compari-
son, and outcome, as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (inter-
vention), compared to lactation support alone (comparison), improve feeding (outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A clinical question was structured according to patient, intervention, comparison, and outcome as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (intervention), compared to lactation support alone (comparison), improve feeding (outcome)?&quot;</span>

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No review protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
The methods section describes the inclusion criteria using PICOS, languages included, and exclusion criteria. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
The search strategy is described including databases, keywords, languages, and date ranges.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
The search terms are listed but the full search strategy for each database is not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
The selection process is depicted in a flow diagram.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No] 
The data extraction process is not described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes]
The primary outcome measures are listed and defined in Table 1.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
The risk of bias was assessed at the study level for RCTs and observational studies. This was incorporated into rating the quality of evidence using GRADE. 

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
The principal summary measures are stated to be risk ratio for dichotomous data and mean difference for continuous data.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Heterogeneity was assessed using Chi-squared test and I2. Random effects model was used when significant heterogeneity was present.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias or selective reporting was done.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
A flow diagram depicts the screening process with number of studies at each stage and reasons for exclusions.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]  
Tables 2-5 present relevant characteristics for each included study.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes]
Risk of bias is presented in Tables 2-5 for each included study.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Summary data and effect estimates are presented in Tables 2-5. Forest plots are provided for meta-analyses.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes]
Results of the meta-analyses are presented in Figure 2 including CIs and measures of heterogeneity.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of risk of bias across studies was done.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses were done. 

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
The main findings and strength of evidence are summarized in the results, discussion, and conclusions sections. The relevance to healthcare providers is discussed.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes] 
Limitations of included studies and the review are discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
The results are interpreted in the context of existing guidelines and implications for future research are discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No sources of funding or conflicts of interest statement is provided.
</pre>
<p><a name='107'></a></p>
</div>
<div id="jia-2011" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0030-1261926' title='Open publication'>Jia
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Aim of the study was to compare the outcomes after laparoscopic pyloromyotomy (LP) with those of open pyloromyotomy (OP) for infantile pyloric stenosis.&quot;</span> The aim is clearly stated.

A2. [No]
No mention of duplicate study selection or data extraction.

A3. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An electronic literature search of all articles from inception to February 2009 was conducted using Medline, the Cochrane Library, SCI, EMBASE, and the Chinese Biomedical Literature Database.&quot;</span> Multiple databases searched. 

A4. [No]
No mention of searching for grey literature.

A5. [No]
No list of included/excluded studies provided.

A6. [Yes] 
Table 1 provides characteristics of included studies.

A7. [Yes] 
Table 2 assesses quality of studies using Cochrane criteria. 

A8. [Yes]
Study quality considered in analyzing results, e.g. <span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

the available trials were of high qual-
ity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎the available trials were of high quality.&quot;</span>

A9. [NA]
No quantitative synthesis/meta-analysis performed.

A10. [NA] 
Publication bias not assessed as fewer than 10 studies included.

A11. [No]
No mention of conflicts of interest or study funding.

P1. [Yes] 
Identified as systematic review and meta-analysis in title.

P2. [Yes]
Structured abstract provided with all relevant subheadings. 

P3. [Yes]
Rationale described in introduction, citing conflicting prior evidence.

P4. [Yes]
PICOS provided - participants, interventions, outcomes specified. 

P5. [No] 
No mention of review protocol.

P6. [Yes]
Inclusion criteria described - RCTs comparing LP and OP.

P7. [Yes]
Literature search described including databases and dates.

P8. [No]
Full search strategy not provided.

P9. [No] 
Study selection process not described. 

P10. [No]
Data extraction process not described.

P11. [Yes] 
Outcomes sought described.

P12. [NA] 
Risk of bias assessment not applicable as no meta-analysis. 

P13. [NA]
No meta-analysis performed.

P14-P23. [NA] 
No meta-analysis.

P24. [Yes]  
Main findings summarized in discussion. 

P25. [Yes]
Limitations discussed. 

P26. [Yes]  
Results interpreted in context of other evidence.

P27. [No]
No mention of sources of funding.
</pre>
<p><a name='108'></a></p>
</div>
<div id="kapralik-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.11.022' title='Open publication'>Kapralik
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.3%):

an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎An 'a priori' design was provided as the research question and inclusion criteria were established through a Delphi-like method before conducting the review.&quot;</span>

A2. "[Yes]" 
<span title='Moderate quote deviation. Best match in prompt (Similarity 88.5%):

there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎There was duplicate study selection and data extraction with two independent reviewers and a consensus procedure for disagreements.&quot;</span>

A3. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 35.9%):

a comprehensive literature search performed?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A comprehensive literature search was performed in 5 databases along with supplementary searching of reference lists.&quot;</span> 

A4. "[No]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 89.2%):

the status of publication (i.e. grey literature) used as an inclusion criterion' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The status of publication was not used as an inclusion criterion.&quot;</span>

A5. "[Yes]" 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.2%):

A list of included and excluded studies should be provided. Not' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A list of included and excluded studies was provided in the flow diagram.&quot;</span>

A6. "[Yes]" 
<span title='Moderate quote deviation. Best match in prompt (Similarity 75.4%):

characteristics of the included studies provided? In' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Characteristics of included studies were provided in Table 1.&quot;</span>

A7. "[Yes]"
<span title='Moderate quote deviation. Best match in fulltext (Similarity 79%):

the Methodological Index for Non-Randomized Studies
(MINORS) to assess the quality of the included studies, as all were
nonrandomized [18]. The MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The methodological quality of included studies was assessed with the MINORS tool.&quot;</span> 

A8. "[Yes]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 77.1%):

quality should be considered in the analysis and the conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The quality assessment was considered in the analysis and conclusions.&quot;</span>

A9. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 43.5%):

ues to assess homogeneity.
Had we included' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Methods to assess heterogeneity were described for the meta-analyses.&quot;</span>

A10. "[No]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 85.3%):

publication bias could not be assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Publication bias was not assessed.&quot;</span>

A11. "[No]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 87.7%):

conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Conflicts of interest were not reported for the included studies.&quot;</span>

P1. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.3%):

the report as a systematic review, meta-analysis, or both' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The report is identified as a systematic review and meta-analysis in the title.&quot;</span>

P2. "[Yes]"  
<span title='Moderate quote deviation. Best match in prompt (Similarity 86%):

a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎A structured summary is provided with objectives, eligibility criteria, sources, synthesis methods, results, limitations.&quot;</span>

P3. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44%):

design provided? The research question' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The rationale describes current controversies around the research question.&quot;</span>

P4. "[Yes]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 78.5%):

f questions being addressed with reference to participants, interventions, comparisons, outcomes' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The review question is stated in terms of participants, interventions, comparisons, outcomes.&quot;</span> 

P5. "[No]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.6%):

a review protocol' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A review protocol is not mentioned.&quot;</span>

P6. "[Yes]"  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.9%):

n including registration number.
P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Eligibility criteria are described including study characteristics and years, language, publication status.&quot;</span>

P7. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.4%):

information sources (e.g., databases with dates' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Information sources are described including databases and dates searched.&quot;</span> 

P8. "[No]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.8%):

search strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A full search strategy is not provided.&quot;</span>

P9. "[Yes]" 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.3%):

the process for selecting studies (i.e., screening, eligibility, included in sy' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The process of study screening and selection is described in the flow diagram.&quot;</span>

P10. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.4%):

Data extraction
One reviewer extracted all data from the included studies, and an-
other checked it for accuracy and completeness. We extract' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data extraction methods are described including the use of forms and independent extraction.&quot;</span>

P11. "[Yes]" 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45.2%):

viewer extracted a' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Variables extracted are listed.&quot;</span>

P12. "[Yes]" 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 40.9%):

Quality assessment
W' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Quality assessment with MINORS is described.&quot;</span>

P13. "[Yes]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 87.1%):

summary measures (e.g., risk ratio, difference in means).
P14. Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Summary measures are described.&quot;</span>

P14. "[NA]"

P15. "[NA]" 

P16. "[NA]"

P17. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.8%):

numbers of studies screened, assessed for eligibility, and included in the review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Numbers of studies screened and excluded are shown in the flow diagram.&quot;</span> 

P18. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52%):

characteristics of the included studies provided?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Characteristics and citations are provided for included studies in Table 1.&quot;</span>

P19. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 38.5%):

f assessment should be pr' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Quality assessment results are presented in Table 1.&quot;</span>

P20. "[Yes]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 80.5%):

summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
P21. Present results of each meta-analysis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Summary data and effect estimates are presented in the meta-analysis figures.&quot;</span>

P21. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60.5%):

results of
this meta-analysis s' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Results of the meta-analyses are presented.&quot;</span>

P22. "[NA]"

P23. "[NA]"

P24. "[Yes]" 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.5%):

funding sources) and any assumptions and simplifications made.
P12. Desc' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Main findings are summarized and clinical implications are discussed.&quot;</span>

P25. "[Yes]"
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.9%):

limitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Limitations are described at the study and review level.&quot;</span>

P26. "[Yes]"
<span title='Moderate quote deviation. Best match in prompt (Similarity 77.2%):

interpretation of the results in the context of other evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Results are interpreted in the context of other evidence.&quot;</span>

P27. "[No]" 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 74.5%):

source of funding or support for the systematic review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Sources of funding are not reported for the review.&quot;</span>
</pre>
<p><a name='109'></a></p>
</div>
<div id="kunz-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.020' title='Open publication'>Kunz
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1: "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We reviewed Medline citations between January 1, 1996 and June 1, 2012 and the Cochrane Database of Systematic Reviews database through June 1, 2012.&quot;</span> 
The review protocol and search dates are specified.

A2: "[Yes]" 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Abstracts for all articles were independently subjected to preliminary review by two investigators (JA, SK) to determine whether inclusion criteria were satisfied.&quot;</span>
There were two independent reviewers for study selection. 

A3: "[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

We reviewed Medline citations between January 1, 1996 and June 1, 2012 and the Cochrane
Database of Systematic Reviews database through June 1, 2012. Citations from DynaMed
and other reviews were included. The search terms used were “gastroschisis” and
[(“treatment outcome” or “prognosis”) or randomized controlled trials]. Reference lists from
selected papers were further used to identify publications of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We reviewed Medline citations between January 1, 1996 and June 1, 2012 and the Cochrane Database of Systematic Reviews database through June 1, 2012. Citations from DynaMed and other reviews were included. Reference lists from selected papers were further used to identify publications of interest.&quot;</span>
At least two databases were searched along with supplementary sources.

A4: "[No]"
No mention of searching for unpublished or grey literature.

A5: "[Yes]" 
Figure 1 provides details on included and excluded studies.

A6: "[Yes]" 
Table 1 provides characteristics of the included studies. 

A7: "[No]"  
No quality assessment of included studies is described.

A8: "[NA]"
Since no quality assessment was done, using it to formulate conclusions is not applicable.

A9: "[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.7%):

Heterogeneity was assessed by the I
2
statistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Heterogeneity was assessed by the I2 statistic.&quot;</span>

A10: "[No]"
No assessment of publication bias is described. 

A11: "[No]"
No mention of conflicts of interest or study funding.

P1: "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary Fascial Closure versus Staged Closure with Silo in Patients with Gastroschisis: A Meta-Analysis&quot;</span>
The title identifies it as a meta-analysis.

P2: "[Yes]" 
The abstract provides a structured summary.

P3: "[Yes]"
The introduction describes the rationale and existing knowledge on the topic.

P4: "[Yes]"
The objectives specify the PICOS elements. 

P5: "[No]"
No review protocol is mentioned.

P6: "[Yes]" 
The eligibility criteria are described.

P7: "[Yes]"
The information sources are described.

P8: "[No]"
The full search strategy is not provided.

P9: "[Yes]" 
The study selection process is described and depicted in Figure 1.

P10: "[Yes]" 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

Data abstraction was conducted
independently by the same two investigators from the studies that met inclusion criteria. A
standard data collection form (Appendix 2) created by the authors (JA, JT, SK) was used to
extract information about study quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was conducted independently by the same two investigators from the studies that met inclusion criteria. A standard data collection form created by the authors was used to extract information about study quality...&quot;</span>

P11: "[Yes]"
Table 1 lists the characteristics extracted.

P12: "[No]"
No risk of bias assessment is described.

P13: "[Yes]"
The outcome measures are described.

P14: "[Yes]" 
Statistical methods are described. 

P15: "[No]" 
No assessment of publication bias is mentioned.

P16: "[NA]"
No additional analyses were done.

P17: "[Yes]"
Figure 1 provides the study flow. 

P18: "[Yes]"
Table 1 provides study characteristics.

P19: "[No]"
No assessment of study bias is provided.

P20: "[Yes]"
Results are presented with effect sizes and confidence intervals.

P21: "[Yes]" 
Meta-analysis results are presented with confidence intervals and consistency measures.

P22: "[NA]" 
Not applicable since no assessment of bias across studies was done.

P23: "[NA]"
No additional analyses were described.

P24: "[Yes]"
The discussion summarizes the main findings and limitations.

P25: "[Yes]"
Limitations are discussed.

P26: "[Yes]"
Results are interpreted in the context of other evidence. 

P27: "[No]"
No statement about sources of funding.
</pre>
<p><a name='110'></a></p>
</div>
<div id="landisch-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.002' title='Open publication'>Landisch
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This study was performed according to guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [6].&quot;</span>
- The study followed PRISMA guidelines. [Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.1%):

reviewed and extracted eligible articles. Bibliographies of identified
studies were examined to identify any additional eligible studies' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles. Bibliographies of identified studies were examined to identify any additional eligible studies.&quot;</span>
- Two independent researchers performed study selection and data extraction. [Yes]  

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

An online database search for all articles published between January
1993 and January 2014 on pediatric patients using the following key-
words was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd pro-
cedure”, “Ivemark”, “asplenia”, and “polysplenia' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An online database search for all articles published between January 1993 and January 2014 on pediatric patients using the following keywords was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd procedure”, “Ivemark”, “asplenia”, and “polysplenia”.&quot;</span> 
- Search included multiple databases and supplemental strategies. [Yes]

A4. Was the status of publication used as an inclusion criterion?  
- No mention of including or excluding studies based on publication status. [No]

A5. Was a list of studies provided?
- Table 1 provides a list of included studies. [Yes] 

A6. Were the characteristics of the included studies provided?
- Table 1 provides aggregated characteristics of included studies. [Yes]

A7. Was the scientific quality of the included studies assessed?
- No mention of quality assessment for included studies. [No] 

A8. Was the scientific quality used appropriately in formulating conclusions?
- No quality assessment performed. [NA]

A9. Were the methods to combine findings appropriate?  
- No quantitative synthesis performed. [NA]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
- No conflict of interest statement. [No]

P1. Identify as systematic review or meta-analysis. [Yes]
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Observation versus prophylactic Ladd procedure for asymptomatic intestinal rotational abnormalities in heterotaxy syndrome: A systematic review&quot;</span>

P2. Structured summary. [Yes]
- Provides background, objectives, eligibility criteria, participants, interventions, methods, results, conclusions in abstract.

P3. Rationale for review. [Yes]  
- Provides context and rationale in the introduction.

P4. Objectives and PICOS. [No] 
- Research question stated but no explicit PICOS provided.

P5. Indicate if protocol exists. [No]
- No mention of a review protocol.

P6. Specify study characteristics and eligibility criteria. [Yes]
- Specifies criteria such as study design, sample size, language for inclusion/exclusion. 

P7. Information sources and dates. [Yes]
- Specifies databases searched and date ranges.

P8. Present search strategy. [No]
- Does not provide full search strategy.

P9. Study selection process. [Yes] 
- Describes process for screening, eligibility assessment, inclusion.

P10. Data extraction process. [Yes]
- States that data extraction was done independently and in duplicate.

P11. List and define all variables collected. [No]
- Does not explicitly list and define variables extracted.

P12. Risk of bias assessment. [No] 
- Does not describe risk of bias assessment methods.

P13. Summary measures. [NA]
- No quantitative synthesis performed.

P14. Synthesis methods. [NA] 
- No quantitative synthesis performed.

P15. Risk of bias across studies. [NA]
- No quantitative synthesis performed.

P16. Additional analyses. [NA]
- No additional analyses mentioned.

P17. Study flow diagram. [Yes]
- Provides a flow diagram of screening and selection process.

P18. Study characteristics. [Yes]
- Table 1 provides key characteristics of included studies.

P19. Study risk of bias. [No] 
- Does not present risk of bias assessments.

P20. Study results. [Yes]
- Presents relevant results for each study in text and tables.

P21. Meta-analysis results. [NA] 
- No meta-analysis performed.

P22. Risk of bias across studies. [NA]
- No quantitative synthesis performed.

P23. Additional analyses. [NA]
- No additional analyses mentioned.

P24. Summary of evidence. [Yes]
- Summarizes main findings and implications in the discussion.

P25. Limitations. [Yes]  
- Discusses limitations of the review.

P26. Conclusions and implications. [Yes]
- Provides interpretation of results and implications for research.

P27. Funding sources. [No]
- Does not describe sources of funding or support.
</pre>
<p><a name='111'></a></p>
</div>
<div id="lane-2010" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-009-2475-Y' title='Open publication'>Lane
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the provided systematic review:

A1. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
"[Yes]"

A2. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>  
No mention of duplicate study selection or data extraction. "[No]"

A3. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span>
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 35%):

ture research.
P27. Describe sources of funding for the systematic review and othe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A literature search was undertaken using Medline, the Cochrane database of systematic reviews and the Cochrane central register of controlled trials." "[Yes]&quot;</span>

A4.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
No mention of searching for grey literature. "[No]" 

A5.
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
Included studies are listed in the references. No list of excluded studies. "[No]"

A6. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
Table 1 provides summary of study characteristics. "[Yes]"

A7.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria)&quot;</span>
No quality assessment mentioned. "[No]"

A8.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.&quot;</span>
No quality assessment performed. "[No]"

A9.
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>
No quantitative synthesis performed. "[NA]"

A10.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span>
No assessment of publication bias. "[No]" 

A11.
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span> 
No mention of sources of funding. "[No]"

P1. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Identify the report as a systematic review, meta-analysis, or both.&quot;</span>
Identified as systematic review in title. "[Yes]"

P2. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>
Structured abstract provided with background, objectives, eligibility criteria, participants, interventions, synthesis methods, results, and conclusions. "[Yes]"

P3.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe the rationale for the review in the context of what is already known.&quot;</span>
Background and rationale described in introduction. "[Yes]"

P4.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;</span> 
Objectives and inclusion criteria outlined, but no explicit PICOS. "[No]"

P5.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;</span>
No protocol mentioned. "[No]"

P6.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;</span>
Inclusion criteria described but no mention of exclusion criteria. "[No]"

P7. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;</span>
Databases and date ranges searched reported. No supplementary search methods described. "[Yes]"

P8. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;</span>
No search strategy provided. "[No]"

P9.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;</span> 
No details on study selection process. "[No]"

P10. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;</span>
No data extraction methodology described. "[No]"

P11.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;</span>
No details on data items sought. "[No]" 

P12.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.&quot;</span>
No risk of bias assessment described. "[No]"

P13. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the principal summary measures (e.g., risk ratio, difference in means).&quot;</span> 
No meta-analysis performed. "[NA]"

P14. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.&quot;</span>
No meta-analysis performed. "[NA]"

P15. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).&quot;</span>
No assessment of risk of bias performed. "[No]"

P16.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.&quot;</span>
No additional analyses described. "[NA]"

P17.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;</span> 
Number of studies included reported, but no details on screening or reasons for exclusion. No flow diagram. "[No]"

P18.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;</span>
Study characteristics presented in Table 1. "[Yes]" 

P19.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).&quot;</span>
No assessment of risk of bias. "[No]"

P20. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.&quot;</span> 
No quantitative synthesis performed. "[NA]"

P21. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present results of each meta-analysis done, including confidence intervals and measures of consistency.&quot;</span>
No meta-analysis performed. "[NA]" 

P22. 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present results of any assessment of risk of bias across studies (see Item P15).&quot;</span>
No assessment of risk of bias performed. "[No]"

P23.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).&quot;</span>
No additional analyses performed. "[NA]"

P24.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;</span>
Main findings summarized in discussion and conclusion. "[Yes]"

P25.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;</span> 
Limitations of individual studies not discussed. Limitations of review methodology not discussed. "[No]"

P26.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;</span>
Results interpreted and implications for research described. "[Yes]"

P27.  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.&quot;</span>
No mention of sources of funding. "[No]"
</pre>
<p><a name='112'></a></p>
</div>
<div id="lansdale-2010" class="section level4">
<h4><a href='https://doi.org/10.1097/SLA.0B013E3181DCA0E8' title='Open publication'>Lansdale
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. "[Yes]"
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 91.2%):

d Search Technique
MEDLINE (1950 to present), Embase (1980 to present) and
Cochrane Controlled Trials Register databases' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We searched Medline (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases&quot;</span>
- Adequate search of multiple databases.

A2. "[Yes]" 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two independent reviewers reviewed all studies in abstract form&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Full-text versions of the remaining studies were retrieved and corresponding authors were contacted for further information if necessary&quot;</span>
- Explicit mention of two independent reviewers for study selection and data extraction.

A3. "[Yes]"
- <span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):

d Search Technique
MEDLINE (1950 to present), Embase (1980 to present) and
Cochrane Controlled Trials Register databases were searched using the
keywords ‘diaphragmatic hernia AND thoracoscopic,’ ‘diaphragmatic
hernia AND laparoscopic,’ and ‘diaphragmatic hernia AND minimally-
invasive' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases using the keywords ‘diaphragmatic hernia AND thoracoscopic,’ ‘diaphragmatic hernia AND laparoscopic,’ and ‘diaphragmatic hernia AND minimally-invasive'&quot;</span>
- Multiple databases searched with keywords provided. 

A4. "[No]"
- No mention of searching for grey literature.

A5. "[Yes]"  
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):

FIGURE 2. Flow chart demonstrating the pro-
cess of study selection' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Figure 2. Flow chart demonstrating the process of study selection&quot;</span>
- Provides a flow chart detailing included and excluded studies.

A6. "[Yes]"
- Table 1 provides characteristics of included studies.

A7. "[No]"
- Does not mention use of a quality assessment tool for included studies.

A8. "[NA]"
- No quality assessment done, so cannot use results to formulate conclusions.

A9. "[Yes]"
- Assesses heterogeneity using Chi-squared test and I2 statistic (Figure 3).

A10. "[No]" 
- Does not assess publication bias.

A11. "[No]"
- Does not report on conflicts of interest.

P1. "[Yes]"
- Title identifies as a systematic review and meta-analysis.

P2. "[Yes]" 
- Provides a structured abstract including objectives, eligibility criteria, sources, synthesis methods, results, limitations.

P3. "[Yes]"
- Provides context and rationale in the introduction.

P4. "[Yes]"
- Specifies participants, interventions, comparisons, and outcomes. 

P5. "[No]"
- Does not mention a review protocol.

P6. "[Yes]"  
- Specifies inclusion criteria including population, interventions, comparators, and outcomes.

P7. "[Yes]"
- Describes literature search sources and dates.

P8. "[No]"
- Does not provide full search strategy.

P9. "[Yes]" 
- Describes process of study selection with flow chart. 

P10. "[Yes]"
- Mentions two independent reviewers extracted data. 

P11. "[Yes]" 
- Specifies variables like demographics, primary and secondary outcomes.

P12. "[No]"
- Does not describe risk of bias assessment.

P13. "[Yes]"
- Specifies use of relative risk and weighted mean difference.

P14. "[NA]"

P15. "[NA]" 

P16. "[NA]"

P17. "[Yes]"
- Provides flow chart with numbers screened, excluded, and reasons.

P18. "[Yes]"
- Provides characteristics of included studies.

P19. "[No]"
- Does not provide risk of bias assessments.

P20. "[Yes]"
- Provides summary data and effect estimates in forest plots.

P21. "[Yes]" 
- Presents meta-analysis results with confidence intervals. 

P22. "[NA]"

P23. "[NA]"

P24. "[Yes]"
- Summarizes main findings and limitations.

P25. "[Yes]"
- Discusses limitations at the review and study levels.

P26. "[Yes]"  
- Provides interpretation in context of other evidence and implications.

P27. "[No]" 
- Does not describe sources of funding.
</pre>
<p><a name='113'></a></p>
</div>
<div id="lee-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2010.06.038' title='Open publication'>Lee
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the given systematic review:

A1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data were obtained from PubMed, MEDLINE, and citation review.&quot;</span>
- The review had a pre-defined scope and inclusion criteria.
[Yes]

A2. 
- No quotes suggesting duplicate study selection or data extraction.
- Not reported.
[No] 

A3. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PubMed and other databases of the English literature (up to August 2009) were analyzed.&quot;</span>
- At least two databases were searched.
[Yes]

A4.  
- No mention of including or excluding studies based on publication status. 
- Publication status not used as an inclusion criterion.
[No]

A5.
- No list of included or excluded studies provided.
- List of studies not provided.
[No]

A6. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎However, we only referenced those studies with the highest class data that were most relevant to answering the questions listed above.&quot;</span> 
- Key characteristics of included studies described.
[Yes]

A7.
- No quotes suggesting quality assessment of included studies. 
- Quality of included studies not assessed.
[No]

A8.  
- Not applicable since quality of studies not assessed.
[NA]

A9. 
- No quantitative synthesis done.
[NA]

A10.  
- No assessment of publication bias mentioned.
[No]

A11.
- No mention of conflicts of interest.
[No]

P1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Antibiotics and appendicitis in the pediatric population: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee Systematic Review&quot;</span>
- Identified as a systematic review in the title. 
[Yes]

P2.
- The abstract provides background, objectives, data sources, study eligibility criteria, results, and conclusions.
[Yes]

P3. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Despite the widespread prevalence of the disease, there is little consensus regarding the diagnosis and management of appendicitis.&quot;</span>
- Rationale described.
[Yes] 

P4.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted a literature search using “appendicitis” combined with “antibiotics” with children as the target patient population.&quot;</span> 
- Review questions and population specified.
[Yes]

P5.
- No mention of a review protocol.
[No]

P6.  
- Inclusion criteria described.
[Yes]

P7. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PubMed and other databases of the English literature (up to August 2009) were analyzed.&quot;</span>
- Information sources described.
[Yes]

P8. 
- No full search strategy provided.
[No]

P9.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies were selected based on relevance for the following questions:&quot;</span>
- Study selection process described.
[Yes]

P10.  
- No description of data extraction process. 
[No]

P11.
- No list of variables sought.
[No] 

P12.
- No assessment of risk of bias mentioned.
[No]

P13.
- Not applicable.
[NA]

P14.  
- Not applicable.
[NA]

P15.  
- Not applicable.
[NA]

P16.
- Not applicable.  
[NA]

P17. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎However, we only referenced those studies with the highest class data that were most relevant to answering the questions listed above.&quot;</span>
- Number of studies included described but not number screened or excluded.
[No]

P18. 
- Key characteristics of included studies summarized in text and tables.
[Yes]

P19. 
- No assessment of risk of bias presented.
[No]

P20.  
- Not applicable.
[NA] 

P21.
- Not applicable.
[NA]

P22.
- Not applicable.
[NA]

P23.  
- Not applicable.
[NA]

P24. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Current evidence supports the use of guidelines as described above for antibiotic therapy in children with acute and perforated appendicitis.&quot;</span>
- Main findings and strength of evidence summarized.
[Yes]

P25. 
- No limitations discussed.
[No]

P26.
- No general interpretation in context of other evidence.
[No]

P27.
- No mention of sources of funding.
[No]
</pre>
<p><a name='114'></a></p>
</div>
<div id="leevan-2016" class="section level4">
<h4><a href='https://doi.org/10.1097/TA.0000000000000950' title='Open publication'>LeeVan
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. <span title='Moderate quote deviation. Best match in fulltext (Similarity 78.6%):

lection criteria, the full article
was obtained and reviewed for inclusion.
15 
Inclusion criteria
were (1) original research articles regarding management of
pediatric blunt renal trauma, (2) involvement of cases of high-
grade renal (Grades IV and V) trauma, and (3) more than one
patient presented per study' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎[The research question and inclusion criteria should be established before the conduct of the review.]" "[Inclusion criteria were (1) original research articles regarding management of pediatric blunt renal trauma, (2) involvement of cases of high-grade renal (Grades IV and V) trauma, and (3) more than one patient presented per study.]&quot;</span> [Yes]

A2. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎[Data from the original studies should be provided on the participants, interventions and outcomes.]&quot;</span> Table 2 provides details on study characteristics including number of subjects, age range, location, study type, hospital stay, and number of patients receiving transfusions. [Yes] 

A3. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span> The search process and selection criteria are described in detail. References for included studies are provided in Table 2. [Yes]

A4. [NA] A search for gray literature is not mentioned.

A5. References for included studies are provided in Table 2. Excluded studies are not listed. [No]

A6. Table 2 provides aggregated details on study characteristics. [Yes] 

A7. Figure 1 shows the risk of bias assessment for included studies. [Yes]

A8. The limitations of the included studies are discussed in the conclusion. [Yes]

A9. [NA] Quantitative synthesis/meta-analysis was not done. 

A10. [NA] Assessment of publication bias not done as there was no meta-analysis.

A11. No information on sources of support or conflicts of interest are provided for the systematic review or included studies. [No]

P1. Title identifies the paper as a systematic review. [Yes] 

P2. Abstract provides structured summary. [Yes]

P3. Introduction describes rationale and context. [Yes] 

P4. Inclusion criteria specify PICOS elements. [Yes]

P5. Review protocol is not mentioned. [No] 

P6. Inclusion criteria describe eligible study characteristics. [Yes]

P7. Search methods and databases are described. [Yes]

P8. Complete search strategy is not provided. [No]

P9. Study selection process is described. [Yes] 

P10. Data extraction methods are not described. [No] 

P11. Extracted variables are not defined. [No]

P12. Risk of bias assessment is described and referenced. [Yes]

P13. [NA] Quantitative synthesis was not done.

P14-P23. [NA] No meta-analysis was performed.

P24. Main findings are summarized. [Yes] 

P25. Limitations are discussed. [Yes]

P26. Results are interpreted in context of other evidence. [Yes]

P27. Sources of funding are not reported. [No]
</pre>
<p><a name='115'></a></p>
</div>
<div id="liang-2011" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0031-1271733' title='Open publication'>Liang
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

A search
was made for all studies published up until 31 August 2010
using the terms “lymphatic sparing varicocelectomy”, “laparos-
copy” , “adolescent ” and “children ” in the Medline (using PubMed
as the search engine), Embase, Ovid, Web of Science, and
Cochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A search was made for all studies published up until 31 August 2010 using the terms “lymphatic sparing varicocelectomy”, “laparoscopy”, “adolescent” and “children” in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span>
- The review had predefined inclusion criteria.
[Yes]

A2. Was there duplicate study selection and data extraction?  
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The citations and/ or abstracts or the full text
of all potentially relevant studies were independently evaluated
and selected by 3 reviewers (LZL, GJ and TQS), and any disagree-
ments were resolved by consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The citations and/ or abstracts or the full text of all potentially relevant studies were independently evaluated and selected by 3 reviewers (LZL, GJ and TQS), and any disagreements were resolved by consensus.&quot;</span>
- There was duplicate study selection. 
[Yes]

A3. Was a comprehensive literature search performed?
- Five databases were searched.
- Search terms were provided.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding based on publication status.
[No] 

A5. Was a list of studies provided?
- A flow diagram of included/excluded studies was provided. 
[Yes]

A6. Were the characteristics of the included studies provided?
- Tables 1-3 summarize the key characteristics of the included studies.
[Yes]  

A7. Was the scientific quality of the included studies assessed?
- No quality assessment mentioned.
[No]

A8. Was the scientific quality used appropriately in formulating conclusions?
- No quality assessment performed.
[NA]

A9. Were the methods to combine findings appropriate?  
- Methods for assessing heterogeneity were described. 
[Yes]

A10. Was publication bias assessed?
- No assessment of publication bias mentioned.
[No]

A11. Was conflict of interest included?
- No conflict of interest statement. 
[No]

P1. Identify as a systematic review, meta-analysis, or both. [Yes]
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review and meta-analysis was performed using odds ratios (ORs) for dichotomous variables.&quot;</span>

P2. Structured summary. [Yes]
- Provides background, objectives, eligibility criteria, participants, interventions, study appraisal, results, and conclusions.

P3. Rationale for review. [Yes]  
- Provides context and rationale in the introduction.

P4. Objectives and PICOS. [No]
- Research question and inclusion criteria provided but not formally framed around PICOS.

P5. Protocol and registration. [No] 
- No mention of a protocol or registration.

P6. Specify study characteristics and report characteristics. [Yes]
- Inclusion criteria, age range, and indications described. 

P7. Information sources and dates. [Yes]
- Five databases searched, no date limits mentioned.

P8. Search strategy. [No]
- Search strategy not provided for any database.

P9. Study selection process. [Yes] 
- Selection process described and flow diagram provided.

P10. Data extraction process. [Yes]
- Extraction done independently by 3 reviewers using a predefined form.

P11. List and define all variables extracted. [No] 
- Does not list all variables for which data sought.

P12. Risk of bias assessment. [No]
- No risk of bias assessment described.

P13. Summary measures. [Yes]
- Odds ratios used for dichotomous outcomes.

P14. Synthesis methods. [NA]
- Not applicable since no meta-analysis done.

P15. Risk of bias across studies. [NA] 
- Not applicable since no meta-analysis done.

P16. Additional analyses. [NA]
- No additional analyses described.

P17. Study flow diagram. [Yes]
- Provides flow diagram of screening process.

P18. Study characteristics. [Yes]
- Reports key characteristics in tables. 

P19. Risk of bias within studies. [No]
- Does not present risk of bias assessments.

P20. Results for each study. [Yes]
- Provides summary results for each study in tables.

P21. Meta-analysis results. [Yes]
- Presents meta-analysis results with forests plots. 

P22. Risk of bias across studies. [NA] 
- Not applicable since no meta-analysis done.

P23. Additional analyses. [NA]
- No additional analyses mentioned.

P24. Summary of evidence. [Yes] 
- Summarizes main findings and strength of evidence in discussion.

P25. Limitations. [Yes]  
- Discusses limitations at study and review level.

P26. Interpretation of results. [Yes]
- Interprets results in context of other evidence.

P27. Funding sources. [No]
- No mention of sources of funding.
</pre>
<p><a name='116'></a></p>
</div>
<div id="lishuang-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3662-7' title='Open publication'>Lishuang
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are my assessments of the AMSTAR and PRISMA items for the attached systematic review:

A1. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):

The following Medical Subject
Headings were used: ‘‘comparative study,’’ ‘‘laparos-
copy,’’ ‘‘biliary atresia,’’ ‘‘surgery,’’ and ‘‘treatment
outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The following Medical Subject Headings were used: ‘comparative study,’ ‘laparoscopy,’ ‘biliary atresia,’ ‘surgery,’ and ‘treatment outcome’.&quot;</span> This indicates the research question and inclusion criteria were pre-determined.

A2. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):

Two
authors (ML and CZ) independently assessed included
studies and divergence was resolved by discussion with the
other reviewers. Two independent authors (QG and ZZ)
using a predefined meta-analysis form extracted relevant
data from each study which resulted in high and satisfac-
tory interobserver agreement' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors (ML and CZ) independently assessed included studies and divergence was resolved by discussion with the other reviewers. Two independent authors (QG and ZZ) using a predefined meta-analysis form extracted relevant data from each study which resulted in high and satisfac¬tory interobserver agreement.&quot;</span> This indicates duplicate study selection and data extraction. 

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

We conducted a system-
atic search of the online databases, including Medline,
Ovid, Elsevier, Google Scholar Embase, Cohrane library,
for studies published between 1995 and 2014 with no
limits for publication language, place of study origin and
sample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases, including Medline, Ovid, Elsevier, Google Scholar Embase, Cohrane library, for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;</span> Multiple databases were searched with supplemental strategies. 

A4. [No] 
No mention of searching for gray literature.

A5. [Yes] 
The number of studies screened, assessed, included and excluded is shown in the PRISMA flow diagram. 

A6. [Yes] 
Table 1 provides detailed characteristics of the included studies.

A7. [Yes]  
The Newcastle-Ottawa Scale was used to assess quality of included studies. 

A8. [No]
The quality assessment does not seem to be incorporated in the analysis and conclusions.

A9. [NA]
Tests for heterogeneity are described but no quantitative synthesis was performed.

A10. [No] 
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest.

P1. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

Laparoscopic portoenterostomy versus open portoenterostomy
for the treatment of biliary atresia: a systematic review and meta-
analysis of comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopic portoenterostomy versus open portoenterostomy for the treatment of biliary atresia: a systematic review and meta-analysis of comparative studies&quot;</span>

P2. [Yes]
The abstract provides the required details.

P3. [Yes]
The introduction describes the rationale in context of existing knowledge.

P4. [No] 
The review question is not explicitly stated in PICOS format.

P5. [No]
No mention of a review protocol. 

P6. [Yes]  
Inclusion criteria are described in the Methods section.

P7. [Yes]
Information sources are described in the Methods section. 

P8. [No]
The search strategy for only one database is provided.

P9. [Yes] 
The selection process is depicted in the PRISMA flow diagram and described in the Methods.

P10. [Yes]  
Data extraction process is described in the Methods.

P11. [Yes] 
Outcomes of interest are pre-defined and listed in Table 2.

P12. [No]
Risk of bias assessment not described at outcome level.

P13. [Yes]
Summary measures described in Methods. 

P14-P23. [NA] 
Not applicable as no meta-analysis was performed.

P24. [Yes]
Main findings are summarized in the Discussion.

P25. [Yes] 
Limitations are described in the Discussion. 

P26. [Yes]  
Results are interpreted in context of other evidence.

P27. [No]
No mention of sources of funding.
</pre>
<p><a name='117'></a></p>
</div>
<div id="livingston-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.020' title='Open publication'>Livingston
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 61.9%):

thods: We conducted a structured search of Medline, Embase, trial registries, and the gray literature' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - An 'a priori' design was provided as the authors state 'We conducted a structured search of Medline, Embase, trial registries, and the gray literature.'&quot;</span>

A2. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66%):

were placed.
1.2. Study selection
Title and abstract screening was completed independently and in
duplicate by two of the authors (MHL, ACS' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - There was duplicate study selection and data extraction as the authors state 'Title and abstract screening was completed independently and in duplicate by two of the authors (MHL, ACS).'&quot;</span>

A3. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 37.8%):

tured search of Medline, Embase, trial registries, and t' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - A comprehensive literature search was performed across multiple databases, trial registries, and supplementary sources.&quot;</span> 

A4. <span title='Moderate quote deviation. Best match in prompt (Similarity 81.9%):

the status of publication (i.e. grey literature) used as an inclusion criterion' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] - The status of publication was not used as an inclusion criterion.&quot;</span>

A5. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.2%):

? A list of included and excluded studies should be provided. No' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - A list of included and excluded studies was provided in Figure 1.&quot;</span>

A6. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.1%):

characteristics of the included studies provided? In' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Characteristics of included studies were provided in Table 1.&quot;</span> 

A7. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.9%):

the scientific quality of the included studies assessed and documented?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The scientific quality of included studies was assessed using the MINORS tool and documented in Table 2.&quot;</span>

A8. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 55.8%):

the scientific quality of the included studies used appropriately in formulating conclusions? The results of the metho' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The scientific quality was considered in formulating conclusions, as the authors state the evidence was very low quality.&quot;</span>

A9. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.1%):

quantitative synthesis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No quantitative synthesis was performed.&quot;</span>

A10. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.9%):

quantitative synthesis (A9) or assessing publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No quantitative synthesis was performed to assess publication bias.&quot;</span>   

A11. <span title='Moderate quote deviation. Best match in prompt (Similarity 80.6%):

conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] - Conflicts of interest were not reported for the included studies.&quot;</span>

P1. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.8%):

the report as a systematic review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The report is identified as a systematic review in the title.&quot;</span>

P2. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40.4%):

a structured summary in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - A structured summary is provided in the abstract.&quot;</span>

P3. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.1%):

the rationale for the review in the' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The rationale is described in the introduction.&quot;</span> 

P4. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 46.5%):

Describe the methods' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - PICOS are described in the methods.&quot;</span>

P5. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.9%):

a review protocol' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] - A review protocol is not mentioned.&quot;</span>

P6. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 31.9%):

study characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Study characteristics and eligibility criteria are described.&quot;</span> 

P7. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 42.1%):

ce were not described in the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - Information sources are described in the methods.&quot;</span> 

P8. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60.9%):

search strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] - A full search strategy is not provided.&quot;</span>

P9. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.4%):

the process for selecting studies (i.e., screening, eligibility, included in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The process for study selection is described and depicted in Figure 1.&quot;</span>

P10. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44.2%):

data extraction? There should be' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Data extraction by two authors is described.&quot;</span>

P11. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 48.8%):

ese procedures and described' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - Outcomes extracted are described.&quot;</span>

P12. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.2%):

2
Risk of bias assessment for individual studies using meth' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - Risk of bias assessment is described using the MINORS tool.&quot;</span>

P13. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 36.8%):

, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No meta-analysis was performed.&quot;</span>  

P14-P23. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 36.8%):

, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No meta-analysis was performed.&quot;</span>   

P24. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.7%):

main findings including the strength of evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Main findings are summarized including strength of evidence.&quot;</span>

P25. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60.9%):

limitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Limitations at the study and review level are discussed.&quot;</span>

P26. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.7%):

interpretation of the results in the context of other evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Results are interpreted in the context of other evidence.&quot;</span>

P27. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.5%):

source of funding or support for the systematic review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] - Sources of funding are not reported for the systematic review.&quot;</span>
</pre>
<p><a name='118'></a></p>
</div>
<div id="mauritz-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S11605-013-2305-3' title='Open publication'>Mauritz
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement.&quot;</span> The review followed PRISMA guidelines which require an a priori design.

A2. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Titles and abstracts of all retrieved records, and subsequently full-text articles (full-texts were obtained for articles that appeared potentially relevant), were examined independently by two authors (F.M. and B.B.) according to the PRISMA statement.&quot;</span> Study selection and data extraction were done in duplicate. 

A3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Using predefined search
terms PubMed (1960 to 2011), EMBASE (from 1980 to
2011), and the Cochrane Library (issue 3, 2011) were system-
atically searched until March 16, 2011 to identify all articles
comparing complete to partial fundoplication in children
with GERD' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD.&quot;</span> Multiple databases were searched systematically. 

A4. [No] Grey literature was not mentioned as being searched.

A5. [Yes] A list of included and excluded studies is provided in the flow diagram. 

A6. [Yes] Characteristics of included studies are provided in Table 1.

A7. [Yes] The methodological quality of included studies was assessed using predefined criteria and the Cochrane Collaboration's tool.

A8. [Yes] The poor quality and retrospective design of most included studies are discussed as limitations.

A9. [Yes] Heterogeneity was assessed and a random effects model used for meta-analysis.

A10. [No] Publication bias was not assessed.

A11. [No] Sources of support were provided for the review but not for the included studies.

P1. [Yes] The report is identified as a systematic review and meta-analysis in the title.

P2. [Yes] A structured abstract is provided summarizing the key information.

P3. [Yes] The rationale for the review is described in the introduction.

P4. [Yes] The review questions are stated in the introduction. 

P5. [No] A review protocol is not mentioned.

P6. [Yes] Eligibility criteria are described in the methods.

P7. [Yes] Information sources including databases and dates searched are described. 

P8. [Yes] The full search strategy is provided for PubMed.

P9. [Yes] The study selection process is diagrammed and described.

P10. [Yes] Data extraction by two independent authors is described. 

P11. [Yes] Outcomes of interest are predefined.

P12. [Yes] Quality assessment methods are described.

P13. [Yes] Summary measures (risk ratios) are stated.

P14. [NA] 

P15. [NA]

P16. [NA]

P17. [Yes] A flow diagram depicts the screening process.

P18. [Yes] Characteristics of included studies are presented in Table 1.

P19. [Yes] A summary of quality assessment is provided in Table 1. 

P20. [Yes] Meta-analysis results are presented with forest plots.

P21. [Yes] Results of meta-analyses are presented with confidence intervals and I2 values.

P22. [NA]

P23. [NA] 

P24. [Yes] Main findings are summarized in the discussion.

P25. [Yes] Limitations are discussed.

P26. [Yes] Results are interpreted and implications described.

P27. [Yes] Sources of funding are provided.
</pre>
<p><a name='119'></a></p>
</div>
<div id="mauritz-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S11605-011-1644-1' title='Open publication'>Mauritz
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Using predefined search terms, PubMed (from 1960),
Embase (from 1980), and the Cochrane library (issue 11,
2010) were systematically searched for all articles pub-
lished until November 10, 2010' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined search terms, PubMed (from 1960), Embase (from 1980), and the Cochrane library (issue 11, 2010) were systematically searched for all articles published until November 10, 2010.&quot;</span>
- The review specifies predefined search terms and databases searched.
[Yes]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction.
[No]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

For PubMed, the follow-
ing search terms were used: (fundoplication[Title/Abstract]
OR nissen[Title/Abstract] OR thal[Title/Abstract] OR tou-
pet[Title/Abstract] OR boerema[Title/Abstract] OR antire-
flux surgery[Title/Abstract]) AND (child[Title/Abstract] OR
children[Title/Abstract] OR infant[Title/Abstract] OR
infants[Title/Abstract] OR pediatric[Title/Abstract] OR pe-
diatrics[Title/Abstract] OR pediatric[Title/Abstract] OR
pediatrics[Title/Abstract' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For PubMed, the following search terms were used: (fundoplication[Title/Abstract] OR nissen[Title/Abstract] OR thal[Title/Abstract] OR toupet[Title/Abstract] OR boerema[Title/Abstract] OR antireflux surgery[Title/Abstract]) AND (child[Title/Abstract] OR children[Title/Abstract] OR infant[Title/Abstract] OR infants[Title/Abstract] OR pediatric[Title/Abstract] OR pediatrics[Title/Abstract] OR pediatric[Title/Abstract] OR pediatrics[Title/Abstract]).&quot;</span>
- Searched at least 2 databases (PubMed, Embase, Cochrane) with specified search terms. 
[Yes]

A4. Was the status of publication used as an inclusion criterion?  
- No mention of including or excluding studies based on publication status.
[No] 

A5. Was a list of studies (included and excluded) provided?
- No list of excluded studies provided.
[No]

A6. Were the characteristics of the included studies provided? 
- Table 1 provides characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- Table 2 provides a subjective assessment of risk of bias for each included study.
[Yes]  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- The review does not explicitly discuss limitations of included studies when interpreting results.
[No]

A9. Were the methods used to combine the findings of studies appropriate?
[NA] - No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? 
[NA] - No quantitative synthesis performed.

A11. Was the conflict of interest included?
- No mention of conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This study aims to systematically review the efficacy of pediatric ARS and its effects on gastroesophageal function, as measured by gastroesophageal function tests. This is the first systematic review comprising only prospective, longitudinal studies, minimizing the risk of bias.&quot;</span>
[Yes]

P2. Provide a structured summary.
- Abstract provides structured summary.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Introduction describes rationale and context.
[Yes] 

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- Objectives described in introduction but no explicit PICOS statement.
[No]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No mention of protocol.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. 
- Inclusion and exclusion criteria described.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
- Databases and date ranges provided. No supplemental search methods described. 
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- Search strategy for PubMed provided.
[Yes]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Study selection process described and flow diagram provided.
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
- No details provided on data extraction process.
[No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  
- Outcomes of interest described. No other variables listed.
[No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- Table 2 provides subjective assessment of risk of bias, but no details on methods provided.
[No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[NA] - No quantitative synthesis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.  
[NA] - No quantitative synthesis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA] - No quantitative synthesis performed.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. 
[NA] - No additional analyses performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- Flow diagram provided detailing study selection process.
[Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
- Table 1 provides key characteristics of included studies.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- Table 2 provides subjective risk of bias assessment for each study.
[Yes]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- Individual study data summarized in tables and text. No forest plots.
[No]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA] - No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). 
[NA] - No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA] - No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Conclusions summarize main findings but do not discuss strength of evidence or relevance to key groups.
[No]  

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations of included studies discussed, but not limitations at the review level.
[No]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted and implications for future research described.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
- No statement on sources of funding or support.
[No]
</pre>
<p><a name='120'></a></p>
</div>
<div id="mei-2011" class="section level4">
<h4><a href='https://doi.org/10.1089/END.2010.0544' title='Open publication'>Mei
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA 2009 assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The review was limited to the published studies, and no attempt was made to contact the authors to obtain unpublished data or unclear information in the studies.&quot;</span>
The review had pre-determined inclusion/exclusion criteria.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.5%):

The literature search, quality assessment, and data extraction
were independently performed by two reviewers.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The literature search, quality assessment, and data extraction were independently performed by two reviewers (MH and TQS).&quot;</span>
Two reviewers performed study selection and data extraction. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched online databases, including Medline (using PubMed as the search engine), Embase, Web of Science, Ovid, and Cochrane, to identify suitable studies until the end of October 2010, without lower date limit.&quot;</span>
Searched multiple databases without date restrictions. 

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status.

A5. Was a list of studies provided? [Yes] 
Table 1 lists the included studies.

A6. Were the characteristics of the included studies provided? [Yes]
Tables 1-4 summarize key characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed? [No]
No formal quality assessment mentioned.

A8. Was the scientific quality used appropriately in formulating conclusions? [NA] 
No quality assessment performed.

A9. Were the methods used to combine findings appropriate? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Meta-analyses were performed for the five primary out-
come parameters: Operative time (in minutes), postoperative
complications (in events per group), duration of hospital stay
(in days), success rate (in events per group), and stenting rate
(in events per group' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Meta-analyses were performed for the five primary outcome parameters: Operative time (in minutes), postoperative complications (in events per group), duration of hospital stay (in days), success rate (in events per group), and stenting rate (in events per group).&quot;</span> Heterogeneity assessed using I2.

A10. Was publication bias assessed? [No]  
No assessment of publication bias mentioned.

A11. Was conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify as systematic review or meta-analysis [Yes]
Identified as <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎systematic review and meta-analysis&quot;</span> in title.

P2. Structured summary [Yes]
Abstract provides structured summary.

P3. Rationale for review [Yes]  
Introduction describes rationale and context.

P4. Objectives and PICOS [Yes] 
Objective to assess LP vs OP for UPJ obstruction in children. Participants, interventions, comparisons clear. Outcomes and study designs not explicitly stated but evident from methods and results.

P5. Protocol and registration [No]  
No mention of review protocol or registration.

P6. Eligibility criteria [Yes]
Inclusion/exclusion criteria described in methods.

P7. Information sources [Yes]
Databases and search strategy described.

P8. Search strategy [No]  
Search strategy not provided.

P9. Study selection process [Yes]  
Study selection process described and depicted in Figure 1.

P10. Data extraction [Yes]
States two reviewers extracted data independently.

P11. Data items [Yes]
Outcomes extracted described in methods.

P12. Risk of bias assessment [No]
No risk of bias assessment described.

P13. Summary measures [Yes]  
Used mean differences and odds ratios as summary measures. 

P14. Synthesis methods [NA]
Not applicable - no meta-analysis.

P15. Risk of bias across studies [NA]  
Not applicable - no assessment of publication bias.

P16. Additional analyses [NA]
No additional analyses mentioned.

P17. Study selection flow [Yes]
Figure 1 shows flow of study selection.

P18. Study characteristics [Yes] 
Tables 1-4 summarize key characteristics of included studies.

P19. Risk of bias within studies [No]
No assessment of risk of bias.

P20. Study results [Yes] 
Results summarize findings from each study. Forest plots show individual and pooled results.

P21. Meta-analysis results [Yes]
Forest plots show results of meta-analyses. 

P22. Risk of bias across studies [NA]
Not applicable - no assessment of publication bias.

P23. Additional analyses [NA]  
No additional analyses mentioned.

P24. Summary of evidence [Yes] 
Conclusions summarize main findings and implications.

P25. Limitations [Yes]  
Limitations discussed in discussion.

P26. Conclusions [Yes]  
Conclusions summarize findings in context of other evidence and implications for research.

P27. Funding [No] 
No statement about sources of funding.
</pre>
<p><a name='121'></a></p>
</div>
<div id="mullassery-2014" class="section level4">
<h4><a href='https://doi.org/10.3109/08880018.2014.947009' title='Open publication'>Mullassery
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the attached systematic review PDF:

A1. Was an 'a priori' design provided? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

We sought to in-
clude randomized controlled trials (if available) and observational studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We sought to include randomized controlled trials (if available) and observational studies.&quot;</span>
The review protocol was designed before searches were undertaken.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Studies were reviewed by PJF and DM independently. Where a difference in opin-
ion occurred the matter was resolved by consensus agreement in conjunction with the
senior author (PDL' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Studies were reviewed by PJF and DM independently. Where a difference in opinion occurred the matter was resolved by consensus agreement in conjunction with the senior author (PDL).&quot;</span>
Two reviewers independently performed study selection and reached consensus. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The following databases were included in the search - Medline, Embase and Cochrane.&quot;</span>
At least two databases were searched.

A4. Was the status of publication used as an inclusion criterion? [No]  
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [Yes]
Included studies are listed in Tables 1 and 2. Excluded studies are listed in Table 2.

A6. Were the characteristics of the included studies provided? [Yes]  
Tables 1 and 2 provide characteristics of included studies like sample size, interventions, outcomes.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No formal quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Meta-analysis was performed according to the recommendations from the Cochrane collaboration and PRISMA guidelines.&quot;</span> Heterogeneity assessed.

A10. Was the likelihood of publication bias assessed? [Yes]  
Funnel plots were generated to assess publication bias.

A11. Was the conflict of interest included? [No] 
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review and meta-analysis is reported to address...&quot;</span>

P2. Provide a structured summary. [Yes]
Abstract provides background, objectives, eligibility criteria, main results, conclusions.

P3. Describe the rationale for the review. [Yes]  
Introduction describes rationale and need for the review.

P4. Provide an explicit statement of questions being addressed. [Yes]  
Objective clearly stated to examine evidence for GTR vs STR in stages 3 and 4 neuroblastoma. 

P5. Indicate if a review protocol exists. [No]
No protocol mentioned.

P6. Specify study characteristics used as criteria for eligibility. [Yes]
Eligibility criteria described including population, interventions, outcomes.

P7. Describe all information sources. [Yes]
Databases and supplementary searches described.

P8. Present full electronic search strategy. [No]
Search strategy not provided.

P9. State the process for selecting studies. [Yes]  
Study selection process described.

P10. Describe method of data extraction. [Yes] 
Data extracted using a custom designed proforma.

P11. List and define all variables for which data were sought. [Yes]
Data sought described in methods.

P12. Describe methods used for assessing risk of bias. [No] 
No risk of bias assessment described.

P13. State the principal summary measures. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Odds ratios (OR) were calculated with 95% confidence intervals.&quot;</span>

P14. Describe the methods of handling data and combining results of studies. [Yes]
Appropriate meta-analytic methods described. 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence. [Yes]
Assessed for publication bias.

P16. Describe methods of additional analyses. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions. [Yes] 
Screening process shown in Figure 1 PRISMA flowchart.

P18. For each study, present characteristics for which data were extracted. [Yes]
Study characteristics presented in Tables 1 and 2. 

P19. Present data on risk of bias of each study. [NA]
No risk of bias assessment.

P20. For all outcomes, present summary data and effect estimates for each study. [Yes] 
Forest plots show effect estimates.

P21. Present results of each meta-analysis done. [Yes]
Results presented with confidence intervals and measures of heterogeneity.

P22. Present results of any assessment of risk of bias across studies. [NA] 
No assessment of risk of bias across studies.

P23. Give results of additional analyses. [NA]
No additional analyses. 

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes]  
Main findings summarized in abstract conclusions.

P25. Discuss limitations at study and outcome level and at review-level. [Yes]
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results discussed in context of other evidence.

P27. Describe sources of funding for the systematic review. [No]
No mention of sources of funding.
</pre>
<p><a name='122'></a></p>
</div>
<div id="nagler-2011" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD001532.pub4' title='Open publication'>Nagler
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

AMSTAR:
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To evaluate the available evidence for both benefits and harms of the currently available treatment options for primary VUR: operative, non-operative or no intervention.&quot;</span> (Objectives)
The review had predefined objectives, inclusion criteria, and outcomes.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently searched the literature, determined study eligibility, assessed quality, extracted and entered data.&quot;</span> (Methods)
Two authors independently performed study selection and data extraction.

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In August 2010 we searched CENTRAL, MEDLINE and EMBASE and screened reference lists of papers and abstracts from conference proceedings.&quot;</span> (Results)
The review searched CENTRAL, MEDLINE, and EMBASE, screened reference lists, and searched conference abstracts. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We captured two studies by screening reference lists of the authors. Both studies were published in conference proceedings only (Morris 1991; Reddy 1997).&quot;</span> (Results)
The review searched conference abstracts/proceedings for unpublished studies.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
[Yes] The review provided aCharacteristics of included studies and Characteristics of excluded studies table listing all included and excluded studies.

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Follow-up poorly reported in general&quot;</span>
[Yes] The review provided a Characteristics of included studies table with details on the participants, interventions, and outcomes for each included study.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
[Yes] The review used the Cochrane risk of bias tool to assess each included study for risk of bias in sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other sources of bias. A risk of bias summary and graph are provided.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
[Yes] The review discussed limitations of the quality of evidence in the Discussion section, such as concerns about bias due to lack of blinding.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Heterogeneity between studies was analysed using the Cochran's Q statistic with the threshold for statistical significance set at alpha = 0.1 (Lau 1997). It was also tested by means of the IS test, reflecting the percentage of total variation across studies that could be ascribed to heterogeneity (Higgins 2003).&quot;</span> A random effects model was used.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.
[No] Publication bias was not assessed. The review stated: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There were insufficient studies to explore potential effect modification using subgroup analysis or meta-regression.&quot;</span>

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.. 
[Yes] Sources of support were reported for the review and included studies. No conflicts of interest were reported.

In summary, the review met 10/11 AMSTAR criteria. The only criteria not met was assessment of publication bias, which was likely not done due to the small number of included studies. Overall, this systematic review was conducted with rigorous methodology.

PRISMA:

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes] The report is titled <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Interventions for primary vesicoureteric reflux&quot;</span> and identified as a Cochrane systematic review in the citation.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[Yes] The abstract provides a structured summary of the background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal methods, results, limitations, and conclusions.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] The background section describes the context of VUR and its hypothesized relationship to UTI and kidney damage. It discusses current management strategies and the rationale for the review.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
[Yes] The objectives state: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The aim of this review was to evaluate the available evidence for both benefits and harms of the currently available treatment options for primary VUR: operative, non-operative or no intervention.&quot;</span> The participants, interventions, comparisons, outcomes, and study designs are described under the eligibility criteria. 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No] The review does not report whether a protocol exists or is registered.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Yes] The types of studies, participants, interventions, comparisons, and outcomes are specified under the eligibility criteria. Study follow-up length ranged from 3 months to 10 years. There were no language restrictions.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
[Yes] The review searched CENTRAL, MEDLINE, EMBASE from inception to August 2010. Reference lists and conference abstracts were screened. Study authors were contacted if necessary for additional data. The exact search strategies are provided in the appendix. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[Yes] The full search strategies for CENTRAL, MEDLINE, and EMBASE are provided in the appendix.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[Yes] The review states: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Titles and abstracts obtained from the above searches were screened for selection independently by at least two authors. In all cases an overly inclusive selection was preferred to avoid losing relevant studies and to ensure additional studies could be identified from the reference lists.&quot;</span>

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data extraction was conducted independently by at least two authors, using a standardised data extraction form.&quot;</span> Study authors were contacted for additional data if necessary. 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[Yes] The data extracted on study characteristics, participant characteristics, interventions, and outcomes are listed and defined in the Characteristics of included studies table.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[Yes] The Cochrane risk of bias tool was used to assess selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. This information was considered when interpreting results, as discussed in the limitations of the evidence.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[Yes] For dichotomous outcomes, the risk ratio and 95% CI were used. For continuous outcomes, the mean difference and 95% CI were used.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
[Yes] The review used a random effects model for meta-analyses. Heterogeneity was assessed using Cochran's Q statistic and the I2 statistic.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[No] Publication bias was not assessed.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[No] No additional analyses were reported.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[Yes] A flow diagram depicts the screening process. 20 RCTs were included in the review. Reasons for excluding 9 studies are provided. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
[Yes] Study characteristics are presented in a table. Full citations are provided.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[Yes] A risk of bias summary and graph are provided for each study.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[Yes] For each outcome, the data for each study are presented in the text and meta-analysis forest plots when applicable. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[Yes] Results of each meta-analysis are presented with 95% CIs and measures of heterogeneity (I2).

P22. Present results of any assessment of risk of bias across studies (see Item P15).
[NA] Publication bias was not assessed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA] No additional analyses were done.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes] The authors' conclusions summarize the main findings and their relevance to practice.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[Yes] Limitations are discussed in the Discussion section, including risk of bias in individual studies and the review.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes] The results are interpreted in the context of other evidence. Implications for future research are discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
[Yes] Sources of support are provided for the systematic review. The review states: <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.8%):

as the conflict of interest' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The authors declare that they have no conflict of interest.&quot;</span>

In summary, this systematic review adhered well to the PRISMA guidelines. The only items not addressed were a protocol, assessment of publication bias, and additional analyses - which were likely not done due to the limited data. Otherwise, the review was very comprehensive in its reporting.

In conclusion, this systematic review had good methodology overall following AMSTAR and PRISMA guidelines. The main limitations were the lack of assessment for publication bias and limited additional analyses, which is understandable given the small number of studies. The review provides moderately strong evidence regarding the benefits and harms of interventions for vesicoureteral reflux in children. The authors' conclusions appear appropriate based on the evidence presented.
</pre>
<p><a name='123'></a></p>
</div>
<div id="narayanan-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.07.020' title='Open publication'>Narayanan
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Choledochal cysts are congenital bile duct anomalies with cystic dilatation of the biliary tree and have potential for various complications.&quot;</span> (Introduction)
States that the inclusion criteria were studies comparing HD and HJ after choledochal cyst excision.

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

A Medline, Ovid, Search Medica, Elsevier Clini-
calKey, Google Scholar and the Cochrane library search
was performed on all studies published between 1950 and
2012 reporting on comparison of HD and HJ for children
undergoing excision of extra-hepatic biliary tree for
choledochal cysts' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.&quot;</span> (Materials and Methods - Study Selection)  
At least two electronic sources searched.

A4. [No]
No mention of searching for or including grey literature.

A5. [No]
No list of included/excluded studies provided.

A6. [Yes] 
Table 1 provides characteristics of included studies including number of patients, cyst diameter, age, follow up time, operative time, and hospital stay.

A7. [No]
No mention of quality assessment of individual studies.

A8. [NA]
No assessment of quality of included studies.

A9. [NA]  
No quantitative synthesis performed.

A10. [NA]
No assessment of publication bias. 

A11. [No]
No mention of sources of support/funding for included studies.

P1. [Yes] 
Title identifies as a systematic review and meta-analysis.

P2. [No] 
No structured summary provided.

P3. [Yes]
Introduction describes rationale and what is known about HD vs HJ.

P4. [No]  
No explicit statement of review questions or PICOS.

P5. [No]
No mention of a review protocol.

P6. [Yes]
Table 1 provides characteristics of included studies - study design, number of patients, age, follow up time.

P7. [Yes]  
Methods describe literature sources searched and time period covered.

P8. [No]
No search strategy provided.

P9. [Yes] 
Methods describe process for study selection and exclusion.  

P10. [No] 
No details provided on data extraction process.

P11. [Yes]
Table 2 provides data extracted for outcomes of interest.

P12. [No]  
No assessment of risk of bias described.

P13. [Yes]
Results present summary measures (OR, MD) with confidence intervals.

P14. [NA] 
No meta-analysis performed.

P15. [NA]
No assessment of publication bias.

P16. [NA]
No additional analyses described.

P17. [Yes]  
Results describe numbers of studies screened and included with reasons for exclusion.  Figure 1 shows flow diagram.

P18. [Yes]
Table 1 provides characteristics of included studies.

P19. [No]
No assessment of risk of bias presented.

P20. [Yes] 
Results present summary data and effect estimates in forest plots. 

P21. [NA] 
No meta-analysis performed.

P22. [NA]  
No assessment of risk of bias across studies.

P23. [NA]
No additional analyses presented.

P24. [Yes]
Discussion summarizes main findings and discusses limitations.

P25. [Yes] 
Discussion describes limitations at the review and outcome level.

P26. [Yes]  
Discussion interprets results in context of existing evidence.

P27. [No]
No statement about sources of funding for review.

In summary, I have provided an assessment of all AMSTAR and PRISMA items for the attached systematic review. Let me know if you need any clarification or have additional questions!
</pre>
<p><a name='124'></a></p>
</div>
<div id="nasr-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2010.02.012' title='Open publication'>Nasr
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are the AMSTAR and PRISMA 2009 assessments for the provided systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All publications describing both surgical procedures for pectus excavatum were sought from the Cochrane Trials Register and the Cochrane Central Register of Controlled Trials (CENTRAL) database.&quot;</span>
This indicates a predefined protocol.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors (AN and PW) independently extracted data from the retrieved articles.&quot;</span>
Two authors performed data extraction. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All studies were identified through electronic searches of MEDLINE (1966 onward), EMBASE (1980 onward), and CINAHL (1982 onward) and from hand-searching journals and conference proceedings.&quot;</span>
Multiple databases and supplementary strategies were used.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [Yes]  
Table 1 provides a list of included studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides aggregated characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [No]
No mention of quality assessment. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment was performed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):

We applied tests for between-study heterogeneity χ
2
(Q test) and the I
2 
statistic to assess the appropriateness of
combining studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We applied tests for between-study heterogeneity χ2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;</span>

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias.

A11. Was the conflict of interest included? [No] 
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our objective was to compare the Nuss procedure to the Ravitch procedure using systematic review and meta-analysis methodology.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
The introduction describes the rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No mention of a protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Inclusion criteria described but no exclusion criteria.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Search strategy is described. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]  
Inclusion criteria described but no details on screening process.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Data extraction described but no confirmation process.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
No list of variables sought.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No] 
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Odds ratios (OR) and weighted mean differences (WMDs) with 95% confidence intervals are presented.&quot;</span>

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Methods described.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No]
No assessment of risk of bias.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA] 
No additional analyses done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
No flow diagram or number screened/assessed provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 presents key characteristics.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA]
No risk of bias assessment done.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes] 
Forest plots provided. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes]
Results provided.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment done.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses done.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Limitations discussed but no assessment of bias.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in discussion.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No mention of funding sources.
</pre>
<p><a name='125'></a></p>
</div>
<div id="nasr-2013" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1347916' title='Open publication'>Nasr
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are my assessments of the systematic review's methodological quality using AMSTAR and reporting quality using PRISMA 2009:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our methodological assessment revealed that the studies ranged from poor to moderate quality.&quot;</span> [No]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Authors extracted data from the retrieved articles.&quot;</span> [No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All publications describing both procedures were reviewed.&quot;</span> [No]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
[NA]

A5. Was a list of studies (included and excluded) provided?
[No] 

A6. Were the characteristics of the included studies provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The overall numbers of study subjects managed in these publications were 71 infants, ranging from 1 to 60 newborns with long-gap EA per study.&quot;</span> [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our methodological assessment revealed that the studies ranged from poor to moderate quality.&quot;</span> [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
[No]

A9. Were the methods used to combine the findings of studies appropriate?
[NA]

A10. Was the likelihood of publication bias assessed?
[NA]

A11. Was the conflict of interest included? 
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.2%):

The purpose of this study is to critically evaluate the existing literature on
this topic and to compare the Foker technique to the more conventional delayed
primary anastomosis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The purpose of this study is to critically evaluate the existing literature on this topic and to compare the outcomes of the Foker technique to the more conventional delayed primary anastomosis.&quot;</span> [Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[No] 

P3. Describe the rationale for the review in the context of what is already known.
<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.2%):

The purpose of this study is to critically evaluate the existing literature on
this topic and to compare the Foker technique to the more conventional delayed
primary anastomosis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The purpose of this study is to critically evaluate the existing literature on this topic and to compare the outcomes of the Foker technique to the more conventional delayed primary anastomosis.&quot;</span> [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
[No]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[No]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
[No]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  
[No]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Authors extracted data from the retrieved articles.&quot;</span> [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our methodological assessment revealed that the studies ranged from poor to moderate quality.&quot;</span> [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P13. State the principal summary measures (e.g., risk ratio, difference in means). 
[NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA] 

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The literature search resulted in a total of 115 articles, after
screening and exclusion of nonrelevant and duplicate pub-
lications. Six articles
36–41 
met our criteria for inclusion and
the full text was examined more in detail' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search resulted in a total of 115 articles, after screening and exclusion of nonrelevant and duplicate publications. Six articles met our criteria for inclusion and the full text was examined more in detail.&quot;</span> [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data about the initial gap length were reported in all studies with a mean of 5.4 cm (range 3–12.5 cm). No study reported data about the preoperative gap length. The time until an anastomosis could be achieved was reported in all studies with a mean of 14 ± 8.2 days. The follow-up time was 5 years (range 0.2–10 years).&quot;</span> [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[No]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency (e.g., I2) for each meta-analysis. 
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

This analysis demonstrated that res-
toration of esophageal continuity was achieved faster using the
mechanical traction approach. Although time to complete oral
intake was not reported in most studies, it is logical to assume
that earlier restoration of esophageal continuity would trans-
late into faster oral intake by the infants' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This analysis demonstrated that restoration of esophageal continuity was achieved faster using the mechanical traction approach. Although time to complete oral intake was not reported in most studies, it is logical to assume that earlier restoration of esophageal continuity would translate into faster oral intake by the infants.&quot;</span> [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] 

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

the results of this meta-
analysis should be interpreted with caution. All studies
published in the literature on this topic are retrospective
and noncomparative' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The results of this meta-analysis should be interpreted with caution. All studies published in the literature on this topic are retrospective and noncomparative.&quot;</span> [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

At the present time, the gold standard technique for
comparing two approaches to a clinical problem is a random-
ized controlled trial. However, this will be difficult to perform
for long-gap EA due to the rarity of the problem, the hetero-
geneity of the patient population, variability in surgical
technique and clinical approach within and between centers,
and well-established bias among pediatric surgeons taking
care of these children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎At the present time, the gold standard technique for comparing two approaches to a clinical problem is a randomized controlled trial. However, this will be difficult to perform for long-gap EA due to the rarity of the problem, the heterogeneity of the patient population, variability in surgical technique and clinical approach within and between centers, and well-established bias among pediatric surgeons taking care of these children.&quot;</span> [Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
[No]
</pre>
<p><a name='126'></a></p>
</div>
<div id="nataraja-2013" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2012.0522 ' title='Open publication'>Nataraja
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used in the formulation of the systematic review and meta-analysis.&quot;</span>
The review followed PRISMA guidelines.

A2. Was there duplicate study selection and data extraction? [No] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

From
these, 284 full-text journal articles were retrieved and re-
viewed in detail. Sixty-six of the latter studies contained data
that was relevant to the formation of an IAA following a
pediatric LA or OA and were therefore included in our
analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From these, 284 full-text journal articles were retrieved and reviewed in detail. Sixty-six of the latter studies contained data that was relevant to the formation of an IAA following a pediatric LA or OA and were therefore included in our analysis.&quot;</span>
Only a single reviewer screened abstracts and performed data extraction. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To ensure that all relevant articles were identified and included in the final analysis, broad search terms were used (including variations of the multiple key words), and multiple databases were screened (Table 1).&quot;</span>
Multiple databases were searched using broad search terms.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes] 
Table 3 provides detailed characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No formal quality assessment of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
Methods described for meta-analysis are appropriate. 

A10. Was the likelihood of publication bias assessed? [Yes]
Funnel plots were used to assess publication bias.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A Systematic Review and Meta-analysis&quot;</span> in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]
The abstract provides this information.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
The introduction describes the rationale and context.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes]
Research objectives and outcomes are stated in the introduction. 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion and exclusion criteria are described in Table 2.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Table 1 lists databases, search terms, and date ranges.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No] 
No full search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
The selection process is described and shown in a flow diagram.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
The data extraction process is not described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes]
Outcomes extracted are listed.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No] 
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Odds ratios were the principal summary measures.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Methods of meta-analysis are described.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [Yes]
Publication bias was assessed with funnel plots.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes] 
A flow diagram is provided showing screening and selection.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 3 provides detailed characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA]
No risk of bias assessment performed. 

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Forest plots are provided for meta-analysis results.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes] 
Meta-analysis results with CIs are presented.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]  
No additional analyses conducted.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings are summarized in the discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]
Limitations are not discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results are interpreted in the context of other evidence.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] 
No statement about sources of funding.
</pre>
<p><a name='127'></a></p>
</div>
<div id="nicolau-2011" class="section level4">
<h4><a href='https://doi.org/pmid:21520776' title='Open publication'>Nicolau
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the given systematic review article:

A1. [Yes] <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45.1%):

rehensive literature search was performed on the
U.S. National Library of Medicine site in Medline and
PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords
such as “laparoscopy and blunt abdominal trauma”.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The study was designed as a systematic review. Relevant literature was identified by searching PubMed and Medline databases using the keywords “laparoscopy and blunt abdominal trauma” in the time interval between January 2000 and December 2007.&quot;</span> This indicates an a priori design with pre-defined research question and inclusion criteria.  

A2. [No] The authors do not mention duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A comprehensive literature search was performed on the U.S. National Library of Medicine site in Medline and PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords such as “laparoscopy and blunt abdominal trauma”.&quot;</span> Two electronic databases searched with keywords and date ranges provided.

A4. [No] The status of publication was not mentioned as an inclusion criterion. 

A5. [No] A list of included and excluded studies was not provided.

A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The articles have been grouped based on their scientific content: original studies on patients with multiples and single organ injuries, reviews, and case reports.&quot;</span> Characteristics of included studies provided in an aggregated form. 

A7. [No] The scientific quality of included studies was not assessed or documented.

A8. [NA] Since quality of studies was not assessed, it was not used in formulating conclusions.

A9. [NA] The studies were not combined quantitatively, so methods for assessing heterogeneity are not applicable.

A10. [No] Publication bias was not assessed.

A11. [No] Conflicts of interest were not reported for the systematic review or included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Is laparoscopy still needed in blunt abdominal trauma?&quot;</span> Identified as a systematic review in the title.

P2. [Yes] Provides a structured abstract including background, objectives, data sources, methods, results, and conclusions. 

P3. [Yes] Describes the rationale and background for the review.

P4. [Yes] Specifies the research question looking at the role of laparoscopy in blunt abdominal trauma.

P5. [No] Does not mention a review protocol.

P6. [Yes] Specifies inclusion criteria and characteristics such as years considered, language, and excludes pediatric surgery, penetrating trauma, etc. 

P7. [Yes] Describes searching PubMed and Medline and provides the date range. 

P8. [No] Does not provide full search strategy.

P9. [Yes] Describes process of screening and selecting studies for inclusion and exclusion criteria.

P10. [No] Does not describe methods for data extraction. 

P11. [No] Does not list variables for which data were sought.

P12. [No] Does not describe methods for assessing risk of bias.

P13. [NA] Does not report summary measures since no meta-analysis was performed.

P14. [NA] Does not describe methods for combining data since no meta-analysis was performed. 

P15. [No] Does not assess risk of bias across studies.

P16. [NA] Does not report additional analyses since no meta-analysis was performed.

P17. [No] Does not provide numbers of studies screened and excluded with reasons.

P18. [Yes] Presents relevant characteristics of included studies in tables. 

P19. [No] Does not present risk of bias assessments. 

P20. [No] Does not present summary data and effect estimates for each study.

P21. [NA] No meta-analysis performed.

P22. [No] Does not assess risk of bias across studies. 

P23. [NA] No additional analyses performed.

P24. [Yes] Summarizes main findings and limitations.

P25. [Yes] Discusses limitations at the review level.

P26. [Yes] Provides interpretation of results and implications for future research.

P27. [No] Does not report sources of funding.
</pre>
<p><a name='128'></a></p>
</div>
<div id="oliveira-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2015.10.003' title='Open publication'>Oliveira
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We performed a Pubmed search using the terms: neophalloplasty, neophallus, and phalloplasty&quot;</span>
- Reports search terms used but does not mention protocol.
[No]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction. 
[No]

A3. Was a comprehensive literature search performed?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A total of 319 articles were identified in the initial search. When limited to the pediatric population, the search was reduced to only 19 articles&quot;</span>
- Searched PubMed and reviewed references of identified studies.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding studies based on publication status.
[No]  

A5. Was a list of studies (included and excluded) provided?
- Included studies summarized in Tables 1 and 2. No list of excluded studies.
[No]

A6. Were the characteristics of the included studies provided?
- Table 1 provides overview of included studies and techniques used. Table 2 focuses on studies in aphallia.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- No mention of quality assessment for included studies.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
- Did not assess quality of included studies.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
- No quantitative synthesis performed.
[NA]  

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias.
[No]

A11. Was the conflict of interest included?
- No conflict of interest statement.
[No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Systematic review&quot;</span> in title.
[Yes]

P2. Provide a structured summary.
- Abstract provides background, objectives, number of studies included, main findings, and conclusions.
[Yes]  

P3. Describe the rationale for the review.  
- Introductory paragraphs describe rationale and objective.
[Yes]

P4. Provide an explicit statement of questions being addressed.
- Objective clearly stated in abstract and introduction.
[Yes]

P5. Indicate if a review protocol exists.
- No mention of protocol.
[No] 

P6. Specify study characteristics used as criteria for eligibility.
- Inclusion criteria described in methods.
[Yes]

P7. Describe information sources and dates last searched. 
- Single database (PubMed) searched, no date provided.  
[No]

P8. Present full electronic search strategy.
- Search terms provided but not full strategy.
[No]

P9. State the process for selecting studies.
- Selection process not described.
[No] 

P10. Describe method of data extraction. 
- No mention of data extraction process.
[No]

P11. List and define all variables for which data were sought.
- Data extracted summarized in Tables 1 and 2.
[Yes]

P12. Describe methods for assessing risk of bias.
- No risk of bias assessment. 
[No]

P13. State principal summary measures.
- No meta-analysis performed.
[NA]

P14-P23. Methods for quantitative syntheses.
- No meta-analysis performed.
[NA] 

P24. Summarize the main findings. 
- Main findings summarized in abstract and discussion.
[Yes]

P25. Discuss limitations at study and outcome level. 
- Limitations discussed in discussion section.
[Yes]

P26. Provide a general interpretation of results.
- Results interpreted and compared to current literature.
[Yes]

P27. Describe sources of funding and support.
- No statement on sources of funding.
[No]
</pre>
<p><a name='129'></a></p>
</div>
<div id="oomen-2012" class="section level4">
<h4><a href='https://doi.org/10.1007/S00464-012-2174-Y' title='Open publication'>Oomen
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
The review had predefined objectives and eligibility criteria.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
Two authors independently reviewed studies for inclusion/exclusion criteria and extracted data. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span> 
The authors searched PubMed, Ovid, and Cochrane databases without language restrictions.

A4. Was the status of publication used as an inclusion criterion? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
The review did not indicate whether unpublished studies or grey literature were sought.

A5. Was a list of studies (included and excluded) provided? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
The excluded studies were referenced in Figure 1. 

A6. Were the characteristics of the included studies provided? [Yes] 
<span title='Moderate quote deviation. Best match in prompt (Similarity 83.3%):

characteristics of the included studies provided? In an aggregated form' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Characteristics of the included studies should be provided in aggregated form.&quot;</span>
Details of the included RCTs were provided in Tables 1 and 2.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.9%):

the methodological quality of a systematic review with the AMSTAR tool and its reporting quality' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The methodological quality of included studies should be assessed using a quality scoring tool.&quot;</span> 
The quality of RCTs was assessed using Cochrane criteria as shown in Table 2.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
<span title='Moderate quote deviation. Best match in prompt (Similarity 89%):

The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The results of the quality assessment should be considered in the analysis and conclusions.&quot;</span>
The quality assessment was considered in the Discussion.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]  
<span title='Moderate quote deviation. Best match in prompt (Similarity 77.6%):

For the pooled results, a test should be done to ensure the studies were combinabl' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎For pooled results, tests should be done to ensure combinability of studies.&quot;</span>
Appropriate tests for heterogeneity were reported for the meta-analyses. 

A10. Was the likelihood of publication bias assessed? [No]
<span title='Moderate quote deviation. Best match in prompt (Similarity 77.2%):

publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tes' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Publication bias should be assessed using graphical and/or statistical methods.&quot;</span>
Publication bias was not assessed.

A11. Was the conflict of interest stated? [Yes] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged.&quot;</span>
The authors declared no conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Identify the report as a systematic review, meta-analysis, or both.&quot;</span>
The report was identified as a systematic review and meta-analysis in the title and abstract.

P2. Provide a structured summary. [Yes]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.2%):

Provide a structured summary including,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Provide a structured abstract including key information about the review.&quot;</span>
A structured abstract was provided summarizing background, methods, results, and conclusions.

P3. Describe the rationale for the review. [Yes] 
<span title='Moderate quote deviation. Best match in prompt (Similarity 84%):

Describe the rationale for the review in the context of what is already know' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Describe the rationale for the review in the context of existing knowledge.&quot;</span>
The rationale was described in the Introduction.

P4. Provide an explicit statement of questions addressed. [Yes]
<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):

Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Provide explicit questions with reference to participants, interventions, comparisons, outcomes, and study designs.&quot;</span>
The objective was stated in the Introduction. 

P5. Indicate if a review protocol exists. [No] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.7%):

Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Indicate whether a review protocol exists and provide registration details if available.&quot;</span>
A protocol was not referenced.

P6. Specify study characteristics used as criteria for eligibility. [Yes]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.7%):

rmation including registration number.
P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Specify eligibility criteria including study characteristics and report characteristics.&quot;</span> 
Eligibility criteria were described in the Methods.

P7. Describe information sources and searches. [Yes]
<span title='Minor quote deviation. Best match in prompt (Similarity 98.1%):

Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Describe information sources and date last searched.&quot;</span>
Details of literature search strategy were provided in Methods.

P8. Present full search strategy for at least one database. [No]
<span title='Minor quote deviation. Best match in prompt (Similarity 98.2%):

Present full electronic search strategy for at least one database' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Present full search strategy for at least one database.&quot;</span>
The search strategy for the databases was not provided.

P9. Describe the study selection process. [Yes] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 55.6%):

e the process for selecting studies (i.e., screening,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Describe the process of study screening and selection.&quot;</span>
The study selection process was described in the Methods and Figure 1.

P10. Describe method of data extraction. [No] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 73.7%):

Describe method of data extraction f' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Describe how data extraction was done.&quot;</span>
The methods for data extraction were not described.

P11. List and define all variables for which data were sought. [No] 
<span title='Moderate quote deviation. Best match in prompt (Similarity 83.3%):

List and define all variables for which data were sought' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎List and define all data items that were sought.&quot;</span>
The data items extracted were not listed.

P12. Describe methods for assessing risk of bias. [Yes]
<span title='Minor quote deviation. Best match in prompt (Similarity 97.7%):

Describe methods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Describe methods for assessing risk of bias.&quot;</span>
The Cochrane criteria were used to assess quality and risk of bias.

P13. Describe principal summary measures. [Yes]
<span title='Moderate quote deviation. Best match in prompt (Similarity 86.8%):

State the principal summary measures (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎State principal summary measures used.&quot;</span>
Mean differences and risk differences were described in the Methods.

P14. Describe synthesis methods. [Yes]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56%):

e methods used to combine the' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Describe methods used to combine and analyze data.&quot;</span> 
Appropriate meta-analytic methods were described. 

P15. Describe assessment of risk of bias across studies. [NA]
<span title='Moderate quote deviation. Best match in prompt (Similarity 89.8%):

Describe methods used for assessing risk of bias of individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Describe methods for assessing risk of bias across studies.&quot;</span>
Not applicable as no assessment of publication bias was done.

P16. Describe additional analyses. [NA]
<span title='Moderate quote deviation. Best match in prompt (Similarity 81.6%):

Describe methods of additional analyses (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Describe methods of additional analyses, if done.&quot;</span>
Not applicable as no additional analyses were done.

P17. Provide study selection flow diagram. [Yes]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.1%):

ith a flow diagram.
P18. For each study,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Provide a flow diagram of study selection.&quot;</span>
A PRISMA flow diagram was provided in Figure 1.

P18. For each study, present characteristics and citations. [Yes]  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 69%):

For each study, present characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎For each study, present relevant characteristics and cite.&quot;</span>
Details were provided in Tables 1 and 2. 

P19. Present risk of bias assessments for each study. [Yes] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 50.9%):

Present results of any assessment of r' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Present risk of bias assessments for each included study.&quot;</span>
Risk of bias was assessed in Table 2.

P20. For each outcome, present summary data for each intervention group. [Yes]
<span title='Moderate quote deviation. Best match in prompt (Similarity 78.3%):

present, for each study: (a) simple summary data for each intervention group' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Present summary data for each outcome by intervention group.&quot;</span> 
Summary data were presented in forest plots.

P21. Present results of meta-analyses. [Yes] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present results of each meta-analysis done.&quot;</span>
Meta-analysis results were presented with forest plots.

P22. Present assessment of risk of bias across studies. [NA] 
<span title='Moderate quote deviation. Best match in prompt (Similarity 79.3%):

Present results of any assessment of risk of bias across studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Present results of risk of bias assessment across studies.&quot;</span>
Not applicable as no assessment of publication bias was done. 

P23. Present results of additional analyses. [NA]
<span title='Moderate quote deviation. Best match in prompt (Similarity 81.8%):

results of additional analyses, if done' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Present results of additional analyses done.&quot;</span>
No additional analyses were done.

P24. Summarize main findings and discuss relevance. [Yes]
<span title='Moderate quote deviation. Best match in prompt (Similarity 90.4%):

Summarize the main findings including the strength of evidence for each main outcome; consider their relevance' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Summarize main findings and discuss their relevance.&quot;</span>
Main findings were summarized in the Discussion. 

P25. Discuss limitations from study and review level. [Yes]  
<span title='Moderate quote deviation. Best match in prompt (Similarity 86.8%):

Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Discuss limitations at the study and outcome level, and at the review level.&quot;</span>
Limitations were described in the Discussion.

P26. Provide a general interpretation of results. [Yes]
<span title='Minor quote deviation. Best match in prompt (Similarity 97.7%):

Provide a general interpretation of the results' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Provide a general interpretation of results.&quot;</span>
Results were interpreted in the Discussion.

P27. Describe sources of funding and role of funders. [Yes]
<span title='Minor quote deviation. Best match in prompt (Similarity 97.9%):

Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Describe sources of funding and role of funders.&quot;</span>
Sources of support were stated.
</pre>
<p><a name='130'></a></p>
</div>
<div id="parolini-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.10.043' title='Open publication'>Parolini
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. [No] No protocol mentioned.
A2. [No] Single data extractor mentioned. 
A3. [Yes] Literature search described - PubMed and reference lists.
A4. [No] Grey literature not mentioned.
A5. [No] List of included/excluded studies not provided.
A6. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 96.2%):

each study, data were extracted for the following outcomes: number of patients, associated anomalies, type of
surgical repair, morbidity and mortality rate' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For each study, data were extracted for the following outcomes: number of patients, associated anomalies, type of surgical repair, morbidity and mortality rate.&quot;</span>
A7. [No] Quality assessment not described.
A8. [NA] No quality assessment done so not applicable.
A9. [NA] No meta-analysis so not applicable.  
A10. [NA] No assessment of publication bias as less than 10 studies included.
A11. [No] Funding sources not reported.

P1. [Yes] Identified as systematic review in title.
P2. [No] Structured summary not provided.
P3. [Yes] Rationale described in introduction.
P4. [No] Review questions not explicitly stated.  
P5. [No] No protocol mentioned.
P6. [No] Eligibility criteria not described.
P7. [Yes] Literature search methods described.
P8. [No] Full search strategy not provided.
P9. [No] Study selection process not described.
P10. [No] Data extraction process not described.
P11. [Yes] Outcomes described.
P12. [NA] Risk of bias assessment not done.
P13. [NA] No meta-analysis performed.
P14. [NA] No meta-analysis performed.
P15. [NA] No assessment of bias across studies.  
P16. [NA] No additional analyses done.
P17. [No] Flow diagram of study selection not provided. 
P18. [No] Study characteristics not presented.
P19. [NA] No assessment of bias.
P20. [No] Results not presented for each study.
P21. [NA] No meta-analysis performed.
P22. [NA] No assessment of bias across studies.
P23. [NA] No additional analyses performed.
P24. [No] No summary of main findings.
P25. [Yes] Limitations described in discussion.
P26. [Yes] Overall interpretation of results provided.
P27. [No] Sources of funding not reported.
</pre>
<p><a name='131'></a></p>
</div>
<div id="parolini-2014" class="section level4">
<h4><a href='https://doi.org/10.1016/J.IJPORL.2014.04.011' title='Open publication'>Parolini
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are my assessments of the systematic review using AMSTAR and PRISMA 2009:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For this systematic review we adhered to PRISMA guidelines [4,5].&quot;</span>
States adhering to PRISMA guidelines. [Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction. [No] 

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) was searched for studies on treatment of H-type TEF that were published since January 1977.&quot;</span> Mentions searching only PubMed. [No]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding based on publication status. [No]

A5. Was a list of studies (included and excluded) provided?
Figure 1 shows a flow diagram of included and excluded studies. [Yes]

A6. Were the characteristics of the included studies provided?
Table 1 and 2 provide characteristics of included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment mentioned. [No]  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
No statement about conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Identified as systematic review in title and abstract. [Yes]

P2. Provide a structured summary including key elements.
Structured abstract provided with objectives, data sources, study selection/characteristics, results, and conclusions. [Yes]

P3. Describe the rationale for the review in the context of what is already known.
Introduction describes rationale and what is known about H-type TEF. [Yes]

P4. Provide an explicit statement of questions being addressed. 
Objective clearly stated in abstract. [Yes]

P5. Indicate if a review protocol exists and if available provide registration information.
No mention of a protocol. [No] 

P6. Specify study characteristics used as criteria for eligibility, giving rationale.
Inclusion and exclusion criteria described in methods. [Yes]

P7. Describe all information sources in the search and date last searched.
Only database searched (PubMed) and time period provided. [No]

P8. Present full electronic search strategy for at least one database. 
No search strategy provided. [No]

P9. State the process for selecting studies.
Study selection process described and shown in Figure 1. [Yes]

P10. Describe method of data extraction from reports.
States data extracted but no details on process. [No] 

P11. List and define all variables for which data were sought.
Primary and secondary outcomes described. [Yes]

P12. Describe methods for assessing risk of bias of individual studies.
No risk of bias assessment mentioned. [No]

P13. State the principal summary measures.
No quantitative synthesis performed. [NA]

P14-P16. Describe methods of synthesis, assessment of consistency, and additional analyses.
No quantitative synthesis performed. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions. 
Screening/selection process shown in Figure 1. [Yes]

P18. For each study, present characteristics and provide citations.
Tables 1 and 2 provide study characteristics and citations. [Yes]  

P19. Present data on risk of bias of each study. 
No risk of bias assessment performed. [No]

P20-P23. Present synthesis results, assessment of bias across studies, and additional analyses.
No quantitative synthesis performed. [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
Main findings summarized in discussion and conclusion. [Yes]

P25. Discuss limitations at study and outcome level and at review level.
Limitations of review discussed. [Yes]

P26. Provide a general interpretation of results in the context of other evidence.
Results interpreted and compared to other evidence in discussion. [Yes]

P27. Describe sources of funding for the review.
No statement about sources of funding. [No]
</pre>
<p><a name='132'></a></p>
</div>
<div id="peters-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2012.11.049' title='Open publication'>Peters
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the systematic review using AMSTAR and PRISMA 2009:

A1. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Search terms used were [total] ([o]esophago-gastric/
gastro-[o]esophageal) (dissociation/disconnection/separation' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Search terms used were [total] ([o]esophago-gastric/gastro-[o]esophageal) (dissociation/disconnection/separation).&quot;</span> (Page 707, Methods)
The search terms indicate an a priori design.

A2. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

A primary procedure is defined as the first operation per-
formed (eg for gastroesophageal reflux) and a rescue procedure
as a further operation following failed earlier operation(s' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A primary procedure is defined as the first operation performed (eg for gastroesophageal reflux) and a rescue procedure as a further operation following failed earlier operation(s).&quot;</span> (Page 707, Methods)
The authors defined criteria for study selection. 

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Medline, PubMed, National Library of Health and Google Scholarly articles from year 1997 to August 2011 were searched.&quot;</span> (Page 707, Methods)
At least two electronic sources were searched.

A4. [No]
The authors do not state whether grey literature was searched.

A5. [No]
A list of included and excluded studies is not provided. 

A6. [Yes] 
Table 1 provides a summary of the number of patients from each included study. Table 2 summarizes patient characteristics and outcomes.

A7. [No]  
The scientific quality of included studies was not formally assessed.

A8. [NA]
Scientific quality was not assessed so this item is not applicable.

A9. [NA]  
The studies were not combined quantitatively, so this item is not applicable.

A10. [NA]
Publication bias was not assessed since no meta-analysis was performed.

A11. [No]
Conflicts of interest were not reported for the systematic review or included studies.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Morbidity and mortality in total esophagogastric dissociation: A systematic review&quot;</span> (Title)
The report is identified as a systematic review.

P2. [No] 
A structured summary is not provided.

P3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The aim of this study was to analyze data from all published cases of TOGD in children with particular attention to patient characteristics, indications, complications and mortality.&quot;</span> (Page 707, Introduction)
The rationale describes the aim to summarize existing evidence on TOGD.

P4. [No]  
The review question is not stated in a PICOS format.

P5. [No]
A review protocol is not mentioned.

P6. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

One hundred eighty-one patients who had undergone
TOGD were identified from 10 articles, personal communi-
cation with authors of these articles and data held at our
institution' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One hundred eighty-one patients who had undergone TOGD were identified from 10 articles, personal communication with authors of these articles and data held at our institution.&quot;</span> (Page 707, Results)
Inclusion criteria relate to patients having undergone TOGD.

P7. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Medline, PubMed, National Library of Health and Google Scholarly articles from year 1997 to August 2011 were searched.&quot;</span> (Page 707, Methods)
Literature sources are described.

P8. [No]
A full search strategy is not provided.

P9. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

A primary procedure is defined as the first operation per-
formed (eg for gastroesophageal reflux) and a rescue procedure
as a further operation following failed earlier operation(s' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A primary procedure is defined as the first operation performed (eg for gastroesophageal reflux) and a rescue procedure as a further operation following failed earlier operation(s).&quot;</span> (Page 707, Methods) 
The process for study selection is described.

P10. [No]  
Data extraction methods are not described. 

P11. [No] 
Variables extracted are not listed.

P12. [No]
Risk of bias assessment is not described.

P13. [NA]
Outcome measures are not relevant since no meta-analysis was performed. 

P14. [NA] 
Methods for combining data are not relevant since no meta-analysis was performed.

P15. [NA]
Assessment of publication bias is not relevant since no meta-analysis was performed.

P16. [NA]  
Additional analyses are not relevant since no meta-analysis was performed.

P17. [No]
A flow diagram of study selection is not provided.

P18. [Yes]
Table 1 lists the included studies and number of patients from each.

P19. [No] 
Risk of bias is not presented for individual studies.

P20. [Yes]
Tables 2 and 3 summarize outcome data for each patient group.

P21. [NA] 
Meta-analysis results are not relevant since no meta-analysis was performed.  

P22. [NA]
Assessment of risk of bias across studies is not relevant since no meta-analysis was performed.

P23. [NA]
Additional analyses are not relevant since no meta-analysis was performed.

P24. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

Review of all available cases of TOGD has revealed an
acceptable complication and mortality rate. Rates of re-
operation are comparable to and lower than some reoperation
rates following fundoplication' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review of all available cases of TOGD has revealed an acceptable complication and mortality rate. Rates of reoperation are comparable to and lower than some reoperation rates following fundoplication.&quot;</span> (Page 711, Discussion)
Main findings are summarized.

P25. [No]  
Limitations are not discussed.

P26. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎TOGD is a useful procedure in managing severe GOR in NI children, in NN children with specific conditions including esophageal atresia and as a rescue procedure following failed fundoplication.&quot;</span> (Page 712, Discussion)
Results are interpreted in the context of previous evidence. 

P27. [No]
Sources of funding are not reported.
</pre>
<p><a name='133'></a></p>
</div>
<div id="peycelon-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0034-1396419' title='Open publication'>Peycelon
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the assessments for the AMSTAR and PRISMA items based on the provided systematic review text:

A1. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

References for this review
were identified by PubMed searches using appropriate search
terms for each section (“minimally invasive surgery,” “lapa-
roscopy,” “thoracoscopy,” “childhood/children/pediatric can-
cer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer").&quot;</span>
Extracted quote shows an a priori design with pre-determined search terms.

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Only papers published in English language were reviewed.&quot;</span>
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

References for this review
were identified by PubMed searches using appropriate search
terms for each section (“minimally invasive surgery,” “lapa-
roscopy,” “thoracoscopy,” “childhood/children/pediatric can-
cer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer").&quot;</span>
Extracted quotes show searching of at least 2 electronic sources (PubMed and references from searched papers).

A4. [No]
No mention of including or excluding grey literature. 

A5. [No]
No explicit list of included and excluded studies provided.

A6. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Laparoscopy adrenalectomy is per-
formed for various indications from benign to malignant
tumors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopy adrenalectomy is performed for various indications from benign to malignant tumors.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Neuroblastoma is the most common abdominal solid tumor in children arising from the adrenal gland in 40% of the cases.&quot;</span> 
Extracted quotes provide characteristics of included studies.

A7. [No]  
No assessment of scientific quality of included studies.

A8. [NA]
Not applicable since A7 is No.

A9. [NA] 
Not applicable since no quantitative synthesis. 

A10. [NA]
Not applicable since no meta-analysis.

A11. [No]
No mention of conflicts of interest.

P1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eur J Pediatr Surg 2014;24:443–449.&quot;</span>
Title identifies report as a review.

P2. [No]
No structured summary provided.

P3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the 1990s, minimally invasive surgery (MIS) has emerged as an alternative to open approach for cancer diagnosis in children.&quot;</span>
Provides context and what is already known.

P4. [No]  
No explicit PICOS statement.

P5. [No]
No mention of a review protocol.

P6. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our review focuses on the data from the past five years from 2009 to 2014 to try to delineate the new upcoming events in the field of MIS in childhood cancer.&quot;</span> 
Specifies years considered.

P7. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

References for this review
were identified by PubMed searches using appropriate search
terms for each section (“minimally invasive surgery,” “lapa-
roscopy,” “thoracoscopy,” “childhood/children/pediatric can-
cer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer").&quot;</span>
Describes information source (PubMed). 

P8. [No]
No full search strategy provided.

P9. [No] 
No description of study selection process.

P10. [No]  
No description of data extraction methods.

P11. [No]
No list of variables extracted.

P12. [No] 
No assessment of risk of bias mentioned.

P13. [NA]
Not applicable since no meta-analysis.

P14. [NA]  
Not applicable since no meta-analysis.

P15. [NA]
Not applicable since no meta-analysis.

P16. [NA]
Not applicable since no meta-analysis.  

P17. [No]
No flow diagram of study selection provided. 

P18. [No]
No characteristics of included studies presented.

P19. [No]  
No assessment of risk of bias per study.

P20. [No] 
No summary data per study provided.

P21. [NA]
Not applicable since no meta-analysis.

P22. [NA]
Not applicable since no meta-analysis.

P23. [NA]
Not applicable since no meta-analysis.

P24. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

MIS is a promising method for removal of thoracic and abdominal
malignancies as long as oncological principles are strictly followed. Long-term follow-
up is mandatory to further delineate objective indications' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term follow-up is mandatory to further delineate objective indications.&quot;</span>
Summarizes main findings and implications.

P25. [No]
No limitations discussed.

P26. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Long-term follow-
up is mandatory to further delineate objective indications' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Long-term follow-up is mandatory to further delineate objective indications.&quot;</span>
Provides implications for future research.

P27. [No]
No mention of sources of funding.
</pre>
<p><a name='134'></a></p>
</div>
<div id="pfistermuller-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2014.12.006' title='Open publication'>Pfistermuller
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was undertaken, using Medline and Pubmed, in order to identify relevant articles.&quot;</span>
- The review did not refer to a predefined protocol. [No]

A2. Was there duplicate study selection and data extraction?
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The following data were extracted independently from each article by two reviewers (K.P and P.C)&quot;</span>
- Two reviewers independently extracted data. [Yes]

A3. Was a comprehensive literature search performed?
-<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Medline and Pubmed were searched in order to identify ar-
ticles published between 1994 and 2012' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Pubmed were searched in order to identify articles published between 1994 and 2012.&quot;</span>
-<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

The search terms
‘tubularized incised plate urethroplasty/Snodgrass repair/
technique  outcomes/complications  follow-up/long term
follow-up’ were used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search terms ‘tubularized incised plate urethroplasty/Snodgrass repair/technique  outcomes/complications  follow-up/long term follow-up’ were used.&quot;</span>
- Only two databases were searched. [No] 

A4. Was the status of publication used as an inclusion criterion?
- Review did not mention search for unpublished literature. [No]

A5. Was a list of studies (included and excluded) provided?
- No list of excluded studies was provided. [No]

A6. Were the characteristics of the included studies provided?
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Table Mean follow-up duration and percentage incidence of complications, and total number of patients assessed from the studies reviewed for each degree of hypospadias.&quot;</span>
- Study characteristics were summarized in a table. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- No quality assessment of included studies was reported. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Since no quality assessment was done, quality was not incorporated in formulating conclusions. [No] 

A9. Were the methods used to combine the findings of studies appropriate?  
- The review did not conduct a quantitative synthesis. [NA]

A10. Was the likelihood of publication bias assessed?
- The review did not assess publication bias. [NA]

A11. Was the conflict of interest included? 
- No conflict of interest statement was provided. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Meta-analysis of complication rates of the tubularized incised plate (TIP) repair&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
- No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
-<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

There is a wide discrepancy between published compli-
cation rates for different repair types [4e16] and a poor
evidence base for the current management of hypospadias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎There is a wide discrepancy between published complication rates for different repair types [4e16] and a poor evidence base for the current management of hypospadias.&quot;</span>

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes]
-"1. Assessing the appropriateness of its application to all degrees of hypospadias. 
2. Evaluating the long-term results by analysing the pooled complication rates to accurately determine representative complication rates for this technique. 
3. Reviewing the effects of technical modifications, length of follow-up and geographical location of these complications."

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
- No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes] 
- Inclusion criteria specified.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [No]
- Search limited to two databases without dates specified.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
- No full search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No]  
- Study selection process not described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The following data were extracted independently from each article by two reviewers (K.P and P.C)&quot;</span>

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
- Outcomes extracted clearly defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
- No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]
- No meta-analysis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA] 
- No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
- No assessment of publication bias or other biases.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [No]
- Subgroup analyses done but not pre-specified. 

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No] 
- No flow diagram provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
- Study characteristics presented in table. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA]
- No risk of bias assessment performed.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [NA]
- No individual study data presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]  
- No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
- No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [No]
- Subgroup analyses presented without mentioning pre-specification.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
- Main findings summarized in discussion and conclusion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes] 
- Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
- Results interpreted and future research implications described.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
- No statement about sources of funding or support.
</pre>
<p><a name='135'></a></p>
</div>
<div id="puligandla-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.09.010' title='Open publication'>Puligandla
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[A total of 3097 abstracts underwent initial title screening.]&quot;</span>
Performed initial screening of titles.
[Yes]

A2: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Two of the principal authors (P.P. and
S.I.) independently scanned all titles as a first screen after which select-
ed abstracts and/or full-length papers were collected for further review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two of the principal authors (P.P. and S.I.) independently scanned all titles as a first screen after which select-ed abstracts and/or full-length papers were collected for further review.]&quot;</span>
Duplicate study selection done. 
[Yes]

A3: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Separate search terms were applied for each question using the MEDLINE, Embase, Cochrane, and Web of Science databases. Searches were limited to articles published in the English language from January 1, 1980 through January 31, 2014.]&quot;</span>
Searched at least 2 databases.
[Yes]

A4: No mention of searching for unpublished or grey literature.
[No]

A5: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[A total of 3097 abstracts underwent initial title screening. Of these, 189 abstracts were selected for in-depth review of the abstract and/or full manuscript. We selected 98 of these manuscripts for the systematic review (Fig. 1).]&quot;</span> 
Provided a list of included studies.
[Yes]

A6: Table 1 provides characteristics of included studies.
[Yes]  

A7: No quality assessment of individual studies mentioned.
[No]

A8: N/A since no quality assessment performed.
[NA]

A9: No quantitative synthesis performed.
[NA]

A10: No assessment of publication bias mentioned.
[No]

A11: No statement about conflicts of interest.
[No]

P1: <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):

ummary
This systematic review by the APSA Outcomes and Evidence-based
Practice Committee attempted to delineate best-evidence recommen-
dations for specific aspects of C' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review by the APSA Outcomes and Evidence-based Practice Committee attempted to delineate best-evidence recommendations for specific aspects of CDH care.&quot;</span>
Identified as a systematic review.
[Yes]

P2: No structured summary provided.
[No]

P3: <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Despite significant advances in neonatal and surgical care, the man-
agement of newborns with congenital diaphragmatic hernia (CDH) re-
mains a challenge. Significant variations in approach exist with regard
to the use of antenatal steroids, ventilation modes, therapies to treat
pulmonary hypertension, the use of extra-corporeal membrane oxy-
genation (ECMO), and the timing and type of surgical repair [1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Despite significant advances in neonatal and surgical care, the management of newborns with congenital diaphragmatic hernia (CDH) remains a challenge. Significant variations in approach exist with regard to the use of antenatal steroids, ventilation modes, therapies to treat pulmonary hypertension, the use of extra-corporeal membrane oxygenation (ECMO), and the timing and type of surgical repair [1].&quot;</span>
Provided context/rationale.
[Yes]

P4: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

The American Pediatric Surgical Association (APSA) Outcomes and
Evidence Based Practice (OEBP) committee selected the following ques-
tions for this systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The American Pediatric Surgical Association (APSA) Outcomes and Evidence Based Practice (OEBP) committee selected the following questions for this systematic review:&quot;</span> 
Provided focused questions.
[Yes]

P5: No protocol mentioned.
[No] 

P6: Inclusion criteria described in methods.
[Yes]

P7: Sources described.
[Yes]

P8: No full search strategy provided.
[No]

P9: Selection process described and depicted in flow diagram. 
[Yes]

P10: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Two of the principal authors (P.P. and
S.I.) independently scanned all titles as a first screen after which select-
ed abstracts and/or full-length papers were collected for further review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two of the principal authors (P.P. and S.I.) independently scanned all titles as a first screen after which selected abstracts and/or full-length papers were collected for further review.]&quot;</span>
Duplicate data extraction mentioned.
[Yes] 

P11: No list of variables provided.
[No]

P12: No assessment of risk of bias mentioned.
[No]

P13: N/A
[NA]

P14: N/A 
[NA]

P15: N/A
[NA] 

P16: N/A
[NA]

P17: Flow diagram of study selection provided. 
[Yes]

P18: References provided but no summary per study.
[No]

P19: No assessment of risk of bias per study.  
[No]

P20: N/A
[NA]

P21: N/A
[NA]

P22: N/A 
[NA]

P23: N/A
[NA]

P24: <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):

ummary
This systematic review by the APSA Outcomes and Evidence-based
Practice Committee attempted to delineate best-evidence recommen-
dations for specific aspects of C' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review by the APSA Outcomes and Evidence-based Practice Committee attempted to delineate best-evidence recommendations for specific aspects of CDH care.&quot;</span> 
Summarized main findings.
[Yes]

P25: Limitations described in discussion. 
[Yes]

P26: <span title='Moderate quote deviation. Best match in fulltext (Similarity 93%):

Thus, it is imperative that we ded-
icate efforts to design high quality studies that will inform the
development of best practices for these' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎It is imperative that we dedicate efforts to design high quality studies that will inform the development of best practices for these infants.&quot;</span>
Discussed implications for future research.
[Yes]

P27: No statement about sources of funding.
[No]
</pre>
<p><a name='136'></a></p>
</div>
<div id="reddy-2010" class="section level4">
<h4><a href='https://doi.org/10.4103/0970-1591.74459' title='Open publication'>Reddy
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span> 
Reasoning: The review has predefined objectives and inclusion criteria.

A2. "[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎ There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
Reasoning: The review mentions two independent extractors. 

A3. "[Yes]"
Quotes: <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 43%):

(Cochrane register/Central counts as 2 sources; a grey literature search' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎MEDLINE, EMBASE, and the Cochrane Controlled Trials Register databases searched&quot;</span>
Reasoning: At least two electronic databases searched.

A4. "[No]"
Quotes: No mention of searching for grey literature.
Reasoning: No indication of searching for grey literature.

A5. "[No]" 
Quotes: No list of included and excluded studies provided.
Reasoning: No list of included/excluded studies provided.

A6. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Table 1 summarizes the body of literature that addresses pediatric URS published in the past 20 years. These data suggest that ureteroscopic lithotripsy is an acceptable treatment modality for the management of pediatric urolithiasis.&quot;</span> 
Reasoning: Table 1 provides aggregated characteristics of included studies.

A7. "[No]"
Quotes: No quality assessment of included studies.
Reasoning: No mention of quality assessment. 

A8. "[NA]"
Reasoning: No quality assessment performed, so using it to formulate conclusions not applicable.

A9. "[NA]"  
Reasoning: No quantitative synthesis performed.

A10. "[NA]"
Reasoning: No assessment of publication bias performed. 

A11. "[No]"
Quotes: No mention of conflicts of interest.
Reasoning: No mention of conflicts of interest.

P1. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Ureteroscopy: The standard of care in the management of upper tract urolithiasis in children&quot;</span> 
Reasoning: Identified as a systematic review in the title.

P2. "[No]" 
Quotes: No structured abstract provided.
Reasoning: No structured abstract with detailed sections.

P3. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The purpose of this review article is to demonstrate that ureteroscopic lithotripsy is now to be considered the standard of care in the management of upper tract urolithiasis in the pediatric patient&quot;</span>
Reasoning: Provides rationale for review.

P4. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pediatric patients under 1 year of age can be adequately positioned for flexible URS in an open leg posture using padded leg boards that extend from the table.&quot;</span>
Reasoning: Specifies population criteria.

P5. "[No]"
Quotes: Does not mention a protocol.
Reasoning: No protocol mentioned.

P6. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We included only those papers that discussed original series of patients in this review.&quot;</span>
Reasoning: Specifies inclusion criteria.

P7. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review of the contemporary urological citations was conducted using the National Library of Medicine (PubMed) search engine.&quot;</span>
Reasoning: Specifies literature search methods.

P8. "[No]"  
Quotes: Does not provide full search strategy.
Reasoning: No full search strategy provided.

P9. "[No]"
Quotes: Does not describe study selection process. 
Reasoning: No details on screening and selection process.

P10. "[No]"
Quotes: Does not describe data extraction process.
Reasoning: No details provided on data extraction.

P11. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Demographic information, including patient age, gender, presenting symptoms, number of URS procedures performed and stone-free rate, were abstracted from the papers reviewed.&quot;</span>
Reasoning: Specifies variables sought.

P12. "[NA]" 
Reasoning: No assessment of risk of bias performed.

P13. "[NA]"
Reasoning: No meta-analysis performed.

P14. "[NA]"
Reasoning: No meta-analysis performed. 

P15. "[NA]"
Reasoning: No assessment of publication bias as no meta-analysis.

P16. "[NA]"
Reasoning: No additional analyses mentioned.

P17. "[No]" 
Quotes: Does not provide details on study selection process.
Reasoning: No flow diagram or details on selection.

P18. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Table 1 summarizes the body of literature that addresses pediatric URS published in the past 20 years.&quot;</span>
Reasoning: Provides citations and key characteristics of included studies.

P19. "[NA]"
Reasoning: No assessment of risk of bias performed.

P20. "[NA]" 
Reasoning: No quantitative synthesis performed.

P21. "[NA]"
Reasoning: No meta-analysis performed.

P22. "[NA]" 
Reasoning: No assessment of bias across studies as no meta-analysis.

P23. "[NA]"
Reasoning: No additional analyses mentioned.

P24. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎URS is safe and efficacious in the management of pediatric urolithiasis. URS should be considered an essential part of the armamentarium of any urologist involved in the care of children and is now considered the standard of care for the management of pediatric urolithiasis.&quot;</span>
Reasoning: Summarizes main findings and implications.

P25. "[No]"
Quotes: Does not discuss limitations at study or outcome level.
Reasoning: No discussion of limitations.

P26. "[Yes]"  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A thorough knowledge of available equipment and the anatomical and physiological differences of pediatric patients will ensure a successful outcome with minimal morbidity to these patients.&quot;</span>
Reasoning: Provides interpretation of results.

P27. "[No]"
Quotes: Does not mention sources of funding.
Reasoning: No mention of funding sources.
</pre>
<p><a name='137'></a></p>
</div>
<div id="romao-2012" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2012.01.009' title='Open publication'>Romao
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The aim of our study was to compare recurrence, small
bowel obstruction (SBO), and mortality rates for CDH repair
between an absorbable (Surgisis [SIS]; Cook Biotech, Inc,
West Lafayette, IN) and a nonabsorbable polytetrafluor-
oethylene (PTFE) (Gore-Tex; W.L. Gore & Associates, Inc,
Neward, DE) material at our institution' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of our study was to compare recurrence, small bowel obstruction (SBO), and mortality rates for CDH repair between an absorbable (Surgisis [SIS]; Cook Biotech, Inc, West Lafayette, IN) and a nonabsorbable polytetrafluoroethylene (PTFE) (Gore-Tex; W.L. Gore & Associates, Inc, Newark, DE) material at our institution.&quot;</span> The aim and inclusion criteria were pre-determined. [Yes]

A2. <span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):

Data were compared using the Student t test for
continuous outcomes and χ
2 
/Fisher&#39;s exact for categorical
one' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were compared using the Student t test for continuous outcomes and χ2/Fisher's exact for categorical ones.&quot;</span> Statistical analysis was done to compare data. [Yes] 

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All studies were identified through electronic searches of MEDLINE (1966 onwards), EMBASE (1980 onwards), and CINAHL (1982 onwards) and from hand-searching journals and conference proceedings.&quot;</span> At least two electronic databases were searched along with supplementary methods. [Yes]

A4. The review did not mention searching for grey literature. [No]

A5. The review did not provide a list of included and excluded studies. [No] 

A6. Table 1 provides characteristics of included studies. [Yes]

A7. The review did not mention assessing quality of included studies. [No] 

A8. The review did not mention using quality assessment in formulating conclusions. [NA]

A9. <span title='Minor quote deviation. Best match in fulltext (Similarity 96.2%):

We applied tests for interstudy heterogeneity χ
2 
(Q test)
and the I
2 
statistic to assess the appropriateness of combining
studi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We applied tests for interstudy heterogeneity χ2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;</span> Tests for heterogeneity were done before meta-analysis. [Yes]

A10. The review did not assess publication bias. [No]

A11. The review did not report on conflicts of interest. [No]

P1. The report is identified as a systematic review and meta-analysis. [Yes] 

P2. The abstract provides background, objectives, data sources, eligibility criteria, methods, results, and conclusions. [Yes]

P3. The introduction describes rationale and context. [Yes]

P4. The aim states the objective, intervention, and outcomes. [Yes] 

P5. The review did not mention a protocol. [No]

P6. Inclusion criteria are described. [Yes]

P7. Literature search methods are described. [Yes]

P8. The full search strategy is not provided. [No]

P9. The selection process is described. [Yes] 

P10. The data extraction process is not described. [No] 

P11. Outcomes assessed are described. [Yes] 

P12. Risk of bias assessment is not described. [No]

P13. Statistical methods are described. [Yes]

P14-P23. Not applicable since no meta-analysis was done. [NA]

P24. Main findings and conclusions are summarized. [Yes]

P25. Limitations are discussed. [Yes] 

P26. Results are interpreted and implications are discussed. [Yes]

P27. Funding sources are not reported. [No]
</pre>
<p><a name='138'></a></p>
</div>
<div id="ross-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3691-2' title='Open publication'>Ross
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

We searched Medline, Embase and the Cochrane con-
trolled trials register from inception to July 2014 using the
terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed
silo’ and ‘silastic silo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed silo’ and ‘silastic silo’.&quot;</span>
- The review protocol is not mentioned.
[No]

A2. Was there duplicate study selection and data extraction?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The literature search, assessment for in-
clusion and data extraction were performed independently
by three reviewers and disagreements resolved by
consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search, assessment for inclusion and data extraction were performed independently by three reviewers and disagreements resolved by consensus.&quot;</span>  
- Multiple reviewers performed study selection and data extraction.
[Yes]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

We searched Medline, Embase and the Cochrane con-
trolled trials register from inception to July 2014 using the
terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed
silo’ and ‘silastic silo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed silo’ and ‘silastic silo’.&quot;</span>
- At least two databases were searched.
[Yes]

A4. Was the status of publication used as an inclusion criterion? 
- The inclusion/exclusion criteria do not mention publication status.
[No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows a flow diagram of included and excluded studies.
[Yes]

A6. Were the characteristics of the included studies provided?
- Table 1 provides key characteristics of the included studies.
[Yes] 

A7. Was the scientific quality of the included studies assessed and documented?
- The quality of individual studies is not assessed.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
- Methods for quantitative synthesis are described.
- Heterogeneity is assessed using I2. 
[Yes]

A10. Was the likelihood of publication bias assessed?
- Publication bias is not assessed.
[No]

A11. Was the conflict of interest included? 
- No statement on conflicts of interest.
[No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review aimed to determine comparative outcomes for infants with gastroschisis treated with either a PFS or alternate treatment strategy.&quot;</span>
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- The abstract provides a structured summary.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- The introduction describes the rationale and background.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- The objectives and inclusion criteria cover PICOS.
[Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- A protocol is not mentioned.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Inclusion criteria cover study characteristics.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
- Databases and search terms are described.
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- The full search strategy is not provided.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- The study selection process is described and shown in a flow diagram. 
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The literature search, assessment for in-
clusion and data extraction were performed independently
by three reviewers and disagreements resolved by
consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search, assessment for inclusion and data extraction were performed independently by three reviewers and disagreements resolved by consensus.&quot;</span>
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 
- Outcomes extracted are listed.
[Yes]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- Risk of bias of individual studies was not assessed.
[No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- Mean difference and risk difference are used.
[Yes] 

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- Subgroup analysis is described.
[Yes]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- A flow diagram is provided showing the screening process.
[Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
- Table 1 presents key characteristics of included studies.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- Risk of bias is not assessed for individual studies.
[No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- Forest plots are provided for meta-analyzed outcomes. Individual study data are presented in the text.
[Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- Results of subgroup analysis are presented.
[Yes]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- The discussion summarizes the main findings and implications.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations are discussed.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results are interpreted and implications for research are discussed.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
- No statement on funding sources.
[No]
</pre>
<p><a name='139'></a></p>
</div>
<div id="ruttenstock-2010" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-010-2695-1' title='Open publication'>Ruttenstock
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PubMed and Medline were searched for all studies that reported cases of patients who had undergone surgical correction of HD on transanal one-stage pull-through operation between 1998 and 2009.&quot;</span> The research question and inclusion criteria were established before conducting the review.

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search terms were ‘‘one-stage transanal pull-through’’, ‘‘transanal one-stage endorectal pull-through’’, ‘‘one-stage Soave pull-through’’, ‘‘single-stage transanal endorectal pull-through’’, ‘‘primary pull-through’’, or ‘‘Soave procedure’’. The reference list from retrieved articles was reviewed for additional cases.&quot;</span> At least two databases were searched along with supplementary methods. 

A4. [No]
No mention of including or excluding studies based on publication status.

A5. [No]
No list of included and excluded studies provided.

A6. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Detailed information was recorded regarding the type of
study, patient’s age and gender, intraoperative details, and
postoperative complications with particular emphasis on
the incidence and outcome of HAEC' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Detailed information was recorded regarding the type of study, patient’s age and gender, intraoperative details, and postoperative complications with particular emphasis on the incidence of HAEC.&quot;</span> Characteristics of included studies provided in aggregated form.

A7. [No]
No assessment of scientific quality of included studies documented.

A8. [NA]
Scientific quality not assessed so not used in formulating conclusions.

A9. [NA] 
No meta-analysis performed. 

A10. [No]
No assessment of publication bias.

A11. [No]
No statement about conflicts of interest.

P1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review and meta-analysis of enterocolitis after one-stage transanal pull-through procedure for Hirschsprung’s disease&quot;</span> Identified as a systematic review.

P2. [Yes] 
Structured abstract provided with background, objectives, eligibility criteria, results, and conclusions.

P3. [Yes]
Rationale described in introduction. 

P4. [No] 
No explicit PICOS statement.

P5. [No]
No mention of a review protocol.

P6. [Yes]
Study characteristics used as eligibility criteria described. 

P7. [Yes] 
Information sources described as PubMed and Medline between 1998-2009.

P8. [No] 
No full electronic search strategy provided.

P9. [Yes] 
Selection process described in methods.

P10. [No]  
No description of data extraction methods. 

P11. [Yes] 
Outcomes sought described in methods.

P12. [No]
No assessment of risk of bias described.

P13. [NA] 
No meta-analysis performed.

P14-P23. [NA] 
No quantitative synthesis performed.

P24. [Yes]
Main findings summarized in discussion. 

P25. [No] 
No limitations discussed.

P26. [Yes]  
Results interpreted in context of other evidence. 

P27. [No]
No statement about sources of funding.
</pre>
<p><a name='140'></a></p>
</div>
<div id="rynja-2011" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2011.02.008' title='Open publication'>Rynja
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PubMed and Medline were searched for all studies that reported cases of patients who had undergone surgical correction of HD on transanal one-stage pull-through operation between 1998 and 2009.&quot;</span>
The review had pre-determined inclusion criteria.

A2. [No]
No mention of duplicate study selection or data extraction.

A3. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search terms were ‘‘one-stage transanal pull-through’’, ‘‘transanal one-stage endorectal pull-through’’, ‘‘one-stage Soave pull-through’’, ‘‘single-stage transanal endorectal pull-through’’, ‘‘primary pull-through’’, or ‘‘Soave procedure’’. The reference list from retrieved articles was reviewed for additional cases.&quot;</span>
At least 2 databases were searched along with supplementary strategies. 

A4. [No]
No mention of including or excluding based on publication status.

A5. [No]  
No explicit list of included/excluded studies provided.

A6. [Yes]
Table 1 provides characteristics of included studies such as number of patients, number with HAEC, and treatment details.

A7. [No]
No assessment of study quality mentioned.

A8. [NA]
Study quality not assessed.

A9. [NA]  
No quantitative synthesis performed. 

A10. [NA]
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest.

P1. [Yes]   
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review and meta-analysis of enterocolitis after one-stage transanal pull-through procedure for Hirschsprung’s disease&quot;</span>
Identified as a systematic review.

P2. [Yes]
Abstract provides background, objectives, eligibility criteria, outcomes, results, and conclusions. 

P3. [Yes]  
Introduction describes rationale and context.

P4. [Yes] 
Objective clearly specified along with condition, intervention, and outcomes of interest.

P5. [No] 
No mention of a review protocol.

P6. [Yes]
Inclusion criteria, years, and language described. 

P7. [Yes]
Sources and dates searched provided.

P8. [No]
Search strategy not provided.

P9. [No] 
Selection process not described.

P10. [No]  
No description of data extraction process.

P11. [NA] 
Not applicable without quantitative synthesis.

P12. [No]
Individual study bias not assessed.

P13. [NA]
Not applicable without quantitative synthesis.

P14-P23. [NA] 
Not applicable without quantitative synthesis.

P24. [Yes]
Main findings summarized including strength of evidence.

P25. [No]
Study limitations not discussed.

P26. [Yes]  
Results interpreted in context of other evidence. 

P27. [No] 
No statement about sources of funding.
</pre>
<p><a name='141'></a></p>
</div>
<div id="saldaña-2013" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2012.0467' title='Open publication'>Saldaña
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments for the 11 AMSTAR and 27 PRISMA items based on the provided systematic review:

A1: 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

We performed a systematic review of the literature to find
out the current state of SIPES procedures, including age, tech-
nical aspects, and operative outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review of the literature to find out the current state of SIPES procedures, including age, technical aspects, and operative outcomes.&quot;</span>
2. The authors state they performed a systematic review.
[Yes]

A2: 
1. No mention of duplicate study selection or data extraction.
2. The authors do not state that duplicate study selection or data extraction was performed.  
[No]

A3:  
1. <span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):

An electronic search in
PubMed up to March 2012 was conducted with the following
terms: ‘‘single’’ AND ‘‘incision’’ OR ‘‘site’’ OR ‘‘port’’ OR ‘‘tro-
car’’ AND ‘‘children.’’ Related articles were also reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎An electronic search in PubMed up to March 2012 was conducted with the following terms: “single” AND “incision” OR “site” OR “port” OR “trocar” AND “children.” Related articles were also reviewed.&quot;</span> 
2. The authors searched PubMed and reviewed related articles.
[No] 

A4:
1. No mention of searching for grey literature.
2. The authors do not state that they searched for grey literature.
[No]

A5:  
1. No list of included/excluded studies provided.
2. The authors do not provide a list of included/excluded studies.
[No]

A6: 
1. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.3%):

(n = 2888 patients), urological (n = 390 patients), gynecological
(n = 27 patients), other abdominal (n = 874 patients), and tho-
racic (n = 33 patients) procedures (Table 1' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We separated types of operations by systems: gastrointestinal (n = 2888 patients), urological (n = 390 patients), gynecological (n = 27 patients), other abdominal (n = 874 patients), and thoracic (n = 33 patients) procedures (Table 1).&quot;</span>
2. The authors provide aggregated data on participants.
[Yes]

A7: 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We used the original classification of levels of evidence described by the Canadian Task Force on the Periodic Health Examination.&quot;</span>
2. The authors assessed quality using a standard tool.
[Yes] 

A8:  
1. No mention of incorporating quality assessment into conclusions.
2. The authors do not state that they incorporated quality assessments into conclusions.
[No]

A9:
1. No quantitative synthesis performed. 
2. The authors did not pool results in a meta-analysis.
[NA]

A10: 
1. No assessment of publication bias mentioned.
2. The authors do not assess publication bias.
[No]

A11: 
1. No mention of conflicts of interest.
2. The authors do not mention conflicts of interest.
[No]

P1: 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Single-Incision Pediatric Endosurgery: A Systematic Review&quot;</span>  
2. The title identifies the report as a systematic review.
[Yes]

P2:
1. The abstract provides a structured summary.
2. The authors provide a structured abstract.
[Yes]

P3: 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

In the search for less invasive procedures, ever since the
development of laparoscopic surgery and with the limitations
and equipment dependence of Natural Orifice Translumenal
endoscopic surgery (NOTES
Ò
; American Society for Gastro-
intestinal Endoscopy [Oak Brook, IL] and Society of American
Gastrointestinal and Endoscopic Surgeons [Los Angeles,
CA]), this new approach through the umbilicus, a natural
embrionary orifice, 
1 
was first reported in 1992 by Pelosi and
Pelosi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In the search for less invasive procedures, ever since the development of laparoscopic surgery and with the limitations and equipment dependence of Natural Orifice Translumenal endoscopic surgery (NOTES®; American Society for Gastrointestinal Endoscopy [Oak Brook, IL] and Society of American Gastrointestinal and Endoscopic Surgeons [Los Angeles, CA]), this new approach through the umbilicus, a natural embrionary orifice, was first reported in 1992 by Pelosi and Pelosi.&quot;</span>
2. The authors describe the rationale for the review.
[Yes]

P4: 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The objective of this review is to show the initial published experience about SIPES to evaluate its real benefits in terms of feasibility and clinical outcomes.&quot;</span>
2. The authors state the review objectives. 
[Yes]

P5:
1. The authors do not mention a review protocol.
2. A review protocol is not mentioned.
[No] 

P6:  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Articles were considered eligible if they met the following
inclusion criteria: (1) Operations were performed through a
single incision. (2) The target population was children under
18 years of age. (3) Operations performed exclusively by pe-
diatric surgeons. (4) Series larger than 100 patients were in-
cluded for appendectomy operations. (5) Case reports, case
series, and comparative and prospective randomized trials
were included in other, nonappendectomy, operations be-
cause of their low incidence. (6) Articles should include age,
operative technical aspects, and operative outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Articles were considered eligible if they met the following inclusion criteria: (1) Operations were performed through a single incision. (2) The target population was children under 18 years of age. (3) Operations performed exclusively by pediatric surgeons. (4) Series larger than 100 patients were included for appendectomy operations. (5) Case reports, case series, and comparative and prospective randomized trials were included in other, nonappendectomy, operations because of their low incidence. (6) Articles should include age, operative technical aspects, and operative outcomes.&quot;</span>
2. The authors describe eligibility criteria.
[Yes]

P7:  
1. <span title='Moderate quote deviation. Best match in fulltext (Similarity 86.7%):

mes. An electronic search in
PubMed up to March 2012 was conducted with the following
terms: ‘‘single’’ AND ‘‘incision’’ OR ‘‘site’’ OR ‘‘port’’ OR ‘‘tro-
car’’ AND ‘‘children.’’ Related articles were also reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We performed an electronic search in PubMed up to March 2012 with the following terms: “single” AND “incision” OR “site” OR “port” OR “trocar” AND “children.” Related articles were also reviewed.&quot;</span>
2. The authors describe the information sources searched. 
[Yes]

P8:
1. The full search strategy is not provided.
2. The full search strategy for PubMed is not provided.
[No]

P9:
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

After
applying our eligibility criteria, we selected 78 articles 
6–83 
to
be included in this systematic review (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎After applying our eligibility criteria, we selected 78 articles to be included in this systematic review (Fig. 1).&quot;</span> 
2. The authors describe the study selection process.
[Yes] 

P10:  
1. No description of data extraction methods.
2. The authors do not describe data extraction methods.
[No]

P11:  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data extracted from these articles were further analyzed for (1) technical aspects (port and instrumentation type) and (2) operative outcomes (operative time, conversion rate, length of stay, pain assessment, and complications).&quot;</span>
2. The authors list variables extracted.
[Yes]

P12:
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We used the original classification of levels of evidence described by the Canadian Task Force on the Periodic Health Examination.&quot;</span> 
2. The authors describe methods for assessing risk of bias.
[Yes]

P13:
1. No quantitative synthesis performed.
2. The authors did not perform a quantitative synthesis.
[NA]

P14: 
1. No quantitative synthesis performed.
2. The authors did not perform a quantitative synthesis.
[NA] 

P15:
1. No assessment of publication bias mentioned.  
2. Publication bias was not assessed.
[NA]

P16:
1. No additional analyses mentioned.
2. Additional analyses are not mentioned.
[NA]

P17: 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

After the PubMed search we identified 197 articles. After
applying our eligibility criteria, we selected 78 articles 
6–83 
to
be included in this systematic review (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎After the PubMed search we identified 197 articles. After applying our eligibility criteria, we selected 78 articles to be included in this systematic review (Fig. 1).&quot;</span>
2. The authors describe the study screening and selection process. 
[Yes]

P18:
1. The characteristics of the included studies are presented in Tables 1, 2, 4 and 5.
2. The authors present the characteristics of the included studies.
[Yes]

P19: 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

According to evidence level we had 1 prospective ran-
domized controlled trial, 12 case-control studies, 49 case se-
ries, and 16 case reports (Table 2' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎According to evidence level we had 1 prospective randomized controlled trial, 12 case-control studies, 49 case series, and 16 case reports (Table 2).&quot;</span>
2. The authors present risk of bias/level of evidence results.
[Yes]

P20:
1. No quantitative synthesis performed.
2. The authors did not perform a quantitative synthesis.
[NA]  

P21:
1. No quantitative synthesis performed.  
2. The authors did not perform a quantitative synthesis.
[NA]

P22:  
1. No assessment of publication bias mentioned.
2. Publication bias was not assessed.
[NA]

P23:
1. No additional analyses mentioned.
2. Additional analyses are not mentioned.  
[NA]

P24: 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

From this systematic review we conclude:
 A wide experience in SIPES and its feasibility have al-
ready been described with good clinical outcomes and
low rate of conversio' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From this systematic review we conclude: A wide experience in SIPES and its feasibility have already been described with good clinical outcomes and low rate of conversion.&quot;</span> 
2. The authors summarize the main findings.
[Yes]

P25:  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Further analysis could not be performed because of the weak nature of the evidence in the majority of publications and some methodological defects of the literature reviewed.&quot;</span>
2. The authors discuss limitations at the review level.
[Yes]

P26:  
1. <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.3%):

Finally, it is suggested that performing pediatric endo-
surgery through multiple incisions for small cannulas and/
or stab incisions (initially described by Ostlie and Holcomb, 
100
noted by Rothenberg et al.
101 
), so-called ‘‘minilaparo-
scopy,’’ 
102 
‘‘reduced port’’ surgery, or ‘‘hydrid surgery’’ in
adults, 
103 
provides a safe and feasible surgery in children,
resulting in minimal trauma and scar' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Finally, it is suggested that performing pediatric endosurgery through multiple incisions for small cannulas and/or stab incisions (initially described by Ostlie and Holcomb, noted by Rothenberg et al.), so-called “minilaparoscopy,” “reduced port” surgery, or “hydrid surgery” in adults, in children, provides a safe and feasible surgery in children, resulting in minimal trauma and scars.&quot;</span>
2. The authors provide an overall interpretation and implications.
[Yes]

P27:
1. No statement about sources of funding.
2. Sources of funding are not mentioned.  
[No]

In summary, based on the AMSTAR assessment, this systematic review has some methodological shortcomings related to duplicate study selection/data extraction, literature search, incorporation of quality assessment into conclusions, and assessment of publication bias. The reporting quality based on PRISMA also has some deficiencies, including lack of protocol and search strategy details. Overall, this review could be improved with more rigorous methodology and transparent reporting.

</file-attachment-contents>

Thank you for the comprehensive assessment using the AMSTAR and PRISMA tools. You have highlighted several limitations in the methodology and reporting of this systematic review. The lack of duplicate study selection/data extraction, limited literature searching, and no assessment of publication bias per AMSTAR are concerning. Not providing the full search strategy per PRISMA also reduces reproducibility. Your analysis provides helpful insights on improving systematic review conduct and reporting quality. Assessing rigor is a key step before using findings to inform evidence-based practice.
</pre>
<p><a name='142'></a></p>
</div>
<div id="sauerland-2010" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD001546.PUB3' title='Open publication'>Sauerland
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality with AMSTAR and reporting quality with PRISMA for the given systematic review:

A1. Was an 'a priori' design provided? 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):

This review compares laparoscopic and conventional surgery with
regard to several peri- and post-operative variables. It addresses
diagnostic and therapeutic laparoscopy separately. Furthermore, it
aims at identifying certain subgroups of patients, in which one of
the techniques might be more appropriate than the other.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomized controlled trials comparing laparoscopic surgery
and open appendectomy for acute appendicitis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This review compares laparoscopic and conventional surgery with regard to several peri- and post-operative variables.", "Types of studies: All randomized controlled trials comparing laparoscopic surgery and open appendectomy for acute appendicitis.&quot;</span>
Reasoning: The review had a clearly defined objective and inclusion criteria before conducting the review.
[Yes]

A2. Was there duplicate study selection and data extraction?  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers independently assessed trial quality.&quot;</span>
Reasoning: Two reviewers independently selected studies and extracted data.
[Yes]

A3. Was a comprehensive literature search performed?
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.5%):

In order to be as comprehensive as possible, the following
search strategies were employed to identify all relevant studies
irrespective of language. Studies predating 1983 were not searched
for, because the first laparoscopic appendectomy was described in
that year.
Electronically, we searched the Cochrane Library, MEDLINE
(PubMed), EMBASE, SciSearch and Biosis.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎In order to be as comprehensive as possible, the following search strategies were employed to identify all relevant studies irrespective of language.", "Electronically, we searched the Cochrane Library, MEDLINE (PubMed), EMBASE, SciSearch and Biosis.", "Abstracts presented to the following international scientific societies were handsearched:&quot;</span>
Reasoning: Multiple databases were searched along with other supplementary methods like screening abstracts and reference lists.
[Yes] 

A4. Was the status of publication used as an inclusion criterion?
Quotes: No mention of including or excluding based on publication status.
Reasoning: Publication status was not mentioned as an inclusion/exclusion criteria.
[No]

A5. Was a list of studies (included and excluded) provided?  
Quotes: Table of included studies provided. References provided for excluded studies. 
Reasoning: Both included and excluded studies were listed.
[Yes]

A6. Were the characteristics of the included studies provided?
Quotes: Table describing characteristics of included studies like participants, interventions, outcomes etc.
Reasoning: Characteristics of included studies provided in table form.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 61.2%):

Two reviewers independently assessed trial quality. Missing information or data was requested from the authors.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two reviewers independently assessed trial quality. Missing information or data was requested from the authors.", "The quality of all included studies was moderate to poor (Figure 1).&quot;</span> 
Reasoning: The quality of included studies was assessed systematically. 
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
Quotes: No mention of study quality in the conclusions.
Reasoning: Study quality was not considered in formulating conclusions.
[No]

A9. Were the methods used to combine the findings of studies appropriate? 
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.9%):

re. For complication
rates, however, Peto&#39;s odds ratios (OR) were calculated, because
simulation studies by Deeks et al. have shown, that this effect
measure is the most robust when dealing with rare or extremely rare
events (Deeks 1999' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We pooled the effect measures within a random effects model (DerSimonian 1986), because these outcomes are heavily influenced by the context of care.", "For complication rates, however, Peto's odds ratios (OR) were calculated, because simulation studies by Deeks et al. have shown, that this effect measure is the most robust when dealing with rare or extremely rare events (Deeks 1999).&quot;</span>
Reasoning: Appropriate methods were used for pooling data like testing for heterogeneity and using random effects model. Rare event outcomes used Peto's OR.
[Yes]

A10. Was the likelihood of publication bias assessed?
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 83.1%):

ure. The funnel plot showed no signs of publication bias' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Furthermore, the funnel plot showed no signs of publication bias.&quot;</span> 
Reasoning: Funnel plot was used to assess publication bias.
[Yes]

A11. Was the conflict of interest included? 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎None.&quot;</span> in Declaration of Interest section.
Reasoning: No conflicts of interest were reported.
[Yes]

P1. Identify the report as a systematic review. 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Systematic Review&quot;</span> in title.
Reasoning: The report is identified as a systematic review in the title.
[Yes]

P2. Provide a structured summary.
Quotes: Structured abstract provided with background, objectives, methods, results, conclusions. 
Reasoning: A structured abstract is provided.
[Yes]

P3. Describe the rationale for the review.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The large number of published trials and the still ongoing debate prompted us to undertake a systematic review of all randomized trials which compared therapeutic and diagnostic advantages of both techniques.&quot;</span>
Reasoning: Rationale described in the background section.
[Yes]

P4. Provide an explicit statement of questions being addressed. 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review compares laparoscopic and conventional surgery with regard to several peri- and post-operative variables.&quot;</span> 
Reasoning: Objectives clearly stated.
[Yes]

P5. Indicate if a protocol exists and if it can be accessed.
Quotes: No mention of a protocol.
Reasoning: Protocol not mentioned. 
[No]

P6. Specify study characteristics used as criteria for eligibility. 
Quotes: Details of participants, interventions, comparators, outcomes, and study designs eligible for inclusion are described in the methods section.
Reasoning: Eligibility criteria detailed.
[Yes]

P7. Describe all information sources in the search and date last searched.
Quotes: Details of literature search provided including databases searched and last search dates.
Reasoning: Literature search methods described.
[Yes] 

P8. Present full electronic search strategy.
Quotes: Search strategy not provided.
Reasoning: Full search strategy not provided.
[No]

P9. State the process for selecting studies.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two observers independently extracted the results of each paper on a data sheet&quot;</span> 
Reasoning: Process of study screening and selection described.
[Yes]

P10. Describe method of data extraction. 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two observers independently extracted the results of each paper on a data sheet&quot;</span>
Reasoning: Data extraction process described.
[Yes]

P11. List and define all variables for which data were sought.
Quotes: Outcomes sought are listed in methods section. 
Reasoning: Outcomes of interest defined.
[Yes]

P12. Describe methods for assessing risk of bias. 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers independently assessed trial quality.&quot;</span> Details provided in Figure 1.
Reasoning: Methods for risk of bias assessment described.
[Yes]

P13. State the principal summary measures.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For dichotomous variables relative risks (RR) with 95% confidence intervals (95% CIs) were the preferred measure. For complication rates, however, Peto's odds ratios (OR) were calculated, because simulation studies by Deeks et al. have shown, that this effect measure is the most robust when dealing with rare or extremely rare events (Deeks 1999).&quot;</span>
Reasoning: Summary measures described.
[Yes]

P14. Describe methods of combining results.
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We pooled the effect measures within a random effects model (DerSimonian 1986), because these outcomes are heavily influenced by the context of care.&quot;</span>
Reasoning: Methods for combining study results described.
[Yes]

P15. Specify any assessment of risk of bias across studies.
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 83.1%):

ure. The funnel plot showed no signs of publication bias' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Furthermore, the funnel plot showed no signs of publication bias.&quot;</span>
Reasoning: Publication bias assessed.
[Yes]

P16. Describe methods of additional analyses.
Quotes: No additional analyses mentioned.
Reasoning: No additional analyses conducted.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions. 
Quotes: Flow diagram not provided. Number of studies included given. References provided for excluded studies with reasons.
Reasoning: Number of included studies given and excluded studies listed with reasons.
[No]

P18. For each study, present characteristics and citations.
Quotes: Table with characteristics of included studies along with citations.
Reasoning: Characteristics and citations of included studies provided in table.
[Yes]

P19. Present data on risk of bias of each study. 
Quotes: Figure 1 summarizing risk of bias assessments for each included study.
Reasoning: Risk of bias assessments presented for each study.
[Yes]

P20. For results of each study, present simple summary data and effect estimates. 
Quotes: Forest plots provided with effect estimates.
Reasoning: Summary data and effect estimates presented in forest plots. 
[Yes]

P21. Present results of meta-analyses, including confidence intervals and measures of consistency.
Quotes: Results of meta-analyses presented with confidence intervals. Measures of heterogeneity (I2) provided.  
Reasoning: Results of meta-analyses presented appropriately.
[Yes] 

P22. Present results of risk of bias across studies.
Quotes: No results of risk of bias across studies presented.
Reasoning: Not provided.
[No]

P23. Give results of additional analyses.
Quotes: No additional analyses mentioned.
Reasoning: Not applicable.
[NA]

P24. Summarize the main findings. 
Quotes: Main findings summarized in the abstract and discussion sections.
Reasoning: Main findings summarized appropriately.
[Yes]

P25. Discuss limitations at study and outcome level.
Quotes: Limitations discussed in the discussion section.
Reasoning: Limitations discussed.
[Yes]

P26. Provide a general interpretation of results.
Quotes: Results summarized and interpreted in the discussion section. 
Reasoning: General interpretation of results provided.
[Yes]

P27. Describe sources of funding. 
Quotes: Sources of funding not reported.
Reasoning: Sources of funding not provided.
[No]
</pre>
<p><a name='143'></a></p>
</div>
<div id="scholfield-2016" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2015.0121' title='Open publication'>Scholfield
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the attached systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our study is the first systematic review and meta-analysis comparing OD and LD pull-through techniques for HD.&quot;</span> (Introduction)
- Indicates this is the first systematic review on this topic, suggesting no protocol existed prior.
[No]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction.
[No]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

A systematic PubMed search was performed to identify
publications that analyzed outcomes for LD or OD pull-through
procedures for HD. All studies between January 1994 and De-
cember 2014 were included in the search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search.&quot;</span> (Materials and Methods)  
- Search limited to only one database, no supplementary sources mentioned.
[No]

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding studies based on publication status.
[No] 

A5. Was a list of studies (included and excluded) provided? 
- Figure 1 provides a flow diagram showing included and excluded studies.
[Yes]

A6. Were the characteristics of the included studies provided?
- Table 1 and 2 provide characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- Figure 2 provides a risk of bias assessment.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Limitations and lack of randomized trials noted in Discussion.
[Yes]

A9. Were the methods used to combine the findings of studies appropriate?  
- Methods described in Materials and Methods, with tests for heterogeneity performed.
[Yes]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included? 
- No conflict of interest statement provided for individual studies or review.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our study is the first systematic review and meta-analysis comparing OD and LD pull-through techniques for HD.&quot;</span> (Introduction)
[Yes]

P2. Provide a structured summary.
- Structured abstract provided. 
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Introduction provides context and rationale.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to PICOS.
- Research objective clearly stated in Introduction.
[Yes]

P5. Indicate if a review protocol exists. 
- No mention of existing protocol.
[No]

P6. Specify study characteristics used as criteria for eligibility.
- Inclusion and exclusion criteria described in Materials and Methods.
[Yes]

P7. Describe all information sources in the search.
- Only one database searched stated. 
[No]

P8. Present full electronic search strategy for at least one database.
- Search strategy not provided.
[No]  

P9. State the process for selecting studies.
- Study selection process described in Figure 1.
[Yes]

P10. Describe method of data extraction.
- No details provided on data extraction process.
[No]

P11. List and define all variables for which data were sought.
- Outcomes described in Introduction.
[Yes]  

P12. Describe methods for assessing risk of bias. 
- Risk of bias assessed in Figure 2.
[Yes]

P13. State the principal summary measures.
- Statistical methods described in Materials and Methods.
[Yes]

P14. Describe the methods of handling data and combining results.
- Meta-analysis methods described.
[Yes]

P15. Specify any assessment of risk of bias across studies.
- No assessment mentioned.
[No]

P16. Describe methods of additional analyses.
- No additional analyses mentioned.
[NA]

P17. Give numbers of studies at each stage with reasons for exclusion. 
- Figure 1 provides study flow diagram.
[Yes]

P18. For each study, present characteristics.
- Study characteristics presented in Tables 1-7.
[Yes]

P19. Present data on risk of bias for each study. 
- Figure 2 provides risk of bias assessment.
[Yes]

P20. For each outcome, present data for each study.
- Results section presents outcome data.
[Yes]

P21. Present results of each meta-analysis done.
- Forest plots provided in Figures 3 and 4.
[Yes] 

P22. Present results of assessment of bias across studies.
- No assessment presented.
[No]

P23. Give results of additional analyses.
- No additional analyses conducted.
[NA]

P24. Summarize main findings including strength of evidence.
- Findings summarized in Discussion.
[Yes]

P25. Discuss limitations at study and outcome level. 
- Limitations described in Discussion.
[Yes]

P26. Provide a general interpretation of results in context of other evidence.
- Results interpreted in Discussion.
[Yes]

P27. Describe sources of funding and support.
- No sources of funding reported.
[No]
</pre>
<p><a name='144'></a></p>
</div>
<div id="sharp-2015" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0035-1544174' title='Open publication'>Sharp
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The PRISMA format was used for the structure of this systematic review.&quot;</span>
Does not mention a protocol.

A2. Was there duplicate study selection and data extraction? [No] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Independent extraction of data was performed by N.E.S using predefined data fields.&quot;</span>
Only one author performed data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.6%):

OVID was used to search for articles focusing on the treatment of
pediatric esophageal achalasia with PD versus HM.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎OVID was used to search for articles focusing on the treatment of pediatric esophageal achalasia with PD versus HM." "The last search was run on May 4, 2014.&quot;</span>
Uses OVID database with specified date range. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]  
Study characteristics summarized in text and tables.

A7. Was the scientific quality of the included studies assessed and documented? [No] 
Does not report assessing quality/risk of bias of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Did not assess quality of included studies (A7).

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
Did not conduct meta-analysis.

A10. Was the likelihood of publication bias assessed? [NA]
Did not assess publication bias.

A11. Was the conflict of interest included? [Yes]
States <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.3%):

No funding was used.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎No funding was used" and "None&quot;</span> for conflict of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Title states <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A Systematic Review.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]  
Provides structured abstract with these elements.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Provides background and rationale in the Introduction.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes]
Specifies objectives, participants, interventions, comparisons, and outcomes in Introduction. 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
Does not mention a protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Specifies eligibility criteria including PICOS, years, and language.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]  
States database, platform, and date range searched.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [Yes]
Provides full search strategy.  

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Describes screening process and selection criteria.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]
States data was extracted independently by one author.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Defines primary and secondary outcomes extracted.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
Does not describe assessing risk of bias.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA] 
No meta-analysis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias or selective reporting.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses performed. 

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
Provides flow diagram of screening process.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Presents characteristics of included studies in text and tables. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No] 
Does not present risk of bias assessments.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [NA]
No meta-analysis performed.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]  
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
Did not assess risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Summarizes main findings in Discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]  
Discusses limitations of included studies and review limitations.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Provides interpretation and implications for future research.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [Yes]
States no funding received.
</pre>
<p><a name='145'></a></p>
</div>
<div id="shawyer-2014" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-014-3548-0' title='Open publication'>Shawyer
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here is the AMSTAR and PRISMA 2009 assessment for the given systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
The authors did not mention following a predefined protocol. 

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Title and abstract screening was carried out independently and in duplicate.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span> 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

A comprehensive search was conducted using MEDLINE/
PubMed, CINHAL, EMBASE/OVID, and CENTRAL (the
Cochrane library) electronic databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted using MEDLINE/PubMed, CINHAL, EMBASE/OVID, and CENTRAL (the Cochrane library) electronic databases.&quot;</span>

A4. Was the status of publication used as an inclusion criterion? [No] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
The authors did not mention searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
No list of excluded studies was provided.

A6. Were the characteristics of the included studies provided? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
Table 1 provides characteristics of included studies and patients. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎‘A priori’ methods of assessment should be provided.&quot;</span>
The authors used the MINORS tool to assess quality.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review.&quot;</span>  
The authors acknowledge the limitations of included studies in the Discussion.

A9. Were the methods used to combine the findings of studies appropriate? [NA] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable.&quot;</span>
No meta-analysis was performed.

A10. Was the likelihood of publication bias assessed? [NA]
<span title='Minor quote deviation. Best match in prompt (Similarity 98.9%):

An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An assessment of publication bias should include graphical aids and/or statistical tests.&quot;</span>  
Publication bias was not assessed as no meta-analysis was performed.

A11. Was the conflict of interest included? [No] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
No statement on conflict of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Identify the report as a systematic review, meta-analysis, or both.&quot;</span>
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.3%):

We performed a
systematic review of the literature regarding routine anti-
reflux medication' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review of the literature regarding anti-reflux medication...&quot;</span>

P2. Provide a structured summary. [Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review. [Yes] 
Rationale described in the Introduction.

P4. Provide an explicit statement of questions being addressed. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The objective of this study was to determine the prevalence of anti-reflux medication use in postoperative EA-TEF patients, and the impact of routine anti-reflux medication on postoperative GER and its associated complications.&quot;</span>

P5. Indicate if a review protocol exists. [No] 
No mention of a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]  
Eligibility criteria described in Methods.

P7. Describe all information sources in the search. [Yes]
Information sources described in Methods. 

P8. Present full electronic search strategy. [No]
The search strategy was not provided.

P9. State the process for selecting studies. [Yes] 
The process is described in the Methods.

P10. Describe method of data extraction. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data abstraction was performed in duplicate.&quot;</span>

P11. List and define all variables for which data were sought. [Yes] 
Outcomes described in Methods.

P12. Describe methods used for assessing risk of bias of individual studies. [Yes]
The MINORS tool was used to assess quality. 

P13. State the principal summary measures. [NA]
No meta-analysis was performed.

P14. Describe the methods of handling data and combining results of studies. [NA] 
No meta-analysis was performed.

P15. Specify any assessment of risk of bias across studies. [NA]
No assessment of publication bias as no meta-analysis was performed.

P16. Describe methods of additional analyses. [NA]
No additional analyses were performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review. [Yes]
Flow diagram provided in Fig. 1. 

P18. For each study, present characteristics for which data were extracted. [Yes]
Study characteristics presented in Table 1.

P19. Present data on risk of bias of each study. [No]
Individual study bias not presented.

P20. For all outcomes, present data for each study. [No] 
Study-level data not presented for outcomes.

P21. Present results of each meta-analysis done. [NA]  
No meta-analysis was performed. 

P22. Present results of any assessment of risk of bias across studies. [NA]
No assessment of publication bias was performed.

P23. Give results of additional analyses. [NA]
No additional analyses were done.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes] 
Main findings are summarized in the Discussion.

P25. Discuss limitations at study and outcome level and at review-level. [Yes]
Limitations discussed in the Discussion.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results are interpreted in the Discussion.

P27. Describe sources of funding for the systematic review. [No]
No statement on sources of funding.
</pre>
<p><a name='146'></a></p>
</div>
<div id="shawyer-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-014-3626-3' title='Open publication'>Shawyer
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA 2009 assessments for the attached systematic review:

# AMSTAR
A1. Was an 'a priori' design provided? [No]
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.9%):

A comprehensive search of MEDLINE, EM-
BASE, CENTRAL, and grey literature was performed
(2000–2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search of MEDLINE, EMBASE, CENTRAL, and grey literature was performed (2000–2014).&quot;</span>
No mention of a protocol.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Full-text screening, data abstraction and quality appraisal were conducted in duplicate.&quot;</span>
Two independent reviewers performed study selection and data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

A comprehensive search was conducted of MEDLINE/
PubMed, EMBASE/OVID and CENTRAL (the Cochrane
Library) electronic databases from 2000 to March 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;</span> 
Searched two databases plus Central.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Grey literature was searched in PapersFirst, ProceedingsFirst and ProQuest electronic databases (keyword search).&quot;</span>
Grey literature was searched.

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Patient characteristics of the included studies are summa-
rized in Tables 1 and 2' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patient characteristics of the included studies are summarized in Tables 1 and 2.&quot;</span>
Table 1 provides characteristics of included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

We appraised the quality of reporting of the included
studies in duplicate (AS and ML), with discrepancies
resolved by discussion and consensus. We used the
Methodological Index for Nonrandomized Studies (MIN-
ORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We appraised the quality of reporting of the included studies in duplicate, with discrepancies resolved by discussion and consensus. We used the Methodological Index for Nonrandomized Studies (MINORS).&quot;</span>
MINORS used to assess quality.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [No]
Quality was assessed but not incorporated into conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [NA] 
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No conflict of interest statements.

# PRISMA 2009
P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review and meta-analysis&quot;</span> in title.

P2. Provide a structured summary including relevant items. [Yes]  
Structured abstract provided with objectives, eligibility criteria, sources, outcomes, main results, limitations.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Introduction describes rationale and what is known.

P4. Provide an explicit statement of questions being addressed with reference to PICOS. [Yes]  
Objectives specify population, intervention, comparison, and outcomes. 

P5. Indicate if a review protocol exists and if available, provide registration information including registration number. [No]   
No protocol mentioned.

P6. Specify study characteristics and report characteristics used as criteria for eligibility, giving rationale. [Yes]
Eligibility criteria specify study design, population, intervention, comparison, outcomes, and years considered.

P7. Describe all information sources in the search and date last searched. [Yes]
Sources (databases) and dates searched provided. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes] 
Screening and selection process described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]
Data extraction in duplicate mentioned. Contacting authors for additional data mentioned.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Outcomes sought described. 

P12. Describe methods used for assessing risk of bias of individual studies and how this information is to be used in any data synthesis. [Yes]
MINORS used to assess quality.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Odds ratios and mean differences described.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]  
No assessment of publication bias.

P16. Describe methods of additional analyses, if done, indicating which were pre-specified. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]  
Flow diagram provided with number screened, assessed, and reasons for exclusions.

P18. For each study, present characteristics for which data were extracted and provide the citations. [Yes] 
Table 1 presents characteristics of included studies with citations.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment. [Yes]  
Quality assessment using MINORS presented. 

P20. For all outcomes considered, present for each study: (a) summary data (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes] 
Forest plots provided with effect estimates and CIs.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis performed. 

P22. Present results of any assessment of risk of bias across studies. [NA]
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done. [NA]
No additional analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes]
Main findings summarized in discussion and conclusions.

P25. Discuss limitations at study and outcome level and at review-level. [Yes] 
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of other evidence. Implications described.

P27. Describe sources of funding for the systematic review and other support; role of funders for the systematic review. [No]
No funding or support described.

In summary, the AMSTAR assessment yielded 3 Yes, 6 No, and 2 NA responses. The PRISMA assessment yielded 18 Yes, 5 No, and 4 NA responses. This indicates several areas where the reporting of methods and findings could be improved in this systematic review based on the AMSTAR and PRISMA guidelines.
</pre>
<p><a name='147'></a></p>
</div>
<div id="shen-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3705-0' title='Open publication'>Shen
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

AMSTAR
A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched databases, including PubMed, Embase, the Science Citation Index, and Cochrane Library updated to November 2014, to identify all related published studies comparing the laparoscopic and the open choledochal cyst excision with hepaticojejunostomy.&quot;</span> No mention of a protocol.
A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 52.3%):

Two reviewers (Huo-Jian Shen and Ming Xu) abstracted
relevant information from each eligible article using a
standardized form independently' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The citations within the reference lists of the articles were searched manually to identify additional eligible studies." "Two reviewers (Huo-Jian Shen and Ming Xu) abstracted relevant information from each eligible article using a standardized form independently.&quot;</span>
A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

We searched databases, including PubMed, Embase, the
Science Citation Index, and Cochrane Library updated to
November 2014, to identify all related published studies
comparing the laparoscopic and the open choledochal cyst
excision with hepaticojejunostomy. The keywords used in
the search were as follows: laparoscopic, open, hepatico-
jejunostomy, choledochal cysts' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched databases, including PubMed, Embase, the Science Citation Index, and Cochrane Library updated to November 2014, to identify all related published studies comparing the laparoscopic and the open choledochal cyst excision with hepaticojejunostomy. The keywords used in the search were as follows: laparoscopic, open, hepaticojejunostomy, choledochal cysts.&quot;</span> Searched multiple databases. 
A4. Was the status of publication used as an inclusion criterion? [No] 
No mention of including or excluding based on publication status.
A5. Was a list of studies (included and excluded) provided? [No]
Included studies described in text and tables, but no list of excluded studies.
A6. Were the characteristics of the included studies provided? [Yes] 
Characteristics summarized in Table 1.
A7. Was the scientific quality of the included studies assessed and documented? [Yes]
Quality assessed using Newcastle-Ottawa scale, results in Table 1.
A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
Limitations due to retrospective study designs discussed. 
A9. Were the methods used to combine the findings of studies appropriate? [Yes]
Heterogeneity assessed and random effects model used when present.
A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.
A11. Was the conflict of interest included? [No] 
No statement about conflicts of interest.

PRISMA
P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic versus open surgery in children with choledochal cysts: a meta-analysis&quot;</span>
P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes] 
Structured abstract provided with all elements.
P3. Describe the rationale for the review in the context of what is already known. [Yes]
Introduction describes rationale and context.
P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement.
P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.
P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion and exclusion criteria described. 
P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Databases and dates searched reported.
P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.
P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Study selection process described. 
P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes] 
Data extraction described.
P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Outcomes analyzed listed. 
P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
Quality assessment with Newcastle-Ottawa scale described. 
P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Mean difference and odds ratio used.
P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Heterogeneity assessed and random effects model used.
P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias or other biases across studies.
P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.
P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No] 
Number of studies included reported but not screened or excluded. No flow diagram.  
P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Study characteristics presented in Table 1.
P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes]
Quality assessment results presented in Table 1.
P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Forest plots provided.
P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes] 
Results presented with CIs and I2 values.
P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of bias across studies.
P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses.
P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in discussion.
P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]
Limitations discussed.
P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted and implications described.
P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of funding or support.
</pre>
<p><a name='148'></a></p>
</div>
<div id="siddiqui-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-010-2698-Y' title='Open publication'>Siddiqui
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here is my assessment of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The objective of this study is to meta-analyse the published literature comparing outcomes after open (ONF) versus laparoscopic Nissen fundoplication (LNF) for gastro-oesophageal reflux disease in children.&quot;</span>
"[Yes]"

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This was performed independently and any conflict resolved prior to final analysis. A third researcher confirmed the data extraction.&quot;</span>  
"[Yes]"

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

We searched the MEDLINE, EM-
BASE and CINAHL available through the National Library
of Health website, the Cochrane library and PubMed dat-
abases available online' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched the MEDLINE, EMBASE and CINAHL available through the National Library of Health website, the Cochrane library and PubMed databases available online.&quot;</span>
"[Yes]" 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of searching for grey literature.
"[No]"

A5. Was a list of studies (included and excluded) provided?
Table 1 provides list of excluded studies with reasons. 
"[Yes]"

A6. Were the characteristics of the included studies provided?
Table 2 provides characteristics of included studies.
"[Yes]"

A7. Was the scientific quality of the included studies assessed and documented?
No assessment of quality of individual studies.
"[No]" 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
No assessment of study quality.
"[No]"

A9. Were the methods used to combine the findings of studies appropriate?
Heterogeneity assessed and random effects model used when present.
"[Yes]"

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned.
"[No]"

A11. Was the conflict of interest included? 
No mention of conflicts of interest.
"[No]"

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The objective of this study is to meta-analyse the published literature comparing outcomes after open (ONF) versus laparoscopic Nissen fundoplication (LNF) for gastro-oesophageal reflux disease in children.&quot;</span>
"[Yes]"

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
Structured abstract provided with background, objectives, eligibility criteria, participants, interventions, synthesis methods, results, and conclusions. No study appraisal or limitations mentioned in abstract. 
"[No]"

P3. Describe the rationale for the review in the context of what is already known.
Introduction describes rationale and context.
"[Yes]"

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
Objective clearly stated along with participants, interventions, comparison, and outcomes. Study design not explicitly specified.
"[No]"

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
No mention of protocol.
"[No]" 

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Inclusion criteria specify study design, participants, interventions, comparison, and outcomes. No language or publication status restrictions mentioned.
"[No]"

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Databases and date range provided. No supplemental search methods described.
"[No]"

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
No search strategy provided.
"[No]"

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Described process of screening and eligibility assessment.
"[Yes]" 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
States double extraction was done and conflicts resolved before analysis. 
"[Yes]"

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Outcomes extracted described. No other variables mentioned.
"[No]"

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
No assessment of risk of bias mentioned.
"[No]"

P13. State the principal summary measures (e.g., risk ratio, difference in means).
Summary measures described.
"[Yes]"

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
"[NA]"

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
"[NA]"

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
"[NA]" 

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Flow diagram provided detailing records screened, assessed for eligibility, and included along with reasons for exclusions. 
"[Yes]"

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
Table 2 provides relevant characteristics and citations for included studies.
"[Yes]"

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
No assessment of risk of bias. 
"[No]"

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Forest plots provided with effect estimates and CIs. Individual study data not provided.
"[No]" 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
"[NA]"

P22. Present results of any assessment of risk of bias across studies (see Item P15).
"[NA]" 

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
"[NA]"

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Main findings summarized in discussion and conclusion sections. No mention of strength of evidence or relevance to key groups.
"[No]"

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). 
Limitations discussed but no mention of risk of bias.
"[No]"

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Results interpreted in context of other evidence. Suggestions for future research provided.
"[Yes]"

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
No mention of funding or conflicts of interest.
"[No]"
</pre>
<p><a name='149'></a></p>
</div>
<div id="siminas-2015" class="section level4">
<h4><a href='https://doi.org/10.1097/SLA.0000000000001191' title='Open publication'>Siminas
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

# AMSTAR
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
"[No]" - No mention of protocol or pre-determined objectives.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.  
"[No]" - No mention of duplicate study selection or data extraction process.

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.4%):

searches of MEDLINE (PubMed), EMBase, Goo-
gle Scholar, and Cochrane Libraries were c' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes]" - Searched MEDLINE, EMbase, Google Scholar. Also searched journals and reference lists.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.  
"[No]" - No mention of including or searching for grey literature.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
"[No]" - No list of excluded studies provided. 

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Follow-up poorly reported in general&quot;</span>
"[Yes]" - Table 1 provides characteristics of included studies. Follow-up duration is poorly reported.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).  
"[No]" - No quality assessment of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.  
"[No]" - Did not assess quality of included studies.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
"[NA]" - No meta-analysis performed.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.  
"[NA]" - No meta-analysis performed.

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
"[No]" - No conflict of interest statement.

# PRISMA
P1. Identify the report as a systematic review, meta-analysis, or both.  
"[Yes]" - Identified as systematic review in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
"[Yes]" - Abstract provides structured summary.

P3. Describe the rationale for the review in the context of what is already known.  
"[Yes]" - Introduction describes rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
"[No]" - No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
"[No]" - No mention of protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.  
"[Yes]" - Inclusion and exclusion criteria described in Methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
"[Yes]" - Information sources described in Methods.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
"[No]" - Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
"[Yes]" - Study selection process described and shown in Figure 2.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  
"[No]" - No data extraction methodology described. 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
"[No]" - Variables not explicitly defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
"[No]" - No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
"[NA]" - No meta-analysis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
"[NA]" - No meta-analysis performed. 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
"[NA]" - No assessment of publication bias or selective reporting.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  
"[NA]" - No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  
"[Yes]" - Figure 2 shows flow diagram of study selection.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
"[Yes]" - Table 1 presents characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
"[No]" - No risk of bias assessment.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
"[No]" - No forest plots or effect estimates presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. 
"[NA]" - No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
"[NA]" - No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
"[NA]" - No additional analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
"[Yes]" - Main findings summarized in Discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
"[Yes]" - Limitations discussed in Discussion.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
"[Yes]" - Results interpreted and future research implications described in Discussion.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
"[No]" - No mention of sources of funding or support.
</pre>
<p><a name='150'></a></p>
</div>
<div id="sklar-2014" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2013.0415 ' title='Open publication'>Sklar
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

To identify all publications comparing
LAP versus open surgery for intussusception in children, two
researchers independently searched the electronic databases
MEDLINE, Embase, CINAHL, and the Cochrane Library,
using the MeSH terms ‘‘intussusception,’’ ‘‘pediatric,’’ and
‘‘laparoscopic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To identify all publications comparing LAP versus open surgery for intussusception in children, two researchers independently searched the electronic databases MEDLINE, Embase, CINAHL, and the Cochrane Library, using the MeSH terms ‘intussusception,’ ‘pediatric,’ and ‘laparoscopic.’&quot;</span>
This indicates there was an a priori protocol. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Two researchers independently screened
the title and abstract of identified articles for potential eligi-
bility and retrieved the full-text version of all articles deemed
relevant' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently screened the title and abstract of identified articles for potential eligibility and retrieved the full-text version of all articles deemed relevant.&quot;</span>
This indicates duplicate study selection. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

To identify all publications comparing
LAP versus open surgery for intussusception in children, two
researchers independently searched the electronic databases
MEDLINE, Embase, CINAHL, and the Cochrane Library,
using the MeSH terms ‘‘intussusception,’’ ‘‘pediatric,’’ and
‘‘laparoscopic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To identify all publications comparing LAP versus open surgery for intussusception in children, two researchers independently searched the electronic databases MEDLINE, Embase, CINAHL, and the Cochrane Library, using the MeSH terms ‘intussusception,’ ‘pediatric,’ and ‘laparoscopic.’&quot;</span>
At least 2 databases were searched. [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of searching for grey literature. [No] 

A5. Was a list of studies (included and excluded) provided?
No list of included/excluded studies provided. [No]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We applied the MINORS criteria to each study (Table 2) and found that all studies were fair to moderate in quality.&quot;</span> 
The MINORS criteria was used to assess quality. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
The quality assessment limitations are mentioned in the discussion but do not appear to be incorporated into the conclusions. [No]

A9. Were the methods used to combine the findings of studies appropriate?
Heterogeneity tests were performed and a random effects model used as appropriate. [Yes] 

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
No mention of conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Second, and most importantly, we sought to conduct a systematic review and meta-analysis, combining our data with existing literature, in order to identify any differences in outcome measures across all identified comparative studies.&quot;</span>

P2. Provide a structured summary including key elements. [Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
The introduction provides context and rationale.

P4. Provide an explicit statement of questions being addressed. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There were two main objectives for this study. First, we aimed to retrospectively review our institution’s experience with the surgical treatment of intussusception, comparing the LAP and open approaches. Second, and most importantly, we sought to conduct a systematic review and meta-analysis, combining our data with existing literature, in order to identify any differences in outcome measures across all identified comparative studies.&quot;</span>

P5. Indicate if a review protocol exists. [No]
No protocol mentioned.

P6. Specify study characteristics used as criteria for eligibility. [Yes]
Inclusion limited to comparative studies of LAP vs open surgery for pediatric intussusception.

P7. Describe information sources including dates of coverage. [No] 
Databases searched mentioned but not dates of coverage.

P8. Present full electronic search strategy for at least one database. [No]
Search strategy not provided.

P9. State the process for selecting studies. [Yes] 
Study selection process described.

P10. Describe method of data extraction. [No]  
No details provided on data extraction process.

P11. List and define all variables for which data were sought. [Yes]
Outcomes assessed defined in methods. 

P12. Describe methods for assessing risk of bias. [Yes]
MINORS criteria used to assess quality/risk of bias.

P13. State the principal summary measures. [Yes]
Clearly defined in analysis section.

P14-P16. Describe methods of synthesis, assessment of consistency, and additional analyses. [NA]
Not applicable - no quantitative synthesis performed.

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusion. [No]
No flow diagram or details provided.

P18. For each study, present key characteristics. [Yes]
Table 1 provides key characteristics.

P19. Present data on risk of bias for each study. [Yes] 
Table 2 provides MINORS score for each study.

P20-P23. Present data and results for each meta-analysis. [NA] 
Not applicable - no quantitative synthesis performed.

P24. Summarize the main findings and discuss relevance. [Yes] 
Main findings summarized in discussion.

P25. Discuss limitations at study and review level. [Yes]
Limitations discussed.

P26. Provide general interpretation of results. [Yes]
Results interpreted in discussion. 

P27. Describe sources of funding. [No]
No mention of sources of funding.
</pre>
<p><a name='151'></a></p>
</div>
<div id="sola-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JSS.2009.05.007' title='Open publication'>Sola
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review from the published literature.&quot;</span>
- An a priori protocol is not mentioned.
[No]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (JES, LGK), using a predefined data extraction form, extracted data from the publications.&quot;</span> 
- Two independent reviewers performed study selection and data extraction.
[Yes]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

The Ovid (Ovid Technologies New York, NY) and Medline search en-
gines were used to examine both the Pubmed and Cochrane libraries
from January 2000 to December 2008' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Ovid (Ovid Technologies New York, NY) and Medline search engines were used to examine both the Pubmed and Cochrane libraries from January 2000 to December 2008.&quot;</span>
- At least two databases were searched.
[Yes]  

A4. Was the status of publication used as an inclusion criterion? 
- Publication status is not mentioned as an inclusion criterion.
[No]

A5. Was a list of studies (included and excluded) provided?
- Tables 1 and 2 list the included and excluded studies.
- The excluded studies are referenced.
[Yes]

A6. Were the characteristics of the included studies provided? 
- Table 1 provides characteristics of the included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- No quality assessment is reported.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Review Manager (RevMan) software version 5.0. (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2008) was uti-
lized to perform the meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review Manager (RevMan) software version 5.0 was utilized to perform the meta-analysis.&quot;</span>
- Heterogeneity was assessed with chi-squared test. 
[Yes]

A10. Was the likelihood of publication bias assessed?  
- Funnel plots are presented but no statistical tests.
[No]

A11. Was the conflict of interest included?
- No conflict of interest statements are provided.
[No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We performed a systematic review from the published literature.&quot;</span>
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

We sought to analyze the most recent available publica-
tions in order to determine the most effective operative
approach for these small, fragile, and critically ill
infants' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We sought to analyze the most recent available publications in order to determine the most effective operative approach for these small, fragile, and critically ill infants.&quot;</span>
[Yes]

P2. Provide a structured summary.
[No] 

P3. Describe the rationale for the review in the context of what is already known.
- The introduction provides context about the controversy regarding surgical management of premature neonates with NEC and IP. 
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
[No]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Inclusion criteria are described in the Methods.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
- Databases and date ranges are provided.
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[No]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (JES, LGK), using a predefined data extraction form, extracted data from the publications.&quot;</span>
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 
[No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[No] 

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- Odds ratios, mean differences, and confidence intervals are presented. 
[Yes]

P14-P16. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
- Table 1 provides relevant characteristics and citations for each included study.
[Yes]

P19-P23. [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- The discussion summarizes the main findings.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations are discussed.
[Yes]  

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- The results are interpreted in the context of previous studies. Implications for practice are discussed.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
[No]
</pre>
<p><a name='152'></a></p>
</div>
<div id="symeonidis-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.IJSU.2016.03.040' title='Open publication'>Symeonidis
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An in-depth search of the literature was performed in the databases of PubMed and Scopus&quot;</span>
- They searched at least two databases. [Yes]

A2. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (ENS and DN) working independently extracted data from all eligible studies; any discrepancies were discussed and consensus was reached.&quot;</span>
- There were two independent data extractors. [Yes]  

A3. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided.&quot;</span>
- They searched two databases and provided keywords. [Yes]

A4. 
- No mention of including or excluding based on publication status. [No]

A5. 
- No list of included/excluded studies provided. [No]  

A6.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎From each eligible study the following parameters were extracted when available:&quot;</span>
- They provided characteristics of included studies. [Yes]

A7.  
- No assessment of study quality mentioned. [No]

A8. 
- Study quality not used in formulating conclusions since it was not assessed. [NA]

A9.  
- No meta-analysis performed. [NA]

A10. 
- No assessment of publication bias mentioned. [No]

A11. 
- No statement on conflicts of interest for individual studies. [No]

P1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoendoscopic single-site surgery (LESS) for major urological procedures in the pediatric population: A systematic review&quot;</span>  
- Identified as a systematic review in title. [Yes]

P2. 
- Provides structured abstract with background, objectives, eligibility criteria, results, conclusions. [Yes]  

P3. 
- Provides context and rationale in the introduction. [Yes]

P4. 
- Clear objective to review LESS for major pediatric urological procedures. [Yes]

P5. 
- No mention of a review protocol. [No]

P6.  
- Specifies inclusion criteria including population, interventions, and outcomes. [Yes]

P7.  
- Describes literature search in PubMed and Scopus. [Yes]

P8. 
- Does not provide full search strategy. [No]

P9.  
- Describes study selection process. [Yes] 

P10. 
- States two reviewers independently extracted data. [Yes]

P11. 
- Lists data extracted from studies. [Yes]

P12. 
- Does not describe risk of bias assessment. [No]

P13.
- Not applicable since no meta-analysis. [NA]

P14.  
- Not applicable since no meta-analysis. [NA]

P15. 
- Not applicable since no meta-analysis. [NA]

P16.  
- Not applicable since no meta-analysis. [NA]

P17. 
- Provides flow diagram of study selection. [Yes]

P18. 
- Presents characteristics of included studies in tables. [Yes]

P19. 
- Does not present risk of bias assessments. [No] 

P20. 
- Not applicable since no meta-analysis. [NA]  

P21.
- Not applicable since no meta-analysis. [NA]

P22.
- Not applicable since no meta-analysis. [NA]

P23.  
- Not applicable since no meta-analysis. [NA]

P24. 
- Summarizes main findings in discussion. [Yes]

P25. 
- Discusses limitations of included studies. [Yes]

P26. 
- Provides general interpretation of results. [Yes] 

P27. 
- No funding sources reported for systematic review. [No]
</pre>
<p><a name='153'></a></p>
</div>
<div id="tan-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDS.2015.12.074' title='Open publication'>Tan
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the systematic review's methodological quality using AMSTAR and reporting quality using PRISMA 2009:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review was performed according to a protocol that was designed a priori and recommended for systematic reviews and meta-analyses.&quot;</span>
The review had a protocol designed before conducting the review. 

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Two authors reviewed all the abstracts independently.
Agreement regarding potential relevance was reached by
consensus. Full-text copies of potentially eligible papers
were obtained, and the same 2 reviewers independently ex-
tracted relevant data on study characteristics and the out-
comes of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors reviewed all the abstracts independently. Agreement regarding potential relevance was reached by consensus. Full-text copies of potentially eligible papers were obtained, and the same 2 reviewers independently extracted relevant data on study characteristics and the outcomes of interest.&quot;</span>
Two reviewers independently performed study selection and data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):

Medline, Embase, Cinahl, and
Cochrane databases were searched electronically on April
24, 2014, and then updated on May 11, 2015; the search
was limited to reports published after January 1, 1980. One
author and 2 librarians were involved in the search, and com-
binations of the relevant medical subject heading terms, key
words, and word variants for “isomerism,” “heterotaxy,” “si-
tus ambiguous,” “Ivemark,” and “malrotation” were used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PubMed, Embase, and Cinahl were searched electronically on April 24, 2014, and then updated on May 11, 2015; the search was limited to reports published after January 1, 1980. One author and 2 librarians were involved in the search, and combinations of the relevant medical subject heading terms, key words, and word variants for “isomerism,” “heterotaxy,” “situs ambiguous,” “Ivemark,” and “malrotation” were used.&quot;</span> 
At least two databases were searched along with supplemental strategies.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]  
The review does not mention searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [Yes]
Table I lists excluded studies with reasons. 

A6. Were the characteristics of the included studies provided? [Yes]  
Table II provides characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Quality assessment of the included studies was performed using the Newcastle-Ottawa Scale (NOS) for cohort and case-control studies.&quot;</span> Table III shows the quality assessment.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The quality of the 24 studies was judged as “low” in 8, “medium” in 10, and “high” in 6. The majority of the included studies showed an overall good rate with regard to the selection and outcome but not for the comparability.&quot;</span> Quality was considered in the discussion.

A9. Were the methods used to combine the findings of studies appropriate? [NA]
No quantitative synthesis was performed.

A10. Was the likelihood of publication bias assessed? [NA]  
Publication bias was not assessed as there were fewer than 10 studies per analysis. 

A11. Was the conflict of interest included? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The authors declare no conflicts of interest.&quot;</span> Conflicts of interest are reported.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
The title identifies it as a systematic review and meta-analysis.

P2. Provide a structured summary. [Yes]
A structured abstract is provided with objectives, data sources, eligibility criteria, outcomes, results, and conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
The introduction describes the rationale and what is known about the topic.

P4. Provide an explicit statement of questions being addressed. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review and meta-analysis aims to establish the role of screening for IRA and the indication for a prophylactic surgery in asymptomatic patients born with heterotaxy.&quot;</span> The objectives are clearly stated.

P5. Indicate if a review protocol exists. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review was performed according to a protocol that was designed a priori...&quot;</span> The protocol is mentioned. 

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]  
Inclusion and exclusion criteria are described.

P7. Describe all information sources and date last searched. [Yes] 
Information sources and dates are provided.

P8. Present full electronic search strategy for at least one database. [No]
The search strategy is not provided.

P9. State the process for selecting studies. [Yes]  
The process for study selection is described. 

P10. Describe method of data extraction. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Two authors reviewed all the abstracts independently.
Agreement regarding potential relevance was reached by
consensus. Full-text copies of potentially eligible papers
were obtained, and the same 2 reviewers independently ex-
tracted relevant data on study characteristics and the out-
comes of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors reviewed all the abstracts independently... The same 2 reviewers independently extracted relevant data on study characteristics and the outcomes of interest.&quot;</span>

P11. List and define all variables for which data were sought. [Yes]
Outcomes investigated are listed and defined. 

P12. Describe methods used for assessing risk of bias. [Yes]
The NOS was used to assess quality of included studies.

P13. State the principal summary measures. [NA] 
Not applicable since no meta-analysis was done.

P14. Describe the methods of handling data and combining results of studies. [NA]
Not applicable since no meta-analysis was done.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence. [NA]
Not applicable since no meta-analysis was done.

P16. Describe methods of additional analyses. [NA]
Not applicable since no meta-analysis was done. 

P17. Give numbers of studies screened, assessed for eligibility, and included in the review. [Yes]
Figure 1 provides a flow diagram of studies.

P18. For each study, present characteristics for which data were extracted. [Yes] 
Table II presents key characteristics of included studies.

P19. Present data on risk of bias of each study. [Yes] 
Table III presents the quality assessment.

P20. For all outcomes, present data for each study. [NA] 
Not applicable since no meta-analysis was done.

P21. Present results of each meta-analysis done. [NA]
Not applicable since no meta-analysis was done. 

P22. Present results of any assessment of risk of bias across studies. [NA]  
Not applicable since no meta-analysis was done.

P23. Give results of additional analyses, if done. [NA]
Not applicable since no meta-analysis was done.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes]
The discussion summarizes the main findings.

P25. Discuss limitations at study and outcome level. [Yes]
Limitations are discussed.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results are interpreted in the context of other evidence.

P27. Describe sources of funding for the systematic review. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The authors declare no conflicts of interest.&quot;</span> Funding sources are reported.
</pre>
<p><a name='154'></a></p>
</div>
<div id="terui-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3765-1' title='Open publication'>Terui
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the AMSTAR and PRISMA items for the given systematic review:

A1. Was an 'a priori' design provided? 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.7%):

a systematic review and meta-analysis of the
effectiveness of endoscopic surgery (ES) for neonatal CDH.
Methods A systematic' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[This systematic review and meta-analysis of the effectiveness of endoscopic surgery (ES) for neonatal congenital diaphragmatic hernia (CDH)](154.pdf)&quot;</span>.
The objective is clear. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two individual authors extracted data from each selected study. The following items were collected:&quot;</span> (154.pdf)
Duplicate process described. [Yes] 

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic searches of English-language articles were conducted by using MEDLINE and the Cochrane Library, including all records dated from their first entries to March 2015.&quot;</span> (154.pdf)
Two databases searched. [Yes]

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
The PRISMA flow diagram shows records screened, excluded, and reasons. [Yes]

A6. Were the characteristics of the included studies provided? 
Table 1 lists key characteristics of included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
The methodological quality is assessed using the GRADE system. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎As assessed on the GRADE scale, the quality of evidence was very low for all outcomes.&quot;</span> (154.pdf)
Quality acknowledged in conclusions. [Yes]

A9. Were the methods used to combine the findings of studies appropriate?  
Heterogeneity assessed using I2. Fixed effect used. [Yes]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
No statement on conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Moderate quote deviation. Best match in fulltext (Similarity 83.7%):

a systematic review and meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review and meta-analysis...&quot;</span> (154.pdf) [Yes]

P2. Provide a structured summary including key elements.
Abstract provides structured summary. [Yes]

P3. Describe the rationale for the review in context of what is already known.
Introduction provides context and rationale. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to PICOS.
Objective and inclusion criteria outline PICOS. [Yes]

P5. Indicate if a review protocol exists and if and where it can be accessed.
No mention of a protocol. [No]

P6. Specify study characteristics and report characteristics used as criteria for eligibility, giving rationale.
Inclusion criteria specify study characteristics. [Yes]

P7. Describe all information sources in the search and date last searched.
Databases and date ranges provided. [Yes] 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Search terms provided but not the full strategy. [No]

P9. State the process for selecting studies. 
Selection process described and depicted in PRISMA flow diagram. [Yes]

P10. Describe method of data extraction from reports and any processes for obtaining and confirming data from investigators.
Data extraction process described. No confirmation from investigators mentioned. [Yes]

P11. List and define all variables for which data were sought and any assumptions and simplifications made.
Table 1 lists variables extracted. [Yes] 

P12. Describe methods used for assessing risk of bias of individual studies and how this information is to be used in any data synthesis.
Risk of bias assessed using GRADE. [Yes]

P13. State the principal summary measures.
Risk ratios calculated. [Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency for each meta-analysis. 
Fixed effect meta-analysis conducted. I2 reported. [Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence.
No assessment of publication bias. [No] 

P16. Describe methods of additional analyses, if done, indicating which were pre-specified.
No additional analyses conducted. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
PRISMA flow diagram provided. [Yes]

P18. For each study, present characteristics for which data were extracted and provide the citations.
Table 1 provides key characteristics and citations. [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment. 
Risk of bias assessed using GRADE. [Yes]

P20. For all outcomes considered, present for each study: (a) summary data for each intervention group, and (b) effect estimates and confidence intervals, ideally with a forest plot.
Forest plots provided with effect sizes and CIs. Summary data in text. [Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Results provided with CIs and I2 values. [Yes]

P22. Present results of any assessment of risk of bias across studies.
No assessment of publication bias. [No]

P23. Give results of additional analyses, if done.
No additional analyses conducted. [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome. 
Main findings summarized in discussion. [Yes]

P25. Discuss limitations at study and outcome level and at review-level.
Limitations discussed. [Yes]

P26. Provide a general interpretation of the results in context of other evidence and implications for future research.
Results interpreted and future research implications described. [Yes]

P27. Describe sources of funding for the systematic review and other support. 
Source of funding stated. [Yes]
</pre>
<p><a name='155'></a></p>
</div>
<div id="thomson-2015" class="section level4">
<h4><a href='https://doi.org/10.1136/BMJOPEN-2014-006063' title='Open publication'>Thomson
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A study protocol outlining the search strategy, outcomes, and methods of data extraction and statistical analysis was designed and prospectively registered with the Prospero database (CRD42013005698).&quot;</span>
[Yes]

A2. Was there duplicate study selection and data extraction?
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Titles and abstracts of potentially relevant papers were screened by two independent authors (DT and BA).&quot;</span>
[Yes]

A3. Was a comprehensive literature search performed?
-<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched all publications from 1 January 1998 to 1 January 2014 from EMBASE, MEDLINE and Cochrane library databases using the search strategy detailed in online supplementary appendix I.&quot;</span>
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of searching for grey literature.
[No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows a flow diagram with included and excluded studies.
[Yes] 

A6. Were the characteristics of the included studies provided?
- Table 2 provides characteristics of the included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
-<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Two independent authors (DT and BA) assessed study
quality using the Newcastle-Ottawa Scale for case–
control and cohort studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors (DT and BA) assessed study quality using the Newcastle-Ottawa Scale for case–control and cohort studies.&quot;</span> 
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- The limitations of the included studies are discussed in the conclusions.
[Yes]

A9. Were the methods used to combine the findings of studies appropriate?  
- Fixed and random effects models used appropriately based on heterogeneity.
[Yes]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned.
[No] 

A11. Was the conflict of interest included? 
-<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 46.2%):

n be accessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎None declared&quot;</span> after competing interests.
[Yes]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 
- Identified as systematic review and meta-analysis in title.
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Structured abstract provided covering all key elements.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Background section describes rationale.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- Clear objective stated in introduction.
[Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- Prospective registration noted.
[Yes]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Inclusion and exclusion criteria provided in Table 1.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.  
- Databases, search terms, and date range described.
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- Full search strategy provided in appendix.
[Yes]  

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Study selection process described and depicted in Figure 1.
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
- Independent dual data extraction described.
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- Outcomes sought described in methods.
[Yes]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- Newcastle-Ottawa scale used to assess quality.
[Yes] 

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- Fixed and random effects models described. 
[Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- Figure 1 shows PRISMA flow diagram. 
[Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
- Table 2 presents key characteristics.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- Risk of bias assessed with Newcastle-Ottawa scale, results presented.
[Yes]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- Forest plots presented where meta-analysis performed.
[Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15). 
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Conclusions summarize main findings and limitations.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations discussed in discussion and conclusion.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results contextualized and future research needs described.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
- Sources of funding described.
[Yes]
</pre>
<p><a name='156'></a></p>
</div>
<div id="thyoka-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S00247-013-2693-2' title='Open publication'>Thyoka
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? 
"[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”&quot;</span>

A2. Was there duplicate study selection and data extraction?
"[No]"  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (M.T. and A.T.) independently abstracted data from all studies onto a predefined data collection form. Any discrepancies were resolved by consensus.&quot;</span>

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched the standard databases (January, 1960–May, 2012): MEDLINE, EMBASE and Cochrane Library Controlled Trials Register (CENTRAL) using the MeSH Terms “esophageal stricture”, “esophageal stenosis” and “balloon dilatation” to identify the studies.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
"[No]"
No mention of searching for unpublished literature or grey literature.

A5. Was a list of studies (included and excluded) provided?
"[No]" 
No lists of included or excluded studies provided.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
Table 1 provides characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
No quality assessment of included studies mentioned. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Since no quality assessment was done, this is not applicable.

A9. Were the methods used to combine the findings of studies appropriate?  
"[NA]"
No quantitative synthesis done.

A10. Was the likelihood of publication bias assessed?
"[No]"
No assessment of publication bias mentioned.

A11. Was the conflict of interest included?
"[No]"
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

In this review, we sought
to review the current published evidence of the outcomes of
balloon dilatation of anastomotic strictures secondary to sur-
gical repair of oesophageal atresia' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In this review, we sought to review the current published evidence of the outcomes of balloon dilatation of anastomotic strictures secondary to surgical repair of oesophageal atresia.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
"[No]"
No structured summary provided.

P3. Describe the rationale for the review in the context of what is already known.
"[Yes]"
The introduction section describes the rationale and context.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  
"[No]" 
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
"[No]"
No mention of a protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
"[Yes]"
The inclusion criteria are described in the methods section. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
"[Yes]"
Databases and date ranges are provided.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
"[No]" 
No full search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
"[Yes]" 
The selection process is described and illustrated in a flow diagram.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (M.T. and A.T.) independently abstracted data from all studies onto a predefined data collection form.&quot;</span>

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
"[No]"
No explicit listing of variables.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
"[NA]" 
No risk of bias assessment done.

P13. State the principal summary measures (e.g., risk ratio, difference in means).  
"[NA]"
No meta-analysis done.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
"[NA]" 
No meta-analysis done.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
"[NA]"
No assessment of publication bias or other biases done.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
"[NA]"
No additional analyses done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  
"[Yes]"
A flow diagram is provided depicting the screening process.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
"[Yes]"
Table 1 provides relevant characteristics and citations for each study.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
"[NA]" 
No risk of bias assessment done.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
"[No]"
No forest plots or effect estimates provided.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
"[NA]"
No meta-analysis done. 

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
"[NA]" 
No assessment done.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
"[NA]"
No additional analyses done.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
"[Yes]" 
The discussion section summarizes the main findings.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
"[Yes]"
Limitations are discussed in the discussion section.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
"[Yes]" 
The discussion section provides interpretation and implications.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
"[No]"
No mention of sources of funding or support.
</pre>
<p><a name='157'></a></p>
</div>
<div id="van-dalen-2015" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD008403.pub3' title='Open publication'>van
Dalen 2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the assessments of the systematic review using AMSTAR and PRISMA 2009:

# AMSTAR

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review is the second update of the first systematic review evaluating the state of evidence on this topic, focusing on randomised controlled trials (RCTs) and controlled clinical trials (CCTs).&quot;</span>
- The review had predefined inclusion criteria for study designs.
- [Yes]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction.  
- [No]

A3. Was a comprehensive literature search performed?
- Searched CENTRAL, MEDLINE/PubMed, EMBASE/Ovid, conference proceedings, reference lists, trial registries. 
- Search strategies provided in appendices.
- [Yes] 

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding based on publication status.
- [No]

A5. Was a list of studies (included and excluded) provided? 
- Provided a flow diagram of included and excluded studies.
- [Yes]

A6. Were the characteristics of the included studies provided?
- No studies were included.
- [NA]

A7. Was the scientific quality of the included studies assessed and documented?
- No studies were included.
- [NA]  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
- No studies were included.
- [NA]

A9. Were the methods used to combine the findings of studies appropriate?
- No meta-analysis was performed.
- [NA]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned.
- [No]

A11. Was the conflict of interest included?  
- Conflicts of interest statement included.
- [Yes]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 86%):

This review is the second update of a previously published Cochrane review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review is the second update of a previously published Cochrane review.&quot;</span>
- [Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Structured abstract provided with background, objectives, methods, results, authors' conclusions. 
- [Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Background section describes rationale and context.
- [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
- Clear objectives stated relating to PICOS.
- [Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No protocol mentioned.
- [No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Clear eligibility criteria described in methods.
- [Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
- Information sources described with dates of last search.
- [Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 
- Full search strategies provided in appendices.
- [Yes]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Study selection process described.
- [Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
- No data extraction performed since no studies were included.
- [NA]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- Outcomes of interest defined in methods section. No data extraction performed.
- [NA]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
- No assessment of risk of bias since no studies were included.
- [NA]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- No summary measures since no meta-analysis performed.
- [NA]  

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
- No data synthesis performed.
- [NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- No assessment of publication bias.
- [NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses performed.
- [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
- Flow diagram provided detailing screening process.
- [Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
- No studies included.
- [NA]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- No assessment of risk of bias since no studies included. 
- [NA]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- No study data presented since no studies included.
- [NA]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- No meta-analysis performed.
- [NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
- No assessment of risk of bias performed.
- [NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses performed.
- [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Main findings summarized in abstract and discussion.
- [Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations discussed in relation to lack of eligible studies.
- [Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted in discussion section.
- [Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  
- Sources of support described.
- [Yes]
</pre>
<p><a name='158'></a></p>
</div>
<div id="vanden-berg-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.UROLONC.2015.07.003' title='Open publication'>Vanden
Berg 2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the given systematic review:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎the protocol was prospectively registered at the international registry of systematic reviews, PROSPERO&quot;</span>
The review had a prospectively registered protocol.

A2. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The 2 reviewers, R.N.W.V. and E.N.B. independently reviewed all study abstracts in duplicate with disagreements resolved by the senior author (J.C.R.). Full-text articles appearing to meet selection criteria were reviewed, and study data was abstracted in the same manner.&quot;</span>
Two independent reviewers performed study selection and data extraction. 

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):

We
searched MEDLINE, EMBASE, the Cochrane Controlled
Trials Register, Google Scholar, and Scopus electronic
databases for studies published between 1980 and 2014
based on Preferred Reporting Items for Systematic reviews
and Meta-Analyses (PRISMA) guidelines [19]. The exploded
search terms were: “nephron-sparing surgery,” “partial neph-
rectomy,” or “nephron sparing surgery,” restricted to
“tumor,” “mass,” “Wilms,” “cancer,” or “renal cell carci-
noma.” These were then restricted to articles retrieved under
a second search for the exploded search terms “pediatric,”
“child,” or “children
”. Reference lists of included studies
were manually screened for any additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched MEDLINE, EMBASE, the Cochrane Controlled Trials Register, Google Scholar, and Scopus electronic databases for studies published between 1980 and 2014." "Reference lists of included studies were manually screened for any additional studies.&quot;</span>
Multiple databases were searched along with supplementary methods.

A4. [No]
No mention of searching for grey literature.

A5. [No] 
No list of included/excluded studies provided.

A6. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

In total, 4,022 patients were included. Of these, 1,632
children (41%) were male patients. Reported ages ranged
from o1 month to 18 years. Bilateral tumors were present
in 1,153 (29%) patients' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total, 4,022 patients were included. Of these, 1,632 children (41%) were male patients...Bilateral tumors were present in 1,153 (29%) patients&quot;</span> 
Characteristics of included studies summarized.

A7. [No]
No assessment of study quality described.

A8. [NA] 
Study quality was not assessed.

A9. [NA]  
No meta-analysis performed. 

A10. [NA]
No assessment of publication bias as no meta-analysis.

A11. [No]
No statement about conflicts of interest.

P1. [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Systematic review&quot;</span> in title.

P2. [Yes]
Structured abstract provided with all necessary elements.

P3. [Yes]  
Rationale described in introduction.

P4. [Yes]  
PICOS provided in methods.

P5. [Yes]
Prospective registration mentioned. 

P6. [Yes]  
Eligibility criteria described.

P7. [Yes]
Information sources described.

P8. [Yes]  
Search strategy provided in appendix.

P9. [Yes] 
Study selection process described and depicted in flow diagram.

P10. [Yes]
Data extraction process described.

P11. [No] 
No list of variables sought.

P12. [No]
No assessment of risk of bias described.

P13. [NA]
No meta-analysis performed.

P14. [NA] 
No meta-analysis performed.

P15. [NA]
No assessment of publication bias as no meta-analysis performed.

P16. [NA]
No additional analyses.

P17. [Yes]
Flow diagram depicts numbers at each stage.

P18. [No] 
No table with study characteristics. 

P19. [No]
No assessment of risk of bias.

P20. [No]
No forest plots with effect sizes.

P21. [NA]  
No meta-analysis performed.

P22. [NA]
No assessment of risk of bias across studies.

P23. [NA]
No additional analyses.

P24. [Yes]
Main findings summarized. 

P25. [Yes]
Limitations described.

P26. [Yes]  
Results interpreted and implications described.

P27. [No]
No mention of funding sources.
</pre>
<p><a name='159'></a></p>
</div>
<div id="van-den-hondel-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1351663' title='Open publication'>van
den Hondel 2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 32.1%):

bles were tested using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Data were collected using specifically designed forms.]&quot;</span> The review had a predefined protocol for data collection. [Yes] 

A2. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two investigators (D.H. and C.S.) independently screened titles and abstracts of retrieved citations, retrieved full texts of eligible articles, and selected relevant articles matching the selection criteria described below.&quot;</span> There was duplicate study selection and data extraction. [Yes]

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was conducted in the PubMed, Embase, and Web of Science databases with the help of an experienced librarian.&quot;</span> Multiple databases were searched. [Yes]  

A4. [NA]

A5. <span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):

Eight of
these met the inclusion and exclusion criteria (
►Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eight of these met the inclusion and exclusion criteria (Fig. 1).&quot;</span> A list of included studies was provided. [Yes]

A6. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎These data concerned study design, study population, follow-up, survival, complications, and reoperations.&quot;</span> Characteristics of included studies were provided in tables. [Yes] 

A7. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Methodological quality was assessed with the checklist pro-
posed by Downs and Black,
5 
with a maximum score of 32 for
the optimal study quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Methodological quality was assessed with the checklist proposed by Downs and Black, with a maximum score of 32 for the optimal study quality.&quot;</span> The quality of included studies was assessed using a standard tool. [Yes]

A8. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The wide range of complication rates in the systematic review may be because of the inconsistency in defining complications.&quot;</span> The quality assessment was considered in interpreting the results. [Yes]

A9. [NA] 

A10. [NA]

A11. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎None.&quot;</span> Sources of support were reported. [Yes]

P1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eur J Pediatr Surg 2014;24:61–69&quot;</span> The report is identified as a systematic review. [Yes]

P2. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 43.2%):

n abstract using the
inclusi' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Abstract: Background...Conclusions...&quot;</span> A structured summary is provided. [Yes] 

P3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In children with an anorectal malformation or Hirschsprung disease, the ideal type (split or loop) and location of the stoma is not clear...&quot;</span> The rationale is described. [Yes]

P4. <span title='Moderate quote deviation. Best match in fulltext (Similarity 93.1%):

this study, we therefore evaluated our own
experiences with colostomies in children with an anorectal
malformation, and performed a systematic review of the
literature on complications of colostomies in children with
an anorectal malformation or Hirschsprung disease' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The aim of this study is therefore to evaluate our experiences with colostomies in children with an anorectal malformation, and performed a systematic review of the literature on complications of colostomies in children with an anorectal malformation or Hirschsprung disease.&quot;</span> The objectives and participants are stated. [Yes]

P5. [No] 

P6. <span title='Moderate quote deviation. Best match in fulltext (Similarity 91.4%):

Inclusion and Exclusion Criteria
Studies were eligible' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Inclusion and Exclusion Criteria: Studies were eligible...&quot;</span> Eligibility criteria are described. [Yes] 

P7. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was conducted in the PubMed, Embase, and Web of Science databases...&quot;</span> Information sources are described. [Yes]

P8. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The general search terms were the
same for the three databases, which are as follows: anorectal
malformations, Hirschsprung disease, colostomy, and chil-
dren' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The general search terms were the same for the three databases, which are as follows: anorectal malformations, Hirschsprung disease, colostomy, and children.&quot;</span> Search terms are provided. [Yes]

P9. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two investigators (D.H. and C.S.) independently screened titles and abstracts of retrieved citations, retrieved full texts of eligible articles, and selected relevant articles matching the selection criteria described below.&quot;</span> Study selection process is described. [Yes]

P10. <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 32.1%):

bles were tested using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Data were collected using specifically designed forms.]&quot;</span> Data extraction methods are described. [Yes] 

P11. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary outcome measure was complication rate in relation to colostomy type (loop or split colostomy) and location (transverse colon or sigmoid colon).&quot;</span> Outcomes are defined. [Yes]

P12. [NA]

P13. [NA] 

P14. [NA]

P15. [NA]

P16. [NA]

P17. <span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):

Eight of
these met the inclusion and exclusion criteria (
►Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eight of these met the inclusion and exclusion criteria (Fig. 1).&quot;</span> A flow diagram of study selection is provided. [Yes]

P18. <span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):

Table 3 Systematic review: overview of included studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Table 3. Systematic review: overview of included studies&quot;</span> Characteristics of included studies are presented. [Yes]

P19. [NA]

P20. [NA] 

P21. [NA]

P22. [NA]

P23. [NA]

P24. <span title='Minor quote deviation. Best match in fulltext (Similarity 96.6%):

Conclusions The complication to be avoided in transverse colostomies is prolapse and
the surgical technique should be modified accordingly. The procedure of split sigmoid
colostomy is meticulous, and the risk of insufficient length for the reconstruction remains' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In conclusion, the complication to be avoided in transverse colostomies is prolapse and the surgical technique should be modified accordingly. The procedure of split sigmoid colostomy is meticulous, and the risk of insufficient length for the reconstruction remains.&quot;</span> Main findings are summarized. [Yes]  

P25. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The wide range of complication rates in the systematic review may be because of the inconsistency in defining complications.&quot;</span> Limitations are discussed. [Yes]

P26. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In each case, also in the developed countries, to prevent complications the surgical technique should be geared to the individual patient.&quot;</span> Findings are placed in context. [Yes]

P27. <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 74.1%):

conflict of interest in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Conflict of Interest: None.&quot;</span> Sources of funding are reported. [Yes]
</pre>
<p><a name='160'></a></p>
</div>
<div id="vernon-roberts-2013" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD006151.pub3 ' title='Open publication'>Vernon-Roberts
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[We sought to include randomised controlled trials that recruited children up to the age of 18 years with neurological impairments and GOR who were undergoing gastrostomy tube insertion.]&quot;</span> 
The research question and inclusion criteria were established before conducting the review.
[Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The review authors worked independently to select trials; none were identified.&quot;</span>
There were at least two independent data extractors.
[Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched the following databases on 23 March 2012: the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, EMBASE, CINAHL, LILACS and ISI Web of Science.&quot;</span>
At least two electronic databases were searched along with supplementary strategies like checking references and contacting experts.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No direct mention of including or excluding based on publication status. 
[No]

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Figure 1 shows a study flow diagram including the number of identified reports, duplicates and discarded studies.&quot;</span>
A flow diagram depicting the screening process was provided.
[Yes]

A6. Were the characteristics of the included studies provided?
No studies were included.
[NA]

A7. Was the scientific quality of the included studies assessed and documented?
No studies were included. 
[NA]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
No studies were included.
[NA] 

A9. Were the methods used to combine the findings of studies appropriate?
No quantitative synthesis was performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias was done.
[No]

A11. Was the conflict of interest included? 
Conflicts of interest for the review authors were reported.
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fundoplication versus postoperative medication for gastro-oesophageal reflux in children with neurological impairment undergoing gastrostomy (Review)&quot;</span>
The report is identified as a systematic review.
[Yes]

P2. Provide a structured summary.
A structured abstract with background, objectives, methods, results, authors' conclusions is provided. 
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
The background section describes the rationale and context for the review.
[Yes] 

P4. Provide an explicit statement of questions being addressed. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To compare the effectiveness of antireflux surgery and antireflux medications for children with neurological impairment and GOR who are undergoing placement of a gastrostomy feeding tube.&quot;</span>
The objective clearly states the question being addressed regarding population, interventions, comparisons.
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
No protocol registration information is provided.
[No]

P6. Specify study characteristics used as criteria for eligibility.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We sought to include randomised controlled trials that recruited children up to the age of 18 years with neurological impairments and GOR who were undergoing gastrostomy tube insertion.&quot;</span> 
Study eligibility criteria are described.
[Yes]

P7. Describe information sources and date last searched.
The information sources and dates searched are described.
[Yes]

P8. Present full electronic search strategy for at least one database. 
The search strategies for multiple databases are provided in the appendix.
[Yes]

P9. State the process for selecting studies.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The review authors worked independently to select trials; none were identified.&quot;</span>
The study selection process is described.
[Yes]

P10. Describe method of data extraction from reports.
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Data extraction forms will be designed to include study design, participant characteristics, study
setting, intervention type and outcomes. Data will be extracted independently by two review au-
thors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data extraction forms will be designed to include study design, participant characteristics, study setting, intervention type and outcomes. Data will be extracted independently by two review authors.&quot;</span>
The planned data extraction process is described.
[Yes]

P11. List and define all variables for which data were sought.
The primary and secondary outcomes are listed and defined in the methods section. 
[Yes]

P12. Describe methods used for assessing risk of bias. 
The planned risk of bias assessment using The Cochrane Collaboration's tool is described.
[Yes]

P13. State the principal summary measures.
No summary measures were calculated since no studies were included.
[NA]

P14-P23. Describe data synthesis, assessment of bias, and additional analyses.
No data synthesis, assessment of bias across studies, or additional analyses were performed since no studies were included.
[NA]

P24. Summarize the main findings including the strength of evidence.
The main findings and implications are summarized in the authors' conclusions.
[Yes]

P25. Discuss limitations at study and outcome level.
The lack of evidence and limitations are discussed.
[Yes]

P26. Provide a general interpretation of the results in context of other evidence.
The results are interpreted in the context of the lack of evidence on this topic.
[Yes]

P27. Describe sources of funding and role of funders.
Sources of funding and conflicts of interest are described.
[Yes]
</pre>
<p><a name='161'></a></p>
</div>
<div id="wang-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-013-3335-3' title='Open publication'>Wang
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are the relevant quotes, explanations, and responses for the AMSTAR and PRISMA assessment:

AMSTAR

A1. Was an 'a priori' design provided? 

Quotes:
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span> (Introduction)

Explanation: The review states that inclusion criteria were pre-determined.

[Yes]

A2. Was there duplicate study selection and data extraction?

Quotes:  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The eligibility determination, quality assessment and data extraction for each study were conducted independently by two of the authors (FRW and YHX) and conflicts were resolved by a third author (HJZ).&quot;</span> (Methods)

Explanation: Two authors independently performed study selection and data extraction. 

[Yes]

A3. Was a comprehensive literature search performed?

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The systematic search of the literature was performed using the electronic databases of PubMed (1950–), Embase (1988–) and Cochrane databases.&quot;</span> (Methods)
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.2%):

The searches on Em-
base and Cochrane Library used the same words' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The searches on EmBASE and Cochrane Library used the same words.&quot;</span> (Methods)

Explanation: Searched multiple databases, provided search terms, and supplemented with other methods.

[Yes]

A4. Was the status of publication used as an inclusion criterion?

Quotes: None.

Explanation: Did not report searching for or using grey literature. 

[No]

A5. Was a list of studies (included and excluded) provided?

Quotes:
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.6%):

) fulfilled the predefined inclusion criteria and
were included in the final analysis (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Twelve studies [2, 3, 10–19] fulfilled the predefined inclusion criteria and were included in the final analysis (Fig. 1).&quot;</span> 

Explanation: Provided references for included studies but not excluded.

[No]  

A6. Were the characteristics of the included studies provided?

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The data extraction were displayed in Tables 1 and 2, respectively.&quot;</span> (Results)

Explanation: Provided tables with details on participants, interventions, outcomes.

[Yes]

A7. Was the scientific quality of the included studies assessed and documented?

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

Level of evidence and publication type was
classified according to the Oxford Center for Evidence-
Based Medicine [5' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Level of evidence and publication type was classified according to the Oxford Center for Evidence-Based Medicine [5].&quot;</span> (Methods)

Explanation: Assessed level of evidence but no other quality measures.

[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?

Quotes: None. 

Explanation: Did not consider study quality in analysis or conclusions.

[No]

A9. Were the methods used to combine the findings of studies appropriate?

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Given the significant clinical heterogeneity between studies, the random-effects model was used for all comparisons.&quot;</span> (Methods)

Explanation: Accounted for heterogeneity by using random effects model.

[Yes]

A10. Was the likelihood of publication bias assessed?

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

Possible publication bias was analyzed by generating fun-
nel plots of the studies used for all of the evaluated com-
parisons of outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Possible publication bias was analyzed by generating funnel plots of the studies used for all of the evaluated comparisons of outcomes.&quot;</span> (Results)  

Explanation: Assessed publication bias using funnel plots.

[Yes] 

A11. Was the conflict of interest included?

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Conflict of interest The authors have declared no conflicts of interest.&quot;</span>

Explanation: Stated no conflicts for systematic review but not for individual studies.

[No]

PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review and meta-analysis of studies comparing the perimeatal-based flap and tubularized incised-plate techniques for primary hypospadias repair&quot;</span> (Title)

Explanation: Identified as a systematic review and meta-analysis in title.

[Yes]

P2. Provide a structured summary.

Quotes: 
Provides structured abstract with background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, and conclusions. (Abstract)

Explanation: Structured abstract provided.

[Yes] 

P3. Describe the rationale for the review in the context of what is already known.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A previous systematic review of the postoperative complication rates following distal hypospadias surgery using the PBF and TIP techniques was published online by Wilkinson et al. [4] in December 2010.&quot;</span> (Introduction)

Explanation: Provided context and rationale based on limitations of previous review.

[Yes]

P4. Provide an explicit statement of questions being addressed. 

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

To conduct a systematic review and meta-anal-
ysis of studies comparing the perimeatal-based flap (PBF)
and tubularized incised-plate (TIP) techniques for primary
hypospadias repair and determine whether the two tech-
niques had similar reported outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To conduct a systematic review and meta-analysis of studies comparing the perimeatal-based flap (PBF) and tubularized incised-plate (TIP) techniques for primary hypospadias repair and determine whether the two techniques had similar reported outcomes.&quot;</span> (Abstract)

Explanation: Clear objective stated relating to PICOS and outcomes.

[Yes]

P5. Indicate if a review protocol exists.

Quotes: None.

Explanation: Did not mention a review protocol.

[No]

P6. Specify study characteristics used as criteria for eligibility.

Quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Our inclusion criteria were as follows: primary hypo-
spadias repair only; including both the PBF and TIP
techniques; at least one of the outcomes obtainable from
study; comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our inclusion criteria were as follows: primary hypospadias repair only; including both the PBF and TIP techniques; at least one of the outcomes obtainable from study; comparative studies.&quot;</span> (Methods)

Explanation: Specified inclusion criteria including participants, interventions, outcomes, and study designs. 

[Yes]

P7. Describe information sources and date last searched.

Quotes:
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66%):

The PubMed, Embase and Cochrane databases
were searched using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The PubMed, Embase and Cochrane databases were searched...The last search was in October 2012.&quot;</span> (Methods)

Explanation: Stated databases searched and date of last search.

[Yes] 

P8. Present full electronic search strategy. 

Quotes: 
Provides full search strategies for PubMed, Embase, and Cochrane. (Appendix)

Explanation: Provided search strategies.

[Yes]

P9. State the process for selecting studies.

Quotes: 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.2%):

equently, the query results were pooled. All titles
and abstracts were reviewed initially to select studies for full
review if they contained results of primary hypospadias repair
including both the PBF and TIP techniques' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The eligibility determination...for each study were conducted independently by two of the authors...All titles and abstracts were reviewed initially to select studies for full review if they contained results of primary hypospadias repair including both the PBF and TIP techniques.&quot;</span> (Methods)

Explanation: Described process for screening, eligibility, and inclusion.

[Yes]

P10. Describe method of data extraction.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We extracted data from each study using a predefined data extraction form.&quot;</span> (Methods) 

Explanation: States data extracted using predefined form. Does not mention process details.

[No] 

P11. List and define all variables for which data were sought.

Quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):

The variables assessed included
first author, publication year and type, level of evidence,
patient age and number, length of follow-up, patient
characteristics, surgical techniques and details (coverage
of the neo-urethra, suture material and fashion, urinary
diversion), and postoperative outcomes (fistula, meatal
stenosis, wound dehiscence and cosmesis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The variables assessed included first author, publication year and type, level of evidence, patient age and number, length of follow-up, patient characteristics, surgical techniques and details...and postoperative outcomes (fistula, meatal stenosis, wound dehiscence and cosmesis).&quot;</span> (Methods)

Explanation: Listed variables extracted.

[Yes]

P12. Describe methods for assessing risk of bias. 

Quotes: None.

Explanation: Did not describe risk of bias assessment. 

[No]

P13. State the principal summary measures.

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

The effect measures estimated were odds ratio (OR) for
dichotomous data and weighted mean difference for con-
tinuous data, both reported with 95 % confidence interval
(CI' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The effect measures estimated were odds ratio (OR) for dichotomous data and weighted mean difference for continuous data, both reported with 95% confidence interval (CI).&quot;</span> (Methods)

Explanation: Stated summary measures used. 

[Yes]

P14-P16. Describe methods of synthesis, additional analyses, and risk of bias across studies.

Quotes: N/A

Explanation: No meta-analysis performed.

[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review. 

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

From the 94 citations initially identified, 12 studies [2, 3,
10–19] including 690 cases (338 cases for PBF and 352
cases for TIP) fulfilled the predefined inclusion criteria and
were included in the final analysis (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From the 94 citations initially identified, 12 studies [2, 3, 10–19] fulfilled the predefined inclusion criteria and were included in the final analysis (Fig. 1).&quot;</span> 

Explanation: Provided details and flow diagram on study selection.

[Yes]

P18. For each study, present characteristics for which data were extracted.

Quotes: 
Presents details on participants, interventions, outcomes for each included study in Tables 1 and 2.

Explanation: Provided extracted data for each included study.

[Yes]

P19. Present data on risk of bias of each study.

Quotes: None.

Explanation: Did not provide risk of bias for individual studies.

[No]

P20. For each outcome, present data for each study. 

Quotes: N/A

Explanation: No meta-analysis performed.

[NA] 

P21-P23. Present results of syntheses, risk of bias across studies, and additional analyses.

Quotes: N/A 

Explanation: No meta-analysis performed.

[NA]

P24. Summarize the main findings.

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎It showed that both the two techniques were effective for primary hypospadias repair, with low rates of postoperative complications. We found that there were no significant differences of the complication rates (fistula, P = 0.20; meatal stenosis, P = 0.11; wound dehiscence, P = 0.76), and the TIP technique was usually of better cosmesis.&quot;</span> (Discussion)

Explanation: Summarized main findings.

[Yes]

P25. Discuss limitations at study and outcome level.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our study has several limitations. First, some critical data were rarely documented as described above, so we could not fully adjust the confounding factors.&quot;</span> (Discussion)

Explanation: Discussed limitations related to study details and confounding.

[Yes]

P26. Provide a general interpretation of results in context of other evidence.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fortunately, this study still provided us with some valuable information. First, the level of evidence on which our review was based was relatively high, although our conclusion was not significantly different from that reached earlier [4].&quot;</span> (Discussion)

Explanation: Interpreted findings in context of previous review.

[Yes]

P27. Describe sources of funding and role of funders.

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Conflict of interest The authors have declared no conflicts of interest.&quot;</span>

Explanation: Stated no conflicts but did not describe sources of funding. 

[No]
</pre>
<p><a name='162'></a></p>
</div>
<div id="wayne-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3676-1' title='Open publication'>Wayne
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL from inception to September 2014.&quot;</span>
The review had predefined inclusion criteria.

A2. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Two reviewers independently assessed each included
study and compared the scores for each item on the ap-
plicable quality assessment tool to reach a consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two reviewers independently assessed each included study and compared the scores for each item on the applicable quality assessment tool to reach a consensus.&quot;</span> 
There was duplicate study selection and data extraction.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL from inception to September 2014.&quot;</span>
At least two electronic databases were searched.

A4. [No]
No mention of including or excluding grey literature.

A5. [Yes]
Figure 1 shows the number of studies included and excluded at each stage. 

A6. [Yes] 
Table 1 summarizes the characteristics of included studies.

A7. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 81.6%):

and quality assessed each
relevant study using AMSTAR for systematic reviews
(SRs), Cochrane ‘Risk of bias’ tool for randomized con-
trolled trials (RCTs), and MINORS for non-randomized
studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We used AMSTAR to assess the quality of all relevant systematic reviews, Cochrane ‘Risk of bias’ tool for randomized controlled trials, and MINORS for non-randomized studies.&quot;</span> Quality was assessed.

A8. [Yes]  
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.8%):

. To miti-
gate the potential bias related to the inclusion of non-ran-
domized studies, we took into consideration each study’s
quality assessment results when drawing conclusions and
making recommendations' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Due to the heterogeneity of the data, a meta-analysis was not possible." And "To mitigate the potential bias related to the inclusion of non-randomized studies, we took into consideration each study’s quality assessment results when drawing conclusions and making recommendations.&quot;</span> Quality was considered in analysis.

A9. [NA] 
No meta-analysis was performed.

A10. [No] 
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted a broad-scope systematic review investigating the ideal surgical management of IAT.&quot;</span> Identified as a systematic review. 

P2. [Yes]
The abstract provides a structured summary.

P3. [Yes]  
The introduction describes the rationale.

P4. [Yes]
The introduction states the aim to determine the ideal surgical approach for IAT.

P5. [No] 
No protocol mentioned.

P6. [Yes]
The methods section describes eligibility criteria. 

P7. [Yes]
The methods describe literature sources searched.

P8. [No]
The full search strategy is not provided.

P9. [Yes]  
The screening process is described and Figure 1 shows a flow diagram.

P10. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

One reviewer extracted data from each of the included
studies, and a second reviewer checked the data for accu-
racy and completeness' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One reviewer extracted data from each of the included studies, and a second reviewer checked the data for accuracy and completeness.&quot;</span> 

P11. [Yes] 
Outcomes of interest are described in the methods.

P12. [Yes]  
Quality assessment tools used are described. 

P13. [NA] 
No meta-analysis performed.

P14. [NA]
No meta-analysis performed. 

P15. [NA]
No meta-analysis performed.

P16. [NA]  
No additional analyses mentioned.

P17. [Yes]
Figure 1 shows the flow diagram of screened studies.

P18. [Yes]
Table 1 presents study characteristics.

P19. [Yes]  
Table 1 includes quality assessment scores.

P20. [NA] 
No quantitative synthesis performed.

P21. [NA]
No meta-analysis performed.

P22. [NA]
No assessment of bias across studies.

P23. [NA]
No additional analyses mentioned.

P24. [Yes] 
The discussion summarizes main findings.

P25. [Yes]
Limitations are discussed.

P26. [Yes]
Conclusions and implications are discussed.

P27. [No] 
No mention of sources of funding.
</pre>
<p><a name='163'></a></p>
</div>
<div id="weih-2012" class="section level4">
<h4><a href='https://doi.org/10.1007/S00423-011-0874-8' title='Open publication'>Weih
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [NA]

A2. Was there duplicate study selection and data extraction? [No]
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes] 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.1%):

methods
An analysis of Medline-published therapeutic options in the
treatment of SBS was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A Medline-analysis of published therapeutic options in the treatment of SBS was performed.&quot;</span>
At least 2 sources searched. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? [No]
No table with characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented? [No] 
No mention of quality assessment of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed. 

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):

A systemic review of Medline-cited studies
dealing with current practice and future perspectives in
the treatment of short bowel in children was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic review of Medline-cited studies dealing with current practice and future perspectives in the treatment of short bowel in children was performed.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
No structured summary provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The medical treatment and care of children with SBS remains challenging and requires a very individual therapeutic strategy.&quot;</span> 

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]  
No PICOS provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [No]
No eligibility criteria described.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [No] 
Only mentions Medline, no dates provided.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
No search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No]  
No selection process described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No data extraction methods described. 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
No list of data sought.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]
No quantitative synthesis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA] 
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses described.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
No flow diagram, number screened, assessed, or reasons for exclusions given.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [No] 
No table with study characteristics. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA] 
No risk of bias assessment.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [NA]
No quantitative synthesis performed.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis performed.  

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses mentioned.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]
No summary of main findings or strength of evidence.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]  
No limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [No]
No interpretation of results or implications for future research provided.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No sources of funding described.
</pre>
<p><a name='164'></a></p>
</div>
<div id="wenk-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.056' title='Open publication'>Wenk
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my AMSTAR and PRISMA assessments for the attached systematic review:

A1. [Yes] 

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Six studies met the inclusion criteria [7,28–32].&quot;</span> (p.2152)  

The research question and inclusion criteria were pre-determined before conducting the review.

A2. [Yes]

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data from selected studies were extracted by two authors (RNV and KW).&quot;</span> (p.2148)

Two authors independently performed study selection and data extraction. 

A3. [Yes] 

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

The Cochrane Central Register of Controlled Trials (The Cochrane li-
brary Issue 7 of 12, July 2014), MEDLINE (January 1966 to August 2014)
and EMBASE (1947 to August 2014) were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Cochrane Central Register of Controlled Trials (The Cochrane library Issue 7 of 12, July 2014), MEDLINE (January 1966 to August 2014) and EMBASE (1947 to August 2014) were searched.&quot;</span> (p.2148)

Multiple databases were searched along with supplementary search strategies.

A4. [No]

The status of publication was not mentioned as an inclusion criterion.

A5. [No]

A list of included and excluded studies was not provided. 

A6. [Yes] 

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

In total 1669 children were
included. Of this number 1405 (84%) were male and 264 (16%) were fe-
male. Nine hundred forty-five (57%) children had right-sided hernia and
545 (33%) children had left-sided hernia at first presentation' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total 1669 children were included. Of this number 1405 (84%) were male and 264 (16%) were female. Nine hundred forty-five (57%) children had right-sided hernia and 545 (33%) children had left-sided hernia at first presentation.&quot;</span> (p.2148)

Participant characteristics were provided in aggregate form.

A7. [No]

The quality of included studies was not assessed.

A8. [NA]

Scientific quality was not assessed.

A9. [Yes]

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We examined heterogeneity between studies with standard chi-square tests and calculated the I-square statistics.&quot;</span> (p.2148)  

Appropriate methods were used to assess heterogeneity and decide on use of fixed vs random effects models.

A10. [No] 

Publication bias was not assessed.

A11. [No]

Conflicts of interest were not reported for the included studies.

P1. [Yes]

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Incidence of metachronous contralateral inguinal hernias in children following unilateral repair — A meta-analysis of prospective studies&quot;</span> (Title)

The report is identified as a meta-analysis.

P2. [Yes] 

A structured abstract with all key information is provided.

P3. [Yes]

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To the authors’ knowledge there are few meta-analyses published reviewing the incidence of MCIH [4–6,9–12], with overall MCIH incidences being 5.8% [6], 7.0% [12], 7.0% [5], 7.2% [4], 7.4% [9], 10.1% [10] and 15.8% [11].&quot;</span> (p.2148)

The rationale is described in the context of previous research.

P4. [Yes]

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

The primary outcome was the overall incidence of MCIH in children
with unilateral inguinal hernia (i). Secondary outcomes consisted of in-
cidence of MCIH in male versus female children (ii); in children younger
than 1 year of age versus older children (iii); in children with primarily
right- versus primarily left-sided inguinal hernia (iv); and in children
with open versus cleft versus closed CPPV (v' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome was the overall incidence of MCIH in children with unilateral inguinal hernia (i). Secondary outcomes consisted of incidence of MCIH in male versus female children (ii); in children younger than 1 year of age versus older children (iii); in children with primarily right- versus primarily left-sided inguinal hernia (iv); and in children with open versus cleft versus closed CPPV (v).&quot;</span> (p.2148) 

The review questions and outcomes are clearly specified.

P5. [No] 

A protocol was not mentioned.

P6. [Yes]

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Inclusion criteria consisted of prospective observational studies (a),
with minimal follow-up time of one year (b), assessing newborns, infants,
children, adolescents and young adults, aged from 0 to 19 years (c), with-
out contralateral groin exploration or laparoscopic closure of CPPV (d' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria consisted of prospective observational studies (a), with minimal follow-up time of one year (b), assessing newborns, infants, children, adolescents and young adults, aged from 0 to 19 years (c), without contralateral groin exploration or laparoscopic closure of CPPV (d).&quot;</span> (p.2148)

Eligibility criteria are described.

P7. [Yes]

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

The initial MEDLINE search yielded 2747 references. Search of
CENTRAL and EMBASE database returned 304 and 3443 references re-
spectively, none in addition to prior search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The initial MEDLINE search yielded 2747 references. Search of CENTRAL and EMBASE database returned 304 and 3443 references respectively, none in addition to prior search.&quot;</span> (p.2148)

Information sources and dates searched are provided. 

P8. [Yes]

The full search strategy for MEDLINE is provided.

P9. [Yes] 

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Six studies met the inclusion criteria [7,28–32].&quot;</span> (p.2152)

The study selection process is described.

P10. [Yes]

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data from selected studies were extracted by two authors (RNV and KW).&quot;</span> (p.2148)

Data extraction by two authors is described.

P11. [Yes]

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

The primary outcome was the overall incidence of MCIH in children
with unilateral inguinal hernia (i). Secondary outcomes consisted of in-
cidence of MCIH in male versus female children (ii); in children younger
than 1 year of age versus older children (iii); in children with primarily
right- versus primarily left-sided inguinal hernia (iv); and in children
with open versus cleft versus closed CPPV (v' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome was the overall incidence of MCIH in children with unilateral inguinal hernia (i). Secondary outcomes consisted of incidence of MCIH in male versus female children (ii); in children younger than 1 year of age versus older children (iii); in children with primarily right- versus primarily left-sided inguinal hernia (iv); and in children with open versus cleft versus closed CPPV (v).&quot;</span> (p.2148)

Outcomes of interest are pre-defined.

P12. [No]

Individual study bias was not assessed.

P13. [Yes] 

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Overall MCIH was 6%.&quot;</span> (p.2149)

Summary measures are described.

P14. [NA]

Not applicable since no meta-analysis was performed.

P15. [NA] 

Not applicable since no meta-analysis was performed.

P16. [NA]

Not applicable since no meta-analysis was performed. 

P17. [No]

The number of studies screened and excluded was not provided.

P18. [Yes]

Characteristics of the included studies are presented in Table 1. 

P19. [No]

Individual study bias was not presented.

P20. [Yes] 

Relevant quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A forest plot was used to summarize and visualize the results of the meta analysis (Fig. 1).&quot;</span> (p.2149)

Summary data and effect estimates are presented for each study.

P21. [NA] 

Not applicable since no meta-analysis was performed.

P22. [NA]

Not applicable since no meta-analysis was performed.

P23. [NA]

Not applicable since no meta-analysis was performed.

P24. [Yes]

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 95.9%):

The present meta-anlaysis shows that the overall risk of MCIH in
children (aged 0–19 years) is 6' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The present meta-analysis shows that the overall risk of MCIH in children (aged 0–19 years) is 6%.&quot;</span> (p.2154) 

Main findings are summarized.

P25. [No]

Limitations were not discussed.

P26. [Yes] 

Relevant quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

Routine contralateral groin exploration prevents a secondary opera-
tion and hence reduces costs, the risks of a secondary anesthesia, dis-
tress to child and parents and the possibility of metachronous
contralateral hernia incarceration. These risks have to be weighed
against operative risks during contralateral hernia repair' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Routine contralateral groin exploration prevents a secondary operation and hence reduces costs, the risks of a secondary anesthesia, distress to child and parents and the possibility of metachronous contralateral hernia incarceration. These risks have to be weighed against operative risks during contralateral hernia repair.&quot;</span> (p.2154)

Implications for practice are discussed.

P27. [No]

Sources of funding were not reported.

In summary, the systematic review was reasonably well conducted but had some deficiencies in reporting based on AMSTAR and PRISMA items. Key limitations were lack of assessment for study bias/quality and not reporting excluded studies or funding sources.
</pre>
<p><a name='165'></a></p>
</div>
<div id="wilkinson-2012" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2010.11.008' title='Open publication'>Wilkinson
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here are my AMSTAR and PRISMA assessments for the attached systematic review:

A1: [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

The Medline (1990eDec 2009), Embase (1990eDec 2009) and
Cochrane databases were searched using the single search
term ‘hypospadias’ to ensure the broadest capture of rele-
vant papers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term ‘hypospadias’ to ensure the broadest capture of relevant papers.&quot;</span>
A comprehensive literature search was performed.

A2: [Unclear <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span>] 
The review does not state whether study selection and data extraction were performed in duplicate.

A3: [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

The Medline (1990eDec 2009), Embase (1990eDec 2009) and
Cochrane databases were searched using the single search
term ‘hypospadias’ to ensure the broadest capture of rele-
vant papers. There were no other limits applied to the
search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term ‘hypospadias’ to ensure the broadest capture of relevant papers. There were no other limits applied to the search.&quot;</span>
At least two electronic databases were searched without limits. 

A4: [No]
The review does not state whether unpublished literature was searched.

A5: [No]  
A list of included and excluded studies was not provided.

A6: [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All results were tabulated and statistical analysis applied using Fisher’s exact test (Statistical Package for Social Sciences v14 .0, SPSS Inc, Chicago, IL, USA).&quot;</span>
Characteristics of included studies were provided in tables.

A7: [No] 
The scientific quality of included studies was not assessed.

A8: [NA]
Scientific quality was not assessed so this item is not applicable.

A9: [NA]  
Studies were not combined in a meta-analysis so this item is not applicable.

A10: [No]
Publication bias was not assessed.

A11: [No]
Conflicts of interest were not reported.

P1: [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Review of Mathieu and TIP repair outcomes&quot;</span>
The report is identified as a systematic review.

P2: [Yes] 
The abstract provides a structured summary.

P3: [Yes]
The introduction describes the rationale for the review.

P4: [Yes]  
The objective specifies the participants, interventions, and outcomes. 

P5: [No]
A protocol was not referenced.

P6: [Yes]
Eligibility criteria are described in the methods.

P7: [Yes] 
Information sources including databases and dates searched are described.

P8: [No]
The full search strategy is not provided.

P9: [Yes]  
The process of study selection is described.

P10: [Unclear <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span>]
Data extraction methods are not described. 

P11: [Yes]
Outcomes extracted are listed.

P12: [No] 
Risk of bias assessment is not described.

P13: [NA] 
Summary measures are not applicable as no meta-analysis was done.

P14: [NA]
Quantitative synthesis methods are not applicable.

P15: [NA]  
Assessment of bias across studies is not applicable.

P16: [NA] 
No additional analyses were done.

P17: [No]
A flow diagram of study selection is not provided.

P18: [Yes] 
Included studies are presented in tables.

P19: [NA]
Individual study risk of bias is not applicable.

P20: [Yes]  
Results for each study are presented in tables.

P21: [NA] 
Meta-analysis results are not applicable. 

P22: [NA]
Bias across studies is not applicable.

P23: [NA] 
No additional analyses were done.

P24: [Yes] 
Main findings are summarized.

P25: [Yes]
Limitations are discussed.

P26: [Yes] 
Results are interpreted in the context of other evidence.

P27: [No] 
Sources of funding are not reported.1
</pre>
<p><a name='166'></a></p>
</div>
<div id="wright-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JURO.2013.02.3234' title='Open publication'>Wright
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here is my assessment of the systematic review using AMSTAR and PRISMA 2009:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

We conducted a comprehensive search of MEDLINE
® 
,
Embase, CINAHL, SciELO, CENTRAL, Cochrane Data-
base of Systematic Reviews and reference lists of promi-
nent studies from 1990 to 2010' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a comprehensive search of MEDLINE®, Embase, CINAHL, SciELO, CENTRAL, Cochrane Database of Systematic Reviews and reference lists of prominent studies from 1990 to 2010.&quot;</span> [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Title and abstract screening was conducted independently by 2 authors to select all citations that might contain comparisons of interest. Full text of each included article was obtained and data were abstracted independently by 2 authors.&quot;</span> [Yes]

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

We conducted a comprehensive search of MEDLINE
® 
,
Embase, CINAHL, SciELO, CENTRAL, Cochrane Data-
base of Systematic Reviews and reference lists of promi-
nent studies from 1990 to 2010' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a comprehensive search of MEDLINE®, Embase, CINAHL, SciELO, CENTRAL, Cochrane Database of Systematic Reviews and reference lists of prominent studies from 1990 to 2010.&quot;</span> [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
No mention of including or excluding based on publication status. [No]

A5. Was a list of studies (included and excluded) provided?
Table 1 provides characteristics of included studies. The full text mentions 17 studies were excluded after full text review, but does not provide a list. [No]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies such as number of patients receiving PHS, surgical technique, age, follow-up duration. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Critical appraisal of the included studies was carried out by 2 independent reviewers using a quality assessment instrument adopted from Elyas et al.&quot;</span> Results provided in Appendix 1. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The discussion mentions the included studies were mostly retrospective observational studies of low to moderate quality. [Yes]  

A9. Were the methods used to combine the findings of studies appropriate?
Four studies were pooled in a meta-analysis using a random effects model. No test for heterogeneity mentioned. [No]

A10. Was the likelihood of publication bias assessed?
Funnel plot asymmetry mentioned in results, suggesting potential publication bias. No statistical test performed. [Yes]

A11. Was the conflict of interest included? 
No mention of conflicts of interest or study funding sources. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Title identifies as systematic review and meta-analysis. [Yes]

P2. Provide a structured summary including applicable items.
Structured abstract provided with background, objectives, data sources, eligibility criteria, interventions, study appraisal, results, conclusions. [Yes]

P3. Describe the rationale for the review in the context of what is already known.
Introduction provides background and rationale. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to PICOS. 
Objectives provided in introduction, including participants, interventions, outcomes. [Yes]

P5. Indicate if a review protocol exists and if available.
No mention of a protocol. [No] 

P6. Specify study characteristics used as criteria for eligibility.
Eligibility criteria provided in methods. [Yes]

P7. Describe all information sources in the search and date last searched.
Databases and dates provided. [Yes]

P8. Present full electronic search strategy for at least one database. 
Search strategy not provided. [No]

P9. State the process for selecting studies.
Described in methods. [Yes] 

P10. Describe method of data extraction and confirmation.
Described in methods. [Yes]

P11. List and define all variables for which data were sought.
Outcomes described in methods. Table 1 provides details on interventions and study characteristics extracted. [Yes]   

P12. Describe methods for assessing risk of bias and how this information is to be used.
Quality assessment process described. Results presented in Appendix 1. Limitations of included studies discussed. [Yes]

P13. State the principal summary measures.
Primarily complication rates, also OR for meta-analysis. [Yes]

P14. Describe the methods of handling and combining data. 
Random effects meta-analysis described. No mention of heterogeneity assessment. [No] 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence.
Funnel plot asymmetry assessed suggesting publication bias. [Yes]

P16. Describe methods of additional analyses, if done, indicating pre-specified analyses.
No additional analyses. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included with reasons for exclusions. 
Numbers provided, but no reasons for exclusions. [No]

P18. For each study, present characteristics for which data were extracted.
Table 1 provides extracted characteristics. [Yes]

P19. Present data on risk of bias of each study.
Quality assessment results in Appendix 1. [Yes]

P20. For each outcome, present data for each intervention group.
Table 2 provides complication rates by intervention group. [Yes] 

P21. Present results of each meta-analysis done, including measures of consistency. 
Figure 3 shows forest plot without measures of consistency. [No]

P22. Present results of any assessment of risk of bias across studies.
Funnel plot assessed, suggesting publication bias. [Yes]

P23. Give results of additional analyses, if done.
No additional analyses. [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
Discussion summarizes the main findings and limitations. [Yes]

P25. Discuss limitations at study and outcome level and at review level.
Limitations discussed. [Yes]

P26. Provide a general interpretation of the results in the context of other evidence.
Results interpreted in context of other evidence in discussion. [Yes]

P27. Describe sources of funding for the systematic review. 
No mention of sources of funding. [No]

In summary, this systematic review meets most of the AMSTAR and PRISMA criteria, with some room for improvement in reporting the search strategy, assessing heterogeneity, reporting exclusion reasons, and declaring conflicts of interest. The major limitations are the lack of a published protocol, limited assessment of heterogeneity in the meta-analysis, and not reporting the sources of funding and support.
</pre>
<p><a name='167'></a></p>
</div>
<div id="yang-2011" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2011.04.001' title='Open publication'>Yang
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Published studies until July 30, 2010, were searched&quot;</span>
The review had pre-determined inclusion criteria.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The citations, abstracts, or full text of all potentially relevant studies were independently evaluated and selected by 3 reviewers&quot;</span>
Study selection and data extraction were done in duplicate.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

All published studies until July 30, 2010, were
searched with the terms laparoscopy, laparoscopic her-
niorrhaphy, pediatric inguinal hernia, and open hernior-
rhaphy from Medline (using PubMed as the search
engine), Embase, Ovid, Web of Science, and Cochrane
databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All published studies until July 30, 2010, were searched with the terms laparoscopy, laparoscopic herniorrhaphy, pediatric inguinal hernia, and open herniorrhaphy from Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases&quot;</span>
At least 2 databases were searched. 

A4. Was the status of publication used as an inclusion criterion? [No] 
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No quality assessment mentioned. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Statistical heterogeneity was
assessed using the I
2 
statistics. If the I
2 
value was less than
50%, then a fixed effects meta-analysis was applied; if the I
2
value was 50% or more, then the random effects meta-
analysis was used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Statistical heterogeneity was assessed using the I2 statistics. If the I2 value was less than 50%, then a fixed effects meta-analysis was applied; if the I2 value was 50% or more, then the random effects meta-analysis was used.&quot;</span>

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

in this systemic review and meta-
analysis, we demonstrated that LH is efficient for the
inguinal hernia repair in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In this systemic review and meta-analysis, we demonstrated that LH is efficient for the inguinal hernia repair in children&quot;</span>

P2. Provide a structured summary. [Yes] 
The abstract provides a structured summary.

P3. Describe the rationale for the review. [Yes]
Rationale described in the Introduction.

P4. Provide an explicit statement of questions being addressed. [No] 
No explicit statement of review questions.

P5. Indicate if a review protocol exists. [No]
No mention of a protocol.

P6. Specify study characteristics used as criteria for eligibility. [Yes]
Study eligibility criteria described in Methods. 

P7. Describe information sources. [Yes] 
Information sources described in Methods.

P8. Present full electronic search strategy. [No]
Search strategy not provided.

P9. State the process for selecting studies. [Yes]  
Study selection process described in Methods and Figure 1.

P10. Describe method of data extraction. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Three reviewers (YCL, ZHY, and TQS) independently
assessed selected studies, extracted, and tabulated data from
each article with a predefined data extraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three reviewers independently assessed selected studies, extracted, and tabulated data from each article with a predefined data extraction form.&quot;</span>

P11. List and define all variables for which data were sought. [Yes]
Outcomes described in Methods.

P12. Describe methods for assessing risk of bias. [No]
No risk of bias assessment described.

P13. State the principal summary measures. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Weighted mean differences (WMDs) and ORs were used for the analysis of continuous and dichotomous variables, respectively.&quot;</span>

P14-P16. Describe methods of synthesis/analysis. [Yes]
Meta-analysis methods described. 

P17. Give numbers of studies at each stage. [Yes] 
Number of studies described in Results and Figure 1.

P18. Present study characteristics. [Yes]
Study characteristics presented in Tables 1-3.

P19. Present risk of bias assessments. [NA] 
No risk of bias assessment.

P20. Present summary data and effect estimates for each study. [Yes]
Summary data and effect estimates presented in forest plots.

P21. Present results of meta-analyses. [Yes] 
Results of meta-analyses presented.

P22. Present assessment of risk of bias across studies. [NA]
No assessment of risk of bias across studies.

P23. Give results of additional analyses. [NA] 
No additional analyses.

P24. Summarize the main findings. [Yes] 
Main findings summarized in Discussion.

P25. Discuss limitations. [Yes]
Limitations discussed in Discussion. 

P26. Provide general interpretation of results. [Yes]
Results interpreted in Discussion.

P27. Describe sources of funding. [Yes]
Funding sources described in Acknowledgments.
</pre>
<p><a name='168'></a></p>
</div>
<div id="yang-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-013-3345-1' title='Open publication'>Yang
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
 Here are my assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. Was an 'a priori' design provided? [No]
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.7%):

MEDLINE electronic
database was searched in April 2013 using key words
‘‘postoperative intussusception' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MEDLINE database was searched in April 2013 using key words “postoperative intussusception”.&quot;</span>
No mention of a predefined protocol.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):

MEDLINE electronic
database was searched in April 2013 using key words
‘‘postoperative intussusception’’. References lists of iden-
tified articles were screened for additional publications of
interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MEDLINE electronic database was searched in April 2013 using key words “postoperative intussusception”. References lists of identified articles were screened for additional publications of interest.&quot;</span>
Searched MEDLINE and screened reference lists.

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included/excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides detailed characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented? [No]  
No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed. 

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No conflict of interest statement.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To review the clinical features of POI, we performed this study based on the systematic review of the published literature.&quot;</span>

P2. Provide a structured summary. [No]
No structured abstract provided.

P3. Describe the rationale for the review. [Yes] 
Rationale described in the introduction.

P4. Provide an explicit statement of questions being addressed. [No]
No explicit review questions stated.

P5. Indicate if a review protocol exists. [No] 
No mention of a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
Inclusion criteria described in methods. 

P7. Describe all information sources in the search and date last searched. [Yes]
Search of MEDLINE described including date.

P8. Present full electronic search strategy for at least one database. [No]  
Search strategy not provided.

P9. State the process for selecting studies. [Yes] 
Study selection process described and depicted in Figure 1.

P10. Describe method of data extraction. [No]  
No details provided on data extraction.

P11. List and define all variables for which data were sought. [No]
No list of data extraction variables provided.

P12-P23. [NA]
Not applicable - no meta-analysis performed.

P24. Summarize the main findings including the strength of evidence for each main outcome. [No]
Main findings summarized but no mention of strength of evidence.

P25. Discuss limitations at study and outcome level and at review-level. [No]
No discussion of limitations. 

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results interpreted in the discussion.

P27. Describe sources of funding for the systematic review. [No] 
No statement on sources of funding.
</pre>
<p><a name='169'></a></p>
</div>
<div id="youssef-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2016.02.010' title='Open publication'>Youssef
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments for the AMSTAR and PRISMA items based on the provided full text:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The protocol of this review was prospectively published in the PROSPERO registry (CRD42015016745)&quot;</span>
The protocol was registered before conducting the review.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All of the resulting titles were twice inspected independently&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Full texts of all titles that were deemed relevant by either reviewer (where possible) were then retrieved.&quot;</span>
Study selection was done independently by two reviewers. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎systematically identified by searching the following sources: AMED, PubMed, MEDLINE, Cochrane, EMBASE, Africa-wide information, Biosys, Global Health, LLAOS, and Web of Science in November 2014 with no date or language restrictions.&quot;</span>
At least two databases were searched along with supplementary sources.

A4. Was the status of publication used as an inclusion criterion? [No] 
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
The Newcastle-Ottawa scale was used to assess quality of included studies. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Given potential advantages of bedside closure and reduced sedation requirements, flap closure may represent the preferred closure strategy.&quot;</span>
Quality issues were considered in the conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [NA]
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [Yes] 
Funnel plot was used to assess publication bias.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Flap versus fascial closure for gastroschisis: a systematic review and meta-analysis&quot;</span>

P2. Provide a structured summary. [Yes]
Structured abstract provided with background, objectives, data sources, eligibility criteria, outcomes, results, and conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
Introduction describes rationale and what is already known.

P4. Provide an explicit statement of questions being addressed. [Yes]  
Objective clearly stated: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎to compare the short-term outcomes of flap closure and fascial closure through a formal systematic literature review and meta-analysis.&quot;</span> 

P5. Indicate if a review protocol exists. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The protocol of this review was prospectively published in the PROSPERO registry (CRD42015016745)&quot;</span>

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]  
Inclusion and exclusion criteria detailed in Methods.

P7. Describe all information sources in the search. [Yes]
Information sources described in Methods. 

P8. Present full electronic search strategy for at least one database. [Yes] 
Full search strategy for PubMed included in Appendix A.

P9. State the process for selecting studies. [Yes]  
Process described in Methods and illustrated in PRISMA flow chart.

P10. Describe method of data extraction. [No] 
No details provided on data extraction process.

P11. List and define all variables for which data were sought. [Yes] 
Outcomes extracted clearly defined in Methods. 

P12. Describe methods used for assessing risk of bias of individual studies. [Yes]
Newcastle-Ottawa scale used to assess quality/risk of bias.

P13. State the principal summary measures. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Given the presumed differences between study contexts, the random effects model (Mantel–Haenszel approach) was used to create standard forest plots of effect size and error bars, with heterogeneity reported for each analysis.&quot;</span>

P14. Describe the methods of handling data and combining results of studies. [NA]
No quantitative synthesis performed. 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence. [NA]  
No quantitative synthesis performed.

P16. Describe methods of additional analyses. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions. [Yes]  
PRISMA flow diagram provided.

P18. For each study, present characteristics for which data were extracted. [Yes] 
Table 1 presents key characteristics of included studies.

P19. Present data on risk of bias of each study. [Yes] 
Table 2 presents quality assessment with Newcastle-Ottawa scale.

P20. For all outcomes considered, present data for each study. [Yes]  
Forest plots present data from each study.

P21. Present results of each meta-analysis done. [NA]  
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies. [NA]
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done. [NA]
No additional analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes] 
Main findings summarized in Results and Discussion.

P25. Discuss limitations at study and outcome level and at review-level. [Yes] 
Limitations discussed in Discussion.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results discussed in context of other evidence in Discussion.

P27. Describe sources of funding for the systematic review. [No] 
No statement about sources of funding.
</pre>
<p><a name='171'></a></p>
</div>
<div id="zhao-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3680-5' title='Open publication'>Zhao
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
 Here is my assessment of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
The review does not mention an a priori protocol.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently extracted data from the list of the included studies, and a third reviewer was required for a final decision in the case of any discrepancies.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span> 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An electronic search was performed using EMBASE, PubMed, MEDLINE from 2000 to 2014.&quot;</span>

A4. Was the status of publication used as an inclusion criterion? [No] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
The review does not mention searching for unpublished studies or grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
No list of excluded studies is provided.

A6. Were the characteristics of the included studies provided? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
Table 1 provides characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎‘A priori’ methods of assessment should be provided.&quot;</span>
The review does not mention assessing quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Quality assessment was not performed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]  
<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):

For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎For the pooled results, a test should be done to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>
Heterogeneity was assessed using I2. 

A10. Was the likelihood of publication bias assessed? [No]
<span title='Minor quote deviation. Best match in prompt (Similarity 99.1%):

An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An assessment of publication bias should include a combination of graphical aids and/or statistical tests.&quot;</span>
Publication bias was not assessed.

A11. Was the conflict of interest included? [No]  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
Sources of funding are not reported.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Single-incision versus conventional laparoscopic appendicectomy in children: a systematic review and meta-analysis&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
No structured summary is provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
The introduction describes the rationale for comparing SILA to CLA.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
The review does not explicitly state the PICOS criteria.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
A protocol is not mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Inclusion/exclusion criteria are described but not organized by PICOS.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Databases and date ranges searched are reported.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No] 
The search strategy is not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No]
The study selection process is not described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] 
Data extraction was done in duplicate but no other details provided. 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Data items sought are not defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
Risk of bias assessment is not described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Mean differences and odds ratios were used.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]  
Methods are described including assessment of heterogeneity using I2.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No]
Risk of bias assessment across studies is not described. 

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [Yes]
A sensitivity analysis is described.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
A flow diagram of study selection is not provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 provides relevant characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No] 
Risk of bias is not presented for individual studies.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes] 
Outcome data and forest plots are presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes]
Results of each meta-analysis are presented with CIs and I2 values.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
Risk of bias assessment was not done.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [Yes]
The sensitivity analysis is presented.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]  
The discussion summarizes the main findings.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Limitations of included studies are discussed but review level limitations are not.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results are interpreted and implications described. 

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
Sources of funding are not reported.
</pre>
<p><a name='172'></a></p>
</div>
<div id="zhu-2016" class="section level4">
<h4><a href='https://doi.org/10.1007/S10029-015-1423-0' title='Open publication'>Zhu
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM 2nd run
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’, ‘unsolicited-ranges’</i>
<pre>
 Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
The research question and inclusion criteria are clearly stated in the Methods section. 

A2. Was there duplicate study selection and data extraction? [No] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
The authors did not report duplicate study selection and data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span> 
The authors searched PubMed, Embase, and Cochrane databases.

A4. Was the status of publication used as an inclusion criterion? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
The authors did not state whether they included or excluded studies based on publication status. 

A5. Was a list of studies (included and excluded) provided? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
No list of excluded studies was provided.

A6. Were the characteristics of the included studies provided? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
Table 1 provides aggregated characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented? [No] 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎‘A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria).&quot;</span>
The authors did not assess the quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.&quot;</span>
The quality of included studies was not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>  
The authors used appropriate fixed and random effects models based on heterogeneity assessments.

A10. Was the likelihood of publication bias assessed? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span>
Publication bias was not assessed.

A11. Was the conflict of interest included? [No]
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
No statement on conflicts of interest was provided.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Objectives To compare the safety and efficacy of mini-
mally invasive surgery (MIS) with traditional open surgical
approach for congenital diaphragmatic hernia (CDH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Objectives To compare the safety and efficacy of minimally invasive surgery (MIS) with traditional open surgical approach for congenital diaphragmatic hernia (CDH).&quot;</span>
The report is identified as a meta-analysis in the Objectives.

P2. Provide a structured summary. [Yes] 
A structured abstract is provided with sections on Objectives, Methods, Results, and Conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
The Introduction section provides background and rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes]
The Objectives statement provides the PICOS criteria. 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol registration was mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Study selection criteria including PICOS and years considered are described in the Methods section. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Details of literature search including databases and date ranges are provided in Methods.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
The search strategy was not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
The study selection process is depicted in a flow diagram and described in the Methods.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No] 
The data extraction process was not described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes]
Outcomes extracted are listed in the Methods. No funding sources were reported.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
Risk of bias assessment was not described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Risk ratios are stated as the principal summary measures.

P14-P16. Describe methods of handling and combining data. [NA]
Items related to quantitative synthesis are not applicable as no meta-analysis was performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
A flow diagram depicts the screening process with reasons for exclusions. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] 
Table 1 presents relevant characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]
Risk of bias was not assessed.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Forest plots with risk ratios and confidence intervals are presented for relevant outcomes.

P21-P23. Present results of each meta-analysis done. [NA] 
Items related to results of quantitative syntheses are not applicable as no meta-analysis was performed. 

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
The Conclusions section summarizes the main findings and their relevance.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Limitations of included studies are discussed in the Discussion section, but review-level limitations are not mentioned.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes] 
The results are interpreted in the context of previous evidence, and suggestions for future research are provided in the Discussion.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No sources of funding or support were reported.
</pre>
</div>
</div>
<div id="quote-accuracy" class="section level3">
<h3>Quote accuracy</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<ul>
<li>851 quotes for 109 / 111 (98.2%) publications, median 5 (IQR 3-10,
range 1-39)</li>
<li>352 / 851 (41.4%) perfect <span
style="border-bottom: 1px dashed black;">quotes from the publication
fulltext</span></li>
<li>110 / 851 (12.9%) perfect <span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">quotes from
the LLM prompt briefing</span></li>
<li>389 / 851 (45.7%) quotes with deviations from source, where the
accuracy was measured by a <a
href="https://maxbachmann.github.io/RapidFuzz/Usage/distance/Levenshtein.html#normalized-similarity">“normalized
Levenshtein similarity”</a> <span
style="border-bottom: 1px dashed black;"
title="Weights for insertion: 1, deletion: 0.5, substitution: 1.5. Penalizes &quot;positive hallucinations&quot; (insertions) more than omissions of e.g. brackets and references (deletions).">with
custom weights</span>, ranging from 0-100%
<ul>
<li><span style="background-color: #ffe9e2">205 minor</span> deviations
(95% ≤ similarity &lt; 100%); mean: 98%</li>
<li><span style="background-color: #ff9e81">65 moderate</span>
deviations (75% ≤ similarity &lt; 95%); mean: 86.3%</li>
<li><span style="background-color: red">119 major</span> deviations
(similarity &lt; 75%); mean: 54.6%</li>
</ul></li>
</ul>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-5154a73372928a625a36" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-5154a73372928a625a36">{"x":{"filter":"none","vertical":false,"fillContainer":false,"data":[["Healy 2015","Healy 2015","Healy 2015","Healy 2015","Healy 2015","Healy 2015","Healy 2015","Healy 2015","Healy 2015","Healy 2016","Healy 2016","Healy 2016","Healy 2016","Healy 2016","Heloury 2012","Heloury 2012","Heloury 2012","Huang 2015","Huang 2015","Huang 2015","Huang 2015","Huang 2015","Huang 2015","Ishii 2014","Ito 2014","Ito 2014","Ito 2014","Jia 2011","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kunz 2013","Kunz 2013","Kunz 2013","Landisch 2015","Landisch 2015","Lane 2010","Lansdale 2010","Lansdale 2010","Lansdale 2010","LeeVan 2016","Liang 2011","Liang 2011","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Mauritz 2013","Mauritz 2011","Mauritz 2011","Mei 2011","Mei 2011","Mullassery 2014","Mullassery 2014","Nagler 2011","Narayanan 2013","Nasr 2010","Nasr 2013","Nasr 2013","Nasr 2013","Nasr 2013","Nasr 2013","Nasr 2013","Nataraja 2013","Nicolau 2011","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Oomen 2012","Parolini 2016","Peters 2013","Peters 2013","Peters 2013","Peters 2013","Peters 2013","Peycelon 2014","Peycelon 2014","Peycelon 2014","Peycelon 2014","Peycelon 2014","Peycelon 2014","Pfistermuller 2015","Pfistermuller 2015","Pfistermuller 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Reddy 2010","Romao 2012","Romao 2012","Romao 2012","Ross 2015","Ross 2015","Ross 2015","Ross 2015","Ruttenstock 2010","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Saldaña 2013","Sauerland 2010","Sauerland 2010","Sauerland 2010","Sauerland 2010","Sauerland 2010","Sauerland 2010","Scholfield 2016","Sharp 2015","Sharp 2015","Shawyer 2014","Shawyer 2014","Shawyer 2014","Shawyer 2015","Shawyer 2015","Shawyer 2015","Shawyer 2015","Shen 2015","Shen 2015","Siddiqui 2011","Siminas 2015","Sklar 2014","Sklar 2014","Sklar 2014","Sola 2010","Sola 2010","Sola 2010","Tan 2016","Tan 2016","Tan 2016","Terui 2015","Terui 2015","Thomson 2015","Thomson 2015","Thyoka 2013","van Dalen 2015","Vanden Berg 2016","Vanden Berg 2016","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","Vernon-Roberts 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wang 2013","Wayne 2015","Wayne 2015","Wayne 2015","Wayne 2015","Weih 2012","Weih 2012","Wenk 2015","Wenk 2015","Wenk 2015","Wenk 2015","Wenk 2015","Wenk 2015","Wenk 2015","Wenk 2015","Wilkinson 2012","Wilkinson 2012","Wright 2013","Wright 2013","Yang 2011","Yang 2011","Yang 2011","Yang 2011","Yang 2013","Yang 2013","Zhao 2015","Zhao 2015","Zhu 2016","Al-Hozaim 2010","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allen 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Alzahem 2011","Apelt 2013","Apelt 2013","Aworanti 2014","Aworanti 2014","Baker 2015","Berger 2012","Berger 2012","Berger 2012","Billingham 2010","Black 2013","Castagnetti 2010","Castagnetti 2010","Castagnetti 2016","Castagnetti 2016","Castagnetti 2016","Chan 2014 (Pediatr Surg Int)","Chan 2014 (Pediatr Surg Int)","Chan 2014 (J Pediatr Surg)","Chan 2014 (J Pediatr Surg)","Chan 2014 (J Pediatr Surg)","Chan 2014 (J Pediatr Surg)","Chan 2014 (J Pediatr Surg)","Chen 2013","Corbett 2015","Corbett 2015","Cullis 2016","Cundy 2014 (BJU Int)","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (Eur J Pediatr Surg)","Ding 2013","Ding 2013","Ding 2013","Dingemann 2014","Dingemann 2014","Dingemann 2014","Dingemann 2014","Dingemann 2014","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Dingemann 2013","Ells 2015","Elyas 2010","Elyas 2010","Esposito 2014","Feng 2016","Feng 2016","Feng 2016","Feng 2016","Feng 2015","Friedmacher 2012","Frongia 2013","Gallo 2012","Graziano 2015","Guo 2011","Guo 2011"],["fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","fulltext","fulltext","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","fulltext","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","prompt","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext"],["<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nThis systematic article was conducted according to the\nPreferred Reporting Items for Systematic Reviews and Meta-\nAnalyses guidelines' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This systematic article was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.2%):\n\n4).\nTwo authors (DD and DH) independently extracted data\nfrom eligible studies using an electronic spreadsheet' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two authors searched Medline and Embase to identify relevant studies.\" \"Two authors (DD and DH) independently extracted data from eligible studies using an electronic spreadsheet.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.6%):\n\n2 authors (DD and MM) independently searched Medline and\nEMBASE up to June 24, 2015 using the following search strategy\n‘‘([paediatric surgery OR pediatric surgery OR pediatric surgeon\nOR paediatric surgeon] AND (appendectomy OR appendicect-\nomy)].’’ The search terms were inputted as free text. Titles and\nabstracts were examined initially and then full manuscripts were\nobtained to finalize eligibility. The reference lists of eligible\nstudies w' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two authors searched Medline and Embase up to June 24, 2015 using the following search strategy ‘‘([paediatric surgery OR pediatric surgery OR pediatric surgeon OR paediatric surgeon] AND (appendectomy OR appendicectomy)].’’\" \"All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nDespite this, our find-\nings must be interpreted with caution as our article is based\nentirely upon observational data' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Despite this, our findings must be interpreted with caution as our article is based entirely upon observational data.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):\n\nWe used Mantel Haenszel random effects models.\nThe potential for publication bias was evaluated by visually\ninspecting funnel plots. Statistical heterogeneity was assessed\nusing the I \n2 \nstatistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We used Mantel Haenszel random effects models.\" \"Statistical heterogeneity was assessed using the I2 statistic.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nAn expanding body of evidence suggests that surgeon\nsubspecialization affects outcomes; studies found that color-\nectal surgery subspecialization \n4 \nand orthopedic surgery sub-\nspecialization \n5 \nlead to improved results and that outcomes from\na variety of cancers are improved with subspecialization' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An expanding body of evidence suggests that surgeon subspecialization affects outcomes; studies found that colorectal surgery subspecialization and orthopedic surgery subspecialization lead to improved results and that outcomes from a variety of cancers are improved with subspecialization.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nThe aim of this study is to assess the influence of surgeon\nspecialization on outcomes following appendicectomy in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of this study is to assess the influence of surgeon specialty on outcomes following appendicectomy in children.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.5%):\n\n2 authors (DD and MM) independently searched Medline and\nEMBASE up to June 24, 2015 using the following search strategy' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Two authors searched Medline and Embase up to June 24, 2015 using the following search strategy&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.2%):\n\npaediatric surgery OR pediatric surgery OR pediatric surgeon\nOR paediatric surgeon] AND (appendectomy OR appendicect-\nomy' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎‘‘([paediatric surgery OR pediatric surgery OR pediatric surgeon OR paediatric surgeon] AND (appendectomy OR appendicectomy)].’’&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nCitations\nof retrieved results were manually reviewed for relevance to\nthe topic of IA by two independent reviewers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Citations of retrieved results were manually reviewed for relevance to the topic by two independent reviewers.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.3%):\n\nW A RT I C L E\nPediatric incidental appendectomy: a systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎REVIEW ARTICLE Pediatric incidental appendectomy: a systematic review&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nA detailed review was\nundertaken of the techniques, pathology, risks of appen-\ndectomy, utility of the appendix, and incidental appen-\ndectomy in the treatment of specific pediatric medical\nconditions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A detailed review was undertaken of the techniques, pathology, risks of appendectomy, utility of the appendix, and incidental appendectomy in the treatment of specific pediatric medical conditions.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nCitations\nof retrieved results were manually reviewed for relevance to\nthe topic of IA by two independent reviewers. If adequate\ninformation was not included in the abstract, the manuscript\nwas reviewed, by default, to determine relevance' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Citations of retrieved results were manually reviewed for relevance to the topic by two independent reviewers. If adequate information was not included in the abstract, the manuscript was reviewed, by default, to determine relevance.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe discus-\nsion includes a variety of situations and comorbid condi-\ntions that may influence a surgeon’s decision to perform\nincidental appendectomy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The discussion includes a variety of situations and comorbid conditions that may influence a surgeon’s decision to perform incidental appendectomy.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nconducted a systematic review of the pediatric and adult literature about MIA' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic review of the pediatric and adult literature about MIA&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.5%):\n\nis promising for removal of small adrenal tumors' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎MIA is promising for removal of small adrenal tumors.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):\n\nis superior to OA for\nthe removal of benign adrenal diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎MIA is superior to OA for the removal of benign adrenal diseases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nA\nsystematic literature search of electronic data-\nbases including PUBMED, Web of science and\nCochrane library was carried out between Jan.\n1966 and Oct. 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic literature search of electronic databases including PUBMED, Web of science and Cochrane library was carried out between Jan. 1966 and Oct. 2014&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nData abstraction was carried out independent-\nly by two authors (Yidong Huang, Yang Wu' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was carried out independently by two authors (Yidong Huang, Yang Wu)&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 84.4%):\n\ne search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎PUBMED, Web of science and Cochrane library were searched\" \"All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nAmong\nthese studies, 37 studies were finally leaved\nbehind for full-text assessment. Detailed steps\nof literature search were shown in Figure 1.\nAfter excluded 21 studies due to different rea-\nsons, 16 studies including one RCT [2], eight\nretrospective studies [5, 8, 9, 12-16], three pro-\nspective studies [6, 17, 18] and four studies\nfrom database [1, 4, 18, 19] were included in\nthe meta-analysi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Among these studies, 37 studies were finally leaved behind for full-text assessment. After excluded 21 studies due to different reasons, 16 studies including one RCT [2], eight retrospective studies [5, 8, 9, 12-16], three prospective studies [6, 17, 18] and four studies from database [1, 4, 18, 19] were included in the meta-analysis.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nHeterogeneity was consid-\nered significant for P value < 0.05 or I\n2 \n> 50%.\nConsidering the heterogeneity of included stud-\nies, we conducted meta-analyses of all com-\nparatives using random effects models' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Heterogeneity was considered significant for P value < 0.05 or I2 > 50%.\" \"Considering the heterogeneity of included studies, we conducted meta-analyses of all comparatives using random effects models.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.1%):\n\nalysis of laparoscopic versus open\npyeloplasty for ureteropelvic junction\nobstruction in children' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Comparison of laparoscopic versus open pyeloplasty for ureteropelvic junction obstruction in children&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe search terms included the following: ‘uretero-\nscopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediat-\nric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’,\n‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search terms included the following: ‘ureteroscopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediatric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’, ‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy’.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nA clinical question was structured according to patient, intervention, compari-\nson, and outcome, as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (inter-\nvention), compared to lactation support alone (comparison), improve feeding (outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A clinical question was structured according to patient, intervention, comparison, and outcome, as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (intervention), compared to lactation support alone (comparison), improve feeding (outcome)?&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nAn electronic literature search was systematically performed\nusing databases including PubMed (January1966–April 2013),\nJapana Centra Revuo Medicina (Igaku Chuo Zasshi, January\n1983–April 2013), CINAHL, and Cochrane Library using the key\nwords “ankyloglossia,” “tongue-tie,” frenotomy,” and/or\n“breastfeeding” in English and the equivalent terms in Japanese' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An electronic literature search was systematically performed using databases including PubMed, Japana Centra Revuo Medicina (Igaku Chuo Zasshi), CINAHL, and Cochrane Library using the key words “ankyloglossia,” “tongue-tie,” “frenotomy,” and/or “breastfeeding” in English and equivalent terms in Japanese.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nA clinical question was structured according to patient, intervention, compari-\nson, and outcome, as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (inter-\nvention), compared to lactation support alone (comparison), improve feeding (outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A clinical question was structured according to patient, intervention, comparison, and outcome as follows: in infants with poor breast-feeding and ankyloglossia (patient), does frenotomy (intervention), compared to lactation support alone (comparison), improve feeding (outcome)?&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nthe available trials were of high qual-\nity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎the available trials were of high quality.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.3%):\n\nan &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎An 'a priori' design was provided as the research question and inclusion criteria were established through a Delphi-like method before conducting the review.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 88.5%):\n\nthere duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎There was duplicate study selection and data extraction with two independent reviewers and a consensus procedure for disagreements.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 35.9%):\n\na comprehensive literature search performed?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A comprehensive literature search was performed in 5 databases along with supplementary searching of reference lists.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 89.2%):\n\nthe status of publication (i.e. grey literature) used as an inclusion criterion' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The status of publication was not used as an inclusion criterion.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.2%):\n\nA list of included and excluded studies should be provided. Not' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A list of included and excluded studies was provided in the flow diagram.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 75.4%):\n\ncharacteristics of the included studies provided? In' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Characteristics of included studies were provided in Table 1.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 79%):\n\nthe Methodological Index for Non-Randomized Studies\n(MINORS) to assess the quality of the included studies, as all were\nnonrandomized [18]. The MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The methodological quality of included studies was assessed with the MINORS tool.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 77.1%):\n\nquality should be considered in the analysis and the conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The quality assessment was considered in the analysis and conclusions.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 43.5%):\n\nues to assess homogeneity.\nHad we included' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Methods to assess heterogeneity were described for the meta-analyses.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 85.3%):\n\npublication bias could not be assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Publication bias was not assessed.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 87.7%):\n\nconflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Conflicts of interest were not reported for the included studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 63.3%):\n\nthe report as a systematic review, meta-analysis, or both' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The report is identified as a systematic review and meta-analysis in the title.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 86%):\n\na structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎A structured summary is provided with objectives, eligibility criteria, sources, synthesis methods, results, limitations.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44%):\n\ndesign provided? The research question' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The rationale describes current controversies around the research question.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 78.5%):\n\nf questions being addressed with reference to participants, interventions, comparisons, outcomes' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The review question is stated in terms of participants, interventions, comparisons, outcomes.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.6%):\n\na review protocol' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A review protocol is not mentioned.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.9%):\n\nn including registration number.\nP6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Eligibility criteria are described including study characteristics and years, language, publication status.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.4%):\n\ninformation sources (e.g., databases with dates' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Information sources are described including databases and dates searched.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.8%):\n\nsearch strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A full search strategy is not provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.3%):\n\nthe process for selecting studies (i.e., screening, eligibility, included in sy' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The process of study screening and selection is described in the flow diagram.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.4%):\n\nData extraction\nOne reviewer extracted all data from the included studies, and an-\nother checked it for accuracy and completeness. We extract' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data extraction methods are described including the use of forms and independent extraction.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45.2%):\n\nviewer extracted a' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Variables extracted are listed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 40.9%):\n\nQuality assessment\nW' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Quality assessment with MINORS is described.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 87.1%):\n\nsummary measures (e.g., risk ratio, difference in means).\nP14. Describe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Summary measures are described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.8%):\n\nnumbers of studies screened, assessed for eligibility, and included in the review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Numbers of studies screened and excluded are shown in the flow diagram.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 52%):\n\ncharacteristics of the included studies provided?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Characteristics and citations are provided for included studies in Table 1.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 38.5%):\n\nf assessment should be pr' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Quality assessment results are presented in Table 1.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 80.5%):\n\nsummary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.\nP21. Present results of each meta-analysis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Summary data and effect estimates are presented in the meta-analysis figures.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60.5%):\n\nresults of\nthis meta-analysis s' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Results of the meta-analyses are presented.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.5%):\n\nfunding sources) and any assumptions and simplifications made.\nP12. Desc' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Main findings are summarized and clinical implications are discussed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.9%):\n\nlimitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Limitations are described at the study and review level.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 77.2%):\n\ninterpretation of the results in the context of other evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Results are interpreted in the context of other evidence.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 74.5%):\n\nsource of funding or support for the systematic review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Sources of funding are not reported for the review.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nWe reviewed Medline citations between January 1, 1996 and June 1, 2012 and the Cochrane\nDatabase of Systematic Reviews database through June 1, 2012. Citations from DynaMed\nand other reviews were included. The search terms used were “gastroschisis” and\n[(“treatment outcome” or “prognosis”) or randomized controlled trials]. Reference lists from\nselected papers were further used to identify publications of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We reviewed Medline citations between January 1, 1996 and June 1, 2012 and the Cochrane Database of Systematic Reviews database through June 1, 2012. Citations from DynaMed and other reviews were included. Reference lists from selected papers were further used to identify publications of interest.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.7%):\n\nHeterogeneity was assessed by the I\n2\nstatistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Heterogeneity was assessed by the I2 statistic.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nData abstraction was conducted\nindependently by the same two investigators from the studies that met inclusion criteria. A\nstandard data collection form (Appendix 2) created by the authors (JA, JT, SK) was used to\nextract information about study quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was conducted independently by the same two investigators from the studies that met inclusion criteria. A standard data collection form created by the authors was used to extract information about study quality...&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.1%):\n\nreviewed and extracted eligible articles. Bibliographies of identified\nstudies were examined to identify any additional eligible studies' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles. Bibliographies of identified studies were examined to identify any additional eligible studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nAn online database search for all articles published between January\n1993 and January 2014 on pediatric patients using the following key-\nwords was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd pro-\ncedure”, “Ivemark”, “asplenia”, and “polysplenia' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An online database search for all articles published between January 1993 and January 2014 on pediatric patients using the following keywords was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd procedure”, “Ivemark”, “asplenia”, and “polysplenia”.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 35%):\n\nture research.\nP27. Describe sources of funding for the systematic review and othe' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A literature search was undertaken using Medline, the Cochrane database of systematic reviews and the Cochrane central register of controlled trials.\" \"[Yes]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.2%):\n\nd Search Technique\nMEDLINE (1950 to present), Embase (1980 to present) and\nCochrane Controlled Trials Register databases' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We searched Medline (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):\n\nd Search Technique\nMEDLINE (1950 to present), Embase (1980 to present) and\nCochrane Controlled Trials Register databases were searched using the\nkeywords ‘diaphragmatic hernia AND thoracoscopic,’ ‘diaphragmatic\nhernia AND laparoscopic,’ and ‘diaphragmatic hernia AND minimally-\ninvasive' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases using the keywords ‘diaphragmatic hernia AND thoracoscopic,’ ‘diaphragmatic hernia AND laparoscopic,’ and ‘diaphragmatic hernia AND minimally-invasive'&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):\n\nFIGURE 2. Flow chart demonstrating the pro-\ncess of study selection' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Figure 2. Flow chart demonstrating the process of study selection&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.6%):\n\nlection criteria, the full article\nwas obtained and reviewed for inclusion.\n15 \nInclusion criteria\nwere (1) original research articles regarding management of\npediatric blunt renal trauma, (2) involvement of cases of high-\ngrade renal (Grades IV and V) trauma, and (3) more than one\npatient presented per study' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎[The research question and inclusion criteria should be established before the conduct of the review.]\" \"[Inclusion criteria were (1) original research articles regarding management of pediatric blunt renal trauma, (2) involvement of cases of high-grade renal (Grades IV and V) trauma, and (3) more than one patient presented per study.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nA search\nwas made for all studies published up until 31 August 2010\nusing the terms “lymphatic sparing varicocelectomy”, “laparos-\ncopy” , “adolescent ” and “children ” in the Medline (using PubMed\nas the search engine), Embase, Ovid, Web of Science, and\nCochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A search was made for all studies published up until 31 August 2010 using the terms “lymphatic sparing varicocelectomy”, “laparoscopy”, “adolescent” and “children” in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe citations and/ or abstracts or the full text\nof all potentially relevant studies were independently evaluated\nand selected by 3 reviewers (LZL, GJ and TQS), and any disagree-\nments were resolved by consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The citations and/ or abstracts or the full text of all potentially relevant studies were independently evaluated and selected by 3 reviewers (LZL, GJ and TQS), and any disagreements were resolved by consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):\n\nThe following Medical Subject\nHeadings were used: ‘‘comparative study,’’ ‘‘laparos-\ncopy,’’ ‘‘biliary atresia,’’ ‘‘surgery,’’ and ‘‘treatment\noutcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The following Medical Subject Headings were used: ‘comparative study,’ ‘laparoscopy,’ ‘biliary atresia,’ ‘surgery,’ and ‘treatment outcome’.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):\n\nTwo\nauthors (ML and CZ) independently assessed included\nstudies and divergence was resolved by discussion with the\nother reviewers. Two independent authors (QG and ZZ)\nusing a predefined meta-analysis form extracted relevant\ndata from each study which resulted in high and satisfac-\ntory interobserver agreement' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors (ML and CZ) independently assessed included studies and divergence was resolved by discussion with the other reviewers. Two independent authors (QG and ZZ) using a predefined meta-analysis form extracted relevant data from each study which resulted in high and satisfac¬tory interobserver agreement.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nWe conducted a system-\natic search of the online databases, including Medline,\nOvid, Elsevier, Google Scholar Embase, Cohrane library,\nfor studies published between 1995 and 2014 with no\nlimits for publication language, place of study origin and\nsample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases, including Medline, Ovid, Elsevier, Google Scholar Embase, Cohrane library, for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nLaparoscopic portoenterostomy versus open portoenterostomy\nfor the treatment of biliary atresia: a systematic review and meta-\nanalysis of comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopic portoenterostomy versus open portoenterostomy for the treatment of biliary atresia: a systematic review and meta-analysis of comparative studies&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 61.9%):\n\nthods: We conducted a structured search of Medline, Embase, trial registries, and the gray literature' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - An 'a priori' design was provided as the authors state 'We conducted a structured search of Medline, Embase, trial registries, and the gray literature.'&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66%):\n\nwere placed.\n1.2. Study selection\nTitle and abstract screening was completed independently and in\nduplicate by two of the authors (MHL, ACS' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - There was duplicate study selection and data extraction as the authors state 'Title and abstract screening was completed independently and in duplicate by two of the authors (MHL, ACS).'&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 37.8%):\n\ntured search of Medline, Embase, trial registries, and t' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - A comprehensive literature search was performed across multiple databases, trial registries, and supplementary sources.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 81.9%):\n\nthe status of publication (i.e. grey literature) used as an inclusion criterion' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] - The status of publication was not used as an inclusion criterion.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 71.2%):\n\n? A list of included and excluded studies should be provided. No' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - A list of included and excluded studies was provided in Figure 1.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.1%):\n\ncharacteristics of the included studies provided? In' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Characteristics of included studies were provided in Table 1.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.9%):\n\nthe scientific quality of the included studies assessed and documented?' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The scientific quality of included studies was assessed using the MINORS tool and documented in Table 2.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 55.8%):\n\nthe scientific quality of the included studies used appropriately in formulating conclusions? The results of the metho' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The scientific quality was considered in formulating conclusions, as the authors state the evidence was very low quality.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.1%):\n\nquantitative synthesis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No quantitative synthesis was performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.9%):\n\nquantitative synthesis (A9) or assessing publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No quantitative synthesis was performed to assess publication bias.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 80.6%):\n\nconflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] - Conflicts of interest were not reported for the included studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.8%):\n\nthe report as a systematic review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The report is identified as a systematic review in the title.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40.4%):\n\na structured summary in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - A structured summary is provided in the abstract.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.1%):\n\nthe rationale for the review in the' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The rationale is described in the introduction.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 46.5%):\n\nDescribe the methods' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - PICOS are described in the methods.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.9%):\n\na review protocol' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] - A review protocol is not mentioned.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 31.9%):\n\nstudy characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Study characteristics and eligibility criteria are described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 42.1%):\n\nce were not described in the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - Information sources are described in the methods.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60.9%):\n\nsearch strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] - A full search strategy is not provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.4%):\n\nthe process for selecting studies (i.e., screening, eligibility, included in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - The process for study selection is described and depicted in Figure 1.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44.2%):\n\ndata extraction? There should be' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Data extraction by two authors is described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 48.8%):\n\nese procedures and described' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - Outcomes extracted are described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.2%):\n\n2\nRisk of bias assessment for individual studies using meth' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] - Risk of bias assessment is described using the MINORS tool.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 36.8%):\n\n, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No meta-analysis was performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 36.8%):\n\n, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] - No meta-analysis was performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 64.7%):\n\nmain findings including the strength of evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Main findings are summarized including strength of evidence.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60.9%):\n\nlimitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Limitations at the study and review level are discussed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.7%):\n\ninterpretation of the results in the context of other evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] - Results are interpreted in the context of other evidence.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.5%):\n\nsource of funding or support for the systematic review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] - Sources of funding are not reported for the systematic review.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nUsing predefined search\nterms PubMed (1960 to 2011), EMBASE (from 1980 to\n2011), and the Cochrane Library (issue 3, 2011) were system-\natically searched until March 16, 2011 to identify all articles\ncomparing complete to partial fundoplication in children\nwith GERD' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nUsing predefined search terms, PubMed (from 1960),\nEmbase (from 1980), and the Cochrane library (issue 11,\n2010) were systematically searched for all articles pub-\nlished until November 10, 2010' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined search terms, PubMed (from 1960), Embase (from 1980), and the Cochrane library (issue 11, 2010) were systematically searched for all articles published until November 10, 2010.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nFor PubMed, the follow-\ning search terms were used: (fundoplication[Title/Abstract]\nOR nissen[Title/Abstract] OR thal[Title/Abstract] OR tou-\npet[Title/Abstract] OR boerema[Title/Abstract] OR antire-\nflux surgery[Title/Abstract]) AND (child[Title/Abstract] OR\nchildren[Title/Abstract] OR infant[Title/Abstract] OR\ninfants[Title/Abstract] OR pediatric[Title/Abstract] OR pe-\ndiatrics[Title/Abstract] OR pediatric[Title/Abstract] OR\npediatrics[Title/Abstract' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For PubMed, the following search terms were used: (fundoplication[Title/Abstract] OR nissen[Title/Abstract] OR thal[Title/Abstract] OR toupet[Title/Abstract] OR boerema[Title/Abstract] OR antireflux surgery[Title/Abstract]) AND (child[Title/Abstract] OR children[Title/Abstract] OR infant[Title/Abstract] OR infants[Title/Abstract] OR pediatric[Title/Abstract] OR pediatrics[Title/Abstract] OR pediatric[Title/Abstract] OR pediatrics[Title/Abstract]).&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 88.5%):\n\nThe literature search, quality assessment, and data extraction\nwere independently performed by two reviewers.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The literature search, quality assessment, and data extraction were independently performed by two reviewers (MH and TQS).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nMeta-analyses were performed for the five primary out-\ncome parameters: Operative time (in minutes), postoperative\ncomplications (in events per group), duration of hospital stay\n(in days), success rate (in events per group), and stenting rate\n(in events per group' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Meta-analyses were performed for the five primary outcome parameters: Operative time (in minutes), postoperative complications (in events per group), duration of hospital stay (in days), success rate (in events per group), and stenting rate (in events per group).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nWe sought to in-\nclude randomized controlled trials (if available) and observational studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We sought to include randomized controlled trials (if available) and observational studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nStudies were reviewed by PJF and DM independently. Where a difference in opin-\nion occurred the matter was resolved by consensus agreement in conjunction with the\nsenior author (PDL' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Studies were reviewed by PJF and DM independently. Where a difference in opinion occurred the matter was resolved by consensus agreement in conjunction with the senior author (PDL).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.8%):\n\nas the conflict of interest' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The authors declare that they have no conflict of interest.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nA Medline, Ovid, Search Medica, Elsevier Clini-\ncalKey, Google Scholar and the Cochrane library search\nwas performed on all studies published between 1950 and\n2012 reporting on comparison of HD and HJ for children\nundergoing excision of extra-hepatic biliary tree for\ncholedochal cysts' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):\n\nWe applied tests for between-study heterogeneity χ\n2\n(Q test) and the I\n2 \nstatistic to assess the appropriateness of\ncombining studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We applied tests for between-study heterogeneity χ2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.2%):\n\nThe purpose of this study is to critically evaluate the existing literature on\nthis topic and to compare the Foker technique to the more conventional delayed\nprimary anastomosis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The purpose of this study is to critically evaluate the existing literature on this topic and to compare the outcomes of the Foker technique to the more conventional delayed primary anastomosis.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.2%):\n\nThe purpose of this study is to critically evaluate the existing literature on\nthis topic and to compare the Foker technique to the more conventional delayed\nprimary anastomosis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The purpose of this study is to critically evaluate the existing literature on this topic and to compare the outcomes of the Foker technique to the more conventional delayed primary anastomosis.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe literature search resulted in a total of 115 articles, after\nscreening and exclusion of nonrelevant and duplicate pub-\nlications. Six articles\n36–41 \nmet our criteria for inclusion and\nthe full text was examined more in detail' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search resulted in a total of 115 articles, after screening and exclusion of nonrelevant and duplicate publications. Six articles met our criteria for inclusion and the full text was examined more in detail.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThis analysis demonstrated that res-\ntoration of esophageal continuity was achieved faster using the\nmechanical traction approach. Although time to complete oral\nintake was not reported in most studies, it is logical to assume\nthat earlier restoration of esophageal continuity would trans-\nlate into faster oral intake by the infants' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This analysis demonstrated that restoration of esophageal continuity was achieved faster using the mechanical traction approach. Although time to complete oral intake was not reported in most studies, it is logical to assume that earlier restoration of esophageal continuity would translate into faster oral intake by the infants.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nthe results of this meta-\nanalysis should be interpreted with caution. All studies\npublished in the literature on this topic are retrospective\nand noncomparative' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The results of this meta-analysis should be interpreted with caution. All studies published in the literature on this topic are retrospective and noncomparative.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nAt the present time, the gold standard technique for\ncomparing two approaches to a clinical problem is a random-\nized controlled trial. However, this will be difficult to perform\nfor long-gap EA due to the rarity of the problem, the hetero-\ngeneity of the patient population, variability in surgical\ntechnique and clinical approach within and between centers,\nand well-established bias among pediatric surgeons taking\ncare of these children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎At the present time, the gold standard technique for comparing two approaches to a clinical problem is a randomized controlled trial. However, this will be difficult to perform for long-gap EA due to the rarity of the problem, the heterogeneity of the patient population, variability in surgical technique and clinical approach within and between centers, and well-established bias among pediatric surgeons taking care of these children.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nFrom\nthese, 284 full-text journal articles were retrieved and re-\nviewed in detail. Sixty-six of the latter studies contained data\nthat was relevant to the formation of an IAA following a\npediatric LA or OA and were therefore included in our\nanalysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From these, 284 full-text journal articles were retrieved and reviewed in detail. Sixty-six of the latter studies contained data that was relevant to the formation of an IAA following a pediatric LA or OA and were therefore included in our analysis.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45.1%):\n\nrehensive literature search was performed on the\nU.S. National Library of Medicine site in Medline and\nPubMed from 1 Ian 2000 to 31 Dec 2007 using keywords\nsuch as “laparoscopy and blunt abdominal trauma”.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The study was designed as a systematic review. Relevant literature was identified by searching PubMed and Medline databases using the keywords “laparoscopy and blunt abdominal trauma” in the time interval between January 2000 and December 2007.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 83.3%):\n\ncharacteristics of the included studies provided? In an aggregated form' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Characteristics of the included studies should be provided in aggregated form.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.9%):\n\nthe methodological quality of a systematic review with the AMSTAR tool and its reporting quality' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The methodological quality of included studies should be assessed using a quality scoring tool.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 89%):\n\nThe results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎The results of the quality assessment should be considered in the analysis and conclusions.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 77.6%):\n\nFor the pooled results, a test should be done to ensure the studies were combinabl' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎For pooled results, tests should be done to ensure combinability of studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 77.2%):\n\npublication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tes' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Publication bias should be assessed using graphical and/or statistical methods.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.2%):\n\nProvide a structured summary including,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Provide a structured abstract including key information about the review.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 84%):\n\nDescribe the rationale for the review in the context of what is already know' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Describe the rationale for the review in the context of existing knowledge.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):\n\nProvide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Provide explicit questions with reference to participants, interventions, comparisons, outcomes, and study designs.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.7%):\n\nIndicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Indicate whether a review protocol exists and provide registration details if available.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.7%):\n\nrmation including registration number.\nP6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Specify eligibility criteria including study characteristics and report characteristics.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.1%):\n\nDescribe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Describe information sources and date last searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.2%):\n\nPresent full electronic search strategy for at least one database' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Present full search strategy for at least one database.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 55.6%):\n\ne the process for selecting studies (i.e., screening,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Describe the process of study screening and selection.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 73.7%):\n\nDescribe method of data extraction f' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Describe how data extraction was done.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 83.3%):\n\nList and define all variables for which data were sought' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎List and define all data items that were sought.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.7%):\n\nDescribe methods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Describe methods for assessing risk of bias.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 86.8%):\n\nState the principal summary measures (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎State principal summary measures used.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56%):\n\ne methods used to combine the' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Describe methods used to combine and analyze data.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 89.8%):\n\nDescribe methods used for assessing risk of bias of individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Describe methods for assessing risk of bias across studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 81.6%):\n\nDescribe methods of additional analyses (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Describe methods of additional analyses, if done.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.1%):\n\nith a flow diagram.\nP18. For each study,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Provide a flow diagram of study selection.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 69%):\n\nFor each study, present characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎For each study, present relevant characteristics and cite.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 50.9%):\n\nPresent results of any assessment of r' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Present risk of bias assessments for each included study.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 78.3%):\n\npresent, for each study: (a) simple summary data for each intervention group' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Present summary data for each outcome by intervention group.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 79.3%):\n\nPresent results of any assessment of risk of bias across studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Present results of risk of bias assessment across studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 81.8%):\n\nresults of additional analyses, if done' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Present results of additional analyses done.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 90.4%):\n\nSummarize the main findings including the strength of evidence for each main outcome; consider their relevance' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Summarize main findings and discuss their relevance.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 86.8%):\n\nDiscuss limitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Discuss limitations at the study and outcome level, and at the review level.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.7%):\n\nProvide a general interpretation of the results' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Provide a general interpretation of results.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 97.9%):\n\nDescribe sources of funding for the systematic review and other support (e.g., supply of data); role of funders' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Describe sources of funding and role of funders.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.2%):\n\neach study, data were extracted for the following outcomes: number of patients, associated anomalies, type of\nsurgical repair, morbidity and mortality rate' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For each study, data were extracted for the following outcomes: number of patients, associated anomalies, type of surgical repair, morbidity and mortality rate.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nSearch terms used were [total] ([o]esophago-gastric/\ngastro-[o]esophageal) (dissociation/disconnection/separation' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Search terms used were [total] ([o]esophago-gastric/gastro-[o]esophageal) (dissociation/disconnection/separation).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nA primary procedure is defined as the first operation per-\nformed (eg for gastroesophageal reflux) and a rescue procedure\nas a further operation following failed earlier operation(s' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A primary procedure is defined as the first operation performed (eg for gastroesophageal reflux) and a rescue procedure as a further operation following failed earlier operation(s).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nOne hundred eighty-one patients who had undergone\nTOGD were identified from 10 articles, personal communi-\ncation with authors of these articles and data held at our\ninstitution' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One hundred eighty-one patients who had undergone TOGD were identified from 10 articles, personal communication with authors of these articles and data held at our institution.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nA primary procedure is defined as the first operation per-\nformed (eg for gastroesophageal reflux) and a rescue procedure\nas a further operation following failed earlier operation(s' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A primary procedure is defined as the first operation performed (eg for gastroesophageal reflux) and a rescue procedure as a further operation following failed earlier operation(s).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nReview of all available cases of TOGD has revealed an\nacceptable complication and mortality rate. Rates of re-\noperation are comparable to and lower than some reoperation\nrates following fundoplication' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review of all available cases of TOGD has revealed an acceptable complication and mortality rate. Rates of reoperation are comparable to and lower than some reoperation rates following fundoplication.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nReferences for this review\nwere identified by PubMed searches using appropriate search\nterms for each section (“minimally invasive surgery,” “lapa-\nroscopy,” “thoracoscopy,” “childhood/children/pediatric can-\ncer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer\").&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nReferences for this review\nwere identified by PubMed searches using appropriate search\nterms for each section (“minimally invasive surgery,” “lapa-\nroscopy,” “thoracoscopy,” “childhood/children/pediatric can-\ncer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer\").&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nLaparoscopy adrenalectomy is per-\nformed for various indications from benign to malignant\ntumors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopy adrenalectomy is performed for various indications from benign to malignant tumors.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nReferences for this review\nwere identified by PubMed searches using appropriate search\nterms for each section (“minimally invasive surgery,” “lapa-\nroscopy,” “thoracoscopy,” “childhood/children/pediatric can-\ncer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer\").&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nMIS is a promising method for removal of thoracic and abdominal\nmalignancies as long as oncological principles are strictly followed. Long-term follow-\nup is mandatory to further delineate objective indications' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MIS is a promising method for removal of thoracic and abdominal malignancies as long as oncological principles are strictly followed. Long-term follow-up is mandatory to further delineate objective indications.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nLong-term follow-\nup is mandatory to further delineate objective indications' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Long-term follow-up is mandatory to further delineate objective indications.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nMedline and Pubmed were searched in order to identify ar-\nticles published between 1994 and 2012' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Pubmed were searched in order to identify articles published between 1994 and 2012.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nThe search terms\n‘tubularized incised plate urethroplasty/Snodgrass repair/\ntechnique \u0002 outcomes/complications \u0002 follow-up/long term\nfollow-up’ were used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search terms ‘tubularized incised plate urethroplasty/Snodgrass repair/technique \u0002 outcomes/complications \u0002 follow-up/long term follow-up’ were used.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThere is a wide discrepancy between published compli-\ncation rates for different repair types [4e16] and a poor\nevidence base for the current management of hypospadias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎There is a wide discrepancy between published complication rates for different repair types [4e16] and a poor evidence base for the current management of hypospadias.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nTwo of the principal authors (P.P. and\nS.I.) independently scanned all titles as a first screen after which select-\ned abstracts and/or full-length papers were collected for further review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two of the principal authors (P.P. and S.I.) independently scanned all titles as a first screen after which select-ed abstracts and/or full-length papers were collected for further review.]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):\n\nummary\nThis systematic review by the APSA Outcomes and Evidence-based\nPractice Committee attempted to delineate best-evidence recommen-\ndations for specific aspects of C' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review by the APSA Outcomes and Evidence-based Practice Committee attempted to delineate best-evidence recommendations for specific aspects of CDH care.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nDespite significant advances in neonatal and surgical care, the man-\nagement of newborns with congenital diaphragmatic hernia (CDH) re-\nmains a challenge. Significant variations in approach exist with regard\nto the use of antenatal steroids, ventilation modes, therapies to treat\npulmonary hypertension, the use of extra-corporeal membrane oxy-\ngenation (ECMO), and the timing and type of surgical repair [1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Despite significant advances in neonatal and surgical care, the management of newborns with congenital diaphragmatic hernia (CDH) remains a challenge. Significant variations in approach exist with regard to the use of antenatal steroids, ventilation modes, therapies to treat pulmonary hypertension, the use of extra-corporeal membrane oxygenation (ECMO), and the timing and type of surgical repair [1].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThe American Pediatric Surgical Association (APSA) Outcomes and\nEvidence Based Practice (OEBP) committee selected the following ques-\ntions for this systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The American Pediatric Surgical Association (APSA) Outcomes and Evidence Based Practice (OEBP) committee selected the following questions for this systematic review:&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nTwo of the principal authors (P.P. and\nS.I.) independently scanned all titles as a first screen after which select-\ned abstracts and/or full-length papers were collected for further review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two of the principal authors (P.P. and S.I.) independently scanned all titles as a first screen after which selected abstracts and/or full-length papers were collected for further review.]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):\n\nummary\nThis systematic review by the APSA Outcomes and Evidence-based\nPractice Committee attempted to delineate best-evidence recommen-\ndations for specific aspects of C' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review by the APSA Outcomes and Evidence-based Practice Committee attempted to delineate best-evidence recommendations for specific aspects of CDH care.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93%):\n\nThus, it is imperative that we ded-\nicate efforts to design high quality studies that will inform the\ndevelopment of best practices for these' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎It is imperative that we dedicate efforts to design high quality studies that will inform the development of best practices for these infants.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 43%):\n\n(Cochrane register/Central counts as 2 sources; a grey literature search' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎MEDLINE, EMBASE, and the Cochrane Controlled Trials Register databases searched&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe aim of our study was to compare recurrence, small\nbowel obstruction (SBO), and mortality rates for CDH repair\nbetween an absorbable (Surgisis [SIS]; Cook Biotech, Inc,\nWest Lafayette, IN) and a nonabsorbable polytetrafluor-\noethylene (PTFE) (Gore-Tex; W.L. Gore & Associates, Inc,\nNeward, DE) material at our institution' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of our study was to compare recurrence, small bowel obstruction (SBO), and mortality rates for CDH repair between an absorbable (Surgisis [SIS]; Cook Biotech, Inc, West Lafayette, IN) and a nonabsorbable polytetrafluoroethylene (PTFE) (Gore-Tex; W.L. Gore & Associates, Inc, Newark, DE) material at our institution.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):\n\nData were compared using the Student t test for\ncontinuous outcomes and χ\n2 \n/Fisher&#39;s exact for categorical\none' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were compared using the Student t test for continuous outcomes and χ2/Fisher's exact for categorical ones.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.2%):\n\nWe applied tests for interstudy heterogeneity χ\n2 \n(Q test)\nand the I\n2 \nstatistic to assess the appropriateness of combining\nstudi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We applied tests for interstudy heterogeneity χ2 (Q test) and the I2 statistic to assess the appropriateness of combining studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nWe searched Medline, Embase and the Cochrane con-\ntrolled trials register from inception to July 2014 using the\nterms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed\nsilo’ and ‘silastic silo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed silo’ and ‘silastic silo’.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe literature search, assessment for in-\nclusion and data extraction were performed independently\nby three reviewers and disagreements resolved by\nconsensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search, assessment for inclusion and data extraction were performed independently by three reviewers and disagreements resolved by consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nWe searched Medline, Embase and the Cochrane con-\ntrolled trials register from inception to July 2014 using the\nterms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed\nsilo’ and ‘silastic silo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed silo’ and ‘silastic silo’.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe literature search, assessment for in-\nclusion and data extraction were performed independently\nby three reviewers and disagreements resolved by\nconsensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search, assessment for inclusion and data extraction were performed independently by three reviewers and disagreements resolved by consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nDetailed information was recorded regarding the type of\nstudy, patient’s age and gender, intraoperative details, and\npostoperative complications with particular emphasis on\nthe incidence and outcome of HAEC' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Detailed information was recorded regarding the type of study, patient’s age and gender, intraoperative details, and postoperative complications with particular emphasis on the incidence of HAEC.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nWe performed a systematic review of the literature to find\nout the current state of SIPES procedures, including age, tech-\nnical aspects, and operative outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review of the literature to find out the current state of SIPES procedures, including age, technical aspects, and operative outcomes.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.3%):\n\nAn electronic search in\nPubMed up to March 2012 was conducted with the following\nterms: ‘‘single’’ AND ‘‘incision’’ OR ‘‘site’’ OR ‘‘port’’ OR ‘‘tro-\ncar’’ AND ‘‘children.’’ Related articles were also reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎An electronic search in PubMed up to March 2012 was conducted with the following terms: “single” AND “incision” OR “site” OR “port” OR “trocar” AND “children.” Related articles were also reviewed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.3%):\n\n(n = 2888 patients), urological (n = 390 patients), gynecological\n(n = 27 patients), other abdominal (n = 874 patients), and tho-\nracic (n = 33 patients) procedures (Table 1' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We separated types of operations by systems: gastrointestinal (n = 2888 patients), urological (n = 390 patients), gynecological (n = 27 patients), other abdominal (n = 874 patients), and thoracic (n = 33 patients) procedures (Table 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nIn the search for less invasive procedures, ever since the\ndevelopment of laparoscopic surgery and with the limitations\nand equipment dependence of Natural Orifice Translumenal\nendoscopic surgery (NOTES\nÒ\n; American Society for Gastro-\nintestinal Endoscopy [Oak Brook, IL] and Society of American\nGastrointestinal and Endoscopic Surgeons [Los Angeles,\nCA]), this new approach through the umbilicus, a natural\nembrionary orifice, \n1 \nwas first reported in 1992 by Pelosi and\nPelosi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In the search for less invasive procedures, ever since the development of laparoscopic surgery and with the limitations and equipment dependence of Natural Orifice Translumenal endoscopic surgery (NOTES®; American Society for Gastrointestinal Endoscopy [Oak Brook, IL] and Society of American Gastrointestinal and Endoscopic Surgeons [Los Angeles, CA]), this new approach through the umbilicus, a natural embrionary orifice, was first reported in 1992 by Pelosi and Pelosi.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nArticles were considered eligible if they met the following\ninclusion criteria: (1) Operations were performed through a\nsingle incision. (2) The target population was children under\n18 years of age. (3) Operations performed exclusively by pe-\ndiatric surgeons. (4) Series larger than 100 patients were in-\ncluded for appendectomy operations. (5) Case reports, case\nseries, and comparative and prospective randomized trials\nwere included in other, nonappendectomy, operations be-\ncause of their low incidence. (6) Articles should include age,\noperative technical aspects, and operative outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Articles were considered eligible if they met the following inclusion criteria: (1) Operations were performed through a single incision. (2) The target population was children under 18 years of age. (3) Operations performed exclusively by pediatric surgeons. (4) Series larger than 100 patients were included for appendectomy operations. (5) Case reports, case series, and comparative and prospective randomized trials were included in other, nonappendectomy, operations because of their low incidence. (6) Articles should include age, operative technical aspects, and operative outcomes.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 86.7%):\n\nmes. An electronic search in\nPubMed up to March 2012 was conducted with the following\nterms: ‘‘single’’ AND ‘‘incision’’ OR ‘‘site’’ OR ‘‘port’’ OR ‘‘tro-\ncar’’ AND ‘‘children.’’ Related articles were also reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We performed an electronic search in PubMed up to March 2012 with the following terms: “single” AND “incision” OR “site” OR “port” OR “trocar” AND “children.” Related articles were also reviewed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\nAfter\napplying our eligibility criteria, we selected 78 articles \n6–83 \nto\nbe included in this systematic review (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎After applying our eligibility criteria, we selected 78 articles to be included in this systematic review (Fig. 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nAfter the PubMed search we identified 197 articles. After\napplying our eligibility criteria, we selected 78 articles \n6–83 \nto\nbe included in this systematic review (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎After the PubMed search we identified 197 articles. After applying our eligibility criteria, we selected 78 articles to be included in this systematic review (Fig. 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nAccording to evidence level we had 1 prospective ran-\ndomized controlled trial, 12 case-control studies, 49 case se-\nries, and 16 case reports (Table 2' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎According to evidence level we had 1 prospective randomized controlled trial, 12 case-control studies, 49 case series, and 16 case reports (Table 2).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nFrom this systematic review we conclude:\n\u000f A wide experience in SIPES and its feasibility have al-\nready been described with good clinical outcomes and\nlow rate of conversio' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From this systematic review we conclude: A wide experience in SIPES and its feasibility have already been described with good clinical outcomes and low rate of conversion.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.3%):\n\nFinally, it is suggested that performing pediatric endo-\nsurgery through multiple incisions for small cannulas and/\nor stab incisions (initially described by Ostlie and Holcomb, \n100\nnoted by Rothenberg et al.\n101 \n), so-called ‘‘minilaparo-\nscopy,’’ \n102 \n‘‘reduced port’’ surgery, or ‘‘hydrid surgery’’ in\nadults, \n103 \nprovides a safe and feasible surgery in children,\nresulting in minimal trauma and scar' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Finally, it is suggested that performing pediatric endosurgery through multiple incisions for small cannulas and/or stab incisions (initially described by Ostlie and Holcomb, noted by Rothenberg et al.), so-called “minilaparoscopy,” “reduced port” surgery, or “hydrid surgery” in adults, in children, provides a safe and feasible surgery in children, resulting in minimal trauma and scars.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):\n\nThis review compares laparoscopic and conventional surgery with\nregard to several peri- and post-operative variables. It addresses\ndiagnostic and therapeutic laparoscopy separately. Furthermore, it\naims at identifying certain subgroups of patients, in which one of\nthe techniques might be more appropriate than the other.\nM E T H O D S\nCriteria for considering studies for this review\nTypes of studies\nAll randomized controlled trials comparing laparoscopic surgery\nand open appendectomy for acute appendicitis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This review compares laparoscopic and conventional surgery with regard to several peri- and post-operative variables.\", \"Types of studies: All randomized controlled trials comparing laparoscopic surgery and open appendectomy for acute appendicitis.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.5%):\n\nIn order to be as comprehensive as possible, the following\nsearch strategies were employed to identify all relevant studies\nirrespective of language. Studies predating 1983 were not searched\nfor, because the first laparoscopic appendectomy was described in\nthat year.\nElectronically, we searched the Cochrane Library, MEDLINE\n(PubMed), EMBASE, SciSearch and Biosis.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎In order to be as comprehensive as possible, the following search strategies were employed to identify all relevant studies irrespective of language.\", \"Electronically, we searched the Cochrane Library, MEDLINE (PubMed), EMBASE, SciSearch and Biosis.\", \"Abstracts presented to the following international scientific societies were handsearched:&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 61.2%):\n\nTwo reviewers independently assessed trial quality. Missing information or data was requested from the authors.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two reviewers independently assessed trial quality. Missing information or data was requested from the authors.\", \"The quality of all included studies was moderate to poor (Figure 1).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.9%):\n\nre. For complication\nrates, however, Peto&#39;s odds ratios (OR) were calculated, because\nsimulation studies by Deeks et al. have shown, that this effect\nmeasure is the most robust when dealing with rare or extremely rare\nevents (Deeks 1999' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We pooled the effect measures within a random effects model (DerSimonian 1986), because these outcomes are heavily influenced by the context of care.\", \"For complication rates, however, Peto's odds ratios (OR) were calculated, because simulation studies by Deeks et al. have shown, that this effect measure is the most robust when dealing with rare or extremely rare events (Deeks 1999).&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 83.1%):\n\nure. The funnel plot showed no signs of publication bias' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Furthermore, the funnel plot showed no signs of publication bias.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 83.1%):\n\nure. The funnel plot showed no signs of publication bias' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Furthermore, the funnel plot showed no signs of publication bias.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nA systematic PubMed search was performed to identify\npublications that analyzed outcomes for LD or OD pull-through\nprocedures for HD. All studies between January 1994 and De-\ncember 2014 were included in the search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 72.6%):\n\nOVID was used to search for articles focusing on the treatment of\npediatric esophageal achalasia with PD versus HM.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎OVID was used to search for articles focusing on the treatment of pediatric esophageal achalasia with PD versus HM.\" \"The last search was run on May 4, 2014.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.3%):\n\nNo funding was used.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎No funding was used\" and \"None&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nA comprehensive search was conducted using MEDLINE/\nPubMed, CINHAL, EMBASE/OVID, and CENTRAL (the\nCochrane library) electronic databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted using MEDLINE/PubMed, CINHAL, EMBASE/OVID, and CENTRAL (the Cochrane library) electronic databases.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.9%):\n\nAn assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An assessment of publication bias should include graphical aids and/or statistical tests.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.3%):\n\nWe performed a\nsystematic review of the literature regarding routine anti-\nreflux medication' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review of the literature regarding anti-reflux medication...&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.9%):\n\nA comprehensive search of MEDLINE, EM-\nBASE, CENTRAL, and grey literature was performed\n(2000–2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search of MEDLINE, EMBASE, CENTRAL, and grey literature was performed (2000–2014).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nA comprehensive search was conducted of MEDLINE/\nPubMed, EMBASE/OVID and CENTRAL (the Cochrane\nLibrary) electronic databases from 2000 to March 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nPatient characteristics of the included studies are summa-\nrized in Tables 1 and 2' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patient characteristics of the included studies are summarized in Tables 1 and 2.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nWe appraised the quality of reporting of the included\nstudies in duplicate (AS and ML), with discrepancies\nresolved by discussion and consensus. We used the\nMethodological Index for Nonrandomized Studies (MIN-\nORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We appraised the quality of reporting of the included studies in duplicate, with discrepancies resolved by discussion and consensus. We used the Methodological Index for Nonrandomized Studies (MINORS).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 52.3%):\n\nTwo reviewers (Huo-Jian Shen and Ming Xu) abstracted\nrelevant information from each eligible article using a\nstandardized form independently' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The citations within the reference lists of the articles were searched manually to identify additional eligible studies.\" \"Two reviewers (Huo-Jian Shen and Ming Xu) abstracted relevant information from each eligible article using a standardized form independently.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nWe searched databases, including PubMed, Embase, the\nScience Citation Index, and Cochrane Library updated to\nNovember 2014, to identify all related published studies\ncomparing the laparoscopic and the open choledochal cyst\nexcision with hepaticojejunostomy. The keywords used in\nthe search were as follows: laparoscopic, open, hepatico-\njejunostomy, choledochal cysts' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched databases, including PubMed, Embase, the Science Citation Index, and Cochrane Library updated to November 2014, to identify all related published studies comparing the laparoscopic and the open choledochal cyst excision with hepaticojejunostomy. The keywords used in the search were as follows: laparoscopic, open, hepaticojejunostomy, choledochal cysts.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nWe searched the MEDLINE, EM-\nBASE and CINAHL available through the National Library\nof Health website, the Cochrane library and PubMed dat-\nabases available online' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched the MEDLINE, EMBASE and CINAHL available through the National Library of Health website, the Cochrane library and PubMed databases available online.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.4%):\n\nsearches of MEDLINE (PubMed), EMBase, Goo-\ngle Scholar, and Cochrane Libraries were c' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes]\" - Searched MEDLINE, EMbase, Google Scholar. Also searched journals and reference lists.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nTo identify all publications comparing\nLAP versus open surgery for intussusception in children, two\nresearchers independently searched the electronic databases\nMEDLINE, Embase, CINAHL, and the Cochrane Library,\nusing the MeSH terms ‘‘intussusception,’’ ‘‘pediatric,’’ and\n‘‘laparoscopic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To identify all publications comparing LAP versus open surgery for intussusception in children, two researchers independently searched the electronic databases MEDLINE, Embase, CINAHL, and the Cochrane Library, using the MeSH terms ‘intussusception,’ ‘pediatric,’ and ‘laparoscopic.’&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nTwo researchers independently screened\nthe title and abstract of identified articles for potential eligi-\nbility and retrieved the full-text version of all articles deemed\nrelevant' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently screened the title and abstract of identified articles for potential eligibility and retrieved the full-text version of all articles deemed relevant.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nTo identify all publications comparing\nLAP versus open surgery for intussusception in children, two\nresearchers independently searched the electronic databases\nMEDLINE, Embase, CINAHL, and the Cochrane Library,\nusing the MeSH terms ‘‘intussusception,’’ ‘‘pediatric,’’ and\n‘‘laparoscopic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To identify all publications comparing LAP versus open surgery for intussusception in children, two researchers independently searched the electronic databases MEDLINE, Embase, CINAHL, and the Cochrane Library, using the MeSH terms ‘intussusception,’ ‘pediatric,’ and ‘laparoscopic.’&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThe Ovid (Ovid Technologies New York, NY) and Medline search en-\ngines were used to examine both the Pubmed and Cochrane libraries\nfrom January 2000 to December 2008' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Ovid (Ovid Technologies New York, NY) and Medline search engines were used to examine both the Pubmed and Cochrane libraries from January 2000 to December 2008.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nReview Manager (RevMan) software version 5.0. (Copenhagen: The\nNordic Cochrane Centre, The Cochrane Collaboration, 2008) was uti-\nlized to perform the meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review Manager (RevMan) software version 5.0 was utilized to perform the meta-analysis.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nWe sought to analyze the most recent available publica-\ntions in order to determine the most effective operative\napproach for these small, fragile, and critically ill\ninfants' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We sought to analyze the most recent available publications in order to determine the most effective operative approach for these small, fragile, and critically ill infants.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTwo authors reviewed all the abstracts independently.\nAgreement regarding potential relevance was reached by\nconsensus. Full-text copies of potentially eligible papers\nwere obtained, and the same 2 reviewers independently ex-\ntracted relevant data on study characteristics and the out-\ncomes of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors reviewed all the abstracts independently. Agreement regarding potential relevance was reached by consensus. Full-text copies of potentially eligible papers were obtained, and the same 2 reviewers independently extracted relevant data on study characteristics and the outcomes of interest.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):\n\nMedline, Embase, Cinahl, and\nCochrane databases were searched electronically on April\n24, 2014, and then updated on May 11, 2015; the search\nwas limited to reports published after January 1, 1980. One\nauthor and 2 librarians were involved in the search, and com-\nbinations of the relevant medical subject heading terms, key\nwords, and word variants for “isomerism,” “heterotaxy,” “si-\ntus ambiguous,” “Ivemark,” and “malrotation” were used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PubMed, Embase, and Cinahl were searched electronically on April 24, 2014, and then updated on May 11, 2015; the search was limited to reports published after January 1, 1980. One author and 2 librarians were involved in the search, and combinations of the relevant medical subject heading terms, key words, and word variants for “isomerism,” “heterotaxy,” “situs ambiguous,” “Ivemark,” and “malrotation” were used.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nTwo authors reviewed all the abstracts independently.\nAgreement regarding potential relevance was reached by\nconsensus. Full-text copies of potentially eligible papers\nwere obtained, and the same 2 reviewers independently ex-\ntracted relevant data on study characteristics and the out-\ncomes of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors reviewed all the abstracts independently... The same 2 reviewers independently extracted relevant data on study characteristics and the outcomes of interest.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 70.7%):\n\na systematic review and meta-analysis of the\neffectiveness of endoscopic surgery (ES) for neonatal CDH.\nMethods A systematic' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[This systematic review and meta-analysis of the effectiveness of endoscopic surgery (ES) for neonatal congenital diaphragmatic hernia (CDH)](154.pdf)&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 83.7%):\n\na systematic review and meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review and meta-analysis...&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nTwo independent authors (DT and BA) assessed study\nquality using the Newcastle-Ottawa Scale for case–\ncontrol and cohort studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors (DT and BA) assessed study quality using the Newcastle-Ottawa Scale for case–control and cohort studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 46.2%):\n\nn be accessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎None declared&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nIn this review, we sought\nto review the current published evidence of the outcomes of\nballoon dilatation of anastomotic strictures secondary to sur-\ngical repair of oesophageal atresia' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In this review, we sought to review the current published evidence of the outcomes of balloon dilatation of anastomotic strictures secondary to surgical repair of oesophageal atresia.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 86%):\n\nThis review is the second update of a previously published Cochrane review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review is the second update of a previously published Cochrane review.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):\n\nWe\nsearched MEDLINE, EMBASE, the Cochrane Controlled\nTrials Register, Google Scholar, and Scopus electronic\ndatabases for studies published between 1980 and 2014\nbased on Preferred Reporting Items for Systematic reviews\nand Meta-Analyses (PRISMA) guidelines [19]. The exploded\nsearch terms were: “nephron-sparing surgery,” “partial neph-\nrectomy,” or “nephron sparing surgery,” restricted to\n“tumor,” “mass,” “Wilms,” “cancer,” or “renal cell carci-\nnoma.” These were then restricted to articles retrieved under\na second search for the exploded search terms “pediatric,”\n“child,” or “children\n”. Reference lists of included studies\nwere manually screened for any additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched MEDLINE, EMBASE, the Cochrane Controlled Trials Register, Google Scholar, and Scopus electronic databases for studies published between 1980 and 2014.\" \"Reference lists of included studies were manually screened for any additional studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nIn total, 4,022 patients were included. Of these, 1,632\nchildren (41%) were male patients. Reported ages ranged\nfrom o1 month to 18 years. Bilateral tumors were present\nin 1,153 (29%) patients' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total, 4,022 patients were included. Of these, 1,632 children (41%) were male patients...Bilateral tumors were present in 1,153 (29%) patients&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 32.1%):\n\nbles were tested using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Data were collected using specifically designed forms.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):\n\nEight of\nthese met the inclusion and exclusion criteria (\n►Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eight of these met the inclusion and exclusion criteria (Fig. 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nMethodological quality was assessed with the checklist pro-\nposed by Downs and Black,\n5 \nwith a maximum score of 32 for\nthe optimal study quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Methodological quality was assessed with the checklist proposed by Downs and Black, with a maximum score of 32 for the optimal study quality.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 43.2%):\n\nn abstract using the\ninclusi' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Abstract: Background...Conclusions...&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.1%):\n\nthis study, we therefore evaluated our own\nexperiences with colostomies in children with an anorectal\nmalformation, and performed a systematic review of the\nliterature on complications of colostomies in children with\nan anorectal malformation or Hirschsprung disease' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The aim of this study is therefore to evaluate our experiences with colostomies in children with an anorectal malformation, and performed a systematic review of the literature on complications of colostomies in children with an anorectal malformation or Hirschsprung disease.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.4%):\n\nInclusion and Exclusion Criteria\nStudies were eligible' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Inclusion and Exclusion Criteria: Studies were eligible...&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe general search terms were the\nsame for the three databases, which are as follows: anorectal\nmalformations, Hirschsprung disease, colostomy, and chil-\ndren' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The general search terms were the same for the three databases, which are as follows: anorectal malformations, Hirschsprung disease, colostomy, and children.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 32.1%):\n\nbles were tested using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Data were collected using specifically designed forms.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):\n\nEight of\nthese met the inclusion and exclusion criteria (\n►Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Eight of these met the inclusion and exclusion criteria (Fig. 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):\n\nTable 3 Systematic review: overview of included studie' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Table 3. Systematic review: overview of included studies&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.6%):\n\nConclusions The complication to be avoided in transverse colostomies is prolapse and\nthe surgical technique should be modified accordingly. The procedure of split sigmoid\ncolostomy is meticulous, and the risk of insufficient length for the reconstruction remains' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In conclusion, the complication to be avoided in transverse colostomies is prolapse and the surgical technique should be modified accordingly. The procedure of split sigmoid colostomy is meticulous, and the risk of insufficient length for the reconstruction remains.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 74.1%):\n\nconflict of interest in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Conflict of Interest: None.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nData extraction forms will be designed to include study design, participant characteristics, study\nsetting, intervention type and outcomes. Data will be extracted independently by two review au-\nthors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data extraction forms will be designed to include study design, participant characteristics, study setting, intervention type and outcomes. Data will be extracted independently by two review authors.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.2%):\n\nThe searches on Em-\nbase and Cochrane Library used the same words' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The searches on EmBASE and Cochrane Library used the same words.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.6%):\n\n) fulfilled the predefined inclusion criteria and\nwere included in the final analysis (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Twelve studies [2, 3, 10–19] fulfilled the predefined inclusion criteria and were included in the final analysis (Fig. 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nLevel of evidence and publication type was\nclassified according to the Oxford Center for Evidence-\nBased Medicine [5' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Level of evidence and publication type was classified according to the Oxford Center for Evidence-Based Medicine [5].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nPossible publication bias was analyzed by generating fun-\nnel plots of the studies used for all of the evaluated com-\nparisons of outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Possible publication bias was analyzed by generating funnel plots of the studies used for all of the evaluated comparisons of outcomes.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nTo conduct a systematic review and meta-anal-\nysis of studies comparing the perimeatal-based flap (PBF)\nand tubularized incised-plate (TIP) techniques for primary\nhypospadias repair and determine whether the two tech-\nniques had similar reported outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To conduct a systematic review and meta-analysis of studies comparing the perimeatal-based flap (PBF) and tubularized incised-plate (TIP) techniques for primary hypospadias repair and determine whether the two techniques had similar reported outcomes.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nOur inclusion criteria were as follows: primary hypo-\nspadias repair only; including both the PBF and TIP\ntechniques; at least one of the outcomes obtainable from\nstudy; comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our inclusion criteria were as follows: primary hypospadias repair only; including both the PBF and TIP techniques; at least one of the outcomes obtainable from study; comparative studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66%):\n\nThe PubMed, Embase and Cochrane databases\nwere searched using the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The PubMed, Embase and Cochrane databases were searched...The last search was in October 2012.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.2%):\n\nequently, the query results were pooled. All titles\nand abstracts were reviewed initially to select studies for full\nreview if they contained results of primary hypospadias repair\nincluding both the PBF and TIP techniques' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The eligibility determination...for each study were conducted independently by two of the authors...All titles and abstracts were reviewed initially to select studies for full review if they contained results of primary hypospadias repair including both the PBF and TIP techniques.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):\n\nThe variables assessed included\nfirst author, publication year and type, level of evidence,\npatient age and number, length of follow-up, patient\ncharacteristics, surgical techniques and details (coverage\nof the neo-urethra, suture material and fashion, urinary\ndiversion), and postoperative outcomes (fistula, meatal\nstenosis, wound dehiscence and cosmesis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The variables assessed included first author, publication year and type, level of evidence, patient age and number, length of follow-up, patient characteristics, surgical techniques and details...and postoperative outcomes (fistula, meatal stenosis, wound dehiscence and cosmesis).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nThe effect measures estimated were odds ratio (OR) for\ndichotomous data and weighted mean difference for con-\ntinuous data, both reported with 95 % confidence interval\n(CI' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The effect measures estimated were odds ratio (OR) for dichotomous data and weighted mean difference for continuous data, both reported with 95% confidence interval (CI).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nFrom the 94 citations initially identified, 12 studies [2, 3,\n10–19] including 690 cases (338 cases for PBF and 352\ncases for TIP) fulfilled the predefined inclusion criteria and\nwere included in the final analysis (Fig. 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎From the 94 citations initially identified, 12 studies [2, 3, 10–19] fulfilled the predefined inclusion criteria and were included in the final analysis (Fig. 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTwo reviewers independently assessed each included\nstudy and compared the scores for each item on the ap-\nplicable quality assessment tool to reach a consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two reviewers independently assessed each included study and compared the scores for each item on the applicable quality assessment tool to reach a consensus.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 81.6%):\n\nand quality assessed each\nrelevant study using AMSTAR for systematic reviews\n(SRs), Cochrane ‘Risk of bias’ tool for randomized con-\ntrolled trials (RCTs), and MINORS for non-randomized\nstudies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We used AMSTAR to assess the quality of all relevant systematic reviews, Cochrane ‘Risk of bias’ tool for randomized controlled trials, and MINORS for non-randomized studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 71.8%):\n\n. To miti-\ngate the potential bias related to the inclusion of non-ran-\ndomized studies, we took into consideration each study’s\nquality assessment results when drawing conclusions and\nmaking recommendations' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Due to the heterogeneity of the data, a meta-analysis was not possible.\" And \"To mitigate the potential bias related to the inclusion of non-randomized studies, we took into consideration each study’s quality assessment results when drawing conclusions and making recommendations.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nOne reviewer extracted data from each of the included\nstudies, and a second reviewer checked the data for accu-\nracy and completeness' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One reviewer extracted data from each of the included studies, and a second reviewer checked the data for accuracy and completeness.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.1%):\n\nmethods\nAn analysis of Medline-published therapeutic options in the\ntreatment of SBS was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A Medline-analysis of published therapeutic options in the treatment of SBS was performed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):\n\nA systemic review of Medline-cited studies\ndealing with current practice and future perspectives in\nthe treatment of short bowel in children was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic review of Medline-cited studies dealing with current practice and future perspectives in the treatment of short bowel in children was performed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nThe Cochrane Central Register of Controlled Trials (The Cochrane li-\nbrary Issue 7 of 12, July 2014), MEDLINE (January 1966 to August 2014)\nand EMBASE (1947 to August 2014) were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Cochrane Central Register of Controlled Trials (The Cochrane library Issue 7 of 12, July 2014), MEDLINE (January 1966 to August 2014) and EMBASE (1947 to August 2014) were searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nIn total 1669 children were\nincluded. Of this number 1405 (84%) were male and 264 (16%) were fe-\nmale. Nine hundred forty-five (57%) children had right-sided hernia and\n545 (33%) children had left-sided hernia at first presentation' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total 1669 children were included. Of this number 1405 (84%) were male and 264 (16%) were female. Nine hundred forty-five (57%) children had right-sided hernia and 545 (33%) children had left-sided hernia at first presentation.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nThe primary outcome was the overall incidence of MCIH in children\nwith unilateral inguinal hernia (i). Secondary outcomes consisted of in-\ncidence of MCIH in male versus female children (ii); in children younger\nthan 1 year of age versus older children (iii); in children with primarily\nright- versus primarily left-sided inguinal hernia (iv); and in children\nwith open versus cleft versus closed CPPV (v' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome was the overall incidence of MCIH in children with unilateral inguinal hernia (i). Secondary outcomes consisted of incidence of MCIH in male versus female children (ii); in children younger than 1 year of age versus older children (iii); in children with primarily right- versus primarily left-sided inguinal hernia (iv); and in children with open versus cleft versus closed CPPV (v).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nInclusion criteria consisted of prospective observational studies (a),\nwith minimal follow-up time of one year (b), assessing newborns, infants,\nchildren, adolescents and young adults, aged from 0 to 19 years (c), with-\nout contralateral groin exploration or laparoscopic closure of CPPV (d' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria consisted of prospective observational studies (a), with minimal follow-up time of one year (b), assessing newborns, infants, children, adolescents and young adults, aged from 0 to 19 years (c), without contralateral groin exploration or laparoscopic closure of CPPV (d).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThe initial MEDLINE search yielded 2747 references. Search of\nCENTRAL and EMBASE database returned 304 and 3443 references re-\nspectively, none in addition to prior search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The initial MEDLINE search yielded 2747 references. Search of CENTRAL and EMBASE database returned 304 and 3443 references respectively, none in addition to prior search.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nThe primary outcome was the overall incidence of MCIH in children\nwith unilateral inguinal hernia (i). Secondary outcomes consisted of in-\ncidence of MCIH in male versus female children (ii); in children younger\nthan 1 year of age versus older children (iii); in children with primarily\nright- versus primarily left-sided inguinal hernia (iv); and in children\nwith open versus cleft versus closed CPPV (v' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The primary outcome was the overall incidence of MCIH in children with unilateral inguinal hernia (i). Secondary outcomes consisted of incidence of MCIH in male versus female children (ii); in children younger than 1 year of age versus older children (iii); in children with primarily right- versus primarily left-sided inguinal hernia (iv); and in children with open versus cleft versus closed CPPV (v).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.9%):\n\nThe present meta-anlaysis shows that the overall risk of MCIH in\nchildren (aged 0–19 years) is 6' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The present meta-analysis shows that the overall risk of MCIH in children (aged 0–19 years) is 6%.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nRoutine contralateral groin exploration prevents a secondary opera-\ntion and hence reduces costs, the risks of a secondary anesthesia, dis-\ntress to child and parents and the possibility of metachronous\ncontralateral hernia incarceration. These risks have to be weighed\nagainst operative risks during contralateral hernia repair' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Routine contralateral groin exploration prevents a secondary operation and hence reduces costs, the risks of a secondary anesthesia, distress to child and parents and the possibility of metachronous contralateral hernia incarceration. These risks have to be weighed against operative risks during contralateral hernia repair.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nThe Medline (1990eDec 2009), Embase (1990eDec 2009) and\nCochrane databases were searched using the single search\nterm ‘hypospadias’ to ensure the broadest capture of rele-\nvant papers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term ‘hypospadias’ to ensure the broadest capture of relevant papers.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nThe Medline (1990eDec 2009), Embase (1990eDec 2009) and\nCochrane databases were searched using the single search\nterm ‘hypospadias’ to ensure the broadest capture of rele-\nvant papers. There were no other limits applied to the\nsearch' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term ‘hypospadias’ to ensure the broadest capture of relevant papers. There were no other limits applied to the search.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nWe conducted a comprehensive search of MEDLINE\n® \n,\nEmbase, CINAHL, SciELO, CENTRAL, Cochrane Data-\nbase of Systematic Reviews and reference lists of promi-\nnent studies from 1990 to 2010' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a comprehensive search of MEDLINE®, Embase, CINAHL, SciELO, CENTRAL, Cochrane Database of Systematic Reviews and reference lists of prominent studies from 1990 to 2010.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nWe conducted a comprehensive search of MEDLINE\n® \n,\nEmbase, CINAHL, SciELO, CENTRAL, Cochrane Data-\nbase of Systematic Reviews and reference lists of promi-\nnent studies from 1990 to 2010' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a comprehensive search of MEDLINE®, Embase, CINAHL, SciELO, CENTRAL, Cochrane Database of Systematic Reviews and reference lists of prominent studies from 1990 to 2010.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nAll published studies until July 30, 2010, were\nsearched with the terms laparoscopy, laparoscopic her-\nniorrhaphy, pediatric inguinal hernia, and open hernior-\nrhaphy from Medline (using PubMed as the search\nengine), Embase, Ovid, Web of Science, and Cochrane\ndatabases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All published studies until July 30, 2010, were searched with the terms laparoscopy, laparoscopic herniorrhaphy, pediatric inguinal hernia, and open herniorrhaphy from Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nStatistical heterogeneity was\nassessed using the I\n2 \nstatistics. If the I\n2 \nvalue was less than\n50%, then a fixed effects meta-analysis was applied; if the I\n2\nvalue was 50% or more, then the random effects meta-\nanalysis was used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Statistical heterogeneity was assessed using the I2 statistics. If the I2 value was less than 50%, then a fixed effects meta-analysis was applied; if the I2 value was 50% or more, then the random effects meta-analysis was used.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nin this systemic review and meta-\nanalysis, we demonstrated that LH is efficient for the\ninguinal hernia repair in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In this systemic review and meta-analysis, we demonstrated that LH is efficient for the inguinal hernia repair in children&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nThree reviewers (YCL, ZHY, and TQS) independently\nassessed selected studies, extracted, and tabulated data from\neach article with a predefined data extraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three reviewers independently assessed selected studies, extracted, and tabulated data from each article with a predefined data extraction form.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.7%):\n\nMEDLINE electronic\ndatabase was searched in April 2013 using key words\n‘‘postoperative intussusception' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MEDLINE database was searched in April 2013 using key words “postoperative intussusception”.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):\n\nMEDLINE electronic\ndatabase was searched in April 2013 using key words\n‘‘postoperative intussusception’’. References lists of iden-\ntified articles were screened for additional publications of\ninterest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MEDLINE electronic database was searched in April 2013 using key words “postoperative intussusception”. References lists of identified articles were screened for additional publications of interest.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.3%):\n\nFor the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎For the pooled results, a test should be done to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.1%):\n\nAn assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An assessment of publication bias should include a combination of graphical aids and/or statistical tests.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nObjectives To compare the safety and efficacy of mini-\nmally invasive surgery (MIS) with traditional open surgical\napproach for congenital diaphragmatic hernia (CDH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Objectives To compare the safety and efficacy of minimally invasive surgery (MIS) with traditional open surgical approach for congenital diaphragmatic hernia (CDH).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):\n\nA systematic search of the MEDLINE, PUBMED, and\nCochrane databases (June 2000 to April 2008) was\nconducted. The search terms used were “laparoscopic,”\n“pull-through,” “anorectal malformation,” and “imperforate\nanus.” In addition, a manual search of 4 surgical journals\nfrom the same period was performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic search of the MEDLINE, PUBMED, and Cochrane databases (June 2000 to April 2008) was conducted.\" \"In addition, a manual search of 4 surgical journals from the same period was performed.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.8%):\n\nthoracotomy (EDT) is rarely utilized in children, and is thus\ndifficult to identify survival factors. We reviewed our experience and performed a systematic review of reports\nof EDT in pediatric patients' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A resuscitative thoracotomy (RT) is rarely utilized in children, and is thus difficult to identify survival factors. We reviewed our experience and performed a systematic review of reports of RT in pediatric patients.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nWe reviewed\npatient records for the presence of vital signs (VS) and/or signs of life\n(SOL) in the field, time without VS in the field, presence of VS or SOL\nupon arrival, MOI, location of injuries, return of spontaneous circulation\n(ROSC), survival, and neurological function of the survivors upon dis-\ncharge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nFor our systematic review of the published data, we obtained all case\nseries regarding pediatric EDT and combined the data from those\nreports with the data from our institution (Table 1) [6–13]. These\nreports were obtained from a Medline search for all publications\nregarding EDT in the pediatric population for the past 40 year using\nthe keywords “thoracotomy”, “emergency”, “trauma”, “resuscitation”,\n“pediatrics”, and “children”. Bibliographies of relevant publications\nwere reviewed to identify reports that were not initially located with\nthe Medline search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For our systematic review of the published data, we obtained all case series regarding pediatric RT and combined the data from those reports with the data from our institution (Table 1) [6–13]. These reports were obtained from a Medline search for all publications regarding RT in the pediatric population for the past 40 year using the keywords “thoracotomy”, “emergency”, “trauma”, “resuscitation”, “pediatrics”, and “children”. Bibliographies of relevant publications were reviewed to identify reports that were not initially located with the Medline search.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nVariables extracted from each report include demo-\ngraphics, MOI, injury location, presence of VS and/or SOL upon arrival,\nROSC, survival to discharge, and neurologic outcomes for survivors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variables extracted from each report include demographics, MOI, injury location, presence of VS and/or SOL upon arrival, ROSC, survival to discharge, and neurologic outcomes for survivors.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nDemo-\ngraphics obtained from our trauma registry included age, sex, mecha-\nnism of injury (MOI), and Injury Severity Score (ISS). We reviewed\npatient records for the presence of vital signs (VS) and/or signs of life\n(SOL) in the field, time without VS in the field, presence of VS or SOL\nupon arrival, MOI, location of injuries, return of spontaneous circulation\n(ROSC), survival, and neurological function of the survivors upon dis-\ncharge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Demographics obtained from our trauma registry included age, sex, mechanism of injury (MOI), and Injury Severity Score (ISS). We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nAlthough each series differs in the specific data reported, the informa-\ntion obtained was pooled and analyzed using the variables and\noutcomes reported by each series' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Although each series differs in the specific data reported, the information obtained was pooled and analyzed using the variables and outcomes reported by each series.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nBackground/purpose: The emergency department thoracotomy (EDT) is rarely utilized in children, and is thus\ndifficult to identify survival factors. We reviewed our experience and performed a systematic review of reports\nof EDT in pediatric patients.\nMethods: Patients age ≤18 years who received an EDT from 1991 to 2012 at our institution and all published case\nseries were reviewed. Data analyzed include age, sex, mechanism of injury (MOI), injury patterns, presence of\nvital signs (VS) or signs of life (SOL) in the field/ED, return of spontaneous circulation (ROSC), and survival.\nResults: A total of 252 patients were analyzed. 84% were male. 51% sustained penetrating injuries, and median age\nwas 15 years. Upon arrival, 17% had VS, and 35% had SOL. After EDT, 30% experienced ROSC. The survival rate was\n1.6% for blunt trauma, 10.2% for penetrating injuries, and 6.0% overall.\nConclusion: Survival of pediatric patients following EDT is comparable to recent analyses in adults. Children who\nsustain blunt injury and are without SOL have been uniformly unsalvageable. Children who sustain penetrating\ntrauma and have SOL or are without SOL for a short time prior to arrival have been salvageable. There are no\nreported EDT survivors less than 14 years of age following blunt injury' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎a b s t r a c t [...] Background/purpose: The emergency department thoracotomy (EDT) is rarely utilized in children, and is thus difficult to identify survival factors. We reviewed our experience and performed a systematic review of reports of EDT in pediatric patients. Methods: Patients age ≤18 years who received an EDT from 1991 to 2012 at our institution and all published case series were reviewed. Data analyzed include age, sex, mechanism of injury (MOI), injury patterns, presence of vital signs (VS) or signs of life (SOL) in the field/ED, return of spontaneous circulation (ROSC), and survival. Results: A total of 252 patients were analyzed. 84% were male. 51% sustained penetrating injuries, and median age was 15 years. Upon arrival, 17% had VS, and 35% had SOL. After EDT, 30% experienced ROSC. The survival rate was 1.6% for blunt trauma, 10.2% for penetrating injuries, and 6.0% overall. Conclusion: Survival of pediatric patients following EDT is comparable to recent analyses in adults. Children who sustain blunt injury and are without SOL have been uniformly unsalvageable. Children who sustain penetrating trauma and have SOL or are without SOL for a short time prior to arrival have been salvageable. There are no reported EDT survivors less than 14 years of age following blunt injury.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 87.2%):\n\nWith recent reports showing the\ndetrimental outcomes associated with a prolonged pre-hospital period,\nthere has been a push for emergency medical services in urban environ-\nments to “scoop and run” rather than “stay and play” [17,18]. Many of\nthese patients in the past would have been pronounced dead at the\nscene or at their community hospital emergency department. During\nthis development, the resuscitative thoracotomy was also added as an\nextension to ATLS techniques [19]. Now after 30 years, we are able to\nTable 1\nSystematic review of the published case series regarding pediatric' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎With recent reports showing the detrimental outcomes associated with a prolonged pre-hospital period, there has been a push for emergency medical services in urban environments to “scoop and run” rather than “stay and play” [17,18]. Many of these patients in the past would have been pronounced dead at the scene or at their community hospital emergency department. During this development, the resuscitative thoracotomy was also added as an extension to ATLS techniques [19]. Now after 30 years, we are able to systematically review the current literature with this relatively aggressive resuscitative measure in the pediatric population.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nDemo-\ngraphics obtained from our trauma registry included age, sex, mecha-\nnism of injury (MOI), and Injury Severity Score (ISS). We reviewed\npatient records for the presence of vital signs (VS) and/or signs of life\n(SOL) in the field, time without VS in the field, presence of VS or SOL\nupon arrival, MOI, location of injuries, return of spontaneous circulation\n(ROSC), survival, and neurological function of the survivors upon dis-\ncharge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Demographics obtained from our trauma registry included age, sex, mechanism of injury (MOI), and Injury Severity Score (ISS). We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nVariables extracted from each report include demo-\ngraphics, MOI, injury location, presence of VS and/or SOL upon arrival,\nROSC, survival to discharge, and neurologic outcomes for survivors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variables extracted from each report include demographics, MOI, injury location, presence of VS and/or SOL upon arrival, ROSC, survival to discharge, and neurologic outcomes for survivors.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nDemo-\ngraphics obtained from our trauma registry included age, sex, mecha-\nnism of injury (MOI), and Injury Severity Score (ISS). We reviewed\npatient records for the presence of vital signs (VS) and/or signs of life\n(SOL) in the field, time without VS in the field, presence of VS or SOL\nupon arrival, MOI, location of injuries, return of spontaneous circulation\n(ROSC), survival, and neurological function of the survivors upon dis-\ncharge' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Demographics obtained from our trauma registry included age, sex, mechanism of injury (MOI), and Injury Severity Score (ISS). We reviewed patient records for the presence of vital signs (VS) and/or signs of life (SOL) in the field, time without VS in the field, presence of VS or SOL upon arrival, MOI, location of injuries, return of spontaneous circulation (ROSC), survival, and neurological function of the survivors upon discharge.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nVariables extracted from each report include demo-\ngraphics, MOI, injury location, presence of VS and/or SOL upon arrival,\nROSC, survival to discharge, and neurologic outcomes for survivors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variables extracted from each report include demographics, MOI, injury location, presence of VS and/or SOL upon arrival, ROSC, survival to discharge, and neurologic outcomes for survivors.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.5%):\n\nOverall, the mortality rates are\ncomparable between adults and pediatric patients following EDT' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Overall, the mortality rates are similar between adults and pediatric patients following EDT.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nPublication bias also exists. It is likely other institu-\ntions have performed this procedure over the same time period,\nhowever none were published' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Publication bias also exists. It is likely other institutions have performed this procedure over the same time period, however none were published.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nOur review allows considerable trends to be made regarding this contro-\nversial topic. Overall, although outcomes appear similar to that of the\nadult population, there may be less benefit in the younger pediatric\npatient and in those who arrive without SOL after sustaining blunt\nforce injury' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our review allows considerable trends to be made regarding this controversial topic. Overall, although outcomes appear similar to that of the adult population, there may be less benefit in the younger pediatric patient and in those who arrive without SOL after sustaining blunt force injury.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nThe review was conducted according to a pre-specified protocol. The protocol was registered\non the Prospero International Prospective Register of Systematic Reviews' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[The review] was conducted according to a pre-specified protocol. The protocol was registered on the Prospero International Prospective Register of Systematic Reviews.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nIdentified titles were assessed for inclusion by two investigators (BA and WT) acting indepen-\ndently. Any conflicts were resolved by a third investigator (MK). Data from included articles\nwere extracted independently by the same two investigators (BA and WT), and any differences\nresolved by discussion' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Identified titles were assessed for inclusion by two investigators (BA and WT) acting independently. Any conflicts were resolved by a third investigator (MK). Data from included articles were extracted independently by the same two investigators (BA and WT), and any differences resolved by discussion.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nMultiple search strategies were used to\nidentify relevant articles from Medline, Embase, Cinahl, the Cochrane library, and Google\nscholar, published between 1\nst \nJanuary 2000 and 31\nst \nDecember 2012' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Multiple search strategies were used to identify relevant articles from Medline, Embase, Cinahl, the Cochrane library, and Google scholar, published between 1st January 2000 and 31st December 2012.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.3%):\n\nquestion if scored “no' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎yes\" because question A7 was scored \"no&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nUsing a conservative cut-off of p<0.01, no statisti-\ncal heterogeneity was detected and therefore fixed-effect methods were used throughout' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using a conservative cut-off of p<0.01, no statistical heterogeneity was detected and therefore fixed-effect methods were used throughout.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nThe aim of this study, therefore, was to perform a systematic review of the literature com-\nparing outcomes of infants with simple gastroschisis following either OPFC or SR' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of this study, therefore, was to perform a systematic review of the literature comparing outcomes of infants with simple gastroschisis following either OPFC or SR.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nDi-\nchotomous outcomes were meta-analysed using Mantel–Haenszel fixed effects methods to\nproduce summary odds ratios with 95% confidence intervals. Continuous variables were meta-\nanalysed using the inverse-variance fixed-effect method to produce weighted mean differences\nand 95% confidence intervals' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Dichotomous outcomes were meta-analysed using Mantel–Haenszel fixed effects methods to produce summary odds ratios with 95% confidence intervals. Continuous variables were meta-analysed using the inverse-variance fixed-effect method to produce weighted mean differences and 95% confidence intervals.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nOur review’s conclusions are ham-\npered by the quality and the small sample size of the most\nincluded studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our review’s conclusions are hampered by the quality and the small sample size of the most included studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nOwing to the absence of any randomized controlled trials\nand the heterogeneous nature of studies, a formal meta-\nFig. 1 Algorithm for the studies selection (based on PRISMA guidelines).\n1790 N. Apelt et al.\n\nanalysis was not performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Owing to the absence of any randomized controlled trials and the heterogeneous nature of studies, a formal meta-analysis was not performed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nOwing to the absence of any randomized controlled trials\nand the heterogeneous nature of studies, a formal meta-\nFig. 1 Algorithm for the studies selection (based on PRISMA guidelines).\n1790 N. Apelt et al.\n\nanalysis was not performed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Owing to the absence of any randomized controlled trials and the heterogeneous nature of studies, a formal meta-analysis was not performed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nAll English language articles pub-\nlished by August 2013, irrespective of design, describing the\nmanagement of, and outcome after, RTEF in children under\n18 years were reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All English language articles published by August 2013, irrespective of design, describing the management of, and outcome after, RTEF in children under 18 years were reviewed.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 82.4%):\n\nA Medline, Embase, and web of science searches were performed\nusing the keywords recurrent tracheoesophageal fistula. The\nindex of all issues of the European Journal of Pediatric Surgery,\nJournal of Pediatric Surgery, Pediatric Surgery International, and\nthe International Journal of Pediatric Otorhinolaryngology was\nsearched for relevant articles; the reference list of all relevant\narticles was also searched. All English language articles pub-\nlished by August 2013, irrespective of design, describing the\nmanagement of, and outcome after, RTEF in children under\n18 years were reviewed. The' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A Medline, Embase, and web of science searches were performed using the keywords “recurrent tracheoesophageal fistula.” All English language articles published by August 2013, irrespective of design, describing the management of, and outcome after, RTEF in children under 18 years were reviewed. The reference list of all relevant articles was also searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nReference lists from the re-\ntrieved articles were then hand searched to identify additional po-\ntentially relevant articles' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References lists from the retrieved articles were then hand searched to identify additional potentially relevant articles.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 34.8%):\n\nreview), based on their publication status, language etc. Note: If review indicates that there' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎One reviewer extracted data from the original publications and a senior reviewer checked the data and the reliability of the analysis, including Independent reviews of the articles.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 31.1%):\n\nesophageal stenosis and\nstricture with special emphasis on pediatric data. The screen\nincluded the use of Mitomycin C' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Databases searched included: PubMed, Scopus, Web of Science, June 2011. Key words used in different cross-combinations: esophagus, esophageal, stenosis, stricture, corrosive, caustic, mitomycin C.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 45%):\n\nreened for publications regard-\ning the application of Mitomycin C in esophageal stenosis and\nstricture with special emphasis on pediatric data. The screen\nincluded the use of Mitomycin C in' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data extracted from the reports included patient demographics, indication for Mitomycin C application, stricture characteristics, dosage, regimen and technique of Mitomycin C administration, adverse events, and outcomes.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThis review was con-\nducted to evaluate the clinical and cost-effective-\nness of this approach for a variety of different\nsurgical indications in pediatric populations' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This review was conducted to evaluate the clinical and cost-effectiveness of this approach for a variety of different surgical indications in pediatric populations.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nTwo\nauthors independently screened the abstracts and extrac-\ntion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nThree doctors reviewed the abstracts. Articles rel-\nevant to the topic of the review were selected by consen-\nsus. A second review was performed of these studies and\ntheir bibliographies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three doctors reviewed the abstracts. A second review was performed of these studies and their bibliographies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60%):\n\nN\nThe present review' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎In the present review study...&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 82.8%):\n\nA systematic search of the literature published after 06/1995\nwas performed in 06/2015 using the keyword “hypospadias' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎[We performed a systematic review of the literature published after 06/1995 was performed in 06/2015 using the keyword “hypospadias.\"]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nThree databases, namely, MEDLINE/PubMed, Scopus,\nand The Cochrane library, were searched for using the free text\n“hypospadias repair,” in all fields of the records for MEDLINE/\nPubMed search, and in the Title and Topic fields for the Web of\nScience and Cochrane library searches' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Three databases, namely, MEDLINE/PubMed, Scopus, and The Cochrane library, were searched for using the free text “hypospadias repair,” in all fields of the records for MEDLINE/PubMed search, and in the Title and Topic fields for the Web of Science and Cochrane library searches.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):\n\na meta-analysis\nof case–control and randomized studies comparing PR vs.\ncircumcision was performed. Two different outcomes were used\nfor the meta-analysis, namely, “hypospadias fistula formation”\nand “overall reoperation rate.” The analysis was conducted using\nReview Manager v5.2 software designed for composing Cochrane\nReviews (Cochrane Collaboration, Oxford, UK). Statistical heter-\nogeneity was tested using the chi-square test' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[A meta-analysis of studies comparing PR vs. circumcision was performed for the outcomes “hypospadias fistula formation” and “reoperation rate.” The analysis was conducted using Review Manager v5.2 software designed for composing Cochrane Reviews (Cochrane Collaboration, Oxford, UK). Statistical heterogeneity was tested using the chi-square test.]&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 82.5%):\n\nIdeal timing of orchiopexy: a systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Abstract: Ideal timing of orchiopexy: a systematic review&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.2%):\n\nThe ideal management of cryptorchidism is a\nhighly debated topic within the field of pediatric surgery.\nThe optimal timing of orchiopexy is particularly unclear, as\nexisting literature reports mixed recommendations' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The ideal timing of orchiopexy is a highly debated topic within the field of pediatric surgery. The optimal timing of orchiopexy is particularly unclear, as existing literature reports mixed recommendations.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nOur initial search of MEDLINE, Embase and CENTRAL yielded 160\nstudies (Fig. 1). After applying our exclusion criteria, 9 studies\nremained. We identified one additional relevant study through hand-\nsearching, thus we included 10 studies in total [8–17' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Our initial search of MEDLINE, Embase and CENTRAL yielded 160 studies (Fig. 1). After applying our exclusion criteria, 9 studies remained. We identified one additional relevant study through hand-searching, thus we included 10 studies in total [8–17].]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.7%):\n\nTwo researchers independently assessed each study for method-\nological quality using MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two researchers independently assessed each study for methodological quality using MINORS.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):\n\nFor\neach outcome, we first assessed the heterogeneity of the studies (Chi \n2\ntest and I \n2 \nstatistic). When heterogeneity was low to moderate (Q test\np N 0.10, I \n2 \nb 50%), we used a fixed-effects model. When heterogeneity\nwas moderate to high (Q test p b 0.10, I \n2 \nN 50%), we used a random-\neffects model [7]. We used weighted mean differences to analyze\ncontinuous data and odds ratios to analyze categorical variables' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[For each outcome, we first assessed the heterogeneity of the studies (Chi2 test and I2 statistic)...We used weighted mean differences to analyze continuous data and odds ratios to analyze categorical variables.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.7%):\n\nTwo researchers independently assessed each study for method-\nological quality using MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Two researchers independently assessed each study for methodological quality using MINORS.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):\n\nFor\neach outcome, we first assessed the heterogeneity of the studies (Chi \n2\ntest and I \n2 \nstatistic). When heterogeneity was low to moderate (Q test\np N 0.10, I \n2 \nb 50%), we used a fixed-effects model. When heterogeneity\nwas moderate to high (Q test p b 0.10, I \n2 \nN 50%), we used a random-\neffects model [7]. We used weighted mean differences to analyze\ncontinuous data and odds ratios to analyze categorical variables' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[For each outcome, we first assessed the heterogeneity of the studies (Chi2 test and I2 statistic)...We used weighted mean differences to analyze continuous data and odds ratios to analyze categorical variables.]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 50.7%):\n\npatients; 444 underwent\nTERPT and 348 underwent' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎patients underwent TERPT and TAB between 1990 to 2008 at each centre.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nMedline and Embase databases were searched using rele-\nvant key search terms (pelviureteric junction, ureter-\nopelvic junction, obstruction, paediatric, pediatric, child$,\nballoon, dilatation, endopyelotomy, open, laparoscopic,\npyeloplasty' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Embase databases were searched using relevant key search terms (pelviureteric junction, ureteropelvic junction, obstruction, paediatric, pediatric, child$, balloon, dilatation, endopyelotomy, open, laparoscopic, pyeloplasty).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.2%):\n\nReview article\nOutcomes of endopyelotomy for\npelviureteric junction obstruction in the\npaediatric population: A systematic\nreview' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review article: Outcomes of endopyelotomy for pelviureteric junction obstruction in the paediatric population: A systematic review&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nWe\nhypothesized that the complication(s) associated with surgical cor-\nrection outweighed the risk of midgut volvulus and its sequelae and\nthat screening in ‘‘asymptomatic patients’’ was unnecessary' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We hypothesized that the complication(s) associated with surgical correction outweighed the risk of midgut volvulus and its sequelae and that screening in “asymptomatic patients” was unnecessary.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nSystematic literature searches were undertaken of the\nCochrane Central Register of Controlled Trials (CENTRAL),\nPubMed, Ovid Medline and EMBASE electronic databases\nusing the following search strategy using the following\nMedical Subject Headings (MeSH): (‘Surgery,\nComputer-Assisted’ OR ‘robotics’ OR ‘da Vinci’ OR ‘telerobotic’\nOR ‘telesurgery’ OR ‘robotic surgery’) AND (‘Pediatrics’ OR\n‘Infant’ OR ‘Child’ OR ‘Adolescent’) AND (‘Kidney’ OR\n‘Pelvi-ureteric Junction Obstruction’ OR ‘Pyeloplasty’). The\nsearch was conducted up to December 2013. The primary\nsearch was supplemented with searches of: i) PubMed related\narticles feature, ii) clinicaltrials.gov registry using the keyword\n‘pyeloplasty’, and iii) abstracts of the International Pediatric\nEndosurgery Group Annual Congresses' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Systematic literature searches were undertaken of the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Ovid Medline and EMBASE electronic databases using the following search strategy using the following Medical Subject Headings (MeSH):...The search was conducted up to December 2013. The primary search was supplemented with searches of: i) PubMed related articles feature, ii) clinicaltrials.gov registry using the keyword ‘pyeloplasty’, and iii) abstracts of the International Pediatric Endosurgery Group Annual Congresses...&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 83%):\n\nSystematic literature searches were undertaken of PubMed and\nEMBASE electronic databases using the following search strategy\n(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da\nVinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND\n(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-\nlescent”\n[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-\nal reflux”[MeSH]). The search period was defined as June 2001 to June\n2013 inclusively. The primary search was supplemented with\nsearches of 1) PubMed related articles feature, 2) clinicaltrials.gov\nregistry using the keyword “fundoplication”, and 3) abstracts of the\nJournal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the International Pediatric Endosurgery Group annual congress from 2002 to 2013.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 83%):\n\nSystematic literature searches were undertaken of PubMed and\nEMBASE electronic databases using the following search strategy\n(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da\nVinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND\n(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-\nlescent”\n[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-\nal reflux”[MeSH]). The search period was defined as June 2001 to June\n2013 inclusively. The primary search was supplemented with\nsearches of 1) PubMed related articles feature, 2) clinicaltrials.gov\nregistry using the keyword “fundoplication”, and 3) abstracts of the\nJournal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the International Pediatric Endosurgery Group annual congress from 2002 to 2013.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):\n\nThe search strategy was as\nfollows: (single-port or single-incision or single-access or\nsingle-site or single or one) AND (laparoscopic or\nlaparoscopy or minimal invasive surgery) AND (appendec-\ntomy or appendi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search strategy was as follows: (single-port or single-incision or single-access or single-site or single or one) AND (laparoscopic or laparoscopy or minimal invasive surgery) AND (appendectomy or appendix).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.2%):\n\nWe used a star scoring system [12] based on criteria related\nto study design, comparability of patient groups, and outcome' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We used a star scoring system [12] based on criteria related to study design, comparability of patient groups, and outcome assessment to assess literature quality.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 99.1%):\n\nFor the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nClinical studies published in the English literature were identi-\nfied by a Medline literature search using PubMed (www.\npubmed.com). The Web site was last accessed on January 2,\n2013. The search limits “humans,” “child: 0–18 years,” “english,”\n“randomized-controlled trials,” “comparative study,” “systemat-\nic reviews,” and “meta-analysis” were applied' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Clinical studies published in the English literature were identified by a Medline literature search using PubMed (www.pubmed.com). The Web site was last accessed on January 2, 2013. The search limits “humans,” “child: 0–18 years,” “english,” “randomized-controlled trials,” “comparative study,” “systematic reviews,” and “meta-analysis” were applied.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nthe main\nresults of the studies with regard to advantages and disad-\nvantages of laparoscopic compared with open surgery are\nsummarized in alphabetical order' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The main results of the studies with regard to advantages and disadvantages of laparoscopic compared with open surgery are summarized in alphabetical order.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nThe use of video-assisted thoracoscopic surgery (VATS) has\nevolved quickly and it has gained widespread acceptance\namong pediatric surgeons during the last decade. Thoraco-\nscopic approaches to a large variety of pediatric and neonatal\nsurgical disease have been described, and safety and feasibili-\nty of VATS have been demonstrated by a multitude of au-\nthors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The use of video-assisted thoracoscopic surgery (VATS) has evolved quickly and it has gained widespread acceptance among pediatric surgeons during the last decade. Thoracoscopic approaches to a large variety of pediatric and neonatal surgical disease have been described, and safety and feasibility of VATS have been demonstrated by a multitude of authors.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nClinical studies published in the English literature were identi-\nfied by a Medline literature search using PubMed (www.\npubmed.com). The Web site was last accessed on January 2,\n2013' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Clinical studies published in the English literature were identified by a Medline literature search using PubMed (www.pubmed.com). The Web site was last accessed on January 2, 2013.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nAccording to a recent CEBM classification,\nclinical studies can be graded into Levels 1 to 5 in descending\nquality.\n6 \nTo give a clear general recommendation for a certain\ntreatment, at least Level 3 evidence must be available. For\npediatric laparoscopy, we have recently shown that studies\nreaching the highest level of the CEBM classification are\navailable for only seven different types of minimally invasive\nabdominal procedures.\n5 \nThis study clearly shows that in the\nfield of pediatric VATS, the availability of high-quality studies is\neven more disenchanting. None of the available comparative\nstudies can be classified as Level 1 or Level 2 according to the\nCEBM criteria' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎According to a recent CEBM classification, clinical studies can be graded into Levels 1 to 5 in descending quality. To give a clear general recommendation for a certain treatment, at least Level 3 evidence must be available. For pediatric laparoscopy, we have recently shown that studies reaching the highest level of the CEBM classification are available for only seven different types of minimally invasive abdominal procedures. This study clearly shows that in the field of pediatric VATS, the availability of high-quality studies is even more disenchanting. None of the available comparative studies can be classified as Level 1 or Level 2 according to the CEBM criteria.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.6%):\n\n? The research question and inclusion criteria should be established before the conduc' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The research question and inclusion criteria are not clearly established a priori in the manuscript.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 39.1%):\n\nthere duplicate study selection and data extraction? There s' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The systematic review does not include a quantitative synthesis, so duplicate study selection and data extraction are not applicable.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40.7%):\n\nype. The authors should state whether or not they excluded any reports (from the systematic review),' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The authors state they performed a systematic review of PubMed, which would involve searching at least two databases.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 34.3%):\n\nreview of the recent\nliterature and meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[NA] Searching for gray literature is not applicable, as the review only includes RCTs and meta-analyses.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.4%):\n\nprovided. Note: Acceptable if the excluded studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Table 3 provides details of all included studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48%):\n\nere the characteristics of the included studies provided? In an aggregated form such as a' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Table 3 provides relevant characteristics of the included studies such as study design, sample size, outcomes assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.2%):\n\nt as a systematic review, meta-analysis, or both.\nP2. Provide a structured summary including, as applicable' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] This is a systematic review of RCTs and meta-analyses only, so assessing study quality is not applicable.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 28.8%):\n\nin quantitative synthesis (A9) or assessing' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] This systematic review does not involve quantitative synthesis, so incorporating study quality is not applicable.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 37.3%):\n\nin quantitative synthesis (A9) or assessing' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The review does not involve quantitative synthesis, so assessing heterogeneity is not applicable.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 54.7%):\n\nt as a systematic review, meta-analysis, or both.\nP2. Provide a structured summary including, as applicable' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] This is a systematic review of RCTs and meta-analyses only, so assessment of publication bias is not applicable.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.9%):\n\nthe systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The systematic review itself does not report sources of support. Assessment of support for individual included studies is not applicable.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.3%):\n\nthe report as a systematic review,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The report is identified as a systematic review in the title.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40%):\n\ncluded and excluded) provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] No structured abstract is provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.5%):\n\negistration number.\nP3. Describe the rationale for the review in the context of what is already know' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The introduction describes the rationale and background, placing the review in context of existing knowledge.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.6%):\n\nthe review in the context of what is already known.\nP4. Provide an explicit statement of questions being addressed with referen' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The review does not provide an explicit statement of objectives or questions with PICOS elements.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51.5%):\n\nIndicate if a review protocol exists' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The authors do not indicate whether a review protocol exists.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 28.6%):\n\ns comparing\nlaparoscopic and open surg' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Inclusion criteria of RCTs and meta-analyses comparing laparoscopic to open surgery are described in the methods.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 24.4%):\n\ninformation source' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The information source (PubMed) and search limits applied are described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 67.4%):\n\nthe search strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The full search strategy is not provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.9%):\n\nthe process for selecting studies (i.e., screenin' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The process of study selection is described in the methods section.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 51%):\n\nmethod of data extraction fr' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Methods for data extraction are not described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 54.4%):\n\nvariables for which data were sought' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Variables for which data were sought are not explicitly listed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.6%):\n\nassessing risk of bias of individual studies (including specification of whether this w' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Assessment of risk of bias in individual studies is not applicable for this review of RCTs and meta-analyses only.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 56.6%):\n\nnot applicable or not relevant to the text (for example, combining data in quantitative synthesis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Statistical methods are not applicable as quantitative synthesis was not done.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 21.2%):\n\nnd synthesis methods; results;' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Quantitative data synthesis was not performed, so items related to describing synthesis methods and results are not applicable.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65%):\n\nSummarize the main findings including the strength of evidence for each main outcome; consider their relevance' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The discussion summarizes the main findings and discusses their relevance.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.2%):\n\nlimitations at study and outcome level (e.g., risk of bias), and at review-level' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Limitations at the review level are not discussed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 53.5%):\n\nlectomy in children and adolescents: review of the recent\nliterature' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] The findings are placed in the context of the current literature.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.3%):\n\nsource of funding or support for the systematic review AND for each of the included studies..\n---\n# PRISMA 2009\nP1. Identify the report as a systematic review, meta-analysis' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] Sources of funding for the review itself are not applicable, as this is a systematic review with no meta-analysis.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nTo test this hypothe-\nsis, we conducted a prospective, randomized controlled trial in a group of severely obese adolescent' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To test this hypothesis, we conducted a prospective, randomized controlled trial in a group of severely obese adolescents&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nEach author was allocated roughly 10 articles, and inde-\npendently abstracted the data and assessed the quality of\nthe reports. Noncomparative case series were evaluated\nusing a quality assessment instrument developed for this\nstudy. A calibration exercise was conducted to clarify any\ndiscordance. Each article was evaluated by 2 of us inde-\npendently and any disagreement was resolved by consen-\nsus with the help of a third reviewer' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Each author was allocated roughly 10 articles, and independently abstracted the data and assessed the quality of the reports.\" \"Each article was evaluated by 2 of us independently and any disagreement was resolved by consensus with the help of a third reviewer.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nThe search strategy used in MEDLINE (Ovid inter-\nface) was Fowler Stephens.mp.; orchidopexy.mp.; or-\nchiopexy.mp.; Laparoscopy [Abnormalities, Adverse Ef-\nfects, Classification, Standards, Statistics and\nNumerical Data, Surgery, Methods, Trends, Utiliza-\ntion].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.;\nInitial search n = 1807\nNon-relevant abstracts and duplicates\nexcluded\nn = 1660\nGrey Literature, conference\nproceedings, reference lists\nn = 13\nHard copies of papers and/or\nabstracts obtained.\nn = 160\nNon-English and non-relevant\npapers excluded. n = 61\nFinal exclusion for relevance\nn = 38 excluded\nStudies included in review\nn = 61\nCitations underwent review\nn = 99\nFigure 1. Flowchart of excluded and included articles\nSTAGED FOWLER-STEPHENS ORCHIOPEXY 2013\n\n6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or\n11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intra-\nabdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18\nand 19.; 20 not 13' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search strategy used in MEDLINE (Ovid interface) was Fowler Stephens.mp.; orchidopexy.mp.; orchiopexy.mp.; Laparoscopy [Abnormalities, Adverse Effects, Classification, Standards, Statistics and Numerical Data, Surgery, Methods, Trends, Utilization].; or/1-4.; Cryptorchi$.mp.; Undescended test$.mp.; 6 or 7.; 5 and 8.; Orchido$.mp.; Orchiop$.mp.; 5 or 10 or 11.; 12 and 8.; 13 not 9.; Impalpable test$.mp.; Intra-abdo$.mp.; Testis [surgery].; 12 or 17.; 8 or 15 or 16.; 18 and 19.; 20 not 13.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nA literature search was performed using PubMed, Cochrane,\nand Medline databases on all studies published during the last\n20 years that described open or laparoscopic operation for in-\nguinal hernia, and the latter was compared with conventional\nOH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A literature search was performed using PubMed, Cochrane, and Medline databases on all studies published during the last 20 years that described open or laparoscopic operation for inguinal hernia, and the latter was compared with conventional OH.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):\n\nTables 2 and 3 outlines the primary\nand secondary outcome results from each study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Tables 1 and 2 outlines the primary and secondary outcome results from each study.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nInclu-\nsion criteria: (1) clinical trials that compared laparoscopic\nversus open splenectomy between 1993 and 2015; (2)\nchildren under 18 years old who suffered from benign or\nmalignant hematological diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Inclusion criteria: (1) clinical trials that compared laparoscopic versus open splenectomy between 1993 and 2015; (2) children under 18 years old who suffered from benign or malignant hematological diseases&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.8%):\n\nFor continuous data, we pre-\nsented mean differences (MDs) with 95 % confidence\nintervals (CIs' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For continuous data, we presented mean differences (MDs) with 95% confidence intervals (CIs).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nMeta-analysis revealed a statistically significant\ndecrease in mean length of hospital stay for LS compared\nwith OS (WMD -1.61, 95 % CI -2.19 to -1.02;\nP = 0.001' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Meta-analysis revealed a statistically significant decrease in mean length of hospital stay for LS compared with OS (WMD -1.61, 95% CI -2.19 to -1.02; P = 0.001)&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nHere, we per-\nformed a meta-analysis on total published randomized\ncontrolled trials (RCTs) to assess whether LH is superior to\nopen herniorrhaphy (OH) in repairing PIH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Here, we performed a meta-analysis on total published randomized controlled trials (RCTs) to assess whether LH is superior to OH in repairing PIH.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.5%):\n\nCommon electronic databases as MEDLINE\nÒ\n, EMBASE\nÒ\n,\nISI Web of Science \nSM \nand the Cochrane Library were\nsearched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Common electronic databases as MEDLINE®, EMBASE®, ISI Web of ScienceSM and the Cochrane Library were searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nThe first pivotal aim in the therapy of SBS is to ensure\nalimentation of the child by parenteral nutrition (PN), which\nresults in significant improvements in mortality rates and\nimproved thrive and quality of life in paediatric SBS [65,66].\nNevertheless, the long-term application of parenteral nutri-\ntion is associated with multiple complications, primarily\nsignificant liver dysfunction. While first-line therapy is\nalways conservative, surgery should be taken into account in\ncases of failed intestinal adaptation. LILT and STEP are both\naccepted procedures potentially able to wean the child from\nPN, therefore promoting intestinal autonomy and patient\noutcome' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The first pivotal aim in the therapy of SBS is to ensure alimentation of the child by parenteral nutrition (PN), which results in significant improvements in mortality rates and improved thrive and quality of life in paediatric SBS [65,66]. Nevertheless, the long-term application of parenteral nutrition is associated with multiple complications, primarily significant liver dysfunction. While first-line therapy is always conservative, surgery should be taken into account in cases of failed intestinal adaptation. LILT and STEP are both accepted procedures potentially able to wean the child from PN, therefore promoting intestinal autonomy and patient outcome.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nA literature search (PubMed and Embase) was performed, and\nall human studies published in the English-language literature\nbetween 2006 and 2011 describing esophageal replacement for\nLGEA were identified, using the medical subject headings\n“Esophageal Atresia,” “Long-gap,” “Esophagoplasty,” “Replace-\nment,” “Interposition,” “Substitution,” “Graft,” and their combi-\nnations. All titles and abstracts were scanned and appropriate\ncitations were reviewed. Also, a manual search of the bibliogra-\nphies of relevant articles was done to identify publications for\npossible inclusion' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A literature search (PubMed and Embase) was performed, and all human studies published in the English-language literature between 2006 and 2011 describing esophageal replacement for LGEA were identified, using the medical subject headings “Esophageal Atresia,” “Long-gap,” “Esophagoplasty,” “Replacement,” “Interposition,” “Substitution,” “Graft,” and their combinations. All titles and abstracts were scanned and appropriate citations were reviewed. Also, a manual search of the bibliographies of relevant articles was done to identify publications for possible inclusion.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nDatabases searched includ-\ned MEDLINE (1980–April 2014), PubMed (1980–May 2014), EMBASE\n(2000–May 2014), and the Cochrane collection' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Databases searched included MEDLINE (1980–April 2014), PubMed (1980–May 2014), EMBASE (2000–May 2014), and the Cochrane collection.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nSince the current study was a systemic review and meta-\nanalysis based on the published articles, the consents of\npatients and approval of Internal Review Boards were not\nincluded' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Since the current study was a systemic review and meta-analysis based on the published articles, the consents of patients and approval of Internal Review Boards were not included.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThree reviewers (GJ, LZL and TQS) independently asses-\nsed selected studies, extracted and tabulated data from each\narticle with a predefined data extraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three reviewers (GJ, LZL and TQS) independently assessed selected studies, extracted and tabulated data from each article with a predefined data extraction form.&quot;<\/span>"],[98.4962406015038,59.2178770949721,70.6422018348624,98.2905982905983,96.3963963963964,98.9655172413793,97.4789915966387,90.5263157894737,92.1875,97.2727272727273,91.304347826087,98.4771573604061,97.8540772532189,98.6394557823129,97.5,92.4528301886792,92.3076923076923,98.0769230769231,98.8235294117647,84.3866171003717,97.9166666666667,98.0099502487562,91.0891089108911,98.6238532110092,99.2857142857143,98.0327868852459,99.2831541218638,97.6190476190476,71.3375796178344,88.5496183206107,35.8974358974359,89.2307692307692,71.2328767123288,75.4098360655738,79.0123456790123,77.1428571428572,43.4782608695652,85.2941176470588,87.6923076923077,63.2911392405063,85.9504132231405,44,78.494623655914,48.5714285714286,72.8971962616823,53.4246575342466,71.7948717948718,51.2820512820513,67.3913043478261,45.1612903225806,40.9090909090909,87.0967741935484,64.7887323943662,52,38.4615384615385,80.5194805194805,60.4651162790698,56.5217391304348,67.8571428571429,77.1929824561403,74.5098039215686,98.6577181208054,95.7446808510638,97.3913043478261,63.0841121495327,98.8188976377953,35.031847133758,91.1504424778761,95.0943396226415,92.3076923076923,78.6350148367952,98.1412639405204,98.5714285714286,97.1428571428571,97.7491961414791,98.1549815498155,99.3630573248408,61.875,65.979381443299,37.7952755905512,81.9444444444444,71.2328767123288,68.1159420289855,58.9285714285714,55.8139534883721,51.063829787234,68.9189189189189,80.5555555555556,47.8260869565217,40.3508771929825,49.0909090909091,46.5116279069767,42.8571428571429,31.8840579710145,42.1052631578947,60.8695652173913,56.4102564102564,44.2307692307692,48.780487804878,58.2089552238806,36.8421052631579,36.8421052631579,64.7058823529412,60.9375,67.6923076923077,72.463768115942,98.1060606060606,98.4455958549223,98.4478935698448,88.5245901639344,98.0988593155894,98.9010989010989,98.3425414364641,45.7627118644068,98.2394366197183,96.9924812030075,90.2061855670103,90.2061855670103,98.6486486486486,98.7878787878788,97.5155279503106,98.6270022883295,97.9919678714859,45.0819672131148,83.3333333333333,57.8947368421053,89.010989010989,77.6315789473684,77.2151898734177,45.2054794520548,84,98.2608695652174,72.7272727272727,72.7272727272727,98.0769230769231,98.1818181818182,55.5555555555556,73.6842105263158,83.3333333333333,97.7272727272727,86.8421052631579,56,89.8305084745763,81.6326530612245,57.1428571428571,68.9655172413793,50.8771929824561,78.3333333333333,79.3103448275862,81.8181818181818,90.3846153846154,86.8421052631579,97.7272727272727,97.9166666666667,96.25,98.2456140350877,98.3425414364641,98.2954545454545,98.3425414364641,98.5,97.6303317535545,97.6303317535545,97.8947368421053,97.6303317535545,99.0476190476191,98.6842105263158,98.9473684210526,98.0392156862745,98.7951807228916,97.8947368421053,94.6428571428571,99.0074441687345,98.7878787878788,97.8835978835979,94.6428571428571,92.9577464788732,43.0379746835443,98.1424148606811,96.3963963963964,96.1538461538462,97.9591836734694,98.0769230769231,97.9591836734694,98.0769230769231,97.9487179487179,98.7421383647799,92.3469387755102,72.3404255319149,98.0972515856237,98.8095238095238,86.6666666666667,96.5217391304348,97.6047904191617,98.6577181208054,98.2456140350877,94.3444730077121,97.1774193548387,71.5116279069767,61.2021857923497,59.9483204134367,83.0769230769231,83.0769230769231,98.5915492957747,72.6114649681529,63.3333333333333,98.5294117647059,98.876404494382,95.3488372093023,96.9387755102041,98.6486486486486,98.7654320987654,97.5124378109453,52.2727272727273,98.3606557377049,98.75,56.3829787234042,97.5265017667845,98.3240223463687,97.5265017667845,98.780487804878,98.8505747126437,98.2658959537572,98.6666666666667,97.1084337349398,98.2248520710059,70.6666666666667,83.7209302325581,98.4375,46.1538461538462,98.3606557377049,86.046511627907,97.2111553784861,97.9310344827586,32.1428571428571,95.3846153846154,98.5815602836879,43.2432432432432,93.0909090909091,91.3793103448276,98.0891719745223,32.1428571428571,95.3846153846154,96.4285714285714,96.6165413533835,74.0740740740741,98.9949748743718,92.1875,74.5901639344262,97.4358974358974,99.2592592592593,98.804780876494,98.4042553191489,65.9574468085106,71.1743772241993,96.797153024911,97.6470588235294,97.5308641975309,98.7341772151899,81.6091954022989,71.7857142857143,98.4848484848485,91.1111111111111,96.8152866242038,98.9189189189189,98.695652173913,98.5148514851485,98.6206896551724,98.8235294117647,98.5148514851485,95.9183673469388,99.0769230769231,98.3516483516484,98.2758620689655,98.8950276243094,98.8950276243094,98.8679245283019,98.2378854625551,98.3606557377049,97.9166666666667,95.6521739130435,96.969696969697,98.3193277310924,99.0566037735849,98.1707317073171,96.9543147208122,90.7834101382488,98.3818770226537,98.0392156862745,98.936170212766,98.8505747126437,98.7951807228916,97.3262032085562,87.1674491392801,98.8505747126437,98.936170212766,98.8505747126437,98.936170212766,93.5483870967742,98.6394557823129,98.6254295532646,97.6047904191617,99.0066225165563,98.4771573604061,51.2820512820513,99.2753623188406,99.4152046783626,98.9966555183946,98.1481481481482,98.5611510791367,98.5611510791367,98.2857142857143,82.4022346368715,98.3606557377049,34.8066298342541,31.1224489795918,45,98.780487804878,97.2727272727273,98.1818181818182,60,82.8358208955224,97.8571428571428,96.2750716332378,82.4561403508772,94.2028985507246,97.6284584980237,96.7391304347826,97.1698113207547,96.7391304347826,97.1698113207547,50.7246376811594,98.3122362869198,96.1538461538462,97.4358974358974,97.4311926605505,82.9971181556196,82.9971181556196,97.1563981042654,74.2331288343558,99.1176470588235,99.1428571428571,97.4358974358974,98.876404494382,98.8950276243094,98.2222222222222,68.5714285714286,39.1304347826087,40.650406504065,34.2857142857143,56.3636363636364,48,58.1818181818182,28.8135593220339,37.2549019607843,54.7008547008547,59.8591549295775,49.2537313432836,40,56.5217391304348,67.6470588235294,51.5151515151515,28.5714285714286,24.3589743589744,67.3913043478261,47.9452054794521,50.9803921568627,54.4117647058824,49.5798319327731,56.6265060240964,21.2121212121212,65,58.1818181818182,53.5211267605634,72.2689075630252,99.1735537190083,98.4674329501916,99.1935483870968,98.3739837398374,95.1219512195122,98.5436893203884,96.7741935483871,97.5155279503106,98.6301369863014,95.4545454545455,98.3433734939759,98.7783595113438,98.4732824427481,98.3240223463687,98.7577639751553]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th>Author & Year<\/th>\n      <th>Source<\/th>\n      <th>Quote with deviation<\/th>\n      <th>Similarity<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"ft","order":[[3,"desc"]],"columnDefs":[{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 1, 3, \",\", \".\", null);\n  }"},{"visible":false,"targets":1},{"className":"dt-right","targets":3}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render"],"jsHooks":[]}</script>
</div>
<div id="formatting-accuracy" class="section level3">
<h3>Formatting accuracy</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<ul>
<li>111 / 112 (99.1%) responses were usable
<ul>
<li>74 / 111 (66.7%) usable responses with correctly formatted
scores</li>
<li>37 / 111 (33.3%) usable responses with minor fixable score
formatting issues
<ul>
<li>24 with ‘unsolicited-ranges’</li>
<li>13 with ‘wrong-response-partial-unclear-etc’</li>
<li>1 with ‘missing-squared-brackets-in-numbered-list’</li>
<li>1 with ‘missing-squared-brackets-na-with-slash’</li>
</ul></li>
</ul></li>
<li>1 / 112 (0.9%) responses were unusable (‘failed’), affecting 1
publications (1 of which were ultimately successful because a repeated
response was usable)
<ul>
<li>1 with failure reason ‘scores-p21-to-p27-missing’</li>
</ul></li>
</ul>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-d8a7fc6f06b89b6c0735" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-d8a7fc6f06b89b6c0735">{"x":{"filter":"none","vertical":false,"fillContainer":false,"data":[["1"],["Frongia 2013"],["scores-p21-to-p27-missing"],[true],[" Here are the responses for the AMSTAR and PRISMA items based on the attached full text:\n\nA1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”\n\nQuotes:\n- 'After screening all titles and abstracts to assess whether each report was potentially eligible for inclusion, and whether or not the full text was available.'\n\nReasoning: The review did not refer to an a priori protocol, ethics approval, or published objectives. The inclusion/exclusion criteria were determined during the review process.\n\nResponse: [No]\n\nA2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.  \n\nQuotes: \n- 'One reviewer (GF) screened all titles and abstracts to assess whether each report was potentially eligible for inclusion, and whether or not the full text was available. Then, the relevant full text articles of all studies, which were considered as appropriate ones, were reviewed by one researcher (GF) who evaluated the articles and extracted their data.'\n- 'Afterwards, two other reviewers checked the data extraction of studies to estimate reliability (SW and AN).'\n\nReasoning: Only one reviewer performed study selection and data extraction initially. Two other reviewers only checked the extracted data for reliability.\n\nResponse: [No]\n\nA3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).\n\nQuotes:\n- 'A systematic literature search was carried out using the search terms “bowel lengthening”, “intestinal lengthening”, “longitudinal intestinal lengthening and tailoring”, “LILT”, “Bianchi procedure”, “serial transverse enteroplasty” and “step procedure”.'\n- 'The reference lists of retrieved relevant articles were also cross-screened for additional studies.'\n\nReasoning: The authors searched multiple sources using relevant keywords, and supplemented searches by screening reference lists. However, details of databases searched and search strategies were not provided.\n\nResponse: [No] \n\nA4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.  \n\nQuotes: None provided.\n\nReasoning: The review did not mention searching for grey literature or unpublished studies. \n\nResponse: [No]\n\nA5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”\n\nQuotes: \n- 'Finally, n = 39 articles with useable information (LILT n = 24 articles, STEP n = 15 articles), including n = 472 patients (LILT n = 363 patients, STEP n = 109 patients) remained to be analyzed and are reviewed here (Table 1).'\n- Table 1 lists the included studies.\n\nReasoning: The review provided a list of included studies in Table 1. No list of excluded studies was provided.\n\nResponse: [No]\n\nA6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.  \n\nQuotes: \n- 'Included studies revealed significant methodological and clinical heterogeneity. Thus, a quantitative meta-analysis for diagnostic and interventional outcomes was not justified.'\n- The results section provides aggregated data on participant characteristics, interventions, and outcomes. \n\nReasoning: The review provided aggregated data on participants, interventions, and outcomes in the results section. However, no table summarizing study characteristics was provided.\n\nResponse: [Yes]\n\nA7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).  \n\nQuotes: \n- 'There were no randomized trials in our review. In all 39 reviewed case series the data had been retrospectively analyzed.' \n- 'Included studies revealed significant methodological and clinical heterogeneity. Thus, a quantitative meta-analysis for diagnostic and interventional outcomes was not justified.'\n\nReasoning: The review stated that all included studies were retrospective case series. No quality assessment of individual studies was documented. \n\nResponse: [No]\n\nA8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.\n\nQuotes: None provided. \n\nReasoning: The quality of included studies was not assessed or considered in formulating conclusions.\n\nResponse: [No]\n\nA9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.\n\nQuotes:  \n- 'Included studies revealed significant methodological and clinical heterogeneity. Thus, a quantitative meta-analysis for diagnostic and interventional outcomes was not justified.'\n\nReasoning: The review did not perform a quantitative synthesis due to heterogeneity between studies.\n\nResponse: [NA]\n\nA10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.  \n\nQuotes: None provided.\n\nReasoning: The review did not assess publication bias.\n\nResponse: [No]\n\nA11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.\n\nQuotes:  \n- 'Conflict of interest: None.'\n\nReasoning: Sources of support were reported for the review but not for the individual studies included. \n\nResponse: [No]\n\nP1. Identify the report as a systematic review, meta-analysis, or both.  \n\nQuotes:\n- 'Comparison of LILT and STEP procedures in children with short bowel syndrome — A systematic review of the literature' (Title)\n\nReasoning: The report is identified as a systematic review in the title.\n\nResponse: [Yes]\n\nP2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.\n\nQuotes: \n- The abstract provides background, objectives, inclusion criteria, participants, interventions, results, and conclusions.\n\nReasoning: A structured abstract is provided summarizing key aspects of the review. \n\nResponse: [Yes]  \n\nP3. Describe the rationale for the review in the context of what is already known.\n\nQuotes:\n- 'The first pivotal aim in the therapy of SBS is to ensure alimentation of the child by parenteral nutrition (PN), which results in significant improvements in mortality rates and improved thrive and quality of life in paediatric SBS [65,66]. Nevertheless, the long-term application of parenteral nutrition is associated with multiple complications, primarily significant liver dysfunction.'\n- 'Further surgical approaches can be subdivided into autologous intestinal reconstruction procedures and small bowel transplantation (SBTX). The two main autologous intestinal reconstruction procedures applied today are the Longitudinal Intestinal Lengthening and Tailoring (LILT) and the Serial Transverse Enteroplasty (STEP) [54].' \n\nReasoning: The introduction provides background on SBS and the rationale for surgical procedures like LILT and STEP.\n\nResponse: [Yes]\n\nP4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  \n\nQuotes: \n- 'The present review highlights most of these basic issues, first giving an overview of autologous intestinal reconstruction procedures with emphasis on LILT and STEP, then an insight into indications criteria for LILT and STEP and finally a comparison of associated outcome of both procedures from published data in children.' (Objectives)\n\nParticipants: Children with short bowel syndrome\nInterventions: LILT, STEP \nComparisons: Comparison of LILT and STEP\nOutcomes: Outcomes like complications, bowel lengthening, etc. \nStudy design: Case series\n\nReasoning: The objectives specify the intent to compare LILT and STEP in children with SBS. The participants, interventions, comparisons, and outcomes are clear from the text.\n\nResponse: [Yes]\n\nP5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.\n\nQuotes: None provided.\n\nReasoning: The review did not mention a protocol.\n\nResponse: [No]\n\nP6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.\n\nQuotes:\n- 'Inclusion and exclusion criteria: The articles were included in this review if they met the following criteria: Population: Studies of humans aged 0–18 years. Intervention: Bianchi and STEP procedure, either alone or in combination. Type of study: All study designs were eligible for inclusion. Case series with 1 or more cases were included.' \n\nReasoning: The inclusion and exclusion criteria specify population, interventions, and study designs included.\n\nResponse: [Yes]\n\nP7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.\n\nQuotes:  \n- 'A systematic literature search was carried out using the search terms “bowel lengthening”, “intestinal lengthening”, “longitudinal intestinal lengthening and tailoring”, “LILT”, “Bianchi procedure”, “serial transverse enteroplasty” and “step procedure”. The last search was done on December, 10th, 2012.'\n- 'The reference lists of retrieved relevant articles were also cross-screened for additional studies.'\n\nReasoning: The information sources searched are described, but details of databases and platforms are not provided. The date of last search is provided. \n\nResponse: [No]\n\nP8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  \n\nQuotes: The search strategy is not provided for any database.\n\nReasoning: The full search strategy for any database was not presented.\n\nResponse: [No]\n\nP9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).\n\nQuotes:  \n- 'One reviewer (GF) screened all titles and abstracts to assess whether each report was potentially eligible for inclusion, and whether or not the full text was available. Then, the relevant full text articles of all studies, which were considered as appropriate ones, were reviewed by one researcher (GF) who evaluated the articles and extracted their data.' \n\nReasoning: The process for screening and selecting studies is described.\n\nResponse: [Yes] \n\nP10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.\n\nQuotes:  \n- 'Then, the relevant full text articles of all studies, which were considered as appropriate ones, were reviewed by one researcher (GF) who evaluated the articles and extracted their data. Afterwards, two other reviewers checked the data extraction of studies to estimate reliability (SW and AN).'\n\nReasoning: The method of data extraction is described - one author extracted data initially which was checked by two others. \n\nResponse: [Yes]\n\nP11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.\n\nQuotes: \n- The results section provides data extracted for variables such as age, anatomy, complications, outcomes etc. \n\nReasoning: The key variables like participant characteristics, interventions, and outcomes are listed and defined in the results section.\n\nResponse: [Yes]\n\nP12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.\n\nQuotes:  \n- 'There were no randomized trials in our review. In all 39 reviewed case series the data had been retrospectively analyzed.'\n\nReasoning: The review did not assess risk of bias in individual studies.\n\nResponse: [No]\n\nP13. State the principal summary measures (e.g., risk ratio, difference in means).\n\nQuotes: \n- 'Mean %-values indicated in this review were calculated from all %-values of the respective item published within reviewed reports.'\n\nReasoning: The principal summary measure (mean) is stated. \n\nResponse: [Yes] \n\nP14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.\n\nQuotes:\n- 'Included studies revealed significant methodological and clinical heterogeneity. Thus, a quantitative meta-analysis for diagnostic and interventional outcomes was not justified.'\n\nReasoning: The review did not perform a quantitative synthesis.\n\nResponse: [NA]\n\nP15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). \n\nQuotes: None provided.\n\nReasoning: Assessment of risk of bias was not performed. \n\nResponse: [No]\n\nP16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.\n\nQuotes: No additional analyses were done.\n\nReasoning: No additional analyses were performed.\n\nResponse: [NA]\n\nP17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  \n\nQuotes:\n- Figure 2 provides a flow diagram of studies screened and included.\n- Reasons for exclusion are provided. \n\nReasoning: A flow diagram documents the screening process including numbers excluded for various reasons.\n\nResponse: [Yes]\n\nP18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.\n\nQuotes: \n- Table 1 provides citation details and number of patients for each included study.\n- The results section provides details on participant characteristics, interventions, outcomes, and follow-up periods.\n\nReasoning: Details of each included study are provided in Table 1 and the results.\n\nResponse: [Yes]\n\nP19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).\n\nQuotes: Risk of bias was not assessed for individual studies. \n\nReasoning: Risk of bias assessment was not performed.\n\nResponse: [No]\n\nP20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. \n\nQuotes: \n- Summary data for relevant outcomes from each study are presented in the results section.\n- No forest plots or effect estimates were provided.\n\nReasoning: Simple summary data for each study are presented, but not forest plots or effect estimates\n"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Author &amp; Year<\/th>\n      <th>Failure reason (click to show LLM response)<\/th>\n      <th>Ultimately successful<\/th>\n      <th>LLM response<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"ft","columnDefs":[{"targets":2,"render":"function(data, type, row, meta) { return '<a onclick=\"javascript:alert(`'+row[4]+'`)\" style=\"cursor: pointer\">' + data + '<\/a>' }"},{"targets":[0,4],"visible":false},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render"],"jsHooks":[]}</script>
</div>
<div id="llm-prompt" class="section level3">
<h3>LLM prompt</h3>
<ul>
<li>Model: <a href="https://www.anthropic.com/index/claude-2">Claude
2</a></li>
<li>Temperature: Chat interface (<a
href="https://docs.anthropic.com/claude/reference/complete_post">probably
<code>1</code></a>)</li>
<li>Briefing derived from: <a
href="https://doi.org/10.1371/journal.pone.0175213">Cullis 2017</a>
Supporting information: <a
href="https://doi.org/10.1371/journal.pone.0175213.s004">S1
Dataset</a></li>
</ul>
<div id="user-prompt" class="section level4">
<h4>User prompt</h4>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<pre>
You are an expert in systematic reviews and are tasked to assess the methodological quality of a systematic review with the AMSTAR tool and its reporting quality with the PRISMA 2009 tool based on the full text of its publication. AMSTAR and PRISMA 2009 consist of the following items:

---
# AMSTAR
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul "Follow-up poorly reported in general"
A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.
A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..
---
# PRISMA 2009
P1. Identify the report as a systematic review, meta-analysis, or both.
P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
P3. Describe the rationale for the review in the context of what is already known.
P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
P13. State the principal summary measures (e.g., risk ratio, difference in means).
P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
P22. Present results of any assessment of risk of bias across studies (see Item P15).
P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
---

The full text to be assessed is attached as PDF.

For each of the 11 AMSTAR questions (A1 to A11) perform the following steps:
1. Extract 1-3 relevant quotes from the full text.
2. Explain your reasoning in 1 sentence.
3. Respond to the question with either "[Yes]" if adequate, "[No]" if inadequate, or "[NA]" if not applicable or not relevant to the text (for example, combining data in quantitative synthesis (A9) or assessing publication bias (A11) in the context of a systematic review without a meta-analysis).

For each of the PRISMA items (P1 to P27) perform the following steps:
1. Extract 1-3 relevant quotes from the full text.
2. Explain your reasoning in 1 sentence.
3. Respond with either "[Yes]" if the item was reported, "[No]" if not reported, or "[NA]" if not applicable (for example, items P14, P15, P16, P21, P22, P23 in the context of a systematic review without a meta-analysis).

Before stopping, make sure you've processed all 11 AMSTAR questions and 27 PRISMA items. Do not provide a final summary paragraph in the end.
 
</pre>
</div>
</div>
</div>

</div>

<script>
$(document).ready(function() {
  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed table-sm');

  // initialize mathjax

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460,
    resize_reload: true
  });
  var navbar = $(".navbar").first();
  var body = $("body").first();
  var sidebar = $(".section.sidebar").first();
  function addNavbarPadding() {
    var navHeight = navbar.outerHeight();
    body.css("padding-top", (navHeight + 8) + "px");
    sidebar.css("top", navHeight + "px");
    var resizeEvent = window.document.createEvent("UIEvents");
    resizeEvent.initUIEvent("resize", true, false, window, 0);
    window.dispatchEvent(resizeEvent);
  }
  if (!window.Shiny) setTimeout(addNavbarPadding, 100);
  $(document).on("shiny:idle", function() {
    setTimeout(addNavbarPadding, 50);
  });
});
</script>

</body>
</html>
